

(19) World Intellectual Property
Organization
International Bureau



(43) International Publication Date
17 February 2005 (17.02.2005)

PCT

(10) International Publication Number
WO 2005/014863 A1

(51) International Patent Classification⁷: **C12Q 01/68**,
C12N 15/01, A61K 39/395, C07K 14/47

Leura Grove, Hawthorn East, Victoria 3123 (AU). **DAVY, Anne** [FR/AU]; 76 Stanley Street, North Adelaide, South Australia 5006 (AU).

(21) International Application Number:
PCT/AU2004/001051

(74) Agent: **GRIFFITH HACK**; Level 10, 167 Eagle Street, Brisbane, Queensland 4000 (AU).

(22) International Filing Date: 6 August 2004 (06.08.2004)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
2003904154 7 August 2003 (07.08.2003) AU

(81) Designated States (*unless otherwise indicated, for every kind of national protection available*): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW.

(71) Applicant (*for all designated States except US*): **BIONOMICS LIMITED** [AU/AU]; 31 Dalglish Street, Thebarton, South Australia 5031 (AU).

(72) Inventors; and

(75) Inventors/Applicants (*for US only*): **MULLEY, John, Charles** [AU/AU]; 13 Dunkley Avenue, Firlc, South Australia 5046 (AU). **HARKIN, Louise, Anne** [AU/AU]; 12 Paddington Avenue, Northgate, South Australia 5085 (AU). **DIBBENS, Leanne, Michelle** [AU/AU]; 14 Trinity Street, College Park, South Australia 5069 (AU). **PHILLIPS, Hilary, Anne** [AU/AU]; 10 Witton Road, Port Noarlunga, South Australia 5167 (AU). **HERON, Sarah, Elizabeth** [AU/AU]; 8 Kinnaird Crescent, Highbury, South Australia 5089 (AU). **BERKOVIC, Samuel, Frank** [AU/AU]; 7 Polo Parade, Caulfield North, Victoria 3161 (AU). **SCHEFFER, Ingrid, Eileen** [AU/AU]; 3

(84) Designated States (*unless otherwise indicated, for every kind of regional protection available*): ARIPO (BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

Published:

— with international search report

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

(54) Title: MUTATIONS IN ION CHANNELS

(57) Abstract: A method of identifying a subject predisposed to a disorder associated with ion channel dysfunction, comprising ascertaining whether at least one of the genes encoding ion channel subunits in said subject has undergone a mutation event as set forth in one of SEQ ID Numbers: 1-72.



WO 2005/014863 A1

MUTATIONS IN ION CHANNELSTechnical Field

The present invention is concerned with mutations in proteins having biological functions as ion channels and, more particularly, with such mutations where they are associated with diseases such as epilepsy and disorders associated with ion channel dysfunction including, but not restricted to, hyper- or hypo-kalemic periodic paralysis, myotonias, malignant hyperthermia, myasthenia, cardiac arrhythmias, episodic ataxia, migraine, Alzheimer's disease, Parkinson's disease, schizophrenia, hyperekplexia, anxiety, depression, phobic obsessive symptoms, neuropathic pain, inflammatory pain, chronic/acute pain, Bartter's syndrome, polycystic kidney disease, Dent's disease, hyperinsulinemic hypoglycemia of infancy, cystic fibrosis, congenital stationary night blindness and total colour-blindness.

Background Art

Epilepsies constitute a diverse collection of brain disorders that affect about 3% of the population at some time in their lives (Annegers, 1996). An epileptic seizure can be defined as an episodic change in behaviour caused by the disordered firing of populations of neurons in the central nervous system. This results in varying degrees of involuntary muscle contraction and often a loss of consciousness. Epilepsy syndromes have been classified into more than 40 distinct types based upon characteristic symptoms, types of seizure, cause, age of onset and EEG patterns (Commission on Classification and Terminology of the International League Against Epilepsy, 1989). However the single feature that is common to all syndromes is the persistent increase in neuronal excitability that is both occasionally and unpredictably expressed as a seizure.

A genetic contribution to the aetiology of epilepsy has been estimated to be present in approximately 40% of

- 2 -

affected individuals (Gardiner, 2000). As epileptic seizures may be the end-point of a number of molecular aberrations that ultimately disturb neuronal synchrony, the genetic basis for epilepsy is likely to be heterogeneous. There are over 200 Mendelian diseases which include epilepsy as part of the phenotype. In these diseases, seizures are symptomatic of underlying neurological involvement such as disturbances in brain structure or function. In contrast, there are also a number of "pure" epilepsy syndromes in which epilepsy is the sole manifestation in the affected individuals. These are termed idiopathic and account for over 60% of all epilepsy cases.

Idiopathic epilepsies have been further divided into partial and generalized sub-types. Partial (focal or local) epileptic fits arise from localized cortical discharges, so that only certain groups of muscles are involved and consciousness may be retained. However, in generalized epilepsy, EEG discharge shows no focus such that all subcortical regions of the brain are involved. Although the observation that generalized epilepsies are frequently inherited is understandable, the mechanism by which genetic defects, presumably expressed constitutively in the brain, give rise to partial seizures is less clear.

The molecular genetic era has resulted in spectacular advances in classification, diagnosis and biological understanding of numerous inherited neurological disorders including muscular dystrophies, familial neuropathies and spinocerebellar degenerations. These disorders are all uncommon or rare and have simple Mendelian inheritance. In contrast, common neurological diseases like epilepsy, have complex inheritance where they are determined by multiple genes sometimes interacting with environmental influences. Molecular genetic advances in disorders with complex inheritance have been far more modest to date (Todd, 1999).

Most of the molecular genetic advances have occurred by a sequential three stage process. First a clinically homogeneous disorder is identified and its mode of inheritance determined. Second, linkage analysis is performed on carefully characterized clinical populations with the disorder. Linkage analysis is a process where the chromosomal localization of a particular disorder is narrowed down to approximately 0.5% of the total genome. Knowledge of linkage imparts no intrinsic biological insights other than the important clue as to where to look in the genome for the abnormal gene. Third, strategies such as positional cloning or the positional candidate approach are used to identify the aberrant gene and its specific mutations within the linked region (Collins, 1995).

Linkage studies in disorders with complex inheritance have been bedevilled by negative results and by failure to replicate positive findings. A sense of frustration permeates current literature in the genetics of complex disorders. Carefully performed, large scale studies involving hundreds of sibpairs in disorders including multiple sclerosis and diabetes have been essentially negative (Bell and Lathrop, 1996; Lernmark and Ott, 1998). An emerging view is that such disorders are due to the summation of many genes of small effect and that identification of these genes may only be possible with very large-scale association studies. Such studies on a genome-wide basis are currently impossible due to incomplete marker sets and computational limitations.

The idiopathic generalized epilepsies (IGE) are the most common group of inherited human epilepsy and do not have simple inheritance. Like other complex disorders, linkage studies in IGE have generated controversial and conflicting claims. Previous authors have suggested the possibility of multifactorial, polygenic, oligogenic or two locus models for the disease (Andermann, 1982; Doose

and Baier, 1989; Greenberg et al., 1988a; 1992; Janz et al., 1992).

Two broad groups of IGE are now known - the classical idiopathic generalized epilepsies (Commission on
5 Classification and Terminology of the International League Against Epilepsy, 1989) and the newly recognized genetic syndrome of generalized epilepsy with febrile seizures plus (GEFS⁺) (Scheffer and Berkovic, 1997; Singh et al., 1999).

10 The classical IGEs are divided into a number of clinically recognizable but overlapping sub-syndromes including childhood absence epilepsy, juvenile absence epilepsy, juvenile myoclonic epilepsy etc (Commission on
15 Classification and Terminology of the International League Against Epilepsy, 1989; Roger et al., 1992). The sub-syndromes are identified by age of onset and the pattern of seizure types (absence, myoclonus and tonic-clonic). Some patients, particularly those with tonic-clonic
20 seizures alone do not fit a specifically recognized sub-syndrome. Arguments for regarding these as separate syndromes, yet recognizing that they are part of a neurobiological continuum, have been presented previously (Berkovic et al. 1987; 1994; Reutens and Berkovic, 1995).

25 GEFS⁺ was originally recognized through large multi-generation families and comprises a variety of sub-syndromes. Febrile seizures plus (FS⁺) is a sub-syndrome where children have febrile seizures occurring outside the age range of 3 months to 6 years, or have associated febrile tonic-clonic seizures. Many family members have a
30 phenotype indistinguishable from the classical febrile convulsion syndrome and some have FS⁺ with additional absence, myoclonic, atonic, or complex partial seizures. The severe end of the GEFS⁺ spectrum includes myoclonic-astatic epilepsy.

35 The cumulative incidence for epilepsy by age 30 years (proportion suffering from epilepsy at some time) is 1.5% (Hauser et al., 1993). Accurate estimates for the

cumulative incidence of the IGEs are unavailable. In epidemiological studies where attempts are made to subclassify epilepsies, rather few cases of IGE are diagnosed, and many cases are unclassified. This is probably because cases are rarely directly examined by epileptologists. In clinic- or office-based series seen by experts, most cases are classifiable and IGEs account for about 25% of cases. This suggests that about 0.3% of the population suffer from IGE at some time.

In outbred populations many patients with classical IGE appear to be sporadic as siblings and parents are usually unaffected. Systematic EEG studies on clinically unaffected family members show an increase in age-dependent occurrence of generalized epileptiform discharges compared to controls. In addition, to the approximate 0.3% of the population with clinical IGE, systematic EEG studies suggest that about 1% of healthy children have generalized epileptiform discharges while awake (Cavazzuti et al., 1980; Okubo et al., 1994).

Approximately 5-10% of first degree relatives of classical IGE probands have seizures with affected relatives usually having IGE phenotypes or febrile seizures. While nuclear families with 2-4 affected individuals are well recognized and 3 generation families or grandparent-grandchild pairs are occasionally observed (Italian League Against Epilepsy Genetic Collaborative Group, 1993), families with multiple affected individuals extending over 4 or more generations are exceptionally rare.

For GEFS⁺, however, a number of large multi-generation families showing autosomal dominant inheritance with incomplete penetrance are known. Similar to classical IGE, analysis of sporadic cases and small families with GEFS⁺ phenotypes does not suggest simple Mendelian inheritance. Indeed, bilineal inheritance, where there is a history of epilepsy on maternal and paternal sides, is observed in both GEFS⁺ and classical IGE families (Singh et al., 1999;

Italian League Against Epilepsy Genetic Collaborative Group, 1993).

Within single families with classical IGE or GEFS⁺, affected individuals often have different sub-syndromes.

5 The closer an affected relative is to the proband, the more similar are their sub-syndromes, and siblings often have similar sub-syndromes (Italian League Against Epilepsy Genetic Collaborative Group, 1993). Less commonly, families are observed where most, or all, known
10 affected individuals have one classical IGE sub-syndrome such as childhood absence epilepsy or juvenile myoclonic epilepsy (Italian League Against Epilepsy Genetic Collaborative Group, 1993).

Importantly, sub-syndromes are identical in affected
15 monozygous twins with IGE. In contrast, affected dizygous twins, may have the same or different sub-syndromes. Classical IGE and GEFS⁺ sub-syndromes tend to segregate separately (Singh et al., 1999).

In some inbred communities, pedigree analysis
20 strongly suggests recessive inheritance for juvenile myoclonic epilepsy and other forms of IGE (Panayiotopoulos and Obeid, 1989; Berkovic et al., 2000). In such families, sub-syndromes are much more similar in affected siblings than in affected sib-pairs from outbred families.
25 Recently, a family with an infantile form of IGE with autosomal recessive inheritance, confirmed by linkage analysis, was described in Italy (Zara et al., 2000).

Most work on the molecular genetics of classical IGEs has been done on the sub-syndrome of juvenile myoclonic
30 epilepsy where a locus in proximity or within the HLA region on chromosome 6p was first reported in 1988 (Greenberg et al., 1988b). This finding was supported by two collaborating laboratories, in separate patient samples, and subsequently three groups provided further
35 evidence for a 6p locus for juvenile myoclonic epilepsy in some, but not all, of their families. However, genetic defects have not been found and the exact locus of the

- 7 -

gene or genes, in relationship to the HLA region, remains controversial. Strong evidence for linkage to chromosome 6 also comes from a study of a single large family with juvenile myoclonic epilepsy, but in this pedigree the locus is well outside the HLA region. A locus on chromosome 15q has also been suggested for juvenile myoclonic epilepsy, but was not confirmed by two other studies.

In general, the results of studies of the putative chromosomal 6p locus in the HLA region in patients with absence epilepsies or other forms of idiopathic generalized epilepsies have been negative. The major exception is that study of probands with tonic-clonic seizures on awakening, a sub-syndrome closely related to juvenile myoclonic epilepsy, suggests linkage to 6p.

Linkage for classical remitting childhood absence epilepsy remains elusive, but in a family with persisting absence evolving into a juvenile myoclonic epilepsy phenotype, linkage to chromosome 1p has been claimed. An Indian pedigree with persisting absence and tonic-clonic seizures may link to 8q24. Linkage to this region was also suggested by a non-parametric analysis in IGE, irrespective of subsyndrome, but was not confirmed in another study. Other loci for IGEs that have been reported in single studies include 3p14, 8p, 18 and possibly 5p. The unusual example of recessively inherited infantile onset IGE described in Italy maps to 16p in a single family.

Thus, like most disorders with complex inheritance, the literature on genetics of classical IGEs is confusing and contradictory. Some, and perhaps much, of this confusion is due to heterogeneity, with the likelihood of a number of loci for IGEs. The studies reviewed above were principally performed on multiple small families, so heterogeneity within and between samples is probable. Whether all, some, or none of the linkages reported above will be found to harbour relevant genes for IGE remains to

be determined. Most of the studies reviewed above used analysis methods assuming Mendelian inheritance, an assumption that is not correct for outbred communities. Some studies used multiple models (autosomal recessive, autosomal dominant). Although parametric linkage analysis may be reliable in some circumstance of analyzing complex disease, it can lead to spurious findings as highlighted by the literature on linkage in major psychoses (Risch and Botstein, 1996).

In so far as GEFS⁺ is concerned, linkage analysis on rare multi-generation large families with clinical evidence of a major autosomal dominant gene have demonstrated loci on chromosomes 19q and 2q. Both the 19q and 2q GEFS⁺ loci have been confirmed in independently ascertained large families, and genetic defects have been identified. Families linked to 19q are known and a mutation in the gene for the $\beta 1$ subunit of the neuronal sodium channel (SCN1B) has been identified (Wallace et al., 1998). This mutation results in the loss of a critical disulphide bridge of this regulatory subunit and causes a loss of function *in vitro*. Families linked to 2q are also known and mutations in the pore-forming α subunit of the neuronal sodium channel (SCN1A) have been identified (PCT/AU01/01648; Wallace et al., 2001b; Escayg et al., 2000). Studies on the more common small families with GEFS⁺ have not revealed these or other mutations to date.

In addition to the SCN1B and SCN1A mutations in GEFS⁺, four other gene defects have been discovered for human idiopathic epilepsies through the study of large families. Mutations in the alpha-4 subunit of the neuronal nicotinic acetylcholine receptor (CHRNA4) occur in the focal epilepsy syndrome of autosomal dominant nocturnal frontal lobe epilepsy (Australian patent AU-B-56247/96; Steinlein et al., 1995). Mutations in the gamma-2 subunit of the GABA_A receptor (GABRG2) have been identified in childhood absence epilepsy, febrile seizures (including febrile

seizures plus) and myoclonic epilepsy (PCT/AU01/00729; Wallace et al., 2001a). Finally, mutations in two potassium channel genes (KCNQ2 and KCNQ3) were identified in benign familial neonatal convulsions (Singh et al., 1998; Biervert et al., 1998; Charlier et al., 1998). Although initially regarded as a special form of IGE, this unusual syndrome is probably a form of inherited focal epilepsy.

Further to these studies, mutations in other genes have been identified to be causative of epilepsy. These include mutations in the beta-2 subunit (CHRNA2) of the neuronal nicotinic acetylcholine receptor (PCT/AU01/00541; Phillips et al., 2001) and the delta subunit (GABRD) of the GABA_A receptor (PCT/AU01/00729).

A number of mouse models approximating human IGE are known. These mice mutants have ataxia in addition to generalized spike-and-wave discharges with absences or tonic-clonic seizures. Recessive mutations in calcium channel subunit genes have been found in lethargic (CACNB4), tottering/leaner (CACNA1A), and stargazer (CACNG2) mutants. The slow-wave epilepsy mouse mutant has a mutation in the sodium/hydrogen exchanger gene, which may have important downstream effects on pH-sensitive ion channels.

The human and mouse literature is now suggesting that the idiopathic epilepsies comprise a family of channelopathies with mutations in ion channel subunits of voltage-gated (eg SCN1A, SCN1B, KCNQ2, KCNQ3) or ligand-gated (eg CHRNA4, CHRNA2, GABRG2, GABRD) types. These channels are typically comprised of a number of subunits, specified by genes on different chromosomes. The stoichiometry and conformation of ion channel subunits are not yet well understood, but many have multiple subunits in a variety of combinations.

The involvement of ion channels in other neuro/physiological disorders has also been observed (reviewed in Dworakowska and Dolowy, 2000). Mutations in

- 10 -

voltage-gated sodium, potassium, calcium and chloride channels as well as ligand-gated channels such as the acetylcholine and GABA receptors may lead to physiological disorders such as hyper- and hypo-kalemic periodic paralysis, myotonias, malignant hyperthermia, myasthenia and cardiac arrhythmias. Neurological disorders other than epilepsy that are associated with ion channel mutations include episodic ataxia, migraine, Alzheimer's disease, Parkinson's disease, schizophrenia, hyperekplexia, anxiety, depression, phobic obsessive symptoms, as well as neuropathic pain, inflammatory pain and chronic/acute pain. Some kidney disorders such as Bartter's syndrome, polycystic kidney disease and Dent's disease, secretion disorders such as hyperinsulinemic hypoglycemia of infancy and cystic fibrosis, and vision disorders such as congenital stationary night blindness and total colour-blindness may also be linked to mutations in ion channels.

Disclosure of the Invention

In a new genetic model for the idiopathic generalised epilepsies (IGEs) described in PCT/AU01/00872 (the disclosure of which is incorporated herein by reference) it has been postulated that most classical IGE and GEFS⁺ cases are due to the combination of two mutations in multi-subunit ion channels. These are typically point mutations resulting in a subtle change of function. The critical postulate is that two mutations, usually, but not exclusively, in different subunit alleles ("digenic model"), are required for clinical expression of IGE. It was further proposed that

a) A number of different mutated subunit pairs can be responsible for IGE. Combinations of two mutated subunits lead to an IGE genotype with ~30% penetrance.

b) The total allele frequency of mutated subunits is ~8%. It was calculated that approximately 15% of the population has one or more mutated

- 11 -

subunit genes and 1% have two or more mutated subunits.

c) Sub-syndromes are principally determined by the specific combination of mutated subunit pairs, although one or more other genes, including ion channel subunits, of smaller effect may modify the phenotype.

d) Mutated subunit combinations that cause classical IGEs are largely separate from those that cause GEFS⁺, although some subunits may be involved in both syndromes.

e) Individuals with single 'change of function' mutations would not have IGE, but such mutations may contribute to simple febrile seizures, which are observed with increased frequency in relatives of IGE probands.

The model also proposes that subunit mutations with more severe functional consequences (eg breaking a disulphide bridge in SCN1B or amino acid substitution in the pore forming regions of SCN1A for GEFS⁺) cause autosomal dominant generalized epilepsies with a penetrance of 60-90%. The precise sub-syndromes in GEFS⁺ are determined by minor allelic variation or mutations in other ion channel subunits. Such "severe" mutations are rare (allele frequency <0.01%) and are infrequent causes of GEFS⁺. They very rarely, or perhaps never, cause classical IGE.

The identification of molecular changes in ion channel subunits is therefore a significant step towards the elucidation of genetic variants that alone or in combination (based on the digenic model) give rise to an epilepsy phenotype, and to other neuro/physiological disorders associated with ion channel dysfunction.

The present inventors have identified a number of novel mutations or variants in genes encoding subunits of ion channels in individuals with epilepsy. It will be appreciated that for each molecular defect one can provide

an isolated nucleic acid molecule coding for a protein having a biological function as part of an ion channel in a mammal, wherein a mutation event selected from the group consisting of point mutations, deletions, insertions and rearrangements has occurred so as to affect the functioning of the ion channel. In some instances this single mutation alone will produce a phenotype of epilepsy or other neuro/physiological disorders associated with ion channel dysfunction.

In the case where a single mutation alone does not produce, say, an epilepsy phenotype, there would be provided one or more additional isolated nucleic acid molecules coding for proteins having a biological function as part of an ion channel in a mammal, wherein a mutation event selected from the group consisting of point mutations, deletions, insertions and rearrangements has occurred so as to affect the functioning of the ion channel. The cumulative effect of the mutations in each isolated nucleic acid molecule *in vivo* is to produce a epilepsy or another neuro/physiological disorders in said mammal. The mutations may be in nucleic acid molecules coding for protein subunits belonging to the same ion channel or may be in nucleic acid molecules coding for protein subunits that belong to different ion channels.

Typically such mutations are point mutations and the ion channels are voltage-gated channels such as a sodium, potassium, calcium or chloride channels or are ligand-gated channels such as members of the nAChR/GABA super family of receptors, or a functional fragment or homologue thereof.

Mutations may include those in non-coding regions of the ion channel subunits (eg mutations in the promoter region which affect the level of expression of the subunit gene, mutations in intronic sequences which affect the correct splicing of the subunit during mRNA processing, or mutations in the 5' or 3' untranslated regions that can affect translation or stability of the mRNA). Mutations

may also and more preferably will be in coding regions of the ion channel subunits (eg nucleotide mutations may give rise to an amino acid change in the encoded protein or nucleotide mutations that do not give rise to an amino acid change but may affect the stability of the mRNA).

Mutation combinations may be selected from, but are not restricted to, those identified in Table 1.

Accordingly in one aspect of the present invention there is provided a method of identifying a subject predisposed to a disorder associated with ion channel dysfunction, comprising ascertaining whether at least one of the genes encoding ion channel subunits in said subject has undergone a mutation event selected from the group consisting of the mutation events set forth in the following Table:

Subunit Gene	Exon/Intron	DNA Mutation
SCN1A	Exon 5	c664C→T
SCN1A	Exon 8	c1152G→A
SCN1A	Exon 9	c1183G→C
SCN1A	Exon 9	c1207T→C
SCN1A	Exon 9	c1237T→A
SCN1A	Exon 9	c1265T→A
SCN1A	Exon 21	c4219C→T
SCN1A	Exon 26	c5339T→C
SCN1A	Exon 26	c5674C→T
SCN1B	Exon 3	c254G→A
SCN2A	Exon 6A	c668G→A
SCN2A	Exon 16	c2674G→A
SCN2A	Exon 17	c3007C→A
SCN2A	Exon 19	c3598A→G
SCN2A	Exon 20	c3956G→A
SCN2A	Exon 12	c1785T→C
SCN2A	Exon 27	c4919T→A
SCN1A	Intron 9	IVS9-1G→A
SCN1A	Intron 23	IVS23+33G→A
SCN2A	Intron 7	IVS7+61T→A
SCN2A	Intron 19	IVS19-55A→G
SCN2A	Intron 22	IVS22-31A→G
SCN2A	Intron 2	IVS2-28G→A
SCN2A	Intron 8	IVS8-3T→C
SCN2A	Intron 11	IVS11+49A→G
SCN2A	Intron 11	IVS11-16C→T

- 14 -

SCN2A	Intron 17	IVS17-71C→T
SCN2A	Intron 17	IVS17-74delG
SCN2A	Intron 17	IVS17-74insG
CHRNA5	Exon 4	c400G→A
CHRNA2	Exon 4	c373G→A
CHRNA3	Exon 2	c110G→A
CHRNA2	Exon 4	c351C→T
CHRNA2	Exon 5	c771C→T
CHRNA3	Exon 2	c159A→G
CHRNA3	Exon 4	c291G→A
CHRNA3	Exon 4	c345G→A
CHRNA2	Intron 3	IVS3-16C→T
CHRNA3	Intron 3	IVS3-5T→C
CHRNA3	Intron 4	IVS4+8G→C
KCNQ2	Exon 1	c204-c205insC
KCNQ2	Exon 1	c1A→G
KCNQ2	Exon 1	c2T→C
KCNQ2	Exon 8	c1057C→G
KCNQ2	Exon 11	c1288C→T
KCNQ2	Exon 14	c1710A→T
KCNQ2	Exon 15	c1856T→G
KCNQ2	Intron 9	IVS9+(46-48)delCCT
KCNQ3	Intron 11	IVS11+43G→A
KCNQ3	Intron 12	IVS12+29G→A
GABRB1	Exon 5	c508C→T
GABRB1	Exon 9	c1329G→A
GABRB1	Exon 8	c975C→T
GABRG3	Exon 8	c995T→C
GABRA1	5' UTR	c-142A→G
GABRA1	5' UTR	c-31C→T
GABRA2	3' UTR	c1615G→A
GABRA5	5' UTR	c-271G→C
GABRA5	5' UTR	c-228A→G
GABRA5	5' UTR	c-149G→C
GABRB2	5' UTR	c-159C→T
GABRB2	3' UTR	c1749C→T
GABRPi	5' UTR	c-101C→T
GABRB1	Intron 1	IVS1+24T→G
GABRB1	Intron 6	IVS6+72T→G
GABRB1	Intron 7	IVS7-34A→G
GABRB3	Intron 1	IVS1-14C→T
GABRB3	Intron 7	IVS7+58delAA
GABRD	Intron 6	IVS6+132insC
GABRD	Intron 6	IVS6+130insC
GABRD	Intron 6	IVS6+73delCGCGCCACCGCCCTTCCGCG
GABRG3	Intron 8	IVS8-102C→T

In a further aspect there is provided a method of identifying a subject predisposed to a disorder associated with ion channel dysfunction, comprising ascertaining whether at least one of the genes encoding ion channel subunits in said subject has undergone a mutation event as set forth in one of SEQ ID Numbers: 1-72.

In another aspect of the present invention there is provided an isolated nucleic acid molecule encoding a mutant or variant ion channel subunit wherein a mutation event selected from the group consisting of the mutation events set forth in the following Table:

Subunit Gene	Exon/Intron	DNA Mutation
SCN1A	Exon 5	c664C→T
SCN1A	Exon 8	c1152G→A
SCN1A	Exon 9	c1183G→C
SCN1A	Exon 9	c1207T→C
SCN1A	Exon 9	c1237T→A
SCN1A	Exon 9	c1265T→A
SCN1A	Exon 21	c4219C→T
SCN1A	Exon 26	c5339T→C
SCN1A	Exon 26	c5674C→T
SCN1B	Exon 3	c254G→A
SCN2A	Exon 6A	c668G→A
SCN2A	Exon 16	c2674G→A
SCN2A	Exon 17	c3007C→A
SCN2A	Exon 19	c3598A→G
SCN2A	Exon 20	c3956G→A
SCN2A	Exon 12	c1785T→C
SCN2A	Exon 27	c4919T→A
SCN1A	Intron 9	IVS9-1G→A
SCN1A	Intron 23	IVS23+33G→A
SCN2A	Intron 7	IVS7+61T→A
SCN2A	Intron 19	IVS19-55A→G
SCN2A	Intron 22	IVS22-31A→G
SCN2A	Intron 2	IVS2-28G→A
SCN2A	Intron 8	IVS8-3T→C
SCN2A	Intron 11	IVS11+49A→G
SCN2A	Intron 11	IVS11-16C→T
SCN2A	Intron 17	IVS17-71C→T
SCN2A	Intron 17	IVS17-74delG
SCN2A	Intron 17	IVS17-74insG
CHRNA5	Exon 4	c400G→A
CHRNA2	Exon 4	c373G→A

- 16 -

CHRNA3	Exon 2	c110G→A
CHRNA2	Exon 4	c351C→T
CHRNA2	Exon 5	c771C→T
CHRNA3	Exon 2	c159A→G
CHRNA3	Exon 4	c291G→A
CHRNA3	Exon 4	c345G→A
CHRNA2	Intron 3	IVS3-16C→T
CHRNA3	Intron 3	IVS3-5T→C
CHRNA3	Intron 4	IVS4+8G→C
KCNQ2	Exon 1	c204-c205insC
KCNQ2	Exon 1	c1A→G
KCNQ2	Exon 1	c2T→C
KCNQ2	Exon 8	c1057C→G
KCNQ2	Exon 11	c1288C→T
KCNQ2	Exon 14	c1710A→T
KCNQ2	Exon 15	c1856T→G
KCNQ2	Intron 9	IVS9+(46-48)delCCT
KCNQ3	Intron 11	IVS11+43G→A
KCNQ3	Intron 12	IVS12+29G→A
GABRB1	Exon 5	c508C→T
GABRB1	Exon 9	c1329G→A
GABRB1	Exon 8	c975C→T
GABRG3	Exon 8	c995T→C
GABRA1	5' UTR	c-142A→G
GABRA1	5' UTR	c-31C→T
GABRA2	3' UTR	c1615G→A
GABRA5	5' UTR	c-271G→C
GABRA5	5' UTR	c-228A→G
GABRA5	5' UTR	c-149G→C
GABRB2	5' UTR	c-159C→T
GABRB2	3' UTR	c1749C→T
GABRPi	5' UTR	c-101C→T
GABRB1	Intron 1	IVS1+24T→G
GABRB1	Intron 6	IVS6+72T→G
GABRB1	Intron 7	IVS7-34A→G
GABRB3	Intron 1	IVS1-14C→T
GABRB3	Intron 7	IVS7+58delAA
GABRD	Intron 6	IVS6+132insC
GABRD	Intron 6	IVS6+130insC
GABRD	Intron 6	IVS6+73delCGCGCCACCGCCCTTCCGCG
GABRG3	Intron 8	IVS8-102C→T

has occurred.

In still another aspect of the present invention there is provided an isolated nucleic acid molecule encoding a mutant or variant ion channel subunit wherein a

mutation event has occurred as set forth in one of SEQ ID Numbers: 1-72.

The mutation event disrupts the functioning of an ion channel so as to produce a phenotype of epilepsy, and/or one or more other disorders associated with ion channel dysfunction, including but not restricted to, hyper- or hypo-kalemic periodic paralysis, myotonias, malignant hyperthermia, myasthenia, cardiac arrhythmias, episodic ataxia, migraine, Alzheimer's disease, Parkinson's disease, schizophrenia, hyperekplexia, anxiety, depression, phobic obsessive symptoms, neuropathic pain, inflammatory pain, chronic/acute pain, Bartter's syndrome, polycystic kidney disease, Dent's disease, hyperinsulinemic hypoglycemia of infancy, cystic fibrosis, congenital stationary night blindness and total colour-blindness, either alone or in combination with one or more additional mutations or variations in the ion channel subunit genes.

In another aspect of the present invention there is provided an isolated nucleic acid molecule encoding a mutant KCNQ2 subunit, wherein the mutation event has occurred in the C-terminal domain of the KCNQ2 subunit and leads to a disturbance in the calmodulin binding affinity of the subunit, so as to produce an epilepsy phenotype.

In one form of the invention, the mutations are in exon 8 or exon 15 of the KCNQ2 subunit and result in the replacement of an arginine residue with a glycine residue at amino acid position 353, or the replacement of a leucine residue with an arginine at amino acid position 619. The R353G mutation occurs as a result of a C to G nucleotide substitution at position 1057 of the KCNQ2 coding sequence as shown in SEQ ID NO: 44. The L619R mutation occurs as a result of a T to G nucleotide substitution at position 1856 of the KCNQ2 coding sequence as shown in SEQ ID NO: 47.

In a further form of the invention, the mutations are in exon 11 or exon 14 of the KCNQ2 subunit and result in

the replacement of an arginine residue with a stop codon at amino acid position 430, or the replacement of an arginine residue with a serine at amino acid position 570. The R430X mutation occurs as a result of a C to T nucleotide substitution at position 1288 of the KCNQ2 coding sequence as shown in SEQ ID NO: 45. The R570S mutation occurs as a result of an A to T nucleotide substitution at position 1710 of the KCNQ2 coding sequence as shown in SEQ ID NO: 46.

Preferably these mutations create a phenotype of benign familial neonatal seizures (BFNS).

In a further aspect of the present invention there is provided a combination of two or more isolated nucleic acid molecules each having a novel mutation event as laid out in Table 1. The cumulative effect of the mutations in each isolated nucleic acid molecule *in vivo* is to produce an epilepsy or another disorder associated with ion channel dysfunction as described above in said mammal.

In a particularly preferred embodiment of the present invention, the isolated nucleic acid molecules have a nucleotide sequence as shown in any one of SEQ ID Numbers: 1-72. The sequences correspond to the novel DNA mutations or variants laid out in Table 1.

In another aspect of the present invention there is provided an isolated nucleic acid molecule comprising any one of the nucleotide sequences set forth in SEQ ID Numbers: 1-72.

In another aspect of the present invention there is provided an isolated nucleic acid molecule consisting of any one of the nucleotide sequences set forth in SEQ ID Numbers: 1-72.

The nucleotide sequences of the present invention can be engineered using methods accepted in the art for a variety of purposes. These include, but are not limited to, modification of the cloning, processing, and/or expression of the gene product. PCR reassembly of gene fragments and the use of synthetic oligonucleotides allow

the engineering of the nucleotide sequences of the present invention. For example, oligonucleotide-mediated site-directed mutagenesis can introduce further mutations that create new restriction sites, alter expression patterns and produce splice variants etc.

As a result of the degeneracy of the genetic code, a number of polynucleotide sequences, some that may have minimal similarity to the polynucleotide sequences of any known and naturally occurring gene, may be produced. Thus, the invention includes each and every possible variation of a polynucleotide sequence that could be made by selecting combinations based on possible codon choices. These combinations are made in accordance with the standard triplet genetic code as applied to the polynucleotide sequences of the present invention, and all such variations are to be considered as being specifically disclosed.

The nucleic acid molecules of this invention are typically DNA molecules, and include cDNA, genomic DNA, synthetic forms, and mixed polymers, both sense and antisense strands, and may be chemically or biochemically modified, or may contain non-natural or derivatised nucleotide bases as will be appreciated by those skilled in the art. Such modifications include labels, methylation, intercalators, alkylators and modified linkages. In some instances it may be advantageous to produce nucleotide sequences possessing a substantially different codon usage than that of the polynucleotide sequences of the present invention. For example, codons may be selected to increase the rate of expression of the peptide in a particular prokaryotic or eukaryotic host corresponding with the frequency that particular codons are utilized by the host. Other reasons to alter the nucleotide sequence without altering the encoded amino acid sequences include the production of RNA transcripts having more desirable properties, such as a greater half-

life, than transcripts produced from the naturally occurring mutated sequence.

The invention also encompasses production of nucleic acid sequences of the present invention entirely by synthetic chemistry. Synthetic sequences may be inserted into expression vectors and cell systems that contain the necessary elements for transcriptional and translational control of the inserted coding sequence in a suitable host. These elements may include regulatory sequences, promoters, 5' and 3' untranslated regions and specific initiation signals (such as an ATG initiation codon and Kozak consensus sequence) which allow more efficient translation of sequences encoding the polypeptides of the present invention. In cases where the complete coding sequence, including the initiation codon and upstream regulatory sequences, are inserted into the appropriate expression vector, additional control signals may not be needed. However, in cases where only coding sequence, or a fragment thereof, is inserted, exogenous translational control signals as described above should be provided by the vector. Such signals may be of various origins, both natural and synthetic. The efficiency of expression may be enhanced by the inclusion of enhancers appropriate for the particular host cell system used (Scharf et al., 1994).

The invention also includes nucleic acid molecules that are the complements of the sequences described herein.

The present invention allows for the preparation of purified polypeptide or protein from the polynucleotides of the present invention, or variants thereof. In order to do this, host cells may be transformed with a novel nucleic acid molecule as described above, or with nucleic acid molecules encoding two or more mutant ion channel subunits. If the mutant subunits form a part of the same ion channel a receptor protein containing two or more mutant subunits may be isolated. If the mutant subunits are subunits of different ion channels the host cells will

express two or more mutant receptor proteins. Typically said host cells are transfected with an expression vector comprising a DNA molecule according to the invention or, in particular, DNA molecules encoding two or more mutant ion channel subunits. A variety of expression vector/host systems may be utilized to contain and express sequences encoding polypeptides of the invention. These include, but are not limited to, microorganisms such as bacteria transformed with plasmid or cosmid DNA expression vectors; yeast transformed with yeast expression vectors; insect cell systems infected with viral expression vectors (e.g., baculovirus); or mouse or other animal or human tissue cell systems. Mammalian cells can also be used to express a protein using a vaccinia virus expression system. The invention is not limited by the host cell or vector employed.

The polynucleotide sequences, or variants thereof, of the present invention can be stably expressed in cell lines to allow long term production of recombinant proteins in mammalian systems. Sequences encoding the polypeptides of the present invention can be transformed into cell lines using expression vectors which may contain viral origins of replication and/or endogenous expression elements and a selectable marker gene on the same or on a separate vector. The selectable marker confers resistance to a selective agent, and its presence allows growth and recovery of cells which successfully express the introduced sequences. Resistant clones of stably transformed cells may be propagated using tissue culture techniques appropriate to the cell type.

The protein produced by a transformed cell may be secreted or retained intracellularly depending on the sequence and/or the vector used. As will be understood by those of skill in the art, expression vectors containing polynucleotides which encode a protein may be designed to contain signal sequences which direct secretion of the protein through a prokaryotic or eukaryotic cell membrane.

In addition, a host cell strain may be chosen for its ability to modulate expression of the inserted sequences or to process the expressed protein in the desired fashion. Such modifications of the polypeptide include, but are not limited to, acetylation, glycosylation, phosphorylation, and acylation. Post-translational cleavage of a "prepro" form of the protein may also be used to specify protein targeting, folding, and/or activity. Different host cells having specific cellular machinery and characteristic mechanisms for post-translational activities (e.g., CHO or HeLa cells), are available from the American Type Culture Collection (ATCC) and may be chosen to ensure the correct modification and processing of the foreign protein.

When large quantities of the protein product of the gene are needed, such as for antibody production, vectors which direct high levels of expression of this protein may be used, such as those containing the T5 or T7 inducible bacteriophage promoter. The present invention also includes the use of the expression systems described above in generating and isolating fusion proteins which contain important functional domains of the protein. These fusion proteins are used for binding, structural and functional studies as well as for the generation of appropriate antibodies.

In order to express and purify the protein as a fusion protein, the appropriate cDNA sequence is inserted into a vector which contains a nucleotide sequence encoding another peptide (for example, glutathionine succinyl transferase). The fusion protein is expressed and recovered from prokaryotic or eukaryotic cells. The fusion protein can then be purified by affinity chromatography based upon the fusion vector sequence. The desired protein is then obtained by enzymatic cleavage of the fusion protein.

Fragments of the polypeptides of the present invention may also be produced by direct peptide synthesis

using solid-phase techniques. Automated synthesis may be achieved by using the ABI 431A Peptide Synthesizer (Perkin-Elmer). Various fragments of this protein may be synthesized separately and then combined to produce the full-length molecule.

The present invention is also concerned with polypeptides having a biological function as an ion channel in a mammal, wherein a mutation event selected from the group consisting of substitutions, deletions, truncations, insertions and rearrangements has occurred so as to affect the functioning of the ion channel. In some instances this single mutation alone will produce an epilepsy phenotype or other neuro/physiological disorders associated with ion channel dysfunction.

In the case where a single mutation alone does not produce, say, an epilepsy phenotype, there would be provided one or more additional isolated mammalian polypeptides having biological functions as part of an ion channel in a mammal, wherein a mutation event selected from the group consisting of substitutions, deletions, truncations, insertions and rearrangements has occurred so as to affect the functioning of the ion channel. The cumulative effect of the mutations in each isolated mammalian polypeptide *in vivo* being to produce epilepsy or another neuro/physiological disorder in said mammal. The mutations may be in polypeptide subunits belonging to the same ion channel as described above, but may also be in polypeptide subunits that belong to different ion channels.

Typically the mutation is an amino acid substitution and the ion channel is a voltage-gated channel such as a sodium, potassium, calcium or chloride channel or a ligand-gated channel such as a member of the nAChR/GABA super family of receptors, or a functional fragment or homologue thereof.

Mutation combinations may be selected from, but are not restricted to, those represented in Table 1.

- 24 -

Accordingly, in a further aspect of the present invention there is provided an isolated polypeptide, said polypeptide being a mutant or variant ion channel subunit wherein a mutation event selected from the group
 5 consisting of the mutation events set forth in the following Table:

Subunit Gene	Amino Acid Change
SCN1A	R222X
SCN1A	W384X
SCN1A	A395P
SCN1A	F403L
SCN1A	Y413N
SCN1A	V422E
SCN1A	R1407X
SCN1A	M1780T
SCN1A	R1892X
SCN1B	R85H
SCN2A	R223Q
SCN2A	V892I
SCN2A	L1003I
SCN2A	T1200A
SCN2A	R1319Q
CHRNA5	V134I
CHRNA2	A125T
CHRNA3	R37H
KCNQ2	K69fsX119
KCNQ2	M1V
KCNQ2	M1T
KCNQ2	R353G
KCNQ2	R430X
KCNQ2	R570S
KCNQ2	L619R

has occurred.

In a further aspect of the invention there is provided an isolated polypeptide, said polypeptide being a
 10 mutant or variant ion channel subunit wherein a mutation event has occurred such that the polypeptide has the amino acid sequence set forth in one of SEQ ID Numbers: 73-95. The mutation event disrupts the functioning of an ion channel so as to produce a phenotype of epilepsy, and/or
 15 one or more other disorders associated with ion channel dysfunction, including but not restricted to, hyper- or hypo-kalemic periodic paralysis, myotonias, malignant hyperthermia, myasthenia, cardiac arrhythmias, episodic

ataxia, migraine, Alzheimer's disease, Parkinson's disease, schizophrenia, hyperekplexia, anxiety, depression, phobic obsessive symptoms, neuropathic pain, inflammatory pain, chronic/acute pain, Bartter's syndrome, polycystic kidney disease, Dent's disease, hyperinsulinemic hypoglycemia of infancy, cystic fibrosis, congenital stationary night blindness and total colour-blindness.

In a particularly preferred embodiment of the present invention, the isolated polypeptide has an amino acid sequence as shown in any one of SEQ ID Numbers: 73-95. The sequences correspond to the novel amino acid changes laid out in Table 1 for those instances where the DNA mutation results in an amino acid change.

According to still another aspect of the present invention there is provided an isolated polypeptide, said polypeptide being a mutant KCNQ2 subunit, wherein the mutation event has occurred in the C-terminal domain of the KCNQ2 subunit and leads to a disturbance in the calmodulin binding affinity of the subunit, so as to produce an epilepsy phenotype.

In one form of the invention the mutations are substitutions in which an arginine residue is replaced with a glycine residue, or a leucine residue is replaced with an arginine. Preferably the substitutions are R353G and L619R transitions as illustrated by SEQ ID NOS: 92 and 95 respectively.

In a further form of the invention the mutations result in the replacement of an arginine for a stop codon, or an arginine is replaced with a serine. Preferably the mutations are R430X and R570S transitions as illustrated by SEQ ID NOS: 93 and 94 respectively.

In a still further aspect of the present invention there is provided a combination of two or more isolated polypeptides each having a novel mutation event as laid out in Table 1. The cumulative effect of the mutations in each isolated polypeptide molecule *in vivo* is to produce

an epilepsy or another disorder associated with ion channel dysfunction as described above in said mammal.

5 In a particularly preferred embodiment of the present invention, the isolated polypeptides have an amino acid sequence as shown in any one of SEQ ID Numbers: 73-95. The sequences correspond to the novel amino acid changes laid out in Table 1.

10 According to still another aspect of the present invention there is provided an isolated polypeptide comprising the amino acid sequence set forth in any one of SEQ ID Numbers: 73-95.

15 According to still another aspect of the present invention there is provided a polypeptide consisting of the amino acid sequence set forth in any one of SEQ ID Numbers: 73-95.

According to still another aspect of the present invention there is provided a method of preparing a polypeptide, comprising the steps of:

- 20 (1) culturing host cells transfected with an expression vector comprising a nucleic acid molecule as described above under conditions effective for polypeptide production; and
(2) harvesting the mutant ion channel subunit.

25 The mutant ion channel subunit may be allowed to assemble with other subunits constituting the channel that are either wild-type or themselves mutant subunits, whereby the assembled ion channel is harvested.

30 According to still another aspect of the invention there is provided a polypeptide which is the product of the process described above.

35 Substantially purified protein or fragments thereof can then be used in further biochemical analyses to establish secondary and tertiary structure. Such methodology is known in the art and includes, but is not restricted to, X-ray crystallography of crystals of the proteins or of the assembled ion channel incorporating the proteins or by nuclear magnetic resonance (NMR).

- 27 -

Determination of structure allows for the rational design of pharmaceuticals to interact with the ion channel as a whole or through interaction with a specific subunit protein (see drug screening below), alter the overall ion channel protein charge configuration or charge interaction with other proteins, or to alter its function in the cell.

It will be appreciated that the mutant ion channel subunits included as part of the present invention will be useful in further applications which include a variety of hybridisation and immunological assays to screen for and detect the presence of either a normal or mutated gene or gene product. The invention enables therapeutic methods for the treatment of epilepsy as well as other disorders associated with ion channel dysfunction and also enables methods for the diagnosis or prognosis of epilepsy as well as other disorders associated with ion channel dysfunction.

Therapeutic Applications

According to still another aspect of the invention there is provided a method of treating epilepsy as well as other disorders associated with ion channel dysfunction, including but not restricted to, hyper- or hypo-kalemic periodic paralysis, myotonias, malignant hyperthermia, myasthenia, cardiac arrhythmias, episodic ataxia, migraine, Alzheimer's disease, Parkinson's disease, schizophrenia, hyperekplexia, anxiety, depression, phobic obsessive symptoms, neuropathic pain, inflammatory pain, chronic/acute pain, Bartter's syndrome, polycystic kidney disease, Dent's disease, hyperinsulinemic hypoglycemia of infancy, cystic fibrosis, congenital stationary night blindness or total colour-blindness, comprising administering a selective antagonist, agonist or modulator of an ion channel or ion channel subunit, when the ion channel contains a mutation in a subunit comprising the channel, as described above, to a subject in need of such treatment. Said mutation event may be causative of the

disorder when expressed alone or when expressed in combination with one or more additional mutations in subunits of the same or different ion channels, which are typically those identified in Table 1.

5 In still another aspect of the invention there is provided the use of a selective antagonist, agonist or modulator of an ion channel or ion channel subunit when the ion channel contains a mutation in a subunit comprising the channel, as described above, said mutation
10 being causative of epilepsy as well as other disorders associated with ion channel dysfunction, including but not restricted to, hyper- or hypo-kalemic periodic paralysis, myotonias, malignant hyperthermia, myasthenia, cardiac arrhythmias, episodic ataxia, migraine, Alzheimer's
15 disease, Parkinson's disease, schizophrenia, hyperekplexia, anxiety, depression, phobic obsessive symptoms, neuropathic pain, inflammatory pain, chronic/acute pain, Bartter's syndrome, polycystic kidney disease, Dent's disease, hyperinsulinemic hypoglycemia of
20 infancy, cystic fibrosis, congenital stationary night blindness or total colour-blindness, when expressed alone or when expressed in combination with a second mutation in a subunit of the same or different ion channel, as described above, in the manufacture of a medicament for
25 the treatment of the disorder.

In one aspect, a suitable antagonist, agonist or modulator will restore wild-type function to the ion channel or channels containing the mutations of the present invention, or will negate the effects the mutant
30 channel or channels have on cell function.

Using methods well known in the art, a mutant ion channel may be used to produce antibodies specific for the mutant channel that is causative of the disease or to screen libraries of pharmaceutical agents to identify
35 those that bind the mutant ion channel.

In one aspect, an antibody, which specifically binds to a mutant ion channel or mutant ion channel subunit of

the invention, may be used directly as an agonist, antagonist or modulator, or indirectly as a targeting or delivery mechanism for bringing a pharmaceutical agent to cells or tissues that express the mutant ion channel.

5 In a still further aspect of the invention there is provided an antibody which is immunologically reactive with a polypeptide as described above, but not with a wild-type ion channel or ion channel subunit thereof.

10 In particular, there is provided an antibody to an assembled ion channel containing a mutation in a subunit comprising the channel, which is causative of epilepsy or another disorder associated with ion channel dysfunction when expressed alone or when expressed in combination with one or more other mutations in subunits of the same or
15 different ion channels. Such antibodies may include, but are not limited to, polyclonal, monoclonal, chimeric, and single chain antibodies as would be understood by the person skilled in the art.

20 For the production of antibodies, various hosts including rabbits, rats, goats, mice, humans, and others may be immunized by injection with a polypeptide as described above or with any fragment or oligopeptide thereof which has immunogenic properties. Various adjuvants may be used to increase immunological response
25 and include, but are not limited to, Freund's, mineral gels such as aluminium hydroxide, and surface-active substances such as lysolecithin. Adjuvants used in humans include BCG (bacilli Calmette-Guerin) and Corynebacterium parvum.

30 It is preferred that the oligopeptides, peptides, or fragments used to induce antibodies to the mutant ion channel have an amino acid sequence consisting of at least 5 amino acids, and, more preferably, of at least 10 amino acids. It is also preferable that these oligopeptides,
35 peptides, or fragments are identical to a portion of the amino acid sequence of the natural protein and contain the entire amino acid sequence of a small, naturally occurring

molecule. Short stretches of ion channel amino acids may be fused with those of another protein, such as K_LH, and antibodies to the chimeric molecule may be produced.

Monoclonal antibodies to a mutant ion channel may be prepared using any technique which provides for the production of antibody molecules by continuous cell lines in culture. These include, but are not limited to, the hybridoma technique, the human B-cell hybridoma technique, and the EBV-hybridoma technique. (For example, see Kohler et al., 1975; Kozbor et al., 1985; Cote et al., 1983; Cole et al., 1984).

Monoclonal antibodies produced may include, but are not limited to, mouse-derived antibodies, humanised antibodies and fully human antibodies.

Antibodies may also be produced by inducing *in vivo* production in the lymphocyte population or by screening immunoglobulin libraries or panels of highly specific binding reagents as disclosed in the literature. (For example, see Orlandi et al., 1989; Winter and Milstein, 1991).

Antibody fragments which contain specific binding sites for a mutant ion channel may also be generated. For example, such fragments include, F(ab')₂ fragments produced by pepsin digestion of the antibody molecule and Fab fragments generated by reducing the disulfide bridges of the F(ab')₂ fragments. Alternatively, Fab expression libraries may be constructed to allow rapid and easy identification of monoclonal Fab fragments with the desired specificity. (For example, see Huse et al., 1989).

Various immunoassays may be used for screening to identify antibodies having the desired specificity. Numerous protocols for competitive binding or immunoradiometric assays using either polyclonal or monoclonal antibodies with established specificities are well known in the art. Such immunoassays typically involve the measurement of complex formation between an ion channel and its specific antibody. A two-site, monoclonal-

based immunoassay utilizing antibodies reactive to two non-interfering ion channel epitopes is preferred, but a competitive binding assay may also be employed.

In a further aspect of the invention there is provided a method of treating epilepsy as well as other disorders associated with ion channel dysfunction, including but not restricted to, hyper- or hypo-kalemic periodic paralysis, myotonias, malignant hyperthermia, myasthenia, cardiac arrhythmias, episodic ataxia, migraine, Alzheimer's disease, Parkinson's disease, schizophrenia, hyperekplexia, anxiety, depression, phobic obsessive symptoms, neuropathic pain, inflammatory pain, chronic/acute pain, Bartter's syndrome, polycystic kidney disease, Dent's disease, hyperinsulinemic hypoglycemia of infancy, cystic fibrosis, congenital stationary night blindness or total colour-blindness, comprising administering an isolated nucleic acid molecule which is the complement (antisense) of any one of the nucleic acid molecules described above and which encodes an RNA molecule that hybridizes with the mRNA encoding a mutant ion channel subunit of the invention, to a subject in need of such treatment.

In a still further aspect of the invention there is provided the use of an isolated nucleic acid molecule which is the complement (antisense) of a nucleic acid molecule of the invention and which encodes an RNA molecule that hybridizes with the mRNA encoding a mutant ion channel subunit of the invention, in the manufacture of a medicament for the treatment of epilepsy as well as other disorders associated with ion channel dysfunction, including but not restricted to, hyper- or hypo-kalemic periodic paralysis, myotonias, malignant hyperthermia, myasthenia, cardiac arrhythmias, episodic ataxia, migraine, Alzheimer's disease, Parkinson's disease, schizophrenia, hyperekplexia, anxiety, depression, phobic obsessive symptoms, neuropathic pain, inflammatory pain, chronic/acute pain, Bartter's syndrome, polycystic kidney

disease, Dent's disease, hyperinsulinemic hypoglycemia of infancy, cystic fibrosis, congenital stationary night blindness or total colour-blindness.

Typically, a vector expressing the complement
5 (antisense) of the polynucleotides of the invention may be administered to a subject in need of such treatment. Many methods for introducing vectors into cells or tissues are available and equally suitable for use *in vivo*, *in vitro*, and *ex vivo*. For *ex vivo* therapy, vectors may be
10 introduced into stem cells taken from the patient and clonally propagated for autologous transplant back into that same patient. Delivery by transfection, by liposome injections, or by polycationic amino polymers may be achieved using methods which are well known in the art.
15 (For example, see Goldman et al., 1997).

Additional antisense or gene-targeted silencing strategies may include, but are not limited to, the use of antisense oligonucleotides, injection of antisense RNA, transfection of antisense RNA expression vectors, and the
20 use of RNA interference (RNAi) or short interfering RNAs (siRNA). Still further, catalytic nucleic acid molecules such as DNazymes and ribozymes may be used for gene silencing (Breaker and Joyce, 1994; Haseloff and Gerlach, 1988). These molecules function by cleaving their target
25 mRNA molecule rather than merely binding to it as in traditional antisense approaches.

In a further aspect, a suitable agonist, antagonist or modulator may include peptides, phosphopeptides or small organic or inorganic compounds that can restore
30 wild-type activity of ion channels containing mutations in the subunits which comprise the channels as described above.

Peptides, phosphopeptides or small organic or inorganic compounds suitable for therapeutic applications
35 may be identified using nucleic acids and peptides of the invention in drug screening applications as described below. Molecules identified from these screens may also be

of therapeutic application in affected individuals carrying other ion channel subunit gene mutations if the molecule is able to correct the common underlying functional deficit imposed by these mutations and those of the invention.

There is therefore provided a method of treating epilepsy as well as other disorders associated with ion channel dysfunction comprising administering a compound that is a suitable agonist, antagonist or modulator of an ion channel and that has been identified using the mutant ion channel subunits of the invention.

In some instances, an appropriate approach for treatment may be combination therapy. This may involve the administering an antibody or complement (antisense) to a mutant ion channel or ion channel subunit of the invention to inhibit its functional effect, combined with administration of wild-type ion channel subunits which may restore levels of wild-type ion channel formation to normal levels. Wild-type ion channel subunits of the invention can be administered using gene therapy approaches as described above for complement administration.

There is therefore provided a method of treating epilepsy as well as other disorders associated with ion channel dysfunction comprising administration of an antibody or complement to a mutant ion channel or ion channel subunit of the invention in combination with administration of wild-type ion channel subunits.

In still another aspect of the invention there is provided the use of an antibody or complement to a mutant ion channel or ion channel subunit of the invention in combination with the use of wild-type ion channel subunits, in the manufacture of a medicament for the treatment of epilepsy as well as other disorders associated with ion channel dysfunction.

In further embodiments, any of the agonists, antagonists, modulators, antibodies, complementary

sequences or vectors of the invention may be administered in combination with other appropriate therapeutic agents. Selection of the appropriate agents may be made by those skilled in the art, according to conventional pharmaceutical principles. The combination of therapeutic agents may act synergistically to effect the treatment or prevention of the various disorders described above. Using this approach, therapeutic efficacy with lower dosages of each agent may be possible, thus reducing the potential for adverse side effects.

Any of the therapeutic methods described above may be applied to any subject in need of such therapy, including, for example, mammals such as dogs, cats, cows, horses, rabbits, monkeys, and most preferably, humans.

Drug Screening

According to still another aspect of the invention, nucleic acid molecules of the invention as well as peptides of the invention, particularly purified mutant ion channel subunit polypeptide and cells expressing these, are useful for the screening of candidate pharmaceutical agents for the treatment of epilepsy as well as other as other disorders associated with ion channel dysfunction, including but not restricted to, hyper- or hypo-kalemic periodic paralysis, myotonias, malignant hyperthermia, myasthenia, cardiac arrhythmias, episodic ataxia, migraine, Alzheimer's disease, Parkinson's disease, schizophrenia, hyperekplexia, anxiety, depression, phobic obsessive symptoms, neuropathic pain, inflammatory pain, chronic/acute pain, Bartter's syndrome, polycystic kidney disease, Dent's disease, hyperinsulinemic hypoglycemia of infancy, cystic fibrosis, congenital stationary night blindness or total colour-blindness.

Still further, it provides the use of a polypeptide complex for the screening of candidate pharmaceutical compounds.

Still further, it provides the use wherein high throughput screening techniques are employed.

Compounds that can be screened in accordance with the invention include, but are not limited to peptides (such as soluble peptides), phosphopeptides and small organic or inorganic molecules (such as natural product or synthetic chemical libraries and peptidomimetics).

In one embodiment, a screening assay may include a cell-based assay utilising eukaryotic or prokaryotic host cells that are stably transformed with recombinant molecules expressing the polypeptides or fragments of the invention, in competitive binding assays. Binding assays will measure the formation of complexes between a specific mutant ion channel subunit polypeptide or ion channel incorporating a mutant ion channel subunit polypeptide, and the compound being tested, or will measure the degree to which a compound being tested will inhibit or restore the formation of a complex between a specific mutant ion channel subunit polypeptide or ion channel incorporating a mutant ion channel subunit polypeptide, and its interactor or ligand.

The invention is particularly useful for screening compounds by using the polypeptides of the invention in transformed cells, transfected or injected oocytes, or animal models bearing mutated ion channel subunits such as transgenic animals or gene targeted (knock-in) animals (see transformed hosts). Drug candidates can be added to cultured cells that express a single mutant ion channel subunit or combination of mutant ion channel subunits (appropriate wild-type ion channel subunits should also be expressed for receptor assembly), can be added to oocytes transfected or injected with either a mutant ion channel subunit or combination of mutant ion channel subunits (appropriate wild-type ion channel subunits must also be injected for receptor assembly), or can be administered to an animal model containing a mutant ion channel or combination of mutant ion channels. Determining the

ability of the test compound to modulate mutant ion channel activity can be accomplished by a number of techniques known in the art. These include for example measuring the effect on the current of the channel (e.g. calcium-, chloride-, sodium-, potassium-ion flux) as compared to the current of a cell or animal containing wild-type ion channels. Current in cells can be measured by a number of approaches including the patch-clamp technique (methods described in Hamill et al, 1981) or using fluorescence based assays as are known in the art (see Gonzalez et al. 1999). Drug candidates that alter the current to a more normal level are useful for treating or preventing epilepsy as well as other disorders associated with ion channel dysfunction.

Non cell-based assays may also be used for identifying compounds that can inhibit or restore binding between the polypeptides of the invention or ion channels incorporating the polypeptides of the invention, and their interactors. Such assays are known in the art and include for example AlphaScreen technology (PerkinElmer Life Sciences, MA, USA). This application relies on the use of beads such that each interaction partner is bound to a separate bead via an antibody. Interaction of each partner will bring the beads into proximity, such that laser excitation initiates a number of chemical reactions ultimately leading to fluorophores emitting a light signal. Candidate compounds that inhibit the binding of the mutant ion channel subunit, or ion channel incorporating the mutant subunit, with its interactor will result in loss of light emission, while candidate compounds that restore the binding of the mutant ion channel subunit, or ion channel incorporating the mutant subunit, with its interactor will result in positive light emission. These assays ultimately enable identification and isolation of the candidate compounds.

High-throughput drug screening techniques may also employ methods as described in WO84/03564. Small peptide

test compounds synthesised on a solid substrate can be assayed for mutant ion channel subunit polypeptide or mutant ion channel binding. Bound mutant ion channel or mutant ion channel subunit polypeptide is then detected by methods well known in the art. In a variation of this technique, purified polypeptides of the invention can be coated directly onto plates to identify interacting test compounds.

The invention also contemplates the use of competition drug screening assays in which neutralizing antibodies capable of specifically binding the mutant ion channel compete with a test compound for binding thereto. In this manner, the antibodies can be used to detect the presence of any peptide that shares one or more antigenic determinants of the mutant ion channel.

The polypeptides of the present invention may also be used for screening compounds developed as a result of combinatorial library technology. This provides a way to test a large number of different substances for their ability to modulate activity of a polypeptide. A substance identified as a modulator of polypeptide function may be peptide or non-peptide in nature. Non-peptide "small molecules" are often preferred for many *in vivo* pharmaceutical applications. In addition, a mimic or mimetic of the substance may be designed for pharmaceutical use. The design of mimetics based on a known pharmaceutically active compound ("lead" compound) is a common approach to the development of novel pharmaceuticals. This is often desirable where the original active compound is difficult or expensive to synthesise or where it provides an unsuitable method of administration. In the design of a mimetic, particular parts of the original active compound that are important in determining the target property are identified. These parts or residues constituting the active region of the compound are known as its pharmacophore. Once found, the pharmacophore structure is modelled according to its

physical properties using data from a range of sources including x-ray diffraction data and NMR. A template molecule is then selected onto which chemical groups which mimic the pharmacophore can be added. The selection can be made such that the mimetic is easy to synthesise, is likely to be pharmacologically acceptable, does not degrade *in vivo* and retains the biological activity of the lead compound. Further optimisation or modification can be carried out to select one or more final mimetics useful for *in vivo* or clinical testing.

It is also possible to isolate a target-specific antibody and then solve its crystal structure. In principle, this approach yields a pharmacophore upon which subsequent drug design can be based as described above. It may be possible to avoid protein crystallography altogether by generating anti-idiotypic antibodies (anti-ids) to a functional, pharmacologically active antibody. As a mirror image of a mirror image, the binding site of the anti-ids would be expected to be an analogue of the original receptor. The anti-id could then be used to isolate peptides from chemically or biologically produced peptide banks.

Another alternative method for drug screening relies on structure-based rational drug design. Determination of the three dimensional structure of the polypeptides of the invention, or the three dimensional structure of the ion channels which incorporate these polypeptides allows for structure-based drug design to identify biologically active lead compounds.

Three dimensional structural models can be generated by a number of applications, some of which include experimental models such as x-ray crystallography and NMR and/or from *in silico* studies of structural databases such as the Protein Databank (PDB). In addition, three dimensional structural models can be determined using a number of known protein structure prediction techniques based on the primary sequences of the polypeptides (e.g.

SYBYL - Tripos Associated, St. Louis, MO), *de novo* protein structure design programs (e.g. MODELER - MSI Inc., San Diego, CA, or MOE - Chemical Computing Group, Montreal, Canada) or *ab initio* methods (e.g. see US Patent Numbers 5 5331573 and 5579250).

Once the three dimensional structure of a polypeptide or polypeptide complex has been determined, structure-based drug discovery techniques can be employed to design biologically-active compounds based on these three dimensional structures. Such techniques are known in the art and include examples such as DOCK (University of California, San Francisco) or AUTODOCK (Scripps Research Institute, La Jolla, California). A computational docking protocol will identify the active site or sites that are deemed important for protein activity based on a predicted protein model. Molecular databases, such as the Available Chemicals Directory (ACD) are then screened for molecules that complement the protein model.

Using methods such as these, potential clinical drug candidates can be identified and computationally ranked in order to reduce the time and expense associated with typical 'wet lab' drug screening methodologies.

Compounds identified through screening procedures as described above, and which are based on the use of the mutant nucleic acid and polypeptides of the invention, can also be tested for their effect on correcting the functional deficit imposed by other gene mutations in affected individuals including other ion channel subunit mutations.

Such compounds form a part of the present invention, as do pharmaceutical compositions containing these and a pharmaceutically acceptable carrier.

Pharmaceutical Preparations

Compounds identified from screening assays and shown to restore ion channel wild-type activity can be administered to a patient at a therapeutically effective

dose to treat or ameliorate epilepsy as well as other disorders associated with ion channel dysfunction, as described above. A therapeutically effective dose refers to that amount of the compound sufficient to result in
5 amelioration of symptoms of the disorder.

Toxicity and therapeutic efficacy of such compounds can be determined by standard pharmaceutical procedures in cell cultures or experimental animals. The data obtained from these studies can then be used in the formulation of
10 a range of dosages for use in humans.

Pharmaceutical compositions for use in accordance with the present invention can be formulated in a conventional manner using one or more physiological acceptable carriers, excipients or stabilisers which are
15 well known. Acceptable carriers, excipients or stabilizers are non-toxic at the dosages and concentrations employed, and include buffers such as phosphate, citrate, and other organic acids; antioxidants including ascorbic acid; low molecular weight (less than about 10 residues)
20 polypeptides; proteins, such as serum albumin, gelatin, or immunoglobulins; binding agents including hydrophilic polymers such as polyvinylpyrrolidone; amino acids such as glycine, glutamine, asparagine, arginine or lysine; monosaccharides, disaccharides, and other carbohydrates
25 including glucose, mannose, or dextrans; chelating agents such as EDTA; sugar alcohols such as mannitol or sorbitol; salt-forming counterions such as sodium; and/or non-ionic surfactants such as Tween, Pluronic or polyethylene glycol (PEG).

30 The formulation of pharmaceutical compositions for use in accordance with the present invention will be based on the proposed route of administration. Routes of administration may include, but are not limited to, inhalation, insufflation (either through the mouth or
35 nose), oral, buccal, rectal or parental administration.

Diagnostic and Prognostic Applications

Polynucleotide sequences encoding an ion channel subunit may be used for the diagnosis or prognosis of epilepsy, as well as other disorders associated with ion channel dysfunction, including but not restricted to, hyper- or hypo-kalemic periodic paralysis, myotonias, malignant hyperthermia, myasthenia, cardiac arrhythmias, episodic ataxia, migraine, Alzheimer's disease, Parkinson's disease, schizophrenia, hyperekplexia, anxiety, depression, phobic obsessive symptoms, neuropathic pain, inflammatory pain, chronic/acute pain, Bartter's syndrome, polycystic kidney disease, Dent's disease, hyperinsulinemic hypoglycemia of infancy, cystic fibrosis, congenital stationary night blindness or total colour-blindness, and the use of the nucleic acid molecules incorporated as part of the invention in diagnosis or prognosis of these disorders, or a predisposition to these disorders, is therefore contemplated. The nucleic acid molecules incorporating the novel mutation events laid out in Table 1 may be used for this purpose.

The polynucleotides that may be used for diagnostic or prognostic purposes include oligonucleotide sequences, genomic DNA and complementary RNA and DNA molecules. The polynucleotides may be used to detect and quantitate gene expression in biological samples. Genomic DNA used for the diagnosis or prognosis may be obtained from body cells, such as those present in the blood, tissue biopsy, surgical specimen, or autopsy material. The DNA may be isolated and used directly for detection of a specific sequence or may be amplified by the polymerase chain reaction (PCR) prior to analysis. Similarly, RNA or cDNA may also be used, with or without PCR amplification. To detect a specific nucleic acid sequence, hybridisation using specific oligonucleotides, restriction enzyme digest and mapping, PCR mapping, RNase protection, and various other methods may be employed. Oligonucleotides specific

to particular sequences can be chemically synthesized and labelled radioactively or nonradioactively and hybridised to individual samples immobilized on membranes or other solid-supports or in solution. The presence, absence or
5 excess expression of any one of the mutant ion channel genes of the invention may then be visualized using methods such as autoradiography, fluorometry, or colorimetry.

In a further diagnostic or prognostic approach, the
10 nucleotide sequences of the invention may be useful in assays that detect the presence of associated disorders, particularly those mentioned previously. The nucleotide sequences may be labelled by standard methods and added to a fluid or tissue sample from a patient under conditions
15 suitable for the formation of hybridisation complexes. After a suitable incubation period, the sample is washed and the signal is quantitated and compared with a standard value. If the amount of signal in the patient sample is significantly altered in comparison to a control sample
20 then the presence of altered levels of nucleotide sequences in the sample indicates the presence of the associated disorder. Such assays may also be used to evaluate the efficacy of a particular therapeutic treatment regimen in animal studies, in clinical trials,
25 or to monitor the treatment of an individual patient.

In order to provide a basis for the diagnosis or prognosis of epilepsy and other disorders as described above, which are associated with the ion channel subunit mutations or variants of the invention, the nucleotide
30 sequence of each gene can be compared between normal tissue and diseased tissue in order to establish whether the patient expresses a mutant gene.

In order to provide a basis for the diagnosis or prognosis of a disorder associated with abnormal
35 expression of an ion channel subunit gene of the invention, a normal or standard profile for expression is established. This may be accomplished by combining body

fluids or cell extracts taken from normal subjects, either animal or human, with a sequence, or a fragment thereof, encoding the relevant ion channel subunit gene, under conditions suitable for hybridisation or amplification.

5 Standard hybridisation may be quantified by comparing the values obtained from normal subjects with values from an experiment in which a known amount of a substantially purified polynucleotide is used. Another method to identify a normal or standard profile for expression of an
10 ion channel subunit gene is through quantitative RT-PCR studies. RNA isolated from body cells of a normal individual is reverse transcribed and real-time PCR using oligonucleotides specific for the relevant gene is conducted to establish a normal level of expression of the
15 gene. Standard values obtained in both these examples may be compared with values obtained from samples from patients who are symptomatic for a disorder. Deviation from standard values is used to establish the presence of a disorder.

20 Once the presence of a disorder is established and a treatment protocol is initiated, hybridisation assays or quantitative RT-PCR studies may be repeated on a regular basis to determine if the level of expression in the patient begins to approximate that which is observed in
25 the normal subject. The results obtained from successive assays may be used to show the efficacy of treatment over a period ranging from several days to months.

According to a further aspect of the invention there is provided the use of a polypeptide as described above in
30 the diagnosis or prognosis of epilepsy as well as other disorders associated with ion channel dysfunction, including but not restricted to, hyper- or hypo-kalemic periodic paralysis, myotonias, malignant hyperthermia, myasthenia, cardiac arrhythmias, episodic ataxia,
35 migraine, Alzheimer's disease, Parkinson's disease, schizophrenia, hyperekplexia, anxiety, depression, phobic obsessive symptoms, neuropathic pain, inflammatory pain,

chronic/acute pain, Bartter's syndrome, polycystic kidney disease, Dent's disease, hyperinsulinemic hypoglycemia of infancy, cystic fibrosis, congenital stationary night blindness or total colour-blindness.

5 When a diagnostic or prognostic assay is to be based upon proteins constituting an ion channel, a variety of approaches are possible. For example, diagnosis or prognosis can be achieved by monitoring differences in the electrophoretic mobility of normal and mutant proteins
10 that form the ion channel. Such an approach will be particularly useful in identifying mutants in which charge substitutions are present, or in which insertions, deletions or substitutions have resulted in a significant change in the electrophoretic migration of the resultant
15 protein. Alternatively, diagnosis or prognosis may be based upon differences in the proteolytic cleavage patterns of normal and mutant proteins, differences in molar ratios of the various amino acid residues, or by functional assays demonstrating altered function of the
20 gene products.

 In another aspect, antibodies that specifically bind mutant ion channels may be used for the diagnosis or prognosis of a disorder, or in assays to monitor patients being treated with a complete ion channel or agonists,
25 antagonists, modulators or inhibitors of an ion channel. Antibodies useful for diagnostic or prognostic purposes may be prepared in the same manner as described above for therapeutics. Diagnostic or prognostic assays for ion
30 channels include methods that utilize the antibody and a label to detect a mutant ion channel in human body fluids or in extracts of cells or tissues. The antibodies may be used with or without modification, and may be labelled by covalent or non-covalent attachment of a reporter molecule.

35 A variety of protocols for measuring the presence of mutant ion channels, including but not restricted to, ELISAs, RIAs, and FACS, are known in the art and provide a

basis for diagnosing or prognosing a disorder. The expression of a mutant ion channel or combination of mutant ion channels is established by combining body fluids or cell extracts taken from test mammalian subjects, preferably human, with antibody to the ion channel or channels under conditions suitable for complex formation. The amount of complex formation may be quantitated by various methods, preferably by photometric means. Antibodies specific for the mutant ion channels will only bind to individuals expressing the said mutant ion channels and not to individuals expressing only wild-type channels (ie normal individuals). This establishes the basis for diagnosing the disorder.

Once an individual has been diagnosed or prognosed with a disorder, effective treatments can be initiated as described above. Treatments can be directed to amend the combination of ion channel subunit mutations or may be directed to one mutation.

Microarray

In further embodiments, complete cDNAs, oligonucleotides or longer fragments derived from any of the polynucleotide sequences described herein may be used as probes in a microarray. The microarray can be used to diagnose or prognose epilepsy, as well as other disorders associated with ion channel dysfunction, through the identification of genetic variants, mutations, and polymorphisms in the ion channel subunits that form part of the invention, to understand the genetic basis of a disorder, or can be used to develop and monitor the activities of therapeutic agents.

According to a further aspect of the present invention, tissue material obtained from genetically modified non-human animal models generated as a result of the identification of specific ion channel subunit human mutations (see below), particularly those disclosed in the present invention, can be used in microarray experiments.

These experiments can be conducted to identify the level of expression of specific ion channel subunits, or the level of expression of any cDNA clone from whole-tissue libraries, in diseased tissue as opposed to normal control tissue. Variations in the expression level of genes, including ion channel subunits, between the two tissues indicates their possible involvement in the disease process either as a cause or consequence of the original ion channel subunit mutation present in the animal model. These experiments may be used to determine gene function, to understand the genetic basis of a disorder, to diagnose or prognose a disorder, and to develop and monitor the activities of therapeutic agents. Microarrays may be prepared, used, and analyzed using methods known in the art. (For example, see Schena et al., 1996; Heller et al., 1997).

Transformed Hosts

The present invention also provides for the production of genetically modified (knock-out, knock-in and transgenic), non-human animal models comprising nucleic acid molecules containing the novel ion channel mutations or variants as laid out in Table 1. These animals are useful for the study of the function of ion channels, to study the mechanisms by which combinations of mutations in ion channel subunits interact to give rise to disease and the effects of these mutations on tissue development, for the screening of candidate pharmaceutical compounds, for the creation of explanted mammalian cell cultures which express mutant ion channels or combinations of mutant ion channels, and for the evaluation of potential therapeutic interventions.

Animal species which are suitable for use in the animal models of the present invention include, but are not limited to, rats, mice, hamsters, guinea pigs, rabbits, dogs, cats, goats, sheep, pigs, and non-human primates such as monkeys and chimpanzees. For initial

studies, genetically modified mice and rats are highly desirable due to the relative ease in generating knock-in, knock-out or transgenics of these animals, their ease of maintenance and their shorter life spans. For certain studies, transgenic yeast or invertebrates may be suitable and preferred because they allow for rapid screening and provide for much easier handling. For longer term studies, non-human primates may be desired due to their similarity with humans.

To create an animal model for a mutated ion channel, or an animal model incorporating a combination of mutations, several methods can be employed. These include, but are not limited to, generation of a specific mutation in a homologous animal gene, insertion of a wild type human gene and/or a humanized animal gene by homologous recombination, insertion of a mutant (single or multiple) human gene as genomic or minigene cDNA constructs using wild type or mutant or artificial promoter elements, or insertion of artificially modified fragments of the endogenous gene by homologous recombination. The modifications include insertion of mutant stop codons, the deletion of DNA sequences, or the inclusion of recombination elements (lox p sites) recognized by enzymes such as Cre recombinase.

To create transgenic mice in order to study gain of gene function *in vivo*, any mutant ion channel subunit gene of the invention can be inserted into a mouse germ line using standard techniques such as oocyte microinjection. Gain of gene function can mean the over-expression of a gene and its protein product, or the genetic complementation of a mutation of the gene under investigation. For oocyte injection, one or more copies of the mutant gene can be inserted into the pronucleus of a just-fertilized mouse oocyte. This oocyte is then reimplanted into a pseudo-pregnant foster mother. The live-born mice can then be screened for integrants using analysis of tail DNA for the presence of the relevant

human ion channel subunit gene sequence. The transgene can be either a complete genomic sequence injected as a YAC, BAC, PAC or other chromosome DNA fragment, a cDNA with either the natural promoter or a heterologous promoter, or a minigene containing all of the coding region and other elements found to be necessary for optimum expression.

To generate knock-out mice or knock-in mice, gene targeting through homologous recombination in mouse embryonic stem (ES) cells may be applied. Knock-out mice are generated to study loss of gene function *in vivo* while knock-in mice (which are preferred) allow the study of gain of function or to study the effect of specific gene mutations. Knock-in mice are similar to transgenic mice however the integration site and copy number are defined in the former.

For knock-out mouse generation, gene targeting vectors can be designed such that they delete (knock-out) the protein coding sequence of the relevant ion channel subunit gene in the mouse genome. In contrast, knock-in mice can be produced whereby a gene targeting vector containing the relevant ion channel subunit gene can integrate into a defined genetic locus in the mouse genome. For both applications, homologous recombination is catalysed by specific DNA repair enzymes that recognise homologous DNA sequences and exchange them via double crossover.

Gene targeting vectors are usually introduced into ES cells using electroporation. ES cell integrants are then isolated via an antibiotic resistance gene present on the targeting vector and are subsequently genotyped to identify those ES cell clones in which the gene under investigation has integrated into the locus of interest. The appropriate ES cells are then transmitted through the germline to produce a novel mouse strain.

In instances where gene ablation results in early embryonic lethality, conditional gene targeting may be employed. This allows genes to be deleted in a temporally

and spatially controlled fashion. As above, appropriate ES cells are transmitted through the germline to produce a novel mouse strain, however the actual deletion of the gene is performed in the adult mouse in a tissue specific or time controlled manner. Conditional gene targeting is most commonly achieved by use of the cre/lox system. The enzyme cre is able to recognise the 34 base pair loxP sequence such that loxP flanked (or floxed) DNA is recognised and excised by cre. Tissue specific cre expression in transgenic mice enables the generation of tissue specific knock-out mice by mating gene targeted floxed mice with cre transgenic mice. Knock-out can be conducted in every tissue (Schwenk et al., 1995) using the 'deleter' mouse or using transgenic mice with an inducible cre gene (such as those with tetracycline inducible cre genes), or knock-out can be tissue specific for example through the use of the CD19-cre mouse (Rickert et al., 1997).

Once knock-in animals have been produced which contain a specific mutation in a particular ion channel subunit, mating combinations may be initiated between such animals so as to produce progeny containing combinations of two or more ion channel mutations. These animals effectively mimic combinations of mutations that are proposed to cause human IGE cases. These animal models can subsequently be used to study the extent and mechanisms of disease as related to the mutated ion channel combinations, as well as for the screening of candidate therapeutic compounds.

According to still another aspect of the invention there is provided the use of genetically modified non-human animals as described above for the screening of candidate pharmaceutical compounds (see drug screening above). These animals are also useful for the evaluation (eg therapeutic efficacy, toxicity, metabolism) of candidate pharmaceutical compounds, including those identified from the invention as described above, for the

treatment of epilepsy as well as other as other disorders associated with ion channel dysfunction as described above.

5 It will be clearly understood that, although a number of prior art publications are referred to herein, this reference does not constitute an admission that any of these documents forms part of the common general knowledge in the art, in Australia or in any other country.

10 Throughout this specification and the claims, the words "comprise", "comprises" and "comprising" are used in a non-exclusive sense, except where the context requires otherwise.

15 It will be apparent to the person skilled in the art that while the invention has been described in some detail for the purposes of clarity and understanding, various modifications and alterations to the embodiments and methods described herein may be made without departing from the scope of the inventive concept disclosed in this specification.

20

Brief Description of the Drawings

25 Preferred forms of the invention will now be described, by way of example only, with reference to the following examples and the accompanying drawings, in which:

30 Figure 1 provides an example of ion channel subunit stoichiometry and the effect of multiple versus single ion channel subunit mutations. Figure 1A: A typical channel may have five subunits of three different types. Figure 1B: In outbred populations complex diseases such as idiopathic generalized epilepsies may be due to mutations in two (or more) different subunit genes. Because only one allele of each subunit gene is abnormal, half the expressed subunits will have the mutation. Figure 1C: In 35 inbred populations, both alleles of a single subunit gene will be affected, so all expressed subunits will be mutated. Figure 1D: Autosomal dominant disorders can be

attributed to single ion channel subunit mutations that give rise to severe functional consequences.

Figure 2 represents the location of mutations identified in the KCNQ2 ion channel subunit constituting the potassium channel. M: Missense mutation; T: Truncation mutation; F: Frameshift mutation; S: Splice site mutation.

Figure 3 provides examples of epilepsy pedigrees where mutation profiles of ion channel subunits for individuals constituting the pedigree have begun to be determined. These examples have been used to illustrate how the identification of novel ion channel subunit mutations and variations in IGE individuals can combine to give rise to the disorder.

Figure 4 shows the results of yeast two-hybrid analysis of R353G and L619R KCNQ2 mutants. Yeast were transformed with the empty DB (BAIT) plasmid (DBLeu), DB-Q2C wt, DB-Q2C R353G mutant or the DB-Q2 L619R mutant as indicated in A and the AD-CaM (TARGET) vector was introduced by gap-repair. Yeast control strains (Invitrogen™) were included on all plates for comparison. Control 1 has no interaction. Control 2 has a weak interaction. Control 3 has a moderately strong interaction. Control 4 has a strong interaction and control 5 has a very strong interaction. B. Growth of transformed yeast and controls on -leu -tryp selection. Yeast can grow on -leu if they contain the DB plasmid, and -tryp if they have AD plasmid. C. Growth of transformed yeast and controls on -leu -tryp -his +40mM 3AT after 48hrs. Yeast can grow on -his+3AT if the *his* reporter gene is activated by interaction between the BAIT and TARGET plasmids. D-F. *LacZ* Filter assay for interaction between BAIT and TARGET plasmids, photos taken after 2hrs (D), 7hrs (E) and 24hrs (F). Activation of the β -galactosidase reporter gene by interaction of the BAIT and TARGET plasmids leads to the dark appearance of colonies.

Figure 5 shows the results of CaM affinity experiments with the R353G and L619R KCNQ2 mutants. The

chart below shows the values from the CPRG assay for β -galactosidase activity as a measure of KCNQ2C-CaM binding efficiency. The area of each bar in the chart equates to the CaM binding efficiency of the BAIT. Broken lines
5 indicate statistical comparison by Student's *t* test * $P < 0.01$, ** $P < 0.001$.

Modes for Performing the Invention

Potassium channels are the most diverse class of ion
10 channel. The *C. elegans* genome encodes about 80 different potassium channel genes and there are probably more in mammals. About ten potassium channel genes are known to be mutated in human disease and include four members of the KCNQ gene sub-family of potassium channels. KCNQ proteins
15 have six transmembrane domains, a single P-loop that forms the selectivity filter of the pore, a positively charged fourth transmembrane domain that probably acts as a voltage sensor, and intracellular amino and carboxy termini. The C-terminus is long and contains a conserved
20 "A domain" followed by a short stretch thought to be involved in subunit assembly.

Four KCNQ subunits are thought to combine to form a functional potassium channel. All five known KCNQ proteins can form homomeric channels *in vitro* and the formation of
25 heteromers appears to be restricted to certain combinations. For instance KCNQ2 and KCNQ3, which are predominantly expressed in the central nervous system, form a heteromultimeric channel that mediates the neuronal muscarinic-regulated current (M-current), also known as
30 the M-channel (or M-type K^+ channel). The M-current is a slowly activating, non-inactivating potassium conductance known to regulate neuronal excitability by determining the firing properties of neurons and their responsiveness to synaptic input (Wang et al., 1998). Because it is the only
35 current active at voltages near the threshold for action potential initiation, the M-current has a major impact on neuronal excitability.

Sodium (the alpha subunit) and calcium channels are thought to have evolved from the potassium channel subunit, and they each consist of four domains covalently linked as the one molecule, each domain being equivalent to one of the subunits that associate to form the potassium channel. Each of the four domains of the sodium and calcium channels are comprised of six transmembrane segments.

Voltage-gated sodium channels are required to generate the electrical excitation in neurones, heart and skeletal muscle fibres, which express tissue specific isoforms. Sodium channels are heteromers of a pore forming alpha subunit and a modulatory beta-1 subunit, with an additional beta-2 subunit in neuronal channels. Ten genes encoding sodium channel alpha subunits and 3 genes encoding different beta subunits have so far been identified. The beta subunits of the sodium channels do not associate with the alpha subunits to form any part of the pore, they do however affect the way the alpha pore forming subunit functions.

As with sodium channels, calcium channels consist of a single pore forming alpha subunit, of which at least six types have been identified to date, and several accessory subunits including four beta, one gamma and one alpha2-delta gene. Many of these subunits also encode multiple splice variants adding to the diversity of receptor subunits of this family of ion channels.

The ion channels in the nAChR/GABA super family show a theoretical pentameric channel. Gamma-Aminobutyric acid (GABA) is the most abundant inhibitory neurotransmitter in the central nervous system. GABA-ergic inhibition is mediated by two major classes of receptors, type A (GABA-A) and type B (GABA-B). GABA-B receptors are members of the class of receptors coupled to G-proteins and mediate a variety of inhibitory effects via secondary messenger cascades. GABA-A receptors are ligand-gated chloride channels that mediate rapid inhibition.

The GABA-A channel has 16 separate, but related, genes encoding subunits. These are grouped on the basis of sequence identity into alpha, beta, gamma, delta, epsilon, theta and pi subunits. There are six alpha subunits ($\alpha 1$ - $\alpha 6$), three beta subunits ($\beta 1$ - $\beta 3$) and three gamma subunits ($\gamma 1$ - $\gamma 3$). Each GABA-A receptor comprises five subunits which may, at least in theory, be selected from any of these subunits.

Neuronal nicotinic acetylcholine receptors (nAChRs) consist of heterologous pentamers comprising various combinations of alpha subunits or alpha and beta subunits ($\alpha 2$ - $\alpha 9$; $\beta 2$ - $\beta 4$). The alpha subunits are characterised by adjacent cysteine residues at amino acid positions 192 and 193, and the beta subunits by the lack of these cysteine residues. They are ligand-gated ion channels differentially expressed throughout the brain to form physiologically and pharmacologically distinct receptors hypothesised to mediate fast, excitatory transmission between neurons of the central nervous system or to modulate neurotransmission from their presynaptic position.

In chicken and rat, the predominant nAChR subtype is composed of alpha-4 and beta-2 subunits. The transmembrane 2 (M2) segments of the subunits are arranged as alpha helices and contribute to the walls of the neurotransmitter-gated ion channel. The alpha helices appear to be kinked and orientated in such a way that the side chains of the highly conserved M2-leucine residues project inwards when the channel is closed. ACh is thought to cause a conformational change by altering the association of the amino acid residues of M2. The opening of the channel seems to be due to rotations of the gate forming side chains of the amino acid residues; the conserved polar serines and threonines may form the critical gate in the open channel.

Example 1: Identification of mutations in ion channels

Previous studies by reference (Wallace et al., 1998; PCT/AU01/00581; Wallace et al., 2001b; Australian patent AU-B-56247/96; Steinlein et al., 1995; PCT/AU01/00541; 5 Phillips et al., 2001; PCT/AU01/00729; PCT/AU01/01648; PCT/AU02/00910; Wallace et al., 2001a, the disclosures of which are incorporated herein by reference) have identified mutations in a number of ion channel subunits associated with epilepsy. These include ion channel 10 subunits of voltage-gated (eg SCN1A, SCN1B, KCNQ2, KCNQ3) or ligand-gated (eg CHRNA4, CHRNB2, GABRG2, GABRD) types. To identify further mutations in ion channel genes, subunits which comprise the ion channels were screened for molecular defects in epilepsy patients.

15 Human genomic sequence available from the Human Genome Project was used to characterize the genomic organisation for each subunit gene. Each gene was subsequently screened for sequence changes using single strand conformation polymorphism (SSCP) analysis in a 20 large sample of epileptics with common sporadic IGE subtypes eg juvenile myoclonic epilepsy (JME), childhood absence epilepsy (CAE), juvenile absence epilepsy (JAE) and epilepsy with generalized tonic-clonic seizures (TCS). Clinical observations can then be compared to the 25 molecular defects characterized in order to establish the combinations of mutant subunits involved in the various disease states, and therefore to provide validated drug targets for each of these disease states. This will provide a basis for novel drug treatments directed at the 30 genetic defects present in each patient.

The coding sequence for each of the ion channel subunits was aligned with human genomic sequence present in available databases at the National Centre for Biotechnology Information (NCBI). The BLASTN algorithm was 35 typically used for sequence alignment and resulted in the genomic organisation (intron-exon structure) of each gene being determined. Where genomic sequence for an ion

channel subunit was not available, BACs or PACs containing the relevant ion channel subunit were identified through screening of high density filters containing these clones and were subsequently sequenced.

5 Availability of entire genomic sequence for each ion channel subunit facilitated the design of intronic primers spanning each exon. These primers were used for both high throughput SSCP screening and direct DNA sequencing.

10 Example 2: Sample preparation for SSCP screening

 A large collection of individuals affected with epilepsy have undergone careful clinical phenotyping and additional data regarding their family history has been collated. Informed consent was obtained from each
15 individual for blood collection and its use in subsequent experimental procedures. Clinical phenotypes incorporated classical IGE cases as well as GEFS+ and febrile seizure cases.

 DNA was extracted from collected blood using the
20 QIAamp DNA Blood Maxi kit (Qiagen) according to manufacturers specifications or through procedures adapted from Wyman and White (1980). Stock DNA samples were kept at a concentration of 1 ug/ul.

 In preparation for SSCP analysis, samples to be
25 screened were formatted into 96-well plates at a concentration of 30 ng/ul. These master plates were subsequently used to prepare exon specific PCR reactions in the 96-well format.

30 Example 3: Identification of sequence alterations in ion channel genes

 SSCP analysis of specific ion channel exons followed by sequencing of SSCP bandshifts was performed on
35 individuals constituting the 96-well plates to identify sequence alterations.

 Primers used for SSCP were labelled at their 5' end with HEX and typical PCR reactions were performed in a

total volume of 10 μ l. All PCR reactions contained 67 mM Tris-HCl (pH 8.8); 16.5 mM $(\text{NH}_4)_2\text{SO}_4$; 6.5 μ M EDTA; 1.5 mM MgCl_2 ; 200 μ M each dNTP; 10% DMSO; 0.17 mg/ml BSA; 10 mM β -mercaptoethanol; 5 μ g/ml each primer and 100 U/ml *Taq* DNA polymerase. PCR reactions were typically performed using 10 cycles of 94°C for 30 seconds, 60°C for 30 seconds, and 72°C for 30 seconds followed by 25 cycles of 94°C for 30 seconds, 55°C for 30 seconds, and 72°C for 30 seconds. A final extension reaction for 10 minutes at 72°C followed.

Ten to twenty μ l of loading dye comprising 50% (v/v) formamide, 12.5 mM EDTA and 0.02% (w/v) bromophenol blue were added to completed reactions which were subsequently run on non-denaturing 4% polyacrylamide gels with a cross-linking ratio of 35:1 (acrylamide:bis-acrylamide) and containing 2% glycerol. Gel thickness was 100 μ m, width 168mm and length 160mm. Gels were run at 1200 volts and approximately 20mA, at 18°C and analysed on the GelScan 2000 system (Corbett Research, Australia) according to manufacturers specifications.

PCR products showing a conformational change were subsequently sequenced. This first involved re-amplification of the amplicon from the relevant individual (primers used in this instance did not contain 5' HEX labels) followed by purification of the PCR amplified templates for sequencing using QiaQuick PCR preps (Qiagen) based on manufacturers procedures. The primers used to sequence the purified amplicons were identical to those used for the initial amplification step. For each sequencing reaction, 25 ng of primer and 100 ng of purified PCR template were used. The BigDye sequencing kit (ABI) was used for all sequencing reactions according to the manufacturers specifications. The products were run on an ABI 377 Sequencer and analysed using the EditView program.

Table 1 shows the novel sequence changes identified in the ion channel subunits screened.

Example 4: Digenic model examples

In some instances a single mutation in an ion channel alone is insufficient to give rise to an epilepsy phenotype. However combinations of mutations each
5 conferring a subtle change of function to an ion channel, as proposed by the digenic model (PCT/AU01/00872), may be sufficient to produce an epilepsy phenotype.

Using mutations and variations in ion channel subunits previously identified, the digenic model may be
10 validated through a parametric analysis of large families in which two abnormal alleles co-segregate by chance to identify mutations which act co-operatively to give an epilepsy phenotype. It is envisaged that the strategy of careful clinical phenotyping in these large families,
15 together with a linkage analysis based on the digenic hypothesis will allow identification of the mutations in ion channels associated with IGEs. If molecular genetic studies in IGE are successful using the digenic hypothesis, such an approach might serve as a model for
20 other disorders with complex inheritance.

The digenic hypothesis predicts that the closer the genetic relationship between affected individuals, the more similar the sub-syndromes, consistent with published data (Italian League Against Epilepsy Genetic
25 Collaborative Group, 1993). This is because more distant relatives are less likely to share the same combinations of mutated subunits.

Identical twins have the same pair of mutated subunits and the same minor alleles so the sub-syndromes
30 are identical. Affected sib-pairs, including dizygous twins, with the same sub-syndrome would also have the same pair of mutated subunits, but differences in minor alleles would lead to less similarity than with monozygous twins. Some sib-pairs and dizygous twins, have quite different
35 sub-syndromes; this would be due to different combinations of mutated subunits, when the parents have more than two mutated alleles between them.

A special situation exists in inbred communities that parallels observations on autosomal recessive mouse models. Here the two mutated alleles of the digenic model are the same and thus result in a true autosomal recessive disorder. Because all affected individuals have the same pair of mutated alleles, and a similar genetic background, the phenotypes are very similar.

In outbred communities approximately 1% of the population would have IGE genotypes (2 mutated alleles) and 0.3% would clinically express IGE. Most of these would have mutations in two different channel subunits. In such communities most cases would appear "sporadic" as the risk to first degree relatives would be less than 10%.

For example, let there be three IGE loci (A,B,C) and let the frequency of abnormal alleles (a^*, b^*, c^*) at each locus be .027 and of normal alleles (a, b, c) be .973. Then, the distribution of genotypes aa^*, a^*a, a^*a^* and aa at locus A will be .0263 ($.027 \times .973$), .0263, .0007 and .9467 respectively, and similarly for loci B and C. In this population .8485 will have no mutated alleles ($.9467^3$), .1413 will have one mutated allele (a^* or b^* or c^* ; $.0263 \times .9467^2 \times 6$), .0098 will have two abnormal alleles (.0020 two same abnormal alleles, .0078, two different abnormal alleles) and 0.00037 will have more than two abnormal alleles. Thus in this population .01, or 1%, will have two or more abnormal alleles (IGE genotype), and the total abnormal allele frequency will be .08 ($3 \times .027$).

To determine the familial risks and allele patterns in affected pairs, the frequency distribution of population matings and the percentage of children with 2 or more abnormal alleles must be determined. The frequency of matings with no abnormal alleles (0×0) is .72 ($.8485^2$), for 1×0 and 0×1 matings .24 ($2 \times .8485 \times .1413$), for a 1×1 mating .020, and for 2×0 and 0×2 matings .0166 etc. From this distribution of matings the frequency of children with 2 or more abnormal alleles can

be shown to be .01. For example, the 0 x 2 and 2 x 0 matings contribute .0033 of this .01 frequency (.0166 [mating frequency] x .2 [chance of that mating producing a child with 2 or more abnormal alleles]).

5 To determine parental risk it can be shown that of children with 2 abnormal alleles (IGE genotype), .49 derive from 1 x 1 matings where no parent is affected, .33 derive from a 2 x 0 and 0 x 2 matings etc. For the 2 x 0 and 0 x 2 matings, half the parents have IGE genotypes and
10 contribute .16 (.33/2) to the parental risk with the total parental risk of an IGE genotype being .258. The other matings that contribute to affected parent-child pairs are 2 x 1, 1 x 2, 3 x 0, 0 x 3 etc.

The sibling risk of an IGE genotype is .305. For
15 example 2 x 0 and 0 x 2 matings contributed .08 to the sibling risk (.33[fraction of children with 2 abnormal alleles] x .25[the chance of that mating producing a child with 2 or more abnormal alleles]). Similarly the offspring risk was determined to be .248 by mating individuals with
20 2 abnormal alleles with the general population. Thus at 30% penetrance the risk for IGE phenotype for parents of a proband is .077, for siblings .091, and for offspring .074.

It can be shown that affected sib pairs share the
25 same abnormal allele pair in 85% of cases. This is because of all affected sib pairs 44% derive from 1 x 1 matings and 23% from 0 x 2 and 2 x 0 matings where all affected siblings have the same genotype. In contrast, 24% derive from 1 x 2 matings and 9% from 3 x 1 and 2 x 2 matings etc
30 where affected sibling genotypes sometimes differ.

For affected parent-child pairs, genotypes are identical in only 58%. Of affected parent child pairs, 43% derive from 0 x 2 matings where genotypes are identical, whereas 38% derive from 0 x 3 and 17% from 1 x 2 where the
35 majority of crosses yield different affected genotypes.

Based on the digenic model it has been postulated that most classical IGE and GEFS⁺ cases are due to the

combination of two mutations in multi-subunit ion channels. These are typically point mutations resulting in a subtle change of function. The critical postulate is that two mutations, usually, but not exclusively, in different subunit alleles ("digenic model"), are required for clinical expression of IGE.

The hypothesis that similar phenotypes can be caused by the combination of mutations in two (or more) different subunits (outbred communities), or by the same mutation in two (or more) alleles of the same subunit (inbred communities), may seem implausible. However, applying the digenic hypothesis to the theoretical pentameric channel shown in Figure 1, in outbred communities IGE will be due to subunit combinations such as $\alpha^*\alpha\beta\beta\Delta$, $\alpha^*\alpha\beta\beta\Delta^*$ or $\alpha\alpha\beta^*\beta\Delta^*$ (mutated subunits indicated by *). In inbred communities $\alpha^*\alpha^*\beta\beta\Delta$ or $\alpha\alpha\beta^*\beta^*\Delta$ combinations might cause IGE phenotypes. We assume that the mutations will not cause reduced expression of the alleles and that the altered ion channel excitability, and consequent IGE phenotype, caused by mutations in two different alleles is similar to that caused by the same mutation in both alleles of one subunit. Finally, subunit mutations with more severe functional consequences (eg breaking a disulphide bridge in SCN1B or amino acid substitution in the pore forming regions of SCN1A for GEFS⁺) cause autosomal dominant generalized epilepsies with a penetrance of 60-90%. Such "severe" mutations are rare (allele frequency <0.01%) and are infrequent causes of GEFS⁺. They very rarely, or perhaps never, cause classical IGE.

The relative separate segregation of classical IGE and GEFS⁺ phenotypes is an anecdotal clinical observation of ours (Singh et al., 1999), although the separation is not absolute. The separation is supported by previous family and EEG studies of Doose and colleagues who described "type A" and "type B" liabilities which we may approximate the GEFS⁺ and classical IGE groupings respectively (Doose and Baier, 1987).

The digenic model predicts that affected sib pairs will share the same genes in 85% of cases whereas they will have at least one different allele in the remaining 15%. In contrast, only 58% of parent-child pairs share the same alleles in a 3 locus model. Thus there should be greater similarity of syndromes between sibling pairs than parent-child pairs. This would be most objectively measured by age of onset and seizure types.

Estimates for the risk of febrile seizures or IGE in relatives vary. The estimates range from 5%-10% for siblings, 4%-6% for offspring, 3%-6% for parents, and 2-3% for grandparents. Underestimation may occur because IGE manifest in youth, and parents and particularly grandparents may be unaware of seizures in themselves in younger years. This is particularly true where there was stigma associated with epilepsy and where the epilepsy may have been mild and unrecognized. Underestimation of sibling and offspring risks occurs when unaffected young children are counted, some of whom will develop IGE in adolescence. Overestimation may occur with misdiagnosis of seizures or inclusion of seizures unrelated to IGE (e.g. due to trauma or tumors)

In autosomal dominant models the risk to affected relatives reduces proportionally (50% for first degree relatives, 25% for second degree etc). For all oligogenic or polygenic models the risk decreases more quickly. For a digenic model with three loci, the risks are 9.1% for siblings, 7.4% for offspring, 7.7% for parents. Rigorous measurement of the familial recurrence rates, with careful phenotyping and age-corrected risk estimates could be compared with the predictions from the digenic model, and it is proposed to do this.

There is a small amount of information on IGE families regarding haplotype distribution. For example, there is some evidence for a locus on 8q as determined by parametric linkage in a single family (Fong et al., 1998) and by non-parametric analysis in multiple small families

(Zara et al., 1995). Interestingly, in the latter study the 8q haplotype not infrequently came from the unaffected parent. This would be quite compatible with the digenic model and evaluation of other data sets in this manner could be used to test the hypothesis, and it is proposed to do this.

Following the analysis of one large family with epilepsy where the two main phenotypes were childhood absence epilepsy (CAE) and febrile seizures (FS), the inheritance of FS was found to be autosomal dominant and the penetrance 75%. However the inheritance of CAE in this family was not simple Mendelian, but suggestive of complex inheritance with the involvement of more than one gene. The power of this large family was used to explore the complex genetics of CAE further.

Linkage analysis on this family in which individuals with CAE, FS and FS+ were deemed affected led to the detection of linkage on chromosome 5q and identification of a mutation in the GABRG2 gene (R43Q) which is localised to this region (Wallace et al., 2001a; PCT/AU01/00729). All 10 tested individuals with FS alone in this family had this mutation and 7 CAE affected individuals in this family also had the mutation. To test the digenic model of IGEs in the CAE affected individuals, the whole genome screen of this family was reanalysed with only individuals with CAE considered affected. Linkage analysis was performed using FASTLINK v4.0, two-point lod scores were calculated assuming 50% penetrance and a 2% phenocopy rate and individuals with FS or FS+ were coded as unknown. Markers producing a lod score greater than 1 were reanalysed without a phenocopy rate and at the observed penetrance for CAE in this family (30%). Results from the analysis revealed significant linkage to chromosome 14q22-q23 (lod 3.4). This provides strong evidence for a second locus segregating with CAE affected individuals in this family. While the GABRG2 mutation is sufficient to cause FS, the CAE phenotype is thought to be due to both the

GABRG2 mutation and a mutation occurring in a gene mapping to the 14q locus, as proposed by the digenic model.

For the application of the digenic model to sporadic cases of IGE and affected individuals belonging to smaller families in which genotyping and linkage analysis is not a feasible approach to disease gene identification, direct mutation analysis of ion channel genes in these individuals has been carried out as described above. In Table 1 there is provided an indication of novel genetic alterations so far identified through mutation analysis screening of these individuals. Figure 2 provides an example to indicate where some of these mutations have occurred with respect to the potassium channel KCNQ2 gene.

The identification of novel mutations and variations in ion channel subunits in IGE individuals provides resources to further test the digenic hypothesis and mutation profiles are starting to accumulate for a number of subunit changes that are observed in the same individuals. Figure 3 provides results from some of these profiles.

Figure 3A shows a 3 generation family in which individual III-1 has myoclonic astatic epilepsy and contains a N43del mutation in the SCN3A gene as well as an A1067T mutation in the SCN1A gene. Individual I-1 also has the SCN3A mutation but alone this mutation is not sufficient to cause epilepsy in this individual. The SCN3A mutation has likely been inherited from the grandfather through the mother, while the SCN1A mutation is likely to arise from the father. Both parents are unaffected but have yet to be screened for the presence of the mutations in these subunits. Individual II-1 is likely to contain an as yet unidentified ion channel subunit mutation acting in co-operation with the SCN3A mutation already identified in this individual.

Figure 3B is another 3 generation family in which individual III-1 has myoclonic astatic epilepsy due to a combination of the same SCN3A and SCN1A mutations as

above. However, in this family both parents have febrile seizures most likely due to the presence of just one of the mutations in each parent, as proposed by the model. This is in contrast to individuals II-2 and II-3 in Figure 4A who also contain one of the mutations in these genes each. These individuals are phenotypically normal most likely due to incomplete penetrance of these mutations in each case.

Figure 3C shows a larger multi-generation family in which individual IV-5 has a mutation in both the SCN3A and GABRG2 subunits. In combination, these give rise to severe myoclonic epilepsy of infancy but alone either cause febrile seizures (GABRG2 mutation in III-3 and IV-4) or are without an effect (SCN3A mutation in III-2) as proposed by the model.

These examples therefore illustrate the digenic model as determined from mutation analysis studies of ion channel subunits in affected individuals and highlight the need to identify genetic alterations in the genes encoding ion channel subunits.

Example 5: Analysis of ion channels and ion channel subunits

The structure and function of the mutant ion channels and mutant ion channel subunits of the present invention can be determined using a variety of molecular biological studies. These studies may provide clues as to the mechanisms by which mutations in ion channel subunits effect the functioning of the ion channel. For instance the identification of proteins that interact with mutant ion channels (or whose interaction is impeded by a mutation in an ion channel subunit) may help determine the molecular mechanisms that are disrupted as a result of a mutation. Procedures such as the yeast two-hybrid system can be used to discover and identify such interacting proteins.

The principle behind the yeast two-hybrid procedure is that many eukaryotic transcriptional activators, including those in yeast, consist of two discrete modular domains. The first is a DNA-binding domain that binds to a specific promoter sequence and the second is an activation domain that directs the RNA polymerase II complex to transcribe the gene downstream of the DNA binding site. Both domains are required for transcriptional activation as neither domain can activate transcription on its own. In the yeast two-hybrid procedure, the gene of interest or parts thereof (BAIT), is cloned in such a way that it is expressed as a fusion to a peptide that has a DNA binding domain. A second gene, or number of genes, such as those from a cDNA library (TARGET), is cloned so that it is expressed as a fusion to an activation domain. Interaction of the protein of interest with its binding partner brings the DNA-binding peptide together with the activation domain and initiates transcription of the reporter genes. The first reporter gene will select for yeast cells that contain interacting proteins (this reporter is usually a nutritional gene required for growth on selective media). The second reporter is used for confirmation and while being expressed in response to interacting proteins it is usually not required for growth.

KCNQ2 interactors

Despite the identification of a number of KCNQ2 mutations responsible for epilepsy, including those of the present study, the underlying biological mechanisms responsible for the epilepsy remains largely uncharacterized. Towards identifying these mechanisms, the large intracellular C-terminal region of KCNQ2 was screened for interactions with other proteins using the yeast-two hybrid procedure. The C-terminus accounts for 63% of the KCNQ2 protein and, in common with other KCNQ subunits, contains a conserved 'A domain' (Jentsch, 2000; Schwake et al., 2000) thought to be involved in subunit

interactions as well as another distal short conserved region that has been associated with subunit assembly, at least in KCNQ1 (Jentsch, 2000; Schmitt et al., 2000).

5 A) Yeast-two hybrid analysis

A yeast two-hybrid screen was carried out using the ProQuest™ Two-Hybrid System with Gateway™ Technology (Invitrogen™) according to manufacturer's directions. A KCNQ2 C-terminal entry (BAIT) clone was generated using
10 the pENTR Directional TOPO® Cloning Kit (Invitrogen™). The following primers were designed to amplify the intracellular C-terminal region of KCNQ2 based on the sequence of human KCNQ2 (Genbank accession number NM_172107): KCNQ2F: 5'-CACCAAGGTTTCAGGAGCAGCACAGG-3' and
15 KCNQ2R: 5'-TCACTTCCTGGGCCCGGCCAGCC-3'. The 1611 base pair cloned fragment included exon 10a (found in all our amplified clones), corresponding to amino acid 373-382 of the KCNQ2 protein. The extra 30 base pairs (10 amino acids) were included in our numbering. The PCR-product was
20 cloned into the pENTR/D-TOPO® vector (Invitrogen™) via the TOPO® Cloning reaction according to the manufacturer's instructions. Following sequence verification, the KCNQ2 cDNA fragment was then subcloned into pDEST™32, the DNA Binding domain (DB) Gateway™ Destination Vector
25 (Invitrogen™).

The ProQuest™ Two-Hybrid human brain cDNA Library (TARGET) with Gateway™ technology (ResGen™, Invitrogen™ Corporation) was amplified according to the manufacturer's instructions. Plasmid DNA was purified from the cell
30 pellet using the HiSpeed Plasmid Maxi Kit (Qiagen) according to the manufacturer's instructions.

Both the DBLeu (empty bait vector) and DB-KCNQ2 wild-type (wt) C-term BAITs were transformed into the yeast strain Mav203 and plated onto minimal selective media
35 lacking leucine. A duplicate was carried out where the empty library TARGET (pAD) vector was co-transformed in addition to each BAIT and plated onto minimal selective

- 68 -

media lacking leucine (-leu) and tryptophan (-tryp). Yeast control strains (Invitrogen™) were included on all plates. Control 1, used as a negative control, contained empty plasmids pPC97 and pPC86. Control 2 had pPC97-RB and pPC86-E2F1, which express a relatively weak interaction. Control 3 contained plasmids encoding the *Drosophila* DP (pPC97) and E2F (pPC86) domains that have a moderately strong interaction, and provide a control for plasmid shuffling. Control 4 contained pPC97-Fos and pPC86-Jun which express a relatively strong interaction, and control 5 had a pCL1 plasmid encoding full-length GAL4p and empty pPC86 and was used as a positive control.

The constructs were tested for self-activation of the *his* and β -gal reporter genes according to Invitrogen™ instructions.

For the yeast-two hybrid screen, competent yeast cells were prepared for each BAIT (DB-KCNQ2 wt C-term construct) to be screened, transformed with 31µg of ProQuest™ Two-Hybrid human brain AD (activation domain)-cDNA Library and plated onto minimal selective media lacking leucine (-leu), tryptophan (-tryp) and histidine (-his) and containing 3-aminotriazole (+3AT). Positive colonies from each screen were PCR-amplified and re-introduced into fresh yeast cells containing the BAIT to re-test for two-hybrid interaction phenotypes. Those giving rise to more than one PCR product or that failed to re-test positively were systematically eliminated. Positives that re-tested were sequenced using the ABI PRISM® BigDye™ Terminators v3.0 technology. Once identified, the sequence of the potential interactor was checked to verify it was in the same translational frame as the Gal4p-AD encoding sequence of the prey construct.

Approximately 3×10^6 clones from the ProQuest™ Two-Hybrid human brain cDNA Library were screened for interaction with the DB-Q2C wt bait. Among 1039 positive AD-cDNAs recovered, re-tested and subsequently sequenced

all were identified as the CALM2 gene, encoding the ubiquitous, Ca^{2+} -binding protein, Calmodulin (CaM).

The interaction between the C-terminal region of KCNQ2 and CaM has also been reported by other studies (Wen and Levitan, 2002; Yus-Najera et al., 2002; Gamper and Shapiro, 2003). In mammals, the CaM protein is coded by a multigene family consisting of three bona fide members, CALM1, CALM2 and CALM3. Within the non-coding regions of the CaM transcripts, no striking homology is observed, and codon usage is maximally divergent amongst the three CaM mRNAs that encode an identical protein. It has been hypothesised that the existence of a multigene family provides a tight and complex level of regulatory control at the level of gene expression (Palfi et al., 2002). CaM genes are differentially expressed in the CNS during development and differential regulation of the CaM genes appears necessary to maintain the temporal and spatial fidelity of the CaM protein levels in all subcellular domains. Besides the fundamental housekeeping functions associated with CaM, it is also involved in specialized neuronal functions, such as the synthesis and release of neurotransmitters, neurite extension, long-term potentiation and axonal transport (Palfi et al., 2002).

B) Effect of epilepsy-associated KCNQ2 mutations on the CaM-KCNQ2 interaction

To assess the effect that the C-terminus mutations of the present invention had on CaM binding, two of the identified mutations (R353G and L619R) were introduced into the DB-Q2C construct by mutagenesis and were re-analysed for an interaction with CaM using the yeast two-hybrid procedure.

The following primers were used to incorporate the c1057C→G (R353G) and c1856T→G (L619R) changes into the pDESTTM32- KCNQ2 C-terminal bait construct.

R353G F 5'-CGCCACCAACCTCTCGGGCACAGACCTGCACTC-3'

- 70 -

R353G R 5'-GAGTGCAGGTCTGTGCCCCGAGAGGTTGGTGGCG-3'

L619R F 5'-CTTGTCCATGGAGAAGAAGCGGGACTTCCTGGTGAATATC-3'

L619R R 5'-GATATTCACCAGGAAGTCCCGCTTCTTCTCCATGGACAAG-3'

5 Overlapping PCR products were generated using the TOPO[®] cloning compatible KCNQ2F primer from the initial cloning and the mutagenesis reverse primers, and the KCNQ2R primer from the initial cloning with the mutagenesis forward primers. Products were gel extracted and purified before a second round of PCR using the initial KCNQ2 F&R primers. These products were also gel extracted before cloning into the pDEST[™]32 bait vector via the TOPO[®] system (as described above). Mutant baits were sequence verified.

15 The interaction between each DB-Q2C mutant and CaM was then tested by the yeast two-hybrid assay and compared to the interaction with DB-Q2 wt. Three different PCR-amplified CaM positive clones from the initial screen were re-introduced by gap-repair²⁰ into the prey vector (pPC86) in the yeast strain expressing either DB-Q2C wt, DB-Q2C mutants or the empty DBLeu vector, used as negative control.

25 CaM interaction with the DB-Q2C wt and mutants was then assessed by expression of the *HIS3* and *LacZ* reporter genes.

30 The Q2C R353G mutant did not interact with CaM, as seen by no growth on *HIS3* selective plate (Figure 4C) and no blue readout in the *LacZ* filter assay (seen as dark squares in Figure 4D-F). On the other hand, the DB-Q2C L619R mutant was shown to still interact with CaM, as seen by growth on *HIS3* selective plate (Figure 4C) and the blue readout in the *LacZ* filter assay. Interestingly, the DB-Q2C L619R mutant showed an even greater growth level on *HIS3* selective plate than the DB-Q2C wt and also appeared to stain faster and more intensely blue in the *LacZ* filter assay, suggesting a stronger interaction between CaM and this mutant.

In order to better quantify β -gal activity, a second assay was carried out using the high sensitivity substrate Chlorophenol Red- β -D-Galactopyranoside (CPRG) in liquid culture. The affinity of the DB-Q2C/AD-CaM interaction was measured in terms of units of β -gal activity, with a zero value indicating no expression of the *LacZ* reporter gene, and hence no interaction.

In the CPRG assay, a value of 0.05 units β -gal activity (Figure 5) was significantly different from the empty bait vector replicate ($P < 0.01$, Student's *t* test), confirming the interaction of the DB-Q2C wt with CaM.

As observed in the *LacZ* filter assay, the CPRG assay showed a significant difference in the interaction between the Q2C R353G mutant and CaM as compared to the wt replicate ($P < 0.01$, Student's *t* test, Figure 4).

These results suggest that the R353G mutation alters the structural conformation of the KCNQ2 C-terminal domain such that it is no longer able to bind to CaM and that this single point mutation is sufficient to abolish the interaction. By abolishing CaM binding, the R353G mutation could lead to an impairment of M-current *in vivo* due to decreased opening of the channel.

In contrast, the CPRG assay for the L619R Q2C mutant showed a significantly higher level of β -gal activity units (0.26 units) than the wt replicate ($P < 0.001$, Student's *t* test, Figure 5). This finding indicates that the L619R mutation alters the conformation of the protein in a manner that increases CaM binding affinity for the KCNQ2 C-terminal domain by approximately 5-fold. The increased affinity for CaM may affect the ability of the complex to change conformation normally in response to calcium signalling. Alternatively, the marked increase in binding of CaM to the KCNQ2 L619R mutant channel may be detrimental to the M-channel function via disruption of the normal neuronal inhibitory/excitatory balance, therefore causing the seizures associated with epilepsy, particularly BFNS. CaM is known to be involved in both the

excitatory and inhibitory neurotransmission pathways (Ohya and Botstein, 1994) and it has been proposed that the temporal and spatial restrictions on CaM itself could enable the tight control of these opposing reactions
5 (Toutenhoofd and Strehler, 2000). Hence, the KCNQ2 L619R mutation could lead to a disruption of the local CaM pool consequently disturbing the finely balanced excitatory and inhibitory neurotransmission systems.

These results implicate CaM in the pathogenesis of
10 epilepsy and specifically in the BFNS syndrome. Whilst further work will be required to fully elucidate the involvement of the KCNQ2-CaM interaction in neuronal excitability and its correlation with idiopathic epilepsy, these data suggest that dysfunction of this interaction
15 leads to aberrant neuronal excitability in some BFNS patients.

The calmodulin gene (and other ion channel interacting genes) may therefore be a target for mutation in epilepsy as well as other disorders associated with ion channel
20 dysfunction. A mutation in an ion channel interacting gene when expressed alone, or when expressed in combination with one or more other ion channel mutations or ion channel interacting gene mutations (based on the digenic model), may give rise to the disorder. The nature of the
25 ion channel interacting genes and proteins can be studied such that these partners can also be targets for drug discovery.

Industrial Applicability

30 The mutant ion channel receptor subunits of the invention are useful in the diagnosis and treatment of diseases such as epilepsy and disorders associated with ion channel dysfunction including, but not limited to, hyper- or hypo-kalemic periodic paralysis, myotonias,
35 malignant hyperthermia, myasthenia, cardiac arrhythmias, episodic ataxia, migraine, Alzheimer's disease, Parkinson's disease, schizophrenia, hyperekplexia,

anxiety, depression, phobic obsessive symptoms,
neuropathic pain, inflammatory pain, chronic/acute pain,
Bartter's syndrome, polycystic kidney disease, Dent's
disease, hyperinsulinemic hypoglycemia of infancy, cystic
5 fibrosis, congenital stationary night blindness and total
colour-blindness.

TABLE 1

Examples of mutations and variations identified in ion channel subunit genes

Subunit Gene	Exon/Intron	DNA Mutation	Amino Acid Change	SEQ ID NOS
Sodium Channel Subunits				
Coding exonic variants – amino acid change				
SCN1A ^r	Exon 5	c664C→T	R222X	1, 73
SCN1A ^r	Exon 8	c1152G→A	W384X	2, 74
SCN1A ^r	Exon 9	c1183G→C	A395P	3, 75
SCN1A ^r	Exon 9	c1207T→C	F403L	4, 76
SCN1A ^r	Exon 9	c1237T→A	Y413N	5, 77
SCN1A ^r	Exon 9	c1265T→A	V422E	6, 78
SCN1A ^r	Exon 21	c4219C→T	R1407X	7, 79
SCN1A ^r	Exon 26	c5339T→C	M1780T	8, 80
SCN1A ^r	Exon 26	c5674C→T	R1892X	9, 81
SCN1B ^r	Exon 3	c254G→A	R85H	10, 82
SCN2A ^r	Exon 6A	c668G→A	R223Q	11, 83
SCN2A ^r	Exon 16	c2674G→A	V892I	12, 84
SCN2A ^r	Exon 17	c3007C→A	L1003I	13, 85
SCN2A ^r	Exon 19	c3598A→G	T1200A	14, 86
SCN2A ^r	Exon 20	c3956G→A	R1319Q	15, 87
Coding exonic variants – no amino acid change				
SCN2A ^c	Exon 12	c1785T→C	-	16
SCN2A ^c	Exon 27	c4919T→A	-	17
Non-coding variants				
SCN1A ^r	Intron 9	IVS9-1G→A	-	18
SCN1A ^c	Intron 23	IVS23+33G→A	-	19
SCN2A ^r	Intron 7	IVS7+61T→A	-	20
SCN2A ^r	Intron 19	IVS19-55A→G	-	21
SCN2A ^r	Intron 22	IVS22-31A→G	-	22
SCN2A ^c	Intron 2	IVS2-28G→A	-	23
SCN2A ^c	Intron 8	IVS8-3T→C	-	24
SCN2A ^c	Intron 11	IVS11+49A→G	-	25
SCN2A ^c	Intron 11	IVS11-16C→T	-	26
SCN2A ^c	Intron 17	IVS17-71C→T	-	27
SCN2A ^c	Intron 17	IVS17-74delG	-	28
SCN2A ^c	Intron 17	IVS17-74insG	-	29
Nicotinic Acetylcholine Receptor Subunits				
Coding exonic variants – amino acid change				
CHRNA5 ^r	Exon 4	c400G→A	V134I	30, 88
CHRNA2 ^c	Exon 4	c373G→A	A125T	31, 89
CHRNA3 ^c	Exon 2	c110G→A	R37H	32, 90
Coding variants – no amino acid change				
CHRNA2 ^c	Exon 4	c351C→T	-	33
CHRNA2 ^c	Exon 5	c771C→T	-	34
CHRNA3 ^c	Exon 2	c159A→G	-	35
CHRNA3 ^c	Exon 4	c291G→A	-	36
CHRNA3 ^c	Exon 4	c345G→A	-	37

TABLE 1 (Continued)

Examples of mutations and variations identified in ion channel subunit genes				
Subunit Gene	Exon/Intron	DNA Mutation	Amino Acid Change	SEQ ID NOS
Non-coding variants				
CHRNA2 ^c	Intron 3	IVS3-16C→T	-	38
CHRNA3 ^c	Intron 3	IVS3-5T→C	-	39
CHRNA3 ^c	Intron 4	IVS4+8G→C	-	40
Potassium Channel Subunits				
Coding exonic variants – amino acid change				
KCNQ2 ^r	Exon 1	c204-c205insC	K69fsX119	41, 91
KCNQ2 ^r	Exon 1	c1A→G	M1V	42
KCNQ2 ^r	Exon 1	c2T→C	M1T	43
KCNQ2 ^r	Exon 8	c1057C→G	R353G	44, 92
KCNQ2 ^r	Exon 11	c1288C→T	R430X	45, 93
KCNQ2 ^r	Exon 14	c1710A→T	R570S	46, 94
KCNQ2 ^r	Exon 15	c1856T→G	L619R	47, 95
Non-coding variants				
KCNQ2 ^r	Intron 9	IVS9+(46-48)delCCT	-	48
KCNQ3 ^r	Intron 11	IVS11+43G→A	-	49
KCNQ3 ^c	Intron 12	IVS12+29G→A	-	50
GABA Receptor Subunits				
Coding exonic variants – no amino acid change				
GABRB1 ^r	Exon 5	c508C→T	-	51
GABRB1 ^r	Exon 9	c1329G→A	-	52
GABRB1 ^c	Exon 8	c975C→T	-	53
GABRG3 ^c	Exon 8	c995T→C	-	54
Non-coding variants				
GABRA1 ^c	5' UTR	c-142A→G	-	55
GABRA1 ^c	5' UTR	c-31C→T	-	56
GABRA2 ^c	3' UTR	c1615G→A	-	57
GABRA5 ^c	5' UTR	c-271G→C	-	58
GABRA5 ^c	5' UTR	c-228A→G	-	59
GABRA5 ^c	5' UTR	c-149G→C	-	60
GABRB2 ^b	5' UTR	c-159C→T	-	61
GABRB2 ^c	3' UTR	c1749C→T	-	62
GABRPi ^c	5' UTR	c-101C→T	-	63
GABRB1 ^c	Intron 1	IVS1+24T→G	-	64
GABRB1 ^c	Intron 5	IVS6+72T→G	-	65
GABRB1 ^c	Intron 7	IVS7-34A→G	-	66
GABRB3 ^r	Intron 1	IVS1-14C→T	-	67
GABRB3 ^r	Intron 7	IVS7+58delA	-	68
GABRD ^r	Intron 6	IVS6+132insC	-	69
GABRD ^r	Intron 6	IVS6+130insC	-	70
GABRD ^r	Intron 6	IVS6+73del	-	71
CGCGCCACCGCCCCCTTCCGCG				
GABRG3 ^c	Intron 8	IVS8-102C→T	-	72

Note: ^r Mutations or variations only occurring in individuals with epilepsy; ^b Variant seen only in normal control samples; ^c Mutations or variants seen in individuals with epilepsy as well as normal control samples. The KCNQ2 numbering is based on the large isoform (inclusion of exon 10a). The numbering of exons and introns for SCN2A is based on the publication of Kasai et al., 2001.

References

References cited herein are listed on the following pages, and are incorporated herein by this reference.

- 5 Andermann, E. (1982). *In: Genetic basis of the epilepsies.*
Anderson, VE. Hauser, WA. Penry, JK. and Singh, CF.
(Editors). New York, Raven Press. 355-374.
- Annegers, JF. (1996). *The treatment of epilepsy:*
10 *Principles and practice.* Second Edition. (Wyllie E
(Ed) Williams and Wilkins).
- Bell, JI. and Lathrop, M. (1996). *Nature Genet.* 13: 377-
378.
- Berkovic, SF. Andermann, F. Andermann, E. and Gloor, P.
(1987). *Neurology* 37: 993-1000.
- 15 Berkovic, SF. Reutens, DC. Andermann, E. and Andermann, F.
(1994). *In: Epileptic seizures and syndromes.* Wolf,
P. (Editor). London: John Libbey. 25-37.
- Berkovic, SF. Mazarib, A. Neufeld, M. et al. (2000).
Neurology (Supplement 3). 54: A356.
- 20 Biervert, C. Schroeder, BC. Kubisch, C. Berkovic, SF.
Propping, P. Jentsch, TJ. and Steinlein, OK. (1998).
Science 279: 403-406.
- Breaker, RR. and Joyce, GF. (1995). *Chem. Biol.*
2: 655-600.
- 25 Cavazzuti, GB. Capella, L. and Nalin, A. (1980). *Epilepsia*
21: 43-55.
- Charlier, C. Singh, NA. Ryan, SG. Lewis, TB. Reus, BE.
Leach, RJ. and Leppert, M. (1998). *Nature Genet.* 18:
53-55.
- 30 Cole, SP. Campling, BG. Atlaw, T. Kozbor, D. and Roder,
JC. (1984). *Mol. Cell Biochem.* 62: 109-120.
- Collins, FS. (1995). *Nature Genet.* 9: 347-350.
- Commission on Classification and Terminology of the
International League against Epilepsy. (1989).
35 *Epilepsia* 30: 389-399.

- Cote, RJ. Morrissey, DM. Houghton, AN. Beattie, EJ Jr. Oettgen, HF. and Old, LJ. (1983). *Proc. Natl. Acad. Sci. USA* 80: 2026-2030.
- 5 Doose, H. and Baier, WK. (1987). *Neuropediatrics* 18 (Supplement 1): 1-64.
- Doose, H. and Baier, W. (1989). *Clev. Clin. J. Med.* 56 (Supplement): s105-s110.
- Dworakowska, B. and Dolowy, K. (2000). *Acta Biochim. Pol.* 47: 685-703.
- 10 Escayg, A. MacDonald, BT. Meisler, MH. Baulac, S. Huberfeld, G. An-Gourfinkel, I. Brice, A. LeGuern, E. Moulard, B. Chaigne, D. Buresi, C. and Malafosse, A. (2000). *Nature Genet.* 24: 343-345.
- Fong, GC. Shah, PU. Gee, MN. Serratos, JM. Castroviejo, IP. Khan, S. Ravat, SH. Mani, J. Huang, Y. Zhao, HZ. Medina, MT. Treiman, LJ. Pineda, G. and Delgado-Escueta, AV. (1998). *Am. J. Hum. Genet.* 63: 1117-1129.
- 15 Gamper, N. and Shapiro, MS. (2003). *J. Gen. Physiol.* 122: 17-31.
- 20 Gardiner, M. (2000). *J Neurol.* 247: 327-334.
- Goldman, CK. Soroceanu, L. Smith, N. Gillespie, GY. Shaw, W. Burgess, S. Bilbao, G. and Curiel, DT. (1997). *Nature Biotechnology* 15: 462-466.
- Gonzalez, JE. et al. (1999). *Drug Discov. Today* 4: 431-439.
- 25 Greenberg, DA. Delgado-Escueta, AV. Maldonado, HM. and Widellitz, H. (1988a). *Genet Epidemiol.* 5: 81-94.
- Greenberg, DA. Delgado-Escueta, AV. Widellitz, H. Sparkes, RS. Treiman, L. Maldonado, HM. Park, MS. and Terasaki, PI. (1988b). *Am. J. Med. Genet.* 31: 185-192.
- 30 Greenberg, DA. Durner, M. and Delgado-Escueta, AV. (1992). *Neurology* 42 (Suppl 5): 56-62.
- Hamill, OP. et al. (1981). *Pflugers Arch.* 391: 85-100.
- Haseloff, J. and Gerlach, WL. (1988). *Nature* 334: 585-591.
- 35 Hauser, WA. Annegers, JF. and Kurland, LT. (1993). *Epilepsia* 34: 453-468.

- Heller, RA. Schena, M. Chai, A. Shalon, D. Bedilion, T. Gilmore, J. Woolley, DE. and Davis RW. (1997). *Proc. Natl. Acad. Sci. USA* 94: 2150-2155.
- Huse, WD. Sastry, L. Iverson, SA. Kang, AS. Alting-Mees, M. Burton, DR. Benkovic, SJ. and Lerner, RA. (1989). *Science* 246: 1275-1281.
- Italian League Against Epilepsy Genetic Collaborative Group. (1993). *Epilepsia* 34: 819-26.
- Janz, D. Beck-Mannagetta, G. and Sander, T. (1992). *Neurology* 42 (Suppl 5): 48-55.
- Jentsch, TJ. (2000). *Nature Rev. Neurosci.* 1: 21-29.
- Kasai, N. Fukushima, K. Ueki, Y. Prasad, S. Nosakowski, J. Sugata, K. Sugata, A. Nishizaki, K. Meyer, NC. and Smith, RJ. (2001). *Gene* 264: 113-122.
- Kohler, G. and Milstein, C. (1975). *Nature* 256: 495-497.
- Kozbor, D. Abramow-Newerly, W. Tripputi, P. Cole, SP. Weibel, J. Roder, JC. and Croce, CM. (1985). *J. Immunol. Methods* 81:31-42.
- Lernmark, A. and Ott, J. (1998). *Nature Genet.* 19: 213-214.
- Ohya, Y. and Botstein, D. (1994). *Science* 263: 963-966.
- Okubo, Y. Matsuura, M. Asai, T. Asai, K. Kato, M. Kojima, T. and Toru, M. (1994). *Epilepsia* 35: 832-841.
- Orlandi, R. Gussow, DH. Jones, PT. and Winter, G. (1989). *Proc. Natl. Acad. Sci. USA* 86: 3833-3837.
- Palfi, A. Kortvely, E. Fekete, E. Kovacs, B. Varszegi, S. and Gulya, K. (2002). *Life Sciences* 70: 2829-2855.
- Panayiotopoulos, CP. and Obeid, T. (1989). *Ann. Neurol.* 25: 440-443.
- Phillips, HA. Favre, I. Kirkpatrick, M. Zuberi, SM. Goudie, D. Heron, SE. Scheffer, IE. Sutherland, GR. Berkovic, SF. Bertrand, D. and Mulley, JC. (2001). *Am. J. Hum. Genet.* 68: 225-231.
- Reutens, DC. and Berkovic, SF. (1995). *Neurology* 45: 1469-1476.
- Rickert, RC. Roes, J. and Rajewsky, K. (1997). *Nucleic Acids Res.* 25: 1317-1318.

- Risch, N. and Botstein, D. (1996). *Nature Genet.* 12: 351-353.
- Roger, J. Bureau, M. Dravet, C. Dreifuss, FE. Perret, A. and Wolf, P. (1992). *Epileptic syndromes in infancy, childhood and adolescence*. 2nd Edition. London, John Libbey.
- Scharf, KD. Materna, T. Treuter, E. and Nover, L. (1994). *Results Probl. Cell Differ.* 20: 125-162.
- Scheffer, IE. and Berkovic, SF. (1997). *Brain* 120: 479-90.
- 10 Schena, M. Shalon, D. Heller, R. Chai, A. Brown, PO. and Davis, RW. (1996). *Proc. Natl. Acad. Sci. USA* 93: 10614-10619.
- Schmitt, N. Schwarz, M. Peretz, A. Abitbol, I. Attali, B. and Pongs, O. (2000). *Embo J.* 19: 332-340.
- 15 Schwake, M. Pusch, M. Kharkovets, T. and Jentsch, TJ. (2000). *J. Biol. Chem.* 275: 13343-13348.
- Schwenk, F. Baron, U. and Rajewsky, K. (1995). *Nucleic Acids Res.* 23: 5080-5081.
- Singh, NA. Charlie, C. Stauffer, D. DuPont, BR. Leach, RJ. 20 Melis, R. Ronen, GM. Bjerre, I. Quattlebaum, T. Murphy, JV. McHarg, ML. Gagnon, D. Rosales, TO. Peiffer, A. Anderson, VE. and Leppert, M. (1998). *Nature Genet.* 18: 25-29.
- Singh, R. Scheffer, IE. Crossland, K. and Berkovic, SF. 25 (1999). *Ann. Neurol.* 45: 75-81.
- Steinlein, OK. Mulley, JC. Propping, P. Wallace, RH. Phillips, HA. Sutherland, GR. Scheffer, IE. and Berkovic, SF. (1995). *Nature Genet.* 11: 201-203.
- Todd, JA. (1999). *Lancet* 354 (Supplement 1): 15-16.
- 30 Toutenhoofd, SL. and Strehler, EE. (2000). *Cell Calcium* 28: 83-96.
- Wallace, RH. Marini, C. Petrou, S. Harkin, LA. Bowser, DN. Panchal, RG. Williams, DA. Sutherland, GR. Mulley, JC. Scheffer, IE. and Berkovic, SF. (2001a). *Nature Genet.* 35 28: 49-52.
- Wallace, RH. Scheffer, IE. Barnett, S. Richards, M. Dibbens, L. Desai, RR. Lerman-Sagie, T. Lev, D.

- Mazarib, A. Brand, N. Ben-Zeev, B. Goikhman, I. Singh, R. Kremmidiotis, G. Gardner, A. Sutherland, GR. George, AL Jr. Mulley, JC. and Berkovic, SF. (2001b). *Am. J. Hum. Genet.* 68: 859-865.
- 5 Wallace, RH. Wang, DW. Singh, R. Scheffer, I. George, A. Phillips, H. Saar, K. Reis, A. Johnson, E. Sutherland, G. Berkovic, S. and Mulley, J. (1998). *Nature Genet.* 19: 366-370.
- 10 Wen, H. and Levitan, IB. (2002). *J. Neurosci.* 22: 7991-8001.
- Winter, G. and Milstein, C. (1991). *Nature* 349: 293-299.
- Wyman, AR. and White, R. (1980). *Proc. Natl. Acad. Sci.* 77: 6754-6758.
- 15 Yus-Najera, E. Santana-Castro, I. and Villarroel, A. (2002). *J. Biol. Chem.* 277: 28545-28553.
- Zara, F. Bianchi, A. Avanzini, G. Di Donato, S. Castellotti, B. Patel, PI. and Pandolfo, M. (1995). *Hum. Mol. Genet.* 4: 1201-1207.
- 20 Zara, F. Gennaro, E. Stabile, M. Carbone, I. Malacarne, M. Majello, L. Santangelo, R. de Falco, FA. and Bricarelli, FD. (2000). *Am. J. Hum. Genet.* 66: 1552-1557.

Claims

1. A method of identifying a subject predisposed to a disorder associated with ion channel dysfunction, comprising ascertaining whether at least one of the genes encoding ion channel subunits in said subject has undergone a mutation event selected from the group consisting of the mutation events set forth in the following Table:

Subunit Gene	Exon/Intron	DNA Mutation
SCN1A	Exon 5	c664C→T
SCN1A	Exon 8	c1152G→A
SCN1A	Exon 9	c1183G→C
SCN1A	Exon 9	c1207T→C
SCN1A	Exon 9	c1237T→A
SCN1A	Exon 9	c1265T→A
SCN1A	Exon 21	c4219C→T
SCN1A	Exon 26	c5339T→C
SCN1A	Exon 26	c5674C→T
SCN1B	Exon 3	c254G→A
SCN2A	Exon 6A	c668G→A
SCN2A	Exon 16	c2674G→A
SCN2A	Exon 17	c3007C→A
SCN2A	Exon 19	c3598A→G
SCN2A	Exon 20	c39556G→A
SCN2A	Exon 12	c1785T→C
SCN2A	Exon 27	c4919T→A
SCN1A	Intron 9	IVS9-1G→A
SCN1A	Intron 23	IVS23+33G→A
SCN2A	Intron 7	IVS7+61T→A
SCN2A	Intron 19	IVS19-55A→G
SCN2A	Intron 22	IVS22-31A→G
SCN2A	Intron 2	IVS2-28G→A
SCN2A	Intron 8	IVS8-3T→C
SCN2A	Intron 11	IVS11+49A→G
SCN2A	Intron 11	IVS11-16C→T
SCN2A	Intron 17	IVS17-71C→T
SCN2A	Intron 17	IVS17-74delG
SCN2A	Intron 17	IVS17-74insG
CHRNA5	Exon 4	c400G→A
CHRNA2	Exon 4	c373G→A
CHRNA3	Exon 2	c110G→A
CHRNA2	Exon 4	c351C→T

- 82 -

CHRNA2	Exon 5	c771C→T
CHRNA3	Exon 2	c159A→G
CHRNA3	Exon 4	c291G→A
CHRNA3	Exon 4	c345G→A
CHRNA2	Intron 3	IVS3-16C→T
CHRNA3	Intron 3	IVS3-5T→C
CHRNA3	Intron 4	IVS4+8G→C
KCNQ2	Exon 1	c204-c205insC
KCNQ2	Exon 1	c1A→G
KCNQ2	Exon 1	c2T→C
KCNQ2	Exon 8	c1057C→G
KCNQ2	Exon 11	c1288C→T
KCNQ2	Exon 14	c1710A→T
KCNQ2	Exon 15	c1856T→G
KCNQ2	Intron 9	IVS9+ (46-48) delCCT
KCNQ3	Intron 11	IVS11+43G→A
KCNQ3	Intron 12	IVS12+29G→A
GABRB1	Exon 5	c508C→T
GABRB1	Exon 9	c1329G→A
GABRB1	Exon 8	c975C→T
GABRG3	Exon 8	c995T→C
GABRA1	5' UTR	c-142A→G
GABRA1	5' UTR	c-31C→T
GABRA2	3' UTR	c1615G→A
GABRA5	5' UTR	c-271G→C
GABRA5	5' UTR	c-228A→G
GABRA5	5' UTR	c-149G→C
GABRB2	5' UTR	c-159C→T
GABRB2	3' UTR	c1749C→T
GABRPi	5' UTR	c-101C→T
GABRB1	Intron 1	IVS1+24T→G
GABRB1	Intron 6	IVS6+72T→G
GABRB1	Intron 7	IVS7-34A→G
GABRB3	Intron 1	IVS1-14C→T
GABRB3	Intron 7	IVS7+58delAA
GABRD	Intron 6	IVS6+132insC
GABRD	Intron 6	IVS6+130insC
GABRD	Intron 6	IVS6+73delCGCGCCACCGCCCCTTCCGCG
GABRG3	Intron 8	IVS8-102C→T

2. A method as claimed in claim 1 wherein a cDNA derived from said subject comprises the sequence set forth in one of SEQ ID NOS: 1-72.

3. A method as claimed in claim 1 wherein a cDNA derived from said subject has the sequence set forth in one of SEQ ID NOS: 1-72.

4. A method as claimed in any one of claims 1 to 3, wherein said mutation event disrupts the functioning of an assembled ion channel so as to produce an epilepsy phenotype in said subject.

5. A method as claimed in any one of claims 1 to 3, wherein said mutation event disrupts the functioning of an assembled ion channel so as to produce one or more disorders associated with ion channel dysfunction, including but not restricted to, hyper- or hypo-kalemic periodic paralysis, myotonias, malignant hyperthermia, myasthenia, cardiac arrhythmias, episodic ataxia, migraine, Alzheimer's disease, Parkinson's disease, schizophrenia, hyperekplexia, anxiety, depression, phobic obsessive symptoms, neuropathic pain, inflammatory pain, chronic/acute pain, Bartter's syndrome, polycystic kidney disease, Dent's disease, hyperinsulinemic hypoglycemia of infancy, cystic fibrosis, congenital stationary night blindness and total colour-blindness in said subject.

6. A method as claimed in any one of claims 1 to 3, wherein said mutation event disrupts the functioning of an assembled ion channel so as to produce an epilepsy phenotype when expressed in combination with one or more additional mutations or variations in said ion channel subunit genes.

7. A method as claimed in any one of claims 1 to 3, wherein said mutation event disrupts the functioning of an assembled ion channel so as to produce one or more disorders associated with ion channel dysfunction, including but not restricted to, hyper- or hypo-kalemic periodic paralysis, myotonias, malignant hyperthermia,

myasthenia, cardiac arrhythmias, episodic ataxia, migraine, Alzheimer's disease, Parkinson's disease, schizophrenia, hyperekplexia, anxiety, depression, phobic obsessive symptoms, neuropathic pain, inflammatory pain, chronic/acute pain, Bartter's syndrome, polycystic kidney disease, Dent's disease, hyperinsulinemic hypoglycemia of infancy, cystic fibrosis, congenital stationary night blindness and total colour-blindness, when expressed in combination with one or more additional mutations or variations in said ion channel subunit genes.

8. An isolated nucleic acid molecule encoding a mutant or variant ion channel subunit wherein a mutation event selected from the group consisting of the mutation events set forth in the following Table:

Subunit Gene	Exon/Intron	DNA Mutation
SCN1A	Exon 5	c664C→T
SCN1A	Exon 8	c1152G→A
SCN1A	Exon 9	c1183G→C
SCN1A	Exon 9	c1207T→C
SCN1A	Exon 9	c1237T→A
SCN1A	Exon 9	c1265T→A
SCN1A	Exon 21	c4219C→T
SCN1A	Exon 26	c5339T→C
SCN1A	Exon 26	c5674C→T
SCN1B	Exon 3	c254G→A
SCN2A	Exon 6A	c668G→A
SCN2A	Exon 16	c2674G→A
SCN2A	Exon 17	c3007C→A
SCN2A	Exon 19	c3598A→G
SCN2A	Exon 20	c3956G→A
SCN2A	Exon 12	c1785T→C
SCN2A	Exon 27	c4919T→A
SCN1A	Intron 9	IVS9-1G→A
SCN1A	Intron 23	IVS23+33G→A
SCN2A	Intron 7	IVS7+61T→A
SCN2A	Intron 19	IVS19-55A→G
SCN2A	Intron 22	IVS22-31A→G
SCN2A	Intron 2	IVS2-28G→A
SCN2A	Intron 8	IVS8-3T→C
SCN2A	Intron 11	IVS11+49A→G
SCN2A	Intron 11	IVS11-16C→T

SCN2A	Intron 17	IVS17-71C→T
SCN2A	Intron 17	IVS17-74delG
SCN2A	Intron 17	IVS17-74insG
CHRNA5	Exon 4	c400G→A
CHRNA2	Exon 4	c373G→A
CHRNA3	Exon 2	c110G→A
CHRNA2	Exon 4	c351C→T
CHRNA2	Exon 5	c771C→T
CHRNA3	Exon 2	c159A→G
CHRNA3	Exon 4	c291G→A
CHRNA3	Exon 4	c345G→A
CHRNA2	Intron 3	IVS3-16C→T
CHRNA3	Intron 3	IVS3-5T→C
CHRNA3	Intron 4	IVS4+8G→C
KCNQ2	Exon 1	c204-c205insC
KCNQ2	Exon 1	c1A→G
KCNQ2	Exon 1	c2T→C
KCNQ2	Exon 8	c1057C→G
KCNQ2	Exon 11	c1288C→T
KCNQ2	Exon 14	c1710A→T
KCNQ2	Exon 15	c1856T→G
KCNQ2	Intron 9	IVS9+ (46-48) delCCT
KCNQ3	Intron 11	IVS11+43G→A
KCNQ3	Intron 12	IVS12+29G→A
GABRB1	Exon 5	c508C→T
GABRB1	Exon 9	c1329G→A
GABRB1	Exon 8	c975C→T
GABRG3	Exon 8	c995T→C
GABRA1	5' UTR	c-142A→G
GABRA1	5' UTR	c-31C→T
GABRA2	3' UTR	c1615G→A
GABRA5	5' UTR	c-271G→C
GABRA5	5' UTR	c-228A→G
GABRA5	5' UTR	c-149G→C
GABRB2	5' UTR	c-159C→T
GABRB2	3' UTR	c1749C→T
GABRPi	5' UTR	c-101C→T
GABRB1	Intron 1	IVS1+24T→G
GABRB1	Intron 6	IVS6+72T→G
GABRB1	Intron 7	IVS7-34A→G
GABRB3	Intron 1	IVS1-14C→T
GABRB3	Intron 7	IVS7+58delAA
GABRD	Intron 6	IVS6+132insC
GABRD	Intron 6	IVS6+130insC
GABRD	Intron 6	IVS6+73delCGCGCCACCGCCCTTCCGCG
GABRG3	Intron 8	IVS8-102C→T

has occurred.

9. An isolated nucleic acid molecule encoding a mutant or variant ion channel subunit as claimed in claim 8
5 wherein a cDNA derived therefrom comprises the sequence set forth in one of SEQ ID NOS: 1-72.

10. An isolated nucleic acid molecule encoding a mutant or variant ion channel subunit as claimed in claim 8
10 wherein a cDNA derived therefrom has the sequence set forth in one of SEQ ID NOS: 1-72.

11. An isolated nucleic acid molecule encoding a mutant or variant ion channel subunit as claimed in any one of
15 claims 8 to 10, wherein said mutation event disrupts the functioning of an assembled ion channel so as to produce an epilepsy phenotype.

12. An isolated nucleic acid molecule encoding a mutant or variant ion channel subunit as claimed in any one of
20 claims 8 to 10, wherein said mutation event disrupts the functioning of an assembled ion channel so as to produce one or more disorders associated with ion channel dysfunction, including but not restricted to, hyper- or
25 hypo-kalemic periodic paralysis, myotonias, malignant hyperthermia, myasthenia, cardiac arrhythmias, episodic ataxia, migraine, Alzheimer's disease, Parkinson's disease, schizophrenia, hyperekplexia, anxiety, depression, phobic obsessive symptoms, neuropathic pain,
30 inflammatory pain, chronic/acute pain, Bartter's syndrome, polycystic kidney disease, Dent's disease, hyperinsulinemic hypoglycemia of infancy, cystic fibrosis, congenital stationary night blindness and total colour-blindness.

35

13. An isolated nucleic acid molecule encoding a mutant or variant ion channel subunit as claimed in any one of

claims 8 to 10, wherein said mutation event disrupts the functioning of an assembled ion channel so as to produce an epilepsy phenotype when expressed in combination with one or more additional mutations or variations in said ion channel subunit genes.

14. An isolated nucleic acid molecule encoding a mutant or variant ion channel subunit as claimed in any one of claims 8 to 10, wherein said mutation event disrupts the functioning of an assembled ion channel so as to produce one or more disorders associated with ion channel dysfunction, including but not restricted to, hyper- or hypo-kalemic periodic paralysis, myotonias, malignant hyperthermia, myasthenia, cardiac arrhythmias, episodic ataxia, migraine, Alzheimer's disease, Parkinson's disease, schizophrenia, hyperekplexia, anxiety, depression, phobic obsessive symptoms, neuropathic pain, inflammatory pain, chronic/acute pain, Bartter's syndrome, polycystic kidney disease, Dent's disease, hyperinsulinemic hypoglycemia of infancy, cystic fibrosis, congenital stationary night blindness and total colour-blindness, when expressed in combination with one or more additional mutations or variations in said ion channel subunit genes.

25

15. An isolated nucleic acid molecule comprising any one of the nucleotide sequences set forth in SEQ ID NOS: 1-72.

16. An isolated nucleic acid molecule consisting of any one of the nucleotide sequences set forth in SEQ ID NOS: 1-72.

17. An isolated nucleic acid molecule encoding a mutant KCNQ2 subunit, wherein the mutation event has occurred in the C-terminal domain of the KCNQ2 subunit and leads to a disturbance in the calmodulin binding affinity of the subunit, so as to produce an epilepsy phenotype.

18. An isolated nucleic acid molecule as claimed in claim 17 wherein the mutation event has occurred in exon 8, exon 11, exon 14 or exon 15.

5

19. An isolated polypeptide, said polypeptide being a mutant or variant ion channel subunit wherein a mutation event selected from the group consisting of the mutation events set forth in the following Table:

Subunit Gene	Amino Acid Change
SCN1A	R222X
SCN1A	W384X
SCN1A	A395P
SCN1A	F403L
SCN1A	Y413N
SCN1A	V422E
SCN1A	R1407X
SCN1A	M1780T
SCN1A	R1892X
SCN1B	R85H
SCN2A	R223Q
SCN2A	V892I
SCN2A	L1003I
SCN2A	T1200A
SCN2A	R1319Q
CHRNA5	V134I
CHRNA2	A125T
CHRNA3	R37H
KCNQ2	K69fsX119
KCNQ2	M1V
KCNQ2	M1T
KCNQ2	R353G
KCNQ2	R430X
KCNQ2	R570S
KCNQ2	L619R

10 has occurred.

20. An isolated polypeptide, said polypeptide being a mutant or variant ion channel subunit as claimed in claim 19 wherein the polypeptide comprises the amino acid sequence set forth in one of SEQ ID NOS: 73-95.

15

21. An isolated polypeptide, said polypeptide being a mutant or variant ion channel subunit as claimed in claim

19 wherein the polypeptide has the amino acid sequence set forth in one of SEQ ID NOS: 73-95.

22. An isolated polypeptide, said polypeptide being a mutant or variant ion channel subunit as claimed in any one of claims 19 to 21, wherein said mutation event disrupts the functioning of an assembled ion channel so as to produce an epilepsy phenotype.

23. An isolated polypeptide, said polypeptide being a mutant or variant ion channel subunit as claimed in any one of claims 19 to 21, wherein said mutation event disrupts the functioning of an assembled ion channel so as to produce one or more disorders associated with ion channel dysfunction, including but not restricted to, hyper- or hypo-kalemic periodic paralysis, myotonias, malignant hyperthermia, myasthenia, cardiac arrhythmias, episodic ataxia, migraine, Alzheimer's disease, Parkinson's disease, schizophrenia, hyperekplexia, anxiety, depression, phobic obsessive symptoms, neuropathic pain, inflammatory pain, chronic/acute pain, Bartter's syndrome, polycystic kidney disease, Dent's disease, hyperinsulinemic hypoglycemia of infancy, cystic fibrosis, congenital stationary night blindness and total colour-blindness.

24. An isolated polypeptide, said polypeptide being a mutant or variant ion channel subunit as claimed in any one of claims 19 to 21, wherein said mutation event disrupts the functioning of an assembled ion channel so as to produce an epilepsy phenotype when expressed in combination with one or more additional mutations or variations in said ion channel subunit genes.

25. An isolated polypeptide, said polypeptide being a mutant or variant ion channel subunit as claimed in any one of claims 19 to 21, wherein said mutation event

disrupts the functioning of an assembled ion channel so as to produce one or more disorders associated with ion channel dysfunction, including but not restricted to, hyper- or hypo-kalemic periodic paralysis, myotonias, malignant hyperthermia, myasthenia, cardiac arrhythmias, episodic ataxia, migraine, Alzheimer's disease, Parkinson's disease, schizophrenia, hyperekplexia, anxiety, depression, phobic obsessive symptoms, neuropathic pain, inflammatory pain, chronic/acute pain, Bartter's syndrome, polycystic kidney disease, Dent's disease, hyperinsulinemic hypoglycemia of infancy, cystic fibrosis, congenital stationary night blindness and total colour-blindness, when expressed in combination with one or more additional mutations or variations in said ion channel subunit genes.

26. An isolated polypeptide comprising any one of the amino acid sequences set forth in SEQ ID NOS: 73-95.

27. An isolated polypeptide consisting of any one of the amino acid sequences set forth in SEQ ID NOS: 73-95.

28. An isolated polypeptide, said polypeptide being a mutant KCNQ2 subunit, wherein the mutation event has occurred in the C-terminal domain of the KCNQ2 subunit and leads to a disturbance in the calmodulin binding affinity of the subunit, so as to produce an epilepsy phenotype.

29. An isolated polypeptide complex, said polypeptide complex being an assembled mammalian ion channel including an ion channel subunit comprising a polypeptide as defined in any one of claims 19 to 28.

30. An expression vector comprising a nucleic acid molecule as claimed in any one of claims 8 to 18.

31. A cell comprising at least one expression vector as claimed in claim 30.

32. A cell as claimed in claim 31 comprising two or more
5 expression vectors.

33. A cell comprising at least one ion channel type, wherein the or each ion channel type incorporates at least one mutant polypeptide as claimed in any one claims 19 to
10 28.

34. A cell as claimed in claim 33 comprising ion channels that incorporate two or more mutant polypeptides.

15 35. A cell as claimed in claim 33 comprising two or more ion channel types each incorporating one or more mutant polypeptides.

20 36. A method of preparing a polypeptide, comprising the steps of:

(1) culturing cells as claimed in any one of claims 31 to 35 under conditions effective for polypeptide production; and

(2) harvesting the polypeptide.

25

37. A polypeptide prepared by the method of claim 36.

30 38. An antibody which is immunologically reactive with an isolated polypeptide as claimed in any one of claims 19 to 28 or claim 37, or an isolated polypeptide complex as claimed in claim 29.

35 39. An antibody as claimed in claim 38 which is selected from the group consisting of a monoclonal antibody, a humanised antibody, a chimeric antibody or an antibody fragment including a Fab fragment, (Fab')₂ fragment, Fv

fragment, single chain antibodies and single domain antibodies.

40. A method of treating epilepsy comprising
5 administering an antibody as claimed in either one of
claims 38 or 39 to a subject in need of such treatment.

41. The use of an antibody, as claimed in either one of
claims 38 or 39, in the manufacture of a medicament for
10 the treatment of epilepsy.

42. A method of treating a disorder associated with ion
channel dysfunction, including but not restricted to,
hyper- or hypo-kalemic periodic paralysis, myotonias,
15 malignant hyperthermia, myasthenia, cardiac arrhythmias,
episodic ataxia, migraine, Alzheimer's disease,
Parkinson's disease, schizophrenia, hyperekplexia,
anxiety, depression, phobic obsessive symptoms,
neuropathic pain, inflammatory pain, chronic/acute pain,
20 Bartter's syndrome, polycystic kidney disease, Dent's
disease, hyperinsulinemic hypoglycemia of infancy, cystic
fibrosis, congenital stationary night blindness or total
colour-blindness, comprising administering an antibody as
claimed in either one of claims 38 or 39 to a subject in
25 need of such treatment.

43. The use of an antibody, as claimed in either one of
claims 38 or 39, in the manufacture of a medicament for
the treatment of a disorder associated with ion channel
30 dysfunction, including but not restricted to, hyper- or
hypo-kalemic periodic paralysis, myotonias, malignant
hyperthermia, myasthenia, cardiac arrhythmias, episodic
ataxia, migraine, Alzheimer's disease, Parkinson's
disease, schizophrenia, hyperekplexia, anxiety,
35 depression, phobic obsessive symptoms, neuropathic pain,
inflammatory pain, chronic/acute pain, Bartter's syndrome,
polycystic kidney disease, Dent's disease,

hyperinsulinemic hypoglycemia of infancy, cystic fibrosis, congenital stationary night blindness or total colour-blindness.

5 44. A method of treating epilepsy comprising administering a selective agonist, antagonist or modulator of an ion channel when it has undergone a mutation event or combination of events as defined in any one of claims 19 to 28 to a subject in need of such treatment.

10 45. The use of a selective agonist, antagonist or modulator of an ion channel when it has undergone a mutation event as defined in any one of claims 19 to 28 in the manufacture of a medicament for the treatment of
15 epilepsy.

46. A method of treating a disorder associated with ion channel dysfunction, including but not restricted to, hyper- or hypo-kalemic periodic paralysis, myotonias,
20 malignant hyperthermia, myasthenia, cardiac arrhythmias, episodic ataxia, migraine, Alzheimer's disease, Parkinson's disease, schizophrenia, hyperekplexia, anxiety, depression, phobic obsessive symptoms, neuropathic pain, inflammatory pain, chronic/acute pain,
25 Bartter's syndrome, polycystic kidney disease, Dent's disease, hyperinsulinemic hypoglycemia of infancy, cystic fibrosis, congenital stationary night blindness or total colour-blindness, comprising administering a selective agonist, antagonist or modulator of an ion channel when it
30 has undergone a mutation event or combination of events as defined in any one of claims 19 to 28 to a subject in need of such treatment.

47. The use of a selective agonist, antagonist or
35 modulator of an ion channel when it has undergone a mutation event as claimed in any one of claims 19 to 28 in the manufacture of a medicament for the treatment of a

disorder associated with ion channel dysfunction, including but not restricted to, hyper- or hypo-kalemic periodic paralysis, myotonias, malignant hyperthermia, myasthenia, cardiac arrhythmias, episodic ataxia, migraine, Alzheimer's disease, Parkinson's disease, schizophrenia, hyperekplexia, anxiety, depression, phobic obsessive symptoms, neuropathic pain, inflammatory pain, chronic/acute pain, Bartter's syndrome, polycystic kidney disease, Dent's disease, hyperinsulinemic hypoglycemia of infancy, cystic fibrosis, congenital stationary night blindness or total colour-blindness.

48. A method of treating epilepsy comprising administering an isolated DNA molecule which is the complement (antisense) of a nucleic acid molecule as claimed in any one of claims 8 to 18 and which encodes an RNA molecule that hybridizes with the mRNA encoded by a nucleic acid molecule as claimed in any one of claims 8 to 18, to a subject in need of such treatment.

49. The use of a DNA molecule which is the complement of a nucleic acid molecule as claimed in any one of claims 8 to 18 and which encodes an RNA molecule that hybridizes with the mRNA encoded by a nucleic acid molecule as claimed in any one of claims 8 to 18, in the manufacture of a medicament for the treatment of epilepsy.

50. A method of treating a disorder associated with ion channel dysfunction, including but not restricted to, hyper- or hypo-kalemic periodic paralysis, myotonias, malignant hyperthermia, myasthenia, cardiac arrhythmias, episodic ataxia, migraine, Alzheimer's disease, Parkinson's disease, schizophrenia, hyperekplexia, anxiety, depression, phobic obsessive symptoms, neuropathic pain, inflammatory pain, chronic/acute pain, Bartter's syndrome, polycystic kidney disease, Dent's disease, hyperinsulinemic hypoglycemia of infancy, cystic

fibrosis, congenital stationary night blindness or total colour-blindness, comprising administering an isolated DNA molecule which is the complement (antisense) of a nucleic acid molecule as claimed in any one of claims 8 to 18 and which encodes an RNA molecule that hybridizes with the mRNA encoded by a nucleic acid molecule as claimed in any one of claims 8 to 18, to a subject in need of such treatment.

51. The use of a DNA molecule which is the complement of a nucleic acid molecule as claimed in any one of claims 8 to 18 and which encodes an RNA molecule that hybridizes with the mRNA encoded by a nucleic acid molecule as claimed in any one of claims 8 to 18, in the manufacture of a medicament for the treatment of a disorder associated with ion channel dysfunction, including but not restricted to, hyper- or hypo-kalemic periodic paralysis, myotonias, malignant hyperthermia, myasthenia, cardiac arrhythmias, episodic ataxia, migraine, Alzheimer's disease, Parkinson's disease, schizophrenia, hyperekplexia, anxiety, depression, phobic obsessive symptoms, neuropathic pain, inflammatory pain, chronic/acute pain, Bartter's syndrome, polycystic kidney disease, Dent's disease, hyperinsulinemic hypoglycemia of infancy, cystic fibrosis, congenital stationary night blindness or total colour-blindness.

52. A method of treating epilepsy comprising administering an antibody, as claimed in either one of claims 38 or 39, administration of an agonist, antagonist or modulator of an ion channel when it has undergone a mutation event or combination of events as defined in any one of claims 19 to 28, or administration of a DNA molecule which is the complement of a nucleic acid molecule as claimed in any one of claims 8 to 18 and which encodes an RNA molecule that hybridizes with the mRNA encoded by a nucleic acid molecule as claimed in any one

of claims 8 to 18, in combination with administration of the wild-type ion channel subunit, to a subject in need of such treatment.

5 53. The use of an antibody, as claimed in claims 38 or 39, use of an agonist, antagonist or modulator of an ion channel when it has undergone a mutation event or combination of events as defined in any one of claims 19 to 28, or use of a DNA molecule which is the complement of
10 a nucleic acid molecule as claimed in any one of claims 8 to 18 and which encodes an RNA molecule that hybridizes with the mRNA encoded by a nucleic acid molecule as claimed in any one of claims 8 to 18, in combination with the use of the wild-type ion channel subunit, in the
15 manufacture of a medicament for the treatment of epilepsy.

54. A method of treating a disorder associated with ion channel dysfunction, including but not restricted to, hyper- or hypo-kalemic periodic paralysis, myotonias,
20 malignant hyperthermia, myasthenia, cardiac arrhythmias, episodic ataxia, migraine, Alzheimer's disease, Parkinson's disease, schizophrenia, hyperekplexia, anxiety, depression, phobic obsessive symptoms, neuropathic pain, inflammatory pain, chronic/acute pain,
25 Bartter's syndrome, polycystic kidney disease, Dent's disease, hyperinsulinemic hypoglycemia of infancy, cystic fibrosis, congenital stationary night blindness or total colour-blindness, comprising administering an antibody, as claimed in either one of claims 38 or 39,
30 administration of an agonist, antagonist or modulator of an ion channel when it has undergone a mutation event or combination of events as defined in any one of claims 19 to 28, or administration of a DNA molecule which is the complement of a nucleic acid molecule as claimed in any
35 one of claims 8 to 18 and which encodes an RNA molecule that hybridizes with the mRNA encoded by a nucleic acid molecule as claimed in any one of claims 8 to 18, in

- 97 -

combination with administration of the wild-type ion channel subunit, to a subject in need of such treatment.

55. The use of an antibody, as claimed in claims 387 or
5 39, use of an agonist, antagonist or modulator of an ion channel when it has undergone a mutation event or combination of events as defined in any one of claims 19 to 28, or use of a DNA molecule which is the complement of a nucleic acid molecule as claimed in any one of claims 8
10 to 18 and which encodes an RNA molecule that hybridizes with the mRNA encoded by a nucleic acid molecule as claimed in any one of claims 8 to 18, in combination with the use of the wild-type ion channel subunit, in the manufacture of a medicament for the treatment of a
15 disorder associated with ion channel dysfunction, including but not restricted to, hyper- or hypo-kalemic periodic paralysis, myotonias, malignant hyperthermia, myasthenia, cardiac arrhythmias, episodic ataxia, migraine, Alzheimer's disease, Parkinson's disease,
20 schizophrenia, hyperekplexia, anxiety, depression, phobic obsessive symptoms, neuropathic pain, inflammatory pain, chronic/acute pain, Bartter's syndrome, polycystic kidney disease, Dent's disease, hyperinsulinemic hypoglycemia of infancy, cystic fibrosis, congenital stationary night
25 blindness or total colour-blindness.

56. Use of a nucleic acid molecule as claimed in any one of claims 8 to 18 for the screening of candidate
30 pharmaceutical agents.

57. Use of a nucleic acid molecule as claimed in any one of claims 8 to 18 for the screening of candidate
35 pharmaceutical agents useful for the treatment of epilepsy.

58. Use of a nucleic acid molecule as claimed in any one of claims 8 to 18 for the screening of candidate

pharmaceutical agents useful for the treatment of a disorder associated with ion channel dysfunction, including but not restricted to, hyper- or hypo-kalemic periodic paralysis, myotonias, malignant hyperthermia, myasthenia, cardiac arrhythmias, episodic ataxia, migraine, Alzheimer's disease, Parkinson's disease, schizophrenia, hyperekplexia, anxiety, depression, phobic obsessive symptoms, neuropathic pain, inflammatory pain, chronic/acute pain, Bartter's syndrome, polycystic kidney disease, Dent's disease, hyperinsulinemic hypoglycemia of infancy, cystic fibrosis, congenital stationary night blindness or total colour-blindness.

59. Use of a polypeptide as claimed in any one of claims 19 to 28 or claim 37, or a polypeptide complex as claimed in claim 29 for the screening of candidate pharmaceutical agents.

60. Use of a polypeptide as claimed in any one of claims 19 to 28 or claim 37, or a polypeptide complex as claimed in claim 29 for the screening of candidate pharmaceutical agents useful for the treatment of epilepsy.

61. Use of a polypeptide as claimed in any one of claims 19 to 28 or claim 37, or a polypeptide complex as claimed in claim 29 for the screening of candidate pharmaceutical agents useful for the treatment of a disorder associated with ion channel dysfunction, including but not restricted to, hyper- or hypo-kalemic periodic paralysis, myotonias, malignant hyperthermia, myasthenia, cardiac arrhythmias, episodic ataxia, migraine, Alzheimer's disease, Parkinson's disease, schizophrenia, hyperekplexia, anxiety, depression, phobic obsessive symptoms, neuropathic pain, inflammatory pain, chronic/acute pain, Bartter's syndrome, polycystic kidney disease, Dent's disease, hyperinsulinemic hypoglycemia of infancy, cystic

fibrosis, congenital stationary night blindness or total colour-blindness.

62. Use of a cell as claimed in any one of claims 31 to 35 for the screening of candidate pharmaceutical agents.

63. Use of a cell as claimed in any one of claims 31 to 35 for the screening of candidate pharmaceutical agents useful for the treatment of epilepsy.

10

64. Use of a cell as claimed in any one of claims 31 to 35 for the screening of candidate pharmaceutical agents useful for the treatment of a disorder associated with ion channel dysfunction, including but not restricted to, hyper- or hypo-kalemic periodic paralysis, myotonias, malignant hyperthermia, myasthenia, cardiac arrhythmias, episodic ataxia, migraine, Alzheimer's disease, Parkinson's disease, schizophrenia, hyperekplexia, anxiety, depression, phobic obsessive symptoms, neuropathic pain, inflammatory pain, chronic/acute pain, Bartter's syndrome, polycystic kidney disease, Dent's disease, hyperinsulinemic hypoglycemia of infancy, cystic fibrosis, congenital stationary night blindness or total colour-blindness.

25

65. A compound when identified through a use as claimed in any one of claims 56 to 64.

30

66. A pharmaceutical composition comprising a compound as claimed in claim 65 and a pharmaceutically acceptable carrier.

35

67. A genetically modified non-human animal comprising an isolated nucleic acid molecule as claimed in any one of claims 8 to 18.

- 100 -

68. A genetically modified, non-human animal which comprises two or more isolated nucleic acid molecules as claimed in any one of claims 8 to 18.

5 69. A genetically modified non-human animal as claimed in either one of claims 67 or 68 in which the animal is selected from the group consisting of rats, mice, hamsters, guinea pigs, rabbits, dogs, cats, goats, sheep, pigs and non-human primates such as monkeys and
10 chimpanzees.

70. A method of producing a non-human transgenic animal comprising a combination of two or more ion channel mutations, comprising the steps of:

- 15 (1) creating a non-human transgenic animal comprising a first nucleic acid molecule as claimed in any one of claims 8 to 18;
- (2) creating one or more additional non-human, transgenic animals comprising a second nucleic
20 acid molecule as claimed in any one of claims 8 to 18; and
- (3) conducting mating combinations so as to produce progeny containing combinations of two or more ion channel mutations which
25 effectively mimic combinations of ion channel mutations responsible for human disease.

71. A non-human, transgenic animal produced by the process of claim 70.

30

72. The use of a genetically modified non-human animal as claimed in any one of claims 67 to 69 or a non-human transgenic animal as claimed in claim 71 in the screening of candidate pharmaceutical compounds.

35

73. The use of a genetically modified non-human animal as claimed in any one of claims 67 to 69 or a non-human

- 101 -

transgenic animal as claimed in claim 71 in the screening of candidate pharmaceutical compounds useful in the treatment of epilepsy.

5 74. The use of a genetically modified non-human animal as claimed in any one of claims 67 to 69 or a non-human transgenic animal as claimed in claim 71 in the screening of candidate pharmaceutical compounds useful in the treatment of a disorder associated with ion channel
10 dysfunction, including but not restricted to, hyper- or hypo-kalemic periodic paralysis, myotonias, malignant hyperthermia, myasthenia, cardiac arrhythmias, episodic ataxia, migraine, Alzheimer's disease, Parkinson's disease, schizophrenia, hyperekplexia, anxiety,
15 depression, phobic obsessive symptoms, neuropathic pain, inflammatory pain, chronic/acute pain, Bartter's syndrome, polycystic kidney disease, Dent's disease, hyperinsulinemic hypoglycemia of infancy, cystic fibrosis, congenital stationary night blindness or total colour-
20 blindness.

75. The use of an isolated nucleic acid molecule as claimed in any one of claims 8 to 18 for the diagnosis or prognosis of epilepsy.

25

76. The use of an isolated nucleic acid molecule as claimed in any one of claims 8 to 18 for the diagnosis or prognosis of a disorder associated with ion channel
30 dysfunction, including but not restricted to, hyper- or hypo-kalemic periodic paralysis, myotonias, malignant hyperthermia, myasthenia, cardiac arrhythmias, episodic ataxia, migraine, Alzheimer's disease, Parkinson's disease, schizophrenia, hyperekplexia, anxiety, depression, phobic obsessive symptoms, neuropathic pain,
35 inflammatory pain, chronic/acute pain, Bartter's syndrome, polycystic kidney disease, Dent's disease, hyperinsulinemic hypoglycemia of infancy, cystic fibrosis,.

congenital stationary night blindness or total colour-blindness.

77. The use of a polypeptide as defined in any one of
5 claims 19 to 28 or claim 37, or polypeptide complex as
claimed in claim 29 in the diagnosis or prognosis of
epilepsy.

78. The use of a polypeptide as defined in any one of
10 claims 19 to 28 or claim 37, or polypeptide complex as
claimed in claim 29 in the diagnosis or prognosis of a
disorder associated with ion channel dysfunction,
including but not restricted to, hyper- or hypo-kalemic
periodic paralysis, myotonias, malignant hyperthermia,
15 myasthenia, cardiac arrhythmias, episodic ataxia,
migraine, Alzheimer's disease, Parkinson's disease,
schizophrenia, hyperekplexia, anxiety, depression, phobic
obsessive symptoms, neuropathic pain, inflammatory pain,
chronic/acute pain, Bartter's syndrome, polycystic kidney
20 disease, Dent's disease, hyperinsulinemic hypoglycemia of
infancy, cystic fibrosis, congenital stationary night
blindness or total colour-blindness.

79. The use of an antibody as claimed in either one of
25 claims 38 or 39 in the diagnosis or prognosis of epilepsy.

80. The use of an antibody as claimed in either one of
claims 38 or 39 in the diagnosis or prognosis of a
disorder associated with ion channel dysfunction,
30 including but not restricted to, hyper- or hypo-kalemic
periodic paralysis, myotonias, malignant hyperthermia,
myasthenia, cardiac arrhythmias, episodic ataxia,
migraine, Alzheimer's disease, Parkinson's disease,
schizophrenia, hyperekplexia, anxiety, depression, phobic
35 obsessive symptoms, neuropathic pain, inflammatory pain,
chronic/acute pain, Bartter's syndrome, polycystic kidney
disease, Dent's disease, hyperinsulinemic hypoglycemia of

infancy, cystic fibrosis, congenital stationary night blindness or total colour-blindness.

81. A method for the diagnosis or prognosis of epilepsy comprising the steps of:

- (1) obtaining DNA from a subject; and
- (2) comparing the DNA of one or more subunits of ion channels from said subject to the DNA of the corresponding native subunits;

wherein identification of one or more DNA molecules as claimed in any one of claims 8 to 18 is an indication of epilepsy, or a predisposition thereto.

82. A method for the diagnosis or prognosis of a disorder associated with ion channel dysfunction, including but not restricted to, hyper- or hypo-kalemic periodic paralysis, myotonias, malignant hyperthermia, myasthenia, cardiac arrhythmias, episodic ataxia, migraine, Alzheimer's disease, Parkinson's disease, schizophrenia, hyperekplexia, anxiety, depression, phobic obsessive symptoms, neuropathic pain, inflammatory pain, chronic/acute pain, Bartter's syndrome, polycystic kidney disease, Dent's disease, hyperinsulinemic hypoglycemia of infancy, cystic fibrosis, congenital stationary night blindness or total colour-blindness, comprising the steps of:

- (1) obtaining DNA from a subject; and
- (2) comparing the DNA of one or more subunits of ion channels from said subject to the DNA of the corresponding native subunits;

wherein identification of one or more DNA molecules as claimed in any one of claims 8 to 18 is an indication of the disorder, or a predisposition thereto.


83. A method as claimed in either one of claims 81 or 82 wherein each DNA fragment is sequenced and the sequences compared.

84. A method as claimed in either one of claims 81 or 82 wherein the DNA fragments are subjected to restriction enzyme analysis.

5

85. A method as claimed in either one of claims 81 or 82 wherein the DNA fragments are subjected to SSCP analysis.

1/5

**FIG. 1**

2/5





FIG. 2

3/5

**FIG. 3**

4/5




FIG. 4

5/5




FIG. 5

SSCP Update Sequences.ST25
SEQUENCE LISTING

<110> Bionomics Limited

<120> P15

<130> SSCP Update PCT

<160> 95

<170> PatentIn version 3.2

<210> 1

<211> 8381

<212> DNA

<213> Homo sapiens

<400> 1

```

atactgcaga ggtctctggt gcatgtgtgt atgtgtgctt ttgtgtgtgt ttgtgtgtct      60
gtgtgtttctg cccagtgag actgcagccc ttgtaaatac ttgacacct ttgcaagaa      120
ggaatctgaa caattgcaac tgaaggcaca ttgttatcat ctctcttttg ggtgatgctg      180
ttcctcactg cagatggata attttccttt taatcaggaa ttcatatgc agaataaatg      240
gtaattaaaa tgtgcaggat gacaagatgg agcaaacagt gcttgtacca ccaggacctg      300
acagcttcaa ctctctcacc agagaatctc ttgctgctat tgaaagacgc attgcagaag      360
aaaaggcaaa gaatcccaaa ccagacaaaa aagatgacga cgaaaatggc ccaaagccaa      420
atagtgaactt ggaagctgga aagaaccttc catttattta tggagacatt cctccagaga      480
tggtgtcaga gcccctggag gacctggacc cctactatat caataagaaa actttttatag      540
tattgaataa attgaaggcc atcttccggt tcagtgccac ctctgccctg tacattttta      600
ctcccttcaa tcctcttagg aaaatagcta ttaagatttt ggtacattca ttattcagca      660
tgctaattat gtgcactatt ttgacaaact gtgtgtttat gacaatgagt aacctctctg      720
attggacaaa gaatgtagaa tacaccttca caggaatata tacttttgaa tcacttataa      780
aaattattgc aaggggattc tgtttagaag attttacttt ccttcgggat ccatggaact      840
ggctcgattt cactgtcatt acatttgcgt acgtcacaga gtttgtggac ctgggcaatg      900
tctcggcatt gagaacattc agagttctct gagcattgaa gacgatttca gtcattccag      960
gcctgaaaac cattgtggga gccctgatcc agtctgtgaa gaagctctca gatgtaatga     1020
tcctgactgt gttctgtctg agcgtatttg ctctaattgg gctgcagctg ttcattgggca     1080
acctgaggaa taaatgtata caatggcctc ccaccaatgc ttccttggag gaacatagta     1140
tagaaaagaa tataactgtg aattataatg gtacacttat aaatgaaact gtctttgagt     1200
ttgactggaa gtcatatatt caagattcaa gatatcatta tttcctggag ggttttttag     1260
atgcactact atgtggaaat agctctgatg caggccaatg tccagaggga tatatgtgtg     1320
tgaaagctgg tagaaatccc aattatggct acacaagctt tgataccttc agttgggctt     1380
ttttgtcctt gtttcgacta atgactcagg acttctggga aaatctttat caactgacat     1440
tacgtgctgc tgggaaaacg tacatgatat tttttgtatt ggtcattttc ttgggctcat     1500

```

SSCP Update Sequences.ST25

tctacctaataaatttgatc	ctggctgtgg	tggccatggc	ctacgaggaa	cagaatcagg	1560
ccaccttgga	agaagcagaa	cagaaagagg	ccgaatttca	gcagatgatt	1620
aaaagcaaca	ggaggcagct	cagcaggcag	caacggcaac	tgcctcagaa	1680
agcccagtgc	agcaggcagg	ctctcagaca	gctcatctga	agcctctaag	1740
agagtgtctaa	ggaaagaaga	aatcggagga	agaaaagaaa	acagaaagag	1800
gggaagagaa	agatgaggat	gaattccaaa	aatctgaatc	tgaggacagc	1860
aaggtttttcg	cttctccatt	gaagggaacc	gattgacata	tgaaaagagg	1920
cacaccagtc	tttgttgagc	atccgtggct	ccctattttc	accaaggcga	1980
caagcctttt	cagctttaga	gggcgagcaa	aggatgtggg	atctgagaac	2040
atgatgagca	cagcaccttt	gaggataacg	agagccgtag	agattccttg	2100
gacgacacgg	agagagacgc	aacagcaacc	tgagtcagac	cagtaggtca	2160
tggcagtgtt	tccagcgaat	gggaagatgc	acagcactgt	ggattgcaat	2220
ccttggttgg	tggaccttca	gttcctacat	cgctgtttgg	acagcttctg	2280
taatagataa	gccagctact	gatgacaatg	gaacaaccac	tgaaactgaa	2340
gaagggtcaag	ttctttccac	gtttccatgg	actttctaga	agatccttcc	2400
gagcaatgag	tatagccagc	attctaacaa	atacagtaga	agaacttgaa	2460
agaaatgccc	accctgttgg	tataaatttt	ccaacatatt	cttaatctgg	2520
catatttggtt	aaaagtgaag	catgttgtca	acctggttgt	gatggacca	2580
tggccatcac	catctgtatt	gtcttaaaata	ctcttttcat	ggccatggag	2640
tgacggacca	tttcaataat	gtgcttacag	taggaaactt	ggttttcact	2700
cagcagaaat	gtttctgaaa	attattgcca	tggatcctta	ctattatttc	2760
ggaatatctt	tgacggtttt	attgtgacgc	ttagcctggg	agaacttgga	2820
tggaaggatt	atctgtttct	cgttcatttc	gattgtctgcg	agttttcaag	2880
cttggccaac	gttaaatatg	ctaataaaga	tcacgggcaa	ttccgtgggg	2940
atttaaccct	cgtcttggcc	atcatcgtct	tcattttttgc	cgtgggtcggc	3000
ttggtaaaag	ctacaaagat	tgtgtctgca	agatcgccag	tgattgtcaa	3060
ggcacatgaa	tgacttcttc	cactccttcc	tgattgtgtt	ccgcgtgctg	3120
ggatagagac	catgtgggac	tgtatggagg	ttgctgggtca	agccatgtgc	3180
tcatgatggg	catggtgatt	ggaaacctag	tggtcctgaa	tctctttctg	3240
tgagctcatt	tagtgacagc	aaccttgacg	ccactgatga	tgataatgaa	3300
tccaaattgc	tgtggatagg	atgcacaaaag	gagtagctta	tgtgaaaaga	3360
aatttatcca	acagtccttc	attaggaaac	aaaagatttt	agatgaaatt	3420
atgatctaaa	caacaagaaa	gacagttgta	tgtccaatca	tacaacagaa	3480
atcttgacta	tcttaaagat	gtaaatggaa	ctacaagtgg	tataggaact	3540

SSCP Update Sequences.ST25

ttgaaaaata	cattattgat	gaaagtgatt	acatgtcatt	cataaacaac	cccagtcctta	3600
ctgtgactgt	accaattgct	gtaggagaat	ctgactttga	aaattttaa	acggaagact	3660
ttagtagtga	atcggatctg	gaagaaagca	aagagaaact	gaatgaaagc	agtagctcat	3720
cagaaggtag	cactgtggac	atcggcgcac	ctgtagaaga	acagcccgtg	gtggaacctg	3780
aagaaactct	tgaaccagaa	gcttgtttca	ctgaaggctg	tgtacaaaga	ttcaagtgtt	3840
gtcaaataca	tgtggaagaa	ggcagaggaa	aacaatgggt	gaacctgaga	aggacgtgtt	3900
tccgaatagt	tgaacataac	tggtttgaga	ccttcattgt	tttcatgatt	ctccttagta	3960
gtggtgctct	ggcatttgaa	gatatatata	ttgatcagcg	aaagacgatt	aagacgatgt	4020
tggaatatgc	tgacaagggt	ttcacttaca	ttttcattct	ggaaatgctt	ctaaaatggg	4080
tggcatatgg	ctatcaaaca	tatttcacca	atgcctgggt	ttggctggac	ttcttaattg	4140
ttgatgtttc	attggtcagt	ttaacagcaa	atgccttggg	ttactcagaa	cttggagcca	4200
tcaaatactt	caggacacta	agagctctga	gacctctaag	agccttatct	cgatttgaag	4260
ggatgagggg	ggttgtgaat	gcccttttag	gagcaattcc	atccatcatg	aatgtgcttc	4320
tggtttgtct	tatatcttgg	ctaattttca	gcatcatggg	cgtaaatttg	tttgctggca	4380
aattctacca	ctgtattaac	accacaactg	gtgacagggt	tgacatcgaa	gacgtgaata	4440
atcatactga	ttgcctaaaa	ctaatagaaa	gaaatgagac	tgctcgatgg	aaaaatgtga	4500
aagtaaactt	tgataatgta	ggatttgggt	atctctcttt	gcttcaagtt	gccacattca	4560
aaggatggat	ggatataatg	tatgcagcag	ttgattccag	aaatgtggaa	ctccagccta	4620
agtatgaaaa	aagtctgtac	atgtatcttt	actttgttat	tttcatcatc	tttgggtcct	4680
tcttcacctt	gaacctgttt	attggtgtca	tcatagataa	tttcaaccag	cagaaaaaga	4740
agtttggagg	tcaagacatc	tttatgacag	aagaacagaa	gaaatactat	aatgcaatga	4800
aaaaattagg	atcgaaaaaa	ccgcaaaagc	ctatacctcg	accaggaaac	aaatttcaag	4860
gaatggctct	tgacttcgta	accagacaag	tttttgacat	aagcatcatg	attctcatct	4920
gtcttaacat	ggtcacaatg	atggtggaaa	cagatgacca	gagtgaatat	gtgactacca	4980
ttttgtcacg	catcaatctg	gtgttcattg	tgctatttac	tggagagtgt	gtactgaaac	5040
tcattctctt	acgccattat	tattttacca	ttggatggaa	tatttttgat	tttgtggttg	5100
tcattctctt	cattgtaggt	atgtttcttg	ccgagctgat	agaaaagtat	ttcgtgtccc	5160
ctaccctgtt	ccgagtgatc	cgtcttgcta	ggattggccg	aatcctacgt	ctgatcaaag	5220
gagcaaaggg	gatccgcacg	ctgctctttg	ctttgatgat	gtcccttcct	gcgttgttta	5280
acatcggcct	cctactcttc	ctagtcatgt	tcattctacgc	catctttggg	atgtccaact	5340
ttgcctatgt	taagagggaa	gttgggatcg	atgacatgtt	caactttgag	acctttggca	5400
acagcatgat	ctgcctattc	caaattacaa	cctctgctgg	ctgggatgga	ttgctagcac	5460
ccattctcaa	cagtaagcca	cccgaactgt	accctaataa	agttaaccct	ggaagctcag	5520
ttaagggaga	ctgtgggaac	ccatctgttg	gaattttctt	ttttgtcagt	tacatcatca	5580

SSCP Update Sequences.ST25

tatccttcct	ggttggtggtg	aacatgtaca	tcgcgggtcat	cctggagaac	ttcagtggtg	5640
ctactgaaga	aagtgcagag	cctctgagtg	aggatgactt	tgagatgttc	tatgagggtt	5700
gggagaagtt	tgatccccgat	gcaactcagt	tcatggaatt	tgaaaaatta	tctcagtttg	5760
cagctgcgct	tgaaccgcct	ctcaatctgc	cacaaccaa	caaactccag	ctcattgcc	5820
tggatttgcc	catggtgagt	ggtgaccgga	tccactgtct	tgatatctta	tttgctttta	5880
caaagcgggt	tctaggagag	agtggagaga	tggatgctct	acgaatacag	atggaagagc	5940
gattcatggc	ttccaatcct	tccaagggtct	cctatcagcc	aatcactact	actttaaaac	6000
gaaaacaaga	ggaagtatct	gctgtcatta	ttcagcgtgc	ttacagacgc	caccttttaa	6060
agcgaactgt	aaaacaagct	tcctttacgt	acaataaaaa	caaaatcaa	ggtggggcta	6120
atcttcttat	aaaagaagac	atgataattg	acagaataaa	tgaaaactct	attacagaaa	6180
aaactgatct	gaccatgtcc	actgcagctt	gtccaccttc	ctatgaccgg	gtgacaaagc	6240
caattgtgga	aaaacatgag	caagaaggca	aagatgaaaa	agccaaaggg	aaataaatga	6300
aaataaataa	aaataattgg	gtgacaaatt	gtttacagcc	tgtgaagggtg	atgtattttt	6360
atcaacagga	ctcctttagg	aggtcaatgc	caaactgact	gtttttacac	aaatctcctt	6420
aaggtcagtg	cctacaataa	gacagtgacc	ccttgtcagc	aaactgtgac	tctgtgtaaa	6480
ggggagatga	ccttgacagg	aggttactgt	tctcactacc	agctgacact	gctgaagata	6540
agatgcacaa	tggctagtca	gactgtaggg	accagtttca	aggggtgcaa	acctgtgatt	6600
ttggggttgt	ttaacatgaa	acactttagt	gtagtaattg	tatccactgt	ttgcatttca	6660
actgccacat	ttgtcacatt	tttatggaat	ctgttagtg	attcatcttt	ttgttaatcc	6720
atgtgtttat	tatatgtgac	tatttttgta	aacgaagttt	ctgttgagaa	ataggctaag	6780
gacctctata	acagggtatgc	cacctggggg	gtatggcaac	cacatggccc	tcccagctac	6840
acaagtcgt	ggtttgcatg	agggcatgct	gcacttagag	atcatgcatg	agaaaaagtc	6900
acaagaaaaa	caaattctta	aatttcacca	tattttctggg	aggggtaatt	gggtgataag	6960
tggaggtgct	ttgttgatct	tgttttgca	aatccagccc	ctagaccaag	tagattat	7020
gtgggtaggc	cagtaaactct	tagcagggtgc	aaacttcatt	caaatgtttg	gagtcataaa	7080
tgttatgttt	ctttttgttg	tattaaaaaa	aaaacctgaa	tagtgaatat	tgccccctac	7140
cctccaccgc	cagaagactg	aattgaccaa	aattactctt	tataaatttc	tgctttttcc	7200
tgcactttgt	ttagccatct	ttgggctctc	agcaagggtg	acactgtata	tgttaatgaa	7260
atgctattta	ttatgtaaat	agtcatttta	ccctgtgggtg	cacgtttgag	caaacaata	7320
atgacctaag	cacagtattt	attgcatcaa	atatgtacca	caagaaatgt	agagtgcag	7380
ctttacacag	gtaataaaaat	gtattctgta	ccatttatag	atagtttgga	tgctatcaat	7440
gcatgtttat	attaccatgc	tgctgtatct	ggtttctctc	actgctcaga	atctcattta	7500
tgagaaacca	tatgtcagtg	gtaaagtcaa	ggaaattggt	caacagatct	catttattta	7560
agtcattaag	caatagtttg	cagcacttta	acagcttttt	ggttattttt	acattttaag	7620

SSCP Update Sequences.ST25

tggataacat atggtatata gccagactgt acagacatgt ttaaaaaaac acactgctta	7680
acctattaaa tatgtgttta gaattttata agcaaataa aatactgtaa aaagtcactt	7740
tattttatatt ttcagcatta tgtacataaa tatgaagagg aaattatctt caggttgata	7800
tcacaatcac ttttcttact ttctgtccat agtacttttt catgaaagaa atttgctaaa	7860
taagacatga aaacaagact gggtagttgt agatttctgc tttttaaatt acatttgcta	7920
attttagatt atttcacaat ttttaaggagc aaaatagggt cacgattcat atccaaatta	7980
tgctttgcaa ttggaaaagg gtttaaaatt ttatttatat ttctggtagt acctgtacta	8040
actgaattga aggtagtgtc tatgttattt ttgttctttt tttctgactt cggtttatgt	8100
tttcatttct ttggagtaat gctgctctag attgttctaa atagaatgtg ggcttcataa	8160
tttttttttc cacaaaaaca gagtagtcaa cttatatagt caattacatc aggacatttt	8220
gtgtttctta cagaagcaaa ccataggctc ctcttttctt taaaactact tagataaact	8280
gtattcgtga actgcatgct ggaaaatgct actattatgc taaataatgc taaccaacat	8340
ttaaaatgtg caaaactaat aaagattaca ttttttattt t	8381

<210> 2
 <211> 8381
 <212> DNA
 <213> Homo sapiens

<400> 2	
atactgcaga ggtctctggt gcatgtgtgt atgtgtgcgt ttgtgtgtgt ttgtgtgtct	60
gtgtgtttctg cccagtgag actgcagccc ttgtaaatac tttgacacct ttgcaagaa	120
ggaatctgaa caattgcaac tgaaggcaca ttgttatcat ctcgtctttg ggtgatgctg	180
ttcctcactg cagatggata attttcttt taatcaggaa tttcatatgc agaataaatg	240
gtaattaaaa tgtgcaggat gacaagatgg agcaaacagt gcttgtacca ccaggacctg	300
acagcttcaa cttcttcacc agagaatctc ttgcggtat tgaaagacgc attgcagaag	360
aaaaggcaaa gaatcccaa ccagacaaaa aagatgacga cgaaaatggc ccaaagccaa	420
atagtactt ggaagctgga aagaacctt catttattta tggagacatt cctccagaga	480
tgggtgtcaga gccctggag gacctggacc cttactatat caataagaaa actttttatag	540
tattgaataa attgaaggcc atcttccggt tcagtgccac ctctgccctg tacattttta	600
ctcccttcaa tcctcttagg aaaatagcta ttaagatttt ggtacattca ttattcagca	660
tgctaattat gtgcactatt ttgacaaact gtgtgtttat gacaatgagt aaccctcctg	720
attggacaaa gaatgtagaa tacaccttca caggaatata tacttttgaa tcacttataa	780
aaattattgc aaggggattc tgtttagaag attttacttt ctttcgggat ccatggaact	840
ggctcgattt cactgtcatt acatttgcgt acgtcacaga gtttgtggac ctgggcaatg	900
tctcggcatt gagaacattc agagtctcc gagcattgaa gacgatttca gtcattccag	960
gcctgaaaac cattgtggga gccctgatcc agtctgtgaa gaagctctca gatgtaatga	1020
tcctgactgt gttctgtctg agcgtatttg ctctaattgg gctgcagctg ttcattgggca	1080

SSCP Update Sequences.ST25

acctgaggaa	taaatgtata	caatggcctc	ccaccaatgc	ttccttggag	gaacatagta	1140
tagaaaagaa	tataactgtg	aattataatg	gtacacttat	aaatgaaact	gtctttgagt	1200
ttgactggaa	gtcatatatt	caagattcaa	gatatcatta	tttcctggag	ggtttttttag	1260
atgcactact	atgtggaaat	agctctgatg	caggccaatg	tccagaggga	tatatgtgtg	1320
tgaaagctgg	tagaaatccc	aattatggct	acacaagctt	tgataccttc	agttgggctt	1380
ttttgtcctt	gtttcgacta	atgactcagg	acttctgaga	aaatctttat	caactgacat	1440
tacgtgctgc	tgggaaaacg	tacatgatat	tttttgtatt	ggtcattttc	ttgggctcat	1500
tctacctaata	aaatttgatc	ctggctgtgg	tggccatggc	ctacgaggaa	cagaatcagg	1560
ccaccttggga	agaagcagaa	cagaaagagg	ccgaatttca	gcagatgatt	gaacagctta	1620
aaaagcaaca	ggaggcagct	cagcaggcag	caacggcaac	tgcctcagaa	cattccagag	1680
agcccagtg	agcaggcagg	ctctcagaca	gctcatctga	agcctctaag	ttgagttcca	1740
agagtgtctaa	ggaaagaaga	aatcggagga	agaaaagaaa	acagaaagag	cagtctggtg	1800
gggaagagaa	agatgaggat	gaattccaaa	aatctgaatc	tgaggacagc	atcaggagga	1860
aaggtttttcg	cttctccatt	gaagggaacc	gattgacata	tgaaaagagg	tactcctccc	1920
cacaccagtc	tttgttgagc	atccgtggct	ccctattttc	accaaggcga	aatagcagaa	1980
caagcctttt	cagctttaga	gggcgagcaa	aggatgtggg	atctgagaac	gacttcgcag	2040
atgatgagca	cagcaccttt	gaggataacg	agagccgtag	agattccttg	tttgtgcccc	2100
gacgacacgg	agagagacgc	aacagcaacc	tgagtcagac	cagtaggtca	tcccggatgc	2160
tggcagtggt	tccagcgaat	gggaagatgc	acagcactgt	ggattgcaat	ggtgtgggtt	2220
ccttggttgg	tggaccttca	gttcctacat	cgctgttgg	acagcttctg	ccagagggtga	2280
taatagataa	gccagctact	gatgacaatg	gaacaaccac	tgaaactgaa	atgagaaaga	2340
gaagggtcaag	ttctttccac	gtttccatgg	actttctaga	agatccttcc	caaaggcaac	2400
gagcaatgag	tatagccagc	attctaacaa	atacagtaga	agaacttgaa	gaatccaggc	2460
agaaatgccc	accctgttgg	tataaatatt	ccaacatatt	cttaatctgg	gactgtttctc	2520
catattgggt	aaaagtga	catgttgtca	acctgggtgt	gatggacca	tttgttgacc	2580
tggccatcac	catctgtatt	gtcttaata	ctcttttcat	ggccatggag	cactatccaa	2640
tgacggacca	tttcaataat	gtgcttacag	taggaaactt	ggttttcact	gggatcttta	2700
cagcagaaat	gtttctgaaa	attattgcca	tggatcctta	ctattatttc	caagaaggct	2760
ggaatatctt	tgacgggttt	attgtgacgc	ttagcctgg	agaacttgga	ctcgccaatg	2820
tggaaggatt	atctgttctc	cgttcatttc	gattgctgcg	agttttcaag	ttggcaaaat	2880
cttggccaac	gttaaataatg	ctaataaaga	tcacggcaa	ttccgtgggg	gctctgggaa	2940
atttaaccct	cgtcttggcc	atcatcgtct	tcatttttgc	cgtggctggc	atgcagctct	3000
ttggtaaaag	ctacaaagat	tgtgtctgca	agatcgccag	tgattgtcaa	ctcccacgct	3060
ggcacatgaa	tgacttcttc	cactccttcc	tgattgtgtt	ccgcgtgctg	tgtggggagt	3120

SSCP Update Sequences.ST25

ggatagagac	catgtgggac	tgtatggagg	ttgctgggtca	agccatgtgc	cttactgtct	3180
tcatgatggg	catgggtgatt	ggaaacctag	tggtcctgaa	tctctttctg	gccttgcttc	3240
tgagctcatt	tagtgcagac	aaccttgacg	ccactgatga	tgataatgaa	atgaataatc	3300
tccaaattgc	tgtggatagg	atgcacaaag	gagtagctta	tgtgaaaaga	aaaatatatg	3360
aattttattca	acagtccttc	attaggaaac	aaaagatttt	agatgaaatt	aaaccacttg	3420
atgatctaaa	caacaagaaa	gacagttgta	tgtccaatca	tacaacagaa	attgggaaag	3480
atcttgacta	tcttaaagat	gtaaatggaa	ctacaagtgg	tatagggaact	ggcagcagtg	3540
ttgaaaaata	cattattgat	gaaagtgatt	acatgtcatt	cataaacaac	cccagtctta	3600
ctgtgactgt	accaattgct	gtaggagaat	ctgactttga	aaatttaaac	acggaagact	3660
ttagtagtga	atcggtactg	gaagaaagca	aagagaaact	gaatgaaagc	agtagctcat	3720
cagaaggtag	cactgtggac	atcggcgcac	ctgtagaaga	acagcccgtg	gtggaacctg	3780
aagaaactct	tgaaccagaa	gcttgtttca	ctgaaggctg	tgtacaaaga	ttcaagtgtt	3840
gtcaaataca	tgtggaagaa	ggcagaggaa	aacaatgggtg	gaacctgaga	aggacgtgtt	3900
tccgaatagt	tgaacataac	tggttttgaga	ccttcattgt	tttcatgatt	ctccttagta	3960
gtggtgctct	ggcatttgaa	gatatatata	ttgatcagcg	aaagacgatt	aagacgatgt	4020
tggaatatgc	tgacaagggt	ttcacttaca	ttttcattct	ggaaatgctt	ctaaaatggg	4080
tggcataatg	ctatcaaaca	tatttcacca	atgcctgggtg	ttggctggac	ttcttaattg	4140
ttgatgtttc	attgggtcagt	ttaacagcaa	atgccttggg	ttactcagaa	cttggaacca	4200
tcaaatactct	caggacacta	agagctctga	gacctctaag	agccttatct	cgatttgaag	4260
ggatgagggg	ggttgtgaat	gcccttttag	gagcaattcc	atccatcatg	aatgtgcttc	4320
tggtttgtct	tatatctctg	ctaattttca	gcatcatggg	cgtaaatttg	tttgctggca	4380
aattctacca	ctgtattaac	accacaactg	gtgacagggt	tgacatcgaa	gacgtgaata	4440
atcatactga	ttgcctaaaa	ctaatagaaa	gaaatgagac	tgctcgatgg	aaaaatgtga	4500
aagtaaaact	tgataatgta	ggatttgggt	atctctcttt	gcttcaagtt	gccacattca	4560
aaggatggat	ggatataatg	tatgcagcag	ttgattccag	aaatgtggaa	ctccagccta	4620
agtatgaaaa	aagtctgtac	atgtatcttt	actttgttat	tttcatcatc	tttgggtcct	4680
tcttcacctt	gaacctgttt	attgggtgtca	tcatagataa	tttcaaccag	cagaaaaaga	4740
agtttgaggg	tcaagacatc	tttatgacag	aagaacagaa	gaaatactat	aatgcaatga	4800
aaaaattagg	atcgaaaaaa	ccgcaaaagc	ctatacctcg	accaggaaac	aaatttcaag	4860
gaatgggtct	tgacttcgta	accagacaag	tttttgacat	aagcatcatg	attctcatct	4920
gtcttaacat	ggtcacaatg	atggtggaaa	cagatgacca	gagtgaatat	gtgactacca	4980
ttttgtcacg	catcaatctg	gtgttcattg	tgctattttac	tggagagtgt	gtactgaaac	5040
tcatctctct	acgccattat	tattttacca	ttggatggaa	tatttttgat	tttgtgggtg	5100
tcattctctc	cattgtaggt	atgtttcttg	ccgagctgat	agaaaagtat	ttcgtgtccc	5160

SSCP Update Sequences.ST25

ctaccctggt	ccgagtgatc	cgtcttgcta	ggattggccg	aatcctacgt	ctgatcaaag	5220
gagcaaaggg	gatccgcacg	ctgctctttg	ctttgatgat	gtcccttcct	gcgttgttta	5280
acatcggcct	cctactcttc	ctagtcatgt	tcatctacgc	catctttggg	atgtccaact	5340
ttgcctatgt	taagagggaa	gttgggatcg	atgacatggt	caactttgag	acctttggca	5400
acagcatgat	ctgcctattc	caaattacaa	cctctgctgg	ctgggatgga	ttgctagcac	5460
ccattctcaa	cagtaagcca	cccgactgtg	accctaataa	agttaaccct	ggaagctcag	5520
ttaagggaga	ctgtgggaac	ccatctgttg	gaattttctt	ttttgtcagt	tacatcatca	5580
tatccttcct	ggttgtggtg	aacatgtaca	tcgcggtcat	cctggagaac	ttcagtgttg	5640
ctactgaaga	aagtgcagag	cctctgagtg	aggatgactt	tgagatgttc	tatgaggttt	5700
gggagaagtt	tgatcccgat	gcaactcagt	tcatggaatt	tgaaaaatta	tctcagtttg	5760
cagctgcgct	tgaaccgcct	ctcaatctgc	cacaaccaa	caaactccag	ctcattgccca	5820
tggatttgcc	catggtgagt	ggtgaccgga	tccactgtct	tgatatctta	tttgctttta	5880
caaagcgggt	tctaggagag	agtggagaga	tggatgctct	acgaatacag	atggaagagc	5940
gattcatggc	ttccaatcct	tccaaggtct	cctatcagcc	aatcactact	actttaaaac	6000
gaaaacaaga	ggaagtatct	gctgtcatta	ttcagcgtgc	ttacagacgc	caccttttaa	6060
agcgaactgt	aaaacaagct	tcctttacgt	acaataaaaa	caaatcaaaa	ggtggggcta	6120
atcttcttat	aaaagaagac	atgataattg	acagaataaa	tgaaaactct	attacagaaa	6180
aaactgatct	gaccatgtcc	actgcagctt	gtccaccttc	ctatgaccgg	gtgacaaagc	6240
caattgtgga	aaaacatgag	caagaaggca	aagatgaaaa	agccaaaggg	aaataaatga	6300
aaataaataa	aaataattgg	gtgacaaatt	gtttacagcc	tgtgaagggtg	atgtatTTTT	6360
atcaacagga	ctccttttagg	aggtcaatgc	caaactgact	gtttttacac	aaatctcctt	6420
aaggtcagtg	cctacaataa	gacagtgacc	ccttgtcagc	aaactgtgac	tctgtgtaaa	6480
ggggagatga	ccttgacagg	aggttactgt	tctcactacc	agctgacact	gctgaagata	6540
agatgcacaa	tggctagtca	gactgtaggg	accagtttca	aggggtgcaa	acctgtgatt	6600
ttggggttgt	ttaacatgaa	acactttagt	gtagtaattg	tatccactgt	ttgcatttca	6660
actgccacat	ttgtcacatt	tttatggaat	ctgttagtggt	attcatcttt	ttgttaatcc	6720
atgtgtttat	tatatgtgac	tatttttgta	aacgaagttt	ctgttgagaa	ataggctaag	6780
gacctctata	acaggtatgc	cacctggggg	gtatggcaac	catatggccc	tcccagctac	6840
acaaagtcgt	ggtttgcatg	agggcatgct	gcacttagag	atcatgcatg	agaaaaagtc	6900
acaagaaaaa	caaatcttta	aatttcacca	tatttctggg	aggggttaatt	gggtgataag	6960
tggaggtgct	ttgttgatct	tgttttgcca	aatccagccc	ctagaccaag	tagattatTTT	7020
gtgggtaggc	cagtaaattct	tagcaggtgc	aaacttcatt	caaagtgttg	gagtcataaaa	7080
tgttatgttt	ctttttgttg	tattaaaaaa	aaaacctgaa	tagtgaatat	tgccccctcac	7140
cctccaccgc	cagaagactg	aattgaccaa	aattactctt	tataaatttc	tgctttttcc	7200

SSCP Update Sequences.ST25

tgcactttgt	ttagccatct	ttgggctctc	agcaagggtg	acactgtata	tgttaatgaa	7260
atgctattta	ttatgtaaat	agtcatttta	ccctgtggtg	cacgtttgag	caaacaaata	7320
atgacctaag	cacagtattt	attgcatcaa	atatgtacca	caagaaatgt	agagtgcagg	7380
ctttacacag	gtaataaaaat	gtattctgta	ccatttatag	atagtttgga	tgctatcaat	7440
gcatgtttat	attaccatgc	tgctgtatct	ggtttctctc	actgctcaga	atctcattta	7500
tgagaaacca	tatgtcagtg	gtaaagtcaa	ggaaattggt	caacagatct	catttattta	7560
agtcattaag	caatagtttg	cagcacttta	acagcttttt	ggttattttt	acattttaag	7620
tggataacat	atggatatata	gccagactgt	acagacatgt	ttaaaaaac	acactgctta	7680
acctattaaa	tatgtgttta	gaattttata	agcaaataata	aatactgtaa	aaagtcactt	7740
tattttattt	ttcagcatta	tgtacataaa	tatgaagagg	aaattatctt	caggttgata	7800
tcacaatcac	ttttcttact	ttctgtccat	agtacttttt	catgaaagaa	atttgctaaa	7860
taagacatga	aaacaagact	gggtagttgt	agatttctgc	tttttaaatt	acatttgcta	7920
atttttagatt	atttcacaat	tttaaggagc	aaaatagggt	cacgattcat	atccaaatta	7980
tgctttgcaa	ttggaaaagg	gtttaaaatt	ttatttatat	ttctggtagt	acctgtacta	8040
actgaattga	aggtagtgct	tatgttattt	ttgttctttt	tttctgactt	cggtttatgt	8100
tttcatttct	ttggagtaat	gctgctctag	attgttctaa	atagaatgtg	ggcttcataa	8160
tttttttttc	cacaaaaaca	gagtagtcaa	cttatatagt	caattacatc	aggacatttt	8220
gtgtttctta	cagaagcaaa	ccataggctc	ctcttttctt	taaaactact	tagataaaact	8280
gtattcgtga	actgcatgct	ggaaaatgct	actattatgc	taaataatgc	taaccaacat	8340
ttaaaatgtg	caaaactaat	aaagattaca	ttttttattt	t		8381

<210> 3
 <211> 8381
 <212> DNA
 <213> Homo sapiens

<400> 3						
atactgcaga	ggctctctgg	gcatgtgtgt	atgtgtgcgt	ttgtgtgtgt	ttgtgtgtct	60
gtgtgtttctg	ccccagtgag	actgcagccc	ttgtaaatac	tttgacacct	tttgcaagaa	120
ggaatctgaa	caattgcaac	tgaaggcaca	ttgttatcat	ctcgtctttg	ggatgatgctg	180
ttcctcactg	cagatggata	atttttcttt	taatcaggaa	tttcatatgc	agaataaatg	240
gtaattaaaa	tgtgcaggat	gacaagatgg	agcaaacagt	gcttgtacca	ccaggacctg	300
acagcttcaa	cttcttcacc	agagaatctc	ttgcggctat	tgaaagacgc	attgcagaag	360
aaaaggcaaa	gaatcccaaa	ccagacaaaa	aagatgacga	cgaaaatggc	caaagccaa	420
atagtgactt	ggaagctgga	aagaaccttc	catttattta	tggagacatt	cctccagaga	480
tgggtgtcaga	gcccctggag	gacctggacc	cctactatat	caataagaaa	acttttatag	540
tattgaataa	attgaaggcc	atcttccggt	tcagtgccac	ctctgccctg	tacattttaa	600

SSCP Update Sequences.ST25

ctcccttcaa	tcctcttagg	aaaatagcta	ttaagatttt	ggtacattca	ttattcagca	660
tgctaattat	gtgcactatt	ttgacaaact	gtgtgtttat	gacaatgagt	aaccctcctg	720
attggacaaa	gaatgtagaa	tacaccttca	caggaatata	tacttttgaa	tcacttataa	780
aaattattgc	aaggggattc	tgtttagaag	atctttacttt	ccttcgggat	ccatggaact	840
ggctcgattt	cactgtcatt	acatttgcgt	acgtcacaga	gtttgtggac	ctgggcaatg	900
tctcggcatt	gagaacattc	agagttctcc	gagcattgaa	gacgatttca	gtcattccag	960
gcctgaaaac	cattgtggga	gccctgatcc	agtctgtgaa	gaagctctca	gatgtaatga	1020
tcctgactgt	gttctgtctg	agcgtatttg	ctctaattgg	gctgcagctg	ttcatgggca	1080
acctgaggaa	taaatgtata	caatggcctc	ccaccaatgc	ttccttgagg	gaacatagta	1140
tagaaaagaa	tataactgtg	aattataatg	gtacacttat	aaatgaaact	gtctttgagt	1200
ttgactggaa	gtcatatatt	caagattcaa	gatatcatta	tttcctggag	ggtttttttag	1260
atgcactact	atgtggaaat	agctctgatg	caggccaatg	tccagaggga	tatatgtgtg	1320
tgaaagctgg	tagaaatccc	aattatggct	acacaagctt	tgataccttc	agttgggctt	1380
ttttgtcctt	gtttcgacta	atgactcagg	acttctggga	aaatctttat	caactgacat	1440
tacgtgctcc	tgggaaaacg	tacatgatat	tttttgtatt	ggtcattttc	ttgggctcat	1500
tctacctaat	aaatttgatc	ctggctgtgg	tggccatggc	ctacgaggaa	cagaatcagg	1560
ccaccttgga	agaagcagaa	cagaaagagg	ccgaatttca	gcagatgatt	gaacagctta	1620
aaaagcaaca	ggaggcagct	cagcaggcag	caacggcaac	tgccctcagaa	cattccagag	1680
agcccagtg	agcaggcagg	ctctcagaca	gctcatctga	agcctctaag	ttgagttcca	1740
agagtgctaa	ggaaagaaga	aatcggagga	agaaaagaaa	acagaaagag	cagtctggtg	1800
gggaagagaa	agatgaggat	gaattccaaa	aatctgaatc	tgaggacagc	atcaggagga	1860
aaggttttcg	cttctccatt	gaagggaacc	gattgacata	tgaaaagagg	tactcctccc	1920
cacaccagtc	tttggttagc	atccgtggct	ccctattttc	accaaggcga	aatagcagaa	1980
caagcctttt	cagctttaga	gggagagcaa	aggatgtggg	atctgagaac	gacttcgcag	2040
atgatgagca	cagcaccttt	gaggataacg	agagccgtag	agattccttg	tttgtgcccc	2100
gacgacacgg	agagagacgc	aacagcaacc	tgagtcagac	cagtaggtca	tcccggatgc	2160
tggcagtggt	tccagcgaat	gggaagatgc	acagcactgt	ggattgcaat	ggtgtggttt	2220
ccttggttgg	tggaccttca	gttcctacat	cgcctgttgg	acagcttctg	ccagagggtga	2280
taatagataa	gccagctact	gatgacaatg	gaacaaccac	tgaaactgaa	atgagaaaga	2340
gaagggtcaag	ttctttccac	gtttccatgg	actttctaga	agatccttcc	caaaggcaac	2400
gagcaatgag	tatagccagc	attctaacaa	atacagtaga	agaacttgaa	gaatccaggc	2460
agaaatgccc	accctgttgg	tataaatttt	ccaacatatt	cttaatctgg	gactgttctc	2520
catattgggt	aaaagtga	catgttgtca	acctgggtgt	gatggacca	tttgttgacc	2580
tggccatcac	catctgtatt	gtcttaaata	ctcttttcat	ggccatggag	cactatccaa	2640

SSCP Update Sequences.ST25

tgacggacca	tttcaataat	gtgcttacag	taggaaactt	ggttttcact	gggatcttta	2700
cagcagaaat	gtttctgaaa	attattgcca	tggatcctta	ctattatttc	caagaaggct	2760
ggaatatctt	tgacggtttt	attgtgacgc	ttagcctggt	agaacttgga	ctcgccaatg	2820
tggaaggatt	atctgttctc	cgttcatttc	gattgctgcg	agttttcaag	ttggcaaaat	2880
cttggccaac	gttaaatatg	ctaataaaga	tcatcggcaa	ttccgtgggg	gctctgggaa	2940
atthaaccct	cgtcttggcc	atcatcgtct	tcattttttgc	cgtggtcggc	atgcagctct	3000
ttggtaaaag	ctacaaagat	tgtgtctgca	agatcgccag	tgattgtcaa	ctcccacgct	3060
ggcacatgaa	tgacttcttc	cactccttcc	tgattgtggt	ccgctgtgctg	tgtggggagt	3120
ggatagagac	catgtgggac	tgtatggagg	ttgctggtca	agccatgtgc	cttactgtct	3180
tcgatgatgt	catggtgatt	ggaaacctag	tggtcctgaa	tctctttctg	gccttgcttc	3240
tgagctcatt	tagtgcagac	aaccttgacg	ccactgatga	tgataatgaa	atgaataatc	3300
tccaaattgc	tgtggatagg	atgcacaaag	gagtagctta	tgtgaaaaga	aaaatatatg	3360
aattttattca	acagtccttc	attaggaaac	aaaagatttt	agatgaaatt	aaaccacttg	3420
atgatctaaa	caacaagaaa	gacagttgta	tgtccaatca	tacaacagaa	attgggaaag	3480
atcttgacta	tcttaaagat	gtaaatggaa	ctacaagtgg	tatagggaact	ggcagcagtg	3540
ttgaaaaata	cattattgat	gaaagtgatt	acatgtcatt	cataaacaac	cccagtctta	3600
ctgtgactgt	accaattgct	gtaggagaat	ctgactttga	aaatttaaac	acggaagact	3660
ttagtagtga	atcggatctg	gaagaaagca	aagagaaact	gaatgaaagc	agtagctcat	3720
cagaaggtag	cactgtggac	atcggcgcac	ctgtagaaga	acagcccgtg	gtggaacctg	3780
aagaaactct	tgaaccagaa	gcttgtttca	ctgaaggctg	tgtacaaaga	ttcaagtgtt	3840
gtcaaataca	tgtggaagaa	ggcagaggaa	aacaatgggtg	gaacctgaga	aggacgtgtt	3900
tccgaatagt	tgaacataac	tggtttgaga	ccttcattgt	tttcatgatt	ctccttagta	3960
gtggtgctct	ggcatttgaa	gatatatata	ttgatcagcg	aaagacgatt	aagacgatgt	4020
tggaatatgc	tgacaagggt	ttcacttac	ttttcattct	ggaaatgctt	ctaaaatggg	4080
tggcataatg	ctatcaaaca	tatttcacca	atgcctgggtg	ttggctggac	ttcttaattg	4140
ttgatgtttc	attggctcag	ttaacagcaa	atgccttggtg	ttactcagaa	cttgagacca	4200
tcaaatctct	caggacacta	agagctctga	gacctctaag	agccttatct	cgatttgaag	4260
ggatgagggg	ggttgtgaat	gcccttttag	gagcaattcc	atccatcatg	aatgtgcttc	4320
tggtttgtct	tatattctgg	ctaattttca	gcacatggg	cgtaaatttg	tttgctggca	4380
aattctacca	ctgtattaac	accacaactg	gtgacagggt	tgacatcgaa	gacgtgaata	4440
atcatactga	ttgcctaaaa	ctaatagaaa	gaaatgagac	tgctcgatgg	aaaaatgtga	4500
aagtaaacct	tgataatgta	ggatttggtg	atctctcttt	gcttcaagtt	gccacattca	4560
aaggatggat	ggatataatg	tatgcagcag	ttgattccag	aaatgtggaa	ctccagccta	4620
agtatgaaaa	aagtctgtac	atgtatcttt	actttgttat	tttcatcatc	tttgggtcct	4680

SSCP Update Sequences.ST25

tcttcacctt	gaacctgttt	attggtgtca	tcatagataa	tttcaaccag	cagaaaaaga	4740
agtttgagg	tcaagacatc	tttatgacag	aagaacagaa	gaaatactat	aatgcaatga	4800
aaaaattagg	atcgaaaaaa	ccgcaaaagc	ctatacctcg	accaggaaac	aaatttcaag	4860
gaatggtctt	tgacttcgta	accagacaag	tttttgacat	aagcatcatg	atttctcatct	4920
gtcttaacat	ggtcacaatg	atggtggaaa	cagatgacca	gagtgaatat	gtgactacca	4980
ttttgtcacg	catcaatctg	gtgttcattg	tgctattttac	tggagagtgt	gtactgaaac	5040
tcatctctct	acgccattat	tatttttacca	ttggatggaa	tattttttgat	tttgtggttg	5100
tcattctctc	cattgtaggt	atgtttcttg	ccgagctgat	agaaaagtat	ttcgtgtccc	5160
ctaccctggt	ccgagtgatc	cgtcttgcta	ggattggccg	aatcctacgt	ctgatcaaag	5220
gagcaaagg	gatccgcacg	ctgctctttg	ctttgatgat	gtcccttcct	gcgttgttta	5280
acatcggcct	cctactcttc	ctagtcatgt	tcatctacgc	catctttggg	atgtccaact	5340
ttgcctatgt	taagagggaa	gttgggatcg	atgacatggt	caactttgag	acctttggca	5400
acagcatgat	ctgcctattc	caaattacaa	cctctgctgg	ctgggatgga	ttgctagcac	5460
ccattctcaa	cagtaagcca	cccgactgtg	accctaataa	agttaaccct	ggaagctcag	5520
ttaagggaga	ctgtgggaac	ccatctgttg	gaattttctt	ttttgtcagt	tacatcatca	5580
tatccttcct	ggttggtgtg	aacatgtaca	tcgcggtcat	cctggagaac	ttcagtgttg	5640
ctactgaaga	aagtgcagag	cctctgagtg	aggatgactt	tgagatgttc	tatgaggttt	5700
gggagaagtt	tgatcccgat	gcaactcagt	tcatggaatt	tgaaaaatta	tctcagtttg	5760
cagctgcgct	tgaaccgcct	ctcaatctgc	cacaaccaa	caaactccag	ctcattgcc	5820
tggatttgcc	catggtgagt	ggtgaccgga	tccactgtct	tgatatctta	tttgctttta	5880
caaagcgggt	tctaggagag	agtggagaga	tggatgtctt	acgaatacag	atggaagagc	5940
gattcatggc	ttccaatcct	tccaagggtct	cctatcagcc	aatcactact	actttaaaac	6000
gaaaacaaga	ggaagtatct	gctgtcatta	ttcagcgtgc	ttacagacgc	caccttttaa	6060
agcgaactgt	aaaacaagct	tcctttacgt	acaataaaaa	caaaatcaaa	ggtggggcta	6120
atcttcttat	aaaagaagac	atgataattg	acagaataaa	tgaaaactct	attacagaaa	6180
aaactgatct	gaccatgtcc	actgcagctt	gtccaccttc	ctatgaccgg	gtgacaaagc	6240
caattgtgga	aaaacatgag	caagaaggca	aagatgaaaa	agccaaagg	aaataaatga	6300
aaataataa	aaataattgg	gtgacaaatt	gtttacagcc	tgtgaagggt	atgtattttt	6360
atcaacagga	ctccttttag	aggtcaatgc	caaactgact	gttttttacac	aatctctctt	6420
aaggctcagt	cctacaataa	gacagtgacc	ccttgtcagc	aaactgtgac	tctgtgtaaa	6480
ggggagatga	ccttgacagg	aggttactgt	tctcactacc	agctgacact	gctgaagata	6540
agatgcacaa	tggctagtca	gactgtaggg	accagtttca	aggggtgcaa	acctgtgatt	6600
ttggggttgt	ttaacatgaa	acacttttag	gtagtaattg	tatccactgt	ttgcatttca	6660
actgccacat	ttgtcacatt	tttatggaat	ctgttagtgg	attcatcttt	ttgttaatcc	6720

SSCP Update Sequences.ST25

atgtgtttat	tatatgtgac	tatTTTTgtgta	aacgaagttt	ctgttgagaa	ataggctaag	6780
gacctctata	acaggtatgc	cacctggggg	gtatggcaac	cacatggccc	tcccagctac	6840
acaaagtcgt	ggtttgcatg	agggcatgct	gcacttagag	atcatgcatg	agaaaaagtc	6900
acaagaaaaa	caaattctta	aatttcacca	tatttctggg	aggggtaatt	gggtgataag	6960
tggaggtgct	ttgttgatct	tgTTTTgCGa	aatccagccc	ctagaccaag	tagattatTT	7020
gtgggtaggc	cagtaaattct	tagcaggtgc	aaacttcatt	caaattgtttg	gagtcataaa	7080
tgttatgttt	ctTTTTgttg	tattaaaaaa	aaaacctgaa	tagtgaatat	tgccccctcac	7140
cctccaccgc	cagaagactg	aattgaccaa	aattactctt	tataaaatttc	tgctTTTTtcc	7200
tgcactttgt	ttagccatct	ttgggctctc	agcaagggtg	acactgtata	tgTTaatgaa	7260
atgctatttta	ttatgtaaat	agtcatttta	ccctgtgggtg	cacgtttgag	caaacaaata	7320
atgacctaag	cacagtatTT	attgcatcaa	atatgtacca	caagaaatgt	agagtgcagg	7380
ctttacacag	gtaataaaaat	gtattctgta	ccattttag	atagtttgga	tgctatcaat	7440
gcatgtttat	attaccatgc	tgctgtatct	ggTTTTctctc	actgctcaga	atctcatttta	7500
tgagaaacca	tatgtcagtg	gtaaagtcaa	ggaaattggt	caacagatct	cattttatttta	7560
agtcattaag	caatagtttg	cagcacttta	acagctTTTT	ggttatTTTT	acattttaag	7620
tggataacat	atggtatatata	gccagactgt	acagacatgt	ttaaaaaaac	acactgctta	7680
acctattaaa	tatgtgttta	gaattttata	agcaaataata	aatactgtaa	aaagtcactt	7740
tattttatTT	ttcagcatta	tgtacataaa	tatgaagagg	aaattatctt	cagggttgata	7800
tcacaatcac	ttttcttact	ttctgtccat	agtactTTTT	catgaaagaa	atttgctaaa	7860
taagacatga	aaacaagact	gggtagttgt	agatttctgc	tttttaaatt	acatttgcta	7920
atttttagatt	atttcacaat	tttaaggagc	aaaatagggt	cacgattcat	atccaaatta	7980
tgctttgcaa	ttggaaaagg	gtttaaaatt	ttatttataat	ttctggtagt	acctgtacta	8040
actgaattga	aggtagtgct	tatgttattt	ttgttctttt	tttctgactt	cggtttatgt	8100
tttcatttct	ttggagtaat	gctgctctag	attgttctaa	atagaatgtg	ggcttcataa	8160
tttttttttc	cacaaaaaca	gagtagtcaa	cttatatagt	caattacatc	aggacatttt	8220
gtgtttctta	cagaagcaaa	ccataggctc	ctcttttctt	taaaactact	tagataaact	8280
gtattcgtga	actgcatgct	ggaaaatgct	actattatgc	taaataatgc	taaccaacat	8340
ttaaaatgtg	caaaactaat	aaagattaca	ttttttatTT	t		8381

<210> 4
 <211> 8381
 <212> DNA
 <213> Homo sapiens

<400> 4						
atactgcaga	ggctctctgggt	gcatgtgtgt	atgtgtgcgt	ttgtgtgtgt	ttgtgtgtct	60
gtgtgttctg	ccccagtgag	actgcagccc	ttgtaaatac	tttgacacct	tttgcaagaa	120
ggaatctgaa	caattgcaac	tgaaggcaca	ttgttatcat	ctcgtctttg	ggatgatgctg	180

SSCP Update Sequences.ST25

ttcctcactg	cagatggata	attttccttt	taatcaggaa	tttcatatgc	agaataaatg	240
gtaattaaaa	tgtgcaggat	gacaagatgg	agcaaacagt	gcttgtacca	ccaggacctg	300
acagcttcaa	cttcttcacc	agagaatctc	ttgcggctat	tgaaagacgc	attgcagaag	360
aaaaggcaaa	gaatcccaaa	ccagacaaaa	aagatgacga	cgaaaatggc	ccaaagccaa	420
atagtgcatt	ggaagctgga	aagaaccttc	cattttattta	tggagacatt	cctccagaga	480
tgggtgtcaga	gcccctggag	gacctggacc	cctactatat	caataagaaa	actttttatag	540
tattgaataa	attgaaggcc	atcttcctgg	tcagtgccac	ctctgccctg	tacatttttaa	600
ctcccttcaa	tcctcttagg	aaaatagcta	ttaagatttt	ggtacattca	ttattcagca	660
tgctaattat	gtgcactatt	ttgacaaact	gtgtgtttat	gacaatgagt	aaccctcctg	720
attggacaaa	gaatgtagaa	tacaccttca	caggaatata	tacttttgaa	tcacttataa	780
aaattattgc	aaggggattc	tgtttagaag	attttacttt	ccttcgggat	ccatggaact	840
ggctcgattt	cactgtcatt	acatttgcgt	acgtcacaga	gtttgtggac	ctgggcaatg	900
tctcggcatt	gagaacattc	agagtctctc	gagcattgaa	gacgatttca	gtcattccag	960
gcctgaaaac	cattgtggga	gccctgatcc	agtctgtgaa	gaagctctca	gatgtaatga	1020
tcctgactgt	gttctgtctg	agcgtatttg	ctctaattgg	gctgcagctg	ttcatgggca	1080
acctgaggaa	taaatgtata	caatggcctc	ccaccaatgc	ttccttggag	gaacatagta	1140
tagaaaagaa	tataactgtg	aattataatg	gtacacttat	aaatgaaact	gtctttgagt	1200
ttgactggaa	gtcatatatt	caagattcaa	gatatcatta	tttcctggag	ggtttttttag	1260
atgcactact	atgtggaaat	agctctgatg	caggccaatg	tccagaggga	tatatgtgtg	1320
tgaaagctgg	tagaaatccc	aattatggct	acacaagctt	tgataccttc	agttgggctt	1380
ttttgtcctt	gtttcgacta	atgactcagg	acttctggga	aaatctttat	caactgacat	1440
tacgtgctgc	tgggaaaacg	tacatgatat	ttcttgtatt	ggtcattttc	ttgggctcat	1500
tctacctaat	aaatttgatc	ctggctgtgg	tggccatggc	ctacgaggaa	cagaatcagg	1560
ccaccttgga	agaagcagaa	cagaaagagg	ccgaatttca	gcagatgatt	gaacagctta	1620
aaaagcaaca	ggaggcagct	cagcaggcag	caacggcaac	tgcttcagaa	cattccagag	1680
agcccagtgc	agcaggcagg	ctctcagaca	gctcatctga	agcctctaag	ttgagttcca	1740
agagtgcata	ggaaagaaga	aatcggagga	agaaaagaaa	acagaaagag	cagtctggtg	1800
gggaagagaa	agatgaggat	gaattccaaa	aatctgaatc	tgaggacagc	atcaggagga	1860
aaggttttcg	cttctccatt	gaagggaacc	gattgacata	tgaaaagagg	tactcctccc	1920
cacaccagtc	tttgttgagc	atccgtggct	ccctattttc	accaaggcga	aatagcagaa	1980
caagcctttt	cagctttaga	gggcgagcaa	aggatgtggg	atctgagaac	gacttcgcag	2040
atgatgagca	cagcaccttt	gaggataacg	agagccgtag	agattccttg	tttgtgcccc	2100
gacgacacgg	agagagacgc	aacagcaacc	tgagtcagac	cagtaggtca	tcccggatgc	2160
tggcagtggt	tccagcgaat	gggaagatgc	acagcactgt	ggattgcaat	ggtgtgggtt	2220

SSCP Update Sequences.ST25

ccttggttgg	tggaccttca	gttcctacat	cgcttgttgg	acagcttctg	ccagaggtga	2280
taatagataa	gccagctact	gatgacaatg	gaacaaccac	tgaaactgaa	atgagaaaga	2340
gaaggtcaag	ttctttccac	gtttccatgg	acttttctaga	agatccttcc	caaaggcaac	2400
gagcaatgag	tatagccagc	attctaacaa	atacagtaga	agaacttgaa	gaatccaggc	2460
agaaatgccc	accctgttgg	tataaatttt	ccaacatatt	cttaatctgg	gactgtttctc	2520
catattgggt	aaaagtgaaa	catgttgtca	acctggttgt	gatggacca	tttggtgacc	2580
tggccatcac	catctgtatt	gtcttaata	ctcttttcat	ggccatggag	cactatccaa	2640
tgacggacca	tttcaataat	gtgcttacag	taggaaactt	ggttttcact	gggatcttta	2700
cagcagaaat	gtttctgaaa	attattgcc	tggatcctta	ctattatttc	caagaaggct	2760
ggaatatctt	tgacggtttt	attgtgacgc	ttagcctggg	agaacttgga	ctcgccaatg	2820
tggaaggatt	atctgttctc	cgttcatttc	gattgctgcg	agttttcaag	ttggcaaaat	2880
cttggccaac	gttaaatatg	ctaataaaga	tcatcggcaa	ttccgtgggg	gctctgggaa	2940
atttaaccct	cgtcttggcc	atcatcgtct	tcatttttgc	cgtggtcggc	atgcagctct	3000
ttggtaaaag	ctacaaagat	tgtgtctgca	agatcgccag	tgattgtcaa	ctccacgct	3060
ggcacatgaa	tgacttcttc	cactccttcc	tgattgtggt	ccgctgctg	tgtggggagt	3120
ggatagagac	catgtgggac	tgtatggagg	ttgctgggtca	agccatgtgc	cttactgtct	3180
tcatgatggg	catggtgatt	ggaaacctag	tggtcctgaa	tctctttctg	gccttgcttc	3240
tgagctcatt	tagtgcagac	aaccttgacg	ccactgatga	tgataatgaa	atgaataatc	3300
tccaaattgc	tgtggatagg	atgcacaaag	gagtagctta	tgtgaaaaga	aaaatatatg	3360
aatttattca	acagtccttc	attaggaaac	aaaagatttt	agatgaaatt	aaaccacttg	3420
atgatctaaa	caacaagaaa	gacagttgta	tgtccaatca	tacaacagaa	attgggaaag	3480
atcttgacta	tcttaaagat	gtaaatggaa	ctacaagtgg	tataggaact	ggcagcagtg	3540
ttgaaaaata	cattattgat	gaaagtgatt	acatgtcatt	cataaacaac	cccagtctta	3600
ctgtgactgt	accaattgct	gtaggagaat	ctgactttga	aaatttaaac	acggaagact	3660
ttagtagtga	atcggatctg	gaagaaagca	aagagaaact	gaatgaaagc	agtagctcat	3720
cagaaggtag	cactgtggac	atcggcgcac	ctgtagaaga	acagcccgtg	gtggaacctg	3780
aagaaactct	tgaaccagaa	gcttgtttca	ctgaaggctg	tgtacaaaga	ttcaagtgtt	3840
gtcaaataca	tgtggaagaa	ggcagaggaa	aacaatggtg	gaacctgaga	aggacgtgtt	3900
tccgaatagt	tgaacataac	tggtttgaga	ccttcattgt	tttcatgatt	ctccttagta	3960
gtggtgctct	ggcatttgaa	gatatatata	ttgatcagcg	aaagacgatt	aagacgatgt	4020
tggaaatatgc	tgacaagggt	ttcacttaca	ttttcattct	ggaaatgctt	ctaaaatggg	4080
tggcatatgg	ctatcaaaca	tatttcacca	atgcctgggtg	ttggctggac	ttcttaattg	4140
ttgatgtttc	attggtcagt	ttaacagcaa	atgccttggg	ttactcagaa	cttggagcca	4200
tcaaatactct	caggacacta	agagctctga	gacctctaag	agccttatct	cgatttgaag	4260

SSCP Update Sequences.ST25

ggatgagggg	ggttgtgaat	gcccttttag	gagcaattcc	atccatcatg	aatgtgcttc	4320
tggtttgtct	tatatcttgg	ctaattttca	gcatcatggg	cgtaaatttg	tttgctggca	4380
aattctacca	ctgtattaac	accacaactg	gtgacagggt	tgacatcgaa	gacgtgaata	4440
atcatactga	ttgcctaaaa	ctaatagaaa	gaaatgagac	tgctcgatgg	aaaaatgtga	4500
aagtaaactt	tgataatgta	ggatttgggt	atctctcttt	gcttcaagtt	gccacattca	4560
aaggatggat	ggatataatg	tatgcagcag	ttgattccag	aaatgtggaa	ctccagccta	4620
agtatgaaaa	aagtctgtac	atgtatcttt	actttgttat	tttcatcatc	tttgggtcct	4680
tcttcacctt	gaacctgttt	attgggtgtca	tcatagataa	tttcaaccag	cagaaaaaga	4740
agtttggagg	tcaagacatc	tttatgacag	aagaacagaa	gaaatactat	aatgcaatga	4800
aaaaattagg	atcgaaaaaa	ccgcaaaagc	ctatacctcg	accaggaaac	aaatttcaag	4860
gaatggctct	tgacttcgta	accagacaag	tttttgacat	aagcatcatg	attctcatct	4920
gtcttaacat	ggtcacaatg	atgggtggaa	cagatgacca	gagtgaatat	gtgactacca	4980
ttttgtcacg	catcaatctg	gtgttcattg	tgctatttac	tggagagtgt	gtactgaaac	5040
tcattctctc	acgccattat	tattttacca	ttggatggaa	tatttttgat	tttgtggttg	5100
tcattctctc	cattgtaggt	atgtttcttg	ccgagctgat	agaaaagtat	ttcgtgtccc	5160
ctaccctgtt	ccgagtgatc	cgtcttgcta	ggattggccg	aatcctacgt	ctgatcaaag	5220
gagcaaaggg	gatccgcacg	ctgctctttg	ctttgatgat	gtcccttcct	gcgttgttta	5280
acatcggcct	cctactcttc	ctagtcatgt	tcattctacgc	catctttggg	atgtccaact	5340
ttgcctatgt	taagagggaa	gttgggatcg	atgacatggt	caactttgag	acctttggca	5400
acagcatgat	ctgcctattc	caaattacaa	cctctgctgg	ctgggatgga	ttgctagcac	5460
ccattctcaa	cagtaagcca	cccgaactgt	accctaataa	agttaaccct	ggaagctcag	5520
ttaagggaga	ctgtgggaac	ccatctgttg	gaattttctt	ttttgtcagt	tacatcatca	5580
tatccttcct	ggttgtgggt	aacatgtaca	tcgcgggtcat	cctgggagaac	ttcagtggtg	5640
ctactgaaga	aagtgcagag	cctctgagtg	aggatgactt	tgagatgttc	tatgaggttt	5700
gggagaagtt	tgatcccgat	gcaactcagt	tcattggaatt	tgaaaaatta	tctcagtttg	5760
cagctgctgt	tgaaccgcct	ctcaatctgc	cacaacaaaa	caaactccag	ctcattgcca	5820
tggatttgcc	catggtgagt	ggtgaccgga	tccactgtct	tgatatctta	tttgctttta	5880
caaagcgggt	tctaggagag	agtggagaga	tggatgctct	acgaatacag	atggaagagc	5940
gattcatggc	ttccaatcct	tccaaggctt	cctatcagcc	aatcactact	actttaaaac	6000
gaaaacaaga	ggaagtatct	gctgtcatta	ttcagcgtgc	ttacagacgc	caccttttaa	6060
agcgaactgt	aaaacaagct	tcctttacgt	acaataaaaa	caaaatcaaa	ggtggggcta	6120
atcttcttat	aaaagaagac	atgataattg	acagaataaa	tgaaaactct	attacagaaa	6180
aaactgatct	gaccatgtcc	actgcagctt	gtccaccttc	ctatgaccgg	gtgacaaagc	6240
caattgtgga	aaaacatgag	caagaaggca	aagatgaaaa	agccaaaggg	aaataaatga	6300

SSCP Update Sequences.ST25

aaataaataa	aaataattgg	gtgacaaatt	gtttacagcc	tgtgaagggtg	atgtattttt	6360
atcaacagga	ctccttttagg	aggtcaatgc	caaactgact	gttttttacac	aaatctcctt	6420
aaggtcagtg	cctacaataa	gacagtgacc	ccttgtcagc	aaactgtgac	tctgtgtaaa	6480
ggggagatga	ccttgacagg	aggttactgt	tctcactacc	agctgacact	gctgaagata	6540
agatgcacaa	tggctagtca	gactgtaggg	accagtttca	aggggtgcaa	acctgtgatt	6600
ttgggggttg	ttaacatgaa	acactttagt	gtagtaattg	tatccactgt	ttgcatttca	6660
actgccacat	ttgtcacatt	tttatggaat	ctgttagtgg	attcatcttt	ttgttaatcc	6720
atgtgtttat	tatatgtgac	tatttttgta	aacgaagttt	ctgttgagaa	ataggctaag	6780
gacctctata	acaggtatgc	cacctggggg	gtatggcaac	cacatggccc	tcccagctac	6840
acaaagtcgt	ggtttgcatg	agggcatgct	gcacttagag	atcatgcatg	agaaaaagtc	6900
acaagaaaaa	caaattctta	aatttcacca	tatttctggg	aggggtaatt	gggtgataag	6960
tggaggtgct	ttgttgatct	tgttttgca	aatccagccc	ctagaccaag	tagattattt	7020
gtgggtaggc	cagtaaattct	tagcagggtgc	aaacttcatt	caaagtgttg	gagtcataaa	7080
tgttatgttt	ctttttgttg	tattaaaaaa	aaaacctgaa	tagtgaatat	tgcccctcac	7140
cctccaccgc	cagaagactg	aattgaccaa	aattactctt	tataaatttc	tgctttttcc	7200
tgcactttgt	ttagccatct	ttgggctctc	agcaagggtg	acactgtata	tgtaaatgaa	7260
atgctattta	ttatgtaaatt	agtcatttta	ccctgtggtg	cacgtttgag	caaacaaata	7320
atgacctaa	cacagtatct	attgcatcaa	atatgtacca	caagaaatgt	agagtgcagg	7380
ctttacacag	gtaataaaat	gtattctgta	ccatttatag	atagtttgga	tgctatcaat	7440
gcatgtttat	attaccatgc	tgctgtatct	ggtttctctc	actgctcaga	atctcattta	7500
tgagaaacca	tatgtcagtg	gtaaagtcaa	ggaaattggt	caacagatct	catttattta	7560
agtcattaag	caatagtttg	cagcacttta	acagcttttt	ggttattttt	acattttaag	7620
tggataacat	atggtatata	gccagactgt	acagacatgt	ttaaaaaaac	acactgctta	7680
acctattaaa	tatgtgttta	gaattttata	agcaaatata	aatactgtaa	aaagtcactt	7740
tattttatct	ttcagcatta	tgtacataaa	tatgaagagg	aaattatctt	caggttgata	7800
tcacaatcac	ttttcttact	ttctgtccat	agtacttttt	catgaaagaa	atttgctaaa	7860
taagacatga	aaacaagact	gggtagttgt	agatttctgc	tttttaaatt	acatttgcta	7920
attttagatt	atttcacaat	tttaaggagc	aaaatagggt	cacgattcat	atccaaatta	7980
tgctttgcaa	ttggaaaagg	gtttaaaatt	ttatttatat	ttctggtagt	acctgtacta	8040
actgaattga	aggtagtgt	tatgttattt	ttgttctttt	tttctgactt	cggtttatgt	8100
tttcatttct	ttggagtaat	gctgctctag	attgttctaa	atagaatgtg	ggcttcataa	8160
tttttttttc	cacaaaaaca	gagtagtcaa	cttatatagt	caattacatc	aggacatttt	8220
gtgtttctta	cagaagcaaa	ccataggctc	ctcttttcct	taaaactact	tagataaaact	8280
gtattcgtga	actgcatgct	ggaaaatgct	actattatgc	taaataatgc	taaccaacat	8340

SSCP Update Sequences.ST25

ttaaaatgtg caaaactaat aaagattaca ttttttattt t 8381

<210> 5
 <211> 8381
 <212> DNA
 <213> Homo sapiens

<400> 5
 atactgcaga ggtctctggt gcatgtgtgt atgtgtgctt ttgtgtgtgt ttgtgtgtct 60
 gtgtgtttctg cccagtgag actgcagccc ttgtaaatac ttgacacct ttgcaagaa 120
 ggaatctgaa caattgcaac tgaaggcaca ttgttatcat ctgctcttg ggtgatgctg 180
 ttcctcactg cagatggata attttccttt taatcaggaa tttcatatgc agaataaatg 240
 gtaattaaaa tgtgcaggat gacaagatgg agcaaacagt gcttgtacca ccaggacctg 300
 acagcttcaa cttcttcacc agagaatctc ttgctgctat tgaaagacgc attgcagaag 360
 aaaaggcaaa gaatcccaaa ccagacaaaa aagatgacga cgaaaatggc ccaaagccaa 420
 atagtgaactt ggaagctgga aagaaccttc catthattta tggagacatt cctccagaga 480
 tgggtgtcaga gcccctggag gacctggacc cctactatat caataagaaa actttttatag 540
 tattgaataa attgaaggcc atcttccggt tcagtgccac ctctgccctg tacattttta 600
 ctcccttcaa tcctcttagg aaaatagcta ttaagatttt ggtacattca ttattcagca 660
 tgctaattat gtgcactatt ttgacaaact gtgtgtttat gacaatgagt aaccctcctg 720
 attggacaaa gaatgtagaa tacaccttca caggaatata tacttttgaa tcacttataa 780
 aaattattgc aaggggattc tgtttagaag attttacttt ccttcgggat ccatggaact 840
 ggctcgattt cactgtcatt acatttgctt acgtcacaga gtttgtggac ctgggcaatg 900
 tctcggcatt gagaacattc agagtctctc gagcattgaa gacgatttca gtcattccag 960
 gcctgaaaac cattgtggga gccctgatcc agtctgtgaa gaagctctca gatgtaatga 1020
 tcctgactgt gttctgtctg agcgtatttg ctctaattgg gctgcagctg ttcattgggca 1080
 acctgaggaa taaatgtata caatggcctc ccaccaatgc ttccttggag gaacatagta 1140
 tagaaaagaa tataactgtg aattataatg gtacacttat aaatgaaact gtctttgagt 1200
 ttgactggaa gtcatatatt caagattcaa gatatcatta tttcctggag ggtttttttag 1260
 atgcactact atgtggaaat agctctgatg caggccaatg tccagaggga tatatgtgtg 1320
 tgaaagctgg tagaaatccc aattatggct acacaagctt tgataccttc agttgggctt 1380
 ttttgtcctt gtttcgacta atgactcagg acttctggga aaatctttat caactgacat 1440
 tacgtgctgc tgggaaaacg tacatgatat tttttgtatt ggtcattttc ttgggctcat 1500
 tcaacctaat aaatttgatc ctggctgtgg tggccatggc ctacgaggaa cagaatcagg 1560
 ccaccttgga agaagcagaa cagaaagagg ccgaatttca gcagatgatt gaacagctta 1620
 aaaagcaaca ggaggcagct cagcaggcag caacggcaac tgcctcagaa cattccagag 1680
 agcccagtg cagcaggcagg ctctcagaca gctcatctga agcctctaag ttgagttcca 1740

SSCP Update Sequences.ST25

agagtgcctaa	ggaaagaaga	aatcggagga	agaaaagaaa	acagaaagag	cagtctggtg	1800
gggaagagaa	agatgaggat	gaattccaaa	aatctgaatc	tgaggacagc	atcaggagga	1860
aaggtttttcg	cttctccatt	gaagggaacc	gattgacata	tgaaaagagg	tactcctccc	1920
cacaccagtc	tttgttgagc	atccgtggct	ccctattttc	accaaggcga	aatagcagaa	1980
caagcctttt	cagctttaga	gggcgagcaa	aggatgtggg	atctgagaac	gacttcgcag	2040
atgatgagca	cagcaccttt	gaggataacg	agagccgtag	agattccttg	tttgtgcccc	2100
gacgacacgg	agagagacgc	aacagcaacc	tgagtcagac	cagtaggtca	tcccggatgc	2160
tggcagtggt	tccagcgaat	gggaagatgc	acagcactgt	ggattgcaat	ggtgtggttt	2220
ccttggttgg	tggaccttca	gttcctacat	cgctgtttgg	acagcttctg	ccagaggtga	2280
taatagataa	gccagctact	gatgacaatg	gaacaaccac	tgaaactgaa	atgagaaaga	2340
gaaggtcaag	ttctttccac	gtttccatgg	actttctaga	agatccttcc	caaaggcaac	2400
gagcaatgag	tatagccagc	attctaacaa	atacagtaga	agaacttgaa	gaatccaggc	2460
agaaatgccc	accctgttgg	tataaatTTT	ccaacatatt	cttaatctgg	gactgtttctc	2520
catattgggt	aaaagtgaag	catgttgtca	acctggttgt	gatggacca	tttgttgacc	2580
tggccatcac	catctgtatt	gtcttaata	ctcttttcat	ggccatggag	cactatccaa	2640
tgacggacca	tttcaataat	gtgcttacag	taggaaactt	ggttttcact	gggatcttta	2700
cagcagaaat	gtttctgaaa	attattgcca	tggatcctta	ctattatttc	caagaaggct	2760
ggaatatctt	tgacggtttt	attgtgacgc	ttagcctggg	agaacttgga	ctcgccaatg	2820
tggaaggatt	atctgtttctc	cgttcatttc	gattgtctgcg	agttttcaag	ttggcaaaat	2880
cttggccaac	gttaaataatg	ctaataaaga	tcatcggcaa	ttccgtgggg	gctctgggaa	2940
atttaaccct	cgtcttggcc	atcatcgtct	tcattttttgc	cgtgggtcggc	atgcagctct	3000
ttggtaaaag	ctacaaagat	tgtgtctgca	agatcgccag	tgattgtcaa	ctcccacgct	3060
ggcacatgaa	tgacttcttc	cactccttcc	tgattgtggt	ccgcgtgctg	tgtggggagt	3120
ggatagagac	catgtgggac	tgtatggagg	ttgctggtca	agccatgtgc	cttactgtct	3180
tcatgatggt	catggtgatt	ggaaacctag	tggtcctgaa	tctctttctg	gccttgcttc	3240
tgagctcatt	tagtgcagac	aaccttgacg	ccactgatga	tgataatgaa	atgaataatc	3300
tccaaattgc	tgtggatagg	atgcacaaag	gagtagctta	tgtgaaaaga	aaaatatatg	3360
aatttattca	acagtccttc	attaggaaac	aaaagatttt	agatgaaatt	aaaccacttg	3420
atgatctaaa	caacaagaaa	gacagttgta	tgtccaatca	tacaacagaa	attgggaaag	3480
atcttgacta	tcttaaagat	gtaaatggaa	ctacaagtgg	tataggaact	ggcagcagtg	3540
ttgaaaaata	cattattgat	gaaagtgatt	acatgtcatt	cataaacaac	cccagtctta	3600
ctgtgactgt	accaattgct	gtaggagaat	ctgactttga	aaatttaaac	acggaagact	3660
ttagtagtga	atcggatctg	gaagaaagca	aagagaaact	gaatgaaagc	agtagctcat	3720
cagaaggtag	cactgtggac	atcggcgcac	ctgtagaaga	acagcccgtg	gtggaacctg	3780

SSCP Update Sequences.ST25

aagaaactct	tgaaccagaa	gcttgtttca	ctgaaggctg	tgtacaaaga	ttcaagtgtt	3840
gtcaaataca	tgtggaagaa	ggcagaggaa	aacaatggtg	gaacctgaga	aggacgtgtt	3900
tccgaatagt	tgaacataac	tggtttgaga	ccttcattgt	tttcatgatt	ctccttagta	3960
gtggtgctct	ggcatttgaa	gatataata	ttgatcagcg	aaagacgatt	aagacgatgt	4020
tggaaatagc	tgacaagggt	ttcacttaca	ttttcattct	ggaaatgctt	ctaaaatggg	4080
tggcatatgg	ctatcaaaca	tatttcacca	atgcctggtg	ttggctggac	ttcttaattg	4140
ttgatgtttc	attgggtcagt	ttaacagcaa	atgccttggg	ttactcagaa	cttggagcca	4200
tcaaatactct	caggacacta	agagctctga	gacctctaag	agccttatct	cgatttgaag	4260
ggatgagggg	ggttgtgaat	gcccttttag	gagcaattcc	atccatcatg	aatgtgcttc	4320
tggtttgtct	tatatctctg	ctaattttca	gcatcatggg	cgtaaatttg	tttgctggca	4380
aattctacca	ctgtattaac	accacaactg	gtgacagggt	tgacatcgaa	gacgtgaata	4440
atcatactga	ttgcctaaaa	ctaatagaaa	gaaatgagac	tgctcgatgg	aaaaatgtga	4500
aagtaaaactt	tgataatgta	ggatttgggt	atctctcttt	gcttcaagtt	gccacattca	4560
aaggatggat	ggatataatg	tatgcagcag	ttgattccag	aaatgtggaa	ctccagccta	4620
agtatgaaaa	aagtctgtac	atgtatcttt	actttgttat	tttcatcatc	tttgggtcct	4680
tcttcacctt	gaacctgttt	attgggtgtca	tcatagataa	tttcaaccag	cagaaaaaga	4740
agtttggagg	tcaagacatc	tttatgacag	aagaacagaa	gaaatactat	aatgcaatga	4800
aaaaattagg	atcgaaaaaa	ccgcaaaagc	ctatacctcg	accaggaaac	aaatttcaag	4860
gaatggtcct	tgacttcgta	accagacaag	tttttgacat	aagcatcatg	attctcatct	4920
gtcttaacat	ggtcacaatg	atggtggaaa	cagatgacca	gagtgaatat	gtgactacca	4980
ttttgtcacg	catcaatctg	gtgttcattg	tgctattttac	tggagagtgt	gtactgaaac	5040
tcatctctct	acgccattat	tattttacca	ttggatggaa	tatttttgat	tttgtggttg	5100
tcattctctc	cattgttaggt	atgtttcttg	ccgagctgat	agaaaagtat	ttcgtgtccc	5160
ctaccctgtt	ccgagtgatc	cgtcttgcta	ggattggccg	aatcctacgt	ctgatcaaaag	5220
gagcaaaggg	gatccgcacg	ctgctctttg	ctttgatgat	gtcccttcct	gcgttggtta	5280
acatcggcct	cctactcttc	ctagtcatgt	tcatctacgc	catctttggg	atgtccaact	5340
ttgcctatgt	taagagggaa	gttgggatcg	atgacatgtt	caactttgag	acctttggca	5400
acagcatgat	ctgcctattc	caaattacaa	cctctgctgg	ctgggatgga	ttgctagcac	5460
ccattctcaa	cagtaagcca	cccgaactgtg	accctaataa	agttaaccct	ggaagctcag	5520
ttaaggggaga	ctgtgggaac	ccatctgttg	gaattttctt	ttttgtcagt	tacatcatca	5580
tatccttcct	ggttgtggtg	aacatgtaca	tcgcggtcat	cctgggagaa	ttcagtgttg	5640
ctactgaaga	aagtgcagag	cctctgagtg	aggatgactt	tgagatgttc	tatgaggttt	5700
gggagaagtt	tgatccccgat	gcaactcagt	tcatggaatt	tgaaaaatta	tctcagtttg	5760
cagctgcgct	tgaaccgcct	ctcaatctgc	cacaaccaa	caaactccag	ctcattgcca	5820

SSCP Update Sequences.ST25

tggatttgcc	catggtgagt	ggtgaccgga	tccactgtct	tgatatctta	tttgctttta	5880
caaagcgggt	tctaggagag	agtggagaga	tggatgctct	acgaatacag	atggaagagc	5940
gattcatggc	ttccaatcct	tccaaggtct	cctatcagcc	aatcactact	actttaaaac	6000
gaaaacaaga	ggaagtatct	gctgtcatta	ttcagcgtgc	ttacagacgc	caccttttaa	6060
agcgaactgt	aaaacaagct	tcctttacgt	acaataaaaa	caaaatcaaa	ggtggggcta	6120
atcttcttat	aaaagaagac	atgataattg	acagaataaa	tgaaaactct	attacagaaa	6180
aaactgatct	gaccatgtcc	actgcagctt	gtccaccttc	ctatgaccgg	gtgacaaagc	6240
caattgtgga	aaaacatgag	caagaaggca	aagatgaaaa	agccaaaggg	aaataaatga	6300
aaataaataa	aaataattgg	gtgacaaatt	gtttacagcc	tgtgaagggtg	atgtattttt	6360
atcaacagga	ctccttttagg	aggtaaatgc	caaactgact	gttttttacac	aaatctcctt	6420
aaggtcagtg	cctacaataa	gacagtgacc	ccttgtcagc	aaactgtgac	tctgtgtaaa	6480
ggggagatga	ccttgacagg	aggttactgt	tctcactacc	agctgacact	gctgaagata	6540
agatgcacaa	tggctagtca	gactgtaggg	accagtttca	aggggtgcaa	acctgtgatt	6600
ttgggggttgt	ttaacatgaa	acactttagt	gtagtaattg	tatccactgt	ttgcatttca	6660
actgccacat	ttgtcacatt	tttatggaat	ctgttagtgg	attcatcttt	ttgttaatcc	6720
atgtgtttat	tatatgtgac	tattttttgta	aacgaagttt	ctgttgagaa	ataggctaag	6780
gacctctata	acaggtatgc	cacctggggg	gtatggcaac	cacatggccc	tcccagctac	6840
acaaagtcgt	ggttttgcatg	agggcatgct	gcacttagag	atcatgcatg	agaaaaagtc	6900
acaagaaaaa	caaattctta	aatttcacca	tatttctggg	aggggtaatt	gggtgataag	6960
tggaggtgct	ttgttgatct	tgttttgcga	aatccagccc	ctagaccaag	tagattattt	7020
gtgggtaggc	cagtaaattct	tagcaggtgc	aaacttcatt	caaagtgttg	gagtcataaa	7080
tgttatgttt	ctttttgttg	tattaaaaaa	aaaacctgaa	tagtgaatat	tgcccctcac	7140
cctccaccgc	cagaagactg	aattgaccaa	aattactctt	tataaatttc	tgctttttcc	7200
tgcactttgt	ttagccatct	ttgggctctc	agcaaggttg	acactgtata	tgттаatgaa	7260
atgctattta	ttatgtaaat	agtcatttta	ccctgtgggtg	cacgtttgag	caaacaaata	7320
atgacctaag	cacagtattt	attgcatcaa	atatgtacca	caagaaatgt	agagtgaag	7380
ctttacacag	gtaataaaat	gtattctgta	ccatttatag	atagtttgga	tgctatcaat	7440
gcatgtttat	attaccatgc	tgctgtatct	ggtttctctc	actgctcaga	atctcattta	7500
tgagaaacca	tatgtcagtg	gtaaagtcaa	ggaaattggt	caacagatct	catttattta	7560
agtcattaag	caatagtttg	cagcacttta	acagcttttt	ggttattttt	acattttaag	7620
tggataacat	atggtatata	gccagactgt	acagacatgt	ttaaaaaac	acactgctta	7680
acctattaaa	tatgtgttta	gaattttata	agcaaataa	aatactgtaa	aaagtcactt	7740
tattttattt	ttcagcatta	tgtacataaa	tatgaagagg	aaattatctt	caggttgata	7800
tcacaatcac	ttttcttact	ttctgtccat	agtacttttt	catgaaagaa	atttgctaaa	7860

SSCP Update Sequences.ST25

taagacatga	aaacaagact	gggtagttgt	agattttctgc	tttttaaatt	acatttgcta	7920
atttttagatt	atttcacaat	tttaaggagc	aaaatagggt	cacgattcat	atccaaatta	7980
tgctttgcaa	ttggaaaagg	gtttaaaatt	ttattttatat	ttctggtagt	acctgtacta	8040
actgaattga	aggtagtgct	tatgttattt	ttgttctttt	tttctgactt	cggtttatgt	8100
tttcatttct	ttggagtaat	gctgctctag	attgttctaa	atagaatgtg	ggcttcataa	8160
tttttttttc	cacaaaaaca	gagtagtcaa	cttatatagt	caattacatc	aggacatttt	8220
gtgtttctta	cagaagcaaa	ccataggctc	ctcttttctt	taaaactact	tagataaact	8280
gtattcgtga	actgcatgct	ggaaaatgct	actattatgc	taaataatgc	taaccaacat	8340
ttaaaatgtg	caaaactaat	aaagattaca	ttttttattt	t		8381

<210> 6
 <211> 8381
 <212> DNA
 <213> Homo sapiens

<400> 6	
atactgcaga	ggctctctggt gcatgtgtgt atgtgtgcgt ttgtgtgtgt ttgtgtgtct 60
gtgtgttctg	ccccagttag actgcagccc ttgtaaatac tttgacacct ttgcaagaa 120
ggaatctgaa	caattgcaac tgaaggcaca ttgttatcat ctctgtctttg ggtgatgctg 180
ttcctcactg	cagatggata attttccttt taatcaggaa ttcatatgc agaataaatg 240
gtaattaaaa	tgtgcaggat gacaagatgg agcaaacagt gcttgtacca ccaggacctg 300
acagcttcaa	cttcttcacc agagaatctc ttgcggctat tgaaagacgc attgcagaag 360
aaaaggcaaa	gaatcccaaa ccagacaaaa aagatgacga cgaaaatggc ccaaagccaa 420
atagtgcatt	ggaagctgga aagaaccttc catttattta tggagacatt cctccagaga 480
tgggtgcaga	gcccctggag gacctggacc cctactatat caataagaaa acttttatag 540
tattgaataa	attgaaggcc atcttccggt tcagtgccac ctctgccctg tacattttaa 600
ctcccttcaa	tcctcttagg aaaatagcta ttaagatttt ggtacattca ttattcagca 660
tgctaattat	gtgcactatt ttgacaaact gtgtgtttat gacaatgagt aaccctcctg 720
attggacaaa	gaatgtagaa tacaccttca caggaatata tacttttgaa tcacttataa 780
aaattattgc	aaggggattc tgtttagaag attttacttt ctttcgggat ccatggaact 840
ggctcgattt	cactgtcatt acatttgcgt acgtcacaga gtttgtggac ctgggcaatg 900
tctcggcatt	gagaacattc agagtctctc gagcattgaa gacgatttca gtcattccag 960
gcctgaaaac	cattgtggga gccctgatcc agtctgtgaa gaagctctca gatgtaatga 1020
tcctgactgt	gttctgtctg agcgtatttg ctctaattgg gctgcagctg ttcatgggca 1080
acctgaggaa	taaatgtata caatggcctc ccaccaatgc ttccttgagg gaacatagta 1140
tagaaaagaa	tataactgtg aattataatg gtacacttat aaatgaaact gtctttgagt 1200
ttgactggaa	gtcatatatt caagattcaa gatatcatta tttcctggag gggttttttag 1260
atgcactact	atgtggaaat agctctgatg caggccaatg tccagagggg tatatgtgtg 1320

SSCP Update Sequences.ST25

tgaaagctgg	tagaaatccc	aattatggct	acacaagctt	tgataccttc	agttgggctt	1380
ttttgtcctt	gtttcgacta	atgactcagg	acttctggga	aaatctttat	caactgacat	1440
tacgtgctgc	tgggaaaacg	tacatgatat	tttttgtatt	ggtcattttc	ttgggctcat	1500
tctaccta	aaatttgatc	ctggctgtgg	aggccatggc	ctacgaggaa	cagaatcagg	1560
ccaccttgga	agaagcagaa	cagaaagagg	ccgaatttca	gcagatgatt	gaacagctta	1620
aaaagcaaca	ggaggcagct	cagcaggcag	caacggcaac	tgccctcagaa	cattccagag	1680
agcccagtg	agcaggcagg	ctctcagaca	gtcatctga	agcctctaag	ttgagttcca	1740
agagtgctaa	ggaaagaaga	aatcggagga	agaaaagaaa	acagaaagag	cagtctggtg	1800
gggaagagaa	agatgaggat	gaattccaaa	aatctgaatc	tgaggacagc	atcaggagga	1860
aaggttttcg	cttctccatt	gaagggaacc	gattgacata	tgaaaagagg	tactcctccc	1920
cacaccagtc	tttgttgagc	atccgtggct	ccctattttc	accaaggcga	aatagcagaa	1980
caagcctttt	cagctttaga	gggcgagcaa	aggatgtggg	atctgagaac	gacttcgcag	2040
atgatgagca	cagcaccttt	gaggataacg	agagccgtag	agattccttg	tttgtgcccc	2100
gacgacacgg	agagagacgc	aacagcaacc	tgagtcagac	cagtaggtca	tcccggatgc	2160
tggcagtgtt	tccagcgaat	gggaagatgc	acagcactgt	ggattgcaat	ggtgtggttt	2220
ccttggttgg	tggaccttca	gttcctacat	cgctgtttgg	acagcttctg	ccagaggtga	2280
taatagataa	gccagctact	gatgacaatg	gaacaaccac	tgaaactgaa	atgagaaaga	2340
gaagggtcaag	ttctttccac	gtttccatgg	actttctaga	agatccttcc	caaaggcaac	2400
gagcaatgag	tatagccagc	attctaacaa	atacagtaga	agaacttgaa	gaatccaggc	2460
agaaatgccc	accctgttgg	tataaatttt	ccaacatatt	cttaatctgg	gactgttctc	2520
catattgggt	aaaagtga	catgttgtca	acctggttgt	gatggaccca	ttgtttgacc	2580
tggccatcac	catctgtatt	gtcttaaata	ctcttttcat	ggccatggag	cactatccaa	2640
tgacggacca	tttcaataat	gtgcttacag	taggaaactt	ggttttcact	gggatcttta	2700
cagcagaaat	gtttctgaaa	attattgcca	tggatcctta	ctattatttc	caagaaggct	2760
ggaatatctt	tgacggtttt	attgtgacgc	ttagcctggt	agaacttgga	ctcgccaatg	2820
tggaaggatt	atctgttctc	cgttcatttc	gattgctg	agttttcaag	ttggcaaaat	2880
cttggccaac	gttaaatatg	ctaataaaga	tcatcggcaa	ttccgtgggg	gctctgggaa	2940
atttaaccct	cgtcttggcc	atcatcgtct	tcatttttgc	cgtggtcggc	atgcagctct	3000
ttggtaaaag	ctacaaagat	tgtgtctgca	agatcgccag	tgattgtcaa	ctcccacgct	3060
ggcacatgaa	tgacttcttc	cactccttcc	tgattgtgtt	ccgcgtgctg	tgtggggagt	3120
ggatagagac	catgtgggac	tgtatggagg	ttgctggtca	agccatgtgc	cttactgtct	3180
tcatgatggt	catggtgatt	ggaaacctag	tggctctgaa	tctctttctg	gccttgcttc	3240
tgagctcatt	tagtgcagac	aaccttgag	ccactgatga	tgataatgaa	atgaataatc	3300
tccaaattgc	tgtggatagg	atgcacaaag	gagtagctta	tgtgaaaaga	aaaatatatg	3360

SSCP Update Sequences.ST25

aatttattca	acagtccttc	attaggaaac	aaaagatttt	agatgaaatt	aaaccacttg	3420
atgatctaaa	caacaagaaa	gacagttgta	tgtccaatca	tacaacagaa	attgggaaag	3480
atcttgacta	tcttaaagat	gtaaatggaa	ctacaagtgg	tataggaact	ggcagcagtg	3540
ttgaaaaata	cattattgat	gaaagtgatt	acatgtcatt	cataaacaac	cccagtctta	3600
ctgtgactgt	accaattgct	gtaggagaat	ctgactttga	aaattttaa	acggaagact	3660
ttagtagtga	atcggatctg	gaagaaagca	aagagaaact	gaatgaaagc	agtagctcat	3720
cagaaggtag	cactgtggac	atcggcgcac	ctgtagaaga	acagcccgtg	gtggaacctg	3780
aagaaactct	tgaaccagaa	gcttgtttca	ctgaaggctg	tgtacaaaga	ttcaagtgtt	3840
gtcaaataca	tgtggaagaa	ggcagaggaa	aacaatgggtg	gaacctgaga	aggacgtgtt	3900
tccgaatagt	tgaacataac	tggtttgaga	ccttcattgt	tttcatgatt	ctccttagta	3960
gtggtgctct	ggcatttgaa	gatataata	ttgatcagcg	aaagacgatt	aagacgatgt	4020
tggaaatatg	tgacaagggt	ttcacttaca	ttttcattct	ggaaatgctt	ctaaaatggg	4080
tggcatatgg	ctatcaaaca	tatttcacca	atgcctgggtg	ttggctggac	ttcttaattg	4140
ttgatgtttc	attggctcag	ttaacagcaa	atgccttggg	ttactcagaa	cttgagacca	4200
tcaaactctc	caggacacta	agagctctga	gacctctaag	agccttatct	cgatttgaag	4260
ggatgagggg	ggttggtgaat	gcccttttag	gagcaattcc	atccatcatg	aatgtgcttc	4320
tggtttgtct	tatatctctg	ctaattttca	gcacatggg	cgtaaatttg	tttgctggca	4380
aattctacca	ctgtattaac	accacaactg	gtgacagggt	tgacatcgaa	gacgtgaata	4440
atcatactga	ttgcctaaaa	ctaatagaaa	gaaatgagac	tgctcgatgg	aaaaatgtga	4500
aagtaaacct	tgataatgta	ggatttgggt	atctctcttt	gcttcaagtt	gccacattca	4560
aaggatggat	ggatataatg	tatgcagcag	ttgattccag	aaatgtggaa	ctccagccta	4620
agtatgaaaa	aagtctgtac	atgtatcttt	actttgttat	tttcatcatc	tttgggtcct	4680
tcttcacctt	gaacctgttt	attgggtgtc	tcatagataa	tttcaaccag	cagaaaaaga	4740
agtttggagg	tcaagacatc	tttatgacag	aagaacagaa	gaaatactat	aatgcaatga	4800
aaaaattagg	atcgaaaaaa	ccgcaaaagc	ctatacctcg	accaggaaac	aaatttcaag	4860
gaatggctct	tgacttcgta	accagacaag	tttttgacat	aagcatcatg	attctcatct	4920
gtcttaacat	ggtcacaatg	atgggtggaa	cagatgacca	gagtgaatat	gtgactacca	4980
ttttgtcacg	catcaatctg	gtgttcattg	tgctattttac	tggagagtgt	gtactgaaac	5040
tcatctctct	acgccattat	tattttacca	ttggatggaa	tatttttgat	tttgtggttg	5100
tcatctctct	cattgtaggt	atgtttcttg	ccgagctgat	agaaaagtat	ttcgtgtccc	5160
ctaccctggt	ccgagtgatc	cgtcttgcta	ggattggccg	aatcctacgt	ctgatcaaag	5220
gagcaaaggg	gatccgcacg	ctgctctttg	ctttgatgat	gtcccttcct	gcgttgttta	5280
acatcggcct	cctactcttc	ctagtcatgt	tcatctacgc	catctttggg	atgtccaact	5340
ttgcctatgt	taagagggaa	gttgggatcg	atgacatgtt	caactttgag	acctttggca	5400

SSCP Update Sequences.ST25

acagcatgat	ctgcctattc	caaattacaa	cctctgctgg	ctgggatgga	ttgctagcac	5460
ccattctcaa	cagtaagcca	cccgactgtg	accctaataa	agttaaccct	ggaagctcag	5520
ttaagggaga	ctgtgggaac	ccatctgttg	gaattttctt	ttttgtcagt	tacatcatca	5580
tatccttcct	ggttgtggtg	aacatgtaca	tcgcggtcat	cctggagaac	ttcagtggtg	5640
ctactgaaga	aagtgcagag	cctctgagtg	aggatgactt	tgagatgttc	tatgaggttt	5700
gggagaagtt	tgatccccgat	gcaactcagt	tcatggaatt	tgaaaaatta	tctcagtttg	5760
cagctgcgct	tgaaccgcct	ctcaatctgc	cacaaccaaa	caaactccag	ctcattgccca	5820
tggatttgcc	catggtgagt	ggtgaccgga	tccactgtct	tgatatctta	tttgctttta	5880
caaagcgggt	tctaggagag	agtggagaga	tggatgtctt	acgaatacag	atggaagagc	5940
gattcatggc	ttccaatcct	tccaaggtct	cctatcagcc	aatcactact	actttaaaac	6000
gaaaacaaga	ggaagtatct	gctgtcatta	ttcagcgtgc	ttacagacgc	caccttttaa	6060
agcgaactgt	aaaacaagct	tcctttacgt	acaataaaaa	caaaatcaaa	ggtggggcta	6120
atcttcttat	aaaagaagac	atgataattg	acagaataaa	tgaaaactct	attacagaaa	6180
aaactgatct	gaccatgtcc	actgcagctt	gtccaccttc	ctatgaccgg	gtgacaaagc	6240
caattgtgga	aaaacatgag	caagaaggca	aagatgaaaa	agccaaaggg	aaataaatga	6300
aaataaataa	aaataattgg	gtgacaaatt	gtttacagcc	tgtgaagggtg	atgtattttt	6360
atcaacagga	ctccttttagg	aggtcaatgc	caaactgact	gtttttacac	aaatctcctt	6420
aaggctcagt	cctacaataa	gacagtgacc	ccttgtcagc	aaactgtgac	tctgtgtaaa	6480
ggggagatga	ccttgacagg	aggttactgt	tctcactacc	agctgacact	gctgaagata	6540
agatgcacaa	tggctagtca	gactgtaggg	accagtttca	aggggtgcaa	acctgtgatt	6600
ttgggggtgt	ttaacatgaa	acactttagt	gtagtaattg	tatccactgt	ttgcatttca	6660
actgccacat	ttgtcacatt	tttatggaat	ctgttagtg	attcatcttt	ttgttaatcc	6720
atgtgtttat	tatatgtgac	tatttttgta	aacgaagttt	ctgttgagaa	ataggctaag	6780
gacctctata	acaggtatgc	cacctggggg	gtatggcaac	cacatggccc	tcccagctac	6840
acaaagtcgt	ggtttgcatg	agggcatgct	gcacttagag	atcatgcatg	agaaaaagtc	6900
acaagaaaaa	caaattctta	aatttcacca	tattttctggg	aggggtaatt	gggtgataag	6960
tggagggtgct	ttgttgatct	tgttttgcga	aatccagccc	ctagaccaag	tagattattt	7020
gtgggtaggc	cagtaaactt	tagcagggtc	aaacttcatt	caaagtgttg	gagtcataaa	7080
tgttatgttt	ctttttgttg	tattaaaaaa	aaaacctgaa	tagtgaatat	tgcccctcac	7140
cctccaccgc	cagaagactg	aattgaccaa	aattactctt	tataaaatttc	tgctttttcc	7200
tgcactttgt	ttagccatct	ttgggctctc	agcaagggtg	acactgtata	tgttaatgaa	7260
atgctattta	ttatgtaaat	agtcatttta	ccctgtgggtg	cacgtttgag	caaacaataa	7320
atgacctaa	cacagtattt	attgcatcaa	atatgtacca	caagaaatgt	agagtgcagg	7380
ctttacacag	gtaataaaat	gtattctgta	ccatttatag	atagtttgga	tgctatcaat	7440

SSCP Update Sequences.ST25

gcatgtttat attaccatgc tgctgtatct ggtttctctc actgctcaga atctcattta 7500
 tgagaaacca tatgtcagtg gtaaagtcaa ggaaattggt caacagatct cttttattta 7560
 agtcattaag caatagtttg cagcacttta acagcttttt ggttattttt acattttaag 7620
 tggataacat atggatatata gccagactgt acagacatgt ttaaaaaaac acactgctta 7680
 acctattaaa tatgtgttta gaattttata agcaaatata aatactgtaa aaagtcactt 7740
 ttttttattt ttcagcatta tgtacataaa tatgaagagg aaattatctt cagggttgata 7800
 tcacaatcac ttttcttact ttctgtccat agtacttttt catgaaagaa atttgctaaa 7860
 taagacatga aaacaagact gggtagttgt agatttctgc tttttaaaatt acatttgcta 7920
 attttagatt atttcacaaat ttttaaggagc aaaatagggtt cacgattcat atccaaatta 7980
 tgctttgcaa ttggaaaagg gtttaaaatt ttattttatat ttctggtagt acctgtacta 8040
 actgaattga aggtagtgct tatgttattt ttgttctttt tttctgactt cggtttatgt 8100
 tttcatttct ttggagtaat gctgctctag attgttctaa atagaatgtg ggcttcataa 8160
 tttttttttc cacaaaaaca gagtagtcaa cttatatagt caattacatc aggacatttt 8220
 gtgtttctta cagaagcaaa ccataggctc ctcttttctt taaaactact tagataaact 8280
 gtattcgtga actgcatgct ggaaaatgct actattatgc taaataatgc taaccaacat 8340
 ttaaaatgtg caaaactaat aaagattaca ttttttattt t 8381

<210> 7
 <211> 8381
 <212> DNA
 <213> Homo sapiens

<400> 7
 atactgcaga ggtctctggt gcatgtgtgt atgtgtgctt ttgtgtgtgt ttgtgtgtct 60
 gtgtgttctg cccagtgag actgcagccc ttgtaaatac ttgacacct ttgcaagaa 120
 ggaatctgaa caattgcaac tgaaggcaca ttgttatcat ctctgtcttg ggtgatgctg 180
 ttctcactg cagatggata attttccttt taatcaggaa tttcatatgc agaataaatg 240
 gtaattaaaa tgtgcaggat gacaagatgg agcaaacagt gcttgtacca ccaggacctg 300
 acagcttcaa cttcttcacc agagaatctc ttgcggctat tgaaagacgc attgcagaag 360
 aaaaggcaaa gaatcccaa ccagacaaaa aagatgacga cgaaaatggc ccaaagccaa 420
 atagtgaact ggaagctgga aagaaccttc cttttattta tggagacatt cctccagaga 480
 tgggtgtcaga gcccctggag gacctggacc cttactatat caataagaaa actttttatag 540
 tattgaataa attgaaggcc atcttccggt tcagtgcac ctctgccctg tacattttta 600
 ctcccttcaa tcctcttagg aaaatagcta ttaagatttt ggtacattca ttattcagca 660
 tgctaattat gtgcactatt ttgacaaact gtgtgtttat gacaatgagt aaccctcctg 720
 attggacaaa gaatgtagaa tacaccttca caggaatata tacttttgaa tcacttataa 780
 aaattattgc aaggggattc tgtttagaag attttacttt cttcgggat ccatggaact 840

SSCP Update Sequences.ST25

ggctcgattt	cactgtcatt	acatttgcgt	acgtcacaga	gtttgtggac	ctgggcaatg	900
tctcggcatt	gagaacattc	agagttctcc	gagcattgaa	gacgatttca	gtcattccag	960
gcctgaaaac	cattgtggga	gccctgatcc	agtctgtgaa	gaagctctca	gatgtaatga	1020
tcctgactgt	gttctgtctg	agcgtatttg	ctctaattgg	gctgcagctg	ttcatgggca	1080
acctgaggaa	taaatgtata	caatggcctc	ccaccaatgc	ttccttggag	gaacatagta	1140
tagaaaagaa	tataactgtg	aattataatg	gtacacttat	aaatgaaact	gtctttgagt	1200
ttgactggaa	gtcatatatt	caagattcaa	gatatcatta	tttcctggag	ggtttttttag	1260
atgcactact	atgtggaaat	agctctgatg	caggccaatg	tccagaggga	tatatgtgtg	1320
tgaaagctgg	tagaaatccc	aattatggct	acacaagctt	tgataccttc	agttgggctt	1380
ttttgtcctt	gtttcgacta	atgactcagg	acttctggga	aaatctttat	caactgacat	1440
tacgtgctgc	tgggaaaacg	tacatgatat	tttttgtatt	ggtcattttc	ttgggctcat	1500
tctaccta	aaatttgatc	ctggctgtgg	tggccatggc	ctacgaggaa	cagaatcagg	1560
ccaccttgg	agaagcagaa	cagaaagagg	ccgaatttca	gcagatgatt	gaacagctta	1620
aaaagcaaca	ggaggcagct	cagcaggcag	caacggcaac	tgcctcagaa	cattccagag	1680
agcccagtg	agcaggcagg	ctctcagaca	gctcatctga	agcctctaag	ttgagttcca	1740
agagtgctaa	ggaaagaaga	aatcggagga	agaaaagaaa	acagaaagag	cagtctgggtg	1800
gggaagagaa	agatgaggat	gaattccaaa	aatctgaatc	tgaggacagc	atcaggagga	1860
aaggttttcg	cttctccatt	gaagggaacc	gattgacata	tgaaaagagg	tactcctccc	1920
cacaccagtc	tttggtgagc	atccgtggct	ccctattttc	accaaggcga	aatagcagaa	1980
caagcctttt	cagctttaga	gggcgagcaa	aggatgtggg	atctgagaac	gacttcgcag	2040
atgatgagca	cagcaccttt	gaggataacg	agagccgtag	agattccttg	tttggtgcccc	2100
gacgacacgg	agagagacgc	aacagcaacc	tgagtcagac	cagtaggtca	tcccggatgc	2160
tggcagtggt	tccagcgaat	gggaagatgc	acagcactgt	ggattgcaat	gggtgtgggtt	2220
ccttggttgg	tggaccttca	gttcctacat	cgctgtttgg	acagcttctg	ccagagggtga	2280
taatagataa	gccagctact	gatgacaatg	gaacaaccac	tgaaactgaa	atgagaaaga	2340
gaagggtcaag	ttctttccac	gtttccatgg	actttctaga	agatccttcc	caaaggcaac	2400
gagcaatgag	tatagccagc	attctaacaa	atacagtaga	agaacttgaa	gaatccaggc	2460
agaaatgccc	accctgtttg	tataaatatt	ccaacatatt	cttaatctgg	gactgtttctc	2520
catattgggt	aaaagtga	catgttgtca	acctgggtgt	gatggacca	tttggttgacc	2580
tggccatcac	catctgtatt	gtcttaata	ctcttttcat	ggccatggag	cactatccaa	2640
tgacggacca	tttcaataat	gtgcttacag	taggaaactt	ggtttctact	gggatcttta	2700
cagcagaaat	gtttctgaaa	attattgcca	tggatcctta	ctattatttc	caagaaggct	2760
ggaatatctt	tgacggtttt	attgtgacgc	ttagcctggg	agaacttgga	ctcgccaatg	2820
tgggaaggatt	atctgttctc	cgttcatttc	gattgctgcg	agttttcaag	ttggcaaaat	2880

SSCP Update Sequences.ST25

cttggccaac	gttaaataatg	ctaataaaga	tcatacgga	ttccgtggg	gctctggga	2940
atttaaccct	cgtcttgcc	atcatcgtct	tcatttttgc	cgtggtcggc	atgcagctct	3000
ttggtaaaag	ctacaaagat	tgtgtctgca	agatcgccag	tgattgtcaa	ctcccacgct	3060
ggcacatgaa	tgacttcttc	cactccttcc	tgatttgtgt	ccgctgtctg	tgtggggagt	3120
ggatagagac	catgtgggac	tgtatggagg	ttgctggta	agccatgtgc	cttactgtct	3180
tcattgatgg	catgggtgatt	ggaaacctag	tggtcctgaa	tctctttctg	gccttgcttc	3240
tgagctcatt	tagtgcagac	aaccttgag	ccactgatga	tgataatgaa	atgaataatc	3300
tccaaattgc	tgtggatagg	atgcacaaag	gagtagctta	tgtgaaaaga	aaaatatatg	3360
aattttattca	acagtccttc	attaggaaac	aaaagatttt	agatgaaatt	aaaccacttg	3420
atgatctaaa	caacaagaaa	gacagttgta	tgtccaatca	tacaacagaa	attgggaaaag	3480
atcttgacta	tcttaaagat	gtaaatggaa	ctacaagtgg	tatagggaact	ggcagcagtg	3540
ttgaaaaata	cattattgat	gaaagtgtat	acatgtcatt	cataaacaac	cccagtctta	3600
ctgtgactgt	accaattgct	gtaggagaat	ctgactttga	aaattttaa	acggaagact	3660
ttagtagtga	atcggtatctg	gaagaaagca	aagagaaact	gaatgaaagc	agtagctcat	3720
cagaaggtag	cactgtggac	atcggcgcac	ctgtagaaga	acagcccgt	gtggaacctg	3780
aagaaactct	tgaaccagaa	gcttgtttca	ctgaaggctg	tgtacaaaga	ttcaagtgtt	3840
gtcaaatcaa	tgtggaagaa	ggcagaggaa	aacaatggtg	gaacctgaga	aggacgtgtt	3900
tccgaatagt	tgaacataac	tggtttgaga	ccttcattgt	tttcatgatt	ctccttagta	3960
gtggtgctct	ggcattttgaa	gatatatata	ttgatcagcg	aaagacgatt	aagacgatgt	4020
tggaatatgc	tgacaagggt	ttcacttaca	ttttcattct	ggaaatgctt	ctaaaatggg	4080
tggcatatgg	ctatcaaaca	tatttcacca	atgcctgggtg	ttggctggac	ttcttaattg	4140
ttgatgtttc	attgggtcagt	ttaacagcaa	atgccttggg	ttactcagaa	cttgagacca	4200
tcaaatctct	caggacacta	agagctctga	gacctctaag	agccttatct	cgatttgaag	4260
ggatgagggg	ggttgtgaat	gcccttttag	gagcaattcc	atccatcatg	aatgtgcttc	4320
tggtttgtct	tatatcttgg	ctaattttca	gcatcatggg	cgtaaatttg	tttgctggca	4380
aattctacca	ctgtattaac	accacaactg	gtgacagggt	tgacatcgaa	gacgtgaata	4440
atcatactga	ttgcctaaaa	ctaatagaaa	gaaatgagac	tgcttgatgg	aaaaatgtga	4500
aagtaaaact	tgataatgta	ggatttgggt	atctctcttt	gcttcaagtt	gccacattca	4560
aaggatggat	ggatataatg	tatgcagcag	ttgattccag	aaatgtggaa	ctccagccta	4620
agtatgaaaa	aagtctgtac	atgtatcttt	actttgttat	tttcatcatc	tttgggtcct	4680
tcttcacctt	gaacctgttt	attggtgtca	tcatagataa	tttcaaccag	cagaaaaaga	4740
agtttgagg	tcaagacatc	tttatgacag	aagaacagaa	gaaatactat	aatgcaatga	4800
aaaaattagg	atcgaaaaaa	ccgcaaaagc	ctatacctcg	accaggaaac	aaatttcaag	4860
gaatggctct	tgacttcgta	accagacaag	tttttgacat	aagcatcatg	attctcatct	4920

SSCP Update Sequences.ST25

gtcttaacat	ggtcacaatg	atggtggaaa	cagatgacca	gagtgaatat	gtgactacca	4980
ttttgtcacg	catcaatctg	gtgttcattg	tgctattttac	tggagagtgt	gtactgaaac	5040
tcattctctct	acgccattat	tattttacca	ttggatggaa	tatttttgat	tttgtggttg	5100
tcattctctc	cattgtaggt	atgtttcttg	ccgagctgat	agaaaagtat	ttcgtgtccc	5160
ctaccctggt	ccgagtgatc	cgtcttgcta	ggattggccg	aatcctacgt	ctgatcaaag	5220
gagcaaaggg	gatccgcacg	ctgctctttg	ctttgatgat	gtcccttcct	gcgttgttta	5280
acatcggcct	cctactcttc	ctagtcatgt	tcattctacgc	catctttggg	atgtccaact	5340
ttgcctatgt	taagagggaa	gttgggatcg	atgacatggt	caactttgag	acctttggca	5400
acagcatgat	ctgcctattc	caaattacaa	cctctgctgg	ctgggatgga	ttgctagcac	5460
ccattctcaa	cagtaagcca	cccgactgtg	accctaataa	agttaaccct	ggaagctcag	5520
ttaagggaga	ctgtgggaac	ccatctgttg	gaattttctt	ttttgtcagt	tacatcatca	5580
tatccttcct	ggttgtgggtg	aacatgtaca	tcgcgggtcat	cctgggagaac	ttcagtgttg	5640
ctactgaaga	aagtgcagag	cctctgagtg	aggatgactt	tgagatgttc	tatgaggttt	5700
gggagaagtt	tgatcccgat	gcaactcagt	tcattggaatt	tgaaaaatta	tctcagtttg	5760
cagctgcgct	tgaaccgcct	ctcaatctgc	cacaaccaa	caaaactccag	ctcattgccca	5820
tggatttgcc	catggtgagt	ggtgaccgga	tccactgtct	tgatatctta	tttgctttta	5880
caaagcgggt	tctaggagag	agtggagaga	tggatgctct	acgaatacag	atggaagagc	5940
gattcatggc	ttccaatcct	tccaaggtct	cctatcagcc	aatcactact	actttaaaac	6000
gaaaacaaga	ggaagtatct	gctgtcatta	ttcagcgtgc	ttacagacgc	caccttttaa	6060
agcgaactgt	aaaacaagct	tcctttacgt	acaataaaaa	caaaatcaaa	ggtggggcta	6120
atcttcttat	aaaagaagac	atgataattg	acagaataaa	tgaaaactct	attacagaaa	6180
aaactgatct	gaccatgtcc	actgcagctt	gtccaccttc	ctatgaccgg	gtgacaaagc	6240
caattgtgga	aaaacatgag	caagaaggca	aagatgaaaa	agccaaaggg	aaataaatga	6300
aaataataaa	aaataattgg	gtgacaaatt	gtttacagcc	tgtgaagggtg	atgtattttt	6360
atcaacagga	ctcctttagg	aggtcaatgc	caaaactgact	gtttttacac	aaatctcctt	6420
aaggctcagt	cctacaataa	gacagtgacc	ccttgtcagc	aaactgtgac	tctgtgtaaa	6480
ggggagatga	ccttgacagg	aggttactgt	tctcactacc	agctgacact	gctgaagata	6540
agatgcacaa	tggctagtca	gactgtaggg	accagtttca	aggggtgcaa	acctgtgatt	6600
ttggggttgt	ttaacatgaa	acactttagt	gtagtaattg	tatccactgt	ttgcatttca	6660
actgccacat	ttgtcacatt	tttatggaat	ctgttagtg	attcatcttt	ttgttaatcc	6720
atgtgtttat	tatatgtgac	tatTTTTgt	aacgaagttt	ctgttgagaa	ataggctaag	6780
gacctctata	acaggtatgc	cacctggggg	gtatggcaac	cacatggccc	tcccagctac	6840
acaaagtcgt	ggtttgcatg	agggcatgct	gcacttagag	atcatgcatg	agaaaaagtc	6900
acaagaaaaa	caaattctta	aatttcacca	tatttctggg	aggggtaatt	gggtgataag	6960

SSCP Update Sequences.ST25

tggaggtgct	ttgttgatct	tgttttgCGA	aatccagccc	ctagaccaag	tagattatTTT	7020
gtgggtaggc	cagtaaactct	tagcaggtgc	aaacttcatt	caaatgtttg	gagtcataaa	7080
tgttatgttt	ctttttgttg	tattaaaaaa	aaaacctgaa	tagtgaatat	tgccccctcac	7140
cctccaccgc	cagaagactg	aattgaccaa	aattactctt	tataaatttc	tgcttttttcc	7200
tgcactttgt	ttagccatct	ttgggctctc	agcaagggtg	acactgtata	tgTTaatgaa	7260
atgctatttta	ttatgtaaat	agtcatttta	ccctgtgggtg	cacgtttgag	caaacaaata	7320
atgacctaag	cacagtatTTT	attgcatcaa	atatgtacca	caagaaatgt	agagtgcAag	7380
ctttacacag	gtaataaaaat	gtattctgta	ccatttatag	atagtTTgga	tgctatcaat	7440
gcatgtttat	attaccatgc	tgctgtatct	ggtttctctc	actgctcaga	atctcatttta	7500
tgagaaacca	tatgtcagtg	gtaaagtcaa	ggaaattgtt	caacagatct	cattttatttta	7560
agtcattaag	caatagtTTg	cagcacttta	acagctTTTT	ggttattTTTT	acattTTaag	7620
tggataacat	atgggtatata	gccagactgt	acagacatgt	ttaaaaaaac	acactgctta	7680
acctattaaa	tatgtgtTTa	gaattttata	agcaaataata	aatactgtaa	aaagtcactt	7740
tattttatTTT	ttcagcatta	tgtacataaa	tatgaagagg	aaattatctt	caggTTgata	7800
tcacaatcac	ttttcttact	ttctgtccat	agtactTTTT	catgaaagaa	atttgctaaa	7860
taagacatga	aaacaagact	gggtagtTgt	agatttctgc	tttttaaatt	acatttgcta	7920
atttttagatt	atttcacaat	tttaaggagc	aaaatagggtt	cacgattcat	atccaaatta	7980
tgctttgcaa	ttggaaaagg	gtttaaaatt	ttattttatat	ttctggtagt	acctgtacta	8040
actgaattga	aggtagtgct	tatgttattt	ttgttctttt	tttctgactt	cggtttatgt	8100
tttcattttct	ttggagtaat	gctgctctag	attgttctaa	atagaatgtg	ggcttcataa	8160
tttttttttcc	cacaaaaaca	gagtagtcaa	cttatatagt	caattacatc	aggacatttt	8220
gtgtttcttta	cagaagcaaa	ccataggctc	ctcttttccct	taaaactact	tagataaaact	8280
gtattcgtga	actgcatgct	ggaaaatgct	actattatgc	taaataatgc	taaccaacat	8340
ttaaaatgtg	caaaactaat	aaagattaca	ttttttatTTT	t		8381

<210> 8

<211> 8381

<212> DNA

<213> Homo sapiens

<400> 8

atactgcaga	ggctctctgg	gcatgtgtgt	atgtgtgcgt	ttgtgtgtgt	ttgtgtgtct	60
gtgtgtttctg	ccccagtgag	actgcagccc	ttgtaaatac	tttgacacct	tttgcaagaa	120
ggaatctgaa	caattgcaac	tgaaggcaca	ttgttatcat	ctcgtctttg	ggatgatgctg	180
ttcctcactg	cagatggata	attttccttt	taatcaggaa	tttcatatgc	agaataaatg	240
gtaattaaaa	tgtgcaggat	gacaagatgg	agcaaacagt	gcttgtacca	ccaggacctg	300
acagcttcaa	cttcttcacc	agagaatctc	ttgcggctat	tgaaagacgc	attgcagaag	360
aaaaggcaaa	gaatcccaaa	ccagacaaaa	aagatgacga	cgaaaatggc	ccaaagccaa	420

SSCP Update Sequences.ST25

atagtgactt	ggaagctgga	aagaaccttc	cattttattta	tggagacatt	cctccagaga	480
tggtgtcaga	gcccctggag	gacctggacc	cctactatat	caataagaaa	actttttatag	540
tattgaataa	attgaaggcc	atcttccggt	tcagtgccac	ctctgccctg	tacatttttaa	600
ctcccttcaa	tcctcttagg	aaaatagcta	ttaagatttt	ggtacattca	ttattcagca	660
tgctaattat	gtgcactatt	ttgacaaact	gtgtgtttat	gacaatgagt	aaccctcctg	720
attggacaaa	gaatgtagaa	tacaccttca	caggaatata	tacttttgaa	tcacttataa	780
aaattattgc	aaggggattc	tgtttagaag	attttacttt	ccttcgggat	ccatggaact	840
ggctcgattt	cactgtcatt	acatttgcgt	acgtcacaga	gtttgtggac	ctgggcaatg	900
tctcggcatt	gagaacattc	agagtctctc	gagcattgaa	gacgatttca	gtcattccag	960
gcctgaaaac	cattgtggga	gccctgatcc	agtctgtgaa	gaagctctca	gatgtaatga	1020
tcctgactgt	gttctgtctg	agcgtatttt	ctctaattgg	gctgcagctg	ttcatgggca	1080
acctgaggaa	taaatgtata	caatggcctc	ccaccaatgc	ttccttggag	gaacatagta	1140
tagaaaagaa	tataactgtg	aattataatg	gtacacttat	aaatgaaact	gtctttgagt	1200
ttgactggaa	gtcatatat	caagattcaa	gatatcatta	tttcctggag	ggtttttttag	1260
atgcactact	atgtggaaat	agctctgatg	caggccaatg	tccagaggga	tatatgtgtg	1320
tgaaagctgg	tagaaatccc	aattatggct	acacaagctt	tgataccttc	agttgggctt	1380
ttttgtcctt	gtttcgacta	atgactcagg	acttctggga	aaatctttat	caactgacat	1440
tacgtgctgc	tgggaaaacg	tacatgatat	tttttgtatt	ggtcattttc	ttgggctcat	1500
tctaccta	aaatttgatc	ctggctgtgg	tggccatggc	ctacgaggaa	cagaatcagg	1560
ccaccttgga	agaagcagaa	cagaaagagg	ccgaatttca	gcagatgatt	gaacagctta	1620
aaaagcaaca	ggaggcagct	cagcaggcag	caacggcaac	tgccctcagaa	cattccagag	1680
agcccagtg	agcaggcagg	ctctcagaca	gctcatctga	agcctctaag	ttgagttcca	1740
agagtgtcaa	ggaaagaaga	aatcggagga	agaaaagaaa	acagaaagag	cagtctggtg	1800
gggaagagaa	agatgaggat	gaattccaaa	aatctgaatc	tgaggacagc	atcaggagga	1860
aaggttttcg	cttctccatt	gaagggaacc	gattgacata	tgaaaagagg	tactcctccc	1920
cacaccagtc	tttgttgagc	atccgtggct	ccctattttc	accaaggcga	aatagcagaa	1980
caagcctttt	cagcttttaga	gggcgagcaa	aggatgtggg	atctgagaac	gacttcgcag	2040
atgatgagca	cagcaccttt	gaggataacg	agagccgtag	agattccttg	tttgtgcccc	2100
gacgacacgg	agagagacgc	aacagcaacc	tgagtcagac	cagtaggtca	tcccggatgc	2160
tggcagtggt	tccagcgaat	gggaagatgc	acagcactgt	ggattgcaat	ggtgtggttt	2220
ccttggttgg	tggaccttca	gttcctacat	cgctgtttgg	acagcttctg	ccagaggtga	2280
taatagataa	gccagctact	gatgacaatg	gaacaaccac	tgaaactgaa	atgagaaaga	2340
gaaggtcaag	ttctttccac	gtttccatgg	actttctaga	agatccttcc	caaaggcaac	2400
gagcaatgag	tatagccagc	attctaacaa	atacagtaga	agaacttgaa	gaatccaggc	2460

SSCP Update Sequences.ST25

agaaatgccc	accctgttgg	tataaat	ttt ccaacatatt	cttaatctgg	gactgttctc	2520
catattgggt	aaaagtga	aaa catgttgtca	acctggttgt	gatggacca	tttgttgacc	2580
tggccatcac	catctgtatt	gtcttaaata	ctcttttcat	ggccatggag	cactatccaa	2640
tgacggacca	tttcaataat	gtgcttacag	taggaaactt	ggttttcact	gggatcttta	2700
cagcagaaat	gtttctgaaa	attattgcca	tggatcctta	ctattatttc	caagaaggct	2760
ggaatatctt	tgacggtttt	attgtgacgc	ttagcctggg	agaacttgga	ctcgccaatg	2820
tggaaggatt	atctgttctc	cgttcatttc	gattgctgcg	agttttcaag	ttggcaaaat	2880
cttggccaac	gttaaataatg	ctaataaaga	tcatcggcaa	ttccgtgggg	gctctgggaa	2940
atttaaccct	cgtcttggcc	atcatcgtct	tcatttttgc	cgtggctggc	atgcagctct	3000
ttggtaaaag	ctacaaagat	tgtgtctgca	agatcgccag	tgattgtcaa	ctcccacgct	3060
ggcacatgaa	tgacttcttc	cactccttcc	tgattgtgtt	ccgcgtgctg	tgtggggagt	3120
ggatagagac	catgtgggac	tgtatggagg	ttgctgggtca	agccatgtgc	cttactgtct	3180
tcgatggtgt	catggtgatt	ggaaacctag	tggtcctgaa	tctctttctg	gccttgcttc	3240
tgagctcatt	tagtgcagac	aaccttgacg	ccactgatga	tgataatgaa	atgaataatc	3300
tccaaattgc	tgtggatagg	atgcacaaag	gagtagctta	tgtgaaaaga	aaaatatatg	3360
aattttattca	acagtccttc	attaggaaac	aaaagatttt	agatgaaatt	aaaccacttg	3420
atgatctaaa	caacaagaaa	gacagttgta	tgtccaatca	tacaacagaa	attgggaaag	3480
atcttgacta	tcttaaagat	gtaaatggaa	ctacaagtgg	tataggaact	ggcagcagtg	3540
ttgaaaaata	cattattgat	gaaagtgatt	acatgtcatt	cataaacaac	cccagtctta	3600
ctgtgactgt	accaattgct	gtaggagaat	ctgactttga	aaattttaa	acggaagact	3660
ttagtagtga	atcggtatctg	gaagaaagca	aagagaaact	gaatgaaagc	agtagctcat	3720
cagaaggtag	cactgtggac	atcggcgcac	ctgtagaaga	acagcccgtg	gtggaacctg	3780
aagaaactct	tgaaccagaa	gcttgtttca	ctgaaggctg	tgtacaaaga	ttcaagtgtt	3840
gtcaaataca	tgtggaagaa	ggcagaggaa	aacaatgggtg	gaacctgaga	aggacgtgtt	3900
tccgaatagt	tgaacataac	tggtttgaga	ccttcattgt	tttcatgatt	ctccttagta	3960
gtggtgctct	ggcatttgaa	gatataatata	ttgatcagcg	aaagacgatt	aagacgatgt	4020
tggaatatgc	tgacaagggt	ttcacttaca	ttttcattct	ggaaatgctt	ctaaaatggg	4080
tggcatatgg	ctatcaaaca	tatttcacca	atgcctgggtg	ttggctggac	ttcttaattg	4140
ttgatgtttc	attgggtcagt	ttaacagcaa	atgccttggg	ttactcagaa	cttgagacca	4200
tcaaatactct	caggacacta	agagctctga	gacctctaag	agccttatct	cgatttgaag	4260
ggatgagggg	ggttgtgaat	gcccttttag	gagcaattcc	atccatcatg	aatgtgcttc	4320
tggtttgtct	tatattctgg	ctaattttca	gcatcatggg	cgtaaatttg	tttgctggca	4380
aattctacca	ctgtattaac	accacaactg	gtgacagggt	tgacatcgaa	gacgtgaata	4440
atcatactga	ttgcctaaaa	ctaatagaaa	gaaatgagac	tgctcgatgg	aaaaatgtga	4500

SSCP Update Sequences.ST25

aagtaaactt	tgataatgta	ggatttgggt	atctctcttt	gcttcaagtt	gccacattca	4560
aaggatggat	ggatataatg	tatgcagcag	ttgattccag	aaatgtggaa	ctccagccta	4620
agtatgaaaa	aagtctgtac	atgtatcttt	actttgttat	tttcatcatc	tttgggtcct	4680
tcttcacctt	gaacctgttt	attggtgtca	tcatagataa	tttcaaccag	cagaaaaaga	4740
agtttggagg	tcaagacatc	tttatgacag	aagaacagaa	gaaatactat	aatgcaatga	4800
aaaaattagg	atcgaaaaaa	ccgcaaaagc	ctatacctcg	accaggaaac	aaatttcaag	4860
gaatggctct	tgacttcgta	accagacaag	tttttgacat	aagcatcatg	attctcatct	4920
gtcttaacat	ggtcacaatg	atggtggaaa	cagatgacca	gagtgaatat	gtgactacca	4980
ttttgtcacg	catcaatctg	gtgttcattg	tgctattttac	tggagagtgt	gtactgaaac	5040
tcatctctct	acgccattat	tattttacca	ttggatggaa	tatttttgat	tttgtggttg	5100
tcattctctc	cattgtaggt	atgtttcttg	ccgagctgat	agaaaagtat	ttcgtgtccc	5160
ctaccctggt	ccgagtgatc	cgtcttgcta	ggattggccg	aatcctacgt	ctgatcaaag	5220
gagcaaaggg	gatccgcacg	ctgctctttg	ctttgatgat	gtcccttcct	gcgttgttta	5280
acatcggcct	cctactcttc	ctagtcatgt	tcatctacgc	catctttggg	atgtccaact	5340
ttgcctatgt	taagagggaa	gttgggatcg	atgacatggt	caactttgag	acctttggca	5400
acagcatgat	ctgcctattc	caaattacaa	cctctgctgg	ctgggatgga	ttgctagcac	5460
ccatttctca	cagtaagcca	cccgactgtg	accctaataa	agttaaccct	ggaagctcag	5520
ttaagggaga	ctgtgggaac	ccatctgttg	gaattttctt	ttttgtcagt	tacatcatca	5580
tatccttcct	ggttgtggtg	aacacgtaca	tcgcgggtcat	cctggagaac	ttcagtgttg	5640
ctactgaaga	aagtgcagag	cctctgagtg	aggatgactt	tgagatgttc	tatgaggttt	5700
gggagaagtt	tgatcccgat	gcaactcagt	tcatggaatt	tgaaaaatta	tctcagtttg	5760
cagctgcgct	tgaaccgcct	ctcaatctgc	cacaaccaa	caaactccag	ctcattgcca	5820
tggatttgcc	catggtgagt	ggtgaccgga	tccactgtct	tgatatctta	tttgctttta	5880
caaagcgggt	tctaggagag	agtggagaga	tggatgctct	acgaatacag	atggaagagc	5940
gattcatggc	ttccaatcct	tccaagggtct	cctatcagcc	aatcactact	actttaaaac	6000
gaaaacaaga	ggaagtatct	gctgtcatta	ttcagcgtgc	ttacagacgc	caccttttaa	6060
agcgaactgt	aaaacaagct	tcctttacgt	acaataaaaa	caaaatcaaa	ggtggggcta	6120
atcttcttat	aaaagaagac	atgataattg	acagaataaa	tgaaaactct	attacagaaa	6180
aaactgatct	gaccatgtcc	actgcagctt	gtccaccttc	ctatgaccgg	gtgacaaagc	6240
caattgtgga	aaaacatgag	caagaaggca	aagatgaaaa	agccaaaggg	aaataaatga	6300
aaataaataa	aaataattgg	gtgacaaatt	gtttacagcc	tgtgaagggtg	atgtattttt	6360
atcaacagga	ctccttttagg	agggtcaatgc	caaactgact	gttttttacac	aaatctcctt	6420
aagggtcagt	cctacaataa	gacagtgacc	ccttgtcagc	aaactgtgac	tctgtgtaaa	6480
ggggagatga	ccttgacagg	aggttactgt	tctcactacc	agctgacact	gctgaagata	6540

SSCP Update Sequences.ST25

```

agatgcacaa tggctagtca gactgtaggg accagtttca aggggtgcaa acctgtgatt 6600
ttgggggttgt ttaacatgaa acacttttagt gtagtaattg tatccactgt ttgcatttca 6660
actgccacat ttgtcacatt tttatggaat ctgttagtggt attcatcttt ttgttaatcc 6720
atgtgtttat tataatgtgac tattttttgta aacgaagttt ctgttgagaa ataggctaag 6780
gacctctata acaggtatgc cacctggggg gtatggcaac cacatggccc tcccagctac 6840
acaaagtcgt ggtttgcatt agggcatgct gcacttagag atcatgcatg agaaaaagtc 6900
acaagaaaaa caaattctta aatttcacca tatttctggg aggggtaatt ggggtgataag 6960
tggaggtgct ttgttgatct tgttttgca aatccagccc ctagaccaag tagattattt 7020
gtgggtaggc cagtaaactt tagcaggtgc aaacttcatt caaatgtttg gagtcataaa 7080
tgttatgttt ctttttggtt tattaaaaaa aaaacctgaa tagtgaatat tgcccctcac 7140
cctccaccgc cagaagactg aattgaccaa aattactctt tataaatttc tgctttttcc 7200
tgcactttgt ttagccatct ttgggctctc agcaagggtt acactgtata tggttaatgaa 7260
atgctattta ttatgtaaag agtcatttta ccctgtggtg cacgtttgag caaacaata 7320
atgacctaag cacagtattt attgcatcaa atatgtacca caagaaatgt agagtgaag 7380
ctttacacag gtaataaaat gtattctgta ccatttatag atagtttgga tgctatcaat 7440
gcatgtttat attaccatgc tgctgtatct ggtttctctc actgctcaga atctcattta 7500
tgagaaacca tatgtcagtg gtaaagtcaa ggaaattggt caacagatct cttttattta 7560
agtcattaag caatagtttg cagcacttta acagcttttt ggttattttt acattttaag 7620
tggataacat atggtatata gccagactgt acagacatgt ttaaaaaaac acactgctta 7680
acctattaaa tatgtgttta gaattttata agcaaataa aatactgtaa aaagtcactt 7740
tattttattt ttcagcatta tgtacataaa tatgaagagg aaattatctt cagggtgata 7800
tcacaatcac ttttcttact ttctgtccat agtacttttt catgaaagaa atttgctaaa 7860
taagacatga aaacaagact gggtagttgt agatttctgc tttttaaatt acatttgcta 7920
atttttagatt atttcacaat ttttaaggagc aaaatagggt cacgattcat atccaaatta 7980
tgctttgcaa ttggaaaagg gtttaaaatt ttatttatat ttctggtagt acctgtacta 8040
actgaattga aggtagtgtt tatgttattt ttgttctttt tttctgactt cggtttatgt 8100
tttcatttct ttggagtaat gctgctctag attgttctaa atagaatgtg ggcttcataa 8160
tttttttttc cacaaaaaca gagtagtcaa cttatatagt caattacatc aggacatttt 8220
gtgtttctta cagaagcaaa ccataggctc ctcttttctt taaaactact tagataaact 8280
gtattcgtga actgcatgct ggaaaatgct actattatgc taaataatgc taaccaacat 8340
ttaaataatg caaaactaat aaagattaca ttttttattt t 8381

```

<210> 9
 <211> 8381
 <212> DNA
 <213> Homo sapiens

SSCP Update Sequences.ST25

<400> 9
 atactgcaga ggtctctggt gcatgtgtgt atgtgtgcgt ttgtgtgtgt ttgtgtgtct 60
 gtgtgttctg cccagtgag actgcagccc ttgtaaatac ttgacacct ttgcaagaa 120
 ggaatctgaa caattgcaac tgaaggcaca ttgttatcat ctctcttttg ggtgatgctg 180
 ttcctcactg cagatggata attttccttt taatcaggaa ttcatatgc agaataaatg 240
 gtaattaaaa tgtgcaggat gacaagatgg agcaaacagt gcttgtacca ccaggacctg 300
 acagcttcaa cttcttcacc agagaatctc ttgcggtat tgaaagacgc attgcagaag 360
 aaaaggcaaa gaatcccaa ccagacaaaa agatgacga cgaaaatggc ccaaagccaa 420
 atagtgaactt ggaagctgga aagaaccttc catttattta tggagacatt cctccagaga 480
 tgggtgtcaga gcccctggag gacctggacc cctactatat caataagaaa acttttatag 540
 tattgaataa attgaaggcc atcttccggt tcagtgccac ctctgccctg tacattttaa 600
 ctcccttcaa tcctcttagg aaaatagcta ttaagatttt ggtacattca ttattcagca 660
 tgctaattat gtgcactatt ttgacaaact gtgtgtttat gacaatgagt aaccctcctg 720
 attggacaaa gaatgtagaa tacaccttca caggaatata tacttttgaa tcacttataa 780
 aaattattgc aaggggattc tgtttagaag attttacttt ccttcgggat ccatggaact 840
 ggctcgattt cactgtcatt acatttgcgt acgtcacaga gtttgtggac ctgggcaatg 900
 tctcggcatt gagaacattc agagtctctc gagcattgaa gacgatttca gtcattccag 960
 gcctgaaaac cattgtggga gccctgatcc agtctgtgaa gaagctctca gatgtaatga 1020
 tcctgactgt gttctgtctg agcgtatttg ctctaatttg gctgcagctg ttcattgggca 1080
 acctgaggaa taaatgtata caatggcctc ccaccaatgc ttccttggag gaacatagta 1140
 tagaaaagaa tataactgtg aattataatg gtacacttat aaatgaaact gtctttgagt 1200
 ttgactggaa gtcatatatt caagattcaa gatatcatta tttcctggag ggttttttag 1260
 atgcactact atgtggaaat agctctgatg caggccaatg tccagaggga tatatgtgtg 1320
 tgaaagctgg tagaaatccc aattatggct acacaagctt tgataccttc agttgggctt 1380
 ttttgtcctt gtttcgacta atgactcagg acttctggga aaatctttat caactgacat 1440
 tacgtgtctg tgggaaaacg tacatgatat tttttgtatt ggtcattttc ttgggctcat 1500
 tctaccta ataatgtatc ctggctgtgg tggccatggc ctacgaggaa cagaatcagg 1560
 ccaccttggga agaagcagaa cagaaagagg ccgaatttca gcagatgatt gaacagctta 1620
 aaaagcaaca ggaggcagct cagcaggcag caacggcaac tgccctcagaa cattccagag 1680
 agcccagtg agcaggcagg ctctcagaca gctcatctga agcctctaag ttgagttcca 1740
 agagtgtctaa ggaaagaaga aatcggagga agaaaagaaa acagaaagag cagtctggtg 1800
 gggaagagaa agatgaggat gaattccaaa aatctgaatc tgaggacagc atcaggagga 1860
 aaggttttcg cttctccatt gaagggaacc gattgacata tgaaaagagg tactcctccc 1920
 cacaccagtc tttgttgagc atccgtggct ccctattttc accaaggcga aatagcagaa 1980

SSCP Update Sequences.ST25

caagcctttt	cagcttttaga	gggcgagcaa	aggatgtggg	atctgagaac	gacttcgcag	2040
atgatgagca	cagcaccttt	gaggataacg	agagccgtag	agattccttg	tttgtgcccc	2100
gacgacacgg	agagagacgc	aacagcaacc	tgagtcagac	cagtaggtca	tcccggatgc	2160
tggcagtgtt	tccagcgaat	gggaagatgc	acagcactgt	ggattgcaat	ggtgtggttt	2220
ccttggttgg	tggaccttca	gttcctacat	cgctgttg	acagcttctg	ccagaggtga	2280
taatagataa	gccagctact	gatgacaatg	gaacaaccac	tgaaactgaa	atgagaaaga	2340
gaagggtcaag	ttctttccac	gtttccatgg	actttctaga	agatccttcc	caaaggcaac	2400
gagcaatgag	tatagccagc	attctaacia	atacagtaga	agaacttgaa	gaatccaggc	2460
agaaatgccc	accctgttgg	tataaatttt	ccaacatatt	cttaatctgg	gactgttctc	2520
catattggtt	aaaagtga	catgttgtca	acctggttgt	gatggacca	tttgttgacc	2580
tggccatcac	catctgtatt	gtcttaata	ctcttttcat	ggccatggag	cactatccaa	2640
tgacggacca	tttcaataat	gtgcttacag	taggaaactt	ggttttcact	gggatcttta	2700
cagcagaaat	gtttctgaaa	attattgcca	tggatcctta	ctattatttc	caagaaggct	2760
ggaatatctt	tgacggtttt	attgtgacgc	ttagcctggg	agaacttgga	ctcgccaatg	2820
tggaaggatt	atctgttctc	cgttcatttc	gattgctgcg	agttttcaag	ttggcaaat	2880
cttggccaac	gttaaataatg	ctaataaaga	tcatcggcaa	ttccgtgggg	gctctgggaa	2940
atttaaccct	cgtcttggcc	atcatcgtct	tcatttttgc	cgtggtcggc	atgcagctct	3000
ttggtaaaag	ctacaaagat	tgtgtctgca	agatcgccag	tgattgtcaa	ctcccacgct	3060
ggcacatgaa	tgacttcttc	cactccttcc	tgattgtgtt	ccgctgtctg	tgtggggagt	3120
ggatagagac	catgtgggac	tgtatggagg	ttgctggtca	agccatgtgc	cttactgtct	3180
tcatgatggg	catgggtgatt	ggaaacctag	tggctctgaa	tctctttctg	gccttgcttc	3240
tgagctcatt	tagtgcagac	aaccttgacg	ccactgatga	tgataatgaa	atgaataatc	3300
tccaaattgc	tgtggatagg	atgcacaaag	gagtagctta	tgtgaaaaga	aaaatatatg	3360
aatttattca	acagtccttc	attaggaaac	aaaagatttt	agatgaaatt	aaaccacttg	3420
atgatctaaa	caacaagaaa	gacagttgta	tgtccaatca	tacaacagaa	attgggaaag	3480
atcttgacta	tcttaaagat	gtaaatggaa	ctacaagtgg	tataggaact	ggcagcagtg	3540
ttgaaaaata	cattattgat	gaaagtgatt	acatgtcatt	cataaacaac	cccagtctta	3600
ctgtgactgt	accaattgct	gtaggagaat	ctgactttga	aaatttaaac	acggaagact	3660
ttagtagtga	atcggtatctg	gaagaaagca	aagagaaact	gaatgaaagc	agtagctcat	3720
cagaaggtag	cactgtggac	atcggcgcac	ctgtagaaga	acagcccgtg	gtggaacctg	3780
aagaaactct	tgaaccagaa	gcttgtttca	ctgaaggctg	tgtacaaaga	ttcaagtgtt	3840
gtcaaataca	tgtggaagaa	ggcagaggaa	aacaatgggtg	gaacctgaga	aggacgtgtt	3900
tccgaatagt	tgaacataac	tggtttgaga	ccttcattgt	tttcatgatt	ctccttagta	3960
gtggtgctct	ggcatttgaa	gatatatata	ttgatcagcg	aaagacgatt	aagacgatgt	4020

SSCP Update Sequences.ST25

tggaatatgc	tgacaagggt	ttcacttaca	ttttcattct	ggaaatgctt	ctaaaatggg	4080
tggcataatgg	ctatcaaaca	tatttcacca	atgcctgggtg	ttggctggac	ttcttaattg	4140
ttgatgtttc	attgggtcagt	ttaacagcaa	atgccttggg	ttactcagaa	cttggagcca	4200
tcaaattctct	caggacacta	agagctctga	gacctctaag	agccttatct	cgatttgaag	4260
ggatgaggggt	ggttggtgaat	gcccttttag	gagcaattcc	atccatcatg	aatgtgcttc	4320
tggtttgtct	tatatctctg	ctaattttca	gcatcatggg	cgtaaatttg	tttgctggca	4380
aattctacca	ctgtattaac	accacaactg	gtgacagggt	tgacatcgaa	gacgtgaata	4440
atcatactga	ttgcctaaaa	ctaataaaaa	gaaatgagac	tgctcgatgg	aaaaatgtga	4500
aagtaaaactt	tgataatgta	ggatttgggt	atctctcttt	gcttcaagtt	gccacattca	4560
aaggatggat	ggatataatg	tatgcagcag	ttgattccag	aaatgtggaa	ctccagccta	4620
agtatgaaaa	aagtctgtac	atgtatcttt	actttgttat	tttcatcatc	tttgggtcct	4680
tcttcacctt	gaacctgttt	attgggtgtca	tcatagataa	tttcaaccag	cagaaaaaga	4740
agtttggagg	tcaagacatc	tttatgacag	aagaacagaa	gaaatactat	aatgcaatga	4800
aaaaattagg	atcgaaaaaa	ccgcaaaagc	ctatacctcg	accaggaaac	aaatttcaag	4860
gaatgggtctt	tgacttcgta	accagacaag	tttttgacat	aagcatcatg	attctcatct	4920
gtcttaacat	ggtcacaatg	atgggtggaaa	cagatgacca	gagtgaatat	gtgactacca	4980
ttttgtcacg	catcaatctg	gtgttcattg	tgctatttac	tggagagtgt	gtactgaaac	5040
tcatctctct	acgccattat	tattttacca	ttggatggaa	tatttttgat	tttgtggttg	5100
tcattctctc	cattgttaggt	atgtttcttg	ccgagctgat	agaaaagtat	ttcgtgtccc	5160
ctaccctggt	ccgagtgatc	cgtcttgcta	ggattggccg	aatcctacgt	ctgatcaaag	5220
gagcaaaggg	gatccgcacg	ctgctctttg	ctttgatgat	gtcccttcct	gcgttggtta	5280
acatcggcct	cctactcttc	ctagtcatgt	tcatctacgc	catctttggg	atgtccaact	5340
ttgcctatgt	taagagggaa	gttgggatcg	atgacatggt	caactttgag	acctttggca	5400
acagcatgat	ctgcctattc	caaattacaa	cctctgctgg	ctgggatgga	ttgctagcac	5460
ccattctcaa	cagtaagcca	cccgaactgtg	accctaataa	agttaaccct	ggaagctcag	5520
ttaagggaga	ctgtgggaac	ccatctgttg	gaattttctt	ttttgtcagt	tacatcatca	5580
tatccttcct	ggttggtgtg	aacatgtaca	tcgcgggtcat	cctgggagaac	ttcagtgttg	5640
ctactgaaga	aagtgcagag	cctctgagtg	aggatgactt	tgagatgttc	tatgaggttt	5700
gggagaagtt	tgatcccgat	gcaactcagt	tcatggaatt	tgaaaaatta	tctcagtttg	5760
cagctgcgct	tgaaccgcct	ctcaatctgc	cacaaccaa	caaactccag	ctcattgcca	5820
tggaatttgcc	catgggtgagt	ggtgaccgga	tccactgtct	tgatatctta	tttgctttta	5880
caaagcgggt	tctaggagag	agtggagaga	tggaatgctct	acgaatacag	atggaagagt	5940
gattcatggc	ttccaatcct	tccaagggtct	cctatcagcc	aatcactact	actttaaaac	6000
gaaaacaaga	ggaagtatct	gctgtcatta	ttcagcgtgc	ttacagacgc	caccttttaa	6060

SSCP Update Sequences.ST25

agcgaactgt	aaaacaagct	tccttttacgt	acaataaaaa	caaaatcaaa	ggtaggggcta	6120
atctttcttat	aaaagaagac	atgataattg	acagaataaa	tgaaaactct	attacagaaa	6180
aaactgatct	gaccatgtcc	actgcagctt	gtccaccttc	ctatgaccgg	gtgacaaagc	6240
caattgtgga	aaaacatgag	caagaaggca	aagatgaaaa	agccaaaggg	aaataaatga	6300
aaataaataa	aaataattgg	gtgacaaatt	gtttacagcc	tgtgaagggtg	atgtattttt	6360
atcaacagga	ctccttttagg	aggtcaatgc	caaactgact	gttttttacac	aaatctcctt	6420
aagggtcagt	cctacaataa	gacagtgtacc	ccttgtcagc	aaactgtgtac	tctgtgtaaa	6480
ggggagatga	ccttgacagg	aggttactgt	tctcactacc	agctgtacact	gctgaagata	6540
agatgcacaa	tggctagtca	gactgtaggg	accagtttca	aggggtgcaa	acctgtgatt	6600
ttgggggtgt	ttaacatgaa	acacttttagt	gtagtaattg	tatccactgt	ttgcatttca	6660
actgccacat	ttgtcacatt	tttatggaat	ctgttagtg	attcatcttt	ttgttaatcc	6720
atgtgtttat	tatatgtgac	tattttttgta	aacgaagttt	ctgttgagaa	ataggctaag	6780
gacctctata	acaggtatgc	cacctggggg	gtatggcaac	cacatggccc	tcccagctac	6840
acaagatcgt	ggttttgcatg	agggcatgct	gcacttagag	atcatgcatg	agaaaaagtc	6900
acaagaaaaa	caaattctta	aatttcacca	tattttctggg	aggggtaatt	gggtgataag	6960
tggagggtgct	ttgttgatct	tgtttttgca	aatccagccc	ctagaccaag	tagattattt	7020
gtgggttaggc	cagtaaactct	tagcagggtgc	aaacttcatt	caaagtgttg	gagtcataaa	7080
tgttatgttt	ctttttgttg	tattaaaaaa	aaaacctgaa	tagtgaatat	tgccccctcac	7140
cctccaccgc	cagaagactg	aattgaccaa	aattactctt	tataaatttc	tgctttttcc	7200
tgcactttgt	ttagccatct	ttgggctctc	agcaagggtg	acactgtata	tgttaatgaa	7260
atgctattta	ttatgtaaat	agtcatttta	ccctgtgggtg	cacgtttgag	caaacaaata	7320
atgacctaa	cacagtattt	attgcatcaa	atatgtacca	caagaaatgt	agagtgcagg	7380
ctttacacag	gtaataaaaat	gtattctgta	ccatttatag	atagtgttga	tgctatcaat	7440
gcatgtttat	attaccatgc	tgctgtatct	ggtttctctc	actgctcaga	atctcattta	7500
tgagaaacca	tatgtcagtg	gtaaagtcaa	ggaaattggt	caacagatct	catttattta	7560
agtcattaag	caatagtttg	cagcacttta	acagcttttt	ggttattttt	acattttaag	7620
tggataacat	atggtatata	gccagactgt	acagacatgt	ttaaaaaac	acactgctta	7680
acctattaaa	tatgtgttta	gaattttata	agcaaataa	aatactgtaa	aaagtcactt	7740
tattttat	ttcagcatta	tgtacataaa	tatgaagagg	aaattatctt	cagggttgata	7800
tcacaatcac	ttttcttact	ttctgtccat	agtacttttt	catgaaagaa	atttgctaaa	7860
taagacatga	aaacaagact	gggtagtgtg	agatttctgc	tttttaaatt	acatttgcta	7920
attttagatt	atttcacaa	tttaaggagc	aaaatagggt	cacgattcat	atccaaatta	7980
tgctttgcaa	ttggaaaagg	gtttaaaatt	ttatttatat	ttctggtagt	acctgtacta	8040
actgaattga	aggtagtgct	tatgttattt	ttgttctttt	tttctgactt	cggtttatgt	8100

SSCP Update Sequences.ST25

tttcatttct	ttggagtaat	gctgctctag	attgtttctaa	atagaatgtg	ggcttcataa	8160
tttttttttc	cacaaaaaca	gagtagtcaa	cttatatagt	caattacatc	aggacatttt	8220
gtgtttctta	cagaagcaaa	ccataggctc	ctcttttctt	taaaactact	tagataaact	8280
gtattcgtga	actgcatgct	ggaaaatgct	actattatgc	taaataatgc	taaccaacat	8340
ttaaaatgtg	caaaactaat	aaagattaca	ttttttattt	t		8381

<210> 10
 <211> 1414
 <212> DNA
 <213> Homo sapiens

<400> 10						
gctccccggg	acatttctaac	cgccgccagg	tcccgccgcc	tctcgccccg	ctattaatac	60
cggcgccccg	ggaggggggc	gcagcacgcg	ccgcgcagcc	atggggaggc	tgctggcctt	120
agtggtcggc	gcggcactgg	tgtcctcagc	ctgcgggggc	tgctggagg	tggaactcga	180
gaccgaggcc	gtgtatggga	tgaccttcaa	aattctttgc	atctcctgca	agcgccgcag	240
cgagaccaac	gctgagacct	tcaccgagtg	gaccttccgc	cagaagggca	ctgaggagtt	300
tgtcaagatc	ctgcgctatg	agaatgaggt	gttgacagctg	gaggaggatg	agcacttcga	360
gggccgcgtg	gtgtggaatg	gcagccgggg	caccaaagac	ctgcaggatc	tgtctatctt	420
catcaccaat	gtcacctaca	accactcggg	cgactacgag	tgccacgtct	accgcctgct	480
cttcttcgaa	aactacgagc	acaacaccag	cgctcgtcaag	aagatccaca	ttgaggtagt	540
ggacaaagcc	aacagagaca	tggcatccat	cgtgtctgag	atcatgatgt	atgtgctcat	600
tgtggtggtg	accatatggc	tcgtggcaga	gatgatttac	tgctacaaga	agatcgctgc	660
cgccacggag	actgctgcac	aggagaatgc	ctcggaatac	ctggccatca	cctctgaaag	720
caaagagaac	tgcacgggcg	tccagggtgg	cgaatagccc	tggccctggg	ccccgcctca	780
aggaagagcc	agccgtaatg	gggactctcc	aggcaccgcc	tgcccccagc	gtgggggtgg	840
ccactcctgg	gccccagaaa	gcctcagagt	cctgcccagc	gagccactgg	gggtgggagg	900
ggcagggggc	ttggctcgca	ccccactttt	cgctcctctc	agctcctgcc	ccgccggccg	960
cgcaccgcc	tgcatgatgg	gtaaagcaat	actgccgctg	ccccaccct	gcttctgctg	1020
cctgtttggg	gagggggggc	gtgaggtggg	ggcagcggcc	ccgcaccct	cctccttgct	1080
gatttgcaca	cattggccgc	ttcagacacg	cacttctggg	gccagcccct	ccccgcctcc	1140
tccctgcctg	gcggcagggg	tcgcgatgat	gggctggagc	agtttggggc	aggggggttct	1200
gggaccact	ccgactcccc	ctccccggca	tcatttcccc	tcccgttcc	tccggctgga	1260
cctgggggtcc	cccctccctg	taatgcactc	ctgccccggc	ccaacctcgc	cctctctcac	1320
cagccttgaa	ctgtggccac	ctagaaaggg	gccattcag	cctcgtctct	ttacagaagt	1380
agttttgttc	atgaaataaa	gactcttgga	cttg			1414

<210> 11
 <211> 6328

SSCP Update Sequences.ST25

<212> DNA

<213> Homo sapiens

<400> 11

ttcttggtgc	cagcttatca	atcccaaact	ctgggtgtaa	aagattctac	agggcacttt	60
cttatgcaag	gagctaaaca	gtgattaaag	gagcaggatg	aaaagatggc	acagtcagtg	120
ctggtaccgc	caggacctga	cagcttccgc	ttctttacca	gggaatccct	tgctgtctatt	180
gaacaacgca	ttgcagaaga	gaaagctaag	agacccaaac	aggaacgcaa	ggatgaggat	240
gatgaaaatg	gcccaaagcc	aaacagtgac	ttggaagcag	gaaaatctct	tccattttatt	300
tatggagaca	ttcctccaga	gatgggtgtca	gtgcccctgg	aggatctgga	cccctactat	360
atcaataaga	aaacgtttat	agtattgaat	aaagggaaag	caatctctcg	attcagtgcc	420
accctgccc	tttacatttt	aactcccctc	aaccctatta	gaaaattagc	tattaagatt	480
ttggtacatt	ctttattcaa	tatgctcatt	atgtgcacga	ttcttaccaa	ctgtgtattt	540
atgaccatga	gtaaccctcc	agactggaca	aagaatgtgg	agtatacctt	tacaggaatt	600
tatacttttg	aatcacttat	taaaataactt	gcaaggggct	tttgtttaga	agatttcaca	660
tttttacggg	atccatggaa	ttggttggat	ttcacagtca	ttacttttgc	atatgtgaca	720
gagtttgtgg	acctgggcaa	tgtctcagcg	ttgagaacat	tcagagttct	ccaagcattg	780
aaaacaattt	cagtcattcc	aggcctgaag	accattgtgg	gggccctgat	ccagtcagtg	840
aagaagcttt	ctgatgtcat	gatcttgact	gtgttctgtc	taagcgtgtt	tgcgctaata	900
ggattgcagt	tgttcatggg	caacctacga	aataaatgtt	tgcaatggcc	tccagataat	960
tcttcctttg	aaataaatat	cacttccttc	tttaacaatt	cattggatgg	gaatggtact	1020
actttcaata	ggacagtgag	catatttaac	tgggatgaat	atattgagga	taaaagtcac	1080
ttttatTTTT	tagaggggca	aaatgatgct	ctgctttgtg	gcaacagctc	agatgcaggc	1140
cagtgtcctg	aaggatacat	ctgtgtgaag	gctggtagaa	accccaacta	tggctacacg	1200
agctttgaca	ccttttagttg	ggcctttttg	tccttatctc	gtctcatgac	tcaagacttc	1260
tgggaaaacc	tttatcaact	gacactacgt	gctgctggga	aaacgtacat	gatatttttt	1320
gtgctggtca	ttttcttggg	ctcattctat	ctaataaatt	tgatcttggc	tgtggtggcc	1380
atggcctatg	aggaacagaa	tcaggccaca	ttggaagagg	ctgaacagaa	ggaagctgaa	1440
tttcagcaga	tgctcgaaca	gttgaaaaag	caacaagaag	aagctcaggc	ggcagctgca	1500
gccgcactctg	ctgaatcaag	agacttcagt	ggtgctggtg	ggataggagt	tttttcagag	1560
agttcttcag	tagcatctaa	gttgagctcc	aaaagtgaag	aagagctgaa	aaacagaaga	1620
aagaaaaaga	aacagaaaga	acagtctgga	gaagaagaga	aaaatgacag	agtcctaaaa	1680
tcggaatctg	aagacagcat	aagaagaaaa	ggtttccggt	tttccttgga	aggaagtagg	1740
ctgacatatg	aaaagagatt	ttcttctcca	caccagtcct	tactgagcat	ccgtggctcc	1800
cttttctctc	caagacgcaa	cagtagggcg	agccttttca	gcttcagagg	tcgagcaaag	1860
gacattggct	ctgagaatga	ctttgctgat	gatgagcaca	gcacctttga	ggacaatgac	1920

SSCP Update Sequences.ST25

agccgaagag	actctctgtt	cgtgccgcac	agacatggag	aacggcgcca	cagcaatgtc	1980
agccaggcca	gccgtgcctc	cagggtgctc	cccacctctgc	ccatgaatgg	gaagatgcat	2040
agcgctgtgg	actgcaatgg	tgtggctctcc	ctggctgggg	gcccttctac	cctcacatct	2100
gctgggcagc	tcctaccaga	gggcacaact	actgaaacag	aaataagaaa	gagacgggtcc	2160
agttcttatc	atgtttccat	ggattttattg	gaagatccta	catcaaggca	aagagcaatg	2220
agtatagcca	gtattttgac	caacacccatg	gaagaacttg	aagaatccag	acagaaatgc	2280
ccaccatgct	ggtataaatt	tgctaatatg	tgtttgattt	gggactgttg	taaaccatgg	2340
ttaaagggtga	aacaccttgt	caacctgggt	gtaatggacc	catttggtga	cctggccatc	2400
accatctgca	ttgtcttaaa	tacactcttc	atggctatgg	agcactatcc	catgacggag	2460
cagttcagca	gtgtactgtc	tgttggaaac	ctggctcttca	cagggatctt	cacagcagaa	2520
atgtttctca	agataattgc	catggatcca	tattattact	ttcaagaagg	ctggaatatt	2580
tttgatgggt	ttattgtgag	ccttagttta	atggaacttg	gtttggcaaa	tgtggaagga	2640
ttgtcagttc	tccgatcatt	ccggctgctc	cgagttttca	agttggcaaa	atcttggtcca	2700
actctaaata	tgctaattaa	gatcattggc	aattctgtgg	gggctctagg	aaacctcacc	2760
ttgggtattgg	ccatcatcgt	cttcattttt	gctgtggtcg	gcatgcagct	ctttggtaag	2820
agctacaaag	aatgtgtctg	caagatttcc	aatgattgtg	aactcccacg	ctggcacatg	2880
catgactttt	tccactcctt	cctgatcgtg	ttccgcgtgc	tgtgtggaga	gtggatagag	2940
accatgtggg	actgtatgga	ggtcgctggc	caaaccatgt	gccttactgt	cttcatgatg	3000
gtcatgggtga	ttggaaatct	agtgggtctg	aacctcttct	tggccttgct	tttgagttcc	3060
ttcagttctg	acaatcttgc	tgccactgat	gatgataacg	aaatgaataa	tctccagatt	3120
gctgtgggaa	ggatgcagaa	aggaatcgat	tttgttaaaa	gaaaaatacg	tgaattttatt	3180
cagaaagcct	ttgttaggaa	gcagaaagct	ttagatgaaa	ttaaaccgct	tgaagatcta	3240
aataataaaa	aagacagctg	tattttccaac	cataccacca	tagaaatagg	caaagacctc	3300
aattatctca	aagacggaaa	tggaactact	agtggcatag	gcagcagtgt	agaaaaatat	3360
gtcgtgggatg	aaagtgatta	catgtcattt	ataaacaacc	ctagcctcac	tgtgacagta	3420
ccaattgctg	ttggagaatc	tgactttgaa	aatttaaata	ctgaagaatt	cagcagcgag	3480
tcagatatgg	aggaaagcaa	agagaagcta	aatgcaacta	gttcactctga	aggcagcacg	3540
gttgatattg	gagctccgcg	cgaggggagaa	cagcctgagg	ttgaacctga	ggaatccctt	3600
gaacctgaag	cctgtttttac	agaagactgt	gtacggaagt	tcaagtgttg	tcagataagc	3660
atagaagaag	gcaaagggaa	actctggtgg	aatttgagga	aaacatgcta	taagatagtg	3720
gagcacaatt	ggttcgaaac	cttcattgtc	ttcatgattc	tgctgagcag	tggggctctg	3780
gcctttgaag	atatatacat	tgagcagcga	aaaaccatta	agaccatgtt	agaatatgct	3840
gacaagggtt	tcacttacat	attcattctg	gaaatgctgc	taaagtgggt	tgcatatggt	3900
tttcaagtgt	attttaccaa	tgcttggtgc	tggctagact	tcctgattgt	tgatgtctca	3960

SSCP Update Sequences.ST25

ctggtttagct taactgcaaa tgccttgggt tactcagaac ttggtgccat caaatccctc	4020
agaacactaa gagctctgag gccactgaga gctttgtccc ggtttgaagg aatgaggggt	4080
gttgtaaagt ctcttttagg agccattcca tctatcatga atgtacttct ggtttgtctg	4140
atcttttggc taatattcag tatcatggga gtgaatctct ttgctggcaa gttttaccat	4200
tgtattaatt acaccactgg agagatgttt gatgtaagcg tggccaacaa ctacagtga	4260
tgcaaagctc tcattgagag caatcaaact gccagggtga aaaatgtgaa agtaaacctt	4320
gataacgtag gacttggata tctgtctcta cttcaagtag ccacgtttta gggatggatg	4380
gatattatgt atgcagctgt tgattcacga aatgtagaat tacaacccaa gtatgaagac	4440
aacctgtaca tgtatcttta ttttgtcatc tttattattt ttggttcatt ctttaccttg	4500
aatcttttca ttggtgtcat catagataac ttcaaccaac agaaaaagaa gtttgagggt	4560
caagacatct ttatgacaga agaacagaag aaatactaca atgcaatgaa aaaactgggt	4620
tcaaagaaac cacaaaaacc catacctcga cctgctaaca aattccaagg aatggctctt	4680
gattttgtaa ccaaacaagt ctttgatata agcatcatga tcctcatctg ccttaacatg	4740
gtcaccatga tgggtggaac cgatgaccag agtcaagaaa tgacaaacat tctgtactgg	4800
attaatctgg tgtttattgt tctgttctact ggagaatgtg tgctgaaact gatctctctt	4860
cgttactact atttcactat tggatggaat atttttgatt ttgtgggtgg cttctctctc	4920
attgtaggaa tgtttctggc tgaactgata gaaaagtatt ttgtgtcccc taccctgttc	4980
cgagtgatcc gtcttgccag gattggccga atcctacgtc tgatcaaagg agcaaagggg	5040
atccgcacgc tgctctttgc tttgatgatg tcccttcctg cgttgtttta catcggcctc	5100
cttcttttcc tggatcatgt catctacgcc atctttggga tgtccaattt tgcctatgtt	5160
aagagggag tgggcatcga tgacatgttc aactttgaga cctttggcaa cagcatgatc	5220
tgctgtttcc aaattacaac ctctgctggc tgggatggat tgctagcacc tattctta	5280
agtggacctc cagactgtga ccctgacaaa gatcaccttg gaagctcagt taaaggagac	5340
tgtgggaacc catctgttgg gatcttcttt tttgtcagtt acatcatcat atccttcctg	5400
gttgtgtcga acatgtacat cgcggtcata ctggagaact tcagtgttgc tactgaagaa	5460
agtgcagagc ctctgagtga ggatgacttt gagatgttct atgaggtttg ggagaagttt	5520
gatcccgatg cgaccagtt tatagagttt gccaaacttt ctgattttgc agatgccctg	5580
gatcctctc ttctcatagc aaaacccaac aaagtccagc tcattgccat ggatctgccc	5640
atgggtgagt gtgaccggat ccactgtctt gacatcttat ttgcttttac aaagcgtgtt	5700
ttgggtgaga gtggagagat ggatgccctt cgaatacaga tggaagagcg attcatggca	5760
tcaaaccctt ccaaagtctc ttatgagccc attacgacca cgttgaaacg caaacaagag	5820
gaggtgtctg ctattattat ccagagggct tacagacgct acctcttgaa gcaaaaagtt	5880
aaaaaggtat caagtatata caagaaagac aaaggcaaag aatgtgatgg aacacccatc	5940
aaagaagata ctctcattga taaactgaat gagaattcaa ctccagagaa aaccgatatg	6000

SSCP Update Sequences.ST25

acgccttcca	ccacgtctcc	accctcgtat	gatagtgtga	ccaaaccaga	aaaagaaaaa	6060
tttgaaaaag	acaaatcaga	aaaggaagac	aaagggaaag	atatcaggga	aagtaaaaag	6120
taaaaagaaa	ccaagaatth	tccattttgt	gatcaattgt	ttacagccc	tgatggtgat	6180
gtgtttgtgt	caacaggact	cccacaggag	gtctatgcca	aactgactgt	ttttacaaat	6240
gtatacttaa	ggtcagtgcc	tataacaaga	cagagacctc	tggtcagcaa	actggaactc	6300
agtaaactgg	agaaatagta	tcgatggg				6328

<210> 12
 <211> 6328
 <212> DNA
 <213> Homo sapiens

<400> 12						
ttcttggtgc	cagcttatca	atcccaaact	ctgggtgtaa	aagattctac	agggcacttt	60
cttatgcaag	gagctaaaca	gtgattaaag	gagcaggatg	aaaagatggc	acagtccagt	120
ctgggtaccgc	caggacctga	cagcttccgc	ttctttacca	gggaatccct	tgctgctatt	180
gaacaacgca	ttgcagaaga	gaaagctaag	agacccaaac	aggaacgcaa	ggatgaggat	240
gatgaaaatg	gccccaaagcc	aaacagtgac	ttggaagcag	gaaaatctct	tccattttatt	300
tatggagaca	ttcctccaga	gatgggtgtca	gtgcccctgg	aggatctgga	cccctactat	360
atcaataaga	aaacgtttat	agtattgaat	aaagggaaag	caatctctcg	attcagtgcc	420
accctgccc	tttacattht	aactcccttc	aacctatta	gaaaattagc	tattaagatt	480
ttggtacatt	ctttattcaa	tatgctcatt	atgtgcacga	ttcttaccaa	ctgtgtatth	540
atgaccatga	gtaaccctcc	agactggaca	agaatgtgg	agtatacctt	tacaggaatt	600
tatacttttg	aatcacttat	taaaataact	gcaaggggct	tttgtttaga	agatttcaca	660
tttttacggg	atccatggaa	ttggttggat	ttcacagtca	ttacttttgc	atatgtgaca	720
gagtttgtgg	acctgggcaa	tgtctcagcg	ttgagaacat	tcagagttct	ccgagcattg	780
aaaacaatth	cagtcattcc	aggcctgaag	accattgtgg	gggccctgat	ccagtcagt	840
aagaagctth	ctgatgtcat	gatcttgact	gtgttctgtc	taagcgtgtt	tgcgctaata	900
ggattgcagt	tgttcatggg	caacctacga	aataaatgtt	tgcaatggcc	tccagataat	960
tcttcctttg	aaataaatat	cacttccttc	tttaacaatt	cattggatgg	gaatggtact	1020
actttcaata	ggacagtga	catatttaac	tgggatgaat	atattgagga	taaaagtcac	1080
ttttattht	tagaggggca	aatgatgct	ctgctttgtg	gcaacagctc	agatgcaggc	1140
cagtgtcctg	aaggatacat	ctgtgtgaag	gctggtagaa	accccaacta	tggctacacg	1200
agctttgaca	ccttttagttg	ggccttht	tccttatttc	gtctcatgac	tcaagacttc	1260
tgggaaaacc	tttatcaact	gacactacgt	gctgctggga	aaacgtacat	gatatht	1320
gtgctggtca	ttttcttggg	ctcattctat	ctaataaatt	tgatcttggc	tgtggtggcc	1380
atggcctatg	aggaacagaa	tcaggccaca	ttggaagagg	ctgaacagaa	ggaagctgaa	1440
tttcagcaga	tgctcgaaca	gttgaaaaag	caacaagaag	aagctcaggc	ggcagctgca	1500

SSCP Update Sequences.ST25

gccgcatctg	ctgaatcaag	agacttcagt	ggtgctggtg	ggataggagt	tttttcagag	1560
agttcttcag	tagcatctaa	gttgagctcc	aaaagtgaaa	aagagctgaa	aaacagaaga	1620
aagaaaaaga	aacagaaaga	acagtctgga	gaagaagaga	aaaatgacag	agtcctaaaa	1680
tcggaatctg	aagacagcat	aagaagaaaa	ggtttccgtt	tttccttgga	aggaagtagg	1740
ctgacatatg	aaaagagatt	ttcttctcca	caccagtcct	tactgagcat	ccgtggctcc	1800
cttttctctc	caagacgcaa	cagtagggcg	agccttttca	gcttcagagg	tcgagcaaag	1860
gacattggct	ctgagaatga	ctttgctgat	gatgagcaca	gcacctttga	ggacaatgac	1920
agccgaagag	actctctgtt	cgtgccgcac	agacatggag	aacggcgcca	cagcaatgtc	1980
agccaggcca	gccgtgcctc	caggggtgctc	cccctcctgc	ccatgaatgg	gaagatgcat	2040
agcgtgtgg	actgcaatgg	tgtggctctcc	ctggctgggg	gcccttctac	cctcacatct	2100
gctgggcagc	tcctaccaga	gggcacaact	actgaaacag	aaataagaaa	gagacggctc	2160
agttcttata	atgtttccat	ggattttattg	gaagatccta	catcaaggca	aagagcaatg	2220
agtatagcca	gtattttgac	caacaccatg	gaagaacttg	aagaatccag	acagaaatgc	2280
ccaccatgct	ggtataaatt	tgctaatatg	tgtttgattt	gggactgttg	taaaccatgg	2340
ttaaagggtga	aacaccttgt	caacctgggt	gtaatggacc	catttggtga	cctggccatc	2400
accatctgca	ttgtcttaaa	tacactcttc	atggctatgg	agcactatcc	catgacggag	2460
cagttcagca	gtgtactgtc	tgttggaaac	ctggctcttca	cagggatctt	cacagcagaa	2520
atgtttctca	agataattgc	catggatcca	tattattact	ttcaagaagg	ctggaatatt	2580
tttgatgggt	ttattgtgag	ccttagttta	atggaacttg	gtttggcaaa	tgtggaagga	2640
ttgtcagttc	tccgatcatt	ccggctgctc	cgagttttca	agttggcaaa	atcttgcca	2700
actctaaata	tgctaattaa	gatcattggc	aattctgtgg	gggctctagg	aaacctcacc	2760
ttggatattg	ccatcatcat	cttcattttt	gctgtggctc	gcatgcagct	ctttggtaag	2820
agctacaaag	aatgtgtctg	caagatttcc	aatgattgtg	aactcccacg	ctggcacatg	2880
catgactttt	tccactcctt	cctgatcgtg	ttccgcgtgc	tgtgtggaga	gtggatagag	2940
accatgtggg	actgtatgga	ggtcgctggc	caaaccatgt	gccttactgt	cttcatgatg	3000
gtcatgggtga	ttggaaatct	agtggttctg	aacctcttct	tggccttgct	tttgagttcc	3060
ttcagttctg	acaatcttgc	tgccactgat	gatgataacg	aaatgaataa	tctccagatt	3120
gctgtgggaa	ggatgcagaa	aggaatcgat	tttgttaaaa	gaaaaatacg	tgaattttatt	3180
cagaaagcct	ttgttaggaa	gcagaaagct	ttagatgaaa	ttaaaccgct	tgaagatcta	3240
aataataaaa	aagacagctg	tatttccaac	cataccacca	tagaaatagg	caaagacctc	3300
aattatctca	aagacggaaa	tggaactact	agtggcatag	gcagcagtgt	agaaaaatat	3360
gtcgtggatg	aaagtgatta	catgtcattt	ataaacaacc	ctagcctcac	tgtgacagta	3420
ccaattgctg	ttggagaatc	tgactttgaa	aattttaata	ctgaagaatt	cagcagcgag	3480
tcagatatgg	aggaaagcaa	agagaagcta	aatgcaacta	gttcatctga	aggcagcacg	3540

SSCP Update Sequences.ST25

gttgatattg	gagctcccg	cgagggagaa	cagcctgagg	ttgaacctga	ggaatccctt	3600
gaacctgaag	cctgttttac	agaagactgt	gtacggaagt	tcaagtgttg	tcagataagc	3660
atagaagaag	gcaaagggaa	actctggttg	aatttgagga	aaacatgcta	taagatagtg	3720
gagcacaatt	ggttcgaaac	cttcattgtc	ttcatgattc	tgctgagcag	tggggctctg	3780
gcctttgaag	atatatacat	tgagcagcga	aaaaccatta	agaccatggt	agaatatgct	3840
gacaaggttt	tcacttacat	attcattctg	gaaatgctgc	taaagtgggt	tgcatatggt	3900
tttcaagtgt	atctttacca	tgccctggtg	tggttagact	tcctgattgt	tgatgtctca	3960
ctggtttagct	taactgcaaa	tgccctgggt	tactcagaac	ttggtgccat	caaatccctc	4020
agaacactaa	gagctctgag	gccactgaga	gctttgtccc	ggtttgaagg	aatgaggggt	4080
gttgtaaatg	ctcttttagg	agccattcca	tctatcatga	atgtacttct	ggtttgtctg	4140
atcttttggc	taatattcag	tatcatggga	gtgaatctct	ttgctggcaa	gttttaccat	4200
tgtattaatt	acaccactgg	agagatgttt	gatgtaagcg	tggtcaacaa	ctacagtga	4260
tgcaaagctc	tcattgagag	caatcaaact	gccaggtgga	aaaatgtgaa	agtaaacctt	4320
gataacgtag	gacttgata	tctgtctcta	cttcaagtag	ccacgttta	gggatggatg	4380
gatattatgt	atgcagctgt	tgattcacga	aatgtagaat	tacaaccaa	gtatgaagac	4440
aacctgtaca	tgtatcttta	ttttgtcatc	tttattat	ttggttcatt	ctttaccttg	4500
aatcttttca	ttggtgtcat	catagataac	ttcaaccaac	agaaaaagaa	gtttggaggt	4560
caagacattt	ttatgacaga	agaacagaag	aaatactaca	atgcaatgaa	aaaactgggt	4620
tcaaagaaac	cacaaaaacc	catacctcga	cctgctaaca	aattccaagg	aatggtcttt	4680
gattttgtaa	ccaacaagt	ctttgatata	agcatcatga	tcctcatctg	ccttaacatg	4740
gtcaccatga	tggtggaaac	cgatgaccag	agtcaagaaa	tgacaaacat	tctgtactgg	4800
attaatctgg	tgtttattgt	tctgttctact	ggagaatgtg	tgctgaaact	gatctctctt	4860
cgttactact	atcttactat	tggttggaat	atcttttgatt	ttgtgggtgg	cattctctcc	4920
attgtaggaa	tgtttctggc	tgaactgata	gaaaagtatt	ttgtgtcccc	taccctgttc	4980
cgagtgatcc	gtcttgccag	gattggccga	atcctacgtc	tgatcaaagg	agcaaagggg	5040
atccgcacgc	tgctctttgc	tttgatgatg	tcccttcctg	cgttgttta	catcggcctc	5100
cttcttttcc	tggtcatggt	catctacgcc	atctttggga	tgtccaattt	tgccatggtt	5160
aagaggggaa	ttgggatcga	tgacatgttc	aactttgaga	cctttggcaa	cagcatgatc	5220
tgctgtttcc	aaattacaac	ctctgctggc	tggtgatggat	tgctagcacc	tattcttaat	5280
agtggacctc	cagactgtga	ccctgacaaa	gatcaccctg	gaagctcagt	taaaggagac	5340
tgtgggaacc	catctgttgg	gattttcttt	tttgtcagtt	acatcatcat	atccttcctg	5400
gttgtgtgta	acatgtacat	cgcggtcatc	ctggagaact	tcagtgttgc	tactgaagaa	5460
agtgcagagc	ctctgagtga	ggatgacttt	gagatgttct	atgaggtttg	ggagaagttt	5520
gatcccgatg	cgacccagtt	tatagagttt	gccaaacttt	ctgattttgc	agatgccttg	5580

SSCP Update Sequences.ST25

gatcctcctc	ttctcatagc	aaaacccaac	aaagtccagc	tcattgccat	ggatctgccc	5640
atggtgagt	gtgaccgat	ccactgtctt	gacatcttat	ttgcttttac	aaagcgtgtt	5700
ttgggtgaga	gtggagagat	ggatgccctt	cgaatacaga	tggaagagcg	attcatggca	5760
tcaaaccctt	ccaaagtctc	ttatgagccc	attacgacca	cgttgaaacg	caaacaagag	5820
gaggtgtctg	ctattattat	ccagagggct	tacagacgct	acctcttgaa	gcaaaaagtt	5880
aaaaaggtat	caagtatata	caagaaagac	aaaggcaaag	aatgtgatgg	aacacccatc	5940
aaagaagata	ctctcattga	taaactgaat	gagaattcaa	ctccagagaa	aaccgatatg	6000
acgccttcca	ccacgtctcc	accctcgtat	gatagtgtga	caaaccaga	aaaagaaaaa	6060
tttgaaaaag	acaaatcaga	aaaggaagac	aaagggaaag	atatcagggg	aagtaaaaag	6120
taaaaagaaa	ccaagaattt	tccattttgt	gatcaattgt	ttacagcccg	tgatggtgat	6180
gtgtttgtgt	caacaggact	cccacaggag	gtctatgcca	aactgactgt	ttttacaaat	6240
gtatacttaa	ggtcagtgcc	tataacaaga	cagagacctc	tggtcagcaa	actggaactc	6300
agtaaactgg	agaaatagta	tcgatggg				6328

<210> 13
 <211> 6328
 <212> DNA
 <213> Homo sapiens

<400> 13						
ttcttgggtgc	cagcttatca	atcccaaact	ctgggtgtaa	aagattctac	agggcacttt	60
cttatgcaag	gagctaaaca	gtgattaaag	gagcaggatg	aaaagatggc	acagtcagtg	120
ctggtaccgc	caggacctga	cagcttccgc	ttctttacca	gggaatccct	tgctgctatt	180
gaacaacgca	ttgcagaaga	gaaagctaag	agacccaaac	aggaacgcaa	ggatgaggat	240
gatgaaaatg	gccccaaagcc	aaacagtgac	ttggaagcag	gaaaatctct	tccattttatt	300
tatggagaca	ttcctccaga	gatggtgtca	gtgcccctgg	aggatctgga	cccctactat	360
atcaataaga	aaacgtttat	agtattgaat	aaagggaaag	caatctctcg	attcagtgcc	420
accctgccc	tttacatttt	aactcccttc	aaccctatta	gaaaattagc	tattaagatt	480
ttggtacatt	ctttattcaa	tatgctcatt	atgtgcacga	ttcttaccaa	ctgtgtattt	540
atgaccatga	gtaaccctcc	agactggaca	aagaatgtgg	agtatacctt	tacaggaatt	600
tatacttttg	aatcacttat	taaaataactt	gcaaggggct	tttgtttaga	agatttcaca	660
tttttacggg	atccatggaa	ttggttggat	ttcacagtca	ttacttttgc	atatgtgaca	720
gagtttgtgg	acctgggcaa	tgtctcagcg	ttgagaacat	tcagagttct	ccgagcattg	780
aaaacaatth	cagtcattcc	aggcctgaag	accattgtgg	gggccctgat	ccagtcagtg	840
aagaagcttt	ctgatgtcat	gatcttgact	gtgttctgtc	taagcgtgtt	tgcgctaata	900
ggattgcagt	tgttcatggg	caacctacga	aataaatgtt	tgcaatggcc	tccagataat	960
tcttcctttg	aaataaatat	cacttccttc	tttaacaatt	cattggatgg	gaatggtact	1020

SSCP Update Sequences.ST25

actttcaata	ggacagtgag	catatttaac	tgggatgaat	atattgagga	taaaagtcac	1080
ttttatTTTT	tagaggggca	aaatgatgct	ctgctttgtg	gcaacagctc	agatgcaggc	1140
cagtgtcctg	aaggatacat	ctgtgtgaag	gctggtagaa	acccaacta	tggctacacg	1200
agctttgaca	ccttttagttg	ggcctttttg	tccttatttc	gtctcatgac	tcaagacttc	1260
tgggaaaacc	tttatcaact	gacactacgt	gctgctggga	aaacgtacat	gatatttttt	1320
gtgctgggtca	ttttcttggg	ctcattctat	ctaataaatt	tgatcttggc	tgtggtggcc	1380
atggcctatg	aggaacagaa	tcaggccaca	ttggaagagg	ctgaacagaa	ggaagctgaa	1440
tttcagcaga	tgctcgaaca	gttgaaaaag	caacaagaag	aagctcaggc	ggcagctgca	1500
gccgcctctg	ctgaatcaag	agacttcagt	ggtgctgggtg	ggataggagt	tttttcagag	1560
agttcttcag	tagcatctaa	gttgagctcc	aaaagtgaaa	aagagctgaa	aaacagaaga	1620
aagaaaaaga	aacagaaaga	acagtctgga	gaagaagaga	aaaatgacag	agtcctaaaa	1680
tcggaatctg	aagacagcat	aagaagaaaa	ggtttccggt	tttccttgga	aggaagtagg	1740
ctgacatatg	aaaagagatt	ttcttctcca	caccagtcct	tactgagcat	ccgtggctcc	1800
cttttctctc	caagacgcaa	cagtagggcg	agccttttca	gcttcagagg	tcgagcaaag	1860
gacattggct	ctgagaatga	ctttgctgat	gatgagcaca	gcacctttga	ggacaatgac	1920
agccgaagag	actctctgtt	cgtgccgcac	agacatggag	aacggcgcca	cagcaatgtc	1980
agccaggcca	gccgtgcctc	cagggtgctc	cccctcctgc	ccatgaatgg	gaagatgcat	2040
agcgctgtgg	actgcaatgg	tgtggtctcc	ctggctgggg	gcccttctac	cctcacatct	2100
gctgggcagc	tcctaccaga	gggcacaact	actgaaacag	aaataagaaa	gagacgggtc	2160
agttctttatc	atgtttccat	ggatttattg	gaagatccta	catcaaggca	aagagcaatg	2220
agtatagcca	gtattttgac	caacaccatg	gaagaacttg	aagaatccag	acagaaatgc	2280
ccaccatgct	ggtataaatt	tgctaatatg	tgtttgattt	gggactgttg	taaaccatgg	2340
ttaaagggtga	aacaccttgt	caacctgggt	gtaatggacc	catttgttga	cctggccatc	2400
accatctgca	ttgtcttaaa	tacactcttc	atggctatgg	agcactatcc	catgacggag	2460
cagttcagca	gtgtactgtc	tgttggaac	ctggctctca	cagggatctt	cacagcagaa	2520
atgtttctca	agataattgc	catggatcca	tattattact	ttcaagaagg	ctggaatatt	2580
tttgatgggt	ttattgtgag	ccttagttta	atggaacttg	gtttggcaaa	tgtggaagga	2640
ttgtcagttc	tccgatcatt	ccggctgctc	cgagttttca	agttggcaaa	atcttggcca	2700
actctaaata	tgctaattaa	gatcattggc	aattctgtgg	gggctctagg	aaacctcacc	2760
ttgggtattgg	ccatcatcgt	cttcattttt	gctgtgggtcg	gcatgcagct	ctttggtaag	2820
agctacaaag	aatgtgtctg	caagatttcc	aatgattgtg	aactcccacg	ctggcacatg	2880
catgactttt	tccactcctt	cctgatcgtg	ttccgcgtgc	tgtgtggaga	gtggatagag	2940
accatgtggg	actgtatgga	ggtcgtggc	caaaccatgt	gccttactgt	cttcatgatg	3000
gtcatgggtga	ttggaaatct	agtggttctg	aacctcttct	tggccttgct	tttgagttcc	3060

SSCP Update Sequences.ST25

ttcagttctg	acaatcttgc	tgccactgat	gatgataacg	aaatgaataa	tatccagatt	3120
gctgtgggaa	ggatgcagaa	aggaatcgat	tttgttaaaa	gaaaaatacg	tgaattttatt	3180
cagaaagcct	ttgttaggaa	gcagaaagct	ttagatgaaa	ttaaaccgct	tgaagatcta	3240
aataataaaa	aagacagctg	tattttccaac	cataccacca	tagaaatagg	caaagacctc	3300
aatttatctca	aagacggaaa	tggaactact	agtggcatag	gcagcagtgt	agaaaaatat	3360
gtcgtggatg	aaagtgatta	catgtcattt	ataaacaacc	ctagcctcac	tgtgacagta	3420
ccaattgctg	ttggagaatc	tgactttgaa	aattttaaata	ctgaagaatt	cagcagcgag	3480
tcagatatgg	aggaaagcaa	agagaagcta	aatgcaacta	gttcatctga	aggcagcacg	3540
gttgatattg	gagctcccg	cgagggagaa	cagcctgagg	ttgaacctga	ggaatccctt	3600
gaacctgaag	cctgtttttac	agaagactgt	gtacggaagt	tcaagtgttg	tcagataagc	3660
atagaagaag	gcaaagggaa	actctggttg	aatttgagga	aaacatgcta	taagatagtg	3720
gagcacaatt	ggttcgaaac	cttcattgtc	ttcatgattc	tgctgagcag	tggggctctg	3780
gcctttgaag	atatatacat	tgagcagcga	aaaaccatta	agaccatgtt	agaatatgct	3840
gacaaggttt	tcacttacat	attcattctg	gaaatgctgc	taaagtgggt	tgcatatggg	3900
tttcaagtgt	atttttacca	tgccctggtg	tggttagact	tcctgattgt	tgatgtctca	3960
ctgggttagct	taactgcaaa	tgccctgggt	tactcagaac	ttggtgccat	caaatccctc	4020
agaacactaa	gagctctgag	gccactgaga	gctttgtccc	ggtttgaagg	aatgagggtt	4080
gttgtaaatg	ctcttttagg	agccattcca	tctatcatga	atgtacttct	ggtttgtctg	4140
atcttttggc	taatattcag	tatcatggga	gtgaatctct	ttgctggcaa	gtttttaccat	4200
tgtattaatt	acaccactgg	agagatgttt	gatgtaagcg	tggtcaacaa	ctacagtgag	4260
tgcaaagctc	tcattgagag	caatcaaact	gccagggtgga	aaaatgtgaa	agtaaacttt	4320
gataacgtag	gacttggata	tctgtctcta	cttcaagtag	ccacgtttta	gggatggatg	4380
gatattatgt	atgcagctgt	tgattcacga	aatgtagaat	tacaacccaa	gtatgaagac	4440
aacctgtaca	tgtatcttta	ttttgtcatc	tttattattt	ttggttcatt	ctttaccttg	4500
aatcttttca	ttggtgtcat	catagataac	ttcaaccaac	agaaaaagaa	gtttggagggt	4560
caagacat	ttatgacaga	agaacagaag	aaatactaca	atgcaatgaa	aaaactgggt	4620
tcaaagaaac	cacaaaaacc	catacctcga	cctgctaaca	aattccaagg	aatggctctt	4680
gattttgtaa	ccaaacaagt	ctttgatatc	agcatcatga	tcctcatctg	ccttaacatg	4740
gtcaccatga	tggtggaaac	cgatgaccag	agtcaagaaa	tgacaaacat	tctgtactgg	4800
attaatctgg	tgtttattgt	tctgttcact	ggagaatgtg	tgctgaaact	gatctctctt	4860
cgttactact	atttcactat	tggttggaat	atttttgatt	ttgtgggtgg	cattctctcc	4920
attgtaggaa	tgtttctggc	tgaactgata	gaaaagtatt	ttgtgtcccc	taccctgttc	4980
cgagtgatcc	gtcttgccag	gattggccga	atcctacgct	tgatcaaagg	agcaaagggg	5040
atccgcacgc	tgctctttgc	tttgatgatg	tcccttcctg	cgttgtttta	catcggcctc	5100

SSCP Update Sequences.ST25

cttcttttcc	tggtcatgtt	catctacgcc	atctttggga	tgtccaat	tgcctatgtt	5160
aagaggggaag	ttgggatcga	tgacatgttc	aactttgaga	cctttggcaa	cagcatgatc	5220
tgcctgttcc	aaattacaac	ctctgctggc	tgggatggat	tgctagcacc	tattcttaat	5280
agtggacctc	cagactgtga	ccctgacaaa	gatcaccctg	gaagctcagt	taaaggagac	5340
tgtgggaacc	catctgttgg	gattttcttt	tttgtcagtt	acatcatcat	atccttcctg	5400
gttgtgtcga	acatgtacat	cgcggtcatc	ctggagaact	tcagtgttgc	tactgaagaa	5460
agtgcagagc	ctctgagtga	ggatgacttt	gagatgttct	atgaggtttg	ggagaagttt	5520
gatccccgatg	cgacccagtt	tatagagttt	gccaaacttt	ctgattttgc	agatgccctg	5580
gatcctcctc	ttctcatagc	aaaacccaac	aaagtccagc	tcattgccat	ggatctgccc	5640
atgggtgagt	gtgaccggat	ccactgtctt	gacatcttat	ttgcttttac	aaagcgtgtt	5700
ttgggtgaga	gtggagagat	ggatgccctt	cgaatacaga	tggaagagcg	attcatggca	5760
tcaaaccctt	ccaaagtctc	ttatgagccc	attacgacca	cgttgaaacg	caaacaagag	5820
gaggtgtctg	ctattattat	ccagagggct	tacagacgct	acctcttgaa	gcaaaaagtt	5880
aaaaaggtat	caagtatata	caagaaagac	aaaggcaaag	aatgtgatgg	aacacccatc	5940
aaagaagata	ctctcattga	taaactgaat	gagaattcaa	ctccagagaa	aaccgatatg	6000
acgccttcca	ccacgtctcc	accctcgtat	gatagtgtga	ccaaaccaga	aaaagaaaaa	6060
tttgaaaaag	acaaatcaga	aaaggaagac	aaagggaaag	atatcaggga	aagtaaaaag	6120
taaaaagaaa	ccaagaat	tccattttgt	gatcaattgt	ttacagcccg	tgatggtgat	6180
gtgttttgt	caacaggact	cccacaggag	gtctatgcca	aactgactgt	ttttacaaat	6240
gtatacttaa	ggtcagtgcc	tataacaaga	cagagacctc	tggtcagcaa	actggaactc	6300
agtaaactgg	agaaatagta	tcgatggg				6328

<210> 14
 <211> 6328
 <212> DNA
 <213> Homo sapiens

<400> 14						
ttcttggtgc	cagcttatca	atcccaaact	ctgggtgtaa	aagattctac	agggcacttt	60
cttatgcaag	gagctaaaca	gtgattaaag	gagcaggatg	aaaagatggc	acagtcagtg	120
ctggtaccgc	caggacctga	cagcttcgc	ttctttacca	gggaatccct	tgctgctatt	180
gaacaacgca	ttgcagaaga	gaaagctaag	agacccaaac	aggaacgcaa	ggatgaggat	240
gatgaaaatg	gccccaaagcc	aaacagtgac	ttggaagcag	gaaaatctct	tccattttatt	300
tatggagaca	ttcctccaga	gatgggtgtca	gtgcccctgg	aggatctgga	cccctactat	360
atcaataaga	aaacgtttat	agtattgaat	aaagggaaag	caatctctcg	attcagtgcc	420
accctgccc	tttacat	aactcccttc	aaccctatta	gaaaattagc	tattaagatt	480
ttggtacatt	ctttattcaa	tatgctcatt	atgtgcacga	ttcttaccaa	ctgtgtat	540
atgaccatga	gtaaccctcc	agactggaca	aagaatgtgg	agtatacctt	tacaggaatt	600

SSCP Update Sequences.ST25

tatactttttg	aatcacttat	taaaataactt	gcaaggggct	tttgtttaga	agatttcaca	660
tttttacggg	atccatggaa	ttggttggat	ttcacagtca	ttactttttgc	atatgtgaca	720
gagtttgtgg	acctgggcaa	tgtctcagcg	ttgagaacat	tcagagttct	ccgagcattg	780
aaaacaatth	cagtcattcc	aggcctgaag	accattgtgg	gggccctgat	ccagtcagtg	840
aagaagctth	ctgatgtcat	gatcttgact	gtgttctgtc	taagcgtgtt	tgcgctaata	900
ggattgcagt	tgttcatggg	caacctacga	aataaatggt	tgcaatggcc	tccagataat	960
tcttcctttg	aaataaatat	cacttccttc	tttaacaatt	cattgggatgg	gaatggtact	1020
actttcaata	ggacagttag	catatttaac	tgggatgaat	atattgagga	taaaagtcac	1080
ttttatthth	tagaggggca	aatgatgtct	ctgctttgtg	gcaacagctc	agatgcaggc	1140
cagtgtcctg	aaggatacat	ctgtgtgaag	gctggtagaa	acccaacta	tggctacacg	1200
agctttgaca	ccttttagttg	ggcctttttg	tccttatttc	gtctcatgac	tcaagacttc	1260
tgggaaaacc	tttatcaact	gacactacgt	gctgctggga	aaacgtacat	gatattthth	1320
gtgctggtca	ttttcttggg	ctcattctat	ctaataaatt	tgatcttggc	tgtggtggcc	1380
atggcctatg	aggaacagaa	tcaggccaca	ttggaagagg	ctgaacagaa	ggaagctgaa	1440
tttcagcaga	tgctcgaaca	gttgaaaaag	caacaagaag	aagctcaggc	ggcagctgca	1500
gccgcacctg	ctgaatcaag	agacttcagt	ggtgctgggtg	ggataggagt	tttttcagag	1560
agttcttcag	tagcatctaa	gttgagctcc	aaaagtgaag	aagagctgaa	aaacagaaga	1620
aagaaaaaga	aacagaaaga	acagtctgga	gaagaagaga	aaaatgacag	agtcctaaaa	1680
tcggaatctg	aagacagcat	aagaagaaaa	ggtttccggt	tttccttggg	aggaagtagg	1740
ctgacatatg	aaaagagatt	ttcttctcca	caccagtcct	tactgagcat	ccgtggctcc	1800
cttttctctc	caagacgcaa	cagtagggcg	agccttttca	gcttcagagg	tcgagcaaag	1860
gacattggct	ctgagaatga	ctttgctgat	gatgagcaca	gcacctttga	ggacaatgac	1920
agccgaagag	actctctgtt	cgtgccgcac	agacatggag	aacggcgcca	cagcaatgtc	1980
agccaggcca	gccgtgcctc	caggggtgctc	cccacctgc	ccatgaatgg	gaagatgcat	2040
agcgctgtgg	actgcaatgg	tgtggtctcc	ctggctgggg	gcccttctac	cctcacatct	2100
gctgggcagc	tcctaccaga	gggcacaact	actgaaacag	aaataagaaa	gagacgggtc	2160
agttcttatc	atgtttccat	ggattttattg	gaagatccta	catcaaggca	aagagcaatg	2220
agtatagcca	gtatthtgac	caacaccatg	gaagaacttg	aagaatccag	acagaaatgc	2280
ccaccatgct	ggtataaatt	tgctaatatg	tgthtgattt	gggactgttg	taaaccatgg	2340
ttaaagggtga	aacaccttgt	caacctgggt	gtaatggacc	catttggtga	cctggccatc	2400
accatctgca	ttgtctthaa	tacactcttc	atggctatgg	agcactatcc	catgacggag	2460
cagttcagca	gtgtactgtc	tgttggaac	ctggcttcca	cagggatctt	cacagcagaa	2520
atgtthtca	agataatthg	catggatcca	tattattact	ttcaagaagg	ctggaatatt	2580
tttgatgggt	ttattgtgag	ccttagthta	atggaaacttg	gtthggcaaa	tgtggaagga	2640

SSCP Update Sequences.ST25

ttgtcagttc	tccgatcatt	ccggctgctc	cgagttttca	agttggcaaa	atcttggcca	2700
actctaaata	tgctaattaa	gatcattggc	aattctgtgg	gggctctagg	aaacctcacc	2760
ttggtattgg	ccatcatcgt	cttcattttt	gctgtggtcg	gcatgcagct	ctttggtaag	2820
agctacaaag	aatgtgtctg	caagattttcc	aatgattgtg	aactcccacg	ctggcacatg	2880
catgactttt	tccactcctt	cctgatcgtg	ttccgcgtgc	tgtgtggaga	gtggatagag	2940
accatgtggg	actgtatgga	ggtcgctggc	caaaccatgt	gccttactgt	cttcatgatg	3000
gtcatggtga	ttggaaatct	agtggttctg	aacctcttct	tggccttgct	tttgagttcc	3060
ttcagttctg	acaatcttgc	tgccactgat	gatgataacg	aaatgaataa	tctccagatt	3120
gctgtgggaa	ggatgcagaa	aggaatcgat	tttgttaaaa	gaaaaatacg	tgaattttatt	3180
cagaaagcct	ttgttaggaa	gcagaaagct	ttagatgaaa	ttaaaccgct	tgaagatcta	3240
aataataaaa	aagacagctg	tattttccaac	cataccacca	tagaaatagg	caaagacctc	3300
aattatctca	aagacggaaa	tggaaactact	agtggcatag	gcagcagtgt	agaaaaatat	3360
gtcgtggatg	aaagtgatta	catgtcattt	ataaacaacc	ctagcctcac	tgtgacagta	3420
ccaattgctg	ttggagaatc	tgactttgaa	aattttaaata	ctgaagaatt	cagcagcgag	3480
tcagatatgg	aggaaagcaa	agagaagcta	aatgcaacta	gttcatctga	aggcagcacg	3540
gttgatattg	gagctcccg	cgaggggagaa	cagcctgagg	ttgaacctga	ggaatccctt	3600
gaacctgaag	cctgtttttac	agaagactgt	gtacggaagt	tcaagtgttg	tcagataagc	3660
atagaagaag	gcaaagggaa	actctggttg	aattttgagga	aagcatgcta	taagatagtg	3720
gagcacaatt	ggttcgaaac	cttcattgtc	ttcatgattc	tgctgagcag	tggggctctg	3780
gcctttgaag	atatatacat	tgagcagcga	aaaaccatta	agaccatggt	agaatatgct	3840
gacaagggtt	tcacttacat	attcattctg	gaaatgctgc	taaagtgggt	tgcatatggt	3900
tttcaagtgt	atttttacaa	tgcttgggtc	tggttagact	tcctgattgt	tgatgtctca	3960
ctggttagct	taactgcaaa	tgcttgggt	tactcagaac	ttggtgccat	caaatccctc	4020
agaacactaa	gagctctgag	gccactgaga	gctttgtccc	ggtttgaagg	aatgagggtt	4080
gttgtaaatg	ctcttttagg	agccattcca	tctatcatga	atgtacttct	ggtttgtctg	4140
atcttttggc	taatattcag	tatcatggga	gtgaatctct	ttgctggcaa	gttttaccat	4200
tgtattaatt	acaccactgg	agagatgttt	gatgtaagcg	tgggtcaaaa	ctacagttag	4260
tgcaaagctc	tcattgagag	caatcaaact	gccagggtga	aaaatgtgaa	agtaaacttt	4320
gataacgtag	gacttggata	tctgtctcta	cttcaagtag	ccacgtttta	gggatggatg	4380
gatattatgt	atgcagctgt	tgattcacga	aatgtagaat	tacaacccaa	gtatgaagac	4440
aacctgtaca	tgtatcttta	ttttgtcatc	tttattattt	ttggttcatt	ctttaccttg	4500
aatcttttca	ttggtgtcat	catagataac	ttcaaccaac	agaaaaagaa	gtttggaggt	4560
caagacatct	ttatgacaga	agaacagaag	aaatactaca	atgcaatgaa	aaaactgggt	4620
tcaaagaaac	cacaaaaacc	catacctcga	cctgctaaca	aattccaagg	aatgggtctt	4680

SSCP Update Sequences.ST25

gattttgtaa	ccaaacaagt	ctttgatatc	agcatcatga	tcctcatctg	ccttaacatg	4740
gtcaccatga	tggtggaaac	cgatgaccag	agtcaagaaa	tgacaaacat	tctgtactgg	4800
attaatctgg	tgtttattgt	tctgttcact	ggagaatgtg	tgctgaaact	gatctctctt	4860
cgttactact	atttcactat	tggatggaat	atTTTTgatt	ttgtggtggg	cattctctcc	4920
attgtaggaa	tgtttctggc	tgaactgata	gaaaagtatt	ttgtgtcccc	taccctgttc	4980
cgagtgatcc	gtcttgccag	gattggccga	atcctacgtc	tgatcaaagg	agcaaagggg	5040
atccgcacgc	tgctctttgc	tttgatgatg	tccttctctg	cgttgtttaa	catcggcctc	5100
cttcttttcc	tggtcatgtt	catctacgcc	atctttggga	tgccaattt	tgccatgtt	5160
aagagggaa	ttgggatcga	tgacatgttc	aactttgaga	cctttggcaa	cagcatgatc	5220
tgccgtgtcc	aaattacaac	ctctgctggc	tgggatggat	tgctagcacc	tattcttaat	5280
agtggaacct	cagactgtga	ccctgacaaa	gatcacctcg	gaagctcagt	taaaggagac	5340
tgtgggaacc	catctgttgg	gattttcttt	ttgtgcagtt	acatcatcat	atccttctctg	5400
gttgtgctga	acatgtacat	cgcggtcatc	ctggagaact	tcagtgttgc	tactgaagaa	5460
agtcgagagc	ctctgagtga	ggatgacttt	gagatgttct	atgagggttg	ggagaagttt	5520
gatcccgatg	cgaccagtt	tatagagttt	gccaaacttt	ctgattttgc	agatgccctg	5580
gatcctctc	ttctcatagc	aaaacccaac	aaagtccagc	tcattgccat	ggatctgccc	5640
atggtgagtg	gtgaccggat	ccactgtctt	gacatcttat	ttgcttttac	aaagcgtgtt	5700
ttgggtgaga	gtggagagat	ggatgccctt	cgaatacaga	tgggaagagc	attcatggca	5760
tcaaaccct	ccaaagtctc	ttatgagccc	attacgacca	cgttgaaacg	caaacaagag	5820
gagggtgtctg	ctattattat	ccagagggct	tacagacgct	acctcttgaa	gcaaaaagtt	5880
aaaaaggtat	caagtatata	caagaaagac	aaaggcaaag	aatgtgatgg	aacacccatc	5940
aaagaagata	ctctcattga	taaactgaat	gagaattcaa	ctccagagaa	aaccgatatg	6000
acgccttcca	ccacgtctcc	accctcgat	gatagtgtga	ccaaaccaga	aaaagaaaaa	6060
tttgaaaaag	acaaatcaga	aaaggaagac	aaagggaaag	atatcagggg	aagtaaaaag	6120
taaaaagaaa	ccaagaat	ttcattttgt	gatcaattgt	ttacagcccg	tgatgggtgat	6180
gtgtttgtgt	caacaggact	cccacaggag	gtctatgcc	aactgactgt	ttttacaaat	6240
gtatacttaa	ggtcagtgcc	tataacaaga	cagagacctc	tggtcagcaa	actggaactc	6300
agtaaactgg	agaaatagta	tcgatggg				6328

<210> 15
 <211> 6328
 <212> DNA
 <213> Homo sapiens

<400> 15	
ttcttgggtgc	cagcttatca atcccaaact ctgggtgtaa aagattctac agggcacttt 60
cttatgcaag	gagctaaaca gtgattaaag gagcaggatg aaaagatggc acagtcagtg 120

SSCP Update Sequences.ST25

ctggtaccgc	caggacctga	cagcttccgc	ttctttacca	gggaatccct	tgctgctatt	180
gaacaacgca	ttgcagaaga	gaaagctaag	agacccaaac	aggaacgcaa	ggatgaggat	240
gatgaaaatg	gccccaaagcc	aaacagtgac	ttggaagcag	gaaaatctct	tccattttatt	300
tatggagaca	ttcctccaga	gatggtgtca	gtgcccctgg	aggatctgga	cccctactat	360
atcaataaga	aaacgtttat	agtattgaat	aaagggaaag	caatctctcg	attcagtgcc	420
acccttgccc	tttacatfff	aactcccttc	aaccctatta	gaaaattagc	tattaagatt	480
ttggtacatt	ctttattcaa	tatgctcatt	atgtgcacga	ttcttaccaa	ctgtgtatfff	540
atgaccatga	gtaaccctcc	agactggaca	agaatgtgg	agtatacctt	tacaggaatt	600
tatacttttg	aatcacttat	taaaatactt	gcaaggggct	tttgtttaga	agatttcaca	660
tttttacggg	atccatggaa	ttggttgga	ttcacagtca	ttacttttgc	atatgtgaca	720
gagtttggtg	acctgggcaa	tgtctcagcg	ttgagaacat	tcagagttct	ccgagcattg	780
aaaacaatff	cagtcattcc	aggcctgaag	accattgtgg	gggccctgat	ccagtcagtg	840
aagaagctff	ctgatgtcat	gatcttgact	gtgttctgtc	taagcgtgtt	tgcgctaata	900
ggattgcagt	tgttcatggg	caacctacga	aataaatgtt	tgcaatggcc	tccagataat	960
tcttcctttg	aaataaatat	cacttccttc	tttaacaatt	cattggatgg	gaatgggtact	1020
actttcaata	ggacagtgag	catatttaac	tgggatgaat	atattgagga	taaaagtcac	1080
ttttatffff	tagaggggca	aaatgatgct	ctgctttgtg	gcaacagctc	agatgcaggc	1140
cagtgtcctg	aaggatacat	ctgtgtgaag	gctggtagaa	accccaacta	tggctacacg	1200
agctttgaca	ccttttagttg	ggcctttttg	tccttatfff	gtctcatgac	tcaagacttc	1260
tgggaaaacc	tttatcaact	gacactacgt	gctgctggga	aaacgtacat	gatatfffff	1320
gtgctggtca	ttttcttggg	ctcattctat	ctaataaatt	tgatcttggc	tgtggtggcc	1380
atggcctatg	aggaacagaa	tcaggccaca	ttggaagagg	ctgaacagaa	ggaagctgaa	1440
tttcagcaga	tgctcgaaca	gttgaaaaag	caacaagaag	aagctcaggc	ggcagctgca	1500
gccgcatctg	ctgaatcaag	agacttcagt	ggtgctggtg	ggataggagt	tttttcagag	1560
agttcttcag	tagcatctaa	gttgagctcc	aaaagtgaag	aagagctgaa	aaacagaaga	1620
aagaaaaaga	aacagaaaga	acagtctgga	gaagaagaga	aaaatgacag	agtcctaaaa	1680
tcggaatctg	aagacagcat	aagaagaaaa	ggtttccggt	tttccttgga	aggaagtagg	1740
ctgacatatg	aaaagagatt	ttcttctcca	caccagtcct	tactgagcat	ccgtggctcc	1800
cttttctctc	caagacgcaa	cagtagggcg	agccttttca	gcttcagagg	tcgagcaaag	1860
gacattggct	ctgagaatga	ctttgctgat	gatgagcaca	gcacctttga	ggacaatgac	1920
agccgaagag	actctctgtt	cgtgccgcac	agacatggag	aacggcgcca	cagcaatgtc	1980
agccaggcca	gccgtgcctc	caggggtgctc	cccatcctgc	ccatgaatgg	gaagatgcat	2040
agcgctgtgg	actgcaatgg	tgtggtctcc	ctggctgggg	gcccttctac	cctcacatct	2100
gctgggcagc	tcctaccaga	gggcacaact	actgaaacag	aaataagaaa	gagacggctc	2160

SSCP Update Sequences.ST25

agttcttatac	atgtttccat	ggattttattg	gaagatccta	catcaaggca	aagagcaatg	2220
agtatagcca	gtatTTTTgac	caacaccatg	gaagaacttg	aagaatccag	acagaaatgc	2280
ccaccatgct	ggtataaaatt	tgctaataatg	tgTTTTgattt	gggactgttg	taaaccatgg	2340
ttaaagggtga	aacaccttgt	caacctgggt	gtaatggacc	catttgttga	cctggccatc	2400
accatctgca	ttgtcttaaa	tacactcttc	atggctatgg	agcactatcc	catgacggag	2460
cagttcagca	gtgtactgtc	tgTTggaaac	ctggTcttca	cagggatctt	cacagcagaa	2520
atgtttctca	agataaattgc	catggatcca	tattattact	ttcaagaagg	ctggaatatt	2580
tttgatgggt	ttattgtgag	ccttagttta	atggaacttg	gtttggcaaa	tgtggaagga	2640
ttgtcagttc	tccgatcatt	ccggctgctc	cgagTTTTca	agttggcaaa	atcttgcca	2700
actctaaata	tgctaattaa	gatcattggc	aattctgtgg	gggctctagg	aaacctcacc	2760
ttggTattgg	ccatcatcgt	cttcattttt	gctgtggTcg	gcatgcagct	ctttggtaag	2820
agctacaaag	aatgtgtctg	caagatttcc	aatgattgtg	aactcccacg	ctggcacatg	2880
catgactttt	tccactcctt	cctgatcgtg	ttccgcgtgc	tgtgtggaga	gtggatagag	2940
accatgtggg	actgtatgga	ggTcgctggc	caaaccatgt	gccttactgt	cttcatgatg	3000
gtcatgggtga	ttggaaatct	agtggTtctg	aacctcttct	tggccttgct	tttgagtTcc	3060
ttcagTtctg	acaatcttgc	tgccactgat	gatgataacg	aaatgaataa	tctccagatt	3120
gctgtgggaa	ggatgcagaa	aggaatcgat	tttgTtaaaa	gaaaaatacg	tgaattttatt	3180
cagaaagcct	ttgttaggaa	gcagaaagct	ttagatgaaa	ttaaaccgct	tgaagatcta	3240
aataataaaa	aagacagctg	tatttccaac	cataccacca	tagaaatagg	caaagacctc	3300
aattatctca	aagacggaaa	tggaactact	agtggcatag	gcagcagtgt	agaaaaatat	3360
gtcgtgggatg	aaagtgatta	catgtcattt	ataaacaacc	ctagcctcac	tgtgacagta	3420
ccaattgctg	ttggagaatc	tgactttgaa	aattttaaata	ctgaagaatt	cagcagcgag	3480
tcagatatgg	aggaaagcaa	agagaagcta	aatgcaacta	gttcatctga	aggcagcacg	3540
gttgatattg	gagctcccg	cgagggagaa	cagcctgagg	ttgaacctga	ggaatccctt	3600
gaacctgaag	cctgtttttac	agaagactgt	gtacggaagt	tcaagtgttg	tcagataagc	3660
atagaagaag	gcaaagggaa	actctggtgg	aatttgagga	aaacatgcta	taagatagtg	3720
gagcacaatt	ggTtcgaaac	cttcattgtc	ttcatgattc	tgctgagcag	tggggctctg	3780
gcctttgaag	atatatacat	tgagcagcga	aaaaccatta	agaccatggt	agaatatgct	3840
gacaaggTtt	tcactttacat	attcatTctg	gaaatgctgc	taaagtgggt	tgcatatggT	3900
tttcaagtgt	atTTTacc	tgcttggtgc	tggttagact	tcctgattgt	tgatgtctca	3960
ctggTtagct	taactgcaaa	tgcttgggt	tactcagaac	ttggTgccat	caaatccctc	4020
agaacactaa	gagctctgag	gccactgaga	gctttgtccc	agtttgaagg	aatgagggtt	4080
gttgtaaatg	ctcttttagg	agccattcca	tctatcatga	atgtacttct	ggtttgtctg	4140
atcttttggc	taatattcag	tatcatggga	gtgaatctct	ttgctggcaa	gttttaccat	4200

SSCP Update Sequences.ST25

tgtattaatt	acaccactgg	agagatgttt	gatgtaagcg	tgggtcaacaa	ctacagtggag	4260
tgcaaagctc	tcattgagag	caatcaaact	gccaggtgga	aaaatgtgaa	agtaaacttt	4320
gataacgtag	gacttggata	tctgtctcta	cttcaagtag	ccacgtttta	gggatggatg	4380
gatattatgt	atgcagctgt	tgattcacga	aatgtagaat	tacaacccaa	gtatgaagac	4440
aacctgtaca	tgtatcttta	ttttgtcatc	tttattatatt	ttggttcatt	ctttaccttg	4500
aatcttttca	ttgggtgtcat	catagataac	ttcaaccaac	agaaaaagaa	gtttggaggt	4560
caagacatatt	ttatgacaga	agaacagaag	aaatactaca	atgcaatgaa	aaaactgggt	4620
tcaaagaaac	cacaaaaacc	catacctcga	cctgctaaca	aattccaagg	aatgggtcttt	4680
gattttgtaa	ccaacaagt	ctttgatatc	agcatcatga	tcctcatctg	ccttaacatg	4740
gtcaccatga	tgggtggaaac	cgatgaccag	agtcaagaaa	tgacaaacat	tctgtactgg	4800
attaatctgg	tgttttattgt	tctgttcact	ggagaatgtg	tgctgaaact	gatctctctt	4860
cgttactact	atcttactat	tggatggaat	atttttgatt	ttgtgggtgg	cattctctcc	4920
attgtaggaa	tgtttctggc	tgaactgata	gaaaagtatt	ttgtgtcccc	taccctgttc	4980
cgagtgatcc	gtcttgccag	gattggccga	atcctacgtc	tgatcaaagg	agcaaagggg	5040
atccgcacgc	tgctctttgc	tttgatgatg	tcccttcctg	cgttgtttta	catcggcctc	5100
cttcttttcc	tgggtcatgtt	catctacgcc	atctttggga	tgtccaattt	tgcctatgtt	5160
aagagggaag	ttgggatcga	tgacatgttc	aactttgaga	cctttggcaa	cagcatgatc	5220
tgctgtttcc	aaattacaac	ctctgctggc	tgggatggat	tgctagcacc	tattcttaat	5280
agtggacctc	cagactgtga	ccctgacaaa	gatcaccctg	gaagctcagt	taaaggagac	5340
tgtgggaacc	catctgttgg	gattttcttt	tttgtcagtt	acatcatcat	atccttcctg	5400
gttgtgctga	acatgtacat	cgcggtcatc	ctggagaact	tcagtgttgc	tactgaagaa	5460
agtgcagagc	ctctgagtga	ggatgacttt	gagatgttct	atgaggtttg	ggagaagttt	5520
gatccccgatg	cgacccagtt	tatagagttt	gccaaacttt	ctgattttgc	agatgccctg	5580
gatcctcctc	ttctcatagc	aaaacccaac	aaagtccagc	tcattgccat	ggatctgccc	5640
atgggtgagt	gtgaccggat	ccactgtctt	gacatcttat	ttgcttttac	aaagcgtgtt	5700
ttgggtgaga	gtggagagat	ggatgccctt	cgaatacaga	tgggaagagc	attcatggca	5760
tcaaaccctt	ccaaagtctc	ttatgagccc	attacgacca	cgttgaaacg	caaacaagag	5820
gaggtgtctg	ctattattat	ccagaggggt	tacagacgct	acctcttgaa	gcaaaaagtt	5880
aaaaaggtat	caagtatata	caagaaagac	aaaggcaaag	aatgtgatgg	aacacccatc	5940
aaagaagata	ctctcattga	taaactgaat	gagaattcaa	ctccagagaa	aaccgatatg	6000
acgccttcca	ccacgtctcc	accctcgtat	gatagtgtga	ccaaaccaga	aaaagaaaaa	6060
tttgaaaaag	acaaatcaga	aaaggaagac	aaagggaaag	atatcaggga	aagtaaaaag	6120
taaaaagaaa	ccaagaattt	tccattttgt	gatcaattgt	ttacagcccg	tgatgggtgat	6180
gtgtttgtgt	caacaggact	cccacaggag	gtctatgcc	aactgactgt	ttttacaaat	6240

SSCP Update Sequences.ST25

gtatacttaa ggtcagtgcc tataacaaga cagagacctc tggtcagcaa actggaactc 6300
 agtaaactgg agaaatagta tcgatggg 6328

<210> 16
 <211> 6328
 <212> DNA
 <213> Homo sapiens

<400> 16
 ttcttggtgc cagcttatca atcccaaact ctgggtgtaa aagattctac agggcacttt 60
 cttatgcaag gagctaaaca gtgattaaag gagcaggatg aaaagatggc acagtcagtg 120
 ctggtaccgc caggacctga cagcttccgc ttctttacca ggaatccct tgctgctatt 180
 gaacaacgca ttgcagaaga gaaagctaag agacccaaac aggaacgcaa ggatgaggat 240
 gatgaaaatg gcccaaagcc aaacagtgc ttggaagcag gaaaatctct tccatttatt 300
 tatggagaca ttcttcaga gâtgggtgtca gtgccctgg aggatctgga cccctactat 360
 atcaataaga aaacgtttat agtattgaat aaagggaaag caatctctcg attcagtgcc 420
 acccctgccc ttacatttt aactcccttc aaccctatta gaaaattagc tattaagatt 480
 ttggtacatt ctttattcaa tatgctcatt atgtgcacga ttcttaccac ctgtgtattt 540
 atgaccatga gtaaccctcc agactggaca aagaatgtgg agtatacctt tacaggaatt 600
 tatacttttg aatcacttat taaaatactt gcaaggggct ttgttttaga agatttcaca 660
 tttttacggg atccatggaa ttggttggat ttcacagtca ttacttttgc atatgtgaca 720
 gagtttgtgg acctgggcaa tgtctcagcg ttgagaacat tcagagttct ccgagcattg 780
 aaaacaattt cagtcattcc aggcctgaag accattgtgg gggccctgat ccagtcagtg 840
 aagaagcttt ctgatgtcat gatcttgact gtgttctgtc taagcgtgtt tgcgctaata 900
 ggattgcagt tgttcatggg caacctacga aataaatgtt tgcaatggcc tccagataat 960
 tcttcctttg aaataaatat cacttccttc tttaacaatt cattggatgg gaatgggtact 1020
 actttcaata ggacagtgc catatttaac tgggatgaat atattgagga taaaagtcac 1080
 ttttattttt tagaggggca aaatgatgct ctgctttgtg gcaacagctc agatgcaggc 1140
 cagtgtcctg aaggatacat ctgtgtgaag gctggtagaa accccaacta tggctacacg 1200
 agctttgaca cctttagttg ggcctttttg tccttatttc gtctcatgac tcaagacttc 1260
 tgggaaacc tttatcaact gacactacgt gctgctggga aaacgtacat gatatttttt 1320
 gtgctgggtca ttttcttggg ctcatcttat ctaataaatt tgatcttggc tgtggtggcc 1380
 atggcctatg aggaacagaa tcaggccaca ttggaagagg ctgaacagaa ggaagctgaa 1440
 tttcagcaga tgctcgaaca gttgaaaaag caacaagaag aagctcaggc ggcagctgca 1500
 gccgcattct ctgaatcaag agacttcagt ggtgctggtg ggataggagt tttttcagag 1560
 agttcttcag tagcatctaa gttgagctcc aaaagtgaag aagagctgaa aaacagaaga 1620
 aagaaaaaga aacagaaaga acagtctgga gaagaagaga aaaatgacag agtcctaaaa 1680
 tcggaatctg aagacagcat aagaagaaaa ggtttccgtt tttccttggga aggaagtagg 1740

SSCP Update Sequences.ST25

ctgacatatg	aaaagagatt	ttcttctcca	caccagtcct	tactgagcat	ccgtggctcc	1800
cttttctctc	caagacgcaa	cagtagggcg	agccttttca	gcttcagagg	tcgagcaaag	1860
gacattggct	ctgagaatga	ctttgctgac	gatgagcaca	gcacctttga	ggacaatgac	1920
agccgaagag	actctctgtt	cgtgccgcac	agacatggag	aacggcgcca	cagcaatgtc	1980
agccaggcca	gccgtgcctc	cagggtgctc	cccacctctg	ccatgaatgg	gaagatgcat	2040
agcgctgtgg	actgcaatgg	tgtggctctc	ctggctgggg	gcccttctac	cctcacatct	2100
gctgggcagc	tcctaccaga	gggcacaact	actgaaacag	aaataagaaa	gagacggctc	2160
agttcttata	atgtttccat	ggatttattg	gaagatccta	catcaaggca	aagagcaatg	2220
agtatagcca	gtattttgac	caacaccatg	gaagaacttg	agaatccag	acagaaatgc	2280
ccaccatgct	ggtataaatt	tgctaatatg	tgtttgattt	gggactgttg	taaaccatgg	2340
ttaaagggtga	aacaccttgt	caacctgggt	gtaatggacc	catttggtga	cctggccatc	2400
accatctgca	ttgtcttaaa	tacactcttc	atggctatgg	agcactatcc	catgacggag	2460
cagttcagca	gtgtactgtc	tgttgaaaac	ctggctctca	cagggatctt	cacagcagaa	2520
atgtttctca	agataattgc	catggatcca	tattattact	ttcaagaagg	ctggaatatt	2580
tttgatgggt	ttattgtgag	ccttagttta	atggaacttg	gtttggcaaa	tgtggaagga	2640
ttgtcagttc	tccgatcatt	ccggctgctc	cgagttttca	agttggcaaa	atcttgcca	2700
actctaaata	tgctaattaa	gatcattggc	aattctgtgg	gggctctagg	aaacctcacc	2760
ttgggtattg	ccatcatcgt	cttcattttt	gctgtggctg	gcatgcagct	ctttggtaag	2820
agctacaaag	aatgtgtctg	caagatttcc	aatgattgtg	aactcccacg	ctggcacatg	2880
catgactttt	tccactcctt	cctgatcgtg	ttccgcgtgc	tgtgtggaga	gtggatagag	2940
accatgtggg	actgtatgga	ggtcgctggc	caaaccatgt	gccttactgt	cttcatgatg	3000
gtcatgggtga	ttggaaatct	agtggttctg	aacctcttct	tggccttgct	tttgagtcc	3060
ttcagttctg	acaatcttgc	tgccactgat	gatgataacg	aaatgaataa	tctccagatt	3120
gctgtgggaa	ggatgcagaa	aggaatcgat	tttgttaaaa	gaaaaatacg	tgaatttatt	3180
cagaaagcct	ttgttaggaa	gcagaaagct	ttagatgaaa	ttaaaccgct	tgaagatcta	3240
aataataaaa	aagacagctg	tattttccaa	cataccacca	tagaaatagg	caaagacctc	3300
aattatctca	aagacggaaa	tggaactact	agtggcatag	gcagcagtg	agaaaaatat	3360
gtcgtggatg	aaagtgatta	catgtcattt	ataaacaacc	ctagcctcac	tgtgacagta	3420
ccaattgctg	ttggagaatc	tgactttgaa	aatttaaata	ctgaagaatt	cagcagcgag	3480
tcagatatgg	aggaaagcaa	agagaagcta	aatgcaacta	gttcatctga	aggcagcacg	3540
gttgatattg	gagctcccg	caggggagaa	cagcctgagg	ttgaacctga	ggaatccctt	3600
gaacctgaag	cctgttttac	agaagactgt	gtacggaagt	tcaagtgttg	tcagataagc	3660
atagaagaag	gcaaagggaa	actctgggtg	aatttgagga	aaacatgcta	taagatagtg	3720
gagcacaatt	ggttcgaaac	cttcattgtc	ttcatgattc	tgctgagcag	tggggctctg	3780

SSCP Update Sequences.ST25

gcctttgaag	atatatacat	tgagcagcga	aaaaccatta	agaccatggt	agaatatgct	3840
gacaagggtt	tcactttacat	attcattctg	gaaatgctgc	taaagtgggt	tgcataatggt	3900
tttcaagtgt	attttaccac	tgcttggtgc	tggttagact	tcctgattgt	tgatgtctca	3960
ctggtttagc	taactgcaaa	tgcttgggt	tactcagaac	ttggtgccat	caaatccctc	4020
agaacactaa	gagctctgag	gccactgaga	gctttgtccc	ggtttgaagg	aatgaggggt	4080
gttgtaaatg	ctcttttagg	agccattcca	tctatcatga	atgtacttct	ggtttgtctg	4140
atcttttggc	taatattcag	tatcatggga	gtgaatctct	ttgctggcaa	gttttaccat	4200
tgtattaatt	acaccactgg	agagatgttt	gatgtaagcg	tggtcaacaa	ctacagtggg	4260
tgcaaagctc	tcattgagag	caatcaaact	gccaggtgga	aaaatgtgaa	agtaaacttt	4320
gataacgtag	gacttggata	tctgtctcta	cttcaagtag	ccacgtttta	gggatggatg	4380
gatattatgt	atgcagctgt	tgattcacga	aatgtagaat	tacaacccaa	gtatgaagac	4440
aacctgtaca	tgtatcttta	ttttgtcatc	tttattatct	ttggttcatt	ctttaccttg	4500
aatcttttca	ttgggtgtcat	catagataac	ttcaaccaac	agaaaaagaa	gtttggaggt	4560
caagacattt	ttatgacaga	agaacagaag	aaatactaca	atgcaatgaa	aaaactgggt	4620
tcaaagaaac	cacaaaaacc	catacctcga	cctgctaaca	aattccaagg	aatgggtctt	4680
gattttgtaa	ccaaacaagt	ctttgatata	agcatcatga	tcctcatctg	ccttaacatg	4740
gtcaccatga	tggtggaaac	cgatgaccag	agtcaagaaa	tgacaaacat	tctgtactgg	4800
attaatctgg	tggtttattgt	tctgttcact	ggagaatgtg	tgctgaaact	gatctctctt	4860
cgttactact	atttcactat	tggttggaat	atcttttgatt	ttgtgggtgg	cattctctcc	4920
attgtaggaa	tggtttctgg	tgaactgata	gaaaagtatt	ttgtgtcccc	tacctgtttc	4980
cgagtgatcc	gtcttgccag	gattggccga	atcctacgtc	tgatcaaagg	agcaaagggg	5040
atccgcacgc	tgctctttgc	tttgatgatg	tcccttcctg	cgttgtttta	catcggcctc	5100
cttcttttcc	tggtcatgtt	catctacgcc	atctttggga	tgtccaattt	tgcttatgtt	5160
aagaggggag	ttgggatcga	tgacatgttc	aactttgaga	cctttggcaa	cagcatgatc	5220
tgctgtttcc	aaattacaac	ctctgctggc	tgggatggat	tgctagcacc	tattcttaat	5280
agtggacctc	cagactgtga	ccctgacaaa	gatcaccctg	gaagctcagt	taaaggagac	5340
tgtgggaacc	catctgttgg	gattttcttt	tttgtcagtt	acatcatcat	atccttcctg	5400
gttggtgctga	acatgtacat	cgcggtcatc	ctggagaact	tcagtgttgc	tactgaagaa	5460
agtgcagagc	ctctgagtga	ggatgacttt	gagatgttct	atgaggtttg	ggagaagttt	5520
gatcccgatg	cgaccaggtt	tatagagtgt	gccaaacttt	ctgattttgc	agatgccctg	5580
gatcctcctc	ttctcatagc	aaaacccaac	aaagtccagc	tcattgccat	ggatctgccc	5640
atggtgagtg	gtgaccggat	ccactgtctt	gacatcttat	ttgcttttac	aaagcgtgtt	5700
ttgggtgaga	gtggagagat	ggatgccctt	cgaatacaga	tggaagagcg	attcatggca	5760
tcaaaccctt	ccaaagtctc	ttatgagccc	attacgacca	cgttgaaacg	caaacaagag	5820

SSCP Update Sequences.ST25

gaggtgtctg	ctattattat	ccagagggct	tacagacgct	acctcttgaa	gcaaaaagtt	5880
aaaaaggtat	caagtatata	caagaaagac	aaaggcaaag	aatgtgatgg	aacacccatc	5940
aaagaagata	ctctcattga	taaactgaat	gagaattcaa	ctccagagaa	aaccgatatg	6000
acgccttcca	ccacgtctcc	accctcgtat	gatagtgtga	ccaaaccaga	aaaagaaaaa	6060
tttgaaaaag	acaaatcaga	aaaggaagac	aaagggaaag	atatcaggga	aagtaaaaag	6120
taaaaagaaa	ccaagaatth	tccattttgt	gatcaattgt	ttacagcccg	tgatggtgat	6180
gtgtttgtgt	caacaggact	cccacaggag	gtctatgcca	aactgactgt	ttttacaaat	6240
gtatacttaa	ggtcagtgcc	tataacaaga	cagagacctc	tggtcagcaa	actggaactc	6300
agtaaactgg	agaaatagta	tcgatggg				6328

<210> 17
 <211> 6328
 <212> DNA
 <213> Homo sapiens

<400> 17						
ttcttggtgc	cagcttatca	atcccaaact	ctgggtgtaa	aagattctac	agggcacttt	60
cttatgcaag	gagctaaaca	gtgattaaag	gagcaggatg	aaaagatggc	acagtcagtg	120
ctggtaccgc	caggacctga	cagcttccgc	ttctttacca	gggaatccct	tgctgctatt	180
gaacaacgca	ttgcagaaga	gaaagctaag	agacccaaac	aggaacgcaa	ggatgaggat	240
gatgaaaatg	gccc aaagcc	aaacagtgac	ttggaagcag	gaaaatctct	tccattttatt	300
tatggagaca	ttcctccaga	gatggtgtca	gtgcccctgg	aggatctgga	cccctactat	360
atcaataaga	aaacgtttat	agtattgaat	aaagggaaag	caatctctcg	attcagtgcc	420
accctgccc	tttacattht	aactcccttc	aaccctatta	gaaaattagc	tattaagatt	480
ttggtacatt	ctttattcaa	tatgctcatt	atgtgcacga	ttcttaccaa	ctgtgtatth	540
atgaccatga	gtaaccctcc	agactggaca	agaatgtgg	agtatacctt	tacaggaatt	600
tatacttttg	aatcacttat	taaaataact	gcaaggggct	tttgtttaga	agatttcaca	660
tttttacggg	atccatggaa	ttggttggat	ttcacagtca	ttacttttgc	atatgtgaca	720
gagtttgtgg	acctgggcaa	tgtctcagcg	ttgagaacat	tcagagttct	ccgagcattg	780
aaaacaatth	cagtcattcc	aggcctgaag	accattgtgg	gggccctgat	ccagtcagtg	840
aagaagctth	ctgatgtcat	gatcttgact	gtgttctgtc	taagcgtgtt	tgcgctaata	900
ggattgcagt	tgthcatggg	caacctacga	aataaatgtt	tgcaatggcc	tccagataat	960
ttttcctttg	aaataaatat	cacttccttc	tttaacaatt	cattggatgg	gaatggtact	1020
actttcaata	ggacagtgag	catatttaac	tgggatgaat	atattgagga	taaaagtcac	1080
ttttatthtt	tagaggggca	aaatgatgct	ctgctttgtg	gcaacagctc	agatgcaggc	1140
cagtgtcctg	aaggatacat	ctgtgtgaag	gctggtagaa	accccaacta	tggttacacg	1200
agctttgaca	cctthtagttg	ggcctthttg	tccttatttc	gtctcatgac	tcaagacttc	1260

SSCP Update Sequences.ST25

tgggaaaacc	tttatcaact	gacactacgt	gctgctggga	aaacgtacat	gatatttttt	1320
gtgctggtca	ttttcttggg	ctcattctat	ctaataaatt	tgatcttggc	tgtggtggcc	1380
atggcctatg	aggaacagaa	tcaggccaca	ttggaagagg	ctgaacagaa	ggaagctgaa	1440
tttcagcaga	tgctcgaaca	gttgaaaaag	caacaagaag	aagctcaggc	ggcagctgca	1500
gccgcactctg	ctgaatcaag	agacttcagt	ggtgctggtg	ggataggagt	tttttcagag	1560
agttcttcag	tagcatctaa	gttgagctcc	aaaagtgaag	aagagctgaa	aaacagaaga	1620
aagaaaaaga	aacagaaaga	acagtctgga	gaagaagaga	aaaatgacag	agtcctaaaa	1680
tcggaatctg	aagacagcat	aagaagaaaa	ggtttccggt	tttccttggg	aggaagtagg	1740
ctgacatatg	aaaagagatt	ttcttctcca	caccagtcct	tactgagcat	ccgtggctcc	1800
cttttctctc	caagacgcaa	cagtagggcg	agccttttca	gcttcagagg	tcgagcaaag	1860
gacattggct	ctgagaatga	ctttgctgat	gatgagcaca	gcacctttga	ggacaatgac	1920
agccgaagag	actctctgtt	cgtgccgcac	agacatggag	aacggcgcca	cagcaatgtc	1980
agccaggcca	gccgtgcctc	cagggtgctc	cccatcctgc	ccatgaatgg	gaagatgcat	2040
agcgtgtgg	actgcaatgg	tgtggtctcc	ctggctgggg	gcccttctac	cctcacatct	2100
gctgggcagc	tcctaccaga	gggcacaact	actgaaacag	aaataagaaa	gagacgggtc	2160
agttcttatc	atgtttccat	ggattttattg	gaagatccta	catcaaggca	aagagcaatg	2220
agtatagcca	gtattttgac	caacacccatg	gaagaacttg	aagaatccag	acagaaatgc	2280
ccaccatgct	ggtataaatt	tgctaatatg	tgtttgattt	gggactgttg	taaaccatgg	2340
ttaaagggtga	aacaccttgt	caacctgggt	gtaatggacc	catttggtga	cctggccatc	2400
accatctgca	ttgtcttaaa	tacactcttc	atggctatgg	agcactatcc	catgacggag	2460
cagttcagca	gtgtactgtc	tgttggaaac	ctggctcttca	cagggatctt	cacagcagaa	2520
atgtttctca	agataattgc	catggatcca	tattattact	ttcaagaagg	ctggaatatt	2580
tttgatgggt	ttattgtgag	ccttagttta	atggaacttg	gtttggcaaa	tgtggaagga	2640
ttgtcagttc	tccgatcatt	ccggctgctc	cgagttttca	agttggcaaa	atcttggccca	2700
actctaaata	tgctaattaa	gatcattggc	aattctgtgg	gggctctagg	aaacctcacc	2760
ttggatattg	ccatcatcgt	cttcattttt	gctgtggtcg	gcatgcagct	ctttggtaag	2820
agctacaaag	aatgtgtctg	caagatttcc	aatgattgtg	aactccacg	ctggcacatg	2880
catgactttt	tccactcctt	cctgatcgtg	ttccgcgtgc	tgtgtggaga	gtggatagag	2940
accatgtggg	actgtatgga	ggtcgctggc	caaaccatgt	gccttactgt	cttcatgatg	3000
gtcatgggtga	ttggaaatct	agtgggtctg	aacctcttct	tggccttgct	tttgagttcc	3060
ttcagttctg	acaatcttgc	tgccactgat	gatgataacg	aaatgaataa	tctccagatt	3120
gctgtgggaa	ggatgcagaa	aggaatcgat	tttgttaaaa	gaaaaatacg	tgaatttatt	3180
cagaaagcct	ttgttaggaa	gcagaaagct	ttagatgaaa	ttaaaccgct	tgaagatcta	3240
aataataaaa	aagacagctg	tattttccaac	cataccacca	tagaaatagg	caaagacctc	3300

SSCP Update Sequences.ST25

aattatctca	aagacggaaa	tggaactact	agtggcatag	gcagcagtgt	agaaaaatat	3360
gtcgtggatg	aaagtgatta	catgtcattt	ataaacaacc	ctagcctcac	tgtgacagta	3420
ccaattgctg	ttggagaatc	tgactttgaa	aattttaaata	ctgaagaatt	cagcagcgag	3480
tcagatatgg	aggaaagcaa	agagaagcta	aatgcaacta	gttcatctga	aggcagcacg	3540
gttgatatgg	gagctcccg	cgaggagaa	cagcctgagg	ttgaacctga	ggaatccctt	3600
gaacctgaag	cctgttttac	agaagactgt	gtacggaagt	tcaagtgttg	tcagataagc	3660
atagaagaag	gcaaagggaa	actctggttg	aatttgagga	aaacatgcta	taagatagtg	3720
gagcacaatt	ggttcgaaac	cttcattgtc	ttcatgattc	tgctgagcag	tggggctctg	3780
gcctttgaag	atatatacat	tgagcagcga	aaaaccatta	agaccatggt	agaatatgct	3840
gacaagggtt	tcacttacat	attcattctg	gaaatgctgc	taaagtgggt	tgcataatggt	3900
tttcaagtgt	atctttacca	tgccctggtg	tggttagact	tcctgattgt	tgatgtctca	3960
ctgggttagct	taactgcaa	tgccctgggt	tactcagaac	ttggtgccat	caaatccctc	4020
agaacactaa	gagctctgag	gccactgaga	gctttgtccc	ggtttgaagg	aatgaggggt	4080
gttgtaaagt	ctcttttagg	agccattcca	tctatcatga	atgtacttct	ggtttgtctg	4140
atcttttggc	taatattcag	tatcatggga	gtgaatctct	ttgctggcaa	gttttaccat	4200
tgtattaatt	acaccactgg	agagatgttt	gatgtaagcg	tgggtcaaca	ctacagttag	4260
tgcaaagctc	tcattgagag	caatcaaact	gccaggtgga	aaaatgtgaa	agtaaacttt	4320
gataacgtag	gacttgagata	tctgtctcta	cttcaagtag	ccacgtttaa	gggatggatg	4380
gatattatgt	atgcagctgt	tgattcacga	aatgtagaat	tacaacccaa	gtatgaagac	4440
aacctgtaca	tgtatcttta	ttttgtcatc	tttattatct	ttggttcatt	ctttaccttg	4500
aatcttttca	ttggtgtcat	catagataac	ttcaaccaac	agaaaaagaa	gtttggaggt	4560
caagacattt	ttatgacaga	agaacagaag	aaatactaca	atgcaatgaa	aaaactgggt	4620
tcaaagaaac	cacaaaaacc	catacctcga	cctgctaaca	aattccaagg	aatggtcttt	4680
gattttgtaa	ccaaacaagt	ctttgatatc	agcatcatga	tcctcatctg	ccttaacatg	4740
gtcaccatga	tgggtgaaac	cgatgaccag	agtcaagaaa	tgacaaacat	tctgtactgg	4800
attaatctgg	tgtttattgt	tctgttcact	ggagaatgtg	tgctgaaact	gatctctctt	4860
cgttactact	atttcactat	tggatggaat	atctttgatt	ttgtggtggg	cattctctcc	4920
attgtaggaa	tgtttctggc	tgaactgata	gaaaagtatt	ttgtgtcccc	taccctgttc	4980
cgagtgatcc	gtcttgccag	gattggccga	atcctacgtc	tgaacaaagg	agcaaagggg	5040
atccgcacgc	tgctctttgc	tttgatgatg	tcccttcctg	cgttgtttta	catcggcctc	5100
cttcttttcc	tgggtcatgtt	catctacgcc	atctttggga	tgtccaattt	tgcctatgtt	5160
aagaggggag	ttgggatcga	tgacatgttc	aactttgaga	cctttggcaa	cagcatgatc	5220
tgcctgttcc	aaattacaac	ctctgctggc	tgggatggat	tgctagcacc	tattcttaat	5280
agtggacctc	cagactgtga	ccctgacaaa	gatcacctg	gaagctcagt	taaaggagac	5340

SSCP Update Sequences.ST25

tgtgggaacc	catctgttgg	gattttcttt	tttgtcagtt	acatcatcat	atccttcctg	5400
gttgtgctga	acatgtacat	cgcggtcatc	ctggagaact	tcagtgttgc	tactgaagaa	5460
agtgcagagc	ctctgagtga	ggatgacttt	gagatgttct	atgaggtttg	ggagaagttt	5520
gatcccgatg	cgacccagtt	tatagagttt	gccaaacttt	ctgattttgc	agatgccctg	5580
gatcctcctc	ttctcatagc	aaaacccaac	aaagtccagc	tcattgccat	ggatctgccc	5640
atggtgagtg	gtgaccggat	ccactgtctt	gacatcttat	ttgcttttac	aaagcgtgtt	5700
ttgggtgaga	gtggagagat	ggatgccctt	cgaatacaga	tggagagcg	attcatggca	5760
tcaaaccctt	ccaaagtctc	ttatgagccc	attacgacca	cgttgaaacg	caaacaagag	5820
gaggtgtctg	ctattattat	ccagaggggt	tacagacgct	acctcttgaa	gcaaaaagtt	5880
aaaaaggtat	caagtatata	caagaaagac	aaaggcaaag	aatgtgatgg	aacacccatc	5940
aaagaagata	ctctcattga	taaactgaat	gagaattcaa	ctccagagaa	aaccgatatg	6000
acgccttcca	ccacgtctcc	accctcgtat	gatagtgtga	ccaaaccaga	aaaagaaaaa	6060
tttgaaaaag	acaaatcaga	aaaggaagac	aaagggaaag	atatcagggg	aagtaaaaag	6120
taaaaagaaa	ccaagaatth	tccattttgt	gatcaattgt	ttacagcccg	tgatggtgat	6180
gtgtttgtgt	caacaggact	cccacaggag	gtctatgcca	aactgactgt	ttttacaaat	6240
gtatacttaa	ggtcagtgcc	tataacaaga	cagagacctc	tggtcagcaa	actggaactc	6300
agtaaactgg	agaaatagta	tcgatggg				6328

<210> 18
 <211> 385
 <212> DNA
 <213> Homo sapiens

<400> 18	ttcaatatat	tttttaaaag	ccatgcaa	aat	acttcagccc	tttcaaagaa	agatacagtc	60
	tcttcagggtg	ctatgttaaa	atcattttctc	ttcaatataa	caggcagcaa	cggcaactgc		120
	ctcagaacat	tccagagagc	ccagtgcagc	aggcaggctc	tcagacagct	catctgaagc		180
	ctctaagttg	agttccaaga	gtgctaagga	aagaagaaat	cggaggaaga	aaagaaaaca		240
	gaaagagcag	tctgggtggg	aagagaaaga	tgaggatgaa	ttccaaaaat	ctgaatctga		300
	ggacagcatc	aggaggaaag	gttttcgctt	ctccattgaa	gggaaccgat	tgacatatga		360
	aaagaggtac	tcctccccac	accag					385

<210> 19
 <211> 238
 <212> DNA
 <213> Homo sapiens

<400> 19	gtggaactcc	agcctaagta	tgaagaaagt	ctgtacatgt	atctttactt	tgttattttc	60
	atcatctttg	ggctcttctt	caccttgaac	ctgtttattg	gtgtcatcat	agataatttc	120
	aaccagcaga	aaaagaagat	aagtatttct	aatattttct	ctccactga	aatagaaaat	180

SSCP Update Sequences.ST25

tattccttgg agtgttttct ctgccaaatg agtacttgaa tttagaaaca aaatggga 238

<210> 20
 <211> 373
 <212> DNA
 <213> Homo sapiens

<400> 20
 gcctgaagac cattgtgggg gccctgatcc agtcagtgaa gaagctttct gatgtcatga 60
 tcttgactgt gttctgtcta agcgtgtttg cgctaataagg attgcagttg ttcattgggca 120
 acctacgaaa taaatgtttg caatggcctc cagataattc ttcctttgaa ataaatatca 180
 cttccttctt taacaattca ttggatggga atgggtactac tttcaatagg acagttagca 240
 tattttaactg ggatgaatat attgaggata aaagtaagat atactctata aaccattaag 300
 ttgttttagtt ctctaaatat taaatattat ataaaatgga aattatctca atttagatgt 360
 gaatcaagtg act 373

<210> 21
 <211> 274
 <212> DNA
 <213> Homo sapiens

<400> 21
 taggcacctg ataagagctt gcctcgtttc cttttttaag aaatcgtcaa ttagagactg 60
 tttctgatca taaaatttaa tagaattttt tgacttacag gcctttgaag atatatacat 120
 tgagcagcga aaaaccatta agaccatggt agaatatgct gacaagggtt tcacttacat 180
 attcattctg gaaatgctgc taaagtgggt tgcatatggt tttcaagtgt attttaccac 240
 tgcctgggtgc tggctagact tcctgattgt tgat 274

<210> 22
 <211> 154
 <212> DNA
 <213> Homo sapiens

<400> 22
 gtattgaata catgtcaaat agaattttga tcaattattc aatttatttt ctaaaattat 60
 aattttgggg aaaaagaaaa tgatatgact tttcttacag gccacgttta agggatggat 120
 ggatattatg tatgcagctg ttgattcacg aaat 154

<210> 23
 <211> 219
 <212> DNA
 <213> Homo sapiens

<400> 23
 ttacagggca atattttataa ataatggttt tactttttctc ttaaaatatt cttaatatat 60
 attctaagtt ttatttttatg tgttgtgttt tctttttcag acgttttatag tattgaataa 120
 agggaaagca atctctcgat tcagtgccac ccctgccctt tacatttttaa ctcccttcaa 180
 ccctattaga aaattagcta ttaagatttt ggtacattc 219

SSCP update Sequences.ST25

<210> 24
 <211> 242
 <212> DNA
 <213> Homo sapiens

 <400> 24
 gtgcctgtat aaaacagaca ttggcatata ttaaaacagg aaaaccaatt agcagacttg 60
 ccgttattga cttcctttct ttcctctaac ctaattacag ccagtgtcct gaaggatata 120
 tctgtgtgaa ggctggtaga aaccccaact atggctacac gagctttgac acctttagtt 180
 gggccttttt gtccttattt cgtctcatga ctcaagactt ctgggaaaac ctttatcaac 240
 tg 242

<210> 25
 <211> 388
 <212> DNA
 <213> Homo sapiens

 <400> 25
 gcggcagctg cagccgcata tgctgaatca agagacttca gtggtgctgg tgggatagga 60
 gttttttcag agagttcttc agtagcatct aagttgagct ccaaaagtga aaaagagctg 120
 aaaaacagaa gaaagaaaaa gaaacagaaa gaacagtctg gagaagaaga gaaaaatgac 180
 agagtcctaa aatcgggaatc tgaagacagc ataagaagaa aaggtttccg tttttccttg 240
 gaaggaagta ggctgacata tgaaaagaga ttttcttctc cacaccaggt aaaaatatta 300
 aattacatga attgtgttct cataaatttt ttaaaagaat atgccagaat ttaatggaga 360
 gaaaaccgcc ttccacctgg atggcaca 388

<210> 26
 <211> 445
 <212> DNA
 <213> Homo sapiens

 <400> 26
 aagtcaatga ctatgacaca atgaatcaaa ttctgttttt cagaatgcca gctcttaact 60
 ctcttcatct catTTTTgtt tcttttcttg ttattcatag tccttactga gcatccgtgg 120
 ctcccttttc tctccaagac gcaacagtag ggcgagcctt ttcagcttca gaggtcgagc 180
 aaaggacatt ggctctgaga atgactttgc tgatgatgag cacagcacct ttgaggacaa 240
 tgacagccga agagactctc tgttcgtgcc gcacagacat ggagaacggc gccacagcaa 300
 tgtcagccag gccagccgtg cctccagggt gctcccatc ctgcccata atgggaagat 360
 gcatagcgct gtggactgca atggtgtggt ctccctgggtc gggggccctt ctaccctcac 420
 atctgctggg cagctcctac cagag 445

<210> 27
 <211> 221
 <212> DNA
 <213> Homo sapiens

<400> 27

SSCP Update Sequences.ST25

aaatgcatac agaagatggg gggggggcat acctaattaa tttttatatt tagattaaag 60
 aaaataatta aatgtgtttt tttgtgggat tgattttcag aagctaaatg caactagttc 120
 atctgaaggc agcacggttg atattggagc tcccgccgag ggagaacagc ctgagggttg 180
 acctgaggaa tcccttgaac ctgaagcctg ttttacagaa g 221

<210> 28
 <211> 221
 <212> DNA
 <213> Homo sapiens

<400> 28
 aaaatgcata cagaagatgg gggggggcac acctaattaa tttttatatt tagattaaag 60
 aaaataatta aatgtgtttt tttgtgggat tgattttcag aagctaaatg caactagttc 120
 atctgaaggc agcacggttg atattggagc tcccgccgag ggagaacagc ctgagggttg 180
 acctgaggaa tcccttgaac ctgaagcctg ttttacagaa g 221

<210> 29
 <211> 221
 <212> DNA
 <213> Homo sapiens

<400> 29
 aatgcataca gaagatgggg gggggggcac acctaattaa tttttatatt tagattaaag 60
 aaaataatta aatgtgtttt tttgtgggat tgattttcag aagctaaatg caactagttc 120
 atctgaaggc agcacggttg atattggagc tcccgccgag ggagaacagc ctgagggttg 180
 acctgaggaa tcccttgaac ctgaagcctg ttttacagaa g 221

<210> 30
 <211> 1679
 <212> DNA
 <213> Homo sapiens

<400> 30
 gggagctgtg ggcgaggagc gcccctctgc tgcgtctgcc ctcgttttgt ctcacgactc 60
 acactcagtg ctccattccc caagagttcg cgttccccgc gcggcggtcg agaggcggct 120
 gccgcgggtc ccgcgcgggc gcggggcgat ggcggcgcgc gggtcagggc ccgcgcgct 180
 ccgcctgctg ctcttggtcc agctggtcgc gggggcgctg cggcttagcc gggcgcggcg 240
 ggcggcgcgc agaggattat ctgaaccttc ttctattgca aaacatgaag atagtttgct 300
 taaggattta tttcaagact acgaaagatg gggtcgtcct gtggaacacc tgaatgacaa 360
 aataaaaata aaatttgac ttgcaatatc tcaattggtg gatgtggatg agaaaaatca 420
 gttaatgaca acaaacgtct gggtgaaaca ggaatggata gatgtaaaat taagatggaa 480
 ccctgatgac tatggtggaa taaaagtat acgtgttcct tcagactcct cgtggacacc 540
 agacatcatt ttgtttgata atgcagatgg acgttttgaa gggaccagta cgaaaacagt 600
 catcaggtag aatggcactg tcacctggac tccaccggca aactacaaaa gttcctgtac 660
 catagatgtc acgtttttcc catttgacct tcagaactgt tccatgaaat ttggttcttg 720

SSCP Update Sequences.ST25

gacttatgat	ggatcacagg	ttgatataat	tctagaggac	caagatgtag	acaagagaga	780
tttttttgat	aatggagaat	gggagattgt	gagtgcaaca	gggagcaaag	gaaacagaac	840
cgacagctgt	tgctgggtatc	cgtatgtcac	ttactcattt	gtaatcaagc	gcctgcctct	900
ctttataacc	ttgttcctta	taataccctg	tattgggctc	tcatttttaa	ctgtacttgt	960
cttctatctt	ccttcaaatg	aagggtgaaa	gatttgtctc	tgcacttcag	tacttgtgtc	1020
tttgactgtc	ttccttctgg	ttattgaaga	gatcatacca	tcacttcaa	aagtcatacc	1080
tctaattgga	gagtatctgg	tattttaccat	gatttttgtg	acactgtcaa	ttatggtaac	1140
cgtcttcgct	atcaacattc	atcatcgttc	ttcctcaaca	cataatgcca	tggcgccctt	1200
gggccgcaag	atatttcttc	acacgcttcc	caaactgctt	tcgatgagaa	gtcatgtaga	1260
caggctacttc	actcagaaaag	aggaaactga	gagtggtagt	ggaccaaagt	cttctagaaa	1320
cacattggaa	gctgcgctcg	attctattcg	ctacattaca	acacacatca	tgaaggaaaa	1380
tgatgtccgt	gagggttgtg	aagattggaa	attcatagcc	cagggttctg	atcggatggt	1440
tctgtggact	tttcttttcg	tttcaattgt	tggatctctt	gggctttttg	ttcctgttat	1500
ttataaatgg	gcaaataatat	taataccagt	tcatattgga	aatgcaaata	agtgaagcct	1560
cccaaggagc	tgaagtatac	atttagttaa	cacacatata	tctgatggca	cctataaaat	1620
tatgaaaatg	taagttatgt	gttaaattta	gtgcaagctt	taacagacta	agttgctaa	1679

<210> 31
 <211> 2664
 <212> DNA
 <213> Homo sapiens

<400> 31						
gagagaacag	cgtgagcctg	tgtgcttgtg	tgctgagccc	tcaccccctc	ctggggccag	60
gcttggggttt	cacctgcaga	atcgcttgtg	ctgggctgcc	tgggctgtcc	tcagtggcac	120
ctgcatgaag	ccgttctggc	tgccagagct	ggacagcccc	aggaaaacc	acctctctgc	180
agagcttgcc	cagctgtccc	cgggaagcca	aatgcctctc	atgtaagtct	tctgctcgac	240
ggggtgtctc	ctaaaccctc	actcttcagc	ctctgtttga	ccatgaaatg	aagtgactga	300
gctctattct	gtacctgcca	ctctatttct	ggggtgactt	ttgtcagctg	cccagaatct	360
ccaagccagg	ctggttctct	gcaccccttc	aatgacctgt	tttcttctgt	aaccacaggt	420
tcggtgggtga	gaggaagcct	cgcagaatcc	agcagaatcc	tcacagaatc	cagcagcagc	480
tctgctgggg	acatggtcca	tggtgcaacc	cacagcaaag	ccctgacctg	acctcctgat	540
gctcaggaga	agccatgggc	ccctcctgtc	ctgtgttcct	gtccttcaca	aagctcagcc	600
tggtggtggct	ccttctgacc	ccagcaggtg	gagaggaagc	taagcgccca	cctcccaggg	660
ctcctggaga	cccactctcc	tctcccagtc	ccacggcatt	gccgcaggga	ggctcgcata	720
ccgagactga	ggaccggctc	ttcaaacacc	tcttccgggg	ctacaaccgc	tgggcgcgcc	780
cggtgcccga	cacttcagac	gtggtgattg	tgcgctttgg	actgtccatc	gctcagctca	840

SSCP Update Sequences.ST25

tcgatgtgga	tgagaagaac	caaatagatga	ccaccaacgt	ctggctaata	caggagtgga	900
gcgactacaa	actgcgctgg	aacccactg	attttggcaa	catcacatct	ctcaggggtcc	960
cttctgagat	gatctggatc	cccgaattg	ttctctacaa	caatgcagat	ggggagtgtg	1020
cagtgacca	catgaccaag	gccacactct	tctccacggg	cactgtgcac	tgggtgcccc	1080
cggccatcta	caagagctcc	tgcagcatcg	acgtcacctt	cttccccctc	gaccagcaga	1140
actgcaagat	gaagtttggc	tcctggactt	atgacaaggc	caagatcgac	ctggagcaga	1200
tggagcagac	tgtggacctg	aaggactact	gggagagcgg	cgagtggggc	atcgtcaatg	1260
ccacgggcac	ctacaacagc	aagaagtacg	actgctgcgc	cgagatctac	cccgaagtca	1320
cctacgcctt	cgatcatccg	cggctgccgc	tcttctacac	catcaacctc	atcatcccct	1380
gcctgctcat	ctcctgcctc	actgtgctgg	tcttctacct	gccctccgac	tgccggcgaga	1440
agatcacgct	gtgcattttc	gtgctgctgt	cactcacctg	cttctgctg	ctcatcactg	1500
agatcatccc	gtccacctcg	ctggatcatc	cgctcatcgg	cgagtacctg	ctgttcacca	1560
tgatcttcgt	caccctgtcc	atcgtcatca	ccgtcttcgt	gctcaatgtg	caccaccgct	1620
ccccagcac	ccacaccatg	ccccactggg	tgcggggggc	ccttctgggc	tgtgtgcccc	1680
gggtggcttct	gatgaaccgg	ccccaccac	ccgtggagct	ctgccacccc	ctacgcctga	1740
agctcagccc	ctcttatcac	tggctggaga	gcaacgtgga	tgccgaggag	agggaggtgg	1800
tgggtggagga	ggaggacaga	tgggcatgtg	cagggtcatgt	ggccccctct	gtgggcaccc	1860
tctgcagcca	cggccacctg	cactctgggg	cctcaggtcc	caaggctgag	gctctgctgc	1920
aggaggtgga	gctgctgcta	tcacccaca	tgcagaaggc	actggaaggt	gtgcactaca	1980
ttgccgacca	cctgcggtct	gaggatgctg	actcttcggt	gaaggaggac	tggaagtatg	2040
ttgccatggt	catcgacagg	atcttcctct	ggctgtttat	catcgtctgc	ttcctgggga	2100
ccatcggcct	ctttctgcct	ccgttcctag	ctggaatgat	ctgactgcac	ctccctcgag	2160
ctggctccca	gggcaaagg	gagggttctt	ggatgtggaa	gggctttgaa	caatgtttag	2220
atttgagat	gagcccaaag	tgccaggagg	aacagccagg	tgagggtgga	ggttgagag	2280
ccaggtgagg	tctctctaag	tcaggctggg	gttgaagttt	ggagtctgtc	cgagtttgca	2340
gggtgctgag	ctgtatggtc	cagcagggga	gtaataagg	ctcttccgga	aggggaggaa	2400
gcgggaggca	ggcctgcacc	tgatgtggag	gtacaggcag	atcttcccta	ccggggagg	2460
atggatgggt	ggatacaggt	ggctgggcta	ttccatccat	ctggaagcac	atttgagcct	2520
ccaggcttct	ccttgacgtc	attcctctcc	ttccttgctg	caaatgggt	ctgcaccagc	2580
cggcccccag	gaggtctggc	agagctgaga	gccatggcct	gcaggggctc	catatgtccc	2640
tacgcgtgca	gcaggcaaac	aaga				2664

<210> 32
 <211> 3020
 <212> DNA
 <213> Homo sapiens

SSCP Update Sequences.ST25

<400> 32
gtcctcccgc ggggtccgagg gcgctggaaa cccagcggcg gcgaagcgga gaggagcccc 60
gcgcgtctcc gcccgcacgg ctccaggtct ggggtctgcg ctggagccgc gcggggagag 120
gccgtctctg cgaccgccgc gcccgctccc gaccgtccgg gtccgcggcc agcccgcca 180
ccagccatgg gctctggccc gctctcgctg cccctggcgc tgtcgccgcc gcggctgctg 240
ctgctgctgc tgtgtctctt gctgccagt ggcagggcct cagaggctga gcaccatcta 300
tttgagcggc tgtttgaaga ttacaatgag atcatccggc ctgtagccaa cgtgtctgac 360
ccagtcata tccatttcga ggtgtccatg tctcagctgg tgaagggtga tgaagtaaac 420
cagatcatgg agaccaacct gtggctcaag caaatctgga atgactacaa gctgaagtgg 480
aaccctctg actatgggtg ggcagagttc atgcgtgtcc ctgcacagaa gatctggaag 540
ccagacattg tgctgtataa caatgctgtt ggggatttcc aggtggacga caagacaaa 600
gccttactca agtacactgg ggaggtgact tggatacctc cggccatctt taagagctcc 660
tgtaaaatcg acgtgacctt cttcccgttt gattacaaaa actgtaccat gaagttcggg 720
tcctggctct acgataaggc gaaaatcgat ctggctctga tcggctcttc catgaacctc 780
aaggactatt gggagagcgg cgagtgggccc atcatcaaag cccagggcta caaacacgac 840
atcaagtaca actgctgcga ggagatctac cccgacatca catactcgct gtacatccgg 900
cgcttgcctt tgttctacac catcaacctc atcatccct gcctgtcat ctccttctc 960
actgtgctcg tcttctacct gccctccgac tgcggtgaga aggtgaccct gtgcatttct 1020
gtcctctctt ccctgacggg gtttctctg gtgatcactg agaccatccc ttccacctcg 1080
ctggatcatc ccctgattgg agagtacctc ctgttcacca tgatttttgt aaccttgctc 1140
atcgtcatca cgtcttctg gctcaacgtg cactacagaa ccccgacgac acacacaatg 1200
ccctcatggg tgaagactgt attcttgaac ctgctcccca gggatcatgt catgaccagg 1260
ccaacaagca acgagggcaa cgctcagaag ccgaggcccc tctacgggtg cgagctctca 1320
aatctgaatt gcttcagccg cgcagagtcc aaaggctgca aggagggcta cccctgccag 1380
gacgggatgt gtggttactg ccaccaccgc aggataaaaa tctccaattt cagtgtaac 1440
ctcacgagaa gctctagttc tgaatctgtt gatgctgtgc tgtccctctc tgctttgtca 1500
ccagaaatca aagaagccat ccaaagtgtc aagtatatgt ctgaaaatat gaaagcacia 1560
aatgaagcca aagagattca agatgattgg aagtatgttg ccatggtgat tgatcgattt 1620
tttctgtggg ttttcaccct ggtgtgcatt ctagggacag caggattgtt tctgcaaccc 1680
ctgatggcca ggaagatgc ataagcacta agctgtgtgc ctgcctggga gacttccttg 1740
tgtcagggca ggaggaggct gcttcctagt aagaacgtac tttctgttat caagctacca 1800
gctttgtttt tggcatttct aggtttactt attttccact tatcttggaa tcatgcaaaa 1860
aaaaaatgt caagagtatt tattaccgat aaatgaacat ttaactagcc tttttggtat 1920
ggtaaagaga tgtcaaaatg tgattctatg tgattagtat gctatgctat ggaatataca 1980
tgtaaaaatg tttcctttta gttgttgaac caaaactgga tagaaaaatg ctgttcagaa 2040

SSCP Update Sequences.ST25

atatgaaaag	tcattcagtt	atcactacag	atctcccagt	aatttttctt	atntagccca	2100
taatctcttt	gaaggtttat	actaattcag	caatcccca	tcgttaccca	tttcttacca	2160
tgcatttctc	gttctttact	gggtctaaag	ggctatgcct	ccatttcaga	gagcttcaac	2220
tacttctctt	gcatacttct	aaattatact	atgagaaatc	atgcctagtt	attcattggt	2280
aatataactg	tcttagtaca	ccataaactg	gggtggattat	aaacaacaga	aacttctcag	2340
ttttggaggt	tgggaggtcc	aagggtcaagg	caccagcaaa	tttggtgtct	ggtaggggtc	2400
ctcttcctca	aagggtgcct	tctagctgtg	tcctcacatg	actgaaggga	ctagctatct	2460
ctgtgggggtc	tatttttataa	gggcactaac	cccattcatg	agagcagagc	ccccatggcc	2520
taatcacctt	tccaaggccc	caccttctat	ctaagacaat	cacgctggga	ataggtttca	2580
acatatgaat	tgggggagga	cacatttgga	ccacagcatg	aacctttaga	acagggtttc	2640
tcagccttag	cactacggac	attttgggct	ggataaatat	gtgttggtac	agaatggggg	2700
tatcctgtgc	attgtaggat	ctttagcagt	accctagcct	caactcacta	gatgccaatg	2760
acataccttg	cttcttcacc	agttatgata	accaagaatg	tctccattgt	taaatgtccc	2820
cttaggagca	aaattgcccc	tggttgagaa	acattgcttt	agacaaattg	ttaagagtat	2880
catgtactac	acttctgaaa	cttaacgtga	tcatcaccac	tgacagatga	ttcacagaga	2940
gagactgttt	gaatcttgtc	tcactagttt	ttcctgtgca	aaaataaaat	ggacagaatt	3000
gcaaaaaaaaa	aaaaaaaaaa					3020

<210> 33
 <211> 2664
 <212> DNA
 <213> Homo sapiens

<400> 33	
gagagaacag	cgtgagcctg tgtgcttgtg tgctgagccc tcatccccctc ctggggccag 60
gcttggggttt	cacctgcaga atcgcttgtg ctgggctgcc tgggctgtcc tcagtggcac 120
ctgcatgaag	ccgttctggc tgccagagct ggacagcccc aggaaaaccc acctctctgc 180
agagcttgcc	cagctgtccc cggaagcca aatgcctctc atgtaagtct tctgctcgac 240
ggggtgtctc	ctaaaccctc actcttcagc ctctgtttga ccatgaaatg aagtgactga 300
gctctattct	gtacctgcca ctctatttct ggggtgactt ttgtcagctg ccagaaatct 360
ccaagccagg	ctggttctct gcaccccttc aatgacctgt tttcttctgt aaccacaggt 420
tcggtggtga	gaggaagcct cgcagaatcc agcagaatcc tcacagaatc cagcagcagc 480
tctgctgggg	acatggtcca tgggtgcaacc cacagcaaag ccctgacctg acctcctgat 540
gctcaggaga	agccatgggc ccctcctgtc ctgtgttcct gtccttcaca aagctcagcc 600
tgtggtggct	ccttctgacc ccagcaggtg gagaggaagc taagcgccca cctcccaggg 660
ctcctggaga	cccactctcc tctcccagtc ccacggcatt gccgcaggga ggctcgcata 720
ccgagactga	ggaccggctc ttcaaaccacc tcttcggggg ctacaaccgc tgggcgcgcc 780

SSCP Update Sequences.ST25

cggtgccc	aa cacttcagac	gtggtgattg	tgcgctttgg	actgtccatc	gctcagctca	840
tcgatgtgga	tgagaagaac	caaatgatga	ccaccaacgt	ctggctaata	caggagtgga	900
gcgattacaa	actgcgctgg	aaccccgctg	atttttggcaa	catcacatct	ctcaggggtcc	960
cttctgagat	gatctggatc	cccgacattg	ttctctacaa	caatgcagat	ggggagtgtt	1020
cagtgaccca	catgaccaag	gcccacctct	tctccacggg	cactgtgcac	tgggtgcccc	1080
cggccatcta	caagagctcc	tgcagcatcg	acgtcacctt	cttccccttc	gaccagcaga	1140
actgcaagat	gaagtttggc	tcctggactt	atgacaaggc	caagatcgac	ctggagcaga	1200
tggagcagac	tgtggacctg	aaggactact	gggagagcgg	cgagtggggc	atcgtcaatg	1260
ccacggggcac	ctacaacagc	aagaagtacg	actgctgcgc	cgagatctac	cccgacgtca	1320
cctacgcctt	cgtcatccgg	cggctgccgc	tcttctacac	catcaacctc	atcatcccct	1380
gcctgctcat	ctcctgcctc	actgtgctgg	tcttctacct	gccctccgac	tgcggcgaga	1440
agatcacgct	gtgcatttct	gtgctgctgt	cactcacctg	cttctctgct	ctcatcactg	1500
agatcatccc	gtccacctcg	ctggatcatc	cgctcatcgg	cgagtacctg	ctgttcacca	1560
tgatcttctg	cacctgtctc	atcgtcatca	ccgtcttctg	gctcaatgtg	caccaccgct	1620
cccccagcac	ccacaccatg	ccccactggg	tgcggggggc	ccttctgggc	tgtgtgcccc	1680
gggtggcttct	gatgaaccgg	ccccaccac	ccgtggagct	ctgccacccc	ctacgcctga	1740
agctcagccc	ctcttatcac	tggctggaga	gcaacgtgga	tgccgaggag	agggaggtgg	1800
tgggtggagga	ggaggacaga	tgggcatgtg	caggtcatgt	ggccccctct	gtgggcaccc	1860
tctgcagcca	cggccacctg	cactctgggg	cctcaggtcc	caaggctgag	gctctgctgc	1920
aggaggggtga	gctgctgcta	tcaccccaca	tgcagaaggc	actggaaggt	gtgcactaca	1980
ttgccgacca	cctgcggtct	gaggatgctg	actcttcggt	gaaggaggac	tgggaagtatg	2040
ttgccatggt	catcgacagg	atcttctctt	ggctgtttat	catcgtctgc	ttcctgggga	2100
ccatcggcct	ctttctgcct	ccgttcctag	ctggaatgat	ctgactgcac	ctccctcgag	2160
ctggctccca	gggcaaaggg	gagggttctt	ggatgtggaa	gggctttgaa	caatgtttag	2220
atttggagat	gagcccaaag	tgccagggag	aacagccagg	tgagggtggga	ggttggagag	2280
ccagggtgagg	tctctctaag	tcaggctggg	gttgaagttt	ggagtctgtc	cgagtttgca	2340
gggtgctgag	ctgtatggtc	cagcagggga	gtaataaggg	ctcttccgga	aggggaggaa	2400
gcgggaggga	ggcctgcacc	tgatgtggag	gtacaggcag	atcttcccta	ccggggaggg	2460
atggatggtt	ggatacaggt	ggctgggcta	ttccatccat	ctggaagcac	atttgagcct	2520
ccaggcttct	ccttgacgtc	attcctctcc	ttccttgctg	caaaatggct	ctgcaccagc	2580
cggccccccag	gaggtctggc	agagctgaga	gccatggcct	gcaggggctc	catatgtccc	2640
tacgcgtgca	gcaggcaaac	aaga				2664

<210> 34
 <211> 2664
 <212> DNA

SSCP Update Sequences.ST25

<213> Homo sapiens

<400> 34

```

gagagaacag cgtgagcctg tgtgcttgtg tgctgagccc tcatcccctc ctggggccag      60
gcttgggttt cacctgcaga atcgcttgtg ctgggctgcc tgggctgtcc tcagtggcac      120
ctgcatgaag ccgttcttggc tgccagagct ggacagcccc aggaaaaccc acctctctgc      180
agagcttgcc cagctgtccc cggaagcca aatgcctctc atgtaagtct tctgctcgac      240
ggggtgtctc ctaaaccctc actcttcagc ctctgtttga ccatgaaatg aagtgactga      300
gctctattct gtacctgcca ctctatttct ggggtgactt ttgtcagctg cccagaatct      360
ccaagccagg ctggttctct gcatcctttc aatgacctgt tttcttctgt aaccacaggt      420
tcggtggtga gaggaagcct cgcagaatcc agcagaatcc tcacagaatc cagcagcagc      480
tctgctgggg acatggtcca tgggtgcaacc cacagcaaag ccctgacctg acctcctgat      540
gctcaggaga agccatgggc ccctcctgtc ctgtgttctt gtccttcaca aagctcagcc      600
tgtggtggct ctttctgacc ccagcaggtg gagaggaagc taagcgccca cctcccaggg      660
ctcctggaga cccactctcc tctcccagtc ccacggcatt gccgcaggga ggctcgcata      720
ccgagactga ggaccggctc ttcaaacacc tcttccgggg ctacaaccgc tgggcgcgcc      780
cggtgcccaa cacttcagac gtggtgattg tgcgctttgg actgtccatc gctcagctca      840
tcgatgtgga tgagaagaac caaatgatga ccaccaacgt ctggctaaaa caggagtgga      900
gcgactacaa actgcgctgg aaccccgctg attttggtcaa catcacatct ctcagggtcc      960
cttctgagat gatctggatc cccgacattg ttctctacaa caatgcagat ggggagtgtt      1020
cagtgacca catgaccaag gccacacctt tctccacggg cactgtgcac tgggtgcccc      1080
cggccatcta caagagctcc tgcagcatcg acgtcacctt cttccccttc gaccagcaga      1140
actgcaagat gaagtttggc tcctggactt atgacaaggc caagatcgac ctggagcaga      1200
tgagagcagac tgtggacctg aaggactact gggagagcgg cgagtgggcc atcgtcaatg      1260
ccacgggcac ctacaacagc aagaagtacg actgctgcgc cgagatctac cccgacgtca      1320
cctatgcctt cgtcatccgg cggtgccgc tcttctacac catcaacctc atcatcccct      1380
gcctgtcat ctctgcctc actgtgctgg tcttctacct gccctccgac tgcggcgaga      1440
agatcacgct gtgcatttcg gtgctgctgt cactcacctg cttcctgctg ctcatcactg      1500
agatcatccc gtccacctcg ctggtcatcc cgctcatcgg cgagtacctg ctgttcacca      1560
tgatcttcgt caccctgtcc atcgtcatca ccgtcttcgt gctcaatgtg caccaccgct      1620
ccccagcac ccacaccatg cccactggg tgcggggggc ctttctgggc tgtgtgcccc      1680
ggtggcttct gatgaaccgg cccccaccac ccgtggagct ctgccacccc ctacgcctga      1740
agctcagccc ctcttatcac tggctggaga gcaacgtgga tgccgaggag agggaggtgg      1800
tgggtggagga ggaggacaga tgggcatgtg cagggtcatgt ggccccctct gtgggcaccc      1860
tctgcagcca cggccacctg cactctgggg cctcaggtcc caaggctgag gctctgctgc      1920
aggagggtga gctgctgcta tcaccccaca tgcagaaggc actggaagggt gtgcactaca      1980

```

SSCP Update Sequences.ST25

ttgccgacca	cctgcggtct	gaggatgctg	actcttcggt	gaaggaggac	tggaagtatg	2040
ttgccatggt	catcgacagg	atcttcctct	ggctgtttat	catcgtctgc	ttcctgggga	2100
ccatcggcct	ctttctgcct	ccgttcctag	ctggaatgat	ctgactgcac	ctccctcgag	2160
ctggctccca	gggcaaagg	gaggggttct	ggatgtggaa	gggctttgaa	caatgtttag	2220
atgttgagat	gagcccaaag	tgccagggag	aacagccagg	tgaggtggga	ggttgagag	2280
ccaggtgagg	tctctctaag	tcaggctggg	gttgaagttt	ggagtctgtc	cgagtgtgca	2340
gggtgctgag	ctgtatggtc	cagcagggga	gtaataagg	ctcttcgga	aggggaggaa	2400
gcgggaggca	ggcctgcacc	tgatgtggag	gtacaggcag	atcttccta	ccggggagg	2460
atggatggtt	ggatacagg	ggctgggcta	ttccatccat	ctggaagcac	atgtgagcct	2520
ccaggcttct	ccttgacgtc	attcctctcc	ttccttgctg	caaaatggct	ctgcaccagc	2580
cggcccccag	gaggtctggc	agagctgaga	gccatggcct	gcaggggctc	catatgtccc	2640
tacgcgtgca	gcaggcaaac	aaga				2664

<210> 35
 <211> 3020
 <212> DNA
 <213> Homo sapiens

<400> 35	
gtcctcccgc	gggtccgagg ggcgtggaaa cccagcggcg gcgaagcgga gaggagcccc 60
gcgcgtctcc	gcccgcacgg ctccaggctt ggggtctgcg ctggagccgc gcggggagag 120
gccgtctctg	cgaccgccgc gcccgctccc gaccgtccgg gtccgcggcc agcccgcca 180
ccagccatgg	gctctggccc gctctcgtg cccctggcgc tgtcgccgcc gcggctgctg 240
ctgctgctgc	tgctgtctct gctgccagt gccagggcct cagaggctga gcaccgtcta 300
tttgagcggc	tgtttgaaga ttacaatgag atcatccggc ctgtggccaa cgtgtctgac 360
ccagtcatca	tccatttcga ggtgtccatg tctcagctgg tgaagggtga tgaagtaa 420
cagatcatgg	agaccaacct gtggctcaag caaatctgga atgactacaa gctgaagtgg 480
aaccctctg	actatgggtg ggcagagttc atgcgtgtcc ctgcacagaa gatctggaag 540
ccagacattg	tgctgtataa caatgctgtt ggggatttcc aggtggacga caagacaaa 600
gccttactca	agtacactgg ggaggtgact tggatactc cgccatctt taagagctcc 660
tgtaaaatcg	acgtgacctt cttcccgttt gattacaaa actgtaccat gaagtccggt 720
tcctggctct	acgataaggc gaaaatcgat ctggctctga tcggctcttc catgaacctc 780
aaggactatt	gggagagcgg cgagtgggcc atcatcaaag cccaggcta caaacacgac 840
atcaagtaca	actgctgcga ggagatctac cccgacatca catactcgct gtacatccgg 900
cgcctgccct	tgttctacac catcaacctc atcatcccct gcctgctcat ctcttcctc 960
actgtgctcg	tcttctacct gccctccgac tgcggtgaga aggtgaccct gtgcatttct 1020
gtcctcctct	ccctgacggg gtttctcctg gtgatcactg agaccatccc ttccacctcg 1080

SSCP Update Sequences.ST25

ctgggtcatcc	ccctgattgg	agagtacctc	ctgttcacca	tgatttttgt	aaccttgtcc	1140
atcgtcatca	ccgtcttcgt	gctcaacgtg	cactacagaa	ccccgacgac	acacacaatg	1200
ccctcatggg	tgaagactgt	attcttgaac	ctgctcccca	gggtcatggt	catgaccagg	1260
ccaacaagca	acgagggcaa	cgctcagaag	ccgaggcccc	tctacggtgc	cgagctctca	1320
aatctgaatt	gcttcagccg	cgcagagtcc	aaaggctgca	aggagggcta	cccctgccag	1380
gacgggatgt	gtggttactg	ccaccaccgc	aggataaaaa	tctccaattt	cagtgctaac	1440
ctcacgagaa	gctctagttc	tgaatctgtt	gatgctgtgc	tgccctctc	tgctttgtca	1500
ccagaaatca	aagaagccat	ccaaagtgtc	aagtatattg	ctgaaaatat	gaaagcacao	1560
aatgaagcca	aagagattca	agatgattgg	aagtatgttg	ccatgggtgat	tgatcgtatt	1620
tttctgtggg	ttttcaccct	gggtgtgcatt	ctagggacag	caggattgtt	tctgcaaccc	1680
ctgatggcca	gggaagatgc	ataagcacta	agctgtgtgc	ctgcctggga	gacttccttg	1740
tgtcagggca	ggaggaggct	gcttcctagt	aagaacgtac	tttctgttat	caagctacca	1800
gctttgtttt	tggcatttcg	aggtttactt	attttccact	tatcttggaa	tcattgcaaaa	1860
aaaaaaatgt	caagagtatt	tattaccgat	aaatgaacat	ttaactagcc	tttttggtat	1920
ggtaaagaga	tgtcaaaatg	tgattctatg	tgattagtat	gctatgctat	ggaatataca	1980
tgtaaaaatg	tttcctttta	gttggtgaaa	caaaactgga	tagaaaaatg	ctgttcagaa	2040
atatgaaaag	tcattcagtt	atcactacag	atctcccagt	aatttttctt	atttagccca	2100
taatctcttt	gaagggttat	actaattcag	caatcccca	tcgttaccca	tttcttacca	2160
tgcatctctc	gttctttact	gggtctaaag	ggctatgcct	ccatttcaga	gagcttcaac	2220
tacttctctt	gcatacttct	aaattatact	atgagaaatc	atgcctagtt	attcattgtt	2280
aatataactg	tcttagtaca	ccataaactg	gggtggattat	aaacaacaga	aacttctcag	2340
ttttggaggt	tggggaggtcc	aagggtcaagg	caccagcaaa	tttggtgtct	ggtgagggtc	2400
ctcttcctca	aaggggtgcct	tctagctgtg	tcctcacatg	actgaaggga	ctagctatct	2460
ctgtggggtc	tatttttataa	gggcactaac	cccattcatg	agagcagagc	ccccatggcc	2520
taatcacctt	tccaaggccc	caccttctat	ctaagacaat	cacgctggga	ataggtttca	2580
acatatgaat	tgggggagga	cacatttgga	ccacagcatg	aacctttaga	acagggtttc	2640
tcagccttag	cactacggac	attttgggct	ggataaatat	gtgttggtac	agaatggggg	2700
tatcctgtgc	attgtaggat	ctttagcagt	accctagcct	caactcacta	gatgccaatg	2760
acataccttg	cttcttcacc	agttatgata	accaagaatg	tctccattgt	taaatgtccc	2820
cttaggagca	aaattgcccc	tggttgagaa	acattgcttt	agacaaattg	ttaagagtat	2880
catgtactac	acttctgaaa	cttaacgtga	tcatcaccac	tgacagatga	ttcacagaga	2940
gagactgttt	gaatcttgtc	tcactagtgt	ttcctgtgca	aaaataaaat	ggacagaatt	3000
gcaaaaaaaa	aaaaaaaaaa					3020

SSCP Update Sequences.ST25

<211> 3020

<212> DNA

<213> Homo sapiens

<400> 36

```

gtcctccccgc ggggtccgagg gcgctggaaa cccagcggcg gcgaagcgga gaggagcccc      60
gcgcgtctcc gcccgcacgg ctccaggtct ggggtctgcg ctggagccgc gcggggagag      120
gccgtctctg cgaccgccgc gcccgctccc gaccgtccgg gtccgcggcc agccccggcca      180
ccagccatgg gctctggccc gctctcgctg cccctggcgc tgtcgccgcc gcggctgctg      240
ctgctgctgc tgctgtctct gctgccagt ggcagggcct cagaggctga gcaccgtcta      300
tttgagcggc tgtttgaaga ttacaatgag atcatccggc ctgtagccaa cgtgtctgac      360
ccagtcatca tccatttcga ggtgtccatg tctcagctgg tgaagggtga tgaagtaaac      420
cagatcatgg agaccaacct gtggctcaag caaatctgga atgactacaa gctgaaatgg      480
aaccctctg actatgggtg ggcagagttc atgcgtgtcc ctgcacagaa gatctggaag      540
ccagacattg tgctgtataa caatgctgtt ggggatttcc aggtggacga caagacaaa      600
gccttactca agtacactgg ggaggtgact tggatacctc cggccatctt taagagctcc      660
tgtaaaatcg acgtgacctt cttcccgttt gattaccaa actgtaccat gaagttcgggt      720
tcctggtcct acgataaggc gaaaatcgat ctggctctga tcggctcttc catgaacctc      780
aaggactatt gggagagcgg cgagtgggcc atcatcaaag cccagggcta caaacacgac      840
atcaagtaca actgctgcga ggagatctac cccgacatca catactcgct gtacatccgg      900
cgctgccct tgttctacac catcaacctc atcatccctt gcctgctcat ctcttcctc      960
actgtgctcg tcttctacct gccctccgac tgcggtgaga aggtgaccct gtgcatttct     1020
gtcctcctct ccctgacggt gtttctcctg gtgatcactg agaccatccc ttccacctcg     1080
ctggatcatcc ccctgattgg agagtacctc ctgttcacca tgatttttgt aaccttgtcc     1140
atcgatcatca ccgtcttcgt gctcaacgtg cactacagaa ccccgacgac acacacaatg     1200
ccctcatggg tgaagactgt attcttgaac ctgctcccca gggatcatgtt catgaccagg     1260
ccaacaagca acgagggcaa cgctcagaag ccgaggcccc tctacgggtgc cgagctctca     1320
aatctgaatt gcttcagccg cgcagagttc aaaggctgca aggagggcta cccctgccag     1380
gacgggatgt gtggttactg ccaccaccgc aggataaaaa tctccaattt cagtgtctaac     1440
ctcacgagaa gctctagttc tgaatctggt gatgctgtgc tgtccctctc tgctttgtca     1500
ccagaaatca aagaagccat ccaaagtgtc aagtatattg ctgaaaatat gaaagcacia     1560
aatgaagcca aagagattca agatgattgg aagtatgttg ccatgggtgat tgatcgtatt     1620
tttctgtggg ttttcacctt ggtgtgcatt ctagggacag caggattgtt tctgcaacct     1680
ctgatggcca gggaagatgc ataagcacta agctgtgtgc ctgcctggga gacttccttg     1740
tgtcagggca ggaggaggct gcttcctagt aagaacgtac tttctgttat caagctacca     1800
gctttgtttt tggcatttcg aggtttactt attttccact tatcttggaa tcatgcaaaa     1860
aaaaaaatgt caagagtatt tattaccgat aaatgaacat ttaactagcc tttttggtat     1920

```

SSCP Update Sequences.ST25

ggtaaagaga	tgtcaaaatg	tgattctatg	tgattagtat	gctatgctat	ggaatataca	1980
tgtaaaaatg	tttcctttta	gttggtgaaa	caaaactgga	tagaaaaatg	ctgttcagaa	2040
atatgaaaag	tcattcagtt	atcactacag	atctcccagt	aatttttctt	atttagccca	2100
taatctcttt	gaaggtttat	actaattcag	caatcccca	tcgttaccca	tttcttacca	2160
tgcatctctc	gttctttact	gggtctaaag	ggctatgcct	ccatttcaga	gagcttcaac	2220
tacttctctt	gcatacttct	aaattatact	atgagaaatc	atgcctagtt	attcattggt	2280
aatataactg	tcttagtaca	ccataaactg	gggtggattat	aaacaacaga	aacttctcag	2340
ttttggaggt	tgggaggtcc	aagggtcaagg	caccagcaaa	tttggtgtct	ggtgagggtc	2400
ctcttcctca	aagggtgcct	tctagctgtg	tcctcacatg	actgaagggg	ctagctatct	2460
ctgtggggtc	tatttttataa	gggcactaac	cccattcatg	agagcagagc	ccccatggcc	2520
taatcacctt	tccaaggccc	caccttctat	ctaagacaat	cacgctggga	ataggtttca	2580
acatatgaat	tgggggagga	cacatttgga	ccacagcatg	aacctttaga	acagggtttc	2640
tcagccttag	cactacggac	attttgggct	ggataaatat	gtgttggtac	agaatggggg	2700
tatcctgtgc	attgtaggat	ctttagcagt	accctagcct	caactcacta	gatgccaatg	2760
acataccttg	cttcttcacc	agttatgata	accaagaatg	tctccattgt	taaatgtccc	2820
cttaggagca	aaattgcccc	tggttgagaa	acattgcttt	agacaaattg	ttaagagtat	2880
catgtactac	acttctgaaa	cttaacgtga	tcatcaccac	tgacagatga	ttcacagaga	2940
gagactgttt	gaatcttgtc	tcactagttt	ttcctgtgca	aaaataaaat	ggacagaatt	3000
gcaaaaaaaaa	aaaaaaaaaaa					3020

<210> 37
 <211> 3020
 <212> DNA
 <213> Homo sapiens

<400> 37	
gtcctcccgc	gggtccgagg
gcgctgga	cccagcggcg
gcgaagcgga	gaggagcccc
60	
gcgctctcc	gcccgcacgg
ctccaggctc	ggggtctg
ctggagccgc	gcggggagag
120	
gccgtctctg	cgaccgccgc
gcccgtctcc	gaccgtccgg
gtccgcggcc	agcccgccca
180	
ccagccatgg	gctctggccc
gctctcgctg	cccctggcgc
tgctgcggcc	gcggctgctg
240	
ctgctgctgc	tgctgtctct
gctgccagtg	gccagggcct
cagaggctga	gcaccgtcta
300	
tttgagcggc	tggttgga
ttacaatgag	atcatccggc
ctgtagccaa	cgtgtctgac
360	
ccagtcatca	tccatttcga
gggtgtccatg	tctcagctgg
tgaagggtgga	tgaagtaa
420	
cagatcatgg	agaccaacct
gtggctcaag	caaactctgga
atgactacaa	gctgaagtgg
480	
aacccctctg	actatgggtg
ggcagagttc	atgcgtgtcc
ctgcacagaa	aatctggaag
540	
ccagacattg	tgctgtataa
caatgctggt	ggggatttcc
aggtggacga	caagacaaa
600	
gccttactca	agtacactgg
ggaggtgact	tggatacctc
cggccatctt	taagagctcc
660	

SSCP Update Sequences.ST25

tgtaaaatcg	acgtgaccta	cttcccgttt	gattacccaa	actgtaccat	gaagttcggg	720
tcctgggcct	acgataaggc	gaaaatcgat	ctggctctga	tcggctcttc	catgaacctc	780
aaggactatt	gggagagcgg	cgagtgggccc	atcatcaaa	ccccaggcta	caaacacgac	840
atcaagtaca	actgctgcga	ggagatctac	cccagacatca	catactcgct	gtacatccgg	900
cgcttgccct	tgttctacac	catcaacctc	atcatccctt	gcctgctcat	ctccttcttc	960
actgtgctcg	tcttctacct	gccctccgac	tgcggtgaga	aggtgaccct	gtgcatttct	1020
gtcctcctct	ccctgacggg	gtttctcctg	gtgatcactg	agaccatccc	ttccacctcg	1080
ctggatcatcc	ccctgattgg	agagtacctc	ctgttcacca	tgatttttgt	aaccttggtc	1140
atcgatcatca	ccgtcttcgt	gctcaacgtg	cactacagaa	ccccgacgac	acacacaatg	1200
ccctcatggg	tgaagactgt	attcttgaac	ctgctcccca	gggtcatggt	catgaccagg	1260
ccaacaagca	acgagggcaa	cgctcagaag	ccgaggcccc	tctacgggtg	cgagctctca	1320
aatctgaatt	gcttcagccg	cgagaggtcc	aaaggctgca	aggaggggta	cccctgccag	1380
gacgggatgt	gtggttactg	ccaccaccgc	aggataaaaa	tctccaattt	cagtgtctaac	1440
ctcacgagaa	gctctagttc	tgaatctgtt	gatgctgtgc	tgccctcttc	tgctttgtca	1500
ccagaaatca	aagaagccat	ccaaagtgtc	aagtatatgt	ctgaaaatat	gaaagcacao	1560
aatgaagcca	aagagattca	agatgattgg	aagtatgttg	ccatgggtgat	tgatcgattt	1620
tttctgtggg	ttttcaccct	ggtgtgcatt	ctaggagacag	caggattggt	tctgcaaccc	1680
ctgatggcca	gggaagatgc	ataagcacta	agctgtgtgc	ctgcctggga	gacttccttg	1740
tgctcagggca	ggaggaggct	gcttcctagt	aagaacgtac	tttctgttat	caagctacca	1800
gctttgtttt	tggcatttcg	aggtttactt	atcttccact	tatcttggaa	tcatgcaaaa	1860
aaaaaaatgt	caagagtatt	tattaccgat	aaatgaacat	ttaactagcc	tttttggtat	1920
ggtaaagaga	tgtcaaaatg	tgattctatg	tgattagtat	gctatgctat	ggaatataca	1980
tgtaaaaatg	tttcctttta	gttggtgaaa	caaaactgga	tagaaaaatg	ctgttcagaa	2040
atatgaaaag	tcatttcagtt	atcactacag	atctcccagt	aatttttctt	atttagccca	2100
taatctcttt	gaagggttat	actaattcag	caatccccc	tcgttaccca	tttcttacca	2160
tgcatctctc	gttctttact	gggtctaaag	ggctatgcct	ccatttcaga	gagcttcaac	2220
tacttctctt	gcatacttct	aaattatact	atgagaaatc	atgcctagtt	attcattggt	2280
aatataactg	tcttagtaca	ccataaactg	ggtggattat	aaacaacaga	aacttctcag	2340
ttttggaggt	tgggaggtcc	aaggtcaagg	caccagcaaa	tttggtgtct	ggtgagggtc	2400
ctcttctca	aagggtgcct	tctagctgtg	tcctcacatg	actgaaggga	ctagctatct	2460
ctgtgggggc	tattttataa	gggcactaac	cccattcatg	agagcagagc	cccatgggcc	2520
taatcacctt	tccaaggccc	caccttctat	ctaagacaat	cacgctggga	atagggttca	2580
acatatgaat	tgggggagga	cacatttgga	ccacagcatg	aacctttaga	acagggtttc	2640
tcagccttag	cactacggac	attttgggct	ggataaatat	gtgttggtac	agaatggggg	2700

SSCP Update Sequences.ST25

tatcctgtgc attgtaggat ctttagcagt accctagcct caactcacta gatgccaatg	2760
acataccttg cttctttcacc agttatgata accaagaatg tctccattgt taaatgtccc	2820
cttaggagca aaattgcccc tgggtgagaa acattgcttt agacaaattg ttaagagtat	2880
catgtactac acttctgaaa cttaacgtga tcatcaccac tgacagatga ttcacagaga	2940
gagactgttt gaatcttgtc tcactagttt ttctgtgca aaaataaaat ggacagaatt	3000
gcaaaaaaaaa aaaaaaaaaa	3020

<210> 38
 <211> 210
 <212> DNA
 <213> Homo sapiens

<400> 38	
gggctgcttg gcccaattct gggcatcccc ggggtgtgct agctttgccc taggctgctc	60
cctggaagcg aggttgacac aacttcttcc ccacacacag gagtggagcg actacaaact	120
gcgctggaac cccgctgatt ttggcaacat cacatctctc aggggccctt ctgagatgat	180
ctggatcccc gacattgttc tctacaacaa	210

<210> 39
 <211> 210
 <212> DNA
 <213> Homo sapiens

<400> 39	
agcaggggtg gggagtcacc aagatgggtg gtgccacggg aagtaaaacc aggctgattc	60
ttttaccgtc tccttctccc tccctgcttc cttccccgag atctggaatg actacaagct	120
gaagtggaac ccctctgact atggtggggc agagttcatg cgtgtccctg cacagaagat	180
ctggaagcca gacattgtgc tgtataacaa	210

<210> 40
 <211> 210
 <212> DNA
 <213> Homo sapiens

<400> 40	
atctggaatg actacaagct gaagtggaac ccctctgact atggtggggc agagttcatg	60
cgtgtccctg cacagaagat ctggaagcca gacattgtgc tgtataacaa gtaaggctcct	120
ggggggccca cgccctctca gggctgtcag cctgggctct gggtttttgg cccactgtgc	180
ttaaaacctg gccttccttg gccttttcca	210

<210> 41
 <211> 7438
 <212> DNA
 <213> Homo sapiens

<400> 41	
gctgagcctg agcccgaccc ggggcgcctc ccgccaggca ccatgggtgca gaagtcgcgc	60
aacggcggcg tataccccgg ccgagcggg gagaagaagc tgaagggtggg cttcgtgggg	120

SSCP Update Sequences.ST25

ctggacccccg	gcgcgccccga	ctccaccccg	gacggggcg	tgctgatcgc	cggctccgag	180
gcccccaagc	gcggcagcat	cctcagcaaa	cctcgcgcg	gcggcgcg	cgccgggaag	240
cccccccaag	cgcaacgcct	tctaccgcaa	gctgcagaat	ttcctctaca	acgtgctgga	300
gcggccgcgc	ggctggg	tcatctacca	cgccctacgtg	ttcctcctgg	ttttctcctg	360
cctcgtgctg	tctgtgtttt	ccaccatcaa	ggagtatgag	aagagctcgg	agggggccct	420
ctacatcctg	gaaatcgtga	ctatcgtgg	gtttggcg	gagtacttcg	tgcggatctg	480
ggccgcaggc	tgctgctgcc	ggtaccgtg	ctggagggg	cggctcaagt	ttgcccggaa	540
accgttctgt	gtgattgaca	tcatggtgct	catcgccctc	attgcggtgc	tggccgccc	600
ctcccagggc	aacgtctttg	ccacatctgc	gctccggagc	ctgcgcttcc	tgagattct	660
gcggatgac	cgcatggacc	ggcggggagg	cacctggaag	ctgctgggct	ctgtggtcta	720
tgcccacagc	aaggagctgg	tactgcctg	gtacatcg	ttcctttgtc	tcatcctggc	780
ctcgttcctg	gtgtacttgg	cagagaagg	ggagaacgac	cactttgaca	cctacgcgga	840
tgactctgg	tggggcctga	tcacgctgac	caccattggc	tacggggaca	agtaccccca	900
gacctggaac	ggcaggctcc	ttgcggcaac	cttcaccctc	atcgggtgtct	ccttcttcgc	960
gctgcctgca	ggcatcttgg	ggtctgggtt	tgccctgaag	gttcaggagc	agcacaggca	1020
gaagcacttt	gagaagaggc	ggaacccggc	agcaggcctg	atccagtcgg	cctggagatt	1080
ctacgccacc	aacctctcgc	gcacagacct	gactccacg	tggcagtact	acgagcgaa	1140
ggtcaccgtg	cccatgtaca	gttcgcaaac	tcaaacctac	ggggcctcca	gacttatccc	1200
cccgtgaac	cagctggagc	tgctgaggaa	cctcaagagt	aaatctggac	tcgctttcag	1260
gaaggacccc	ccgccggagc	cgtctccaag	ccagaagg	agtttgaaag	atcgtgtctt	1320
ctccagcccc	cgaggcggtg	ctgccaagg	gaaggggtcc	ccgcaggccc	agactgtgag	1380
gcggtcacc	agcgccgacc	agagcctcga	ggacagcccc	agcaagggtc	ccaagagctg	1440
gagcttcggg	gaccgcagcc	gggcacgcca	ggctttccgc	atcaagggtg	ccgcgtcacg	1500
gcagaactca	gaagaagcaa	gcctccccgg	agaggacatt	gtggatgaca	agagctgccc	1560
ctgcgagttt	gtgaccgagg	acctgacccc	gggcctcaaa	gtcagcatca	gagccgtgtg	1620
tgtcatgcgg	ttcctgggtg	ccaagcggaa	gttcaaggag	agcctgcggc	cctacgacgt	1680
gatggacgtc	atcgagcagt	actcagccgg	ccacctggac	atgctgtccc	gaattaagag	1740
cctgcagtcc	agagtggacc	agatcgtggg	gcggggccca	gcgatcacgg	acaaggaccg	1800
caccaagggc	ccggccgagg	cggagctgcc	cgaggacccc	agcatgatgg	gacggctcgg	1860
gaagggtggag	aagcagggtct	tgtccatgga	gaagaagctg	gacttcctgg	tgaatatcta	1920
catgcagcgg	atgggcatcc	ccccgacaga	gaccgaggcc	tactttgggg	ccaaagagcc	1980
ggagccggcg	ccgccgtacc	acagcccggg	agacagccgg	gagcatgtcg	acaggcacgg	2040
ctgcattgtc	aagatcgtgc	gctccagcag	ctccacgggc	cagaagaact	tctcggcgcc	2100
cccgcccgcg	ccccctgtcc	agtgtccgcc	ctccacctcc	tggcagccac	agagccaccc	2160

SSCP Update Sequences.ST25

gcgccagggc	cacggcacct	cccccgtagg	ggaccacggc	tccctgggtg	gcaccccgcc	2220
gccgcctgcc	cacgagcggg	cgctgtccgc	ctacggcggg	ggcaaccgcg	ccagcatgga	2280
gttcctgcgg	caggaggaca	ccccgggctg	caggcccccc	gaggggaccc	tgcgggacag	2340
cgacacgtcc	atctccatcc	cgctccgtga	ccacgaggag	ctggagcggt	ccttcagcgg	2400
ccttcagcatc	tcccagtgca	aggagaacct	ggatgtctct	aacagctgct	acgcggccgt	2460
ggcgccctgt	gccaaagtca	ggccctacat	tgcggagggg	gagtcagaca	ccgactccga	2520
cctctgtacc	ccgtgcgggc	ccccgccacg	ctcggccacc	ggcgaggggt	cctttgggtg	2580
cgtagggctg	gccggggcca	ggaagtggag	cgccgctggg	ccagtggacc	cgcccgcggc	2640
cctcctcagc	acggtgcctc	cgaggttttg	aggcgggaac	cctctggggc	ccttttctta	2700
cagtaactga	gtgtggcggg	aagggtgggc	cctggagggg	cccatgtggg	ctgaaggatg	2760
ggggctcctg	gcagtgcctt	tttacaaga	ttattttcca	acagggcact	cccaggccct	2820
gtcgccattg	agggtgcctc	gctgggctgt	ctcctcacc	ctccctgtgc	tggagcctgt	2880
ccaaaaagg	tgccaactgg	gaggcctcgg	aagccactgt	ccaggctccc	actgcctgtc	2940
tgctctgttc	ccaaaggcag	cggtgtgtgg	ctcgggccct	gcggtggcat	gaagcatccc	3000
ttctgggtgt	ggcatcgcta	cggtttttgg	gggcagcggt	tcacggcggg	gcccttgctg	3060
tctcccttgg	gctggctcga	gcctgggggc	catgtccctt	tgccgtcccg	tcattggggc	3120
gggaatccat	agcggggccc	acaggcaggg	gtatgagtg	gtcccacca	acgcagcacc	3180
agccccggcc	accgctcccc	gtgtccccag	ttccgtctca	gctacctgga	ctccaggacc	3240
ctggagaagg	gagacctggc	agtggaggga	ggctgtgctg	tgtgtcccc	tgcagggtgt	3300
accccgccct	ctctttcctc	ccccgccagg	tgtggccccg	cctgctcttt	cctccccac	3360
cagtatggcc	ccacctgtc	tttctcccc	ccccagggtg	tggccccacc	tgttctttcc	3420
tcccttgccg	agggtgtgac	ccacctgtc	tttctccct	cccagtatgg	ccccacctgc	3480
tctttcctcc	cccgagggtg	ggccccgcct	gctctttcct	cccatgggag	ccgctgaggc	3540
gtgcgcacct	gggcacagg	tggggctctg	caggatgagg	aagacaggcc	aatcccttcc	3600
ctcccagaag	ctggccgccc	agcaggagg	actgaggcca	gactcatgtc	cagcaaggaa	3660
cggtgtgtgt	gtccccctgg	aagtctctgg	gccctgggaa	gaggggaagg	gcacgtcctg	3720
ggatgggttg	ggggccctgt	tttgggagac	aaaggggtag	agggctctgt	ttggggcccc	3780
ccagactcta	gcccagagcag	tgcagccacc	tactgcccc	cctcagagaa	gtgcagcggg	3840
aaggaggctg	gagggtgggt	ggcgctgcct	cggtgtgtct	cgatgaatg	cgtaggccaag	3900
gaccagtggc	acctcatggc	aaagagctcc	cgcagtgttt	gttagagtgc	acatcctacg	3960
tgccacttgg	cacacacacg	tgctcacata	catgtccgcg	tacaggcgta	cacatgcacg	4020
cctgcacaca	tgacacacag	ccacatagca	cacatgtgca	ctgaccacac	ctgtatagac	4080
catgcacagt	acacatacgt	gcatacacat	gcctgcatac	aggcatacac	atgcacgctt	4140
acatgtacac	gtgcacagat	cacacacatg	cacacacgtg	tagctcacac	acagtataca	4200

SSCP Update Sequences.ST25

catacacaag	tgcacagacc	acacacagca	ctaacacatg	cacacacaaa	gtgcataggc	4260
cacacagcac	atgcacacag	gtgcacagac	cacacagcac	acacaagtgc	acagagcaca	4320
ctgcacacat	gcacacacac	acgcgtgcat	gcacactcct	cgacttcca	gccttggagc	4380
ccttctgtct	ctggtctttc	tctttgacct	tgctgagtgt	aagctgcctg	gggaggggct	4440
acaaggagta	attgtggctt	taggggtcgt	ggtgatgctg	gaatgtcaag	cgccgtcgtg	4500
gggtatccga	ctgtccgggc	tcctgggtccg	cagtggcaga	gcgccaggca	gagccaatca	4560
gggtctcgtg	ctgcccttcc	ccccacagc	ctggcagcca	tccagaggag	gggctctacc	4620
agatgccaa	gtgccccggt	gtctgtatgg	gtgtccgggt	gggtcctgtg	tttgggtctgc	4680
cctggagggtg	gctggggcct	cctgggatgg	gtggctcagc	ctcgaatccc	aggccccagc	4740
ccaggcagggt	gctgctgcct	gttgtggttt	cctggcccag	cttctccttc	tccctctgca	4800
taaaatcaca	gtccgtgagt	cttccagctg	ccaccacggc	tgggacacgc	tgggggaggg	4860
ctcctcccat	gcctcctgca	cacagccgtc	tgagcagggc	aggtgccaac	acccccacc	4920
ggagacacgc	tgccccctcag	cgatgccccct	accttttggg	gggcctcgtc	tcaagcccc	4980
ccttggaggc	tgaaatcacc	ccaggcactg	tgagggttcc	tccaggggga	caccctttga	5040
gctgtgggtc	tgatcacc	aagtcccgca	cacggaggag	aggcacagcc	agggcgtgtg	5100
gtttaatgtt	tgcccccttcg	gggctggagg	tctcagtgtt	tctagattcc	agaccctgct	5160
gccagagaga	cctgctgccg	gagagaaggg	gaggaggact	ccagctgggc	tcggtcccc	5220
acagtcaggg	acccccataa	aggacacccc	cttctctcta	gaaagagctg	ggctctcagc	5280
tatttctagt	tgcttcccag	aagccgagga	gcagaaggag	ctgtgagagc	tttgagaaa	5340
cgcccttgct	cccgccctcc	tgagctatga	atgccgtaca	gagcagaggc	tggggcattg	5400
gcaagatcac	aggttgatgc	tgcacagccc	cattgacaca	aaccctcaaa	gcagacgtga	5460
gagggacgggt	tcacaaagct	tggacctgcc	gtggaggggtg	ccgggcagac	gtggcgtgag	5520
agggacggct	cacgaggctt	ggacctgctg	tggaggggtgc	ccagcagacg	tgggtgtgaga	5580
ggaacggctc	acgagacttg	gacctgggtg	aggggtgcca	gcagacgtgg	tgtgagaggg	5640
acggctcaca	gggcttggac	cggagagaga	tggctcatga	gacttggacc	tgccgtggag	5700
ggtgcccagc	agacgtggta	tgagagggat	ggctcacgag	gcttggacct	ggtggaggggt	5760
gcccggcaga	cgtgtgagag	ggacggttca	caaggcttgg	acctgccatg	gaggggtgcc	5820
agcagacgtg	gtgtgagagg	gacagctcac	gaggcttggga	cctgccgtgg	aggggtgcca	5880
gcagggggct	gagctctgag	gggtgggtgc	tcagtgcacg	ggtgccccca	gtgtcctctg	5940
atcctgtccg	gtgcctcccc	caacccccac	acccatgcag	aactcccagg	tcacatgcac	6000
gtatgtccag	ggcatggggg	tggcgtgaag	aggcctgggtc	agggccttta	ggggctgcag	6060
gacggaatgg	ccacctgggg	agcctgtgtg	gctgtgccgg	gcagccatcc	tgcattccca	6120
cccagcgcgc	agtctccacc	tcggccccag	caaagcgcta	agcagccgga	gagacagcca	6180
gggcggcttc	ctgaaggatg	tgggatgggtg	gactccgggg	tcgagggaat	acgcagggttc	6240

SSCP Update Sequences.ST25

ctgtcctccg	ggagacctag	agaagctgca	cacccaggag	ctttccatga	cccgggagca	6300
tgagtgaatg	gggggttcca	gtttgctgaa	ctttgctgtc	ttgtaagggt	gggggctgac	6360
ggccgaccct	gggaggaggt	gacaccgcag	ggggagggtt	tgggcaacgg	tggaggagga	6420
gagacgggag	gggaccattt	gggatggagg	ggcctcttca	gagttttaaa	aggcgtttgt	6480
gggggtggagt	tgagtgtgct	ctgggcttgg	acacttgccg	tggtgcccct	ggctggccga	6540
ggagactggc	tctggccagg	gccccgtcct	gagaggctct	cagcgtctga	ctctcgccca	6600
ggcgccagca	aggaggggcc	ggtccccggg	gctaccaggc	aggcacgtgc	acatcgccat	6660
cgccacacgc	caactccgcc	tgggtttttac	aaagtcgttg	ccttaatgca	tgtggacagg	6720
aactccctga	ggtcgcccca	tgccccctgg	ctgtgccagg	tacggacgcc	ctggaccctg	6780
cgaacaggtg	gggcgggcga	ggggcccaag	ggacgggctc	cagagacacg	cgcagggcag	6840
gaggggtctc	acggaggggt	ctcgcaactga	ggcgcccaga	gctggtggtc	ccgctggacg	6900
ccatccctct	gccccgggatc	cacacggccc	acgtgtgccc	gccatgcccg	cgccccacgc	6960
cattgcagtc	ttccatcctc	tggccgtgac	ggtggctgca	gcttccccat	ttgcgcggtt	7020
gcctctggct	gtctgcactt	ttgttcatgc	tccaaagaac	atttcataat	gccttcagta	7080
ccgacgtaca	cttctgacca	ttttgtatgt	gtccttgtgc	cgtagtgacc	aggccttttt	7140
ttgggtggatg	tgttaccctg	cacacttcaa	tctcaacttt	gtgcaccgtc	catttttctag	7200
ggatagacgc	ccagggaatg	aactctagtt	ttctaacaga	ttagctgaga	tattaactta	7260
ctcacacgga	caggttgatg	ccagagccgt	aagaatgcgc	cagtgcgggt	ttgcggggga	7320
cttcgggtgt	ggggtcctgc	ggccgcgatg	gccgtggaag	gttctgggga	tccctgctgc	7380
cacggggacg	agttcggacg	ccagggtggac	ctgtgcactc	agtaaaacgc	agtgattc	7438

<210> 42
 <211> 7437
 <212> DNA
 <213> Homo sapiens

<400> 42						
gctgagcctg	agccccgaccc	ggggcgccctc	ccgccaggca	ccgtgggtgca	gaagtcgcgc	60
aacggcgggc	tatacccccg	cccagagcggg	gagaagaagc	tgaagggtggg	cttcgtgggg	120
ctggaccccc	gcgcgccccga	ctccaccccg	gacggggcgc	tgctgatcgc	cggctccgag	180
gcccccaagc	gcggcagcat	cctcagcaaa	cctcgcgcgg	gcggcgcggg	cgccgggaag	240
ccccccaagc	gcaacgcctt	ctaccgcaag	ctgcagaatt	tcctctacaa	cgtgctggag	300
cggccgcgcg	gctgggcggt	catctaccac	gcctacgtgt	tcctcctggg	tttctcctgc	360
ctcgtgctgt	ctgtgttttc	caccatcaag	gagtatgaga	agagctcgga	gggggccttc	420
tacatcctgg	aaatcgtgac	tatcgtgggt	tttggcggtg	agtacttcgt	gcggatctgg	480
gccgcaggct	gctgctgccg	gtaccgtggc	tggagggggc	ggctcaagtt	tgcccgga	540
ccgttctgtg	tgattgacat	catggtgctc	atcgcctcca	ttgcggtgct	ggccgcccgc	600
tcccagggca	acgtctttgc	cacatctgcg	ctccggagcc	tcgccttcct	gcagattctg	660

SSCP Update Sequences.ST25

cggatgatcc	gcatggaccg	gcggggaggg	acctggaagc	tgctgggctc	tgtggtctat	720
gcccacagca	aggagctggg	cactgcctgg	tacatcggct	tcctttgtct	catcctggcc	780
tcgttcctgg	tgtacttggc	agagaagggg	gagaacgacc	actttgacac	ctacgcggat	840
gcactctggg	ggggcctgat	cacgctgacc	accattggct	acggggacaa	gtacccccag	900
acctggaacg	gcaggctcct	tgcggcaacc	ttcacctca	tcggtgtctc	cttcttcgcg	960
ctgcctgcag	gcatcttggg	gtctggggtt	gccctgaagg	ttcaggagca	gcacaggcag	1020
aagcactttg	agaagaggcg	gaacccggca	gcaggcctga	tccagtcggc	ctggagattc	1080
tacgccacca	acctctcgcg	cacagacctg	cactccacgt	ggcagtacta	cgagcgaacg	1140
gtcaccgtgc	ccatgtacag	ttcgcaaaact	caaacctacg	gggcctccag	acttatcccc	1200
ccgctgaacc	agctggagct	gctgaggaac	ctcaagagta	aatctggact	cgctttcagg	1260
aaggaccccc	cgccggagcc	gtctccaagc	cagaagggtca	gtttgaaaga	tcgtgtcttc	1320
tccagcccc	gaggcgtggc	tgccaagggg	aaggggtccc	cgcaggccca	gactgtgagg	1380
cggtcacca	gcgccgacca	gagcctcgag	gacagcccca	gcaagggtgc	caagagctgg	1440
agcttcgggg	accgcagccg	ggcacgccag	gctttccgca	tcaagggtgc	cgcgtcacgg	1500
cagaactcag	aagaagcaag	cctccccgga	gaggacattg	tggatgacaa	gagctgcccc	1560
tgcgagtttg	tgaccgagga	cctgaccccg	ggcctcaaag	tcagcatcag	agccgtgtgt	1620
gtcatgcggt	tcctggtgtc	caagcggaag	ttcaaggaga	gcctgcggcc	ctacgacgtg	1680
atggacgtca	tcgagcagta	ctcagccggc	cacctggaca	tgctgtcccg	aattaagagc	1740
ctgcagtcca	gagtggacca	gatcgtgggg	cggggcccag	cgatcacgga	caaggaccgc	1800
accaagggcc	cggccgaggg	ggagctgccc	gaggacccca	gcatgatggg	acggctcggg	1860
aagggtggaga	agcagggtctt	gtccatggag	aagaagctgg	acttcctggg	gaatatctac	1920
atgcagcgga	tgggcatccc	cccgcagag	accgaggcct	actttggggc	caaagagccg	1980
gagccggcgc	cgccgtacca	cagcccgga	gacagccggg	agcatgtcga	caggcacggc	2040
tgcattgtca	agatcgtgcg	ctccagcagc	tccacggggc	agaagaactt	ctcggcgccc	2100
ccggccgcgc	cccctgtcca	gtgtccgccc	tccacctcct	ggcagccaca	gagccacccg	2160
cgccagggcc	acggcacctc	ccccgtgggg	gaccacggct	ccctgggtgcg	catcccgcgcg	2220
ccgcctgccc	acgagcggtc	gctgtccgcc	tacggcgggg	gcaaccgcgc	cagcatggag	2280
ttcctgcggc	aggaggacac	cccgggctgc	aggccccccg	aggggaccct	gcgggacagc	2340
gacacgtcca	tctccatccc	gtccgtggac	cacgaggagc	tggagcggtc	cttcagcggc	2400
ttcagcatct	cccagtccaa	ggagaacctg	gatgtctctca	acagctgcta	cgcgggcctg	2460
gcgccttgtg	ccaaagtcag	gccctacatt	gcggagggag	agtcagacac	cgactccgac	2520
ctctgtaccc	cgtgcggggc	cccgccacgc	tcggccaccg	gcgaggggtcc	ctttgggtgac	2580
gtgggctggg	ccgggcccag	gaagtgaggc	ggcgctgggc	cagtggaccc	gcccgcggcc	2640
ctcctcagca	cgggtgcctcc	gagggttttga	ggcggaacc	ctctggggcc	cttttcttac	2700

SSCP Update Sequences.ST25

agtaactgag	tgtggcgggga	aggggtggggcc	ctggagggggc	ccatgtggggc	tgaaggatgg	2760
gggctcctgg	cagtgcacctt	ttacaaaagt	tatttttccaa	cagggcactc	ccaggccctg	2820
tcgccattga	ggtgcctccg	ctgggctgtc	tcctcacccc	tccctgtgct	ggagcctgtc	2880
ccaaaaaggt	gccaaactggg	aggcctcgga	agccactgtc	caggctccca	ctgcctgtct	2940
gctctgttcc	caaaggcagc	gtgtgtggcc	tcggggccctg	cgggtggcatg	aagcatccct	3000
tctggtgtgg	gcatcgctac	gtgttttggg	ggcagcgttt	cacggcggtg	cccttgctgt	3060
ctcccttggg	ctggctcgag	cctgggggtcc	atgtcccttt	gccgtcccgt	catggggcag	3120
ggaatccata	gcggggccca	caggcagggg	tatgagtgcg	tcccacccaa	cgcagcacca	3180
gccccggcca	ccgctccccg	tgtccccagt	tccgtctcag	ctacctggac	tccaggaccc	3240
tggagaaggg	agacctggca	gtggagggag	gctgtgctgt	gtgtccccct	gcagggtgtga	3300
ccccgcctgc	tctttcctcc	cccgccaggt	gtggccccgc	ctgctctttc	ctccccacc	3360
agtatggccc	cacctgctct	ttcctcccc	cccaagggtg	ggccccacct	gttctttcct	3420
cccctgccga	ggtgtgacct	cacctgctct	ttcctccctc	ccagtatggc	cccacctgct	3480
ctttcctccc	ccgaggtag	gccccgcctg	ctctttcctc	ccatgggagc	cgctgaggcg	3540
tgcgcacctg	ggcacagggt	ggggctctgc	aggatgagga	agacaggcca	atcccttccc	3600
tcccagaagc	tggccgcccc	gcaggagggga	ctgaggccag	actcatgtcc	agcaagggaac	3660
gtgtggtgtg	tcccctggga	agtctctggg	ccctgggaag	aggggaagggtg	cacgtcctgg	3720
gatggttgcg	gggcccgtgt	ttgggagaca	aaggggtaga	gggtctgtct	tgggcccccc	3780
cagactctag	cccagcagct	gcagccacct	actgccccac	ctcagagaag	tgcagcggga	3840
aggaggctgg	aggtggtgcg	gcgctgcctc	gggtgtctgc	gtgaatgagc	gtggccaagg	3900
accagtgcc	cctcatggca	aagagctccc	gcagtgtttg	ttagagtgca	catcctacgt	3960
gcccactggc	acacacacgt	gctcacatac	atgtccgcgt	acaggcgtag	acatgcacgc	4020
ttgcacacat	gcacacagac	cacatagcac	acatgtgcac	tgaccacacc	tgtatagacc	4080
atgcacagta	cacatacgtg	catacacatg	cctgcataca	ggcatacaca	tgcacgctta	4140
catgtacacg	tgcacagatc	acacacatgc	acacacgtgt	agctcacaca	cagtatacac	4200
atacacaagt	gcacagacca	cacacagcac	taacacatgc	acacacaaag	tgcataggcc	4260
acacagcaca	tgcacacagg	tgcacagacc	acacagcaca	cacaagtgca	cagagcacac	4320
tgcacacatg	cacacacaca	cgcgtgcatg	cacactcctc	gcacttccag	ccttgagacc	4380
cttctgtctc	tggcttttct	ctttgaccct	gctgagtgtg	agctgcctgg	ggaggggcta	4440
caaggagtaa	ttgtggcttt	aggggtcgtg	gtgatgctgg	aatgtcaagc	gccgtcgtgg	4500
ggtatccgac	tgtccgggct	cctgggtccgc	agtggcagag	cgccaggcag	agccaatcag	4560
ggtctcgtgc	tgcccttccc	ccccacagcc	tggcagccat	ccagaggagg	ggctctacca	4620
gatgccaagg	tgccccgggtg	tctgtatggg	tgtccggttg	ggcctgtgtg	ttggtctgcc	4680
ctggaggtgg	ctggggccctc	ctgggatggg	tggctcagcc	tcgaatccca	ggccccagcc	4740

SSCP Update Sequences.ST25

caggcaggtg	ctgctgcctg	ttgtggtttc	ctggcccagc	ttctccttct	ccctctgcat	4800
aaaatcacag	tccgtgagtc	ttccagctgc	caccacggct	gggacacgct	gggggagggc	4860
tcctcccatg	cctcctgcac	acagccgtct	gagcagggca	ggtgccaaca	ccccccaccg	4920
gagacacgct	gccccctcagc	gatgccccta	ccttttgggg	ggcctcgtct	caagcccccc	4980
cttggaggct	gaaatcaccc	caggcactgt	gagggcttct	ccagggggac	accctttgag	5040
ctgtgggtct	gatcacccca	agtcccgac	acggaggaga	ggcacagcca	gggcgtgtgg	5100
tttaatgttt	gcccccttcg	ggctggaggt	ctcagtgttt	ctagattcca	gacctgtctg	5160
ccagagagac	ctgctgccgg	agagaagggg	aggaggactc	cagctgggct	cggccccca	5220
cagtcaggga	cccccataaa	ggacaccccc	ttctctctag	aaagagctgg	gctctcagct	5280
atttctagtt	gcttcccaga	agccgaggag	cagaaggagc	tgtgagagct	ttgcagaaac	5340
gcccttgtcc	ccgccctcct	gagctatgaa	tgccgtacag	agcagaggct	ggggcatttg	5400
caagatcaca	ggttgatgct	gcacagcccc	attgacacaa	accctcaaag	cagacgtgag	5460
agggacggtt	cacaaagctt	ggacctgccg	tggaggggtc	ccggcagacg	tggcgtgaga	5520
gggacggctc	acgaggcttg	gacctgctgt	ggaggggtgc	cagcagacgt	ggtgtgagag	5580
gaacggctca	cgagacttgg	acctggtgga	gggtgcccag	cagacgtggt	gtgagaggga	5640
cggctcacag	ggcttggacc	ggagagagat	ggctcatgag	acttggacct	gccgtggagg	5700
gtgcccagca	gacgtggtat	gagaggggat	gctcacgagg	cttggacctg	gtggaggggtg	5760
cccggcagac	gtgtgagagg	gacggttcac	aaggcttgga	cctgccatgg	aggggtgcca	5820
gcagacgtgg	tgtgagaggg	acagctcacg	aggcttgga	ctgccgtgga	gggtgcccag	5880
cagggggctg	agctctgagg	ggtgggtgct	cagtgcacgg	gtgccccccag	tgtcctctga	5940
tcctgtccgg	tgcctcccc	aacccccaca	cccatgcaga	actcccagg	cacatgcacg	6000
tatgtccagg	gcatgggggt	ggcgtgaaga	ggcctggtca	gggccttttag	gggctgcagg	6060
acggaatggc	cacctgggga	gcctgtgtgg	ctgtgccggg	cagccatcct	gcattcccac	6120
ccagcgcgca	gtctccacct	cggccccagc	aaagcgctaa	gcagccggag	agacagccag	6180
ggcggcttcc	tgaaggatgt	gggatggtgg	actccgggggt	cgagggaata	cgcaggttcc	6240
tgtcctccgg	gagacctaga	gaagctgcac	accaggagc	tttccatgac	ccgggagcat	6300
gagtgaatgg	ggggttccag	tttgctgaac	tttgctgtct	tgttaagggtg	ggggctgacg	6360
gccgacctg	ggaggagggtg	acaccgcagg	gggagggtgt	gggcaacgggt	ggaggaggag	6420
agacgggagg	ggaccatttg	ggatggagg	gcctcttcag	agttttaaaa	ggcgtttgtg	6480
gggtggagtt	gagtgtgtct	tgggcttgga	cacttgccgt	ggtgcccctg	gctggccgag	6540
gagactggct	ctggccagg	ccccgtcctg	agaggtcctc	agcgtctgac	tctcgccag	6600
gcgccagcaa	ggagggggcg	gtccccgggg	ctaccaggca	ggcacgtgca	catcgccatc	6660
gccacacgcc	aactccgcct	gggtttttaca	aagtcgttgc	cttaatgcat	gtggacagga	6720
actccctgag	gtcgcccat	gccccctggc	tgtgccaggt	acggacgccc	tggacctg	6780

SSCP Update Sequences.ST25

gaacaggtgg	ggcgggag	gggcccagg	gacgggctcc	agagacacgc	gcagggcagg	6840
aggggtctca	cggaggggtc	tcgcactgag	gcgcccagag	ctggtggtcc	cgctggacgc	6900
catccctctg	cccgggatcc	acacggccca	cgtgtgcccc	ccatgcccgc	gccccacgcc	6960
attgcagtct	tccatcctct	ggccgtgacg	gtggctgcag	cttccccatt	tgcgccgttg	7020
cctctggctg	tctgcacttt	tgttcatgct	caaagaaca	tttcataatg	ccttcagtac	7080
cgacgtacac	ttctgaccat	tttgtatgtg	tccttgtgcc	gtagtgacca	ggcctttttt	7140
tggtggatgt	gttaccgccg	acacttcaat	ctcaactttg	tgcaccgtcc	atcttctagg	7200
gatagacgcc	cagggaatga	actctagttt	tctaacagat	tagctgagat	attaacttac	7260
tcacacggac	aggttgatgc	cagagccgta	agaatgcgcc	agtgcggggt	tgcgggggac	7320
ttcgggtgtg	gggtcctgcg	gccgcgatgg	ccgtggaagg	ttctggggat	ccctgctgcc	7380
acggggacga	gttcggacgc	caggtggacc	tgtgcactca	gtaaaacgca	gtgatttc	7437

<210> 43
 <211> 7437
 <212> DNA
 <213> Homo sapiens

<400> 43	
gctgagcctg	agccccgaccc ggggcgccctc ccgcccaggca ccacgggtgca gaagtcgcgc 60
aacggcgggc	tatacccccg cccgagcggg gagaagaagc tgaagggtggg cttcgtgggg 120
ctggaccccc	gcgcgcccga ctccaccccg gacggggcg cgcgtgatcgc cggctccgag 180
gcccccaagc	gcggcgagcat cctcagcaaa cctcgcgcgg gcggcgcggg cgccgggaag 240
ccccccaagc	gcaacgcctt ctaccgcaag ctgcagaatt tcctctacaa cgtgctggag 300
cgccgcgcgc	gctgggcggt catctaccac gcctacgtgt tcctcctggg tttctcctgc 360
ctcgtgctgt	ctgtgttttc caccatcaag gagtatgaga agagctcgga gggggccctc 420
tacatcctgg	aaatcgtgac tatcgtgggtg tttggcgtgg agtacttcgt gcggatctgg 480
gccgcaggct	gctgctgccg gtaccgtggc tggagggggc ggctcaagtt tgcccggaaa 540
ccgttctgtg	tgattgacat catggtgctc atcgccctcca ttgcggtgct ggccgccggc 600
tcccagggca	acgtctttgc cacatctgcg ctccggagcc tgcgcttcct gcagattctg 660
cggatgatcc	gcatggaccg gcggggaggc acctggaagc tgctgggctc tgtggtctat 720
gcccacagca	aggagctggg cactgcctgg tacatcggtc tcctttgtct catcctggcc 780
tcgttcctgg	tgtacttggc agagaagggg gagaacgacc actttgacac ctacgcggat 840
gcactctggg	ggggcctgat cacgctgacc accattggct acggggacaa gtacccccag 900
acctggaacg	gcaggctcct tgcggcaacc ttcaccctca tcgggtgtctc cttcttcgcg 960
ctgcctgcag	gcatcttggg gtctggggtt gccctgaagg ttcaggagca gcacaggcag 1020
aagcactttg	agaagaggcg gaacccggca gcaggcctga tccagtcggc ctggagattc 1080
tacgccacca	acctctcgcg cacagacctg cactccacgt ggcagtacta cgagcgaacg 1140

SSCP Update Sequences.ST25

gtcaccgtgc	ccatgtacag	ttcgaaact	caaacctacg	gggcctccag	acttatcccc	1200
ccgctgaacc	agctggagct	gctgaggaac	ctcaagagta	aatctggact	cgctttcagg	1260
aaggaccccc	cgccggagcc	gtctccaagc	cagaagggtca	gtttgaaaga	tcgtgtcttc	1320
tccagcccc	gaggcgtggc	tgccaagggg	aaggggtccc	cgcaggccca	gactgtgagg	1380
cggtcaccca	gcgccgacca	gagcctcgag	gacagcccca	gcaagggtgcc	caagagctgg	1440
agcttcgggg	accgcagccg	ggcacgccag	gctttccgca	tcaagggtgc	cgcgtcacgg	1500
cagaactcag	aagaagcaag	cctccccgga	gaggacattg	tggatgacaa	gagctgcccc	1560
tgcgagtttg	tgaccgagga	cctgacccc	ggcctcaaag	tcagcatcag	agccgtgtgt	1620
gtcatgcggt	tcctggtgtc	caagcggaag	ttcaaggaga	gcctgcggcc	ctacgacgtg	1680
atggacgtca	tcgagcagta	ctcagccggc	cacctggaca	tgctgtccc	aattaagagc	1740
ctgcagtcca	gagtggacca	gatcgtgggg	cggggcccag	cgatcacgga	caaggaccgc	1800
accaagggcc	cggccgaggc	ggagctgccc	gaggacccca	gcatgatggg	acggctcggg	1860
aagggtggaga	agcaggtctt	gtccatggag	aagaagctgg	acttcctggt	gaatatctac	1920
atgcagcgga	tgggcatccc	cccgcagag	accgaggcct	actttggggc	caaagagccg	1980
gagccggcgc	cgccgtacca	cagcccggaa	gacagccggg	agcatgtcga	caggcacggc	2040
tgcatgttca	agatcgtgcg	ctccagcagc	tccacgggcc	agaagaactt	ctcggcgccc	2100
ccggccgcgc	cccctgtcca	gtgtccgccc	tccacctcct	ggcagccaca	gagccacccg	2160
cgccagggcc	acggcacctc	ccccgtgggg	gaccacggct	ccctggtgcg	catcccgcgc	2220
ccgcctgccc	acgagcggtc	gctgtccgcc	tacggcgggg	gcaaccgcgc	cagcatggag	2280
ttcctgcggc	aggaggacac	cccgggctgc	aggccccccg	aggggaccct	gcgggacagc	2340
gacacgtcca	tctccatccc	gtccgtggac	cacgaggagc	tggagcgttc	cttcagcggc	2400
ttcagcatct	cccagtccaa	ggagaacctg	gatgtcttca	acagctgcta	cgcgcccggtg	2460
gcgccttggtg	ccaaagtccag	gccctacatt	gcggagggag	agtcagacac	cgactccgac	2520
ctctgtaccc	cgtgcggggc	cccgccacgc	tcggccaccg	gcgaggggtcc	ctttggtgac	2580
gtgggctggg	ccgggcccag	gaagtgaggc	ggcgctgggc	cagtggaccc	gcccgcggcc	2640
ctcctcagca	cgggtgcctcc	gaggttttga	ggcggaacc	ctctggggcc	cttttcttac	2700
agtaactgag	tgtggcgggg	agggtggggc	ctggaggggc	ccatgtgggc	tgaaggatgg	2760
gggctcctgg	cagtgcctt	ttacaaaagt	tatttttccaa	cagggcactc	ccaggccctg	2820
tcgccattga	ggtgcctccg	ctgggctgtc	tcctcacc	tccctgtgct	ggagcctgtc	2880
ccaaaaaggt	gccaactggg	aggcctcgga	agccactgtc	caggctccca	ctgcctgtct	2940
gctctgttcc	caaaggcagc	gtgtgtggcc	tcgggccctg	cgggtggcatg	aagcatccct	3000
tctggtgtgg	gcatcgctac	gtgttttggg	ggcagcgttt	cacggcggtg	cccttgctgt	3060
ctcccttggg	ctggctcgag	cctgggggtcc	atgtcccttt	gccgtcccgt	catggggcag	3120
ggaatccata	gcggggccca	caggcagggg	tatgagtgcg	tcccacccaa	cgcagcacca	3180

SSCP Update Sequences.ST25

gccccggcca	ccgctccccg	tgtccccagt	tccgtctcag	ctacctggac	tccaggaccc	3240
tggagaaggg	agacctggca	gtggagggag	gctgtgctgt	gtgtccccct	gcaggtgtga	3300
ccccgcctgc	tctttcctcc	cccgccaggt	gtggccccgc	ctgctctttc	ctccccacc	3360
agtatggccc	cacctgctct	ttcctcccc	cccaaggtgt	ggccccacct	gttctttcct	3420
cccctgccga	ggtgtgaccc	cacctgctct	ttcctccctc	ccagtatggc	cccacctgct	3480
ctttcctccc	ccgaggtgag	gccccgcctg	ctctttcctc	ccatgggagc	cgctgaggcg	3540
tgcgcacctg	ggcacagggt	ggggctctgc	aggatgagga	agacaggcca	atcccttccc	3600
tcccagaagc	tggccgcccc	gcaggagggg	ctgaggccag	actcatgtcc	agcaaggaac	3660
gtgtggtgtg	tcccctggga	agtctctggg	ccctgggaag	aggggaaggtg	cacgtcctgg	3720
gatggttgcg	gggccctggt	ttgggagaca	aaggggtaga	gggtctgtct	tggggccccc	3780
cagactctag	cccgagcagt	gcagccacct	actgccccac	ctcagagaag	tgcagcgggg	3840
aggaggctgg	agggtggtgcg	gcgctgcctc	gggtgtctgc	gtgaatgagc	gtggccaagg	3900
accagtgcc	cctcatggca	aagagctccc	gcagtgtttg	ttagagtgc	catcctacgt	3960
gcccactggc	acacacacgt	gctcacatac	atgtccgcgt	acaggcgtac	acatgcacgc	4020
ttgcacacat	gcacacagac	cacatagcac	acatgtgcac	tgaccacacc	tgtatagacc	4080
atgcacagta	cacatacgtg	catacacatg	cctgcataca	ggcatacaca	tgcacgctta	4140
catgtacacg	tgcacagatc	acacacatgc	acacacgtgt	agctcacaca	cagtatacac	4200
atacacaagt	gcacagacca	cacacagcac	taacacatgc	acacacaaag	tgcataggcc	4260
acacagcaca	tgcacacagg	tgcacagacc	acacagcaca	cacaagtgc	cagagcacac	4320
tgcacacatg	cacacacaca	cgcgatgc	cacactcctc	gcacttccag	ccttgagacc	4380
cttctgtctc	tgggtctttct	ctttgaccct	gctgagtgtg	agctgcctgg	ggaggggcta	4440
caaggagtaa	ttgtggcctt	aggggtcgtg	gtgatgctgg	aatgtcaagc	gccgtcgtgg	4500
ggtatccgac	tgtccgggct	cctgggtccgc	agtggcagag	cgccaggcag	agccaatcag	4560
ggtctcgtgc	tgcccttccc	ccccacagcc	tggcagccat	ccagaggagg	ggctctacca	4620
gatgccaagg	tgccccggtg	tctgtatggg	tgtccggttg	ggtcctgtgt	ttggtctgcc	4680
ctggaggtgg	ctgggcccctc	ctgggatggg	tggctcagcc	tcgaatccca	ggccccagcc	4740
caggcaggtg	ctgctgcctg	ttgtggtttc	ctggcccagc	ttctccttct	ccctctgcat	4800
aaaatcacag	tccgtgagtc	ttccagctgc	caccacggct	gggacacgct	gggggagggc	4860
tcctcccatg	cctcctgcac	acagccgtct	gagcagggca	ggtgccaaca	ccccccaccg	4920
gagacacgct	gccccctcagc	gatgccccta	cctttttggg	ggcctcgtct	caagcccccc	4980
cttgagggtc	gaaatcaccc	caggcactgt	gagggcttct	ccagggggac	accctttgag	5040
ctgtgggtct	gatcacccca	agtcccgcac	acggaggaga	ggcacagcca	gggcgtgtgg	5100
tttaatgttt	gcccccttcg	ggctggaggt	ctcagtgttt	ctagattcca	gaccctgctg	5160
ccagagagac	ctgctgccgg	agagaagggg	aggaggactc	cagctgggct	cggtcccca	5220

SSCP Update Sequences.ST25

cagtcagggga	cccccataaa	ggacaccccc	ttctctctag	aaagagctgg	gctctcagct	5280
atttctagtt	gcttcccaga	agccgaggag	cagaaggagc	tgtgagagct	ttgcagaaac	5340
gcccttggtcc	cgcacctcct	gagctatgaa	tgccgtacag	agcagaggct	ggggcattgg	5400
caagatcaca	ggttgatgct	gcacagcccc	attgacacaa	accctcaaag	cagacgtgag	5460
agggacgggtt	cacaaagctt	ggacctgccc	tggagggtgc	ccggcagacg	tggcgtgaga	5520
gggacggctc	acgaggcttg	gacctgctgt	ggagggtgcc	cagcagacgt	ggtgtgagag	5580
gaacggctca	cgagacttgg	acctggtgga	gggtgcccag	cagacgtggt	gtgagagggga	5640
cggctcacag	ggcttggaac	ggagagagat	ggctcatgag	acttggaact	gccgtggagg	5700
gtgcccagca	gacgtggtat	gagagggatg	gctcacgagg	cttggaactg	gtggaggggtg	5760
cccgccagac	gtgtgagagg	gacggttcac	aaggcttgga	cctgccatgg	aggggtgccc	5820
gcagacgtgg	tgtgagaggg	acagctcacg	aggcttgga	ctgccgtgga	gggtgcccag	5880
cagggggctg	agctctgagg	ggtgggtgct	cagtgcacgg	gtgccccag	tgtcctctga	5940
tcctgtccgg	tgcctcccc	aacccccaca	cccatgcaga	actcccaggt	cacatgcacg	6000
tatgtccagg	gcatgggggt	ggcgtgaaga	ggcctggtca	gggcctttag	gggctgcagg	6060
acggaatggc	cacctgggga	gcctgtgtgg	ctgtgccggg	cagccatcct	gcattcccac	6120
ccagcgcgca	gtctccacct	cggccccagc	aaagcgctaa	gcagccggag	agacagccag	6180
ggcggcttcc	tgaaggatgt	gggatgggtg	actccggggg	cgagggaata	cgcaggttcc	6240
tgtcctccgg	gagacctaga	gaagctgcac	acccaggagc	tttccatgac	ccgggagcat	6300
gagtgaatgg	ggggttccag	tttgctgaac	tttgctgtct	tgtaagggtg	ggggctgacg	6360
gccgaccctg	ggaggagggt	acaccgcagg	gggaggttgt	gggcaacggg	ggaggaggag	6420
agacgggagg	ggaccatttg	ggatggaggg	gcctcttcag	agttttaaaa	ggcgtttgtg	6480
gggtggagtt	gagtgtgctc	tgggcttgga	cacttgccgt	ggtgcccctg	gctggccgag	6540
gagactggct	ctggccaggg	ccccgtcctg	agaggtcctc	agcgtctgac	tctcggccag	6600
gcgccagcaa	ggaggggccc	gtccccgggg	ctaccaggca	ggcacgtgca	catcgccatc	6660
gccacacgcc	aactccgcct	gggttttaca	aagtcgttgc	cttaatgcat	gtggacagga	6720
actccctgag	gtcgccccat	gccccctggc	tgtgccagggt	acggacgccc	tggaccctgc	6780
gaacagggtg	ggcgggcgag	gggcccagg	gacgggctcc	agagacacgc	gcagggcagg	6840
aggggtctca	cggagggggtc	tcgcactgag	gcgccagag	ctgggtggtcc	cgctggacgc	6900
catccctctg	cccgggatcc	acacggccca	cgtgtgcccc	ccatgcccgc	gccccacgcc	6960
attgcagtct	tccatcctct	ggcgtgacg	gtggctgcag	cttccccatt	tgcgccgttg	7020
cctctggctg	tctgcacttt	tgttcatgct	ccaaagaaca	tttcataatg	ccttcagtac	7080
cgacgtacac	ttctgaccat	tttgatgtg	tccttggtgcc	gtagtaccca	ggcctttttt	7140
tgggtggatgt	gttaccgcc	acacttcaat	ctcaactttg	tgcaccgtcc	atcttctagg	7200
gatagacgcc	caggggaatga	actctagttt	tctaacagat	tagctgagat	attaacttac	7260

SSCP Update Sequences.ST25

tcacacggac aggttgatgc cagagccgta agaatgcgcc agtgcgggtt tgcgggggac	7320
ttcgggtgtg gggctcctgcg gccgcgatgg ccgtggaagg ttctggggat ccctgctgcc	7380
acggggacga gttcggacgc caggtggacc tgtgcactca gtaaacgca gtgattc	7437

<210> 44
 <211> 7437
 <212> DNA
 <213> Homo sapiens

<400> 44
 gctgagcctg agcccgaccc ggggcgccctc ccgccaggca ccatggtgca gaagtcgcgc 60
 aacggcggcg tatacccccg cccgagcggg gagaagaagc tgaagggtggg cttcgtgggg 120
 ctggacccccg gcgcgccccga ctccaccccg gacggggcgcg tgctgatcgc cggctccgag 180
 gcccccaagc gcggcagcat cctcagcaaa cctcgcgcgg gcggcgcggg cgccgggaag 240
 ccccccaagc gcaacgcctt ctaccgcaag ctgcagaatt tcctctacaa cgtgctggag 300
 cggccgcgcg gctgggcggt catctaccac gcctacgtgt tcctcctggg tttctcctgc 360
 ctctgtctgt ctgtgttttc caccatcaag gagtatgaga agagctcgga gggggccctc 420
 tacatcctgg aaatcgtgac tatcgtggtg tttggcgtgg agtacttcgt gcggatctgg 480
 gccgcaggct gctgctgccg gtaccgtggc tggagggggc ggctcaagtt tgcccggaaa 540
 ccgttctgtg tgattgacat catggtgctc atcgccctca ttgcgggtgct ggccgccggc 600
 tcccagggca acgtctttgc cacatctgcg ctccggagcc tgcgcttcct gcagattctg 660
 cggtatgatcc gcatggaccg gcggggaggc acctggaagc tgctgggctc tgtggtctat 720
 gccacagca aggagctggg cactgcctgg tacatcggct tcctttgtct catcctggcc 780
 tcgttcctgg tgtacttggc agagaagggg gagaacgacc actttgacac ctacgcggat 840
 gcactctggt ggggcctgat cacgctgacc accattggct acggggacaa gtacccccag 900
 acctggaacg gcaggctcct tgcggaacc ttaccctca tcggtgtctc cttcttcgcg 960
 ctgcctgcag gcatcttggg gtctgggttt gccctgaagg ttcaggagca gcacaggcag 1020
 aagcactttg agaagaggcg gaaccggca gcaggcctga tccagtcggc ctggagattc 1080
 tacgccacca acctctcggg cacagacctg cactccacgt ggcagtacta cgagcgaacg 1140
 gtcaccgtgc ccatgtacag ttcgcaaact caaacctacg gggcctccag acttatcccc 1200
 ccgtgaacc agctggagct gctgaggaac ctcaagagta aatctggact cgctttcagg 1260
 aaggaccccc cgccggagcc gtctccaagc cagaagggtca gtttgaaaga tcgtgtcttc 1320
 tccagcccc gaggcgtggc tgccaagggg aaggggtccc cgaggcca gactgtgagg 1380
 cggtcacca gcgccacca gagcctcgag gacagcccca gcaagggtgcc caagagctgg 1440
 agcttcgggg accgcagccg ggcacgccag gctttccgca tcaaggggtgc cgcgtcacgg 1500
 cagaactcag aagaagcaag cctccccgga gaggacattg tggatgacaa gagctgcccc 1560
 tgcgagtttg tgaccgagga cctgaccccc ggcctcaaag tcagcatcag agccgtgtgt 1620
 gtcatgcggg tcctgggtgt caagcggaag ttcaaggaga gcctgcggcc ctacgacgtg 1680

SSCP Update Sequences.ST25

atggacgtca	tcgagcagta	ctcagccggc	cacctggaca	tgctgtcccg	aattaagagc	1740
ctgcagtcca	gagtggacca	gatcgtgggg	cggggcccag	cgatcacgga	caaggaccgc	1800
accaagggcc	cggccgaggc	ggagctgccc	gaggacccca	gcatgatggg	acggctcggg	1860
aaggtggaga	agcaggtctt	gtccatggag	aagaagctgg	acttcctggg	gaatatctac	1920
atgcagcggg	tgggcatccc	cccagacagag	accgaggcct	actttggggc	caaagagccg	1980
gagccggcgc	cgccgtacca	cagcccggaa	gacagccggg	agcatgtcga	caggcacggc	2040
tgcatgttca	agatcgtgcg	ctccagcagc	tccacgggcc	agaagaactt	ctcggcgccc	2100
ccggccgcgc	ccccgtcca	gtgtccgccc	tccacctcct	ggcagccaca	gagccacccg	2160
cgccagggcc	acggcacctc	ccccgtgggg	gaccacgggt	ccctggtgcg	catcccgcgc	2220
ccgcctgccc	acgagcggtc	gctgtccgcc	tacggcgggg	gcaaccgcgc	cagcatggag	2280
ttcctgcggc	aggaggacac	cccgggctgc	aggccccccg	aggggaccct	gcgggacagc	2340
gacacgtcca	tctccatccc	gtccgtggac	cacgaggagc	tggagcgttc	cttcagcggc	2400
ttcagcatct	cccagtccaa	ggagaacctg	gatgtctctca	acagctgcta	cgcgcccggtg	2460
gcgccttggtg	ccaaagtcag	gccctacatt	gcggaggggag	agtcagacac	cgactccgac	2520
ctctgtaccc	cgtgcggggc	cccgccacgc	tcggccaccg	gcgaggggtcc	ctttggtgac	2580
gtgggctggg	ccgggcccag	gaagtgaggc	ggcgttgggc	cagtggaccc	gcccgcggcc	2640
ctcctcagca	cgggtgcctcc	gaggttttga	ggcgggaacc	ctctggggcc	cttttcttac	2700
agtaactgag	tgtggcgggg	agggtggggc	ctggagggggc	ccatgtgggc	tgaaggatgg	2760
gggctcctgg	cagtgcacctt	ttacaaaagt	tatttttccaa	cagggcactc	ccaggccctg	2820
tcgccattga	ggtgcctccg	ctgggctgtc	tcctcacccc	tccctgtgct	ggagcctgtc	2880
ccaaaaaggt	gccaactggg	aggcctcgga	agccactgtc	caggctccca	ctgcctgtct	2940
gctctgttcc	caaaggcagc	gtgtgtggcc	tcgggcccctg	cgggtggcatg	aagcatccct	3000
tctggtgtgg	gcatcgctac	gtgttttggg	ggcagcgttt	cacggcggtg	cccttgctgt	3060
ctcccttggg	ctggctcgag	cctgggggtcc	atgtcccttt	gccgtcccgt	catggggcag	3120
ggaatccata	gcggggccca	caggcagggg	tatgagtgcg	tcccacccaa	cgcagcacca	3180
gccccggcca	ccgctccccg	tgtccccagt	tccgtctcag	ctacctggac	tccaggaccc	3240
tggagaaggg	agacctggca	gtggagggag	gctgtgctgt	gtgtccccct	gcaggtgtga	3300
ccccgcctgc	tctttcctcc	cccgccaggt	gtggccccgc	ctgctctttc	ctccccacc	3360
agtatggccc	cacctgctct	ttcctcccc	cccaagggtgt	ggccccacct	gttctttcct	3420
cccctgccga	ggtgtgacct	cacctgctct	ttcctccctc	ccagtatggc	cccacctgct	3480
ctttcctccc	ccgaggtgag	gccccgcctg	ctctttcctc	ccatgggagc	cgctgaggcg	3540
tgcgcacctg	ggcacagggt	ggggctctgc	aggatgagga	agacaggcca	atcccttccc	3600
tcccagaagc	tggccgcccc	gcaggagggg	ctgaggccag	actcatgtcc	agcaagggaac	3660
gtgtggtgtg	tcccctggga	agtctctggg	ccctgggaag	aggggaagggtg	cacgtcctgg	3720

SSCP Update Sequences.ST25

gatggttgcg	gggccctggt	ttgggagaca	aaggggtaga	gggtctgtct	tgggcccccc	3780
cagactctag	cccgagcagt	gcagccacct	actgccccac	ctcagagaag	tgcagcggga	3840
aggaggctgg	aggtgggtgcg	gcgctgcctc	gggtgtctgc	gtgaatgagc	gtggccaagg	3900
accagtgccca	cctcatggca	aagagctccc	gcagtgtttg	ttagagtgca	catcctacgt	3960
gcccactggc	acacacacgt	gctcacatac	atgtccgcgt	acaggcgtac	acatgcacgc	4020
ttgcacacat	gcacacagac	cacatagcac	acatgtgcac	tgaccacacc	tgtatagacc	4080
atgcacagta	cacatacgtg	catacacatg	cctgcataca	ggcatacaca	tgcacgctta	4140
catgtacacg	tgcacagatc	acacacatgc	acacacgtgt	agctcacaca	cagtatacac	4200
atacacaagt	gcacagacca	cacacagcac	taacacatgc	acacacaaag	tgcataggcc	4260
acacagcaca	tgcacacagg	tgcacagacc	acacagcaca	cacaagtgca	cagagcacac	4320
tgcacacatg	cacacacaca	cgctgcatg	cacactcctc	gcacttccag	ccttggagcc	4380
cttctgtctc	tgggtctttct	ctttgaccct	gctgagtgtg	agctgcctgg	ggaggggcta	4440
caaggagtaa	ttgtggcttt	aggggtcgtg	gtgatgctgg	aatgtcaagc	gccgtcgtgg	4500
ggtatccgac	tgtccgggct	cctggtccgc	agtggcagag	cgccaggcag	agccaatcag	4560
ggtctcgtgc	tgcccttccc	ccccacagcc	tggcagccat	ccagaggagg	ggctctacca	4620
gatgccaagg	tgccccggtg	tctgtatggg	tgtccggttg	ggtcctgtgt	ttgggtctgcc	4680
ctggagggtg	ctggggccctc	ctgggatggg	tggctcagcc	tcgaatccca	ggccccagcc	4740
caggcagggtg	ctgctgcctg	ttgtgggtttc	ctggcccagc	ttctccttct	ccctctgcat	4800
aaaatcacag	tccgtgagtc	ttccagctgc	caccacggct	gggacacgct	gggggagggc	4860
tcctcccatg	cctcctgcac	acagccgtct	gagcagggca	ggtgccaaca	ccccccaccg	4920
gagacacgct	gcccctcagc	gatgccccta	ccttttgggg	ggcctcgtct	caagcccccc	4980
cttggaggct	gaaatcacc	caggcactgt	gagggttct	ccagggggac	accctttgag	5040
ctgtgggtct	gatcacccca	agtcccgac	acggaggaga	ggcacagcca	gggcgtgtgg	5100
tttaatgttt	gccccttcgg	ggctggagg	ctcagtgttt	ctagattcca	gaccctgctg	5160
ccagagagac	ctgctgccgg	agagaagggg	aggaggactc	cagctgggct	cggtccccca	5220
cagtcaggga	cccccataaa	ggacaccccc	ttctctctag	aaagagctgg	gctctcagct	5280
atttctagtt	gcttcccaga	agccgaggag	cagaaggagc	tgtgagagct	ttgcagaaac	5340
gcccttgtcc	ccgccctcct	gagctatgaa	tgccgtacag	agcagaggct	ggggcattgg	5400
caagatcaca	ggttgatgct	gcacagcccc	attgacacaa	accctcaaag	cagacgtgag	5460
agggacgggt	cacaaagctt	ggacctgccg	tggagggtgc	ccggcagacg	tggcgtgaga	5520
gggacggctc	acgaggcttg	gacctgctgt	ggagggtgcc	cagcagacgt	ggtgtgagag	5580
gaacggctca	cgagacttgg	acctgggtgga	gggtgcccag	cagacgtggt	gtgagaggga	5640
cggctcacag	ggcttggacc	ggagagagat	ggctcatgag	acttggacct	gccgtggagg	5700
gtgcccagca	gacgtggtat	gagagggatg	gctcacgagg	cttggacctg	gtggagggtg	5760

SSCP Update Sequences.ST25

```

cccggcagac gtgtgagagg gacgggtcac aaggcttgga cctgccatgg agggtgccca 5820
gcagacgtgg tgtgagaggg acagctcacg aggccttgga ctgccgtgga ggggtgcccag 5880
cagggggctg agctctgagg ggtgggtgct cagtgcacgg gtgccccag tgtcctctga 5940
tcctgtccgg tgccctcccc aacccccaca cccatgcaga actcccaggt cacatgcacg 6000
tatgtccagg gcatgggggt ggcgtgaaga ggcctgggtca gggccttttag gggctgcagg 6060
acggaatggc cacctgggga gcctgtgtgg ctgtgccggg cagccatcct gcattcccac 6120
ccagcgcga gtctccacct cggccccagc aaagcgctaa gcagccggag agacagccag 6180
ggcggcttcc tgaaggatgt gggatgggtg actccgggggt cgaggggaata cgcaggttcc 6240
tgtcctccgg gagacctaga gaagctgcac acccaggagc tttccatgac ccgggagcat 6300
gagtgaatgg ggggttccag tttgctgaac tttgctgtct tgtaagggtg ggggctgacg 6360
gccgaccctg ggaggagggt acaccgcagg gggaggttgt gggcaacggg ggaggaggag 6420
agacgggagg ggaccatttg ggatggaggg gcctcttcag agttttaaaa ggcgtttgtg 6480
gggtggagtt gagtgtgctc tgggcttga cacttgccgt ggtgcccctg gctggccgag 6540
gagactggct ctggccaggg ccccgctctg agaggctctc agcgtctgac tctcggccag 6600
gcgccagcaa ggaggggccc gtccccgggg ctaccaggca ggcacgtgca catcgccatc 6660
gccacacgcc aactccgcct gggttttaca aagtcgttgc cttaatgcat gtggacagga 6720
actccctgag gtcgccccat gccccctggc tgtgccagggt acggacgccc tggaccctgc 6780
gaacagggtg ggcgggcgag gggcccaagg gacgggctcc agagacacgc gcagggcagg 6840
aggggtctca cggaggggtc tcgcactgag gcgcccagag ctggtggtcc cgctggacgc 6900
catccctctg cccgggatcc acacggccca cgtgtgcccg ccatgcccgc gccccacgcc 6960
attgcagtct tccatcctct ggccgtgacg gtggctgcag cttccccatt tgcgccgttg 7020
cctctggctg tctgcacttt tgttcatgct ccaagaaca tttcataatg ctttcagtac 7080
cgacgtacac ttctgaccat tttgtatgtg tccttgtgcc gtagtgacca ggcctttttt 7140
tggtggatgt gttacccgc acacttcaat ctcaactttg tgcaccgtcc attttctagg 7200
gatagacgcc cagggaatga actctagttt tctaacagat tagctgagat attaacctac 7260
tcacacggac aggttgatgc cagagccgta agaatgcgcc agtgcggtt tgcgggggac 7320
ttcgggtgtg gggctcctgc gccgcgatgg ccgtggaagg ttctggggat ccctgctgcc 7380
acggggacga gttcggacgc cagggtggacc tgtgcactca gtaaacgca gtgattc 7437

```

```

<210> 45
<211> 7437
<212> DNA
<213> Homo sapiens

```

```

<400> 45
gctgagcctg agcccgaccc ggggcgcctc ccgccaggca ccatggtgca gaagtcgcgc 60
aacggcggcg tataccccgg cccgagcggg gagaagaagc tgaagggtggg cttcgtgggg 120

```

SSCP Update Sequences.ST25

ctggacccccg	gcgcgccccga	ctccaccccg	gacggggcg	tgctgatcgc	cggctccgag	180
gcccccaagc	gcggcagcat	cctcagcaaa	cctcgcgcgg	gcggcgcggg	cgccgggaag	240
ccccccaagc	gcaacgcctt	ctaccgcaag	ctgcagaatt	tcctctacaa	cgtgctggag	300
cggccgcgcg	gctgggcgtt	catctaccac	gcctacgtgt	tcctcctggt	tttctcctgc	360
ctcgtgctgt	ctgtgttttc	caccatcaag	gagtatgaga	agagctcgga	gggggcccctc	420
tacatcctgg	aaatcgtgac	tatcgtgggt	tttggcgtgg	agtacttcgt	gcggatctgg	480
gccgcaggct	gctgctgccg	gtaccgtggc	tggagggggc	ggctcaagtt	tgcccgga	540
ccgttctgtg	tgattgacat	catggtgctc	atgcctcca	ttgcggtgct	ggccgccggc	600
tcccagggca	acgtctttgc	cacatctgcg	ctccggagcc	tcgccttcct	gcagattctg	660
cggatgatcc	gcatggaccg	gcggggaggc	acctggaagc	tgctgggctc	tgtgggtctat	720
gcccacagca	aggagctggg	cactgcctgg	tacatcggt	tcctttgtct	catcctggcc	780
tcgttcctgg	tgtacttggc	agagaagggg	gagaacgacc	actttgacac	ctacgcggat	840
gcactctggg	ggggcctgat	cacgctgacc	accattggct	acggggacaa	gtacccccag	900
acctggaacg	gcaggctcct	tgcggaacc	ttcacctca	tcggtgtctc	cttcttcgcg	960
ctgcctgcag	gcatcttggg	gtctgggttt	gccctgaagg	ttcaggagca	gcacaggcag	1020
aagcactttg	agaagaggcg	gaacccggca	gcaggcctga	tccagtcggc	ctggagattc	1080
tacgccacca	acctctcgcg	cacagacctg	cactccacgt	ggcagtacta	cgagcgaacg	1140
gtcaccgtgc	ccatgtacag	ttcgaaaact	caaacctacg	gggcctccag	acttatcccc	1200
ccgtgaacc	agctggagct	gctgagggaac	ctcaagagta	aatctggact	cgctttcagg	1260
aaggaccccc	cgccggagcc	gtctccaagc	cagaagggtca	gtttgaaaga	tcgtgtcttc	1320
tccagcccct	gaggcggtgc	tgccaagggg	aaggggtccc	cgcaggccca	gactgtgagg	1380
cggtcaccca	gcgccgacca	gagcctcgag	gacagcccca	gcaagggtgcc	caagagctgg	1440
agcttcgggg	accgcagccg	ggcacgccag	gctttccgca	tcaaggggtgc	cgcgtcacgg	1500
cagaactcag	aagaagcaag	cctccccgga	gaggacattg	tggatgacaa	gagctgcccc	1560
tgcgagtttg	tgaccgagga	cctgaccccg	ggcctcaaag	tcagcatcag	agccgtgtgt	1620
gtcatgcggt	tcctggtgtc	caagcggaag	ttcaaggaga	gcctgcggcc	ctacgacgtg	1680
atggacgtca	tcgagcagta	ctcagccggc	cacctggaca	tgctgtcccg	aattaagagc	1740
ctgcagtcca	gagtggacca	gatcgtgggg	cggggcccag	cgatcacgga	caaggaccgc	1800
accaagggcc	cggccgaggc	ggagctgccc	gaggacccca	gcatgatggg	acggctcggg	1860
aagggtggaga	agcaggctct	gtccatggag	aagaagctgg	acttcctggg	gaatatctac	1920
atgcagcgga	tgggcatccc	cccagacagag	accgaggcct	actttggggc	caaagagccg	1980
gagccggcgc	cgccgtacca	cagcccggaa	gacagccggg	agcatgtcga	caggcacggc	2040
tgcatgtgtca	agatcgtgcg	ctccagcagc	tccacgggcc	agaagaactt	ctcggcgccc	2100
ccggccgcgc	cccctgtcca	gtgtccgccc	tccacctcct	ggcagccaca	gagccacccg	2160

SSCP Update Sequences.ST25

cgccagggcc	acggcacctc	ccccgtgggg	gaccacgggt	ccctggtgcg	catcccgcgc	2220
ccgcctgccc	acgagcggtc	gctgtccgcc	tacggcgggg	gcaaccgcgc	cagcatggag	2280
ttcctgcggc	aggaggacac	cccgggctgc	aggcccccg	aggggaccct	gcgggacagc	2340
gacacgtcca	tctccatccc	gtccgtggac	cacgaggagc	tggagcgttc	cttcagcggc	2400
ttcagcatct	cccagtccaa	ggagaacctg	gatgtcttca	acagctgcta	cgcgcccggtg	2460
gcgccttggtg	ccaaagttag	gccctacatt	gcggagggag	agtcagacac	cgactccgac	2520
ctctgtaccc	cgtgcggggc	cccgccacgc	tcggccaccg	gcgaggggtcc	ctttggtgac	2580
gtgggctggg	ccgggcccag	gaagttaggc	ggcgtggggc	cagtggaccc	gcccgcggcc	2640
ctcctcagca	cgggtgcctcc	gaggttttga	ggcgggaacc	ctctggggcc	cttttcttac	2700
agtaactgag	tgtggcgggg	aggggtggggc	ctggagggggc	ccatgtgggc	tgaaggatgg	2760
gggctcctgg	cagtgcacct	ttacaaaagt	tattttccaa	cagggcactc	ccaggccctg	2820
tcgccattga	ggtgcctccg	ctgggctgtc	tcctcacccc	tccctgtgct	ggagcctgtc	2880
ccaaaaaggt	gccaactggg	aggcctcgga	agccactgtc	caggctccca	ctgcctgtct	2940
gctctgttcc	caaaggcagc	gtgtgtggcc	tcggggccctg	cgggtggcatg	aagcatccct	3000
tctggtgtgg	gcatcgctac	gtgttttggg	ggcagcgttt	cacggcggtg	cccttgctgt	3060
ctcccttggg	ctggctcgag	cctgggggtcc	atgtcccttt	gccgtcccgt	catggggcag	3120
ggaatccata	gcggggccca	caggcagggg	tatgagtgcg	tcccacccaa	cgcagcacca	3180
gccccggcca	ccgctccccg	tgtccccagt	tccgtctcag	ctacctggac	tccaggaccc	3240
tggagaaggg	agacctggca	gtggagggag	gctgtgctgt	gtgtccccct	gcagggtgtga	3300
ccccgcctgc	tctttcctcc	cccgccaggt	gtggccccgc	ctgctctttc	ctccccacc	3360
agtatggccc	cacctgctct	ttcctcccc	cccaagggtgt	ggccccacct	gttctttcct	3420
cccctgccga	ggtgtgacct	cacctgctct	ttcctccctc	ccagtatggc	cccacctgct	3480
ctttcctccc	ccgaggtgag	gccccgcctg	ctctttcctc	ccatgggagc	cgctgaggcg	3540
tgcgcacctg	ggcacagggt	ggggctctgc	aggatgagga	agacaggcca	atcccttccc	3600
tcccagaagc	tggccgcccc	gcaggaggga	ctgaggccag	actcatgtcc	agcaagggaac	3660
gtgtggtgtg	tccccctggg	agtctctggg	ccctgggaag	aggggaagggtg	cacgtcctgg	3720
gatggttgcg	gggcccctgtt	ttgggagaca	aaggggtaga	gggtctgtct	tgggcccccc	3780
cagactctag	cccagcagct	gcagccacct	actgccccac	ctcagagaag	tgcagcggga	3840
aggaggctgg	aggtggtgcg	gcgctgcctc	gggtgtctgc	gtgaatgagc	gtggccaagg	3900
accagtgcc	cctcatggca	aagagctccc	gcagtgtttg	ttagagtgc	catcctacgt	3960
gcccactggc	acacacacgt	gctcacatac	atgtccgcgt	acaggcgtag	acatgcacgc	4020
ttgcacacat	gcacacagac	cacatagcac	acatgtgcac	tgaccacacc	tgtatagacc	4080
atgcacagta	cacatacgtg	catacacatg	cctgcataca	ggcatacaca	tgcacgctta	4140
catgtacacg	tgcacagatc	acacacatgc	acacacgtgt	agctcacaca	cagtatacac	4200

SSCP Update Sequences.ST25

atacacaagt	gcacagacca	cacacagcac	taacacatgc	acacacaaag	tgcataaggcc	4260
acacagcaca	tgcacacagg	tgcacagacc	acacagcaca	cacaagtgca	cagagcacac	4320
tgcacacatg	cacacacaca	cgcgtgcatg	cacactcctc	gcacttccag	ccttggagcc	4380
cttctgtctc	tggctcttct	ctttgaccct	gctgagtgtg	agctgcctgg	ggaggggcta	4440
caaggagtaa	ttgtggcctt	aggggtcgtg	gtgatgctgg	aatgtcaagc	gccgtcgtgg	4500
ggatatccgac	tgtccgggct	cctgggtccgc	agtggcagag	cgccaggcag	agccaatcag	4560
ggctctcgtgc	tgcccttccc	ccccacagcc	tggcagccat	ccagaggagg	ggctctacca	4620
gatgccaaagg	tgtcccgggtg	tctgtatggg	tgtccggttg	ggctcctgtgt	ttggctctgcc	4680
ctggagggtgg	ctgggccctc	ctgggatggg	tggctcagcc	tcgaatccca	ggccccagcc	4740
caggcagggtg	ctgctgcctg	ttgtgggtttc	ctggcccagc	ttctccttct	ccctctgcat	4800
aaaatcacag	tccgtgagtc	ttccagctgc	caccacggct	gggacacgct	gggggagggc	4860
tcctcccag	cctcctgcac	acagccgtct	gagcagggca	ggtgccaaaca	ccccccaccg	4920
gagacacgct	gcccctcagc	gatgccccta	ccttttgggg	ggcctcgtct	caagcccccc	4980
cctggagggt	gaaatcacc	caggcactgt	gagggcttct	ccagggggac	accctttgag	5040
ctgtgggtct	gatcaccca	agtcccgac	acggaggaga	ggcacagcca	gggcgtgtgg	5100
tttaatgttt	gccccttcgg	ggctggagggt	ctcagtgttt	ctagattcca	gaccctgctg	5160
ccagagagac	ctgctgccgg	agagaagggg	aggaggactc	cagctgggct	cgggtcccca	5220
cagtcaggga	ccccataaa	ggacaccccc	ttctctctag	aaagagctgg	gctctcagct	5280
atttctagtt	gcttcccaga	agccgaggag	cagaaggagc	tgtgagagct	ttgcagaaac	5340
gcccttgtcc	ccgccctcct	gagctatgaa	tgccgtacag	agcagaggct	ggggcattgg	5400
caagatcaca	ggttgatgct	gcacagcccc	attgacacaa	accctcaaag	cagacgtgag	5460
agggacgggt	cacaaagctt	ggacctgccg	tggaggggtgc	ccggcagacg	tggcgtgaga	5520
gggacggctc	acgaggcttg	gacctgctgt	ggaggggtgcc	cagcagacgt	ggtgtgagag	5580
gaacgggtca	cgagacttgg	acctgggtgga	gggtgcccag	cagacgtggg	gtgagagggg	5640
cggctcacag	ggcttggacc	ggagagagat	ggctcatgag	acttggacct	gccgtggagg	5700
gtgcccagca	gacgtggtat	gagaggggatg	gtcacagagg	cctggacctg	gtggaggggtg	5760
cccggcagac	gtgtgagagg	gacggttcac	aaggcttgga	cctgccatgg	agggtgccca	5820
gcagacgtgg	tgtgagaggg	acagctcacg	aggcttgga	ctgccgtgga	gggtgcccag	5880
cagggggctg	agctctgagg	ggtgggtgct	cagtgcacgg	gtgccccag	tgtcctctga	5940
tcctgtccgg	tgcctcccc	aacccccaca	cccatgcaga	actcccagg	cacatgcacg	6000
tatgtccagg	gcatgggggt	ggcgtgaaga	ggcctgggtca	gggccttttag	gggctgcagg	6060
acggaatggc	cacctgggga	gcctgtgtgg	ctgtgccggg	cagccatcct	gcattcccac	6120
ccagcgcga	gtctccacct	cggccccagc	aaagcgctaa	gcagccggag	agacagccag	6180
ggcggcttcc	tgaaggatgt	gggatgggtg	actccggggg	cagaggaata	cgcaggttcc	6240

SSCP Update Sequences.ST25

tgtcctccgg	gagacctaga	gaagctgcac	accaggagc	tttccatgac	ccgggagcat	6300
gagtgaatgg	ggggttccag	tttgctgaac	tttgctgtct	tgtaaggggtg	ggggctgacg	6360
gccgaccctg	ggaggagggtg	acaccgcagg	gggagggtgt	gggcaacggt	ggaggaggag	6420
agacgggagg	ggaccatttg	ggatggaggg	gcctcttcag	agttttaaaa	ggcgtttgtg	6480
gggtggagtt	gagtgtgctc	tgggcttgga	cacttgccgt	ggtgcccctg	gctggccgag	6540
gagactggct	ctggccaggg	ccccgtcctg	agaggtcctc	agcgtctgac	tctcggccag	6600
gcgccagcaa	ggaggggccc	gtccccgggg	ctaccaggca	ggcacgtgca	catcgccatc	6660
gccacacgcc	aactccgcct	gggttttaca	aagtcgttgc	cttaatgcat	gtggacagga	6720
actccctgag	gtcgccccat	gccccctggc	tgtgccagggt	acggacgccc	tggaccctgc	6780
gaacagggtg	ggcgggagag	gggcccgaag	gacgggctcc	agagacacgc	gcagggcagg	6840
aggggtctca	cggaggggtc	tcgcactgag	gcgcccagag	ctggtggtcc	cgctggacgc	6900
catccctctg	cccgggatcc	acacggccca	cgtgtgcccg	ccatgcccgc	gccccacgcc	6960
attgcagtct	tccatcctct	ggccgtgacg	gtggctgcag	cttccccatt	tgcgccgttg	7020
cctctggctg	tctgcacttt	tgttcatgct	caaagaaca	tttcataatg	ccttcagtac	7080
cgacgtacac	ttctgaccat	tttgtatgtg	tccttgtgcc	gtagtgacca	ggcctttttt	7140
tggtggatgt	gttaccgccg	acacttcaat	ctcaactttg	tgcaccgtcc	attttctagg	7200
gatagacgcc	cagggaatga	actctagttt	tctaacagat	tagctgagat	attaacttac	7260
tcacacggac	aggttgatgc	cagagccgta	agaatgcgcc	agtgcgggtt	tgcgggggac	7320
ttcgggtgtg	gggtcctgcg	gccgcgatgg	ccgtggaagg	ttctggggat	ccctgctgcc	7380
acggggacga	gttcggacgc	caggtggacc	tgtgcactca	gtaaaacgca	gtgatttc	7437

<210> 46
 <211> 7437
 <212> DNA
 <213> Homo sapiens

<400> 46	
gctgagcctg	agccccgaccc
aacggcgggc	tataccccgg
ctggaccccc	gcgcgcccga
gcccccaagc	gcggcagcat
ccccccaagc	gcaacgcctt
cggccgcgcg	gctgggctgt
ctcgtgctgt	ctgtgttttc
tacatcctgg	aaatcgtgac
gccgcaggct	gctgctgccg
ccgttctgtg	tgattgacat
tcccagggca	acgtctttgc
ggggcgccctc	ccgccaggca
gagaagaagc	tgaagggtgg
tgctgatcgc	cggctccgag
gcggcgcggg	cgccgggaag
tcctctacaa	cgtgctggag
tcctcctggg	tttctcctgc
agagctcgga	gggggcccctc
agtgctcggt	gcggatctgg
ggctcaagtt	tgcccgga
ttgcgggtgt	ggccgcccggc
tgcgcttcct	gcagattctg

SSCP Update Sequences.ST25

cggatgatcc	gcatggaccg	gcggggaggg	acctggaagc	tgctgggctc	tgtgggtctat	720
gcccacagca	aggagctggg	cactgcctgg	tacatcggct	tcctttgtct	catcctggcc	780
tcgttcctgg	tgtacttggc	agagaagggg	gagaacgacc	actttgacac	ctacgcggat	840
gcactctggg	ggggcctgat	cacgctgacc	accattgggt	acggggacaa	gtacccccag	900
acctggaacg	gcaggctcct	tgcggaacc	ttcacctca	tcggtgtctc	cttcttcgcg	960
ctgcctgcag	gcatcttggg	gtctgggttt	gccctgaagg	ttcaggagca	gcacaggcag	1020
aagcactttg	agaagaggcg	gaacccggca	gcaggcctga	tccagtcggc	ctggagattc	1080
tacgccacca	acctctcgcg	cacagacctg	cactccacgt	ggcagtacta	cgagcgaacg	1140
gtcaccgtgc	ccatgtacag	ttcgaaact	caaacctacg	gggcctccag	acttatcccc	1200
ccgctgaacc	agctggagct	gctgaggaac	ctcaagagta	aatctggact	cgctttcagg	1260
aaggaccccc	cgccggagcc	gtctccaagc	cagaagggtca	gtttgaaaga	tcgtgtcttc	1320
tccagcccc	gaggcgtggc	tgccaagggg	aaggggtccc	cgcaggccca	gactgtgagg	1380
cggtcaccca	gcgccgacca	gagcctcgag	gacagcccca	gcaagggtgcc	caagagctgg	1440
agcttcgggg	accgcagccg	ggcacgccag	gctttccgca	tcaagggtgc	cgcgtcacgg	1500
cagaactcag	aagaagcaag	cctccccgga	gaggacattg	tggatgacaa	gagctgcccc	1560
tgcgagtttg	tgaccgagga	cctgaccccg	ggcctcaaag	tcagcatcag	agccgtgtgt	1620
gtcatgcggt	tcctggtgtc	caagcggaag	ttcaaggaga	gcctgcggcc	ctacgacgtg	1680
atggacgtca	tcgagcagta	ctcagccggc	cacctggaca	tgctgtcccc	aattaagagc	1740
ctgcagtcca	gtgtggacca	gatcgtgggg	cggggcccag	cgatcacgga	caaggaccgc	1800
accaagggcc	cggccgaggg	ggagctgccc	gaggacccca	gcatgatggg	acggctcggg	1860
aagggtggaga	agcagggtctt	gtccatggag	aagaagctgg	acttcctggg	gaatatctac	1920
atgcagcgga	tgggcatccc	cccgacagag	accgaggcct	actttggggc	caaagagccg	1980
gagccggcgc	cgccgtacca	cagcccgga	gacagccggg	agcatgtcga	caggcacggc	2040
tgcatgttca	agatcgtgcg	ctccagcagc	tccacggggc	agaagaactt	ctcggcgccc	2100
ccggccgcgc	cccctgtcca	gtgtccgccc	tccacctctt	ggcagccaca	gagccacccg	2160
cgccagggcc	acggcacctc	ccccgtgggg	gaccacgggt	ccctggtgcg	catcccgcgc	2220
ccgcctgccc	acgagcggtc	gctgtccgcc	tacggcgggg	gcaaccgcgc	cagcatggag	2280
ttcctgcggc	aggaggacac	cccgggctgc	aggccccccg	aggggaccct	gcgggacagc	2340
gacacgtcca	tctccatccc	gtccgtggac	cacgaggagc	tggagcgttc	cttcagcggc	2400
ttcagcatct	cccagtccaa	ggagaacctg	gatgtctctca	acagctgcta	cgcggccgtg	2460
gcgccttggt	ccaaagtcag	gccctacatt	gcggagggag	agtcagacac	cgactccgac	2520
ctctgtaccc	cgtgcggggc	cccgccacgc	tcggccaccg	gcgaggggtcc	ctttggtgac	2580
gtgggctggg	ccgggcccag	gaagtgaggc	ggcgctgggc	cagtggaccc	gcccgcggcc	2640
ctcctcagca	cgggtgcctcc	gaggttttga	ggcggaacc	ctctggggcc	cttttcttac	2700

SSCP Update Sequences.ST25

agtaactgag	tgtggcgggga	aggggtggggc	ctggagggggc	ccatgtgggc	tgaaggatgg	2760
gggctcctgg	cagtgcacctt	ttacaaaagt	tatttttccaa	cagggcactc	ccaggccctg	2820
tcgccattga	ggtgcctccg	ctgggctgtc	tcctcacccc	tccctgtgct	ggagcctgtc	2880
ccaaaaaggt	gccaaactggg	aggcctcggga	agccactgtc	caggctccca	ctgcctgtct	2940
gctctgtttc	caaaggcagc	gtgtgtggcc	tcggggccctg	cgggtggcatg	aagcatccct	3000
tctgggtgtgg	gcatcgctac	gtgtttttggg	ggcagcgttt	cacggcggtg	cccttgctgt	3060
ctcccttggg	ctggctcgag	cctgggggtcc	atgtcccttt	gccgtcccgt	catggggcag	3120
ggaatccata	gcgggggccc	caggcagggg	tatgagtgcg	tcccacccaa	cgcagcacca	3180
gccccggcca	ccgctccccg	tgtccccagt	tccgtctcag	ctacctggac	tccaggaccc	3240
tggagaaggg	agacctggca	gtggagggag	gctgtgtgtg	gtgtccccct	gcagggtgtga	3300
ccccgcctgc	tcttttctcc	cccgccaggt	gtggccccgc	ctgctctttc	ctccccacc	3360
agtatggccc	cacctgctct	ttcctcccc	ccaagggtgt	ggccccacct	gttctttcct	3420
cccctgcca	ggtgtgacct	cacctgctct	ttcctccctc	ccagtatggc	cccacctgct	3480
ctttcctccc	ccgaggtgag	gccccgcctg	ctctttcctc	ccatgggagc	cgctgaggcg	3540
tgcgcacctg	ggcacagggt	ggggctctgc	aggatgagga	agacaggcca	atcccttccc	3600
tcccagaagc	tggccgccc	gcaggagggga	ctgaggccag	actcatgtcc	agcaagggaac	3660
gtgtggtgtg	tccccctggga	agtctctggg	ccctgggaag	agggaaagggtg	cacgtcctgg	3720
gatggttgcg	ggggccctgtt	ttgggagaca	aaggggtaga	gggtctgtct	tggggccccc	3780
cagactctag	cccgagcagt	gcagccacct	actgccccac	ctcagagaag	tgcagcggga	3840
aggaggctgg	aggtggtgag	gcgctgcctc	gggtgtctgc	gtgaatgagc	gtggccaagg	3900
accagtgcc	cctcatggca	aagagctccc	gcagtgtttg	ttagagtgc	catcctacgt	3960
gcccactggc	acacacacgt	gctcacatac	atgtccgcgt	acaggcgtag	acatgcacgc	4020
ttgcacacat	gcacacagac	cacatagcac	acatgtgcac	tgaccacacc	tgtatagacc	4080
atgcacagta	cacatacgtg	catacacatg	cctgcataca	ggcatacaca	tgcacgctta	4140
catgtacacg	tgcacagatc	acacacatgc	acacacgtgt	agctcacaca	cagtatacac	4200
atacacaagt	gcacagacca	cacacagcac	taacacatgc	acacacaaag	tgcataggcc	4260
acacagcaca	tgcacacagg	tgcacagacc	acacagcaca	cacaagtgc	cagagcacac	4320
tgcacacatg	cacacacaca	cgcgtagcatg	cacactcctc	gcacttccag	ccttggagcc	4380
cttctgtctc	tgggtctttct	ctttgaccct	gctgagtgtg	agctgcctgg	ggaggggcta	4440
caaggagtaa	ttgtggcttt	aggggtcgtg	gtgatgctgg	aatgtcaagc	gccgtcgtgg	4500
ggatatccgac	tgtccgggct	cctgggtccgc	agtggcagag	cgccaggcag	agccaatcag	4560
ggtctcgtgc	tgcccttccc	ccccacagcc	tggcagccat	ccagaggagg	ggctctacca	4620
gatgccaaagg	tgccccgggtg	tctgtatggg	tgtccgggtg	ggctcctgtgt	ttgggtctgcc	4680
ctggagggtgg	ctggggccctc	ctgggatggg	tggctcagcc	tcgaatccca	ggccccagcc	4740

SSCP Update Sequences.ST25

caggcaggtg	ctgctgcctg	ttgtggtttc	ctggcccagc	ttctccttct	ccctctgcat	4800
aaaatcacag	tccgtgagtc	ttccagctgc	caccacggct	gggacacgct	gggggagggc	4860
tcctcccatg	cctcctgcac	acagccgtct	gagcagggca	ggtgccaaca	ccccccaccg	4920
gagacacgct	gcccctcagc	gatgccccta	ccttttgggg	ggcctcgtct	caagcccccc	4980
cttggaggct	gaaatcaccc	caggcactgt	gagggcttct	ccagggggac	accctttgag	5040
ctgtgggtct	gatcacccca	agtcccgac	acggaggaga	ggcacagcca	gggcgtgtgg	5100
tttaatgttt	gccccttcgg	ggctggagg	ctcagtgttt	ctagattcca	gaccctgctg	5160
ccagagagac	ctgctgccgg	agagaagggg	aggaggactc	cagctgggct	cggccccca	5220
cagtcaggga	cccccataaa	ggacaccccc	ttctctctag	aaagagctgg	gctctcagct	5280
atttctagtt	gcttcccaga	agccgaggag	cagaaggagc	tgtgagagct	ttgcagaaac	5340
gcccttgtcc	ccgcccctct	gagctatgaa	tgccgtacag	agcagaggct	ggggcattgg	5400
caagatcaca	ggttgatgct	gcacagcccc	attgacacaa	accctcaaag	cagacgtgag	5460
agggacggtt	cacaaagctt	ggacctgccg	tggaggggtg	ccggcagacg	tggcgtgaga	5520
gggacggctc	acgaggcttg	gacctgctgt	ggaggggtgcc	cagcagacgt	ggtgtgagag	5580
gaacggctca	cgagacttgg	acctggtgga	gggtgcccag	cagacgtggt	gtgagaggga	5640
cggctcacag	ggcttggacc	ggagagagat	ggctcatgag	acttggacct	gccgtggagg	5700
gtgcccagca	gacgtggtat	gagagggatg	gctcacgagg	cttggacctg	gtggaggggtg	5760
ccgggcagac	gtgtgagagg	gacggttcac	aaggcttggg	cctgccatgg	aggggtgcca	5820
gcagacgtgg	tgtgagaggg	acagctcacg	aggcttggac	ctgccgtgga	gggtgcccag	5880
cagggggctg	agctctgagg	ggtgggtgct	cagtgcacgg	gtgccccag	tgtcctctga	5940
tcctgtccgg	tgcctcccc	aacccccaca	cccatgcaga	actcccaggt	cacatgcacg	6000
tatgtccagg	gcatgggggt	ggcgtgaaga	ggcctggtca	gggcctttag	gggctgcagg	6060
acggaatggc	cacctgggga	gcctgtgtgg	ctgtgccggg	cagccatcct	gcattcccac	6120
ccagcgcgca	gtctccacct	cggccccagc	aaagcgctaa	gcagccggag	agacagccag	6180
ggcggcttcc	tgaaggatgt	gggatgggtg	actccgggg	cgagggaata	cgcaggttcc	6240
tgtcctccgg	gagacctaga	gaagctgcac	accaggagc	tttccatgac	ccgggagcat	6300
gagtgaatgg	ggggttccag	tttgctgaac	tttgctgtct	tgttaagggtg	ggggctgacg	6360
gccgaccctg	ggaggagggt	acaccgcagg	gggaggttgt	gggcaacggt	ggaggaggag	6420
agacgggagg	ggaccatttg	ggatggaggg	gcctcttcag	agttttaaaa	ggcgtttgtg	6480
gggtggagtt	gagtgtgctc	tgggcttggg	cacttgccgt	ggtgcccctg	gctggccgag	6540
gagactggct	ctggccaggg	ccccgtcctg	agaggtcctc	agcgtctgac	tctcggccag	6600
gcgccagcaa	ggagggggccg	gtccccgggg	ctaccaggca	ggcacgtgca	catcgccatc	6660
gccacacgcc	aactccgcct	gggtttttaca	aagtcgttgc	cttaatgcat	gtggacagga	6720
actccctgag	gtcgccccat	gccccctggc	tgtgccaggt	acggacgccc	tggaccctgc	6780

SSCP Update Sequences.ST25

gaacaggtgg	ggcgggag	gggccaagg	gacgggctcc	agagacacgc	gcagggcagg	6840
aggggtctca	cggaggggtc	tcgcactgag	gcgccagag	ctggtggtcc	cgctggacgc	6900
catccctctg	cccgggatcc	acacggcca	cgtgtgccg	ccatgccgc	gccccacgcc	6960
attgcagtct	tccatcctct	ggccgtgacg	gtggctgcag	cttccccatt	tgcgccgttg	7020
cctctggctg	tctgcacttt	tgttcattgct	caaagaaca	tttcataatg	ccttcagtac	7080
cgacgtacac	ttctgaccat	tttgtatgtg	tccttgtgcc	gtagtgacca	ggcctttttt	7140
tggtggatgt	gttaccgcc	acacttcaat	ctcaactttg	tgaccgtcc	attttctagg	7200
gatagacgcc	cagggaatga	actctagttt	tctaacagat	tagctgagat	attaacttac	7260
tcacacggac	aggttgatgc	cagagccgta	agaatgcgc	agtgcgggtt	tgcgggggac	7320
ttcgggtgtg	gggtcctgcg	gccgcgatgg	ccgtggaagg	ttctggggat	ccctgctgcc	7380
acggggacga	gttcggacgc	caggtggacc	tgtgcactca	gtaaaacgca	gtgattc	7437

<210> 47
 <211> 7437
 <212> DNA
 <213> Homo sapiens

<400> 47	
gctgagcctg	agcccgaccc ggggcgcctc ccgccaggca ccatggtgca gaagtcgcgc 60
aacggcggcg	tataccccgg ccgagcggg gagaagaagc tgaagggtggg cttcgtgggg 120
ctggacccccg	gcgcgccga ctccacccgg gacggggcgc tgctgatcgc cggctccgag 180
gcccccaagc	gcggcagcat cctcagcaaa cctcgcgcgg gcggcgcggg cgccgggaag 240
ccccccaagc	gcaacgcctt ctaccgcaag ctgcagaatt tcctctacaa cgtgctggag 300
cggccgcgcg	gctgggcgtt catctaccac gcctacgtgt tcctcctggg tttctcctgc 360
ctcgtgctgt	ctgtgttttc caccatcaag gagtatgaga agagctcgga gggggccctc 420
tacatcctgg	aaatcgtgac tatcgtgggtg tttggcgtgg agtacttcgt gcggatctgg 480
gccgcaggct	gctgctgccg gtaccgtggc tggagggggc ggctcaagtt tgcccggaaa 540
ccgttctgtg	tgattgacat catggtgctc atcgccctca ttgcggtgct ggccgcccgc 600
tcccaggggca	acgtcctttgc cacatctgcg ctccggagcc tgcgcttcct gcagattctg 660
cggatgatcc	gcatggaccg gcggggaggc acctggaagc tgctgggctc tgtggtctat 720
gcccacagca	aggagctggg cactgcctgg tacatcggct tcctttgtct catcctggcc 780
tcgttcctgg	tgtacttggc agagaagggg gagaacgacc actttgacac ctacgcggat 840
gcactctggg	ggggcctgat cacgctgacc accattggct acggggacaa gtacccccag 900
acctggaacg	gcaggctcct tgccgcaacc ttcaccctca tcggtgtctc cttcttcgcg 960
ctgcctgcag	gcatcttggg gtctgggttt gccctgaagg ttcaggagca gcacaggcag 1020
aagcactttg	agaagaggcg gaaccggca gcaggcctga tccagtcggc ctggagattc 1080
tacgccacca	acctctcgcg cacagacctg cactccacgt ggcagtacta cgagcgaacg 1140

SSCP Update Sequences.ST25

gtcaccgtgc	ccatgtacag	ttcgaaact	caaacctacg	gggcctccag	acttatcccc	1200
ccgctgaacc	agctggagct	gctgaggaac	ctcaagagta	aatctggact	cgcttttcagg	1260
aaggaccccc	cgccggagcc	gtctccaagc	cagaagggtca	gtttgaaaga	tcgtgtcttc	1320
tccagcccc	gaggcgtggc	tgccaagggg	aaggggtccc	cgcaggccca	gactgtgagg	1380
cggtcaccca	gcgccgacca	gagcctcgag	gacagcccca	gcaagggtgcc	caagagctgg	1440
agcttcgggg	accgcagccg	ggcacgccag	gctttccgca	tcaagggtgc	cgcgtcacgg	1500
cagaactcag	aagaagcaag	cctccccgga	gaggacattg	tggatgacaa	gagctgcccc	1560
tgcgagtttg	tgaccgagga	cctgaccccc	ggcctcaaag	tcagcatcag	agccgtgtgt	1620
gtcatgcggt	tcctggtgtc	caagcggaag	ttcaaggaga	gcctgcggcc	ctacgacgtg	1680
atggacgtca	tcgagcagta	ctcagccggc	cacctggaca	tgctgtcccg	aattaagagc	1740
ctgcagtcca	gagtggacca	gatcgtgggg	cggggcccag	cgatcacgga	caaggaccgc	1800
accaagggcc	cggccgaggc	ggagctgccc	gaggacccca	gcatgatggg	acggctcggg	1860
aagggtggaga	agcaggctct	gtccatggag	aagaagcggg	acttcctggg	gaatatctac	1920
atgcagcgga	tgggcatccc	cccgacagag	accgaggcct	actttggggc	caaagagccg	1980
gagccggcgc	cgccgtacca	cagcccggaa	gacagccggg	agcatgtcga	caggcacggc	2040
tgcatgttca	agatcgtgcg	ctccagcagc	tccacgggcc	agaagaactt	ctcggcgccc	2100
ccggccgcgc	cccctgtcca	gtgtccgccc	tccacctcct	ggcagccaca	gagccacccg	2160
cgccagggcc	acggcacctc	ccccgtgggg	gaccacgggt	ccctggtgcg	catcccgcgc	2220
ccgcctgccc	acgagcggtc	gctgtccgcc	tacggcgggg	gcaaccgcgc	cagcatggag	2280
ttcctgcggc	aggaggacac	cccgggctgc	aggccccccg	aggggaccct	gcgggacagc	2340
gacacgtcca	tctccatccc	gtccgtggac	cacgaggagc	tggagcgttc	cttcagcggc	2400
ttcagcatct	cccagtccaa	ggagaacctg	gatgtcttca	acagctgcta	cgcgcccggtg	2460
gcgccttggtg	ccaaagtccag	gccctacatt	gcggagggag	agtcagacac	cgactccgac	2520
ctctgtaccc	cgtgcggggc	cccgccacgc	tcggccaccg	gcgaggggtcc	ctttggtgac	2580
gtgggctggg	ccgggcccag	gaagtgaggc	ggcgtggggc	cagtggaccc	gcccgcggcc	2640
ctcctcagca	cgggtgcctcc	gaggttttga	ggcgggaacc	ctctggggcc	cttttcttac	2700
agtaactgag	tgtggcgggg	agggtggggc	ctggaggggc	ccatgtgggc	tgaaggatgg	2760
gggctcctgg	cagtgcacct	ttacaaaagt	tatttttcaa	cagggcactc	ccaggccctg	2820
tcgccattga	ggtgcctccg	ctgggctgtc	tcctcacccc	tccctgtgct	ggagcctgtc	2880
ccaaaaaggt	gccaactggg	aggcctcgga	agccactgtc	caggctccca	ctgcctgtct	2940
gctctgtttc	caaaggcagc	gtgtgtggcc	tcgggcccctg	cgggtggcatg	aagcatccct	3000
tctggtgtgg	gcatcgctac	gtgttttggg	ggcagcgttt	cacggcggtg	cccttgctgt	3060
ctcccttggg	ctggctcgag	cctgggggtcc	atgtcccttt	gccgtcccgt	catggggcag	3120
ggaatccata	gcggggccca	caggcagggg	tatgagtgcg	tcccacccaa	cgcagcacca	3180

SSCP Update Sequences.ST25

gccccggcca	ccgctccccg	tgtccccagt	tccgtctcag	ctacctggac	tccaggaccc	3240
tggagaaggg	agacctggca	gtggagggag	gctgtgctgt	gtgtccccct	gcaggtgtga	3300
ccccgcctgc	tctttcctcc	cccgccaggt	gtggccccgc	ctgctctttc	ctccccacc	3360
agtatggccc	cacctgctct	ttcctcccc	ccaagggtgt	ggccccacct	gttctttcct	3420
cccctgccga	ggtgtgaccc	cacctgctct	ttcctccctc	ccagtatggc	cccacctgct	3480
ctttcctccc	ccgaggtgag	gccccgcctg	ctctttcctc	ccatgggagc	cgctgaggcg	3540
tgcgcacctg	ggcacagggt	ggggctctgc	aggatgagga	agacaggcca	atcccttccc	3600
tcccagaagc	tggccgcca	gcaggagggg	ctgaggccag	actcatgtcc	agcaaggaac	3660
gtgtggtgtg	tcccctggga	agtctctggg	ccctgggaag	agggaaaggtg	cacgtcctgg	3720
gatggttgcg	gggccctgtt	ttgggagaca	aaggggtaga	gggtctgtct	tggggccccc	3780
cagactctag	cccgagcagt	gcagccacct	actgccccac	ctcagagaag	tgcagcggga	3840
aggaggctgg	aggtggtgcg	gcgctgcctc	gggtgtctgc	gtgaatgagc	gtggccaagg	3900
accagtgcc	cctcatggca	aagagctccc	gcagtgtttg	ttagagtgca	catcctacgt	3960
gcccactggc	acacacacgt	gctcacatac	atgtccgcgt	acaggcgtag	acatgcacgc	4020
ttgcacacat	gcacacagac	cacatagcac	acatgtgcac	tgaccacacc	tgtatagacc	4080
atgcacagta	cacatacgtg	catacacatg	cctgcataca	ggcatacaca	tgcacgctta	4140
catgtacacg	tgcacagatc	acacacatgc	acacacgtgt	agctcacaca	cagtatacac	4200
atacacaagt	gcacagacca	cacacagcac	taacacatgc	acacacaaag	tgcataggcc	4260
acacagcaca	tgcacacagg	tgcacagacc	acacagcaca	cacaagtgca	cagagcacac	4320
tgcacacatg	cacacacaca	cgcgtagcatg	cacactcctc	gcacttccag	ccttgagacc	4380
cttctgtctc	tggctctttct	ctttgaccct	gctgagtgtg	agctgcctgg	ggaggggcta	4440
caaggagtaa	ttgtggcttt	aggggtcgtg	gtgatgctgg	aatgtcaagc	gccgtcgtgg	4500
ggtatccgac	tgtccgggct	cctgggtccgc	agtggcagag	cgccaggcag	agccaatcag	4560
ggtctcgtgc	tgcccttccc	ccccacagcc	tggcagccat	ccagaggagg	ggctctacca	4620
gatgccaagg	tgccccggtg	tctgtatggg	tgtccggttg	ggctcctgtgt	ttggtctgcc	4680
ctggagggtg	ctgggccctc	ctgggatggg	tggctcagcc	tcgaatccca	ggccccagcc	4740
caggcaggtg	ctgctgcctg	ttgtggtttc	ctggcccagc	ttctccttct	ccctctgcat	4800
aaaatcacag	tccgtgagtc	ttccagctgc	caccacggct	gggacacgct	gggggagggc	4860
tcctcccatg	cctcctgcac	acagccgtct	gagcagggca	ggtgccaaaca	ccccccaccg	4920
gagacacgct	gcccctcagc	gatgccccta	ccttttgggg	ggcctcgtct	caagcccccc	4980
cttggaggct	gaaatcacc	caggcactgt	gagggcttct	ccagggggac	accctttgag	5040
ctgtgggtct	gatcacccca	agtcccgcac	acggaggaga	ggcacagcca	gggcgtgtgg	5100
tttaatgttt	gccccttcgg	ggctggagggt	ctcagtgttt	ctagattcca	gacctgctg	5160
ccagagagac	ctgctgccgg	agagaagggg	aggaggactc	cagctgggct	cggtcccca	5220

SSCP Update Sequences.ST25

cagtcagggga	cccccataaa	ggacaccccc	ttctctctag	aaagagctgg	gctctcagct	5280
atttctagtt	gcttcccaga	agccgaggag	cagaaggagc	tgtgagagct	ttgcagaaac	5340
gcccttgtcc	ccgccctcct	gagctatgaa	tgccgtacag	agcagaggct	ggggcattgg	5400
caagatcaca	ggttgatgct	gcacagcccc	attgacacaa	accctcaaag	cagacgtgag	5460
agggacgggt	cacaaagctt	ggacctgccg	tggagggtgc	ccggcagacg	tggcgtgaga	5520
gggacggctc	acgaggcttg	gacctgctgt	ggagggtgcc	cagcagacgt	ggtgtgagag	5580
gaacggctca	cgagacttgg	acctggtgga	gggtgcccag	cagacgtggt	gtgagaggga	5640
cggctcacag	ggcttggacc	ggagagagat	ggctcatgag	acttggacct	gccgtggagg	5700
gtgcccagca	gacgtggtat	gagagggatg	gctcacgagg	cttggacctg	gtggagggtg	5760
ccggcgagac	gtgtgagagg	gacggttcac	aaggcttgga	cctgccatgg	agggtgccca	5820
gcagacgtgg	tgtgagaggg	acagctcacg	aggcttgga	ctgccgtgga	gggtgcccag	5880
cagggggctg	agctctgagg	ggtgggtgct	cagtgcacgg	gtgccccag	tgtcctctga	5940
tcctgtccgg	tgcctcccc	aacccccaca	cccatgcaga	actcccaggt	cacatgcacg	6000
tatgtccagg	gcatgggggt	ggcgtgaaga	ggcctggtca	gggcctttag	gggctgcagg	6060
acggaatggc	cacctgggga	gcctgtgtgg	ctgtgccggg	cagccatcct	gcattccac	6120
ccagcgcgca	gtctccacct	cggccccagc	aaagcgctaa	gcagccggag	agacagccag	6180
ggcggcttcc	tgaaggatgt	gggatggtgg	actccgggg	cgagggaata	cgcaggttcc	6240
tgtcctccgg	gagacctaga	gaagctgcac	accagggagc	tttccatgac	ccgggagcat	6300
gagtgaatgg	ggggttccag	tttgctgaac	tttgctgtct	tgtagggtg	ggggctgacg	6360
gccgaccctg	ggaggagggt	acaccgcagg	gggaggttgt	gggcaacggt	ggaggaggag	6420
agacgggagg	ggaccatttg	ggatggaggg	gcctcttcag	agttttaaaa	ggcgtttgtg	6480
gggtggagtt	gagtgtgctc	tgggcttggg	cacttgccgt	ggtgcccctg	gctggccgag	6540
gagactggct	ctggccaggg	ccccgtcctg	agagggtcct	agcgtctgac	tctcggccag	6600
gcgccagcaa	ggaggggccc	gtccccgggg	ctaccaggca	ggcacgtgca	catcgccatc	6660
gccacacgcc	aactccgcct	gggttttaca	aagtcgttgc	cttaatgcat	gtggacagga	6720
actccctgag	gtcgccccat	gccccctggc	tgtgccagg	acggacgccc	tggaccctgc	6780
gaacagggtg	ggcgggagag	gggcccagg	gacgggctcc	agagacacgc	gcagggcagg	6840
aggggtctca	cggaggggtc	tcgcactgag	gcgcccagag	ctggtggtcc	cgctggacgc	6900
catccctctg	cccgggatcc	acacggccca	cgtgtgccc	ccatgcccgc	gccccacgcc	6960
attgcagtct	tccatcctct	ggcgtgacg	gtggctgcag	cttccccatt	tgcgccgttg	7020
cctctggctg	tctgcacttt	tggtcatgct	ccaaagaaca	tttcataatg	ccttcagtac	7080
cgacgtacac	ttctgaccat	tttgtatgtg	tccttgtgcc	gtagtgacca	ggcctttttt	7140
tggtggatgt	gttaccgccg	acacttcaat	ctcaactttg	tgcaccgtcc	atcttctagg	7200
gatagacgcc	caggggaatga	actctagttt	tctaacagat	tagctgagat	attaacttac	7260

SSCP Update Sequences.ST25

tcacacggac	aggttgatgc	cagagccgta	agaatgcgcc	agtgcggggtt	tgcgggggac	7320
ttcgggtgtg	gggtcctgcg	gccgcgatgg	ccgtggaagg	ttctggggat	ccctgctgcc	7380
acggggacga	gttcggacgc	caggtggacc	tgtgcactca	gtaaaacgca	gtgattc	7437

<210> 48
 <211> 169
 <212> DNA
 <213> Homo sapiens

<400> 48	
acttatcccc	ccgctgaacc agctggagct gctgaggaac ctcaagagta aatctggact 60
cgctttcagg	tcagctgggg agctccaggt ggggcgggtg ggcgtctcag tcctgggggc 120
cccagctgcc	cacagaagac acgccaggac agtgccccag ggactccag 169

<210> 49
 <211> 203
 <212> DNA
 <213> Homo sapiens

<400> 49	
atgccgggac	aggtgacccc atggcggaag acaggggcta tgggaatgac ttcccatcgc 60
aagacatgat	ccccaccctg aaggccgcca tccgagccgt caggtaatgc cccacaggtc 120
ccacctgtgc	ctgtgtgcct ccccccactcc agctcaactc ccacaggaag gggcttataa 180
aattatcttg	cactttggga agg 203

<210> 50
 <211> 232
 <212> DNA
 <213> Homo sapiens

<400> 50	
aattctacaa	ttccgtctct ataaaaaaaa attcaaggag actttgaggc cttacgatgt 60
gaaggatgtg	attgagcagt attctgccgg gcatctcgac atgctttcca ggataaagta 120
ccttcagacg	aggtgagaca gtcacatctg gagggactgc actccccctca aagccctatg 180
aaccttagag	tttaagggtga gaggtattca gaaataattc aaaatgcagg ga 232

<210> 51
 <211> 1925
 <212> DNA
 <213> Homo sapiens

<400> 51	
ggtccattcg	ggaattactg cccagcagcc gactaagttg cattccttga atcttcgcag 60
aaaagacaat	tcttttaatc agagttagta atgtggacag tacaaaatcg agagagtctg 120
gggcttctct	ctttccctgt gatgattacc atgggtctgtt gtgcacacag caccaatgaa 180
cccagcaaca	tgccatacgt gaaagagaca gtggacagat tgctcaaagg atatgacatt 240
cgcttgccgc	cggacttcgg agggccccc gtcgacgttg ggatgcggat cgatgtcgcc 300
agcatagaca	tggtctccga agtgaatatg gattatacac tcaccatgta tttccagcag 360

SSCP Update Sequences.ST25

tcttggaag	acaaaaggct	ttcttattct	ggaatccac	tgaacctcac	cctagacaat	420
agggtagctg	accaactctg	ggtaccagac	acctactttc	tgaatgacaa	gaaatcattt	480
gtgcatgggg	tcacagtga	aaatcgaatg	attcgactgc	atcctgatgg	aacagttctc	540
tatggactcc	gaatcacaa	cacagctgca	tgtatgatgg	atcttcgaag	atatccattg	600
gatgagcaga	actgcaccct	ggagatcgaa	agttatggct	ataccactga	tgacattgaa	660
ttttactgga	atggaggaga	aggggcagtc	actggtgtta	ataaaaatcga	acttcctcaa	720
ttttcaattg	ttgactacaa	gatggtgtct	aagaagggtg	agttcacaa	aggagcgtat	780
ccacgactgt	cactaagttt	tcgtctaaag	agaaacattg	gttacttcat	tttgcaaacc	840
tacatgcctt	ctacactgat	tacaattctg	tcctgggtgt	ctttttggat	caactatgat	900
gcatctgcag	ccagagtcgc	actaggaatc	acgacagtgc	ttacaatgac	aaccatcagc	960
accacactca	gggagaccct	gccaaagatc	ccttatgtca	aagcgattga	tatttatctg	1020
atgggttgct	ttgtgtttgt	gttcctggct	ctgctggagt	atgcctttgt	aaattacatc	1080
ttctttggga	aaggccctca	gaaaaaggga	gctagcaaac	aagaccagag	tgccaatgag	1140
aagaataaac	tggagatgaa	taaagtccag	gtcgacgccc	acggtaacat	tctcctcagc	1200
accctggaaa	tccggaatga	gacgagtggc	tcggaagtgc	tcacgagcgt	gagcgacccc	1260
aaggccacca	tgtactccta	tgacagcgcc	agcatccagt	accgcaagcc	cctgagcagc	1320
cgcgaggcct	acgggcgcgc	cctggaccgg	cacggggtag	ccagcaaggg	gcgcattccgc	1380
aggcgtgcct	cccagctcaa	agtcaagatc	cccgacttga	ctgatgtgaa	ttccatagac	1440
aagtggctcc	gaatgttttt	ccccatcacc	ttttctcttt	ttaatgtcgt	ctattggcct	1500
tactatgtac	actgaggtct	gttctaattg	ttccatttag	actactttcc	tcttctattg	1560
ttttttaacc	ttacaggtcc	ccaacagcga	tactgctggt	tctcgaggta	agagattcag	1620
ccatccaatt	ggtttttaggt	cttgcatatc	agttttatta	ctgcaccatg	tttacttcaa	1680
aaagacaaaa	caaaaaaaaa	attatttttc	cagtctaccg	tgggtccaggt	tatcagctct	1740
ttaagagctc	tattaattgc	catgtttaca	aacaaacaca	aagagagaag	ttagacaggt	1800
agatcttttag	cagtcttttc	tagtttcctt	ggatttcact	gattttatctt	ttagggaaaa	1860
tgaaaagagg	accttgctgt	ccgcctgcac	tgcttcctgg	taaactataa	caaacttatg	1920
ctgcc						1925

<210> 52
 <211> 1925
 <212> DNA
 <213> Homo sapiens

<400> 52	
ggtccattcg	ggaattactg cccagcagcc gactaagttg cattccttga atcttcgcag 60
aaaagacaat	tcttttaaatc agagttagta atgtggacag tacaaaatcg agagagtctg 120
gggctttctt	ctttccctgt gatgattacc atgggtctggt gtgcacacag caccaatgaa 180
cccagcaaca	tgccatacgt gaaagagaca gtggacagat tgctcaaagg atatgacatt 240

SSCP Update Sequences.ST25

cgcttgccggc	cggacttcgg	agggccccc	gtcgacgttg	ggatgcggat	cgatgtcgcc	300
agcatagaca	tgggtctccga	agtgaatatg	gattatacac	tcaccatgta	tttccagcag	360
tcttggaag	acaaaaggct	ttcttattct	ggaatcccac	tgaacctcac	cctagacaat	420
agggtagctg	accaactctg	ggtaccagac	acctactttc	tgaatgacaa	gaaatcattt	480
gtgcatgggg	tcacagtga	aaatcgaatg	attcgactgc	atcctgatgg	aacagttctc	540
tatggactcc	gaatcacaa	cacagctgca	tgtatgatgg	atcttcgaag	atatccactg	600
gatgagcaga	actgcaccct	ggagatcgaa	agttatggct	ataccactga	tgacattgaa	660
ttttactgga	atggaggaga	aggggcagtc	actggtgtta	ataaaatcga	acttcctcaa	720
ttttcaattg	ttgactacaa	gatgggtgtct	aagaagggtg	agttcacaa	aggagcgtat	780
ccacgactgt	cactaagttt	tcgtctaaag	agaaacattg	gttacttcat	tttgcaaacc	840
tacatgcctt	ctacactgat	tacaattctg	tcctgggtgt	ctttttggat	caactatgat	900
gcatctgcag	ccagagtcgc	actaggaatc	acgacagtgc	ttacaatgac	aaccatcagc	960
accacactca	gggagaccct	gccaaagatc	ccttatgtca	aagcgattga	tatttatctg	1020
atgggttgct	ttgtgtttgt	gttcctggct	ctgctggagt	atgcctttgt	aaattacatc	1080
ttctttggga	aaggccctca	gaaaaaggga	gctagcaaac	aagaccagag	tgccaatgag	1140
aagaataaac	tggagatgaa	taaagtccag	gtcgacgccc	acggtaacat	tctcctcagc	1200
accctggaaa	tccggaatga	gacgagtggc	tcggaagtgc	tcacgagcgt	gagcgacccc	1260
aaggccacca	tgtactccta	tgacagcgcc	agcatccagt	accgcaagcc	cctgagcagc	1320
cgcgaggcct	acgggcgcgc	cctggaccgg	cacggggtag	ccagcaaggg	gcgcatccgc	1380
aggcgtgcct	cccagctcaa	agtcaagatc	cccgaactta	ctgatgtgaa	ttccatagac	1440
aagtgggtccc	gaatgttttt	ccccatcacc	ttttctcttt	ttaatgtcgt	ctattggctt	1500
tactatgtac	actgaggctc	gttctaattg	ttccatttag	actactttcc	tcttctattg	1560
ttttttaacc	ttacaggtcc	ccaacagcga	tactgctgtt	tctcgaggta	agagattcag	1620
ccatccaatt	ggtttttaggt	cttgcatatc	agttttatta	ctgcacatg	ttacttcaa	1680
aaagacaaaa	caaaaaaaaa	attatttttc	cagtctaccg	tgggtccagg	tatcagctct	1740
ttaagagctc	tattaattgc	catgtttaca	aacaaacaca	aagagagaag	ttagacaggt	1800
agatctttag	cagtcttttc	tagtttccct	ggatttcact	gatttatatt	ttagggaaaa	1860
tgaaaagagg	accttgctgt	ccgcctgcac	tgcttcctgg	taaactataa	caaacttatg	1920
ctgcc						1925

<210> 53
 <211> 1925
 <212> DNA
 <213> Homo sapiens

<400> 53						
gggccattcg	ggaattactg	cccagcagcc	gactaagttg	catttccttga	atcttcgcag	60

SSCP Update Sequences.ST25

aaaagacaat	tcttttaatc	agagttagta	atgtggacag	tacaaaatcg	agagagtctg	120
gggcttctct	ctttccctgt	gatgattacc	atgggtctgtt	gtgcacacag	caccaatgaa	180
cccagcaaca	tgccatacgt	gaaagagaca	gtggacagat	tgctcaaagg	atatgacatt	240
cgcttgccgc	cggacttcgg	agggccccc	gtcgacgttg	ggatgcggat	cgatgtcgcc	300
agcatagaca	tggtctccga	agtgaatatg	gattatacac	tcacatgta	tttcagcag	360
tcttgaaag	acaaaaggct	ttcttattct	ggaatccac	tgaacctcac	cctagacaat	420
agggtagctg	accaactctg	ggtaccagac	acctactttc	tgaatgacaa	gaaatcattt	480
gtgcatgggg	tcacagtga	aaatcgaatg	attcgactgc	atcctgatgg	aacagttctc	540
tatggactcc	gaatcacac	cacagctgca	tgtatgatgg	atcttcgaag	atatccactg	600
gatgagcaga	actgcaccct	ggagatcgaa	agttatggct	ataccactga	tgacattgaa	660
ttttactgga	atggaggaga	aggggcagtc	actgggtgtta	ataaaatcga	acttcctcaa	720
ttttcaattg	ttgactacaa	gatggtgtct	aagaagggtg	agttcacac	aggagcgtat	780
ccacgactgt	cactaagttt	tcgtctaaag	agaaacattg	gttacttcat	tttgcaaacc	840
tacatgcctt	ctacactgat	tacaattctg	tcctgggtgt	ctttttggat	caactatgat	900
gcatctgcag	ccagagtcgc	actaggaatc	acgacagtgc	ttacaatgac	aaccatcagc	960
accacactca	gggagaccct	gccaaagatc	ccttatgtca	aagcgattga	tattttatctg	1020
atgggttgct	ttgtgtttgt	gttcctggct	ctgctggagt	atgcttttgt	aaattacatc	1080
ttctttggga	aaggccctca	gaaaaaggga	gctagcaaac	aagaccagag	tgccaatgag	1140
aagaataaac	tggagatgaa	taaagtccag	gtcgacgccc	acggtaacat	tctcctcagc	1200
accctggaaa	tccggaatga	gacgagtggc	tcggaagtgc	tcacgagcgt	gagcgacccc	1260
aaggccacca	tgtactccta	tgacagcgcc	agcatccagt	accgcaagcc	cctgagcagc	1320
cgcgaggcct	acgggcgcgc	cctggaccgg	cacgggttac	ccagcaaggg	gcgcatccgc	1380
aggcgtgcct	cccagctcaa	agtcaagatc	cccgacttga	ctgatgtgaa	ttccatagac	1440
aagtgggtccc	gaatgttttt	ccccatcacc	ttttctcttt	ttaatgtcgt	ctattggctt	1500
tactatgtac	actgaggtct	gttctaattg	ttccatttag	actactttcc	tcttctattg	1560
ttttttaacc	ttacaggtcc	ccaacagcga	tactgctggt	tctcgaggta	agagattcag	1620
ccatccaatt	ggttttaggt	cttgcatatc	agttttatta	ctgcaccatg	tttacttcaa	1680
aaagacaaaa	caaaaaaaaa	attatttttc	cagtctaccg	tggtccagggt	tatcagctct	1740
ttaagagctc	tattaattgc	catgtttaca	aacaaacaca	aagagagaag	ttagacagggt	1800
agatcttttag	cagtcttttc	tagtttccct	ggattttcact	gattttatttt	ttagggaataa	1860
tgaaaagagg	accttgctgt	ccgcctgcac	tgcttcctgg	taaactataa	caaacttatg	1920
ctgcc						1925

<210> 54
 <211> 1536
 <212> DNA

SSCP Update Sequences.ST25

<213> Homo sapiens

<400> 54

```

tgaattcgtg agatggcgag ctccacggca ccatggcccc gaagctgctg ctctctctct      60
gcctgttctc gggccttgac gcgcgggtcca gaaagggtgga agaggatgaa tatgaagatt     120
catcatcaaa ccaaaagtgg gtcttggtctc caaaatccca agacaccgac gtgactctta      180
ttctcaacaa gttgctaaga gagtatgata aaaagctgag gccagatatt ggaataaaac       240
cgaccgtaat tgacgttgac atttatgtta acagcattgg tcctgtgtca tcaataaaca       300
tggaataacca aattgacata ttttttgctc agacctggac agatagtcgc cttcgattca      360
acagcacaat gaaaattctt actctgaaca gcaacatggg ggggttaatc tggatcccag      420
acaccatctt ccgcaattct aaaaccgcag aggtctactg gatcaccaca cccaatcagc      480
tcctccggat ttggaatgac gggaaaatcc tttacacttt gagggctcacc atcaatgctg      540
agtgccagct gcagctgcac aacttcccca tggacgaaca ctcttgcccc ctgattttct      600
ccagctatgg ctatcccaaa gaagaaatga tttatagatg gagaaaaaat tcagtggagg      660
cagctgacca gaaatcatgg cggctttatc agtttgactt catgggcctc agaaacacca      720
cagaaatcgt gacaacgtct gcaggtgatt atgttgatcat gactatatat tttgaattga      780
gtagaagaat gggatacttc accattcaga catacattcc ctgtatactg actgtggttt      840
tatcctgggt gtcatttttg atcaaaaaag atgctacgcc agcaagaaca gcattaggca      900
tcaccacggt gctgaccatg accaccctga gcaccatcgc caggaagtcc ttgccacgcg      960
tgtcctacgt gaccgccatg gacctttttg tgactgtgtg cttcctgttt gtcttcgccg     1020
cgctgacgga gtatgccacc ctcaactact attccagctg tagaaaacca accaccacga     1080
aaaagacaac atcgttacta catccagatt cctcaagatg gattcctgag cgaataagcc     1140
tacaagcccc ttccaactat tccctcctgg acatgaggcc accaccacct gcgatgatca     1200
ctttaaacaa ttccgtttac tggcaggaat ttgaagatac ctgtgtctat gagtgtctgg     1260
atggcaaaga ctgtcagagc ttcttctgct gctatgaaga atgtaaatca ggatcctgga     1320
ggaaagggcg tattcacata gacatcttgg agctggactc gtactcccgg gtctttttcc     1380
ccacgtcctt cctgctcttt aacctggtct actgggttgg atacctgtat ctctaagtgt     1440
tgctcagagt gaagagtga gagcatttgg tacacacttg accttctgtc gtccccagac     1500
cagtagtgac caatcgggag tagcaaggaa ggacac                                  1536

```

<210> 55

<211> 1843

<212> DNA

<213> Homo sapiens

<400> 55

```

gcacaattca gaggtaacag cgctgctgtt ttctccatga taacatagac aaacagttgc      60
ctccaaagct gcagattgga tattgggaag caaatattggg tgtgaaatct tcagcaaagg     120
agcacgcaga gtccatgatg gctcagacca agtgagttag aggcagagcg agggcgcccc     180

```

SSCP Update Sequences.ST25

tctgctctgg	cgcgcccgga	ctcggactcg	cagactcgcg	ctggctccag	tctctccacg	240
attctctctc	ccagactttt	ccccggtctt	aagagatcct	gtgtccagag	ggggccttag	300
ctgctccagc	ccgcatgag	gaaaagtcca	ggctctgtctg	actgtctttg	ggcctggatc	360
ctccttctga	gcacactgac	tggaagaagc	tatggacagc	cgtcattaca	agatgaactt	420
aaagacaata	ccactgtctt	caccaggatt	ttggacagac	tcctagatgg	ttatgacaat	480
cgcttgagac	caggattggg	agagcgtgta	accgaagtga	agactgatat	cttcgtcacc	540
agtttcggac	ccgtttcaga	ccatgatatg	gaatatacaa	tagatgtatt	tttccgtcaa	600
agctggaagg	atgaaagggt	aaaattttaa	ggacctatga	cagtcctccg	gttaaataac	660
ctaattggcaa	gtaaaatccg	gactccggac	acatttttcc	acaatggaaa	gaagtcagtg	720
gccacaaca	tgaccatgcc	caacaaactc	ctgcggatca	cagaggatgg	caccttgctg	780
tacaccatga	ggctgacagt	gagagctgaa	tgtccgatgc	atgtggagga	cttccttatg	840
gatgcccatg	cttgcccact	aaaatttggg	agttatgctt	atacaagagc	agaagttggt	900
tatgaatgga	ccagagagcc	agcacgctca	gtggttgtag	cagaagatgg	atcacgtcta	960
aaccagtatg	accttcttgg	acaaacagta	gactctggaa	ttgtccagtc	aagtacagga	1020
gaatatgttg	ttatgaccac	tcatttccac	ttgaagagaa	agattggcta	ctttgttatt	1080
caaacatacc	tgccatgcat	aatgacagtg	attctctcac	aagtctcctt	ctggctcaac	1140
agagagtctg	taccagcaag	aactgtcttt	ggagtaacaa	ctgtgctcac	catgacaaca	1200
ttgagcatca	gtgccagaaa	ctccctccct	aagggtggctt	atgcaacagc	tatggattgg	1260
tttattgccc	tgtgctatgc	ctttgtgttc	tcagctctga	ttgagtttgc	cacagtaaac	1320
tatttcacta	agagagggtta	tgcatgggat	ggcaaaagtg	tggttccaga	aaagccaaag	1380
aaagtaaagg	atcctcttat	taagaaaaac	aacacttacg	ctccaacagc	aaccagctac	1440
accctaatt	tggccagggg	cgacccgggc	ttagccacca	ttgctaaaag	tgcaaccata	1500
gaacctaaag	aggtcaagcc	cgaaacaaaa	ccaccagaac	ccaagaaaac	ctttaacagt	1560
gtcagcaaaa	ttgaccgact	gtcaagaata	gccttcccg	tgctatttgg	aatctttaac	1620
ttagtctact	gggctacgta	tttaaacaga	gagcctcagc	taaaagcccc	cacaccacat	1680
caatagatct	tttactcaca	ttctgttggt	cagttcctct	gcactgggaa	tttatttatg	1740
ttctcaacgc	agtaattccc	atctgccttt	attgcctctg	tcttaaagaa	tttgaaagtt	1800
tccttatttt	cataattcat	ttaagacaag	agaccctgt	ctg		1843

<210> 56
 <211> 1843
 <212> DNA
 <213> Homo sapiens

<400> 56	gcacaattca	gaggtaacag	cgcttgcgtt	ttctccatga	taacatagac	aaacagttgc	60
	ctccaaagct	gcagattgga	tattgggaag	caaatttggg	tgtgaaatct	tcagcaaagg	120
	agcacgcaga	gtccatgatg	gctcagacca	agtgagtgg	aggcagagcg	aggacgcccc	180

SSCP Update Sequences.ST25

tctgctcttg	cgcgcccga	ctcggactcg	cagactcgcg	ctggctccag	tctctccacg	240
attctctctc	ccagactttt	ccccggtctt	aagagatcct	gtgttcagag	ggggccttag	300
ctgctccagc	ccgcgatgag	gaaaagtcca	ggtctgtctg	actgtctttg	ggcctggatc	360
ctccttctga	gcacactgac	tggaagaagc	tatggacagc	cgtcattaca	agatgaactt	420
aaagacaata	ccactgtctt	caccaggatt	ttggacagac	tcctagatgg	ttatgacaat	480
cgcctgagac	caggattggg	agagcgtgta	accgaagtga	agactgatat	cttcgtcacc	540
agtttcggac	ccgtttcaga	ccatgatatg	gaatatacaa	tagatgtatt	tttccgtcaa	600
agctggaagg	atgaaagggt	aaaatttaaa	ggacctatga	cagtcctccg	gttaaataac	660
ctaattggca	gtaaaatccg	gactccggac	acatttttcc	acaatggaaa	gaagtcagt	720
gcccacaaca	tgaccatgcc	caacaaactc	ctgcggatca	cagaggatgg	caccttgctg	780
tacaccatga	ggctgacagt	gagagctgaa	tgtccgatgc	atgtggagga	cttccctatg	840
gatgcccatt	cttgcccact	aaaatttgga	agttatgctt	atacaagagc	agaagttggt	900
tatgaatgga	ccagagagcc	agcacgctca	gtggttgtag	cagaagatgg	atcacgtcta	960
aaccagtatg	accttcttgg	acaaacagta	gactctggaa	ttgtccagtc	aagtacagga	1020
gaatatgttg	ttatgaccac	tcatttccac	ttgaagagaa	agattggcta	ctttgttatt	1080
caaacatacc	tgccatgcat	aatgacagt	attctctcac	aagtctcctt	ctggctcaac	1140
agagagtctg	taccagcaag	aactgtcttt	ggagtaacaa	ctgtgctcac	catgacaaca	1200
ttgagcatca	gtgccagaaa	ctccctccct	aagggtggctt	atgcaacagc	tatggattgg	1260
tttattgccg	tgtgctatgc	ctttgtgttc	tcagctctga	ttgagtttgc	cacagtaaac	1320
tatttacta	agagagggtta	tgcattggat	ggcaaaagt	tggttccaga	aaagccaaag	1380
aaagtaaagg	atcctcttat	taagaaaaac	aacacttacg	ctccaacagc	aaccagctac	1440
acccttaatt	tggccagggg	cgaccggggc	ttagccacca	ttgctaaaag	tgcaaccata	1500
gaacctaaag	aggtcaagcc	cgaacaaaaa	ccaccagaac	ccaagaaaac	ctttaacagt	1560
gtcagcaaaa	ttgaccgact	gtcaagaata	gccttcccgc	tgctatttgg	aatctttaac	1620
ttagtctact	gggctacgta	tttaaacaga	gagcctcagc	taaaagcccc	cacaccacat	1680
caatagatct	tttactcaca	ttctgttggt	cagttcctct	gcactgggaa	tttatttatg	1740
ttctcaacgc	agtaattccc	atctgccttt	attgcctctg	tcttaaagaa	tttgaaagtt	1800
tccttatttt	cataattcat	ttaagacaag	agaccctgt	ctg		1843

<210> 57
 <211> 2189
 <212> DNA
 <213> Homo sapiens

<400> 57		
cctagcgtc	ctctccggct tccaccagcc catcgtcca cgctctcttg gctgctgcag	60
tctcggtctc	tctctctctc tctctctctc tctctctctc tctctctctc tctctctctc	120

SSCP Update Sequences.ST25

tctctctctc tctctcccaa gtttcctatc tcgtcaagat cagggcaaaa gaagaaaaca	180
ccgaattctg cttgccgttt cagagcggcg gtgatgaaga caaaattgaa catctacaac	240
atcgagttcc tgctttttgt tttcttggtg tgggaccctg ccaggttggt gctggctaac	300
atccaagaag atgaggctaa aaataacatt accatcttta cgagaattct tgacagactt	360
ctggatgggt acgataatcg gcttagacca ggactgggag acagtattac tgaagtcttc	420
actaacatct acgtgaccag ttttggccct gtctcagata cagatatgga atatacaatt	480
gatgttttct ttcgacaaaa atggaaagat gaacgtttta aatttaaagg tcctatgaat	540
atccttcgac taaacaattt aatggctagc aaaatctgga ctccagatac cttttttcac	600
aatgggaaga aatcagtagc tcataatatg acaatgccaa ataagttgct tcgaattcag	660
gatgatggga ctctgctgta taccatgagg cttacagttc aagctgaatg cccaatgcac	720
ttggaggatt tcccaatgga tgctcattca tgtcctctga aatttggcag ctatgcatat	780
acaacttcag aggtcactta tatttggtgact tacaatgcat ctgattcagt acaggttgct	840
cctgatggct ctaggttaaa tcaatatgac ctgctgggcc aatcaatcgg aaaggagaca	900
attaaatcca gtacaggtga atatactgta atgacagctc atttccacct gaaaagaaaa	960
attgggtatt ttgtgattca aacctatctg ccttgcatca tgactgtcat tctctcccaa	1020
gtttcattct ggcttaacag agaatctgtg cctgcaagaa ctgtgtttgg agtaacaact	1080
gtcctaacaa tgacaactct aagcatcagt gctcgggaatt ctctcccaa agtggcttat	1140
gcaactgcc a tggactgggt tatttgctgtt tgttatgcat ttgtgttctc tgccctaatt	1200
gaatttgcaa ctgttaatta cttcaccaaa agaggatgga cttgggatgg gaagagtgt	1260
gtaaatgaca agaaaaaaga aaaggcttcc gttatgatac agaacaacgc ttatgcagt	1320
gctgttgcca attatgcccc gaatctttca aaagatccag ttctctccac catctccaag	1380
agtgcaacca cgccagaacc caacaagaag ccagaaaaca agccagctga agcaaagaaa	1440
actttcaaca gtgttagcaa aattgacaga atgtccagaa tagtttttcc agttttgttt	1500
ggtagcttta atttagttta ctgggctaca tatttaaaaca gagaacctgt attaggggtc	1560
agtccttgaa ttgagacca tgttatcttt gggatgtata gcaacattaa atttggtttg	1620
ttttgctatg tacagtctga ctaataactg ctaatttgtg atccaacatg tacagtatgt	1680
atatagtgac atagcttacc agtagacctt taatggagac atgcatttgc taactcatgg	1740
aactgcagac agaaagcact ccatgcgaaa acagccattg ctttttttaa agatttaccc	1800
taggacctga tttaaagtga atttcaaag acctgattaa tttcctattc ttccaaatga	1860
gatgaaaatg gggatcctgt acaacccttt gtggaccctt ttggtttagc tcttaagtag	1920
gggtattttc tactgttgct taattatgat ggaagataac attgtcattc ctagatgaat	1980
cctttgaagt aacaaacatt gtatctgaca tcagctctgt tcatgagtgc tcagagtccc	2040
tgctaagtga attggaagct tggtagacat aagaaaaact agagatttga aatctagcta	2100
tgaattactc tatatagtat ctatagccat gtacatatta cagcatgaca agctcgaaat	2160

SSCP Update Sequences.ST25

aattatgagt cagcccgaaa gatgttaat

2189

<210> 58
 <211> 2352
 <212> DNA
 <213> Homo sapiens

<400> 58
 gaagatgctg ttgagggccc tggagaaact tcagcagaac agggcctctc cccttgacagg 60
 ccgagccgcg gccctgcgcc ctccccctcc gccagctcg gccaaagggcg cttttgctga 120
 gcgtctggcg gcctctaccg gagcacctct gcagagggcc gatcctccag cccagagacg 180
 acatgtggcg ctcgggcgag tgccttgacg agagaggagt agcttgctgg ctttgaacgc 240
 gtggcgtggc agatatttca gaaagcttca agaacaagct ggagaaggga agagttattc 300
 ctccatattc acctgcttca actactattc ttattgggaa tggacaatgg aatgttctct 360
 ggttttatca tgatcaaaaa cctccttctc ttttgtattt ccatgaactt atccagtcac 420
 tttggctttt cacagatgcc aaccagttca gtgaaagatg agaccaatga caacatcacg 480
 atattttacca ggatcttggg tgggctcttg gatggctacg acaacagact tcggcccggg 540
 ctggggagagc gcatcactca ggtgaggacc gacatctacg tcaccagctt cggcccgggtg 600
 tccgacacgg aatggagta caccatagac gtgtttttcc gacaaagctg gaaagatgaa 660
 aggccttcggt ttaagggggc catgcagcgc ctccctctca acaacctcct tgccagcaag 720
 atctggaccc cagacacgtt cttccacaac gggagaagat ccatcgctca caacatgacc 780
 acgcccaca agctgctgcg gctggaggac gacggcacc tcgtctacac catgcgcttg 840
 accatctctg cagagtgcc catgcagctt gaggacttcc cgatggatgc gcacgcttg 900
 cctctgaaat ttggcagcta tgcgtaccct aattctgaag tcgtttacgt ctggaccaac 960
 ggctccacca agtcggtggt ggtggcggaa gatggctcca gactgaacca gtaccacctg 1020
 atggggcaga cggtgggcac tgagaacatc agcaccagca caggcgaata cacaatcatg 1080
 acagctcact tccacctgaa aaggaagatt ggctactttg tcatccagac ctaccttccc 1140
 tgcataatga ccgtgatctt atcacaggtg tccttttggc tgaaccggga atcagtccca 1200
 gccaggacag tttttggggt caccacggtg ctgaccatga cgaccctcag catcagcgcc 1260
 aggaactctc tgcccaaagt ggcctacgcc accgccatgg actgggtcat agctgtgtgc 1320
 tatgccttcg tcttctcggc gctgatagag tttgccacgg tcaattactt taccaagaga 1380
 ggctgggcct gggatggcaa aaaagccttg gaagcagcca agatcaagaa aaagcgtgaa 1440
 gtcatactaa ataagtcaac aaacgctttt acaactggga agatgtctca cccccaaac 1500
 attccgaagg aacagacccc agcagggacg tcgaatacaa cctcagtctc agtaaaaccc 1560
 tctgaagaga agacttctga aagcaaaaag acttacaaca gtatcagcaa aattgacaaa 1620
 atgtcccgaa tcgtattccc agtcttggtc ggcactttca acttagttta ctgggcaacg 1680
 tatttgaata gggagccggt gataaaagga gccgcctctc caaaataacc ggccacactc 1740
 ccaaactcca agacagccat acttccagcg aaatggtacc aaggagaggt tttgctcaca 1800

SSCP Update Sequences.ST25

```

gggactctcc atatgtgagc actatctttc aggaaatfff tgcatgttta ataatatgta 1860
caaataatat tgccttgatg tttctatatg taacttcaga tgtttccaag atgtccatt 1920
gataattcga gcaaacaact ttctggaaaa acaggatacg atgactgaca ctccagatgcc 1980
cagtatcata cggtgatagt ttacaaacaa gatacgtata tttttaactg cttcaagtgt 2040
tacctaacaa tgttttttat acttcaaatg tcatttcata caaatfctcc cagtgaataa 2100
atatttttagg aaactctcca tgattattag aagaccaact atattgagag aaacagagat 2160
cataaagagc acgttttcca ttatgaggaa acttgacat ttatgtacaa aatgaattgc 2220
ctttgataat tcttactgtt ctgaaattag gaaagtactt gcatgatctt acacgaagaa 2280
atagaatagg caaactttta tgtaggcaga ttaataacag aaatacatca tatgttagat 2340
acacaaaata tt 2352

```

```

<210> 59
<211> 2352
<212> DNA
<213> Homo sapiens

```

```

<400> 59
gaagatgctg ttgagggccc tggagaaact tcagcagaac agggcctctc cccttgagag 60
ccgagccggg gccctgcgcc ctccccctcc gccagctcg gccaaagggcg cgtttgctga 120
gcgtctggcg gcctctaccg gagcacctct gcagagggcc gatcctccag cccagagacg 180
acatgtggcg ctccggcgag tgccttgagc agagaggagt agcttgctgg ctttgaacgc 240
gtggcgtggc agatatttca gaaagcttca agaacaagct ggagaaggga agagttattc 300
ctccatattc acctgcttca actactattc ttattgggaa tggacaatgg aatgttctct 360
ggttttatca tgatcaaaaa cctccttctc ttttgtatft ccatgaactt atccagtcac 420
tttggtttt cacagatgcc aaccagttca gtgaaagatg agaccaatga caacatcacg 480
atattttacca ggatcttgga tgggctcttg gatggctacg acaacagact tcggccccggg 540
ctgggagagc gcatcactca ggtgaggacc gacatctacg tcaccagctt cggccccggtg 600
tccgacacgg aatggagta caccatagac gtgtttttcc gacaaagctg gaaagatgaa 660
aggcttcggt ttaagggggc catgcagcgc ctccctctca acaacctcct tgccagcaag 720
atctggaccc cagacacgtt cttccacaac gggaagaagt ccatcgctca caacatgacc 780
acgcccaca agctgctgcg gctggaggac gacggcacc tgctctacac catgcgcttg 840
accatctctg cagagtgcct catgcagctt gaggacttcc cgatggatgc gcacgcttgc 900
cctctgaaat ttggcagcta tgcgtaccct aattctgaag tcgtttacgt ctggaccaac 960
ggctccacca agtcggtggg ggtggcgga gatggctcca gactgaacca gtaccacctg 1020
atggggcaga cggtgggcac tgagaacatc agcaccagca caggcgaata cacaatcatg 1080
acagctcact tccacctgaa aaggaagatt ggctactttg tcatccagac ctaccttccc 1140
tgcataatga ccgtgatctt atcacagggt tccttttggc tgaaccggga atcagtcacca 1200

```

SSCP Update Sequences.ST25

gccaggacag	tttttggggg	caccacgggtg	ctgaccatga	cgaccctcag	catcagcgcc	1260
aggaactctc	tgcccaaagt	ggcctacgcc	accgccatgg	actggttcat	agctgtgtgc	1320
tatgccttcg	tcttctcggc	gctgatagag	tttgccacgg	tcaattactt	taccaagaga	1380
ggctgggcct	gggatggcaa	aaaagccttg	gaagcagcca	agatcaagaa	aaagcgtgaa	1440
gtcatactaa	ataagtcaac	aaacgccttt	acaactggga	agatgtctca	ccccccaaac	1500
attccgaagg	aacagacccc	agcagggacg	tcgaatacaa	cctcagtctc	agtaaaaccc	1560
tctgaagaga	agacttctga	aagcaaaaag	acttacaaca	gtatcagcaa	aattgacaaa	1620
atgtcccgaa	tcgtattccc	agtcttggtc	ggcactttca	acttagttta	ctgggcaacg	1680
tatttgaata	gggagccggg	gataaaaagga	gccgcctctc	caaaataaacc	ggccacactc	1740
ccaaactcca	agacagccat	acttccagcg	aaatgggtacc	aaggagaggt	tttgctcaca	1800
gggactctcc	atatgtgagc	actatctttc	aggaaatfff	tgcatgttta	ataatatgta	1860
caaataatat	tgccttgatg	tttctatatg	taacttcaga	tgtttccaag	atgtcccatt	1920
gataattcga	gcaaacaact	ttctggaaaa	acaggatacg	atgactgaca	ctcagatgcc	1980
cagtatcata	cgttgatagt	ttacaaacaa	gatacgtata	tttttaactg	cttcaagtgt	2040
tacctaacaa	tgttttttat	acttcaaagt	tcatttcata	caaattttcc	cagtgaataa	2100
atatttttagg	aaactctcca	tgattattag	aagaccaact	atattgcgag	aaacagagat	2160
cataaagagc	acgtttttcca	ttatgaggaa	acttggacat	ttatgtacaa	aatgaattgc	2220
ctttgataat	tcttactgtt	ctgaaattag	gaaagtactt	gcatgatctt	acacgaagaa	2280
atagaatagg	caaactttta	tgtaggcaga	ttaataacag	aaatacatca	tatgttagat	2340
acacaaaata	tt					2352

<210> 60
 <211> 2373
 <212> DNA
 <213> Homo sapiens

<400> 60	
gcgcgcggcc	cggggcgcgg cgcgagcgg agctgcaggg cggcggcggg agcgcggggc 60
gcaagagccg	ctccgccggg agtgccgggg aagttcgcgc tggcagcatg gggcgggtgac 120
gccgcaccgg	ccttccgcgc ctgccagccg ggcgagagca ggcggaggag aaggaggatg 180
catcctcacc	gacggctcgc ctcccggggc ccgcgcgcag gtgccttgca gagagaggag 240
tagcttgctg	gctttgaacg cgtggcgtgg cagatatttc agaaagcttc aagaacaagc 300
tggagaaggg	aagagttatt cctccatatt cacctgcttc aactactatt cttattggga 360
atggacaatg	gaatgttctc tgggtttatc atgatcaaaa acctccttct cttttgtatt 420
tccatgaact	tatccagtca ctttggcttt tcacagatgc caaccagttc agtgaaagat 480
gagaccaatg	acaacatcac gatattttacc aggatcttgg atgggctctt ggatggctac 540
gacaacagac	ttcggccccg gctgggagag cgcatcactc aggtgaggac cgacatctac 600
gtcaccagct	tcggccccgg gtccgacacg gaaatggagt acaccataga cgtgtttttc 660

SSCP Update Sequences.ST25

cgacaaagct ggaaagatga aaggcttcgg tttaaggggc ccatgcāgcg cctccctctc 720
 aacaacctcc ttgccagcaa gatctggacc ccagacacgt tcttccacaa cggaagaag 780
 tccatcgctc acaacatgac cacgccaac aagctgctgc ggctggagga cgacggcacc 840
 ctgctctaca ccatgcgctt gaccatctct gcagagtgcc ccatgcagct tgaggacttc 900
 ccgatggatg cgcacgcttg ccctctgaaa ttggcagct atgcgtacc taattctgaa 960
 gtcgtttacg tctggaccaaa cggctccacc aagtcggtgg tggcggcga agatggctcc 1020
 agactgaacc agtaccacct gatggggcag acgggtgggca ctgagaacat cagcaccagc 1080
 acaggcgaat acacaatcat gacagctcac ttccacctga aaaggaagat tggctacttt 1140
 gtcattccaga cctaccttcc ctgcataatg accgtgatct tatcacaggt gtccttttgg 1200
 ctgaaccggg aatcagtcct agccaggaca gtttttgggg tcaccacggg gctgaccatg 1260
 acgacctca gcatcagcgc caggaaactct ctgcccaaag tggcctacgc caccgccatg 1320
 gactggttca tagctgtgtg ctatgccttc gtcttctcgg cgctgataga gtttgccacg 1380
 gtcaattact ttaccaagag aggctgggcc tgggatggca aaaaagcctt ggaagcagcc 1440
 aagatcaaga aaaagcgtga agtcatacta aataagtcaa caaacgcctt tacaactggg 1500
 aagatgtctc accccccaaa cattccgaag gaacagaccc cagcaggac gtcgaatata 1560
 acctcagtct cagtaaaacc ctctgaagag aagacttctg aaagcaaaaa gacttacaac 1620
 agtatcagca aaattgacaa aatgtcccga atcgtattcc cagtcttggt cggcactttc 1680
 aacttagttt actgggcaac gtatttgaat agggagccgg tgataaaagg agccgcctct 1740
 ccaaaataac cggccacact cccaaactcc aagacagcca tacttccagc gaaatggtac 1800
 caaggagagg ttttgctcac agggactctc catatgtgag cactatcttt caggaaattt 1860
 ttgcatgttt aataatatgt acaataata ttgccttgat gtttctatat gtaacttcag 1920
 atgtttccaa gatgtcccat tgataattcg agcaaacaac tttctggaaa aacaggatac 1980
 gatgactgac actcagatgc ccagtatcat acgttgatag tttaacaaca agatacgtat 2040
 atttttaact gcttcaagtg ttacctaaaca atgtttttta tacttcaaata gtcatttcat 2100
 acaaattttc ccagtgaata aatatttttag gaaactctcc atgattatta gaagaccaac 2160
 tatattgcca gaaacagaga tcataaagag cacgttttcc attatgagga aacttggaca 2220
 tttatgtaca aaatgaattg cttttgataa ttcttactgt tctgaaatta ggaaagtact 2280
 tgcattgatct tacacgaaga aatagaatag gcaaactttt atgtaggcag attaataaca 2340
 gaaatacatc atatgttaga tacacaaaat att 2373

<210> 61
 <211> 1974
 <212> DNA
 <213> Homo sapiens

<400> 61
 cgcgcgggga aggaagaag aggacgaggt ggcgcagaga ccgcgggaga acacagtgtc 60

SSCP Update Sequences.ST25

tccggaggaa atctgctcgg tccccggcag ccgcgcttcc cctttgatgt tttggtacgc	120
cgtggccatg cgcctcacat tagaattact gcactgggca gactaagttg gatctcctct	180
cttcagtga accctcaatt ccatcaaaaa ctaaagggat gtggagagtc cggaaaaggg	240
gctacttttg gatttggtcc ttccccctaa taatcgccgc tgtctgtgcg cagagtgtca	300
atgaccctag taatatgtcg ctgggttaaag agacgggtga tagactcctg aaaggctatg	360
acattcgtct gagaccagat tttggagggtc cccccgtggc tgtgggggatg aacattgaca	420
ttgccagcat cgatatggtt tctgaagtca atatggatta taccttgaca atgtactttc	480
aacaagcctg gagagataag aggctgtcct ataatgtaat acctttaaac ttgactctgg	540
acaacagagt ggcagaccag ctctgggtgc ctgataccta tttcctgaac gataagaagt	600
catttgtgca cggagtgact gttaagaacc gcatgattcg cctgcacccct gatggcaccg	660
tcctttatgg actcagaatc acaaccacag ctgcctgcat gatggaccta aggaggtacc	720
cactggatga acaaaactgc accttggaaa ttgagagcta tggatacaca actgatgaca	780
ttgagtttta ctggcgtggc gatgataatg cagtaacagg agtaacgaaa attgaacttc	840
cacagttctc tattgtagat tacaaactta tcaccaagaa gggtgttttt tccacaggtt	900
cctatcccag gttatccctc agctttaagc ttaagagaaa cattggctac tttatcctgc	960
aaacatacat gccttccatc ctgattacca tcctctcctg ggtctccttc tggattaatt	1020
acgatgcttc agctgcaagg gtggcattag gaatcacaaac tgcctcaca atgaccacaa	1080
tcaacacca cctccgggaa actctcccta aaatccccta tgtgaaggcc attgacatgt	1140
acctgatggg gtgctttgtc ttcgttttca tggcccttct ggaatatgcc ctagtcaact	1200
acatcttctt tgggaggggg cccaacgcc aaaagaaagc agctgagaag gctgccagt	1260
ccaacaatga gaagatgcgc ctggatgtca acaagatttt ttataaagat attaaacaaa	1320
atgggaccca atatcgatcc ttgtgggacc ctactggaaa cctctcccca actagacgga	1380
ctaccaatta cgatttctct ctgtatacga tggaccccca tgagaacatc ttactgagca	1440
ctctcgagat aaaaaatgaa atggccacat ctgaggctgt gatgggactt ggagaccca	1500
gaagcacaat gctagcctat gatgcctcca gcatccagta tcggaaagct gggttgccca	1560
ggcatagttt tggccgaaat gctctggaac gacatgtggc gcaaaagaaa agtcgcctga	1620
ggagacgcgc ctccaactg aaaatcacca tccctgactt gactgatgtg aatgccatag	1680
atcggtggtc ccgcataattc ttcccagtgg ttttttcctt cttcaacatc gtctattggc	1740
tttactatgt gaactaaaca tggcctccca ctggaagcaa ggactagatt cctcctcaaa	1800
ccagttgtac agcctgatgt aggacttggg aaacacatca atccaggaca aaagtgacgc	1860
taaaatacct tagttgctgg cctatcctgt ggtccatttc ataccatttg ggttgcttct	1920
gctaagtaat gaatacacta aggtccttgt ggttttccag ttaaaacgca agta	1974

<210> 62
 <211> 1974
 <212> DNA

SSCP Update Sequences.ST25

<213> Homo sapiens

<400> 62

```

cgcgcgggga agggagaag aggcagaggt ggcgcagaga ccgcgggaga acacagtgcc      60
tccggaggaa atctgctcgg tccccggcag ccgcgcttcc cctttgatgt tttggtacgc      120
cgtggccatg cgccctcacat tagaattact gcaactgggca gactaagttg gatctcctct      180
cttcagtga accctcaatt ccatcaaaaa ctaaagggat gtggagagtc cggaaaaggg      240
gctacttttg gatttgggtc tttcccttaa taatcgccgc tgtctgtgcg cagagtgtca      300
atgaccctag taatatgtcg ctggttaaag agacgggtga tagactcctg aaaggctatg      360
acattcgtct gagaccagat tttggaggtc cccccgtggc tgtggggatg aacattgaca      420
ttgccagcat cgatatggtt tctgaagtca atatggatta taccttgaca atgtactttc      480
aacaagcctg gagagataag aggctgtcct ataatgtaat acctttaaac ttgactctgg      540
acaacagagt ggcagaccag ctctgggtgc ctgataccta tttcctgaac gataagaagt      600
catttgtgca cggagtgact gttaagaacc gcatgattcg cctgcatcct gatggcaccg      660
tcctttatgg actcagaatc acaaccacag ctgcctgcat gatggaccta aggagggtacc      720
cactggatga acaaaactgc accttgaaa ttgagagcta tggatacaca actgatgaca      780
ttgagtttta ctggcgtggc gatgataatg cagtaacagg agtaacgaaa attgaacttc      840
cacagtcttc tattgtagat tacaaactta tcaccaagaa ggttggtttt tccacaggtt      900
cctatcccag gttatccctc agctttaagc ttaagagaaa cattggctac tttatcctgc      960
aaacatacat gccttccatc ctgattacca tcctctcctg ggtctccttc tggattaatt     1020
acgatgcttc agctgcaagg gtggcattag gaatcacaac tgtcctcaca atgaccacaa     1080
tcaacacca cctccgggaa actctcccta aaatccccta tgtgaaggcc attgacatgt     1140
acctgatggg gtgctttgtc ttcgttttca tggcccttct ggaatatgcc ctagtcaact     1200
acatcttctt tgggaggggg cccaacgcc aaaagaaagc agctgagaag gctgccagtg     1260
ccaacaatga gaagatgcgc ctggatgtca acaagatttt ttataaagat attaaacaaa     1320
atgggacca atactgatcc ttgtgggacc ctactggaaa cctctccca actagacgga     1380
ctaccaatta cgatttctct ctgtatacga tggaccccca tgagaacatc ttactgagca     1440
ctctcgagat aaaaaatgaa atggccacat ctgaggctgt gatgggactt ggagacccca     1500
gaagcacaat gctagcctat gatgcctcca gcatccagta tcggaaagct gggttgcccc     1560
ggcatagttt tggccgaaat gctctggaac gacatgtggc gcaaaagaaa agtcgcctga     1620
ggagacgcgc ctccaactg aaaatcacca tccctgactt gactgatgtg aatgccatag     1680
atcggtggtc ccgcatattc tttccagtgg ttttttctt cttcaacatc gtctattggc     1740
tttactatgt gaactaaaca tggcctccca ctggaagcaa ggactagatt cctcctcaaa     1800
ccagttgtac agcctgatgt aggacttgga aaacacatca atccaggaca aaagtgacgc     1860
taaaatacct tagttgctgg cctatcctgt ggtccatttc ataccatttg ggttgcttct     1920
gctaagtaat gaatacacta aggtccttgt ggttttccag taaaatgca agta          1974

```

SSCP Update Sequences.ST25

<210> 63
 <211> 3282
 <212> DNA
 <213> Homo sapiens

<400> 63
 gggacagggc tgaggatgag gagaaccctg gggacccaga agaccgtgcc ttgcctggaa 60
 gtcctgcctg taggcctgaa ggacttgccc taacagagcc tcaacaacta cctggtgatt 120
 cctacttcag ccccttggtg tgagcagctt ctcaacatga actacagcct ccacttggcc 180
 ttcgtgtgtc tgagtctctt cactgagagg atgtgcatcc aggggagtca gttcaacgtc 240
 gaggtcggca gaagtgacaa gctttccctg cctggccttg agaacctcac agcaggatat 300
 aacaaatttc tcaggcccaa ttttggtgga gaaccctgac agatagcgct gactctggac 360
 attgcaagta tctctagcat ttcagagagt aacatggact acacagccac catatacctc 420
 cgacagcgct ggatggacca gcggctggtg tttgaaggca acaagagctt cactctggat 480
 gccgcctcg tggagttcct ctgggtgcca gatacttaca ttgtggagtc caagaagtcc 540
 ttcttccatg aagtcactgt gggaaacagg ctcatccgcc tcttctcaa tggcacggtc 600
 ctgtatgccc tcagaatcac gacaactgtt gcatgtaaca tggatctgtc taaatacccc 660
 atggacacac agacatgcaa gttgcagctg gaaagctggg gctatgatgg aaatgatgtg 720
 gagttcacct ggctgagagg gaacgactct gtgcgtggac tggaacacct gcggcttgct 780
 cagtacacca tagagcggta tttcacctta gtcaccagat cgcagcagga gacaggaaat 840
 tacactagat tgggtcttaca gtttgagctt cggaggaatg ttctgtatctt ctttttgaa 900
 acctacgttc cttccacttt cctggtggtg ttgtcctggg tttcattttg gatctctctc 960
 gattcagtcc ctgcaagaac ctgcattgga gtgacgaccg tggtatcaat gaccacactg 1020
 atgatcgggt cccgcacttc tcttcccaac accaactgct tcatcaaggc catcgatgtg 1080
 tacctgggga tctgcttttag ctttgtgttt ggggccttgc tagaatatgc agttgctcac 1140
 tacagttcct tacagcagat ggcagccaaa gataggggga caacaaagga agtagaagaa 1200
 gtcagtatta ctaatatcat caacagctcc atctccagct ttaaacggaa gatcagcttt 1260
 gccagcattg aaatttccag cgacaacgtt gactacagtg acttgacaat gaaaaccagc 1320
 gacaagttca agtttgtctt ccgagaaaag atgggcagga ttgttgatta tttcacaatt 1380
 caaaacccca gtaatgttga tcaactattcc aaactactgt ttcctttgat ttttatgcta 1440
 gccaatgtat tttactgggc atactacatg ttttttgag tcaatgttaa atttcttgca 1500
 tgccataggt cttcaacagg acaagataat gatgtaaatg gtatttttagg ccaagtgtgc 1560
 acccacatcc aatggtgcta caagtgactg aaataatatt tgagtctttc tgctcaaaga 1620
 atgaagctcc aaccattgtt ctaagctgtg tagaagtcct agcattatag gatcttgtaa 1680
 tagaaacatc agtccattcc tctttcatct taatcaagga cattcccatg gagcccaaga 1740
 ttacaaatgt actcagggtt gtttattcgg tggctccctg gtttgcatctt acctcatata 1800

SSCP Update Sequences.ST25

aagaatggga aggagaccat tgggtaaccc tcaagtgtca gaagttgttt ctaaagtaac 1860
tatacatggt ttttactaaa tctctgcagt gcttataaaa tacattgttg cctatttagg 1920
gagtaacatt ttctagtttt tgtttctggt taaaatgaaa tatgggctta tgtcaattca 1980
ttggaagtca atgcactaac tcaataccaa gatgagtttt taaataatga atattattta 2040
ataccacaac agaattatcc ccaatttcca ataagtccta tcattgaaaa ttcaaatata 2100
agtgaagaaa aaattagtag atcaacaatc taaacaaatc cctcggttct aagatacaat 2160
ggattcccca tactggaagg actctgaggc tttattcccc cactatgcat atcttatcat 2220
tttattatta tacacacatc catcctaaac tataactaaag cccttttccc atgcatggat 2280
ggaaatggaa gatttttttg taacttggtc tagaagtctt aatatgggct gttgccatga 2340
aggcttgcat aattgagtc attttctagc tgcctttatt cacatagtgat tgggggtacta 2400
aaagtactgg gttgactcag agagtcgctg tcattctgtc attgctgcta ctctaact 2460
gagcaacact ctccagtgag cagatcccc ctatcattcc aagaggagca ttcattccctt 2520
tgctctaata atcaggaatg atgcttatta gaaaacaaac tgcttgaccc aggaacaagt 2580
ggcttagctt aagtaaaact ggctttgctc agatccctga tccttccagc tgggtctgctc 2640
tgagtggctt atcccgcag agcaggagcg tgctggccct gagtactgaa ctttctgagt 2700
aacaatgaga cacgttacag aacctatgtt cagggttgcgg gtgagctgcc ctctccaaat 2760
ccagccagag atgcacattc ctcgccagc ctgagccaac agtaccacaa gtgatttttg 2820
agtgtgccag ggtaaaaggc tccagttcag cctcagttat tttagacaat ctgcccattc 2880
ttaatttctt agcttctctg tctaataaat gcacggcttt acctttcctg tcagaaataa 2940
accaaggctc taaaagatga tttcccttct gtaactccct agagccacag gttctcattc 3000
cttttcccat tatacttctc acaattcagt ttctatgagt ttgatcacct gattttttta 3060
acaaaatatt tctaacggga atgggtggga gtgctgggta aaagagatga aatgtgggtg 3120
tatgagccaa tcatatttgt gattttttta aaaaagttta aaaggaaata tctgttctga 3180
aaccctactt aagcattgtt tttatataaa aacaatgata aagatgtgaa ctgtgaaata 3240
aatataccat attagctacc caccaaaaaa aaaaaaaaaa aa 3282

<210> 64
<211> 270
<212> DNA
<213> Homo sapiens

<400> 64
gggccattcg ggaattactg cccagcagcc gactaagttg cattccttga atcttcgcag 60
aaaagacaat tcttttaatc agagtttagta atgtggacag tacaaaatcg agagagtctg 120
gggcttctct ctttccctgt gatgattacc atggctctgt gtgcacacag gtgagctgct 180
gttgttgaat ctgcctctct ctctctcttt ttttcttggg atgtttcttt ttacgtgtct 240
gctggatcat gtatcttggt gtttgggggt 270

SSCP Update Sequences.ST25

<210> 65
 <211> 238
 <212> DNA
 <213> Homo sapiens

<400> 65
 atggctatac cactgatgac attgaatttt actggaatgg aggagaaggg gcagtcactg 60
 gtgttaataa aatcgaactt cctcaatttt caattgttga ctacaagatg gtgtctaaga 120
 aggtggagtt cacaacaggt gaggttgttt cccccaaat gtactagggg tgctgtgaaa 180
 ggaagaagat ggttccaacc aaataatggg ctgattactt gtcttttgtt tctcaact 238

<210> 66
 <211> 345
 <212> DNA
 <213> Homo sapiens

<400> 66
 gcaccaataa ggaagtggca aatggcatct gtcctctcaa tcttgaaaaa ggaacttaat 60
 agtggcgcct tcagctaagt gttgtctttc tctttcacag gaatcacgac agtgcttaca 120
 atgacaacca tcagcaccca cctcaggag accctgccaa agatccctta tgtcaaagcg 180
 attgatattt atctgatggg ttgctttgtg tttgtgttcc tggctctgct ggagtatgcc 240
 tttgtaaatt acatcttctt tgggaaaggc cctcagaaaa agggagctag caaacaagac 300
 cagagtgcc aatgagaagaa taaactggag atgaataaag tccag 345

<210> 67
 <211> 190
 <212> DNA
 <213> Homo sapiens

<400> 67
 ggggtgggccg ggcgggcggcg ggcagggcgc ggggtgcccgc gggcgctggc ggctgagccg 60
 cccctgacct cgctctttgt gctccctgtc cctccccag tgtgaacgat cccgggaaca 120
 tgtcctttgt gaaggagacg gtggacaagc tgttgaaagg ctacgacatt cgcctaagac 180
 ccgacttcgg 190

<210> 68
 <211> 253
 <212> DNA
 <213> Homo sapiens

<400> 68
 gtgcctatcc tcgactgtca ctgagctttc ggttgaagag gaacattgga tacttcattc 60
 ttcagactta tatgccctct atactgataa cgattctgtc gtgggtgtcc ttctggatca 120
 attatgatgc atctgctgct agagttgccc tcggtatgtg ctatttttaa gtgatattta 180
 aatgtaaagt aaccgtatca ttacagtatt gagagttcaa aggctgtagt tcaactacca 240
 ttttttgaca gcg 253

<210> 69
 <211> 288

SSCP Update Sequences.ST25

<212> DNA
 <213> Homo sapiens

<400> 69
 acggttactc atcggaggac atcgtctact actggtcgga gagccaggag cacatccacg 60
 ggctggacaa gctgcagctg gcgcagttca ccatcaccag ctaccgcttc accacggagc 120
 tgatgaactt caagtccggt aacatatgcc cgccgcccct tccgcatgtg cccgccgccc 180
 cttccgcgcg cgcccaccgc cccttccgcg cgcgcccacc gccccttccg cgtgcgcccc 240
 cctgtggttt tcatgtttt tagtcaagcc gcccgcaggc ccccaggg 288

<210> 70
 <211> 288
 <212> DNA
 <213> Homo sapiens

<400> 70
 acggttactc atcggaggac atcgtctact actggtcgga gagccaggag cacatccacg 60
 ggctggacaa gctgcagctg gcgcagttca ccatcaccag ctaccgcttc accacggagc 120
 tgatgaactt caagtccggt aacatatgcc cgccgcccct tccgcatgtg cccgccgccc 180
 cttccgcgcg cgcccaccgc cccttccgcg cgcgcccacc gccccttccg cgtgcgcccc 240
 cctgtggttt tcatgtttt tagtcaacgc gcccgcaggc ccccaggg 288

<210> 71
 <211> 288
 <212> DNA
 <213> Homo sapiens

<400> 71
 acggttactc atcggaggac atcgtctact actggtcgga gagccaggag cacatccacg 60
 ggctggacaa gctgcagctg gcgcagttca ccatcaccag ctaccgcttc accacggagc 120
 tgatgaactt caagtccggt aacatatgcc cgccgcccct tccgcatgtg cccgccgccc 180
 cttccgcgcg cgcccaccgc cccttccgcg tgcgcccgcc tgtggttttc atgcttttta 240
 gtcaagcgcc cgcaggcccc cagggcctct ggggatgcag ctgggacg 288

<210> 72
 <211> 170
 <212> DNA
 <213> Homo sapiens

<400> 72
 accggtgatg tggcttggtt tagtcatacc ctaaagattg ctcttaagag tgatcttga 60
 tgcaaagtgt catgacagtt tcctagttat tttttcttct tttctttag ttactacatc 120
 cagattcctc aagatggatt cctgagcgaa taagcctaca agccccttcc 170

<210> 73
 <211> 221
 <212> PRT
 <213> Homo sapiens

<400> 73

SSCP Update Sequences.ST25

Met Glu Gln Thr Val Leu Val Pro Pro Gly Pro Asp Ser Phe Asn Phe
 1 5 10 15
 Phe Thr Arg Glu Ser Leu Ala Ala Ile Glu Arg Arg Ile Ala Glu Glu
 20 25 30
 Lys Ala Lys Asn Pro Lys Pro Asp Lys Lys Asp Asp Asp Glu Asn Gly
 35 40 45
 Pro Lys Pro Asn Ser Asp Leu Glu Ala Gly Lys Asn Leu Pro Phe Ile
 50 55 60
 Tyr Gly Asp Ile Pro Pro Glu Met Val Ser Glu Pro Leu Glu Asp Leu
 65 70 75 80
 Asp Pro Tyr Tyr Ile Asn Lys Lys Thr Phe Ile Val Leu Asn Lys Leu
 85 90 95
 Lys Ala Ile Phe Arg Phe Ser Ala Thr Ser Ala Leu Tyr Ile Leu Thr
 100 105 110
 Pro Phe Asn Pro Leu Arg Lys Ile Ala Ile Lys Ile Leu Val His Ser
 115 120 125
 Leu Phe Ser Met Leu Ile Met Cys Thr Ile Leu Thr Asn Cys Val Phe
 130 135 140
 Met Thr Met Ser Asn Pro Pro Asp Trp Thr Lys Asn Val Glu Tyr Thr
 145 150 155 160
 Phe Thr Gly Ile Tyr Thr Phe Glu Ser Leu Ile Lys Ile Ile Ala Arg
 165 170 175
 Gly Phe Cys Leu Glu Asp Phe Thr Phe Leu Arg Asp Pro Trp Asn Trp
 180 185 190
 Leu Asp Phe Thr Val Ile Thr Phe Ala Tyr Val Thr Glu Phe Val Asp
 195 200 205
 Leu Gly Asn Val Ser Ala Leu Arg Thr Phe Arg Val Leu
 210 215 220
 <210> 74
 <211> 383
 <212> PRT
 <213> Homo sapiens
 <400> 74
 Met Glu Gln Thr Val Leu Val Pro Pro Gly Pro Asp Ser Phe Asn Phe
 1 5 10 15

SSCP Update Sequences.ST25

Phe Thr Arg Glu Ser Leu Ala Ala Ile Glu Arg Arg Ile Ala Glu Glu
 20 25 30
 Lys Ala Lys Asn Pro Lys Pro Asp Lys Lys Asp Asp Asp Glu Asn Gly
 35 40 45
 Pro Lys Pro Asn Ser Asp Leu Glu Ala Gly Lys Asn Leu Pro Phe Ile
 50 55 60
 Tyr Gly Asp Ile Pro Pro Glu Met Val Ser Glu Pro Leu Glu Asp Leu
 65 70 75 80
 Asp Pro Tyr Tyr Ile Asn Lys Lys Thr Phe Ile Val Leu Asn Lys Leu
 85 90 95
 Lys Ala Ile Phe Arg Phe Ser Ala Thr Ser Ala Leu Tyr Ile Leu Thr
 100 105 110
 Pro Phe Asn Pro Leu Arg Lys Ile Ala Ile Lys Ile Leu Val His Ser
 115 120 125
 Leu Phe Ser Met Leu Ile Met Cys Thr Ile Leu Thr Asn Cys Val Phe
 130 135 140
 Met Thr Met Ser Asn Pro Pro Asp Trp Thr Lys Asn Val Glu Tyr Thr
 145 150 155 160
 Phe Thr Gly Ile Tyr Thr Phe Glu Ser Leu Ile Lys Ile Ile Ala Arg
 165 170 175
 Gly Phe Cys Leu Glu Asp Phe Thr Phe Leu Arg Asp Pro Trp Asn Trp
 180 185 190
 Leu Asp Phe Thr Val Ile Thr Phe Ala Tyr Val Thr Glu Phe Val Asp
 195 200 205
 Leu Gly Asn Val Ser Ala Leu Arg Thr Phe Arg Val Leu Arg Ala Leu
 210 215 220
 Lys Thr Ile Ser Val Ile Pro Gly Leu Lys Thr Ile Val Gly Ala Leu
 225 230 235 240
 Ile Gln Ser Val Lys Lys Leu Ser Asp Val Met Ile Leu Thr Val Phe
 245 250 255
 Cys Leu Ser Val Phe Ala Leu Ile Gly Leu Gln Leu Phe Met Gly Asn
 260 265 270
 Leu Arg Asn Lys Cys Ile Gln Trp Pro Pro Thr Asn Ala Ser Leu Glu
 275 280 285

SSCP Update Sequences.ST25

Glu His Ser Ile Glu Lys Asn Ile Thr Val Asn Tyr Asn Gly Thr Leu
 290 295 300

Ile Asn Glu Thr Val Phe Glu Phe Asp Trp Lys Ser Tyr Ile Gln Asp
 305 310 315 320

Ser Arg Tyr His Tyr Phe Leu Glu Gly Phe Leu Asp Ala Leu Leu Cys
 325 330 335

Gly Asn Ser Ser Asp Ala Gly Gln Cys Pro Glu Gly Tyr Met Cys Val
 340 345 350

Lys Ala Gly Arg Asn Pro Asn Tyr Gly Tyr Thr Ser Phe Asp Thr Phe
 355 360 365

Ser Trp Ala Phe Leu Ser Leu Phe Arg Leu Met Thr Gln Asp Phe
 370 375 380

<210> 75
 <211> 2009
 <212> PRT
 <213> Homo sapiens

<400> 75

Met Glu Gln Thr Val Leu Val Pro Pro Gly Pro Asp Ser Phe Asn Phe
 1 5 10 15

Phe Thr Arg Glu Ser Leu Ala Ala Ile Glu Arg Arg Ile Ala Glu Glu
 20 25 30

Lys Ala Lys Asn Pro Lys Pro Asp Lys Lys Asp Asp Asp Glu Asn Gly
 35 40 45

Pro Lys Pro Asn Ser Asp Leu Glu Ala Gly Lys Asn Leu Pro Phe Ile
 50 55 60

Tyr Gly Asp Ile Pro Pro Glu Met Val Ser Glu Pro Leu Glu Asp Leu
 65 70 75 80

Asp Pro Tyr Tyr Ile Asn Lys Lys Thr Phe Ile Val Leu Asn Lys Leu
 85 90 95

Lys Ala Ile Phe Arg Phe Ser Ala Thr Ser Ala Leu Tyr Ile Leu Thr
 100 105 110

Pro Phe Asn Pro Leu Arg Lys Ile Ala Ile Lys Ile Leu Val His Ser
 115 120 125

Leu Phe Ser Met Leu Ile Met Cys Thr Ile Leu Thr Asn Cys Val Phe
 130 135 140

Met Thr Met Ser Asn Pro Pro Asp Trp Thr Lys Asn Val Glu Tyr Thr
 Page 124

SSCP Update Sequences.ST25

145 150 155 160
 Phe Thr Gly Ile Tyr Thr Phe Glu Ser Leu Ile Lys Ile Ile Ala Arg
 165 170 175
 Gly Phe Cys Leu Glu Asp Phe Thr Phe Leu Arg Asp Pro Trp Asn Trp
 180 185 190
 Leu Asp Phe Thr Val Ile Thr Phe Ala Tyr Val Thr Glu Phe Val Asp
 195 200 205
 Leu Gly Asn Val Ser Ala Leu Arg Thr Phe Arg Val Leu Arg Ala Leu
 210 215 220
 Lys Thr Ile Ser Val Ile Pro Gly Leu Lys Thr Ile Val Gly Ala Leu
 225 230 235 240
 Ile Gln Ser Val Lys Lys Leu Ser Asp Val Met Ile Leu Thr Val Phe
 245 250 255
 Cys Leu Ser Val Phe Ala Leu Ile Gly Leu Gln Leu Phe Met Gly Asn
 260 265 270
 Leu Arg Asn Lys Cys Ile Gln Trp Pro Pro Thr Asn Ala Ser Leu Glu
 275 280 285
 Glu His Ser Ile Glu Lys Asn Ile Thr Val Asn Tyr Asn Gly Thr Leu
 290 295 300
 Ile Asn Glu Thr Val Phe Glu Phe Asp Trp Lys Ser Tyr Ile Gln Asp
 305 310 315 320
 Ser Arg Tyr His Tyr Phe Leu Glu Gly Phe Leu Asp Ala Leu Leu Cys
 325 330 335
 Gly Asn Ser Ser Asp Ala Gly Gln Cys Pro Glu Gly Tyr Met Cys Val
 340 345 350
 Lys Ala Gly Arg Asn Pro Asn Tyr Gly Tyr Thr Ser Phe Asp Thr Phe
 355 360 365
 Ser Trp Ala Phe Leu Ser Leu Phe Arg Leu Met Thr Gln Asp Phe Trp
 370 375 380
 Glu Asn Leu Tyr Gln Leu Thr Leu Arg Ala Pro Gly Lys Thr Tyr Met
 385 390 395 400
 Ile Phe Phe Val Leu Val Ile Phe Leu Gly Ser Phe Tyr Leu Ile Asn
 405 410 415
 Leu Ile Leu Ala Val Val Ala Met Ala Tyr Glu Glu Gln Asn Gln Ala

SSCP Update Sequences.ST25
425 430

420

Thr Leu Glu Glu Ala Glu Gln Lys Glu Ala Glu Phe Gln Gln Met Ile
435 440 445

Glu Gln Leu Lys Lys Gln Gln Glu Ala Ala Gln Gln Ala Ala Thr Ala
450 455 460

Thr Ala Ser Glu His Ser Arg Glu Pro Ser Ala Ala Gly Arg Leu Ser
465 470 475 480

Asp Ser Ser Ser Glu Ala Ser Lys Leu Ser Ser Lys Ser Ala Lys Glu
485 490 495

Arg Arg Asn Arg Arg Lys Lys Arg Lys Gln Lys Glu Gln Ser Gly Gly
500 505 510

Glu Glu Lys Asp Glu Asp Glu Phe Gln Lys Ser Glu Ser Glu Asp Ser
515 520 525

Ile Arg Arg Lys Gly Phe Arg Phe Ser Ile Glu Gly Asn Arg Leu Thr
530 535 540

Tyr Glu Lys Arg Tyr Ser Ser Pro His Gln Ser Leu Leu Ser Ile Arg
545 550 555 560

Gly Ser Leu Phe Ser Pro Arg Arg Asn Ser Arg Thr Ser Leu Phe Ser
565 570 575

Phe Arg Gly Arg Ala Lys Asp Val Gly Ser Glu Asn Asp Phe Ala Asp
580 585 590

Asp Glu His Ser Thr Phe Glu Asp Asn Glu Ser Arg Arg Asp Ser Leu
595 600 605

Phe Val Pro Arg Arg His Gly Glu Arg Arg Asn Ser Asn Leu Ser Gln
610 615 620

Thr Ser Arg Ser Ser Arg Met Leu Ala Val Phe Pro Ala Asn Gly Lys
625 630 635 640

Met His Ser Thr Val Asp Cys Asn Gly Val Val Ser Leu Val Gly Gly
645 650 655

Pro Ser Val Pro Thr Ser Pro Val Gly Gln Leu Leu Pro Glu Val Ile
660 665 670

Ile Asp Lys Pro Ala Thr Asp Asp Asn Gly Thr Thr Thr Glu Thr Glu
675 680 685

Met Arg Lys Arg Arg Ser Ser Ser Phe His Val Ser Met Asp Phe Leu
Page 126

SSCP Update Sequences.ST25

690

695

700

Glu Asp Pro Ser Gln Arg Gln Arg Ala Met Ser Ile Ala Ser Ile Leu
 705 710 715 720

Thr Asn Thr Val Glu Glu Leu Glu Glu Ser Arg Gln Lys Cys Pro Pro
 725 730 735

Cys Trp Tyr Lys Phe Ser Asn Ile Phe Leu Ile Trp Asp Cys Ser Pro
 740 745 750

Tyr Trp Leu Lys Val Lys His Val Val Asn Leu Val Val Met Asp Pro
 755 760 765

Phe Val Asp Leu Ala Ile Thr Ile Cys Ile Val Leu Asn Thr Leu Phe
 770 775 780

Met Ala Met Glu His Tyr Pro Met Thr Asp His Phe Asn Asn Val Leu
 785 790 795 800

Thr Val Gly Asn Leu Val Phe Thr Gly Ile Phe Thr Ala Glu Met Phe
 805 810 815

Leu Lys Ile Ile Ala Met Asp Pro Tyr Tyr Tyr Phe Gln Glu Gly Trp
 820 825 830

Asn Ile Phe Asp Gly Phe Ile Val Thr Leu Ser Leu Val Glu Leu Gly
 835 840 845

Leu Ala Asn Val Glu Gly Leu Ser Val Leu Arg Ser Phe Arg Leu Leu
 850 855 860

Arg Val Phe Lys Leu Ala Lys Ser Trp Pro Thr Leu Asn Met Leu Ile
 865 870 875 880

Lys Ile Ile Gly Asn Ser Val Gly Ala Leu Gly Asn Leu Thr Leu Val
 885 890 895

Leu Ala Ile Ile Val Phe Ile Phe Ala Val Val Gly Met Gln Leu Phe
 900 905 910

Gly Lys Ser Tyr Lys Asp Cys Val Cys Lys Ile Ala Ser Asp Cys Gln
 915 920 925

Leu Pro Arg Trp His Met Asn Asp Phe Phe His Ser Phe Leu Ile Val
 930 935 940

Phe Arg Val Leu Cys Gly Glu Trp Ile Glu Thr Met Trp Asp Cys Met
 945 950 955 960

Glu Val Ala Gly Gln Ala Met Cys Leu Thr Val Phe Met Met Val Met

SSCP Update Sequences.ST25

965

970

975

Val Ile Gly Asn Leu Val Val Leu Asn Leu Phe Leu Ala Leu Leu Leu
 980 985 990

Ser Ser Phe Ser Ala Asp Asn Leu Ala Ala Thr Asp Asp Asp Asn Glu
 995 1000 1005

Met Asn Asn Leu Gln Ile Ala Val Asp Arg Met His Lys Gly Val
 1010 1015 1020

Ala Tyr Val Lys Arg Lys Ile Tyr Glu Phe Ile Gln Gln Ser Phe
 1025 1030 1035

Ile Arg Lys Gln Lys Ile Leu Asp Glu Ile Lys Pro Leu Asp Asp
 1040 1045 1050

Leu Asn Asn Lys Lys Asp Ser Cys Met Ser Asn His Thr Thr Glu
 1055 1060 1065

Ile Gly Lys Asp Leu Asp Tyr Leu Lys Asp Val Asn Gly Thr Thr
 1070 1075 1080

Ser Gly Ile Gly Thr Gly Ser Ser Val Glu Lys Tyr Ile Ile Asp
 1085 1090 1095

Glu Ser Asp Tyr Met Ser Phe Ile Asn Asn Pro Ser Leu Thr Val
 1100 1105 1110

Thr Val Pro Ile Ala Val Gly Glu Ser Asp Phe Glu Asn Leu Asn
 1115 1120 1125

Thr Glu Asp Phe Ser Ser Glu Ser Asp Leu Glu Glu Ser Lys Glu
 1130 1135 1140

Lys Leu Asn Glu Ser Ser Ser Ser Ser Glu Gly Ser Thr Val Asp
 1145 1150 1155

Ile Gly Ala Pro Val Glu Glu Gln Pro Val Val Glu Pro Glu Glu
 1160 1165 1170

Thr Leu Glu Pro Glu Ala Cys Phe Thr Glu Gly Cys Val Gln Arg
 1175 1180 1185

Phe Lys Cys Cys Gln Ile Asn Val Glu Glu Gly Arg Gly Lys Gln
 1190 1195 1200

Trp Trp Asn Leu Arg Arg Thr Cys Phe Arg Ile Val Glu His Asn
 1205 1210 1215

Trp Phe Glu Thr Phe Ile Val Phe Met Ile Leu Leu Ser Ser Gly

SSCP Update Sequences.ST25

1220														
Ala	Leu	Ala	Phe	Glu	Asp	Ile	Tyr	Ile	Asp	Gln	Arg	Lys	Thr	Ile
1235						1240					1245			
Lys	Thr	Met	Leu	Glu	Tyr	Ala	Asp	Lys	Val	Phe	Thr	Tyr	Ile	Phe
1250						1255					1260			
Ile	Leu	Glu	Met	Leu	Leu	Lys	Trp	Val	Ala	Tyr	Gly	Tyr	Gln	Thr
1265						1270					1275			
Tyr	Phe	Thr	Asn	Ala	Trp	Cys	Trp	Leu	Asp	Phe	Leu	Ile	Val	Asp
1280						1285					1290			
Val	Ser	Leu	Val	Ser	Leu	Thr	Ala	Asn	Ala	Leu	Gly	Tyr	Ser	Glu
1295						1300					1305			
Leu	Gly	Ala	Ile	Lys	Ser	Leu	Arg	Thr	Leu	Arg	Ala	Leu	Arg	Pro
1310						1315					1320			
Leu	Arg	Ala	Leu	Ser	Arg	Phe	Glu	Gly	Met	Arg	Val	Val	Val	Asn
1325						1330					1335			
Ala	Leu	Leu	Gly	Ala	Ile	Pro	Ser	Ile	Met	Asn	Val	Leu	Leu	Val
1340						1345					1350			
Cys	Leu	Ile	Phe	Trp	Leu	Ile	Phe	Ser	Ile	Met	Gly	Val	Asn	Leu
1355						1360					1365			
Phe	Ala	Gly	Lys	Phe	Tyr	His	Cys	Ile	Asn	Thr	Thr	Thr	Gly	Asp
1370						1375					1380			
Arg	Phe	Asp	Ile	Glu	Asp	Val	Asn	Asn	His	Thr	Asp	Cys	Leu	Lys
1385						1390					1395			
Leu	Ile	Glu	Arg	Asn	Glu	Thr	Ala	Arg	Trp	Lys	Asn	Val	Lys	Val
1400						1405					1410			
Asn	Phe	Asp	Asn	Val	Gly	Phe	Gly	Tyr	Leu	Ser	Leu	Leu	Gln	Val
1415						1420					1425			
Ala	Thr	Phe	Lys	Gly	Trp	Met	Asp	Ile	Met	Tyr	Ala	Ala	Val	Asp
1430						1435					1440			
Ser	Arg	Asn	Val	Glu	Leu	Gln	Pro	Lys	Tyr	Glu	Lys	Ser	Leu	Tyr
1445						1450					1455			
Met	Tyr	Leu	Tyr	Phe	Val	Ile	Phe	Ile	Ile	Phe	Gly	Ser	Phe	Phe
1460						1465					1470			
Thr	Leu	Asn	Leu	Phe	Ile	Gly	Val	Ile	Ile	Asp	Asn	Phe	Asn	Gln

SSCP Update Sequences ST25

1475													
Gln	Lys	Lys	Lys	Phe	Gly	Gly	Gln	Asp	Ile	Phe	Met	Thr	Glu
1490						1495					1500		
Gln	Lys	Lys	Tyr	Tyr	Asn	Ala	Met	Lys	Lys	Leu	Gly	Ser	Lys
1505						1510					1515		
Pro	Gln	Lys	Pro	Ile	Pro	Arg	Pro	Gly	Asn	Lys	Phe	Gln	Gly
1520						1525					1530		
Val	Phe	Asp	Phe	Val	Thr	Arg	Gln	Val	Phe	Asp	Ile	Ser	Ile
1535						1540					1545		
Ile	Leu	Ile	Cys	Leu	Asn	Met	Val	Thr	Met	Met	Val	Glu	Thr
1550						1555					1560		
Asp	Gln	Ser	Glu	Tyr	Val	Thr	Thr	Ile	Leu	Ser	Arg	Ile	Asn
1565						1570					1575		
Val	Phe	Ile	Val	Leu	Phe	Thr	Gly	Glu	Cys	Val	Leu	Lys	Leu
1580						1585					1590		
Ser	Leu	Arg	His	Tyr	Tyr	Phe	Thr	Ile	Gly	Trp	Asn	Ile	Phe
1595						1600					1605		
Phe	Val	Val	Val	Ile	Leu	Ser	Ile	Val	Gly	Met	Phe	Leu	Ala
1610						1615					1620		
Leu	Ile	Glu	Lys	Tyr	Phe	Val	Ser	Pro	Thr	Leu	Phe	Arg	Val
1625						1630					1635		
Arg	Leu	Ala	Arg	Ile	Gly	Arg	Ile	Leu	Arg	Leu	Ile	Lys	Gly
1640						1645					1650		
Lys	Gly	Ile	Arg	Thr	Leu	Leu	Phe	Ala	Leu	Met	Met	Ser	Leu
1655						1660					1665		
Ala	Leu	Phe	Asn	Ile	Gly	Leu	Leu	Leu	Phe	Leu	Val	Met	Phe
1670						1675					1680		
Tyr	Ala	Ile	Phe	Gly	Met	Ser	Asn	Phe	Ala	Tyr	Val	Lys	Arg
1685						1690					1695		
Val	Gly	Ile	Asp	Asp	Met	Phe	Asn	Phe	Glu	Thr	Phe	Gly	Asn
1700						1705					1710		
Met	Ile	Cys	Leu	Phe	Gln	Ile	Thr	Thr	Ser	Ala	Gly	Trp	Asp
1715						1720					1725		
Leu	Leu	Ala	Pro	Ile	Leu	Asn	Ser	Lys	Pro	Pro	Asp	Cys	Asp

SSCP Update Sequences.ST25

1730													
Asn	Lys	Val	Asn	Pro	Gly	Ser	Ser	Val	Lys	Gly	Asp	Cys	Gly
1745						1750					1755		
Pro	Ser	Val	Gly	Ile	Phe	Phe	Phe	Val	Ser	Tyr	Ile	Ile	Ile
1760						1765					1770		
Phe	Leu	Val	Val	Val	Asn	Met	Tyr	Ile	Ala	Val	Ile	Leu	Glu
1775						1780					1785		
Phe	Ser	Val	Ala	Thr	Glu	Glu	Ser	Ala	Glu	Pro	Leu	Ser	Glu
1790						1795					1800		
Asp	Phe	Glu	Met	Phe	Tyr	Glu	Val	Trp	Glu	Lys	Phe	Asp	Pro
1805						1810					1815		
Ala	Thr	Gln	Phe	Met	Glu	Phe	Glu	Lys	Leu	Ser	Gln	Phe	Ala
1820						1825					1830		
Ala	Leu	Glu	Pro	Pro	Leu	Asn	Leu	Pro	Gln	Pro	Asn	Lys	Leu
1835						1840					1845		
Leu	Ile	Ala	Met	Asp	Leu	Pro	Met	Val	Ser	Gly	Asp	Arg	Ile
1850						1855					1860		
Cys	Leu	Asp	Ile	Leu	Phe	Ala	Phe	Thr	Lys	Arg	Val	Leu	Gly
1865						1870					1875		
Ser	Gly	Glu	Met	Asp	Ala	Leu	Arg	Ile	Gln	Met	Glu	Glu	Arg
1880						1885					1890		
Met	Ala	Ser	Asn	Pro	Ser	Lys	Val	Ser	Tyr	Gln	Pro	Ile	Thr
1895						1900					1905		
Thr	Leu	Lys	Arg	Lys	Gln	Glu	Glu	Val	Ser	Ala	Val	Ile	Ile
1910						1915					1920		
Arg	Ala	Tyr	Arg	Arg	His	Leu	Leu	Lys	Arg	Thr	Val	Lys	Gln
1925						1930					1935		
Ser	Phe	Thr	Tyr	Asn	Lys	Asn	Lys	Ile	Lys	Gly	Gly	Ala	Asn
1940						1945					1950		
Leu	Ile	Lys	Glu	Asp	Met	Ile	Ile	Asp	Arg	Ile	Asn	Glu	Asn
1955						1960					1965		
Ile	Thr	Glu	Lys	Thr	Asp	Leu	Thr	Met	Ser	Thr	Ala	Ala	Cys
1970						1975					1980		
Pro	Ser	Tyr	Asp	Arg	Val	Thr	Lys	Pro	Ile	Val	Glu	Lys	His

1985 SSCP Update Sequences.ST25
1990 1995

Gln Glu Gly Lys Asp Glu Lys Ala Lys Gly Lys
2000 2005

<210> 76
<211> 2009
<212> PRT
<213> Homo sapiens
<400> 76

Met Glu Gln Thr Val Leu Val Pro Pro Gly Pro Asp Ser Phe Asn Phe
1 5 10 15

Phe Thr Arg Glu Ser Leu Ala Ala Ile Glu Arg Arg Ile Ala Glu Glu
20 25 30

Lys Ala Lys Asn Pro Lys Pro Asp Lys Lys Asp Asp Asp Glu Asn Gly
35 40 45

Pro Lys Pro Asn Ser Asp Leu Glu Ala Gly Lys Asn Leu Pro Phe Ile
50 55 60

Tyr Gly Asp Ile Pro Pro Glu Met Val Ser Glu Pro Leu Glu Asp Leu
65 70 75 80

Asp Pro Tyr Tyr Ile Asn Lys Lys Thr Phe Ile Val Leu Asn Lys Leu
85 90 95

Lys Ala Ile Phe Arg Phe Ser Ala Thr Ser Ala Leu Tyr Ile Leu Thr
100 105 110

Pro Phe Asn Pro Leu Arg Lys Ile Ala Ile Lys Ile Leu Val His Ser
115 120 125

Leu Phe Ser Met Leu Ile Met Cys Thr Ile Leu Thr Asn Cys Val Phe
130 135 140

Met Thr Met Ser Asn Pro Pro Asp Trp Thr Lys Asn Val Glu Tyr Thr
145 150 155 160

Phe Thr Gly Ile Tyr Thr Phe Glu Ser Leu Ile Lys Ile Ile Ala Arg
165 170 175

Gly Phe Cys Leu Glu Asp Phe Thr Phe Leu Arg Asp Pro Trp Asn Trp
180 185 190

Leu Asp Phe Thr Val Ile Thr Phe Ala Tyr Val Thr Glu Phe Val Asp
195 200 205

Leu Gly Asn Val Ser Ala Leu Arg Thr Phe Arg Val Leu Arg Ala Leu
210 215 220

SSCP Update Sequences.ST25

Lys Thr Ile Ser Val Ile Pro Gly Leu Lys Thr Ile Val Gly Ala Leu
 225 230 235 240
 Ile Gln Ser Val Lys Lys Leu Ser Asp Val Met Ile Leu Thr Val Phe
 245 250 255
 Cys Leu Ser Val Phe Ala Leu Ile Gly Leu Gln Leu Phe Met Gly Asn
 260 265 270
 Leu Arg Asn Lys Cys Ile Gln Trp Pro Pro Thr Asn Ala Ser Leu Glu
 275 280 285
 Glu His Ser Ile Glu Lys Asn Ile Thr Val Asn Tyr Asn Gly Thr Leu
 290 295 300
 Ile Asn Glu Thr Val Phe Glu Phe Asp Trp Lys Ser Tyr Ile Gln Asp
 305 310 315 320
 Ser Arg Tyr His Tyr Phe Leu Glu Gly Phe Leu Asp Ala Leu Leu Cys
 325 330 335
 Gly Asn Ser Ser Asp Ala Gly Gln Cys Pro Glu Gly Tyr Met Cys Val
 340 345 350
 Lys Ala Gly Arg Asn Pro Asn Tyr Gly Tyr Thr Ser Phe Asp Thr Phe
 355 360 365
 Ser Trp Ala Phe Leu Ser Leu Phe Arg Leu Met Thr Gln Asp Phe Trp
 370 375 380
 Glu Asn Leu Tyr Gln Leu Thr Leu Arg Ala Ala Gly Lys Thr Tyr Met
 385 390 395 400
 Ile Phe Leu Val Leu Val Ile Phe Leu Gly Ser Phe Tyr Leu Ile Asn
 405 410 415
 Leu Ile Leu Ala Val Val Ala Met Ala Tyr Glu Glu Gln Asn Gln Ala
 420 425 430
 Thr Leu Glu Glu Ala Glu Gln Lys Glu Ala Glu Phe Gln Gln Met Ile
 435 440 445
 Glu Gln Leu Lys Lys Gln Gln Glu Ala Ala Gln Gln Ala Ala Thr Ala
 450 455 460
 Thr Ala Ser Glu His Ser Arg Glu Pro Ser Ala Ala Gly Arg Leu Ser
 465 470 475 480
 Asp Ser Ser Ser Glu Ala Ser Lys Leu Ser Ser Lys Ser Ala Lys Glu
 485 490 495

SSCP Update Sequences.ST25

Arg Arg Asn Arg Arg Lys Lys Arg Lys Gln Lys Glu Gln Ser Gly Gly
 500 505 510
 Glu Glu Lys Asp Glu Asp Glu Phe Gln Lys Ser Glu Ser Glu Asp Ser
 515 520 525
 Ile Arg Arg Lys Gly Phe Arg Phe Ser Ile Glu Gly Asn Arg Leu Thr
 530 535 540
 Tyr Glu Lys Arg Tyr Ser Ser Pro His Gln Ser Leu Leu Ser Ile Arg
 545 550 555 560
 Gly Ser Leu Phe Ser Pro Arg Arg Asn Ser Arg Thr Ser Leu Phe Ser
 565 570 575
 Phe Arg Gly Arg Ala Lys Asp Val Gly Ser Glu Asn Asp Phe Ala Asp
 580 585 590
 Asp Glu His Ser Thr Phe Glu Asp Asn Glu Ser Arg Arg Asp Ser Leu
 595 600 605
 Phe Val Pro Arg Arg His Gly Glu Arg Arg Asn Ser Asn Leu Ser Gln
 610 615 620
 Thr Ser Arg Ser Ser Arg Met Leu Ala Val Phe Pro Ala Asn Gly Lys
 625 630 635 640
 Met His Ser Thr Val Asp Cys Asn Gly Val Val Ser Leu Val Gly Gly
 645 650 655
 Pro Ser Val Pro Thr Ser Pro Val Gly Gln Leu Leu Pro Glu Val Ile
 660 665 670
 Ile Asp Lys Pro Ala Thr Asp Asp Asn Gly Thr Thr Thr Glu Thr Glu
 675 680 685
 Met Arg Lys Arg Arg Ser Ser Ser Phe His Val Ser Met Asp Phe Leu
 690 695 700
 Glu Asp Pro Ser Gln Arg Gln Arg Ala Met Ser Ile Ala Ser Ile Leu
 705 710 715 720
 Thr Asn Thr Val Glu Glu Leu Glu Glu Ser Arg Gln Lys Cys Pro Pro
 725 730 735
 Cys Trp Tyr Lys Phe Ser Asn Ile Phe Leu Ile Trp Asp Cys Ser Pro
 740 745 750
 Tyr Trp Leu Lys Val Lys His Val Val Asn Leu Val Val Met Asp Pro
 755 760 765

SSCP Update Sequences.ST25

Phe Val Asp Leu Ala Ile Thr Ile Cys Ile Val Leu Asn Thr Leu Phe
 770 775 780
 Met Ala Met Glu His Tyr Pro Met Thr Asp His Phe Asn Asn Val Leu
 785 790 795 800
 Thr Val Gly Asn Leu Val Phe Thr Gly Ile Phe Thr Ala Glu Met Phe
 805 810 815
 Leu Lys Ile Ile Ala Met Asp Pro Tyr Tyr Tyr Phe Gln Glu Gly Trp
 820 825 830
 Asn Ile Phe Asp Gly Phe Ile Val Thr Leu Ser Leu Val Glu Leu Gly
 835 840 845
 Leu Ala Asn Val Glu Gly Leu Ser Val Leu Arg Ser Phe Arg Leu Leu
 850 855 860
 Arg Val Phe Lys Leu Ala Lys Ser Trp Pro Thr Leu Asn Met Leu Ile
 865 870 875 880
 Lys Ile Ile Gly Asn Ser Val Gly Ala Leu Gly Asn Leu Thr Leu Val
 885 890 895
 Leu Ala Ile Ile Val Phe Ile Phe Ala Val Val Gly Met Gln Leu Phe
 900 905
 Gly Lys Ser Tyr Lys Asp Cys Val Cys Lys Ile Ala Ser Asp Cys Gln
 915 920 925
 Leu Pro Arg Trp His Met Asn Asp Phe Phe His Ser Phe Leu Ile Val
 930 935 940
 Phe Arg Val Leu Cys Gly Glu Trp Ile Glu Thr Met Trp Asp Cys Met
 945 950 955 960
 Glu Val Ala Gly Gln Ala Met Cys Leu Thr Val Phe Met Met Val Met
 965 970 975
 Val Ile Gly Asn Leu Val Val Leu Asn Leu Phe Leu Ala Leu Leu Leu
 980 985 990
 Ser Ser Phe Ser Ala Asp Asn Leu Ala Ala Thr Asp Asp Asp Asn Glu
 995 1000 1005
 Met Asn Asn Leu Gln Ile Ala Val Asp Arg Met His Lys Gly Val
 1010 1015 1020
 Ala Tyr Val Lys Arg Lys Ile Tyr Glu Phe Ile Gln Gln Ser Phe
 1025 1030 1035

SSCP Update Sequences.ST25

Ile Arg Lys Gln Lys Ile Leu Asp Glu Ile Lys Pro Leu Asp Asp
 1040 1045 1050
 Leu Asn Asn Lys Lys Asp Ser Cys Met Ser Asn His Thr Thr Glu
 1055 1060 1065
 Ile Gly Lys Asp Leu Asp Tyr Leu Lys Asp Val Asn Gly Thr Thr
 1070 1075 1080
 Ser Gly Ile Gly Thr Gly Ser Ser Val Glu Lys Tyr Ile Ile Asp
 1085 1090 1095
 Glu Ser Asp Tyr Met Ser Phe Ile Asn Asn Pro Ser Leu Thr Val
 1100 1105 1110
 Thr Val Pro Ile Ala Val Gly Glu Ser Asp Phe Glu Asn Leu Asn
 1115 1120 1125
 Thr Glu Asp Phe Ser Ser Glu Ser Asp Leu Glu Glu Ser Lys Glu
 1130 1135 1140
 Lys Leu Asn Glu Ser Ser Ser Ser Ser Glu Gly Ser Thr Val Asp
 1145 1150 1155
 Ile Gly Ala Pro Val Glu Glu Gln Pro Val Val Glu Pro Glu Glu
 1160 1165 1170
 Thr Leu Glu Pro Glu Ala Cys Phe Thr Glu Gly Cys Val Gln Arg
 1175 1180 1185
 Phe Lys Cys Cys Gln Ile Asn Val Glu Glu Gly Arg Gly Lys Gln
 1190 1195 1200
 Trp Trp Asn Leu Arg Arg Thr Cys Phe Arg Ile Val Glu His Asn
 1205 1210 1215
 Trp Phe Glu Thr Phe Ile Val Phe Met Ile Leu Leu Ser Ser Gly
 1220 1225 1230
 Ala Leu Ala Phe Glu Asp Ile Tyr Ile Asp Gln Arg Lys Thr Ile
 1235 1240 1245
 Lys Thr Met Leu Glu Tyr Ala Asp Lys Val Phe Thr Tyr Ile Phe
 1250 1255 1260
 Ile Leu Glu Met Leu Leu Lys Trp Val Ala Tyr Gly Tyr Gln Thr
 1265 1270 1275
 Tyr Phe Thr Asn Ala Trp Cys Trp Leu Asp Phe Leu Ile Val Asp
 1280 1285 1290

SSCP Update Sequences.ST25

Val	Ser	Leu	Val	Ser	Leu	Thr	Ala	Asn	Ala	Leu	Gly	Tyr	Ser	Glu
	1295					1300					1305			
Leu	Gly	Ala	Ile	Lys	Ser	Leu	Arg	Thr	Leu	Arg	Ala	Leu	Arg	Pro
	1310					1315					1320			
Leu	Arg	Ala	Leu	Ser	Arg	Phe	Glu	Gly	Met	Arg	Val	Val	Val	Asn
	1325					1330					1335			
Ala	Leu	Leu	Gly	Ala	Ile	Pro	Ser	Ile	Met	Asn	Val	Leu	Leu	Val
	1340					1345					1350			
Cys	Leu	Ile	Phe	Trp	Leu	Ile	Phe	Ser	Ile	Met	Gly	Val	Asn	Leu
	1355					1360					1365			
Phe	Ala	Gly	Lys	Phe	Tyr	His	Cys	Ile	Asn	Thr	Thr	Thr	Gly	Asp
	1370					1375					1380			
Arg	Phe	Asp	Ile	Glu	Asp	Val	Asn	Asn	His	Thr	Asp	Cys	Leu	Lys
	1385					1390					1395			
Leu	Ile	Glu	Arg	Asn	Glu	Thr	Ala	Arg	Trp	Lys	Asn	Val	Lys	Val
	1400					1405					1410			
Asn	Phe	Asp	Asn	Val	Gly	Phe	Gly	Tyr	Leu	Ser	Leu	Leu	Gln	Val
	1415					1420					1425			
Ala	Thr	Phe	Lys	Gly	Trp	Met	Asp	Ile	Met	Tyr	Ala	Ala	Val	Asp
	1430					1435					1440			
Ser	Arg	Asn	Val	Glu	Leu	Gln	Pro	Lys	Tyr	Glu	Lys	Ser	Leu	Tyr
	1445					1450					1455			
Met	Tyr	Leu	Tyr	Phe	Val	Ile	Phe	Ile	Ile	Phe	Gly	Ser	Phe	Phe
	1460					1465					1470			
Thr	Leu	Asn	Leu	Phe	Ile	Gly	Val	Ile	Ile	Asp	Asn	Phe	Asn	Gln
	1475					1480					1485			
Gln	Lys	Lys	Lys	Phe	Gly	Gly	Gln	Asp	Ile	Phe	Met	Thr	Glu	Glu
	1490					1495					1500			
Gln	Lys	Lys	Tyr	Tyr	Asn	Ala	Met	Lys	Lys	Leu	Gly	Ser	Lys	Lys
	1505					1510					1515			
Pro	Gln	Lys	Pro	Ile	Pro	Arg	Pro	Gly	Asn	Lys	Phe	Gln	Gly	Met
	1520					1525					1530			
Val	Phe	Asp	Phe	Val	Thr	Arg	Gln	Val	Phe	Asp	Ile	Ser	Ile	Met
	1535					1540					1545			

SSCP Update Sequences.ST25

Ile	Leu	Ile	Cys	Leu	Asn	Met	Val	Thr	Met	Met	Val	Glu	Thr	Asp
	1550					1555					1560			
Asp	Gln	Ser	Glu	Tyr	Val	Thr	Thr	Ile	Leu	Ser	Arg	Ile	Asn	Leu
	1565					1570					1575			
Val	Phe	Ile	Val	Leu	Phe	Thr	Gly	Glu	Cys	Val	Leu	Lys	Leu	Ile
	1580					1585					1590			
Ser	Leu	Arg	His	Tyr	Tyr	Phe	Thr	Ile	Gly	Trp	Asn	Ile	Phe	Asp
	1595					1600					1605			
Phe	Val	Val	Val	Ile	Leu	Ser	Ile	Val	Gly	Met	Phe	Leu	Ala	Glu
	1610					1615					1620			
Leu	Ile	Glu	Lys	Tyr	Phe	Val	Ser	Pro	Thr	Leu	Phe	Arg	Val	Ile
	1625					1630					1635			
Arg	Leu	Ala	Arg	Ile	Gly	Arg	Ile	Leu	Arg	Leu	Ile	Lys	Gly	Ala
	1640					1645					1650			
Lys	Gly	Ile	Arg	Thr	Leu	Leu	Phe	Ala	Leu	Met	Met	Ser	Leu	Pro
	1655					1660					1665			
Ala	Leu	Phe	Asn	Ile	Gly	Leu	Leu	Leu	Phe	Leu	Val	Met	Phe	Ile
	1670					1675					1680			
Tyr	Ala	Ile	Phe	Gly	Met	Ser	Asn	Phe	Ala	Tyr	Val	Lys	Arg	Glu
	1685					1690					1695			
Val	Gly	Ile	Asp	Asp	Met	Phe	Asn	Phe	Glu	Thr	Phe	Gly	Asn	Ser
	1700					1705					1710			
Met	Ile	Cys	Leu	Phe	Gln	Ile	Thr	Thr	Ser	Ala	Gly	Trp	Asp	Gly
	1715					1720					1725			
Leu	Leu	Ala	Pro	Ile	Leu	Asn	Ser	Lys	Pro	Pro	Asp	Cys	Asp	Pro
	1730					1735					1740			
Asn	Lys	Val	Asn	Pro	Gly	Ser	Ser	Val	Lys	Gly	Asp	Cys	Gly	Asn
	1745					1750					1755			
Pro	Ser	Val	Gly	Ile	Phe	Phe	Phe	Val	Ser	Tyr	Ile	Ile	Ile	Ser
	1760					1765					1770			
Phe	Leu	Val	Val	Val	Asn	Met	Tyr	Ile	Ala	Val	Ile	Leu	Glu	Asn
	1775					1780					1785			
Phe	Ser	Val	Ala	Thr	Glu	Glu	Ser	Ala	Glu	Pro	Leu	Ser	Glu	Asp
	1790					1795					1800			

SSCP Update Sequences.ST25

Asp Phe Glu Met Phe Tyr Glu Val Trp Glu Lys Phe Asp Pro Asp
1805 1810 1815

Ala Thr Gln Phe Met Glu Phe Glu Lys Leu Ser Gln Phe Ala Ala
1820 1825 1830

Ala Leu Glu Pro Pro Leu Asn Leu Pro Gln Pro Asn Lys Leu Gln
1835 1840 1845

Leu Ile Ala Met Asp Leu Pro Met Val Ser Gly Asp Arg Ile His
1850 1855 1860

Cys Leu Asp Ile Leu Phe Ala Phe Thr Lys Arg Val Leu Gly Glu
1865 1870 1875

Ser Gly Glu Met Asp Ala Leu Arg Ile Gln Met Glu Glu Arg Phe
1880 1885 1890

Met Ala Ser Asn Pro Ser Lys Val Ser Tyr Gln Pro Ile Thr Thr
1895 1900 1905

Thr Leu Lys Arg Lys Gln Glu Glu Val Ser Ala Val Ile Ile Gln
1910 1915 1920

Arg Ala Tyr Arg Arg His Leu Leu Lys Arg Thr Val Lys Gln Ala
1925 1930 1935

Ser Phe Thr Tyr Asn Lys Asn Lys Ile Lys Gly Gly Ala Asn Leu
1940 1945 1950

Leu Ile Lys Glu Asp Met Ile Ile Asp Arg Ile Asn Glu Asn Ser
1955 1960 1965

Ile Thr Glu Lys Thr Asp Leu Thr Met Ser Thr Ala Ala Cys Pro
1970 1975 1980

Pro Ser Tyr Asp Arg Val Thr Lys Pro Ile Val Glu Lys His Glu
1985 1990 1995

Gln Glu Gly Lys Asp Glu Lys Ala Lys Gly Lys
2000 2005

<210> 77
<211> 2009
<212> PRT
<213> Homo sapiens

<400> 77

Met Glu Gln Thr Val Leu Val Pro Pro Gly Pro Asp Ser Phe Asn Phe
1 5 10 15

SSCP Update Sequences.ST25

Phe Thr Arg Glu Ser Leu Ala Ala Ile Glu Arg Arg Ile Ala Glu Glu
 20 25 30
 Lys Ala Lys Asn Pro Lys Pro Asp Lys Lys Asp Asp Asp Glu Asn Gly
 35 40 45
 Pro Lys Pro Asn Ser Asp Leu Glu Ala Gly Lys Asn Leu Pro Phe Ile
 50 55 60
 Tyr Gly Asp Ile Pro Pro Glu Met Val Ser Glu Pro Leu Glu Asp Leu
 65 70 75 80
 Asp Pro Tyr Tyr Ile Asn Lys Lys Thr Phe Ile Val Leu Asn Lys Leu
 85 90 95
 Lys Ala Ile Phe Arg Phe Ser Ala Thr Ser Ala Leu Tyr Ile Leu Thr
 100 105 110
 Pro Phe Asn Pro Leu Arg Lys Ile Ala Ile Lys Ile Leu Val His Ser
 115 120 125
 Leu Phe Ser Met Leu Ile Met Cys Thr Ile Leu Thr Asn Cys Val Phe
 130 135 140
 Met Thr Met Ser Asn Pro Pro Asp Trp Thr Lys Asn Val Glu Tyr Thr
 145 150 155 160
 Phe Thr Gly Ile Tyr Thr Phe Glu Ser Leu Ile Lys Ile Ile Ala Arg
 165 170 175
 Gly Phe Cys Leu Glu Asp Phe Thr Phe Leu Arg Asp Pro Trp Asn Trp
 180 185 190
 Leu Asp Phe Thr Val Ile Thr Phe Ala Tyr Val Thr Glu Phe Val Asp
 195 200 205
 Leu Gly Asn Val Ser Ala Leu Arg Thr Phe Arg Val Leu Arg Ala Leu
 210 215 220
 Lys Thr Ile Ser Val Ile Pro Gly Leu Lys Thr Ile Val Gly Ala Leu
 225 230 235 240
 Ile Gln Ser Val Lys Lys Leu Ser Asp Val Met Ile Leu Thr Val Phe
 245 250 255
 Cys Leu Ser Val Phe Ala Leu Ile Gly Leu Gln Leu Phe Met Gly Asn
 260 265 270
 Leu Arg Asn Lys Cys Ile Gln Trp Pro Pro Thr Asn Ala Ser Leu Glu
 275 280 285

SSCP Update Sequences.ST25

Glu His Ser Ile Glu Lys Asn Ile Thr Val Asn Tyr Asn Gly Thr Leu
 290 295 300
 Ile Asn Glu Thr Val Phe Glu Phe Asp Trp Lys Ser Tyr Ile Gln Asp
 305 310 315 320
 Ser Arg Tyr His Tyr Phe Leu Glu Gly Phe Leu Asp Ala Leu Leu Cys
 325 330 335
 Gly Asn Ser Ser Asp Ala Gly Gln Cys Pro Glu Gly Tyr Met Cys Val
 340 345 350
 Lys Ala Gly Arg Asn Pro Asn Tyr Gly Tyr Thr Ser Phe Asp Thr Phe
 355 360 365
 Ser Trp Ala Phe Leu Ser Leu Phe Arg Leu Met Thr Gln Asp Phe Trp
 370 375 380
 Glu Asn Leu Tyr Gln Leu Thr Leu Arg Ala Ala Gly Lys Thr Tyr Met
 385 390 395 400
 Ile Phe Phe Val Leu Val Ile Phe Leu Gly Ser Phe Asn Leu Ile Asn
 405 410 415
 Leu Ile Leu Ala Val Val Ala Met Ala Tyr Glu Glu Gln Asn Gln Ala
 420 425 430
 Thr Leu Glu Glu Ala Glu Gln Lys Glu Ala Glu Phe Gln Gln Met Ile
 435 440 445
 Glu Gln Leu Lys Lys Gln Gln Glu Ala Ala Gln Gln Ala Ala Thr Ala
 450 455 460
 Thr Ala Ser Glu His Ser Arg Glu Pro Ser Ala Ala Gly Arg Leu Ser
 465 470 475 480
 Asp Ser Ser Ser Glu Ala Ser Lys Leu Ser Ser Lys Ser Ala Lys Glu
 485 490 495
 Arg Arg Asn Arg Arg Lys Lys Arg Lys Gln Lys Glu Gln Ser Gly Gly
 500 505 510
 Glu Glu Lys Asp Glu Asp Glu Phe Gln Lys Ser Glu Ser Glu Asp Ser
 515 520 525
 Ile Arg Arg Lys Gly Phe Arg Phe Ser Ile Glu Gly Asn Arg Leu Thr
 530 535 540
 Tyr Glu Lys Arg Tyr Ser Ser Pro His Gln Ser Leu Leu Ser Ile Arg
 545 550 555 560

SSCP Update Sequences.ST25

Gly Ser Leu Phe Ser Pro Arg Arg Asn Ser Arg Thr Ser Leu Phe Ser
 565 570 575
 Phe Arg Gly Arg Ala Lys Asp Val Gly Ser Glu Asn Asp Phe Ala Asp
 580 585 590
 Asp Glu His Ser Thr Phe Glu Asp Asn Glu Ser Arg Arg Asp Ser Leu
 595 600 605
 Phe Val Pro Arg Arg His Gly Glu Arg Arg Asn Ser Asn Leu Ser Gln
 610 615 620
 Thr Ser Arg Ser Ser Arg Met Leu Ala Val Phe Pro Ala Asn Gly Lys
 625 630 635 640
 Met His Ser Thr Val Asp Cys Asn Gly Val Val Ser Leu Val Gly Gly
 645 650 655
 Pro Ser Val Pro Thr Ser Pro Val Gly Gln Leu Leu Pro Glu Val Ile
 660 665 670
 Ile Asp Lys Pro Ala Thr Asp Asp Asn Gly Thr Thr Thr Glu Thr Glu
 675 680 685
 Met Arg Lys Arg Arg Ser Ser Ser Phe His Val Ser Met Asp Phe Leu
 690 695 700
 Glu Asp Pro Ser Gln Arg Gln Arg Ala Met Ser Ile Ala Ser Ile Leu
 705 710 715 720
 Thr Asn Thr Val Glu Glu Leu Glu Glu Ser Arg Gln Lys Cys Pro Pro
 725 730 735
 Cys Trp Tyr Lys Phe Ser Asn Ile Phe Leu Ile Trp Asp Cys Ser Pro
 740 745 750
 Tyr Trp Leu Lys Val Lys His Val Val Asn Leu Val Val Met Asp Pro
 755 760 765
 Phe Val Asp Leu Ala Ile Thr Ile Cys Ile Val Leu Asn Thr Leu Phe
 770 775 780
 Met Ala Met Glu His Tyr Pro Met Thr Asp His Phe Asn Asn Val Leu
 785 790 795 800
 Thr Val Gly Asn Leu Val Phe Thr Gly Ile Phe Thr Ala Glu Met Phe
 805 810 815
 Leu Lys Ile Ile Ala Met Asp Pro Tyr Tyr Tyr Phe Gln Glu Gly Trp
 820 825 830

SSCP Update Sequences.ST25

Asn Ile Phe Asp Gly Phe Ile Val Thr Leu Ser Leu Val Glu Leu Gly
 835 840 845
 Leu Ala Asn Val Glu Gly Leu Ser Val Leu Arg Ser Phe Arg Leu Leu
 850 855 860
 Arg Val Phe Lys Leu Ala Lys Ser Trp Pro Thr Leu Asn Met Leu Ile
 865 870 875 880
 Lys Ile Ile Gly Asn Ser Val Gly Ala Leu Gly Asn Leu Thr Leu Val
 885 890 895
 Leu Ala Ile Ile Val Phe Ile Phe Ala Val Val Gly Met Gln Leu Phe
 900 905
 Gly Lys Ser Tyr Lys Asp Cys Val Cys Lys Ile Ala Ser Asp Cys Gln
 915 920 925
 Leu Pro Arg Trp His Met Asn Asp Phe Phe His Ser Phe Leu Ile Val
 930 935 940
 Phe Arg Val Leu Cys Gly Glu Trp Ile Glu Thr Met Trp Asp Cys Met
 945 950 955 960
 Glu Val Ala Gly Gln Ala Met Cys Leu Thr Val Phe Met Met Val Met
 965 970 975
 Val Ile Gly Asn Leu Val Val Leu Asn Leu Phe Leu Ala Leu Leu Leu
 980 985 990
 Ser Ser Phe Ser Ala Asp Asn Leu Ala Ala Thr Asp Asp Asp Asn Glu
 995 1000 1005
 Met Asn Asn Leu Gln Ile Ala Val Asp Arg Met His Lys Gly Val
 1010 1015 1020
 Ala Tyr Val Lys Arg Lys Ile Tyr Glu Phe Ile Gln Gln Ser Phe
 1025 1030 1035
 Ile Arg Lys Gln Lys Ile Leu Asp Glu Ile Lys Pro Leu Asp Asp
 1040 1045 1050
 Leu Asn Asn Lys Lys Asp Ser Cys Met Ser Asn His Thr Thr Glu
 1055 1060 1065
 Ile Gly Lys Asp Leu Asp Tyr Leu Lys Asp Val Asn Gly Thr Thr
 1070 1075 1080
 Ser Gly Ile Gly Thr Gly Ser Ser Val Glu Lys Tyr Ile Ile Asp
 1085 1090 1095

SSCP Update Sequences.ST25

Glu Ser Asp Tyr Met Ser Phe Ile Asn Asn Pro Ser Leu Thr Val
 1100 1105 1110
 Thr Val Pro Ile Ala Val Gly Glu Ser Asp Phe Glu Asn Leu Asn
 1115 1120 1125
 Thr Glu Asp, Phe Ser Ser Glu Ser Asp Leu Glu Glu Ser Lys Glu
 1130 1135 1140
 Lys Leu Asn Glu Ser Ser Ser Ser Ser Glu Gly Ser Thr Val Asp
 1145 1150 1155
 Ile Gly Ala Pro Val Glu Glu Gln Pro Val Val Glu Pro Glu Glu
 1160 1165 1170
 Thr Leu Glu Pro Glu Ala Cys Phe Thr Glu Gly Cys Val Gln Arg
 1175 1180 1185
 Phe Lys Cys Cys Gln Ile Asn Val Glu Glu Gly Arg Gly Lys Gln
 1190 1195 1200
 Trp Trp Asn Leu Arg Arg Thr Cys Phe Arg Ile Val Glu His Asn
 1205 1210 1215
 Trp Phe Glu Thr Phe Ile Val Phe Met Ile Leu Leu Ser Ser Gly
 1220 1225 1230
 Ala Leu Ala Phe Glu Asp Ile Tyr Ile Asp Gln Arg Lys Thr Ile
 1235 1240 1245
 Lys Thr Met Leu Glu Tyr Ala Asp Lys Val Phe Thr Tyr Ile Phe
 1250 1255 1260
 Ile Leu Glu Met Leu Leu Lys Trp Val Ala Tyr Gly Tyr Gln Thr
 1265 1270 1275
 Tyr Phe Thr Asn Ala Trp Cys Trp Leu Asp Phe Leu Ile Val Asp
 1280 1285 1290
 Val Ser Leu Val Ser Leu Thr Ala Asn Ala Leu Gly Tyr Ser Glu
 1295 1300 1305
 Leu Gly Ala Ile Lys Ser Leu Arg Thr Leu Arg Ala Leu Arg Pro
 1310 1315 1320
 Leu Arg Ala Leu Ser Arg Phe Glu Gly Met Arg Val Val Val Asn
 1325 1330 1335
 Ala Leu Leu Gly Ala Ile Pro Ser Ile Met Asn Val Leu Leu Val
 1340 1345 1350

SSCP Update Sequences.ST25

Cys Leu Ile Phe Trp Leu Ile Phe Ser Ile Met Gly Val Asn Leu
 1355 1360 1365
 Phe Ala Gly Lys Phe Tyr His Cys Ile Asn Thr Thr Thr Gly Asp
 1370 1375 1380
 Arg Phe Asp Ile Glu Asp Val Asn Asn His Thr Asp Cys Leu Lys
 1385 1390 1395
 Leu Ile Glu Arg Asn Glu Thr Ala Arg Trp Lys Asn Val Lys Val
 1400 1405 1410
 Asn Phe Asp Asn Val Gly Phe Gly Tyr Leu Ser Leu Leu Gln Val
 1415 1420 1425
 Ala Thr Phe Lys Gly Trp Met Asp Ile Met Tyr Ala Ala Val Asp
 1430 1435 1440
 Ser Arg Asn Val Glu Leu Gln Pro Lys Tyr Glu Lys Ser Leu Tyr
 1445 1450 1455
 Met Tyr Leu Tyr Phe Val Ile Phe Ile Ile Phe Gly Ser Phe Phe
 1460 1465 1470
 Thr Leu Asn Leu Phe Ile Gly Val Ile Ile Asp Asn Phe Asn Gln
 1475 1480 1485
 Gln Lys Lys Lys Phe Gly Gly Gln Asp Ile Phe Met Thr Glu Glu
 1490 1495 1500
 Gln Lys Lys Tyr Tyr Asn Ala Met Lys Lys Leu Gly Ser Lys Lys
 1505 1510 1515
 Pro Gln Lys Pro Ile Pro Arg Pro Gly Asn Lys Phe Gln Gly Met
 1520 1525 1530
 Val Phe Asp Phe Val Thr Arg Gln Val Phe Asp Ile Ser Ile Met
 1535 1540 1545
 Ile Leu Ile Cys Leu Asn Met Val Thr Met Met Val Glu Thr Asp
 1550 1555 1560
 Asp Gln Ser Glu Tyr Val Thr Thr Ile Leu Ser Arg Ile Asn Leu
 1565 1570 1575
 Val Phe Ile Val Leu Phe Thr Gly Glu Cys Val Leu Lys Leu Ile
 1580 1585 1590
 Ser Leu Arg His Tyr Tyr Phe Thr Ile Gly Trp Asn Ile Phe Asp
 1595 1600 1605

SSCP Update Sequences.ST25

Phe Val Val Val Ile Leu Ser Ile Val Gly Met Phe Leu Ala Glu
 1610 1615 1620
 Leu Ile Glu Lys Tyr Phe Val Ser Pro Thr Leu Phe Arg Val Ile
 1625 1630 1635
 Arg Leu Ala Arg Ile Gly Arg Ile Leu Arg Leu Ile Lys Gly Ala
 1640 1645 1650
 Lys Gly Ile Arg Thr Leu Leu Phe Ala Leu Met Met Ser Leu Pro
 1655 1660 1665
 Ala Leu Phe Asn Ile Gly Leu Leu Leu Phe Leu Val Met Phe Ile
 1670 1675 1680
 Tyr Ala Ile Phe Gly Met Ser Asn Phe Ala Tyr Val Lys Arg Glu
 1685 1690 1695
 Val Gly Ile Asp Asp Met Phe Asn Phe Glu Thr Phe Gly Asn Ser
 1700 1705 1710
 Met Ile Cys Leu Phe Gln Ile Thr Thr Ser Ala Gly Trp Asp Gly
 1715 1720 1725
 Leu Leu Ala Pro Ile Leu Asn Ser Lys Pro Pro Asp Cys Asp Pro
 1730 1735 1740
 Asn Lys Val Asn Pro Gly Ser Ser Val Lys Gly Asp Cys Gly Asn
 1745 1750 1755
 Pro Ser Val Gly Ile Phe Phe Phe Val Ser Tyr Ile Ile Ile Ser
 1760 1765 1770
 Phe Leu Val Val Val Asn Met Tyr Ile Ala Val Ile Leu Glu Asn
 1775 1780 1785
 Phe Ser Val Ala Thr Glu Glu Ser Ala Glu Pro Leu Ser Glu Asp
 1790 1795 1800
 Asp Phe Glu Met Phe Tyr Glu Val Trp Glu Lys Phe Asp Pro Asp
 1805 1810 1815
 Ala Thr Gln Phe Met Glu Phe Glu Lys Leu Ser Gln Phe Ala Ala
 1820 1825 1830
 Ala Leu Glu Pro Pro Leu Asn Leu Pro Gln Pro Asn Lys Leu Gln
 1835 1840 1845
 Leu Ile Ala Met Asp Leu Pro Met Val Ser Gly Asp Arg Ile His
 1850 1855 1860

SSCP Update Sequences.ST25

Cys Leu Asp Ile Leu Phe Ala Phe Thr Lys Arg Val Leu Gly Glu
1865 1870 1875

Ser Gly Glu Met Asp Ala Leu Arg Ile Gln Met Glu Glu Arg Phe
1880 1885 1890

Met Ala Ser Asn Pro Ser Lys Val Ser Tyr Gln Pro Ile Thr Thr
1895 1900 1905

Thr Leu Lys Arg Lys Gln Glu Glu Val Ser Ala Val Ile Ile Gln
1910 1915 1920

Arg Ala Tyr Arg Arg His Leu Leu Lys Arg Thr Val Lys Gln Ala
1925 1930 1935

Ser Phe Thr Tyr Asn Lys Asn Lys Ile Lys Gly Gly Ala Asn Leu
1940 1945 1950

Leu Ile Lys Glu Asp Met Ile Ile Asp Arg Ile Asn Glu Asn Ser
1955 1960 1965

Ile Thr Glu Lys Thr Asp Leu Thr Met Ser Thr Ala Ala Cys Pro
1970 1975 1980

Pro Ser Tyr Asp Arg Val Thr Lys Pro Ile Val Glu Lys His Glu
1985 1990 1995

Gln Glu Gly Lys Asp Glu Lys Ala Lys Gly Lys
2000 2005

<210> 78
<211> 2009
<212> PRT
<213> Homo sapiens

<400> 78

Met Glu Gln Thr Val Leu Val Pro Pro Gly Pro Asp Ser Phe Asn Phe
1 5 10 15

Phe Thr Arg Glu Ser Leu Ala Ala Ile Glu Arg Arg Ile Ala Glu Glu
20 25 30

Lys Ala Lys Asn Pro Lys Pro Asp Lys Lys Asp Asp Asp Glu Asn Gly
35 40 45

Pro Lys Pro Asn Ser Asp Leu Glu Ala Gly Lys Asn Leu Pro Phe Ile
50 55 60

Tyr Gly Asp Ile Pro Pro Glu Met Val Ser Glu Pro Leu Glu Asp Leu
65 70 75 80

SSCP Update Sequences.ST25

Asp Pro Tyr Tyr Ile Asn Lys Lys Thr Phe Ile Val Leu Asn Lys Leu
 85 90 95
 Lys Ala Ile Phe Arg Phe Ser Ala Thr Ser Ala Leu Tyr Ile Leu Thr
 100 105 110
 Pro Phe Asn Pro Leu Arg Lys Ile Ala Ile Lys Ile Leu Val His Ser
 115 120 125
 Leu Phe Ser Met Leu Ile Met Cys Thr Ile Leu Thr Asn Cys Val Phe
 130 135 140
 Met Thr Met Ser Asn Pro Pro Asp Trp Thr Lys Asn Val Glu Tyr Thr
 145 150 155 160
 Phe Thr Gly Ile Tyr Thr Phe Glu Ser Leu Ile Lys Ile Ile Ala Arg
 165 170 175
 Gly Phe Cys Leu Glu Asp Phe Thr Phe Leu Arg Asp Pro Trp Asn Trp
 180 185 190
 Leu Asp Phe Thr Val Ile Thr Phe Ala Tyr Val Thr Glu Phe Val Asp
 195 200 205
 Leu Gly Asn Val Ser Ala Leu Arg Thr Phe Arg Val Leu Arg Ala Leu
 210 215 220
 Lys Thr Ile Ser Val Ile Pro Gly Leu Lys Thr Ile Val Gly Ala Leu
 225 230 235 240
 Ile Gln Ser Val Lys Lys Leu Ser Asp Val Met Ile Leu Thr Val Phe
 245 250 255
 Cys Leu Ser Val Phe Ala Leu Ile Gly Leu Gln Leu Phe Met Gly Asn
 260 265 270
 Leu Arg Asn Lys Cys Ile Gln Trp Pro Pro Thr Asn Ala Ser Leu Glu
 275 280 285
 Glu His Ser Ile Glu Lys Asn Ile Thr Val Asn Tyr Asn Gly Thr Leu
 290 295 300
 Ile Asn Glu Thr Val Phe Glu Phe Asp Trp Lys Ser Tyr Ile Gln Asp
 305 310 315 320
 Ser Arg Tyr His Tyr Phe Leu Glu Gly Phe Leu Asp Ala Leu Leu Cys
 325 330 335
 Gly Asn Ser Ser Asp Ala Gly Gln Cys Pro Glu Gly Tyr Met Cys Val
 340 345 350

SSCP Update Sequences.ST25

Lys Ala Gly Arg Asn Pro Asn Tyr Gly Tyr Thr Ser Phe Asp Thr Phe
 355 360 365
 Ser Trp Ala Phe Leu Ser Leu Phe Arg Leu Met Thr Gln Asp Phe Trp
 370 375 380
 Glu Asn Leu Tyr Gln Leu Thr Leu Arg Ala Ala Gly Lys Thr Tyr Met
 385 390 395 400
 Ile Phe Phe Val Leu Val Ile Phe Leu Gly Ser Phe Tyr Leu Ile Asn
 405 410 415
 Leu Ile Leu Ala Val Glu Ala Met Ala Tyr Glu Glu Gln Asn Gln Ala
 420 425 430
 Thr Leu Glu Glu Ala Glu Gln Lys Glu Ala Glu Phe Gln Gln Met Ile
 435 440 445
 Glu Gln Leu Lys Lys Gln Gln Glu Ala Ala Gln Gln Ala Ala Thr Ala
 450 455 460
 Thr Ala Ser Glu His Ser Arg Glu Pro Ser Ala Ala Gly Arg Leu Ser
 465 470 475 480
 Asp Ser Ser Ser Glu Ala Ser Lys Leu Ser Ser Lys Ser Ala Lys Glu
 485 490 495
 Arg Arg Asn Arg Arg Lys Lys Arg Lys Gln Lys Glu Gln Ser Gly Gly
 500 505 510
 Glu Glu Lys Asp Glu Asp Glu Phe Gln Lys Ser Glu Ser Glu Asp Ser
 515 520 525
 Ile Arg Arg Lys Gly Phe Arg Phe Ser Ile Glu Gly Asn Arg Leu Thr
 530 535 540
 Tyr Glu Lys Arg Tyr Ser Ser Pro His Gln Ser Leu Leu Ser Ile Arg
 545 550 555 560
 Gly Ser Leu Phe Ser Pro Arg Arg Asn Ser Arg Thr Ser Leu Phe Ser
 565 570 575
 Phe Arg Gly Arg Ala Lys Asp Val Gly Ser Glu Asn Asp Phe Ala Asp
 580 585 590
 Asp Glu His Ser Thr Phe Glu Asp Asn Glu Ser Arg Arg Asp Ser Leu
 595 600 605
 Phe Val Pro Arg Arg His Gly Glu Arg Arg Asn Ser Asn Leu Ser Gln
 610 615 620

SSCP Update Sequences.ST25

Thr Ser Arg Ser Ser Arg Met Leu Ala Val Phe Pro Ala Asn Gly Lys
 625 630 635 640
 Met His Ser Thr Val Asp Cys Asn Gly Val Val Ser Leu Val Gly Gly
 645 650 655
 Pro Ser Val Pro Thr Ser Pro Val Gly Gln Leu Leu Pro Glu Val Ile
 660 665 670
 Ile Asp Lys Pro Ala Thr Asp Asp Asn Gly Thr Thr Thr Glu Thr Glu
 675 680 685
 Met Arg Lys Arg Arg Ser Ser Ser Phe His Val Ser Met Asp Phe Leu
 690 695 700
 Glu Asp Pro Ser Gln Arg Gln Arg Ala Met Ser Ile Ala Ser Ile Leu
 705 710 715 720
 Thr Asn Thr Val Glu Glu Leu Glu Glu Ser Arg Gln Lys Cys Pro Pro
 725 730 735
 Cys Trp Tyr Lys Phe Ser Asn Ile Phe Leu Ile Trp Asp Cys Ser Pro
 740 745 750
 Tyr Trp Leu Lys Val Lys His Val Val Asn Leu Val Val Met Asp Pro
 755 760 765
 Phe Val Asp Leu Ala Ile Thr Ile Cys Ile Val Leu Asn Thr Leu Phe
 770 775 780
 Met Ala Met Glu His Tyr Pro Met Thr Asp His Phe Asn Asn Val Leu
 785 790 795 800
 Thr Val Gly Asn Leu Val Phe Thr Gly Ile Phe Thr Ala Glu Met Phe
 805 810 815
 Leu Lys Ile Ile Ala Met Asp Pro Tyr Tyr Tyr Phe Gln Glu Gly Trp
 820 825 830
 Asn Ile Phe Asp Gly Phe Ile Val Thr Leu Ser Leu Val Glu Leu Gly
 835 840 845
 Leu Ala Asn Val Glu Gly Leu Ser Val Leu Arg Ser Phe Arg Leu Leu
 850 855 860
 Arg Val Phe Lys Leu Ala Lys Ser Trp Pro Thr Leu Asn Met Leu Ile
 865 870 875 880
 Lys Ile Ile Gly Asn Ser Val Gly Ala Leu Gly Asn Leu Thr Leu Val
 885 890 895

SSCP Update Sequences.ST25

Leu Ala Ile Ile Val Phe Ile Phe Ala Val Val Gly Met Gln Leu Phe
 900 905 910

Gly Lys Ser Tyr Lys Asp Cys Val Cys Lys Ile Ala Ser Asp Cys Gln
 915 920 925

Leu Pro Arg Trp His Met Asn Asp Phe Phe His Ser Phe Leu Ile Val
 930 935 940

Phe Arg Val Leu Cys Gly Glu Trp Ile Glu Thr Met Trp Asp Cys Met
 945 950 955 960

Glu Val Ala Gly Gln Ala Met Cys Leu Thr Val Phe Met Met Val Met
 965 970 975

Val Ile Gly Asn Leu Val Val Leu Asn Leu Phe Leu Ala Leu Leu Leu
 980 985 990

Ser Ser Phe Ser Ala Asp Asn Leu Ala Ala Thr Asp Asp Asp Asn Glu
 995 1000 1005

Met Asn Asn Leu Gln Ile Ala Val Asp Arg Met His Lys Gly Val
 1010 1015 1020

Ala Tyr Val Lys Arg Lys Ile Tyr Glu Phe Ile Gln Gln Ser Phe
 1025 1030 1035

Ile Arg Lys Gln Lys Ile Leu Asp Glu Ile Lys Pro Leu Asp Asp
 1040 1045 1050

Leu Asn Asn Lys Lys Asp Ser Cys Met Ser Asn His Thr Thr Glu
 1055 1060 1065

Ile Gly Lys Asp Leu Asp Tyr Leu Lys Asp Val Asn Gly Thr Thr
 1070 1075 1080

Ser Gly Ile Gly Thr Gly Ser Ser Val Glu Lys Tyr Ile Ile Asp
 1085 1090 1095

Glu Ser Asp Tyr Met Ser Phe Ile Asn Asn Pro Ser Leu Thr Val
 1100 1105 1110

Thr Val Pro Ile Ala Val Gly Glu Ser Asp Phe Glu Asn Leu Asn
 1115 1120 1125

Thr Glu Asp Phe Ser Ser Glu Ser Asp Leu Glu Glu Ser Lys Glu
 1130 1135 1140

Lys Leu Asn Glu Ser Ser Ser Ser Ser Glu Gly Ser Thr Val Asp
 1145 1150 1155

SSCP Update Sequences.ST25

Ile Gly Ala Pro Val Glu Glu Gln Pro Val Val Glu Pro Glu Glu
 1160 1165 1170
 Thr Leu Glu Pro Glu Ala Cys Phe Thr Glu Gly Cys Val Gln Arg
 1175 1180 1185
 Phe Lys Cys Cys Gln Ile Asn Val Glu Glu Gly Arg Gly Lys Gln
 1190 1195 1200
 Trp Trp Asn Leu Arg Arg Thr Cys Phe Arg Ile Val Glu His Asn
 1205 1210 1215
 Trp Phe Glu Thr Phe Ile Val Phe Met Ile Leu Leu Ser Ser Gly
 1220 1225 1230
 Ala Leu Ala Phe Glu Asp Ile Tyr Ile Asp Gln Arg Lys Thr Ile
 1235 1240 1245
 Lys Thr Met Leu Glu Tyr Ala Asp Lys Val Phe Thr Tyr Ile Phe
 1250 1255 1260
 Ile Leu Glu Met Leu Leu Lys Trp Val Ala Tyr Gly Tyr Gln Thr
 1265 1270 1275
 Tyr Phe Thr Asn Ala Trp Cys Trp Leu Asp Phe Leu Ile Val Asp
 1280 1285 1290
 Val Ser Leu Val Ser Leu Thr Ala Asn Ala Leu Gly Tyr Ser Glu
 1295 1300 1305
 Leu Gly Ala Ile Lys Ser Leu Arg Thr Leu Arg Ala Leu Arg Pro
 1310 1315 1320
 Leu Arg Ala Leu Ser Arg Phe Glu Gly Met Arg Val Val Val Asn
 1325 1330 1335
 Ala Leu Leu Gly Ala Ile Pro Ser Ile Met Asn Val Leu Leu Val
 1340 1345 1350
 Cys Leu Ile Phe Trp Leu Ile Phe Ser Ile Met Gly Val Asn Leu
 1355 1360 1365
 Phe Ala Gly Lys Phe Tyr His Cys Ile Asn Thr Thr Thr Gly Asp
 1370 1375 1380
 Arg Phe Asp Ile Glu Asp Val Asn Asn His Thr Asp Cys Leu Lys
 1385 1390 1395
 Leu Ile Glu Arg Asn Glu Thr Ala Arg Trp Lys Asn Val Lys Val
 1400 1405 1410

SSCP Update Sequences.ST25

Asn	Phe	Asp	Asn	Val	Gly	Phe	Gly	Tyr	Leu	Ser	Leu	Leu	Gln	Val
1415						1420					1425			
Ala	Thr	Phe	Lys	Gly	Trp	Met	Asp	Ile	Met	Tyr	Ala	Ala	Val	Asp
1430						1435					1440			
Ser	Arg	Asn	Val	Glu	Leu	Gln	Pro	Lys	Tyr	Glu	Lys	Ser	Leu	Tyr
1445						1450					1455			
Met	Tyr	Leu	Tyr	Phe	Val	Ile	Phe	Ile	Ile	Phe	Gly	Ser	Phe	Phe
1460						1465					1470			
Thr	Leu	Asn	Leu	Phe	Ile	Gly	Val	Ile	Ile	Asp	Asn	Phe	Asn	Gln
1475						1480					1485			
Gln	Lys	Lys	Lys	Phe	Gly	Gly	Gln	Asp	Ile	Phe	Met	Thr	Glu	Glu
1490						1495					1500			
Gln	Lys	Lys	Tyr	Tyr	Asn	Ala	Met	Lys	Lys	Leu	Gly	Ser	Lys	Lys
1505						1510					1515			
Pro	Gln	Lys	Pro	Ile	Pro	Arg	Pro	Gly	Asn	Lys	Phe	Gln	Gly	Met
1520						1525					1530			
Val	Phe	Asp	Phe	Val	Thr	Arg	Gln	Val	Phe	Asp	Ile	Ser	Ile	Met
1535						1540					1545			
Ile	Leu	Ile	Cys	Leu	Asn	Met	Val	Thr	Met	Met	Val	Glu	Thr	Asp
1550						1555					1560			
Asp	Gln	Ser	Glu	Tyr	Val	Thr	Thr	Ile	Leu	Ser	Arg	Ile	Asn	Leu
1565						1570					1575			
Val	Phe	Ile	Val	Leu	Phe	Thr	Gly	Glu	Cys	Val	Leu	Lys	Leu	Ile
1580						1585					1590			
Ser	Leu	Arg	His	Tyr	Tyr	Phe	Thr	Ile	Gly	Trp	Asn	Ile	Phe	Asp
1595						1600					1605			
Phe	Val	Val	Val	Ile	Leu	Ser	Ile	Val	Gly	Met	Phe	Leu	Ala	Glu
1610						1615					1620			
Leu	Ile	Glu	Lys	Tyr	Phe	Val	Ser	Pro	Thr	Leu	Phe	Arg	Val	Ile
1625						1630					1635			
Arg	Leu	Ala	Arg	Ile	Gly	Arg	Ile	Leu	Arg	Leu	Ile	Lys	Gly	Ala
1640						1645					1650			
Lys	Gly	Ile	Arg	Thr	Leu	Leu	Phe	Ala	Leu	Met	Met	Ser	Leu	Pro
1655						1660					1665			

SSCP Update Sequences.ST25

Ala	Leu	Phe	Asn	Ile	Gly	Leu	Leu	Leu	Phe	Leu	Val	Met	Phe	Ile
	1670					1675					1680			
Tyr	Ala	Ile	Phe	Gly	Met	Ser	Asn	Phe	Ala	Tyr	Val	Lys	Arg	Glu
	1685					1690					1695			
Val	Gly	Ile	Asp	Asp	Met	Phe	Asn	Phe	Glu	Thr	Phe	Gly	Asn	Ser
	1700					1705					1710			
Met	Ile	Cys	Leu	Phe	Gln	Ile	Thr	Thr	Ser	Ala	Gly	Trp	Asp	Gly
	1715					1720					1725			
Leu	Leu	Ala	Pro	Ile	Leu	Asn	Ser	Lys	Pro	Pro	Asp	Cys	Asp	Pro
	1730					1735					1740			
Asn	Lys	Val	Asn	Pro	Gly	Ser	Ser	Val	Lys	Gly	Asp	Cys	Gly	Asn
	1745					1750					1755			
Pro	Ser	Val	Gly	Ile	Phe	Phe	Phe	Val	Ser	Tyr	Ile	Ile	Ile	Ser
	1760					1765					1770			
Phe	Leu	Val	Val	Val	Asn	Met	Tyr	Ile	Ala	Val	Ile	Leu	Glu	Asn
	1775					1780					1785			
Phe	Ser	Val	Ala	Thr	Glu	Glu	Ser	Ala	Glu	Pro	Leu	Ser	Glu	Asp
	1790					1795					1800			
Asp	Phe	Glu	Met	Phe	Tyr	Glu	Val	Trp	Glu	Lys	Phe	Asp	Pro	Asp
	1805					1810					1815			
Ala	Thr	Gln	Phe	Met	Glu	Phe	Glu	Lys	Leu	Ser	Gln	Phe	Ala	Ala
	1820					1825					1830			
Ala	Leu	Glu	Pro	Pro	Leu	Asn	Leu	Pro	Gln	Pro	Asn	Lys	Leu	Gln
	1835					1840					1845			
Leu	Ile	Ala	Met	Asp	Leu	Pro	Met	Val	Ser	Gly	Asp	Arg	Ile	His
	1850					1855					1860			
Cys	Leu	Asp	Ile	Leu	Phe	Ala	Phe	Thr	Lys	Arg	Val	Leu	Gly	Glu
	1865					1870					1875			
Ser	Gly	Glu	Met	Asp	Ala	Leu	Arg	Ile	Gln	Met	Glu	Glu	Arg	Phe
	1880					1885					1890			
Met	Ala	Ser	Asn	Pro	Ser	Lys	Val	Ser	Tyr	Gln	Pro	Ile	Thr	Thr
	1895					1900					1905			
Thr	Leu	Lys	Arg	Lys	Gln	Glu	Glu	Val	Ser	Ala	Val	Ile	Ile	Gln
	1910					1915					1920			

SSCP Update Sequences, ST25

Arg Ala Tyr Arg Arg His Leu Leu Lys Arg Thr Val Lys Gln Ala
 1925 1930 1935

Ser Phe Thr Tyr Asn Lys Asn Lys Ile Lys Gly Gly Ala Asn Leu
 1940 1945 1950

Leu Ile Lys Glu Asp Met Ile Ile Asp Arg Ile Asn Glu Asn Ser
 1955 1960 1965

Ile Thr Glu Lys Thr Asp Leu Thr Met Ser Thr Ala Ala Cys Pro
 1970 1975 1980

Pro Ser Tyr Asp Arg Val Thr Lys Pro Ile Val Glu Lys His Glu
 1985 1990 1995

Gln Glu Gly Lys Asp Glu Lys Ala Lys Gly Lys
 2000 2005

<210> 79
 <211> 1406
 <212> PRT
 <213> Homo sapiens

<400> 79

Met Glu Gln Thr Val Leu Val Pro Pro Gly Pro Asp Ser Phe Asn Phe
 1 5 10 15

Phe Thr Arg Glu Ser Leu Ala Ala Ile Glu Arg Arg Ile Ala Glu Glu
 20 25 30

Lys Ala Lys Asn Pro Lys Pro Asp Lys Lys Asp Asp Asp Glu Asn Gly
 35 40 45

Pro Lys Pro Asn Ser Asp Leu Glu Ala Gly Lys Asn Leu Pro Phe Ile
 50 55 60

Tyr Gly Asp Ile Pro Pro Glu Met Val Ser Glu Pro Leu Glu Asp Leu
 65 70 75 80

Asp Pro Tyr Tyr Ile Asn Lys Lys Thr Phe Ile Val Leu Asn Lys Leu
 85 90 95

Lys Ala Ile Phe Arg Phe Ser Ala Thr Ser Ala Leu Tyr Ile Leu Thr
 100 105 110

Pro Phe Asn Pro Leu Arg Lys Ile Ala Ile Lys Ile Leu Val His Ser
 115 120 125

Leu Phe Ser Met Leu Ile Met Cys Thr Ile Leu Thr Asn Cys Val Phe
 130 135 140

Met Thr Met Ser Asn Pro Pro Asp Trp Thr Lys Asn Val Glu Tyr Thr
 Page 155

145 150 155 160

Leu Ile Leu Ala Val Val Ala Met Ala Tyr Glu Glu Gln Asn Gln Ala

SSCP Update Sequences.ST25
425 430

420

Thr Leu Glu Glu Ala Glu Gln Lys Glu Ala Glu Phe Gln Gln Met Ile
435 440 445

Glu Gln Leu Lys Lys Gln Gln Glu Ala Ala Gln Gln Ala Ala Thr Ala
450 455 460

Thr Ala Ser Glu His Ser Arg Glu Pro Ser Ala Ala Gly Arg Leu Ser
465 470 475 480

Asp Ser Ser Ser Glu Ala Ser Lys Leu Ser Ser Lys Ser Ala Lys Glu
485 490 495

Arg Arg Asn Arg Arg Lys Lys Arg Lys Gln Lys Glu Gln Ser Gly Gly
500 505 510

Glu Glu Lys Asp Glu Asp Glu Phe Gln Lys Ser Glu Ser Glu Asp Ser
515 520 525

Ile Arg Arg Lys Gly Phe Arg Phe Ser Ile Glu Gly Asn Arg Leu Thr
530 535 540

Tyr Glu Lys Arg Tyr Ser Ser Pro His Gln Ser Leu Leu Ser Ile Arg
545 550 555 560

Gly Ser Leu Phe Ser Pro Arg Arg Asn Ser Arg Thr Ser Leu Phe Ser
565 570 575

Phe Arg Gly Arg Ala Lys Asp Val Gly Ser Glu Asn Asp Phe Ala Asp
580 585 590

Asp Glu His Ser Thr Phe Glu Asp Asn Glu Ser Arg Arg Asp Ser Leu
595 600 605

Phe Val Pro Arg Arg His Gly Glu Arg Arg Asn Ser Asn Leu Ser Gln
610 615 620

Thr Ser Arg Ser Ser Arg Met Leu Ala Val Phe Pro Ala Asn Gly Lys
625 630 635 640

Met His Ser Thr Val Asp Cys Asn Gly Val Val Ser Leu Val Gly Gly
645 650 655

Pro Ser Val Pro Thr Ser Pro Val Gly Gln Leu Leu Pro Glu Val Ile
660 665 670

Ile Asp Lys Pro Ala Thr Asp Asp Asn Gly Thr Thr Thr Glu Thr Glu
675 680 685

Met Arg Lys Arg Arg Ser Ser Ser Phe His Val Ser Met Asp Phe Leu
Page 157

SSCP Update Sequences.ST25

690

695

700

Glu Asp Pro Ser Gln Arg Gln Arg Ala Met Ser Ile Ala Ser Ile Leu
 705 710 715 720

Thr Asn Thr Val Glu Glu Leu Glu Glu Ser Arg Gln Lys Cys Pro Pro
 725 730 735

Cys Trp Tyr Lys Phe Ser Asn Ile Phe Leu Ile Trp Asp Cys Ser Pro
 740 745 750

Tyr Trp Leu Lys Val Lys His Val Val Asn Leu Val Val Met Asp Pro
 755 760 765

Phe Val Asp Leu Ala Ile Thr Ile Cys Ile Val Leu Asn Thr Leu Phe
 770 775 780

Met Ala Met Glu His Tyr Pro Met Thr Asp His Phe Asn Asn Val Leu
 785 790 795 800

Thr Val Gly Asn Leu Val Phe Thr Gly Ile Phe Thr Ala Glu Met Phe
 805 810 815

Leu Lys Ile Ile Ala Met Asp Pro Tyr Tyr Tyr Phe Gln Glu Gly Trp
 820 825 830

Asn Ile Phe Asp Gly Phe Ile Val Thr Leu Ser Leu Val Glu Leu Gly
 835 840 845

Leu Ala Asn Val Glu Gly Leu Ser Val Leu Arg Ser Phe Arg Leu Leu
 850 855 860

Arg Val Phe Lys Leu Ala Lys Ser Trp Pro Thr Leu Asn Met Leu Ile
 865 870 875 880

Lys Ile Ile Gly Asn Ser Val Gly Ala Leu Gly Asn Leu Thr Leu Val
 885 890 895

Leu Ala Ile Ile Val Phe Ile Phe Ala Val Val Gly Met Gln Leu Phe
 900 905 910

Gly Lys Ser Tyr Lys Asp Cys Val Cys Lys Ile Ala Ser Asp Cys Gln
 915 920 925

Leu Pro Arg Trp His Met Asn Asp Phe Phe His Ser Phe Leu Ile Val
 930 935 940

Phe Arg Val Leu Cys Gly Glu Trp Ile Glu Thr Met Trp Asp Cys Met
 945 950 955 960

Glu Val Ala Gly Gln Ala Met Cys Leu Thr Val Phe Met Met Val Met
 Page 158

SSCP update Sequences.ST25

965

970

975

Val Ile Gly Asn Leu Val Val Leu Asn Leu Phe Leu Ala Leu Leu Leu
 980 985 990

Ser Ser Phe Ser Ala Asp Asn Leu Ala Ala Thr Asp Asp Asp Asn Glu
 995 1000 1005

Met Asn Asn Leu Gln Ile Ala Val Asp Arg Met His Lys Gly Val
 1010 1015 1020

Ala Tyr Val Lys Arg Lys Ile Tyr Glu Phe Ile Gln Gln Ser Phe
 1025 1030 1035

Ile Arg Lys Gln Lys Ile Leu Asp Glu Ile Lys Pro Leu Asp Asp
 1040 1045 1050

Leu Asn Asn Lys Lys Asp Ser Cys Met Ser Asn His Thr Thr Glu
 1055 1060 1065

Ile Gly Lys Asp Leu Asp Tyr Leu Lys Asp Val Asn Gly Thr Thr
 1070 1075 1080

Ser Gly Ile Gly Thr Gly Ser Ser Val Glu Lys Tyr Ile Ile Asp
 1085 1090 1095

Glu Ser Asp Tyr Met Ser Phe Ile Asn Asn Pro Ser Leu Thr Val
 1100 1105 1110

Thr Val Pro Ile Ala Val Gly Glu Ser Asp Phe Glu Asn Leu Asn
 1115 1120 1125

Thr Glu Asp Phe Ser Ser Glu Ser Asp Leu Glu Glu Ser Lys Glu
 1130 1135 1140

Lys Leu Asn Glu Ser Ser Ser Ser Ser Glu Gly Ser Thr Val Asp
 1145 1150 1155

Ile Gly Ala Pro Val Glu Glu Gln Pro Val Val Glu Pro Glu Glu
 1160 1165 1170

Thr Leu Glu Pro Glu Ala Cys Phe Thr Glu Gly Cys Val Gln Arg
 1175 1180 1185

Phe Lys Cys Cys Gln Ile Asn Val Glu Glu Gly Arg Gly Lys Gln
 1190 1195 1200

Trp Trp Asn Leu Arg Arg Thr Cys Phe Arg Ile Val Glu His Asn
 1205 1210 1215

Trp Phe Glu Thr Phe Ile Val Phe Met Ile Leu Leu Ser Ser Gly

SSCP Update Sequences.ST25

1220 1225 1230

Ala Leu Ala Phe Glu Asp Ile Tyr Ile Asp Gln Arg Lys Thr Ile
1235 1240 1245

Lys Thr Met Leu Glu Tyr Ala Asp Lys Val Phe Thr Tyr Ile Phe
1250 1255 1260

Ile Leu Glu Met Leu Leu Lys Trp Val Ala Tyr Gly Tyr Gln Thr
1265 1270 1275

Tyr Phe Thr Asn Ala Trp Cys Trp Leu Asp Phe Leu Ile Val Asp
1280 1285 1290

Val Ser Leu Val Ser Leu Thr Ala Asn Ala Leu Gly Tyr Ser Glu
1295 1300 1305

Leu Gly Ala Ile Lys Ser Leu Arg Thr Leu Arg Ala Leu Arg Pro
1310 1315 1320

Leu Arg Ala Leu Ser Arg Phe Glu Gly Met Arg Val Val Val Asn
1325 1330 1335

Ala Leu Leu Gly Ala Ile Pro Ser Ile Met Asn Val Leu Leu Val
1340 1345 1350

Cys Leu Ile Phe Trp Leu Ile Phe Ser Ile Met Gly Val Asn Leu
1355 1360 1365

Phe Ala Gly Lys Phe Tyr His Cys Ile Asn Thr Thr Thr Gly Asp
1370 1375 1380

Arg Phe Asp Ile Glu Asp Val Asn Asn His Thr Asp Cys Leu Lys
1385 1390 1395

Leu Ile Glu Arg Asn Glu Thr Ala
1400 1405

<210> 80
 <211> 2009
 <212> PRT
 <213> Homo sapiens

<400> 80

Met Glu Gln Thr Val Leu Val Pro Pro Gly Pro Asp Ser Phe Asn Phe
1 5 10 15

Phe Thr Arg Glu Ser Leu Ala Ala Ile Glu Arg Arg Ile Ala Glu Glu
20 25 30

Lys Ala Lys Asn Pro Lys Pro Asp Lys Lys Asp Asp Asp Glu Asn Gly
35 40 45

SSCP update Sequences.ST25

Pro Lys Pro Asn Ser Asp Leu Glu Ala Gly Lys Asn Leu Pro Phe Ile
 50 55 60
 Tyr Gly Asp Ile Pro Pro Glu Met Val Ser Glu Pro Leu Glu Asp Leu
 65 70 75 80
 Asp Pro Tyr Tyr Ile Asn Lys Lys Thr Phe Ile Val Leu Asn Lys Leu
 85 90 95
 Lys Ala Ile Phe Arg Phe Ser Ala Thr Ser Ala Leu Tyr Ile Leu Thr
 100 105 110
 Pro Phe Asn Pro Leu Arg Lys Ile Ala Ile Lys Ile Leu Val His Ser
 115 120 125
 Leu Phe Ser Met Leu Ile Met Cys Thr Ile Leu Thr Asn Cys Val Phe
 130 135 140
 Met Thr Met Ser Asn Pro Pro Asp Trp Thr Lys Asn Val Glu Tyr Thr
 145 150 155 160
 Phe Thr Gly Ile Tyr Thr Phe Glu Ser Leu Ile Lys Ile Ile Ala Arg
 165 170 175
 Gly Phe Cys Leu Glu Asp Phe Thr Phe Leu Arg Asp Pro Trp Asn Trp
 180 185 190
 Leu Asp Phe Thr Val Ile Thr Phe Ala Tyr Val Thr Glu Phe Val Asp
 195 200 205
 Leu Gly Asn Val Ser Ala Leu Arg Thr Phe Arg Val Leu Arg Ala Leu
 210 215 220
 Lys Thr Ile Ser Val Ile Pro Gly Leu Lys Thr Ile Val Gly Ala Leu
 225 230 235 240
 Ile Gln Ser Val Lys Lys Leu Ser Asp Val Met Ile Leu Thr Val Phe
 245 250 255
 Cys Leu Ser Val Phe Ala Leu Ile Gly Leu Gln Leu Phe Met Gly Asn
 260 265 270
 Leu Arg Asn Lys Cys Ile Gln Trp Pro Pro Thr Asn Ala Ser Leu Glu
 275 280 285
 Glu His Ser Ile Glu Lys Asn Ile Thr Val Asn Tyr Asn Gly Thr Leu
 290 295 300
 Ile Asn Glu Thr Val Phe Glu Phe Asp Trp Lys Ser Tyr Ile Gln Asp
 305 310 315 320

SSCP Update Sequences.ST25

Ser Arg Tyr His Tyr Phe Leu Glu Gly Phe Leu Asp Ala Leu Leu Cys
 325 330 335
 Gly Asn Ser Ser Asp Ala Gly Gln Cys Pro Glu Gly Tyr Met Cys Val
 340 345 350
 Lys Ala Gly Arg Asn Pro Asn Tyr Gly Tyr Thr Ser Phe Asp Thr Phe
 355 360 365
 Ser Trp Ala Phe Leu Ser Leu Phe Arg Leu Met Thr Gln Asp Phe Trp
 370 375 380
 Glu Asn Leu Tyr Gln Leu Thr Leu Arg Ala Ala Gly Lys Thr Tyr Met
 385 390 395 400
 Ile Phe Phe Val Leu Val Ile Phe Leu Gly Ser Phe Tyr Leu Ile Asn
 405 410 415
 Leu Ile Leu Ala Val Val Ala Met Ala Tyr Glu Glu Gln Asn Gln Ala
 420 425 430
 Thr Leu Glu Glu Ala Glu Gln Lys Glu Ala Glu Phe Gln Gln Met Ile
 435 440 445
 Glu Gln Leu Lys Lys Gln Gln Glu Ala Ala Gln Gln Ala Ala Thr Ala
 450 455 460
 Thr Ala Ser Glu His Ser Arg Glu Pro Ser Ala Ala Gly Arg Leu Ser
 465 470 475 480
 Asp Ser Ser Ser Glu Ala Ser Lys Leu Ser Ser Lys Ser Ala Lys Glu
 485 490 495
 Arg Arg Asn Arg Arg Lys Lys Arg Lys Gln Lys Glu Gln Ser Gly Gly
 500 505 510
 Glu Glu Lys Asp Glu Asp Glu Phe Gln Lys Ser Glu Ser Glu Asp Ser
 515 520 525
 Ile Arg Arg Lys Gly Phe Arg Phe Ser Ile Glu Gly Asn Arg Leu Thr
 530 535 540
 Tyr Glu Lys Arg Tyr Ser Ser Pro His Gln Ser Leu Leu Ser Ile Arg
 545 550 555 560
 Gly Ser Leu Phe Ser Pro Arg Arg Asn Ser Arg Thr Ser Leu Phe Ser
 565 570 575
 Phe Arg Gly Arg Ala Lys Asp Val Gly Ser Glu Asn Asp Phe Ala Asp
 580 585 590

SSCP Update Sequences.ST25

Asp Glu His Ser Thr Phe Glu Asp Asn Glu Ser Arg Arg Asp Ser Leu
 595 600 605
 Phe Val Pro Arg Arg His Gly Glu Arg Arg Asn Ser Asn Leu Ser Gln
 610 615 620
 Thr Ser Arg Ser Ser Arg Met Leu Ala Val Phe Pro Ala Asn Gly Lys
 625 630 635 640
 Met His Ser Thr Val Asp Cys Asn Gly Val Val Ser Leu Val Gly Gly
 645 650 655
 Pro Ser Val Pro Thr Ser Pro Val Gly Gln Leu Leu Pro Glu Val Ile
 660 665 670
 Ile Asp Lys Pro Ala Thr Asp Asp Asn Gly Thr Thr Thr Glu Thr Glu
 675 680 685
 Met Arg Lys Arg Arg Ser Ser Ser Phe His Val Ser Met Asp Phe Leu
 690 695 700
 Glu Asp Pro Ser Gln Arg Gln Arg Ala Met Ser Ile Ala Ser Ile Leu
 705 710 715 720
 Thr Asn Thr Val Glu Glu Leu Glu Glu Ser Arg Gln Lys Cys Pro Pro
 725 730 735
 Cys Trp Tyr Lys Phe Ser Asn Ile Phe Leu Ile Trp Asp Cys Ser Pro
 740 745 750
 Tyr Trp Leu Lys Val Lys His Val Val Asn Leu Val Val Met Asp Pro
 755 760 765
 Phe Val Asp Leu Ala Ile Thr Ile Cys Ile Val Leu Asn Thr Leu Phe
 770 775 780
 Met Ala Met Glu His Tyr Pro Met Thr Asp His Phe Asn Asn Val Leu
 785 790 795 800
 Thr Val Gly Asn Leu Val Phe Thr Gly Ile Phe Thr Ala Glu Met Phe
 805 810 815
 Leu Lys Ile Ile Ala Met Asp Pro Tyr Tyr Tyr Phe Gln Glu Gly Trp
 820 825 830
 Asn Ile Phe Asp Gly Phe Ile Val Thr Leu Ser Leu Val Glu Leu Gly
 835 840 845
 Leu Ala Asn Val Glu Gly Leu Ser Val Leu Arg Ser Phe Arg Leu Leu
 850 855 860

SSCP Update Sequences.ST25

Arg Val Phe Lys Leu Ala Lys Ser Trp Pro Thr Leu Asn Met Leu Ile
 865 870 875 880
 Lys Ile Ile Gly Asn Ser Val Gly Ala Leu Gly Asn Leu Thr Leu Val
 885 890 895
 Leu Ala Ile Ile Val Phe Ile Phe Ala Val Val Gly Met Gln Leu Phe
 900 905 910
 Gly Lys Ser Tyr Lys Asp Cys Val Cys Lys Ile Ala Ser Asp Cys Gln
 915 920 925
 Leu Pro Arg Trp His Met Asn Asp Phe Phe His Ser Phe Leu Ile Val
 930 935 940
 Phe Arg Val Leu Cys Gly Glu Trp Ile Glu Thr Met Trp Asp Cys Met
 945 950 955 960
 Glu Val Ala Gly Gln Ala Met Cys Leu Thr Val Phe Met Met Val Met
 965 970 975
 Val Ile Gly Asn Leu Val Val Leu Asn Leu Phe Leu Ala Leu Leu Leu
 980 985 990
 Ser Ser Phe Ser Ala Asp Asn Leu Ala Ala Thr Asp Asp Asp Asn Glu
 995 1000 1005
 Met Asn Asn Leu Gln Ile Ala Val Asp Arg Met His Lys Gly Val
 1010 1015 1020
 Ala Tyr Val Lys Arg Lys Ile Tyr Glu Phe Ile Gln Gln Ser Phe
 1025 1030 1035
 Ile Arg Lys Gln Lys Ile Leu Asp Glu Ile Lys Pro Leu Asp Asp
 1040 1045 1050
 Leu Asn Asn Lys Lys Asp Ser Cys Met Ser Asn His Thr Thr Glu
 1055 1060 1065
 Ile Gly Lys Asp Leu Asp Tyr Leu Lys Asp Val Asn Gly Thr Thr
 1070 1075 1080
 Ser Gly Ile Gly Thr Gly Ser Ser Val Glu Lys Tyr Ile Ile Asp
 1085 1090 1095
 Glu Ser Asp Tyr Met Ser Phe Ile Asn Asn Pro Ser Leu Thr Val
 1100 1105 1110
 Thr Val Pro Ile Ala Val Gly Glu Ser Asp Phe Glu Asn Leu Asn
 1115 1120 1125

SSCP Update Sequences.ST25

Thr Glu Asp Phe Ser Ser Glu Ser Asp Leu Glu Glu Ser Lys Glu
 1130 1135 1140
 Lys Leu Asn Glu Ser Ser Ser Ser Ser Glu Gly Ser Thr Val Asp
 1145 1150 1155
 Ile Gly Ala Pro Val Glu Glu Gln Pro Val Val Glu Pro Glu Glu
 1160 1165 1170
 Thr Leu Glu Pro Glu Ala Cys Phe Thr Glu Gly Cys Val Gln Arg
 1175 1180 1185
 Phe Lys Cys Cys Gln Ile Asn Val Glu Glu Gly Arg Gly Lys Gln
 1190 1195 1200
 Trp Trp Asn Leu Arg Arg Thr Cys Phe Arg Ile Val Glu His Asn
 1205 1210 1215
 Trp Phe Glu Thr Phe Ile Val Phe Met Ile Leu Leu Ser Ser Gly
 1220 1225 1230
 Ala Leu Ala Phe Glu Asp Ile Tyr Ile Asp Gln Arg Lys Thr Ile
 1235 1240 1245
 Lys Thr Met Leu Glu Tyr Ala Asp Lys Val Phe Thr Tyr Ile Phe
 1250 1255 1260
 Ile Leu Glu Met Leu Leu Lys Trp Val Ala Tyr Gly Tyr Gln Thr
 1265 1270 1275
 Tyr Phe Thr Asn Ala Trp Cys Trp Leu Asp Phe Leu Ile Val Asp
 1280 1285 1290
 Val Ser Leu Val Ser Leu Thr Ala Asn Ala Leu Gly Tyr Ser Glu
 1295 1300 1305
 Leu Gly Ala Ile Lys Ser Leu Arg Thr Leu Arg Ala Leu Arg Pro
 1310 1315 1320
 Leu Arg Ala Leu Ser Arg Phe Glu Gly Met Arg Val Val Val Asn
 1325 1330 1335
 Ala Leu Leu Gly Ala Ile Pro Ser Ile Met Asn Val Leu Leu Val
 1340 1345 1350
 Cys Leu Ile Phe Trp Leu Ile Phe Ser Ile Met Gly Val Asn Leu
 1355 1360 1365
 Phe Ala Gly Lys Phe Tyr His Cys Ile Asn Thr Thr Thr Gly Asp
 1370 1375 1380

SSCP Update Sequences.ST25

Arg Phe Asp Ile Glu Asp Val Asn Asn His Thr Asp Cys Leu Lys
 1385 1390 1395
 Leu Ile Glu Arg Asn Glu Thr Ala Arg Trp Lys Asn Val Lys Val
 1400 1405 1410
 Asn Phe Asp Asn Val Gly Phe Gly Tyr Leu Ser Leu Leu Gln Val
 1415 1420 1425
 Ala Thr Phe Lys Gly Trp Met Asp Ile Met Tyr Ala Ala Val Asp
 1430 1435 1440
 Ser Arg Asn Val Glu Leu Gln Pro Lys Tyr Glu Lys Ser Leu Tyr
 1445 1450 1455
 Met Tyr Leu Tyr Phe Val Ile Phe Ile Ile Phe Gly Ser Phe Phe
 1460 1465 1470
 Thr Leu Asn Leu Phe Ile Gly Val Ile Ile Asp Asn Phe Asn Gln
 1475 1480 1485
 Gln Lys Lys Lys Phe Gly Gly Gln Asp Ile Phe Met Thr Glu Glu
 1490 1495 1500
 Gln Lys Lys Tyr Tyr Asn Ala Met Lys Lys Leu Gly Ser Lys Lys
 1505 1510 1515
 Pro Gln Lys Pro Ile Pro Arg Pro Gly Asn Lys Phe Gln Gly Met
 1520 1525 1530
 Val Phe Asp Phe Val Thr Arg Gln Val Phe Asp Ile Ser Ile Met
 1535 1540 1545
 Ile Leu Ile Cys Leu Asn Met Val Thr Met Met Val Glu Thr Asp
 1550 1555 1560
 Asp Gln Ser Glu Tyr Val Thr Thr Ile Leu Ser Arg Ile Asn Leu
 1565 1570 1575
 Val Phe Ile Val Leu Phe Thr Gly Glu Cys Val Leu Lys Leu Ile
 1580 1585 1590
 Ser Leu Arg His Tyr Tyr Phe Thr Ile Gly Trp Asn Ile Phe Asp
 1595 1600 1605
 Phe Val Val Val Ile Leu Ser Ile Val Gly Met Phe Leu Ala Glu
 1610 1615 1620
 Leu Ile Glu Lys Tyr Phe Val Ser Pro Thr Leu Phe Arg Val Ile
 1625 1630 1635

SSCP Update Sequences.ST25

Arg Leu Ala Arg Ile Gly Arg Ile Leu Arg Leu Ile Lys Gly Ala
 1640 1645 1650
 Lys Gly Ile Arg Thr Leu Leu Phe Ala Leu Met Met Ser Leu Pro
 1655 1660 1665
 Ala Leu Phe Asn Ile Gly Leu Leu Leu Phe Leu Val Met Phe Ile
 1670 1675 1680
 Tyr Ala Ile Phe Gly Met Ser Asn Phe Ala Tyr Val Lys Arg Glu
 1685 1690 1695
 Val Gly Ile Asp Asp Met Phe Asn Phe Glu Thr Phe Gly Asn Ser
 1700 1705 1710
 Met Ile Cys Leu Phe Gln Ile Thr Thr Ser Ala Gly Trp Asp Gly
 1715 1720 1725
 Leu Leu Ala Pro Ile Leu Asn Ser Lys Pro Pro Asp Cys Asp Pro
 1730 1735 1740
 Asn Lys Val Asn Pro Gly Ser Ser Val Lys Gly Asp Cys Gly Asn
 1745 1750 1755
 Pro Ser Val Gly Ile Phe Phe Phe Val Ser Tyr Ile Ile Ile Ser
 1760 1765 1770
 Phe Leu Val Val Val Asn Thr Tyr Ile Ala Val Ile Leu Glu Asn
 1775 1780 1785
 Phe Ser Val Ala Thr Glu Glu Ser Ala Glu Pro Leu Ser Glu Asp
 1790 1795 1800
 Asp Phe Glu Met Phe Tyr Glu Val Trp Glu Lys Phe Asp Pro Asp
 1805 1810 1815
 Ala Thr Gln Phe Met Glu Phe Glu Lys Leu Ser Gln Phe Ala Ala
 1820 1825 1830
 Ala Leu Glu Pro Pro Leu Asn Leu Pro Gln Pro Asn Lys Leu Gln
 1835 1840 1845
 Leu Ile Ala Met Asp Leu Pro Met Val Ser Gly Asp Arg Ile His
 1850 1855 1860
 Cys Leu Asp Ile Leu Phe Ala Phe Thr Lys Arg Val Leu Gly Glu
 1865 1870 1875
 Ser Gly Glu Met Asp Ala Leu Arg Ile Gln Met Glu Glu Arg Phe
 1880 1885 1890

SSCP update Sequences.ST25

Met Ala Ser Asn Pro Ser Lys Val Ser Tyr Gln Pro Ile Thr Thr
 1895 1900 1905
 Thr Leu Lys Arg Lys Gln Glu Glu Val Ser Ala Val Ile Ile Gln
 1910 1915 1920
 Arg Ala Tyr Arg Arg His Leu Leu Lys Arg Thr Val Lys Gln Ala
 1925 1930 1935
 Ser Phe Thr Tyr Asn Lys Asn Lys Ile Lys Gly Gly Ala Asn Leu
 1940 1945 1950
 Leu Ile Lys Glu Asp Met Ile Ile Asp Arg Ile Asn Glu Asn Ser
 1955 1960 1965
 Ile Thr Glu Lys Thr Asp Leu Thr Met Ser Thr Ala Ala Cys Pro
 1970 1975 1980
 Pro Ser Tyr Asp Arg Val Thr Lys Pro Ile Val Glu Lys His Glu
 1985 1990 1995
 Gln Glu Gly Lys Asp Glu Lys Ala Lys Gly Lys
 2000 2005
 <210> 81
 <211> 1891
 <212> PRT
 <213> Homo sapiens
 <400> 81
 Met Glu Gln Thr Val Leu Val Pro Pro Gly Pro Asp Ser Phe Asn Phe
 1 5 10 15
 Phe Thr Arg Glu Ser Leu Ala Ala Ile Glu Arg Arg Ile Ala Glu Glu
 20 25 30
 Lys Ala Lys Asn Pro Lys Pro Asp Lys Lys Asp Asp Asp Glu Asn Gly
 35 40 45
 Pro Lys Pro Asn Ser Asp Leu Glu Ala Gly Lys Asn Leu Pro Phe Ile
 50 55 60
 Tyr Gly Asp Ile Pro Pro Glu Met Val Ser Glu Pro Leu Glu Asp Leu
 65 70 75 80
 Asp Pro Tyr Tyr Ile Asn Lys Lys Thr Phe Ile Val Leu Asn Lys Leu
 85 90 95
 Lys Ala Ile Phe Arg Phe Ser Ala Thr Ser Ala Leu Tyr Ile Leu Thr
 100 105 110

SSCP Update Sequences.ST25

Pro Phe Asn Pro Leu Arg Lys Ile Ala Ile Lys Ile Leu Val His Ser
 115 120 125
 Leu Phe Ser Met Leu Ile Met Cys Thr Ile Leu Thr Asn Cys Val Phe
 130 135 140
 Met Thr Met Ser Asn Pro Pro Asp Trp Thr Lys Asn Val Glu Tyr Thr
 145 150 155 160
 Phe Thr Gly Ile Tyr Thr Phe Glu Ser Leu Ile Lys Ile Ile Ala Arg
 165 170 175
 Gly Phe Cys Leu Glu Asp Phe Thr Phe Leu Arg Asp Pro Trp Asn Trp
 180 185 190
 Leu Asp Phe Thr Val Ile Thr Phe Ala Tyr Val Thr Glu Phe Val Asp
 195 200 205
 Leu Gly Asn Val Ser Ala Leu Arg Thr Phe Arg Val Leu Arg Ala Leu
 210 215 220
 Lys Thr Ile Ser Val Ile Pro Gly Leu Lys Thr Ile Val Gly Ala Leu
 225 230 235 240
 Ile Gln Ser Val Lys Lys Leu Ser Asp Val Met Ile Leu Thr Val Phe
 245 250 255
 Cys Leu Ser Val Phe Ala Leu Ile Gly Leu Gln Leu Phe Met Gly Asn
 260 265 270
 Leu Arg Asn Lys Cys Ile Gln Trp Pro Pro Thr Asn Ala Ser Leu Glu
 275 280 285
 Glu His Ser Ile Glu Lys Asn Ile Thr Val Asn Tyr Asn Gly Thr Leu
 290 295 300
 Ile Asn Glu Thr Val Phe Glu Phe Asp Trp Lys Ser Tyr Ile Gln Asp
 305 310 315 320
 Ser Arg Tyr His Tyr Phe Leu Glu Gly Phe Leu Asp Ala Leu Leu Cys
 325 330 335
 Gly Asn Ser Ser Asp Ala Gly Gln Cys Pro Glu Gly Tyr Met Cys Val
 340 345 350
 Lys Ala Gly Arg Asn Pro Asn Tyr Gly Tyr Thr Ser Phe Asp Thr Phe
 355 360 365
 Ser Trp Ala Phe Leu Ser Leu Phe Arg Leu Met Thr Gln Asp Phe Trp
 370 375 380

SSCP Update Sequences.ST25

Glu Asn Leu Tyr Gln Leu Thr Leu Arg Ala Ala Gly Lys Thr Tyr Met
 385 390 395 400
 Ile Phe Phe Val Leu Val Ile Phe Leu Gly Ser Phe Tyr Leu Ile Asn
 405 410 415
 Leu Ile Leu Ala Val Val Ala Met Ala Tyr Glu Glu Gln Asn Gln Ala
 420 425 430
 Thr Leu Glu Glu Ala Glu Gln Lys Glu Ala Glu Phe Gln Gln Met Ile
 435 440 445
 Glu Gln Leu Lys Lys Gln Gln Glu Ala Ala Gln Gln Ala Ala Thr Ala
 450 455 460
 Thr Ala Ser Glu His Ser Arg Glu Pro Ser Ala Ala Gly Arg Leu Ser
 465 470 475 480
 Asp Ser Ser Ser Glu Ala Ser Lys Leu Ser Ser Lys Ser Ala Lys Glu
 485 490 495
 Arg Arg Asn Arg Arg Lys Lys Arg Lys Gln Lys Glu Gln Ser Gly Gly
 500 505 510
 Glu Glu Lys Asp Glu Asp Glu Phe Gln Lys Ser Glu Ser Glu Asp Ser
 515 520 525
 Ile Arg Arg Lys Gly Phe Arg Phe Ser Ile Glu Gly Asn Arg Leu Thr
 530 535 540
 Tyr Glu Lys Arg Tyr Ser Ser Pro His Gln Ser Leu Leu Ser Ile Arg
 545 550 555 560
 Gly Ser Leu Phe Ser Pro Arg Arg Asn Ser Arg Thr Ser Leu Phe Ser
 565 570 575
 Phe Arg Gly Arg Ala Lys Asp Val Gly Ser Glu Asn Asp Phe Ala Asp
 580 585 590
 Asp Glu His Ser Thr Phe Glu Asp Asn Glu Ser Arg Arg Asp Ser Leu
 595 600 605
 Phe Val Pro Arg Arg His Gly Glu Arg Arg Asn Ser Asn Leu Ser Gln
 610 615 620
 Thr Ser Arg Ser Ser Arg Met Leu Ala Val Phe Pro Ala Asn Gly Lys
 625 630 635 640
 Met His Ser Thr Val Asp Cys Asn Gly Val Val Ser Leu Val Gly Gly
 645 650 655

SSCP Update Sequences.ST25

Pro Ser Val Pro Thr Ser Pro Val Gly Gln Leu Leu Pro Glu Val Ile
 660 665 670
 Ile Asp Lys Pro Ala Thr Asp Asp Asn Gly Thr Thr Thr Glu Thr Glu
 675 680 685
 Met Arg Lys Arg Arg Ser Ser Ser Phe His Val Ser Met Asp Phe Leu
 690 695 700
 Glu Asp Pro Ser Gln Arg Gln Arg Ala Met Ser Ile Ala Ser Ile Leu
 705 710 715 720
 Thr Asn Thr Val Glu Glu Leu Glu Glu Ser Arg Gln Lys Cys Pro Pro
 725 730 735
 Cys Trp Tyr Lys Phe Ser Asn Ile Phe Leu Ile Trp Asp Cys Ser Pro
 740 745 750
 Tyr Trp Leu Lys Val Lys His Val Val Asn Leu Val Val Met Asp Pro
 755 760 765
 Phe Val Asp Leu Ala Ile Thr Ile Cys Ile Val Leu Asn Thr Leu Phe
 770 775 780
 Met Ala Met Glu His Tyr Pro Met Thr Asp His Phe Asn Asn Val Leu
 785 790 795 800
 Thr Val Gly Asn Leu Val Phe Thr Gly Ile Phe Thr Ala Glu Met Phe
 805 810 815
 Leu Lys Ile Ile Ala Met Asp Pro Tyr Tyr Tyr Phe Gln Glu Gly Trp
 820 825 830
 Asn Ile Phe Asp Gly Phe Ile Val Thr Leu Ser Leu Val Glu Leu Gly
 835 840 845
 Leu Ala Asn Val Glu Gly Leu Ser Val Leu Arg Ser Phe Arg Leu Leu
 850 855 860
 Arg Val Phe Lys Leu Ala Lys Ser Trp Pro Thr Leu Asn Met Leu Ile
 865 870 875 880
 Lys Ile Ile Gly Asn Ser Val Gly Ala Leu Gly Asn Leu Thr Leu Val
 885 890 895
 Leu Ala Ile Ile Val Phe Ile Phe Ala Val Val Gly Met Gln Leu Phe
 900 905 910
 Gly Lys Ser Tyr Lys Asp Cys Val Cys Lys Ile Ala Ser Asp Cys Gln
 915 920 925

SSCP Update Sequences.ST25

Leu Pro Arg Trp His Met Asn Asp Phe Phe His Ser Phe Leu Ile Val
 930 935 940
 Phe Arg Val Leu Cys Gly Glu Trp Ile Glu Thr Met Trp Asp Cys Met
 945 950 955 960
 Glu Val Ala Gly Gln Ala Met Cys Leu Thr Val Phe Met Met Val Met
 965 970 975
 Val Ile Gly Asn Leu Val Val Leu Asn Leu Phe Leu Ala Leu Leu Leu
 980 985 990
 Ser Ser Phe Ser Ala Asp Asn Leu Ala Ala Thr Asp Asp Asp Asn Glu
 995 1000 1005
 Met Asn Asn Leu Gln Ile Ala Val Asp Arg Met His Lys Gly Val
 1010 1015 1020
 Ala Tyr Val Lys Arg Lys Ile Tyr Glu Phe Ile Gln Gln Ser Phe
 1025 1030 1035
 Ile Arg Lys Gln Lys Ile Leu Asp Glu Ile Lys Pro Leu Asp Asp
 1040 1045 1050
 Leu Asn Asn Lys Lys Asp Ser Cys Met Ser Asn His Thr Thr Glu
 1055 1060 1065
 Ile Gly Lys Asp Leu Asp Tyr Leu Lys Asp Val Asn Gly Thr Thr
 1070 1075 1080
 Ser Gly Ile Gly Thr Gly Ser Ser Val Glu Lys Tyr Ile Ile Asp
 1085 1090 1095
 Glu Ser Asp Tyr Met Ser Phe Ile Asn Asn Pro Ser Leu Thr Val
 1100 1105 1110
 Thr Val Pro Ile Ala Val Gly Glu Ser Asp Phe Glu Asn Leu Asn
 1115 1120 1125
 Thr Glu Asp Phe Ser Ser Glu Ser Asp Leu Glu Glu Ser Lys Glu
 1130 1135 1140
 Lys Leu Asn Glu Ser Ser Ser Ser Ser Glu Gly Ser Thr Val Asp
 1145 1150 1155
 Ile Gly Ala Pro Val Glu Glu Gln Pro Val Val Glu Pro Glu Glu
 1160 1165 1170
 Thr Leu Glu Pro Glu Ala Cys Phe Thr Glu Gly Cys Val Gln Arg
 1175 1180 1185

SSCP Update Sequences.ST25

Phe	Lys	Cys	Cys	Gln	Ile	Asn	Val	Glu	Glu	Gly	Arg	Gly	Lys	Gln
	1190					1195					1200			
Trp	Trp	Asn	Leu	Arg	Arg	Thr	Cys	Phe	Arg	Ile	Val	Glu	His	Asn
	1205					1210					1215			
Trp	Phe	Glu	Thr	Phe	Ile	Val	Phe	Met	Ile	Leu	Leu	Ser	Ser	Gly
	1220					1225					1230			
Ala	Leu	Ala	Phe	Glu	Asp	Ile	Tyr	Ile	Asp	Gln	Arg	Lys	Thr	Ile
	1235					1240					1245			
Lys	Thr	Met	Leu	Glu	Tyr	Ala	Asp	Lys	Val	Phe	Thr	Tyr	Ile	Phe
	1250					1255					1260			
Ile	Leu	Glu	Met	Leu	Leu	Lys	Trp	Val	Ala	Tyr	Gly	Tyr	Gln	Thr
	1265					1270					1275			
Tyr	Phe	Thr	Asn	Ala	Trp	Cys	Trp	Leu	Asp	Phe	Leu	Ile	Val	Asp
	1280					1285					1290			
Val	Ser	Leu	Val	Ser	Leu	Thr	Ala	Asn	Ala	Leu	Gly	Tyr	Ser	Glu
	1295					1300					1305			
Leu	Gly	Ala	Ile	Lys	Ser	Leu	Arg	Thr	Leu	Arg	Ala	Leu	Arg	Pro
	1310					1315					1320			
Leu	Arg	Ala	Leu	Ser	Arg	Phe	Glu	Gly	Met	Arg	Val	Val	Val	Asn
	1325					1330					1335			
Ala	Leu	Leu	Gly	Ala	Ile	Pro	Ser	Ile	Met	Asn	Val	Leu	Leu	Val
	1340					1345					1350			
Cys	Leu	Ile	Phe	Trp	Leu	Ile	Phe	Ser	Ile	Met	Gly	Val	Asn	Leu
	1355					1360					1365			
Phe	Ala	Gly	Lys	Phe	Tyr	His	Cys	Ile	Asn	Thr	Thr	Thr	Gly	Asp
	1370					1375					1380			
Arg	Phe	Asp	Ile	Glu	Asp	Val	Asn	Asn	His	Thr	Asp	Cys	Leu	Lys
	1385					1390					1395			
Leu	Ile	Glu	Arg	Asn	Glu	Thr	Ala	Arg	Trp	Lys	Asn	Val	Lys	Val
	1400					1405					1410			
Asn	Phe	Asp	Asn	Val	Gly	Phe	Gly	Tyr	Leu	Ser	Leu	Leu	Gln	Val
	1415					1420					1425			
Ala	Thr	Phe	Lys	Gly	Trp	Met	Asp	Ile	Met	Tyr	Ala	Ala	Val	Asp
	1430					1435					1440			

SSCP Update Sequences.ST25

Ser	Arg	Asn	Val	Glu	Leu	Gln	Pro	Lys	Tyr	Glu	Lys	Ser	Leu	Tyr
	1445					1450					1455			
Met	Tyr	Leu	Tyr	Phe	Val	Ile	Phe	Ile	Ile	Phe	Gly	Ser	Phe	Phe
	1460					1465					1470			
Thr	Leu	Asn	Leu	Phe	Ile	Gly	Val	Ile	Ile	Asp	Asn	Phe	Asn	Gln
	1475					1480					1485			
Gln	Lys	Lys	Lys	Phe	Gly	Gly	Gln	Asp	Ile	Phe	Met	Thr	Glu	Glu
	1490					1495					1500			
Gln	Lys	Lys	Tyr	Tyr	Asn	Ala	Met	Lys	Lys	Leu	Gly	Ser	Lys	Lys
	1505					1510					1515			
Pro	Gln	Lys	Pro	Ile	Pro	Arg	Pro	Gly	Asn	Lys	Phe	Gln	Gly	Met
	1520					1525					1530			
Val	Phe	Asp	Phe	Val	Thr	Arg	Gln	Val	Phe	Asp	Ile	Ser	Ile	Met
	1535					1540					1545			
Ile	Leu	Ile	Cys	Leu	Asn	Met	Val	Thr	Met	Met	Val	Glu	Thr	Asp
	1550					1555					1560			
Asp	Gln	Ser	Glu	Tyr	Val	Thr	Thr	Ile	Leu	Ser	Arg	Ile	Asn	Leu
	1565					1570					1575			
Val	Phe	Ile	Val	Leu	Phe	Thr	Gly	Glu	Cys	Val	Leu	Lys	Leu	Ile
	1580					1585					1590			
Ser	Leu	Arg	His	Tyr	Tyr	Phe	Thr	Ile	Gly	Trp	Asn	Ile	Phe	Asp
	1595					1600					1605			
Phe	Val	Val	Val	Ile	Leu	Ser	Ile	Val	Gly	Met	Phe	Leu	Ala	Glu
	1610					1615					1620			
Leu	Ile	Glu	Lys	Tyr	Phe	Val	Ser	Pro	Thr	Leu	Phe	Arg	Val	Ile
	1625					1630					1635			
Arg	Leu	Ala	Arg	Ile	Gly	Arg	Ile	Leu	Arg	Leu	Ile	Lys	Gly	Ala
	1640					1645					1650			
Lys	Gly	Ile	Arg	Thr	Leu	Leu	Phe	Ala	Leu	Met	Met	Ser	Leu	Pro
	1655					1660					1665			
Ala	Leu	Phe	Asn	Ile	Gly	Leu	Leu	Leu	Phe	Leu	Val	Met	Phe	Ile
	1670					1675					1680			
Tyr	Ala	Ile	Phe	Gly	Met	Ser	Asn	Phe	Ala	Tyr	Val	Lys	Arg	Glu
	1685					1690					1695			

SSCP Update Sequences.ST25

Val Gly Ile Asp Asp Met Phe Asn Phe Glu Thr Phe Gly Asn Ser
 1700 1705 1710
 Met Ile Cys Leu Phe Gln Ile Thr Thr Ser Ala Gly Trp Asp Gly
 1715 1720 1725
 Leu Leu Ala Pro Ile Leu Asn Ser Lys Pro Pro Asp Cys Asp Pro
 1730 1735 1740
 Asn Lys Val Asn Pro Gly Ser Ser Val Lys Gly Asp Cys Gly Asn
 1745 1750 1755
 Pro Ser Val Gly Ile Phe Phe Phe Val Ser Tyr Ile Ile Ile Ser
 1760 1765 1770
 Phe Leu Val Val Val Asn Met Tyr Ile Ala Val Ile Leu Glu Asn
 1775 1780 1785
 Phe Ser Val Ala Thr Glu Glu Ser Ala Glu Pro Leu Ser Glu Asp
 1790 1795 1800
 Asp Phe Glu Met Phe Tyr Glu Val Trp Glu Lys Phe Asp Pro Asp
 1805 1810 1815
 Ala Thr Gln Phe Met Glu Phe Glu Lys Leu Ser Gln Phe Ala Ala
 1820 1825 1830
 Ala Leu Glu Pro Pro Leu Asn Leu Pro Gln Pro Asn Lys Leu Gln
 1835 1840 1845
 Leu Ile Ala Met Asp Leu Pro Met Val Ser Gly Asp Arg Ile His
 1850 1855 1860
 Cys Leu Asp Ile Leu Phe Ala Phe Thr Lys Arg Val Leu Gly Glu
 1865 1870 1875
 Ser Gly Glu Met Asp Ala Leu Arg Ile Gln Met Glu Glu
 1880 1885 1890

<210> 82
 <211> 218
 <212> PRT
 <213> Homo sapiens

<400> 82

Met Gly Arg Leu Leu Ala Leu Val Val Gly Ala Ala Leu Val Ser Ser
 1 5 10 15

Ala Cys Gly Gly Cys Val Glu Val Asp Ser Glu Thr Glu Ala Val Tyr
 20 25 30

SSCP Update Sequences.ST25

Gly Met Thr Phe Lys Ile Leu Cys Ile Ser Cys Lys Arg Arg Ser Glu
 35 40 45
 Thr Asn Ala Glu Thr Phe Thr Glu Trp Thr Phe Arg Gln Lys Gly Thr
 50 55 60
 Glu Glu Phe Val Lys Ile Leu Arg Tyr Glu Asn Glu Val Leu Gln Leu
 65 70 75 80
 Glu Glu Asp Glu His Phe Glu Gly Arg Val Val Trp Asn Gly Ser Arg
 85 90 95
 Gly Thr Lys Asp Leu Gln Asp Leu Ser Ile Phe Ile Thr Asn Val Thr
 100 105 110
 Tyr Asn His Ser Gly Asp Tyr Glu Cys His Val Tyr Arg Leu Leu Phe
 115 120 125
 Phe Glu Asn Tyr Glu His Asn Thr Ser Val Val Lys Lys Ile His Ile
 130 135 140
 Glu Val Val Asp Lys Ala Asn Arg Asp Met Ala Ser Ile Val Ser Glu
 145 150 155 160
 Ile Met Met Tyr Val Leu Ile Val Val Leu Thr Ile Trp Leu Val Ala
 165 170 175
 Glu Met Ile Tyr Cys Tyr Lys Lys Ile Ala Ala Ala Thr Glu Thr Ala
 180 185 190
 Ala Gln Glu Asn Ala Ser Glu Tyr Leu Ala Ile Thr Ser Glu Ser Lys
 195 200 205
 Glu Asn Cys Thr Gly Val Gln Val Ala Glu
 210 215

<210> 83
 <211> 2005
 <212> PRT
 <213> Homo sapiens

<400> 83

Met Ala Gln Ser Val Leu Val Pro Pro Gly Pro Asp Ser Phe Arg Phe
 1 5 10 15
 Phe Thr Arg Glu Ser Leu Ala Ala Ile Glu Gln Arg Ile Ala Glu Glu
 20 25 30
 Lys Ala Lys Arg Pro Lys Gln Glu Arg Lys Asp Glu Asp Asp Glu Asn
 35 40 45
 Gly Pro Lys Pro Asn Ser Asp Leu Glu Ala Gly Lys Ser Leu Pro Phe

SSCP Update Sequences.ST25

50

55

60

Ile Tyr Gly Asp Ile Pro Pro Glu Met Val Ser Val Pro Leu Glu Asp
65 70 75 80

Leu Asp Pro Tyr Tyr Ile Asn Lys Lys Thr Phe Ile Val Leu Asn Lys
85 90 95

Gly Lys Ala Ile Ser Arg Phe Ser Ala Thr Pro Ala Leu Tyr Ile Leu
100 105 110

Thr Pro Phe Asn Pro Ile Arg Lys Leu Ala Ile Lys Ile Leu Val His
115 120 125

Ser Leu Phe Asn Met Leu Ile Met Cys Thr Ile Leu Thr Asn Cys Val
130 135 140

Phe Met Thr Met Ser Asn Pro Pro Asp Trp Thr Lys Asn Val Glu Tyr
145 150 155 160

Thr Phe Thr Gly Ile Tyr Thr Phe Glu Ser Leu Ile Lys Ile Leu Ala
165 170 175

Arg Gly Phe Cys Leu Glu Asp Phe Thr Phe Leu Arg Asp Pro Trp Asn
180 185 190

Trp Leu Asp Phe Thr Val Ile Thr Phe Ala Tyr Val Thr Glu Phe Val
195 200 205

Asp Leu Gly Asn Val Ser Ala Leu Arg Thr Phe Arg Val Leu Gln Ala
210 215 220

Leu Lys Thr Ile Ser Val Ile Pro Gly Leu Lys Thr Ile Val Gly Ala
225 230 235 240

Leu Ile Gln Ser Val Lys Lys Leu Ser Asp Val Met Ile Leu Thr Val
245 250 255

Phe Cys Leu Ser Val Phe Ala Leu Ile Gly Leu Gln Leu Phe Met Gly
260 265 270

Asn Leu Arg Asn Lys Cys Leu Gln Trp Pro Pro Asp Asn Ser Ser Phe
275 280 285

Glu Ile Asn Ile Thr Ser Phe Phe Asn Asn Ser Leu Asp Gly Asn Gly
290 295 300

Thr Thr Phe Asn Arg Thr Val Ser Ile Phe Asn Trp Asp Glu Tyr Ile
305 310 315 320

Glu Asp Lys Ser His Phe Tyr Phe Leu Glu Gly Gln Asn Asp Ala Leu
Page 177

SSCP Update Sequences.ST25

325

330

335

Leu Cys Gly Asn Ser Ser Asp Ala Gly Gln Cys Pro Glu Gly Tyr Ile
 340 345 350

Cys Val Lys Ala Gly Arg Asn Pro Asn Tyr Gly Tyr Thr Ser Phe Asp
 355 360 365

Thr Phe Ser Trp Ala Phe Leu Ser Leu Phe Arg Leu Met Thr Gln Asp
 370 375 380

Phe Trp Glu Asn Leu Tyr Gln Leu Thr Leu Arg Ala Ala Gly Lys Thr
 385 390 395 400

Tyr Met Ile Phe Phe Val Leu Val Ile Phe Leu Gly Ser Phe Tyr Leu
 405 410 415

Ile Asn Leu Ile Leu Ala Val Val Ala Met Ala Tyr Glu Glu Gln Asn
 420 425 430

Gln Ala Thr Leu Glu Glu Ala Glu Gln Lys Glu Ala Glu Phe Gln Gln
 435 440 445

Met Leu Glu Gln Leu Lys Lys Gln Gln Glu Glu Ala Gln Ala Ala Ala
 450 455 460

Ala Ala Ala Ser Ala Glu Ser Arg Asp Phe Ser Gly Ala Gly Gly Ile
 465 470 475 480

Gly Val Phe Ser Glu Ser Ser Ser Val Ala Ser Lys Leu Ser Ser Lys
 485 490 495

Ser Glu Lys Glu Leu Lys Asn Arg Arg Lys Lys Lys Lys Gln Lys Glu
 500 505 510

Gln Ser Gly Glu Glu Glu Lys Asn Asp Arg Val Leu Lys Ser Glu Ser
 515 520 525

Glu Asp Ser Ile Arg Arg Lys Gly Phe Arg Phe Ser Leu Glu Gly Ser
 530 535 540

Arg Leu Thr Tyr Glu Lys Arg Phe Ser Ser Pro His Gln Ser Leu Leu
 545 550 555 560

Ser Ile Arg Gly Ser Leu Phe Ser Pro Arg Arg Asn Ser Arg Ala Ser
 565 570 575

Leu Phe Ser Phe Arg Gly Arg Ala Lys Asp Ile Gly Ser Glu Asn Asp
 580 585 590

Phe Ala Asp Asp Glu His Ser Thr Phe Glu Asp Asn Asp Ser Arg Arg
 Page 178

SSCP Update Sequences.ST25
600 605

595

Asp Ser Leu Phe Val Pro His Arg His Gly Glu Arg Arg His Ser Asn
 610 615 620
 Val Ser Gln Ala Ser Arg Ala Ser Arg Val Leu Pro Ile Leu Pro Met
 625 630 635 640
 Asn Gly Lys Met His Ser Ala Val Asp Cys Asn Gly Val Val Ser Leu
 645 650 655
 Val Gly Gly Pro Ser Thr Leu Thr Ser Ala Gly Gln Leu Leu Pro Glu
 660 665 670
 Gly Thr Thr Thr Glu Thr Glu Ile Arg Lys Arg Arg Ser Ser Ser Tyr
 675 680 685
 His Val Ser Met Asp Leu Leu Glu Asp Pro Thr Ser Arg Gln Arg Ala
 690 695 700
 Met Ser Ile Ala Ser Ile Leu Thr Asn Thr Met Glu Glu Leu Glu Glu
 705 710 715 720
 Ser Arg Gln Lys Cys Pro Pro Cys Trp Tyr Lys Phe Ala Asn Met Cys
 725 730 735
 Leu Ile Trp Asp Cys Cys Lys Pro Trp Leu Lys Val Lys His Leu Val
 740 745 750
 Asn Leu Val Val Met Asp Pro Phe Val Asp Leu Ala Ile Thr Ile Cys
 755 760 765
 Ile Val Leu Asn Thr Leu Phe Met Ala Met Glu His Tyr Pro Met Thr
 770 775 780
 Glu Gln Phe Ser Ser Val Leu Ser Val Gly Asn Leu Val Phe Thr Gly
 785 790 795 800
 Ile Phe Thr Ala Glu Met Phe Leu Lys Ile Ile Ala Met Asp Pro Tyr
 805 810 815
 Tyr Tyr Phe Gln Glu Gly Trp Asn Ile Phe Asp Gly Phe Ile Val Ser
 820 825 830
 Leu Ser Leu Met Glu Leu Gly Leu Ala Asn Val Glu Gly Leu Ser Val
 835 840 845
 Leu Arg Ser Phe Arg Leu Leu Arg Val Phe Lys Leu Ala Lys Ser Trp
 850 855 860
 Pro Thr Leu Asn Met Leu Ile Lys Ile Ile Gly Asn Ser Val Gly Ala

SSCP Update Sequences.ST25

865 870 875 880

Leu Gly Asn Leu Thr Leu Val Leu Ala Ile Ile Val Phe Ile Phe Ala
 885 890 895

Val Val Gly Met Gln Leu Phe Gly Lys Ser Tyr Lys Glu Cys Val Cys
 900 905 910

Lys Ile Ser Asn Asp Cys Glu Leu Pro Arg Trp His Met His Asp Phe
 915 920 925

Phe His Ser Phe Leu Ile Val Phe Arg Val Leu Cys Gly Glu Trp Ile
 930 935 940

Glu Thr Met Trp Asp Cys Met Glu Val Ala Gly Gln Thr Met Cys Leu
 945 950 955 960

Thr Val Phe Met Met Val Met Val Ile Gly Asn Leu Val Val Leu Asn
 965 970 975

Leu Phe Leu Ala Leu Leu Leu Ser Ser Phe Ser Ser Asp Asn Leu Ala
 980 985 990

Ala Thr Asp Asp Asp Asn Glu Met Asn Asn Leu Gln Ile Ala Val Gly
 995 1000 1005

Arg Met Gln Lys Gly Ile Asp Phe Val Lys Arg Lys Ile Arg Glu
 1010 1015 1020

Phe Ile Gln Lys Ala Phe Val Arg Lys Gln Lys Ala Leu Asp Glu
 1025 1030 1035

Ile Lys Pro Leu Glu Asp Leu Asn Asn Lys Lys Asp Ser Cys Ile
 1040 1045 1050

Ser Asn His Thr Thr Ile Glu Ile Gly Lys Asp Leu Asn Tyr Leu
 1055 1060 1065

Lys Asp Gly Asn Gly Thr Thr Ser Gly Ile Gly Ser Ser Val Glu
 1070 1075 1080

Lys Tyr Val Val Asp Glu Ser Asp Tyr Met Ser Phe Ile Asn Asn
 1085 1090 1095

Pro Ser Leu Thr Val Thr Val Pro Ile Ala Val Gly Glu Ser Asp
 1100 1105 1110

Phe Glu Asn Leu Asn Thr Glu Glu Phe Ser Ser Glu Ser Asp Met
 1115 1120 1125

Glu Glu Ser Lys Glu Lys Leu Asn Ala Thr Ser Ser Ser Glu Gly

SSCP Update Sequences.ST25

1130 1135 1140
 Ser Thr Val Asp Ile Gly Ala Pro Ala Glu Gly Glu Gln Pro Glu
 1145 1150 1155
 Val Glu Pro Glu Glu Ser Leu Glu Pro Glu Ala Cys Phe Thr Glu
 1160 1165 1170
 Asp Cys Val Arg Lys Phe Lys Cys Cys Gln Ile Ser Ile Glu Glu
 1175 1180 1185
 Gly Lys Gly Lys Leu Trp Trp Asn Leu Arg Lys Thr Cys Tyr Lys
 1190 1195 1200
 Ile Val Glu His Asn Trp Phe Glu Thr Phe Ile Val Phe Met Ile
 1205 1210 1215
 Leu Leu Ser Ser Gly Ala Leu Ala Phe Glu Asp Ile Tyr Ile Glu
 1220 1225 1230
 Gln Arg Lys Thr Ile Lys Thr Met Leu Glu Tyr Ala Asp Lys Val
 1235 1240 1245
 Phe Thr Tyr Ile Phe Ile Leu Glu Met Leu Leu Lys Trp Val Ala
 1250 1255 1260
 Tyr Gly Phe Gln Val Tyr Phe Thr Asn Ala Trp Cys Trp Leu Asp
 1265 1270 1275
 Phe Leu Ile Val Asp Val Ser Leu Val Ser Leu Thr Ala Asn Ala
 1280 1285 1290
 Leu Gly Tyr Ser Glu Leu Gly Ala Ile Lys Ser Leu Arg Thr Leu
 1295 1300 1305
 Arg Ala Leu Arg Pro Leu Arg Ala Leu Ser Arg Phe Glu Gly Met
 1310 1315 1320
 Arg Val Val Val Asn Ala Leu Leu Gly Ala Ile Pro Ser Ile Met
 1325 1330 1335
 Asn Val Leu Leu Val Cys Leu Ile Phe Trp Leu Ile Phe Ser Ile
 1340 1345 1350
 Met Gly Val Asn Leu Phe Ala Gly Lys Phe Tyr His Cys Ile Asn
 1355 1360 1365
 Tyr Thr Thr Gly Glu Met Phe Asp Val Ser Val Val Asn Asn Tyr
 1370 1375 1380
 Ser Glu Cys Lys Ala Leu Ile Glu Ser Asn Gln Thr Ala Arg Trp

1395

Page 182

SSCP Update Sequences ST25

1640														
Met	Met	Ser	Leu	Pro	Ala	Leu	Phe	Asn	Ile	Gly	Leu	Leu	Leu	Phe
	1655					1660					1665			
Leu	Val	Met	Phe	Ile	Tyr	Ala	Ile	Phe	Gly	Met	Ser	Asn	Phe	Ala
	1670					1675					1680			
Tyr	Val	Lys	Arg	Glu	Val	Gly	Ile	Asp	Asp	Met	Phe	Asn	Phe	Glu
	1685					1690					1695			
Thr	Phe	Gly	Asn	Ser	Met	Ile	Cys	Leu	Phe	Gln	Ile	Thr	Thr	Ser
	1700					1705					1710			
Ala	Gly	Trp	Asp	Gly	Leu	Leu	Ala	Pro	Ile	Leu	Asn	Ser	Gly	Pro
	1715					1720					1725			
Pro	Asp	Cys	Asp	Pro	Asp	Lys	Asp	His	Pro	Gly	Ser	Ser	Val	Lys
	1730					1735					1740			
Gly	Asp	Cys	Gly	Asn	Pro	Ser	Val	Gly	Ile	Phe	Phe	Phe	Val	Ser
	1745					1750					1755			
Tyr	Ile	Ile	Ile	Ser	Phe	Leu	Val	Val	Leu	Asn	Met	Tyr	Ile	Ala
	1760					1765					1770			
Val	Ile	Leu	Glu	Asn	Phe	Ser	Val	Ala	Thr	Glu	Glu	Ser	Ala	Glu
	1775					1780					1785			
Pro	Leu	Ser	Glu	Asp	Asp	Phe	Glu	Met	Phe	Tyr	Glu	Val	Trp	Glu
	1790					1795					1800			
Lys	Phe	Asp	Pro	Asp	Ala	Thr	Gln	Phe	Ile	Glu	Phe	Ala	Lys	Leu
	1805					1810					1815			
Ser	Asp	Phe	Ala	Asp	Ala	Leu	Asp	Pro	Pro	Leu	Leu	Ile	Ala	Lys
	1820					1825					1830			
Pro	Asn	Lys	Val	Gln	Leu	Ile	Ala	Met	Asp	Leu	Pro	Met	Val	Ser
	1835					1840					1845			
Gly	Asp	Arg	Ile	His	Cys	Leu	Asp	Ile	Leu	Phe	Ala	Phe	Thr	Lys
	1850					1855					1860			
Arg	Val	Leu	Gly	Glu	Ser	Gly	Glu	Met	Asp	Ala	Leu	Arg	Ile	Gln
	1865					1870					1875			
Met	Glu	Glu	Arg	Phe	Met	Ala	Ser	Asn	Pro	Ser	Lys	Val	Ser	Tyr
	1880					1885					1890			
Glu	Pro	Ile	Thr	Thr	Thr	Leu	Lys	Arg	Lys	Gln	Glu	Glu	Val	Ser

SSCP Update Sequences.ST25

1895 1900 1905

Ala Ile Ile Ile Gln Arg Ala Tyr Arg Arg Tyr Leu Leu Lys Gln
1910 1915 1920

Lys Val Lys Lys Val Ser Ser Ile Tyr Lys Lys Asp Lys Gly Lys
1925 1930 1935

Glu Cys Asp Gly Thr Pro Ile Lys Glu Asp Thr Leu Ile Asp Lys
1940 1945 1950

Leu Asn Glu Asn Ser Thr Pro Glu Lys Thr Asp Met Thr Pro Ser
1955 1960 1965

Thr Thr Ser Pro Pro Ser Tyr Asp Ser Val Thr Lys Pro Glu Lys
1970 1975 1980

Glu Lys Phe Glu Lys Asp Lys Ser Glu Lys Glu Asp Lys Gly Lys
1985 1990 1995

Asp Ile Arg Glu Ser Lys Lys
2000 2005

<210> 84
 <211> 2005
 <212> PRT
 <213> Homo sapiens

<400> 84

Met Ala Gln Ser Val Leu Val Pro Pro Gly Pro Asp Ser Phe Arg Phe
1 5 10 15

Phe Thr Arg Glu Ser Leu Ala Ala Ile Glu Gln Arg Ile Ala Glu Glu
20 25 30

Lys Ala Lys Arg Pro Lys Gln Glu Arg Lys Asp Glu Asp Asp Glu Asn
35 40 45

Gly Pro Lys Pro Asn Ser Asp Leu Glu Ala Gly Lys Ser Leu Pro Phe
50 55 60

Ile Tyr Gly Asp Ile Pro Pro Glu Met Val Ser Val Pro Leu Glu Asp
65 70 75 80

Leu Asp Pro Tyr Tyr Ile Asn Lys Lys Thr Phe Ile Val Leu Asn Lys
85 90 95

Gly Lys Ala Ile Ser Arg Phe Ser Ala Thr Pro Ala Leu Tyr Ile Leu
100 105 110

Thr Pro Phe Asn Pro Ile Arg Lys Leu Ala Ile Lys Ile Leu Val His
115 120 125

SSCP Update Sequences.ST25

Ser Leu Phe Asn Met Leu Ile Met Cys Thr Ile Leu Thr Asn Cys Val
 130 135 140
 Phe Met Thr Met Ser Asn Pro Pro Asp Trp Thr Lys Asn Val Glu Tyr
 145 150 155 160
 Thr Phe Thr Gly Ile Tyr Thr Phe Glu Ser Leu Ile Lys Ile Leu Ala
 165 170 175
 Arg Gly Phe Cys Leu Glu Asp Phe Thr Phe Leu Arg Asp Pro Trp Asn
 180 185 190
 Trp Leu Asp Phe Thr Val Ile Thr Phe Ala Tyr Val Thr Glu Phe Val
 195 200 205
 Asp Leu Gly Asn Val Ser Ala Leu Arg Thr Phe Arg Val Leu Arg Ala
 210 215 220
 Leu Lys Thr Ile Ser Val Ile Pro Gly Leu Lys Thr Ile Val Gly Ala
 225 230 235 240
 Leu Ile Gln Ser Val Lys Lys Leu Ser Asp Val Met Ile Leu Thr Val
 245 250 255
 Phe Cys Leu Ser Val Phe Ala Leu Ile Gly Leu Gln Leu Phe Met Gly
 260 265 270
 Asn Leu Arg Asn Lys Cys Leu Gln Trp Pro Pro Asp Asn Ser Ser Phe
 275 280 285
 Glu Ile Asn Ile Thr Ser Phe Phe Asn Asn Ser Leu Asp Gly Asn Gly
 290 295 300
 Thr Thr Phe Asn Arg Thr Val Ser Ile Phe Asn Trp Asp Glu Tyr Ile
 305 310 315 320
 Glu Asp Lys Ser His Phe Tyr Phe Leu Glu Gly Gln Asn Asp Ala Leu
 325 330 335
 Leu Cys Gly Asn Ser Ser Asp Ala Gly Gln Cys Pro Glu Gly Tyr Ile
 340 345 350
 Cys Val Lys Ala Gly Arg Asn Pro Asn Tyr Gly Tyr Thr Ser Phe Asp
 355 360 365
 Thr Phe Ser Trp Ala Phe Leu Ser Leu Phe Arg Leu Met Thr Gln Asp
 370 375 380
 Phe Trp Glu Asn Leu Tyr Gln Leu Thr Leu Arg Ala Ala Gly Lys Thr
 385 390 395 400

SSCP Update Sequences.ST25

Tyr Met Ile Phe Phe Val Leu Val Ile Phe Leu Gly Ser Phe Tyr Leu
 405 410 415
 Ile Asn Leu Ile Leu Ala Val Val Ala Met Ala Tyr Glu Glu Gln Asn
 420 425 430
 Gln Ala Thr Leu Glu Glu Ala Glu Gln Lys Glu Ala Glu Phe Gln Gln
 435 440 445
 Met Leu Glu Gln Leu Lys Lys Gln Gln Glu Glu Ala Gln Ala Ala Ala
 450 455 460
 Ala Ala Ala Ser Ala Glu Ser Arg Asp Phe Ser Gly Ala Gly Gly Ile
 465 470 475 480
 Gly Val Phe Ser Glu Ser Ser Ser Val Ala Ser Lys Leu Ser Ser Lys
 485 490 495
 Ser Glu Lys Glu Leu Lys Asn Arg Arg Lys Lys Lys Lys Gln Lys Glu
 500 505 510
 Gln Ser Gly Glu Glu Glu Lys Asn Asp Arg Val Leu Lys Ser Glu Ser
 515 520 525
 Glu Asp Ser Ile Arg Arg Lys Gly Phe Arg Phe Ser Leu Glu Gly Ser
 530 535 540
 Arg Leu Thr Tyr Glu Lys Arg Phe Ser Ser Pro His Gln Ser Leu Leu
 545 550 555 560
 Ser Ile Arg Gly Ser Leu Phe Ser Pro Arg Arg Asn Ser Arg Ala Ser
 565 570 575
 Leu Phe Ser Phe Arg Gly Arg Ala Lys Asp Ile Gly Ser Glu Asn Asp
 580 585 590
 Phe Ala Asp Asp Glu His Ser Thr Phe Glu Asp Asn Asp Ser Arg Arg
 595 600 605
 Asp Ser Leu Phe Val Pro His Arg His Gly Glu Arg Arg His Ser Asn
 610 615 620
 Val Ser Gln Ala Ser Arg Ala Ser Arg Val Leu Pro Ile Leu Pro Met
 625 630 635 640
 Asn Gly Lys Met His Ser Ala Val Asp Cys Asn Gly Val Val Ser Leu
 645 650 655
 Val Gly Gly Pro Ser Thr Leu Thr Ser Ala Gly Gln Leu Leu Pro Glu
 660 665 670

SSCP update Sequences.ST25

Gly Thr Thr Thr Glu Thr Glu Ile Arg Lys Arg Arg Ser Ser Ser Tyr
 675 680 685
 His Val Ser Met Asp Leu Leu Glu Asp Pro Thr Ser Arg Gln Arg Ala
 690 695 700
 Met Ser Ile Ala Ser Ile Leu Thr Asn Thr Met Glu Glu Leu Glu Glu
 705 710 715 720
 Ser Arg Gln Lys Cys Pro Pro Cys Trp Tyr Lys Phe Ala Asn Met Cys
 725 730 735
 Leu Ile Trp Asp Cys Cys Lys Pro Trp Leu Lys Val Lys His Leu Val
 740 745 750
 Asn Leu Val Val Met Asp Pro Phe Val Asp Leu Ala Ile Thr Ile Cys
 755 760 765
 Ile Val Leu Asn Thr Leu Phe Met Ala Met Glu His Tyr Pro Met Thr
 770 775 780
 Glu Gln Phe Ser Ser Val Leu Ser Val Gly Asn Leu Val Phe Thr Gly
 785 790 795 800
 Ile Phe Thr Ala Glu Met Phe Leu Lys Ile Ile Ala Met Asp Pro Tyr
 805 810 815
 Tyr Tyr Phe Gln Glu Gly Trp Asn Ile Phe Asp Gly Phe Ile Val Ser
 820 825 830
 Leu Ser Leu Met Glu Leu Gly Leu Ala Asn Val Glu Gly Leu Ser Val
 835 840 845
 Leu Arg Ser Phe Arg Leu Leu Arg Val Phe Lys Leu Ala Lys Ser Trp
 850 855 860
 Pro Thr Leu Asn Met Leu Ile Lys Ile Ile Gly Asn Ser Val Gly Ala
 865 870 875 880
 Leu Gly Asn Leu Thr Leu Val Leu Ala Ile Ile Ile Phe Ile Phe Ala
 885 890 895
 Val Val Gly Met Gln Leu Phe Gly Lys Ser Tyr Lys Glu Cys Val Cys
 900 905 910
 Lys Ile Ser Asn Asp Cys Glu Leu Pro Arg Trp His Met His Asp Phe
 915 920 925
 Phe His Ser Phe Leu Ile Val Phe Arg Val Leu Cys Gly Glu Trp Ile
 930 935 940

SSCP Update Sequences.ST25

Glu Thr Met Trp Asp Cys Met Glu Val Ala Gly Gln Thr Met Cys Leu
 945 950 955 960
 Thr Val Phe Met Met Val Met Val Ile Gly Asn Leu Val Val Leu Asn
 965 970 975
 Leu Phe Leu Ala Leu Leu Leu Ser Ser Phe Ser Ser Asp Asn Leu Ala
 980 985 990
 Ala Thr Asp Asp Asp Asn Glu Met Asn Asn Leu Gln Ile Ala Val Gly
 995 1000 1005
 Arg Met Gln Lys Gly Ile Asp Phe Val Lys Arg Lys Ile Arg Glu
 1010 1015 1020
 Phe Ile Gln Lys Ala Phe Val Arg Lys Gln Lys Ala Leu Asp Glu
 1025 1030 1035
 Ile Lys Pro Leu Glu Asp Leu Asn Asn Lys Lys Asp Ser Cys Ile
 1040 1045 1050
 Ser Asn His Thr Thr Ile Glu Ile Gly Lys Asp Leu Asn Tyr Leu
 1055 1060 1065
 Lys Asp Gly Asn Gly Thr Thr Ser Gly Ile Gly Ser Ser Val Glu
 1070 1075 1080
 Lys Tyr Val Val Asp Glu Ser Asp Tyr Met Ser Phe Ile Asn Asn
 1085 1090 1095
 Pro Ser Leu Thr Val Thr Val Pro Ile Ala Val Gly Glu Ser Asp
 1100 1105 1110
 Phe Glu Asn Leu Asn Thr Glu Glu Phe Ser Ser Glu Ser Asp Met
 1115 1120 1125
 Glu Glu Ser Lys Glu Lys Leu Asn Ala Thr Ser Ser Ser Glu Gly
 1130 1135 1140
 Ser Thr Val Asp Ile Gly Ala Pro Ala Glu Gly Glu Gln Pro Glu
 1145 1150 1155
 Val Glu Pro Glu Glu Ser Leu Glu Pro Glu Ala Cys Phe Thr Glu
 1160 1165 1170
 Asp Cys Val Arg Lys Phe Lys Cys Cys Gln Ile Ser Ile Glu Glu
 1175 1180 1185
 Gly Lys Gly Lys Leu Trp Trp Asn Leu Arg Lys Thr Cys Tyr Lys
 1190 1195 1200

SSCP Update Sequences.ST25

Ile	Val	Glu	His	Asn	Trp	Phe	Glu	Thr	Phe	Ile	Val	Phe	Met	Ile
	1205					1210					1215			
Leu	Leu	Ser	Ser	Gly	Ala	Leu	Ala	Phe	Glu	Asp	Ile	Tyr	Ile	Glu
	1220					1225					1230			
Gln	Arg	Lys	Thr	Ile	Lys	Thr	Met	Leu	Glu	Tyr	Ala	Asp	Lys	Val
	1235					1240					1245			
Phe	Thr	Tyr	Ile	Phe	Ile	Leu	Glu	Met	Leu	Leu	Lys	Trp	Val	Ala
	1250					1255					1260			
Tyr	Gly	Phe	Gln	Val	Tyr	Phe	Thr	Asn	Ala	Trp	Cys	Trp	Leu	Asp
	1265					1270					1275			
Phe	Leu	Ile	Val	Asp	Val	Ser	Leu	Val	Ser	Leu	Thr	Ala	Asn	Ala
	1280					1285					1290			
Leu	Gly	Tyr	Ser	Glu	Leu	Gly	Ala	Ile	Lys	Ser	Leu	Arg	Thr	Leu
	1295					1300					1305			
Arg	Ala	Leu	Arg	Pro	Leu	Arg	Ala	Leu	Ser	Arg	Phe	Glu	Gly	Met
	1310					1315					1320			
Arg	Val	Val	Val	Asn	Ala	Leu	Leu	Gly	Ala	Ile	Pro	Ser	Ile	Met
	1325					1330					1335			
Asn	Val	Leu	Leu	Val	Cys	Leu	Ile	Phe	Trp	Leu	Ile	Phe	Ser	Ile
	1340					1345					1350			
Met	Gly	Val	Asn	Leu	Phe	Ala	Gly	Lys	Phe	Tyr	His	Cys	Ile	Asn
	1355					1360					1365			
Tyr	Thr	Thr	Gly	Glu	Met	Phe	Asp	Val	Ser	Val	Val	Asn	Asn	Tyr
	1370					1375					1380			
Ser	Glu	Cys	Lys	Ala	Leu	Ile	Glu	Ser	Asn	Gln	Thr	Ala	Arg	Trp
	1385					1390					1395			
Lys	Asn	Val	Lys	Val	Asn	Phe	Asp	Asn	Val	Gly	Leu	Gly	Tyr	Leu
	1400					1405					1410			
Ser	Leu	Leu	Gln	Val	Ala	Thr	Phe	Lys	Gly	Trp	Met	Asp	Ile	Met
	1415					1420					1425			
Tyr	Ala	Ala	Val	Asp	Ser	Arg	Asn	Val	Glu	Leu	Gln	Pro	Lys	Tyr
	1430					1435					1440			
Glu	Asp	Asn	Leu	Tyr	Met	Tyr	Leu	Tyr	Phe	Val	Ile	Phe	Ile	Ile
	1445					1450					1455			

SSCP Update Sequences.ST25

Phe	Gly	Ser	Phe	Phe	Thr	Leu	Asn	Leu	Phe	Ile	Gly	Val	Ile	Ile
	1460					1465					1470			
Asp	Asn	Phe	Asn	Gln	Gln	Lys	Lys	Lys	Phe	Gly	Gly	Gln	Asp	Ile
	1475					1480					1485			
Phe	Met	Thr	Glu	Glu	Gln	Lys	Lys	Tyr	Tyr	Asn	Ala	Met	Lys	Lys
	1490					1495					1500			
Leu	Gly	Ser	Lys	Lys	Pro	Gln	Lys	Pro	Ile	Pro	Arg	Pro	Ala	Asn
	1505					1510					1515			
Lys	Phe	Gln	Gly	Met	Val	Phe	Asp	Phe	Val	Thr	Lys	Gln	Val	Phe
	1520					1525					1530			
Asp	Ile	Ser	Ile	Met	Ile	Leu	Ile	Cys	Leu	Asn	Met	Val	Thr	Met
	1535					1540					1545			
Met	Val	Glu	Thr	Asp	Asp	Gln	Ser	Gln	Glu	Met	Thr	Asn	Ile	Leu
	1550					1555					1560			
Tyr	Trp	Ile	Asn	Leu	Val	Phe	Ile	Val	Leu	Phe	Thr	Gly	Glu	Cys
	1565					1570					1575			
Val	Leu	Lys	Leu	Ile	Ser	Leu	Arg	Tyr	Tyr	Tyr	Phe	Thr	Ile	Gly
	1580					1585					1590			
Trp	Asn	Ile	Phe	Asp	Phe	Val	Val	Val	Ile	Leu	Ser	Ile	Val	Gly
	1595					1600					1605			
Met	Phe	Leu	Ala	Glu	Leu	Ile	Glu	Lys	Tyr	Phe	Val	Ser	Pro	Thr
	1610					1615					1620			
Leu	Phe	Arg	Val	Ile	Arg	Leu	Ala	Arg	Ile	Gly	Arg	Ile	Leu	Arg
	1625					1630					1635			
Leu	Ile	Lys	Gly	Ala	Lys	Gly	Ile	Arg	Thr	Leu	Leu	Phe	Ala	Leu
	1640					1645					1650			
Met	Met	Ser	Leu	Pro	Ala	Leu	Phe	Asn	Ile	Gly	Leu	Leu	Leu	Phe
	1655					1660					1665			
Leu	Val	Met	Phe	Ile	Tyr	Ala	Ile	Phe	Gly	Met	Ser	Asn	Phe	Ala
	1670					1675					1680			
Tyr	Val	Lys	Arg	Glu	Val	Gly	Ile	Asp	Asp	Met	Phe	Asn	Phe	Glu
	1685					1690					1695			
Thr	Phe	Gly	Asn	Ser	Met	Ile	Cys	Leu	Phe	Gln	Ile	Thr	Thr	Ser
	1700					1705					1710			

SSCP Update Sequences.ST25

Ala Gly Trp Asp Gly Leu Leu Ala Pro Ile Leu Asn Ser Gly Pro
 1715 1720 1725
 Pro Asp Cys Asp Pro Asp Lys Asp His Pro Gly Ser Ser Val Lys
 1730 1735 1740
 Gly Asp Cys Gly Asn Pro Ser Val Gly Ile Phe Phe Phe Val Ser
 1745 1750 1755
 Tyr Ile Ile Ile Ser Phe Leu Val Val Leu Asn Met Tyr Ile Ala
 1760 1765 1770
 Val Ile Leu Glu Asn Phe Ser Val Ala Thr Glu Glu Ser Ala Glu
 1775 1780 1785
 Pro Leu Ser Glu Asp Asp Phe Glu Met Phe Tyr Glu Val Trp Glu
 1790 1795 1800
 Lys Phe Asp Pro Asp Ala Thr Gln Phe Ile Glu Phe Ala Lys Leu
 1805 1810 1815
 Ser Asp Phe Ala Asp Ala Leu Asp Pro Pro Leu Leu Ile Ala Lys
 1820 1825 1830
 Pro Asn Lys Val Gln Leu Ile Ala Met Asp Leu Pro Met Val Ser
 1835 1840 1845
 Gly Asp Arg Ile His Cys Leu Asp Ile Leu Phe Ala Phe Thr Lys
 1850 1855 1860
 Arg Val Leu Gly Glu Ser Gly Glu Met Asp Ala Leu Arg Ile Gln
 1865 1870 1875
 Met Glu Glu Arg Phe Met Ala Ser Asn Pro Ser Lys Val Ser Tyr
 1880 1885 1890
 Glu Pro Ile Thr Thr Thr Leu Lys Arg Lys Gln Glu Glu Val Ser
 1895 1900 1905
 Ala Ile Ile Ile Gln Arg Ala Tyr Arg Arg Tyr Leu Leu Lys Gln
 1910 1915 1920
 Lys Val Lys Lys Val Ser Ser Ile Tyr Lys Lys Asp Lys Gly Lys
 1925 1930 1935
 Glu Cys Asp Gly Thr Pro Ile Lys Glu Asp Thr Leu Ile Asp Lys
 1940 1945 1950
 Leu Asn Glu Asn Ser Thr Pro Glu Lys Thr Asp Met Thr Pro Ser
 1955 1960 1965

SSCP Update Sequences.ST25

Thr Thr Ser Pro Pro Ser Tyr Asp Ser Val Thr Lys Pro Glu Lys
1970 1975 1980

Glu Lys Phe Glu Lys Asp Lys Ser Glu Lys Glu Asp Lys Gly Lys
1985 1990 1995

Asp Ile Arg Glu Ser Lys Lys
2000 2005

<210> 85
<211> 2005
<212> PRT
<213> Homo sapiens

<400> 85

Met Ala Gln Ser Val Leu Val Pro Pro Gly Pro Asp Ser Phe Arg Phe
1 5 10 15

Phe Thr Arg Glu Ser Leu Ala Ala Ile Glu Gln Arg Ile Ala Glu Glu
20 25 30

Lys Ala Lys Arg Pro Lys Gln Glu Arg Lys Asp Glu Asp Asp Glu Asn
35 40 45

Gly Pro Lys Pro Asn Ser Asp Leu Glu Ala Gly Lys Ser Leu Pro Phe
50 55 60

Ile Tyr Gly Asp Ile Pro Pro Glu Met Val Ser Val Pro Leu Glu Asp
65 70 75 80

Leu Asp Pro Tyr Tyr Ile Asn Lys Lys Thr Phe Ile Val Leu Asn Lys
85 90 95

Gly Lys Ala Ile Ser Arg Phe Ser Ala Thr Pro Ala Leu Tyr Ile Leu
100 105 110

Thr Pro Phe Asn Pro Ile Arg Lys Leu Ala Ile Lys Ile Leu Val His
115 120 125

Ser Leu Phe Asn Met Leu Ile Met Cys Thr Ile Leu Thr Asn Cys Val
130 135 140

Phe Met Thr Met Ser Asn Pro Pro Asp Trp Thr Lys Asn Val Glu Tyr
145 150 155 160

Thr Phe Thr Gly Ile Tyr Thr Phe Glu Ser Leu Ile Lys Ile Leu Ala
165 170 175

Arg Gly Phe Cys Leu Glu Asp Phe Thr Phe Leu Arg Asp Pro Trp Asn
180 185 190

SSCP Update Sequences.ST25

Trp Leu Asp Phe Thr Val Ile Thr Phe Ala Tyr Val Thr Glu Phe Val
 195 200 205
 Asp Leu Gly Asn Val Ser Ala Leu Arg Thr Phe Arg Val Leu Arg Ala
 210 215 220
 Leu Lys Thr Ile Ser Val Ile Pro Gly Leu Lys Thr Ile Val Gly Ala
 225 230 235 240
 Leu Ile Gln Ser Val Lys Lys Leu Ser Asp Val Met Ile Leu Thr Val
 245 250 255
 Phe Cys Leu Ser Val Phe Ala Leu Ile Gly Leu Gln Leu Phe Met Gly
 260 265 270
 Asn Leu Arg Asn Lys Cys Leu Gln Trp Pro Pro Asp Asn Ser Ser Phe
 275 280 285
 Glu Ile Asn Ile Thr Ser Phe Phe Asn Asn Ser Leu Asp Gly Asn Gly
 290 295 300
 Thr Thr Phe Asn Arg Thr Val Ser Ile Phe Asn Trp Asp Glu Tyr Ile
 305 310 315 320
 Glu Asp Lys Ser His Phe Tyr Phe Leu Glu Gly Gln Asn Asp Ala Leu
 325 330 335
 Leu Cys Gly Asn Ser Ser Asp Ala Gly Gln Cys Pro Glu Gly Tyr Ile
 340 345 350
 Cys Val Lys Ala Gly Arg Asn Pro Asn Tyr Gly Tyr Thr Ser Phe Asp
 355 360 365
 Thr Phe Ser Trp Ala Phe Leu Ser Leu Phe Arg Leu Met Thr Gln Asp
 370 375 380
 Phe Trp Glu Asn Leu Tyr Gln Leu Thr Leu Arg Ala Ala Gly Lys Thr
 385 390 395 400
 Tyr Met Ile Phe Phe Val Leu Val Ile Phe Leu Gly Ser Phe Tyr Leu
 405 410 415
 Ile Asn Leu Ile Leu Ala Val Val Ala Met Ala Tyr Glu Glu Gln Asn
 420 425 430
 Gln Ala Thr Leu Glu Glu Ala Glu Gln Lys Glu Ala Glu Phe Gln Gln
 435 440 445
 Met Leu Glu Gln Leu Lys Lys Gln Gln Glu Glu Ala Gln Ala Ala Ala
 450 455 460

SSCP Update Sequences.ST25

Ala Ala Ala Ser Ala Glu Ser Arg Asp Phe Ser Gly Ala Gly Gly Ile
 465 470 475 480
 Gly Val Phe Ser Glu Ser Ser Ser Val Ala Ser Lys Leu Ser Ser Lys
 485 490 495
 Ser Glu Lys Glu Leu Lys Asn Arg Arg Lys Lys Lys Lys Gln Lys Glu
 500 505 510
 Gln Ser Gly Glu Glu Glu Lys Asn Asp Arg Val Leu Lys Ser Glu Ser
 515 520 525
 Glu Asp Ser Ile Arg Arg Lys Gly Phe Arg Phe Ser Leu Glu Gly Ser
 530 535 540
 Arg Leu Thr Tyr Glu Lys Arg Phe Ser Ser Pro His Gln Ser Leu Leu
 545 550 555 560
 Ser Ile Arg Gly Ser Leu Phe Ser Pro Arg Arg Asn Ser Arg Ala Ser
 565 570 575
 Leu Phe Ser Phe Arg Gly Arg Ala Lys Asp Ile Gly Ser Glu Asn Asp
 580 585 590
 Phe Ala Asp Asp Glu His Ser Thr Phe Glu Asp Asn Asp Ser Arg Arg
 595 600 605
 Asp Ser Leu Phe Val Pro His Arg His Gly Glu Arg Arg His Ser Asn
 610 615 620
 Val Ser Gln Ala Ser Arg Ala Ser Arg Val Leu Pro Ile Leu Pro Met
 625 630 635 640
 Asn Gly Lys Met His Ser Ala Val Asp Cys Asn Gly Val Val Ser Leu
 645 650 655
 Val Gly Gly Pro Ser Thr Leu Thr Ser Ala Gly Gln Leu Leu Pro Glu
 660 665 670
 Gly Thr Thr Thr Glu Thr Glu Ile Arg Lys Arg Arg Ser Ser Ser Tyr
 675 680 685
 His Val Ser Met Asp Leu Leu Glu Asp Pro Thr Ser Arg Gln Arg Ala
 690 695 700
 Met Ser Ile Ala Ser Ile Leu Thr Asn Thr Met Glu Glu Leu Glu Glu
 705 710 715 720
 Ser Arg Gln Lys Cys Pro Pro Cys Trp Tyr Lys Phe Ala Asn Met Cys
 725 730 735

SSCP Update Sequences.ST25

Leu Ile Trp Asp Cys Cys Lys Pro Trp Leu Lys Val Lys His Leu Val
 740 745 750
 Asn Leu Val Val Met Asp Pro Phe Val Asp Leu Ala Ile Thr Ile Cys
 755 760 765
 Ile Val Leu Asn Thr Leu Phe Met Ala Met Glu His Tyr Pro Met Thr
 770 775 780
 Glu Gln Phe Ser Ser Val Leu Ser Val Gly Asn Leu Val Phe Thr Gly
 785 790 795 800
 Ile Phe Thr Ala Glu Met Phe Leu Lys Ile Ile Ala Met Asp Pro Tyr
 805 810 815
 Tyr Tyr Phe Gln Glu Gly Trp Asn Ile Phe Asp Gly Phe Ile Val Ser
 820 825 830
 Leu Ser Leu Met Glu Leu Gly Leu Ala Asn Val Glu Gly Leu Ser Val
 835 840 845
 Leu Arg Ser Phe Arg Leu Leu Arg Val Phe Lys Leu Ala Lys Ser Trp
 850 855 860
 Pro Thr Leu Asn Met Leu Ile Lys Ile Ile Gly Asn Ser Val Gly Ala
 865 870 875 880
 Leu Gly Asn Leu Thr Leu Val Leu Ala Ile Ile Val Phe Ile Phe Ala
 885 890 895
 Val Val Gly Met Gln Leu Phe Gly Lys Ser Tyr Lys Glu Cys Val Cys
 900 905 910
 Lys Ile Ser Asn Asp Cys Glu Leu Pro Arg Trp His Met His Asp Phe
 915 920 925
 Phe His Ser Phe Leu Ile Val Phe Arg Val Leu Cys Gly Glu Trp Ile
 930 935 940
 Glu Thr Met Trp Asp Cys Met Glu Val Ala Gly Gln Thr Met Cys Leu
 945 950 955 960
 Thr Val Phe Met Met Val Met Val Ile Gly Asn Leu Val Val Leu Asn
 965 970 975
 Leu Phe Leu Ala Leu Leu Leu Ser Ser Phe Ser Ser Asp Asn Leu Ala
 980 985 990
 Ala Thr Asp Asp Asp Asn Glu Met Asn Asn Ile Gln Ile Ala Val Gly
 995 1000 1005

SSCP Update Sequences.ST25

Arg Met Gln Lys Gly Ile Asp Phe Val Lys Arg Lys Ile Arg Glu
 1010 1015 1020
 Phe Ile Gln Lys Ala Phe Val Arg Lys Gln Lys Ala Leu Asp Glu
 1025 1030 1035
 Ile Lys Pro Leu Glu Asp Leu Asn Asn Lys Lys Asp Ser Cys Ile
 1040 1045 1050
 Ser Asn His Thr Thr Ile Glu Ile Gly Lys Asp Leu Asn Tyr Leu
 1055 1060 1065
 Lys Asp Gly Asn Gly Thr Thr Ser Gly Ile Gly Ser Ser Val Glu
 1070 1075 1080
 Lys Tyr Val Val Asp Glu Ser Asp Tyr Met Ser Phe Ile Asn Asn
 1085 1090 1095
 Pro Ser Leu Thr Val Thr Val Pro Ile Ala Val Gly Glu Ser Asp
 1100 1105 1110
 Phe Glu Asn Leu Asn Thr Glu Glu Phe Ser Ser Glu Ser Asp Met
 1115 1120 1125
 Glu Glu Ser Lys Glu Lys Leu Asn Ala Thr Ser Ser Ser Glu Gly
 1130 1135 1140
 Ser Thr Val Asp Ile Gly Ala Pro Ala Glu Gly Glu Gln Pro Glu
 1145 1150 1155
 Val Glu Pro Glu Glu Ser Leu Glu Pro Glu Ala Cys Phe Thr Glu
 1160 1165 1170
 Asp Cys Val Arg Lys Phe Lys Cys Cys Gln Ile Ser Ile Glu Glu
 1175 1180 1185
 Gly Lys Gly Lys Leu Trp Trp Asn Leu Arg Lys Thr Cys Tyr Lys
 1190 1195 1200
 Ile Val Glu His Asn Trp Phe Glu Thr Phe Ile Val Phe Met Ile
 1205 1210 1215
 Leu Leu Ser Ser Gly Ala Leu Ala Phe Glu Asp Ile Tyr Ile Glu
 1220 1225 1230
 Gln Arg Lys Thr Ile Lys Thr Met Leu Glu Tyr Ala Asp Lys Val
 1235 1240 1245
 Phe Thr Tyr Ile Phe Ile Leu Glu Met Leu Leu Lys Trp Val Ala
 1250 1255 1260

SSCP Update Sequences.ST25

Tyr Gly Phe Gln Val Tyr Phe Thr Asn Ala Trp Cys Trp Leu Asp
 1265 1270 1275
 Phe Leu Ile Val Asp Val Ser Leu Val Ser Leu Thr Ala Asn Ala
 1280 1285 1290
 Leu Gly Tyr Ser Glu Leu Gly Ala Ile Lys Ser Leu Arg Thr Leu
 1295 1300 1305
 Arg Ala Leu Arg Pro Leu Arg Ala Leu Ser Arg Phe Glu Gly Met
 1310 1315 1320
 Arg Val Val Val Asn Ala Leu Leu Gly Ala Ile Pro Ser Ile Met
 1325 1330 1335
 Asn Val Leu Leu Val Cys Leu Ile Phe Trp Leu Ile Phe Ser Ile
 1340 1345 1350
 Met Gly Val Asn Leu Phe Ala Gly Lys Phe Tyr His Cys Ile Asn
 1355 1360 1365
 Tyr Thr Thr Gly Glu Met Phe Asp Val Ser Val Val Asn Asn Tyr
 1370 1375 1380
 Ser Glu Cys Lys Ala Leu Ile Glu Ser Asn Gln Thr Ala Arg Trp
 1385 1390 1395
 Lys Asn Val Lys Val Asn Phe Asp Asn Val Gly Leu Gly Tyr Leu
 1400 1405 1410
 Ser Leu Leu Gln Val Ala Thr Phe Lys Gly Trp Met Asp Ile Met
 1415 1420 1425
 Tyr Ala Ala Val Asp Ser Arg Asn Val Glu Leu Gln Pro Lys Tyr
 1430 1435 1440
 Glu Asp Asn Leu Tyr Met Tyr Leu Tyr Phe Val Ile Phe Ile Ile
 1445 1450 1455
 Phe Gly Ser Phe Phe Thr Leu Asn Leu Phe Ile Gly Val Ile Ile
 1460 1465 1470
 Asp Asn Phe Asn Gln Gln Lys Lys Lys Phe Gly Gly Gln Asp Ile
 1475 1480 1485
 Phe Met Thr Glu Glu Gln Lys Lys Tyr Tyr Asn Ala Met Lys Lys
 1490 1495 1500
 Leu Gly Ser Lys Lys Pro Gln Lys Pro Ile Pro Arg Pro Ala Asn
 1505 1510 1515

SSCP Update Sequences.ST25

Lys	Phe	Gln	Gly	Met	Val	Phe	Asp	Phe	Val	Thr	Lys	Gln	Val	Phe
	1520					1525					1530			
Asp	Ile	Ser	Ile	Met	Ile	Leu	Ile	Cys	Leu	Asn	Met	Val	Thr	Met
	1535					1540					1545			
Met	Val	Glu	Thr	Asp	Asp	Gln	Ser	Gln	Glu	Met	Thr	Asn	Ile	Leu
	1550					1555					1560			
Tyr	Trp	Ile	Asn	Leu	Val	Phe	Ile	Val	Leu	Phe	Thr	Gly	Glu	Cys
	1565					1570					1575			
Val	Leu	Lys	Leu	Ile	Ser	Leu	Arg	Tyr	Tyr	Tyr	Phe	Thr	Ile	Gly
	1580					1585					1590			
Trp	Asn	Ile	Phe	Asp	Phe	Val	Val	Val	Ile	Leu	Ser	Ile	Val	Gly
	1595					1600					1605			
Met	Phe	Leu	Ala	Glu	Leu	Ile	Glu	Lys	Tyr	Phe	Val	Ser	Pro	Thr
	1610					1615					1620			
Leu	Phe	Arg	Val	Ile	Arg	Leu	Ala	Arg	Ile	Gly	Arg	Ile	Leu	Arg
	1625					1630					1635			
Leu	Ile	Lys	Gly	Ala	Lys	Gly	Ile	Arg	Thr	Leu	Leu	Phe	Ala	Leu
	1640					1645					1650			
Met	Met	Ser	Leu	Pro	Ala	Leu	Phe	Asn	Ile	Gly	Leu	Leu	Leu	Phe
	1655					1660					1665			
Leu	Val	Met	Phe	Ile	Tyr	Ala	Ile	Phe	Gly	Met	Ser	Asn	Phe	Ala
	1670					1675					1680			
Tyr	Val	Lys	Arg	Glu	Val	Gly	Ile	Asp	Asp	Met	Phe	Asn	Phe	Glu
	1685					1690					1695			
Thr	Phe	Gly	Asn	Ser	Met	Ile	Cys	Leu	Phe	Gln	Ile	Thr	Thr	Ser
	1700					1705					1710			
Ala	Gly	Trp	Asp	Gly	Leu	Leu	Ala	Pro	Ile	Leu	Asn	Ser	Gly	Pro
	1715					1720					1725			
Pro	Asp	Cys	Asp	Pro	Asp	Lys	Asp	His	Pro	Gly	Ser	Ser	Val	Lys
	1730					1735					1740			
Gly	Asp	Cys	Gly	Asn	Pro	Ser	Val	Gly	Ile	Phe	Phe	Phe	Val	Ser
	1745					1750					1755			
Tyr	Ile	Ile	Ile	Ser	Phe	Leu	Val	Val	Leu	Asn	Met	Tyr	Ile	Ala
	1760					1765					1770			

SSCP Update Sequences.ST25

Val Ile Leu Glu Asn Phe Ser Val Ala Thr Glu Glu Ser Ala Glu
 1775 1780 1785
 Pro Leu Ser Glu Asp Asp Phe Glu Met Phe Tyr Glu Val Trp Glu
 1790 1795 1800
 Lys Phe Asp Pro Asp Ala Thr Gln Phe Ile Glu Phe Ala Lys Leu
 1805 1810 1815
 Ser Asp Phe Ala Asp Ala Leu Asp Pro Pro Leu Leu Ile Ala Lys
 1820 1825 1830
 Pro Asn Lys Val Gln Leu Ile Ala Met Asp Leu Pro Met Val Ser
 1835 1840 1845
 Gly Asp Arg Ile His Cys Leu Asp Ile Leu Phe Ala Phe Thr Lys
 1850 1855 1860
 Arg Val Leu Gly Glu Ser Gly Glu Met Asp Ala Leu Arg Ile Gln
 1865 1870 1875
 Met Glu Glu Arg Phe Met Ala Ser Asn Pro Ser Lys Val Ser Tyr
 1880 1885 1890
 Glu Pro Ile Thr Thr Thr Leu Lys Arg Lys Gln Glu Glu Val Ser
 1895 1900 1905
 Ala Ile Ile Ile Gln Arg Ala Tyr Arg Arg Tyr Leu Leu Lys Gln
 1910 1915 1920
 Lys Val Lys Lys Val Ser Ser Ile Tyr Lys Lys Asp Lys Gly Lys
 1925 1930 1935
 Glu Cys Asp Gly Thr Pro Ile Lys Glu Asp Thr Leu Ile Asp Lys
 1940 1945 1950
 Leu Asn Glu Asn Ser Thr Pro Glu Lys Thr Asp Met Thr Pro Ser
 1955 1960 1965
 Thr Thr Ser Pro Pro Ser Tyr Asp Ser Val Thr Lys Pro Glu Lys
 1970 1975 1980
 Glu Lys Phe Glu Lys Asp Lys Ser Glu Lys Glu Asp Lys Gly Lys
 1985 1990 1995
 Asp Ile Arg Glu Ser Lys Lys
 2000 2005

<210> 86
 <211> 2005
 <212> PRT

SSCP Update Sequences.ST25

<213> Homo sapiens

<400> 86

Met Ala Gln Ser Val Leu Val Pro Pro Gly Pro Asp Ser Phe Arg Phe
1 5 10 15

Phe Thr Arg Glu Ser Leu Ala Ala Ile Glu Gln Arg Ile Ala Glu Glu
20 25 30

Lys Ala Lys Arg Pro Lys Gln Glu Arg Lys Asp Glu Asp Asp Glu Asn
35 40 45

Gly Pro Lys Pro Asn Ser Asp Leu Glu Ala Gly Lys Ser Leu Pro Phe
50 55 60

Ile Tyr Gly Asp Ile Pro Pro Glu Met Val Ser Val Pro Leu Glu Asp
65 70 75 80

Leu Asp Pro Tyr Tyr Ile Asn Lys Lys Thr Phe Ile Val Leu Asn Lys
85 90 95

Gly Lys Ala Ile Ser Arg Phe Ser Ala Thr Pro Ala Leu Tyr Ile Leu
100 105 110

Thr Pro Phe Asn Pro Ile Arg Lys Leu Ala Ile Lys Ile Leu Val His
115 120 125

Ser Leu Phe Asn Met Leu Ile Met Cys Thr Ile Leu Thr Asn Cys Val
130 135 140

Phe Met Thr Met Ser Asn Pro Pro Asp Trp Thr Lys Asn Val Glu Tyr
145 150 155 160

Thr Phe Thr Gly Ile Tyr Thr Phe Glu Ser Leu Ile Lys Ile Leu Ala
165 170 175

Arg Gly Phe Cys Leu Glu Asp Phe Thr Phe Leu Arg Asp Pro Trp Asn
180 185 190

Trp Leu Asp Phe Thr Val Ile Thr Phe Ala Tyr Val Thr Glu Phe Val
195 200 205

Asp Leu Gly Asn Val Ser Ala Leu Arg Thr Phe Arg Val Leu Arg Ala
210 215 220

Leu Lys Thr Ile Ser Val Ile Pro Gly Leu Lys Thr Ile Val Gly Ala
225 230 235 240

Leu Ile Gln Ser Val Lys Lys Leu Ser Asp Val Met Ile Leu Thr Val
245 250 255

SSCP Update Sequences.ST25

Phe Cys Leu Ser Val Phe Ala Leu Ile Gly Leu Gln Leu Phe Met Gly
 260 265 270
 Asn Leu Arg Asn Lys Cys Leu Gln Trp Pro Pro Asp Asn Ser Ser Phe
 275 280 285
 Glu Ile Asn Ile Thr Ser Phe Phe Asn Asn Ser Leu Asp Gly Asn Gly
 290 295 300
 Thr Thr Phe Asn Arg Thr Val Ser Ile Phe Asn Trp Asp Glu Tyr Ile
 305 310 315 320
 Glu Asp Lys Ser His Phe Tyr Phe Leu Glu Gly Gln Asn Asp Ala Leu
 325 330 335
 Leu Cys Gly Asn Ser Ser Asp Ala Gly Gln Cys Pro Glu Gly Tyr Ile
 340 345 350
 Cys Val Lys Ala Gly Arg Asn Pro Asn Tyr Gly Tyr Thr Ser Phe Asp
 355 360 365
 Thr Phe Ser Trp Ala Phe Leu Ser Leu Phe Arg Leu Met Thr Gln Asp
 370 375 380
 Phe Trp Glu Asn Leu Tyr Gln Leu Thr Leu Arg Ala Ala Gly Lys Thr
 385 390 395 400
 Tyr Met Ile Phe Phe Val Leu Val Ile Phe Leu Gly Ser Phe Tyr Leu
 405 410 415
 Ile Asn Leu Ile Leu Ala Val Val Ala Met Ala Tyr Glu Glu Gln Asn
 420 425 430
 Gln Ala Thr Leu Glu Glu Ala Glu Gln Lys Glu Ala Glu Phe Gln Gln
 435 440 445
 Met Leu Glu Gln Leu Lys Lys Gln Gln Glu Glu Ala Gln Ala Ala Ala
 450 455 460
 Ala Ala Ala Ser Ala Glu Ser Arg Asp Phe Ser Gly Ala Gly Gly Ile
 465 470 475 480
 Gly Val Phe Ser Glu Ser Ser Ser Val Ala Ser Lys Leu Ser Ser Lys
 485 490 495
 Ser Glu Lys Glu Leu Lys Asn Arg Arg Lys Lys Lys Lys Gln Lys Glu
 500 505 510
 Gln Ser Gly Glu Glu Glu Lys Asn Asp Arg Val Leu Lys Ser Glu Ser
 515 520 525

SSCP Update Sequences.ST25

Glu Asp Ser Ile Arg Arg Lys Gly Phe Arg Phe Ser Leu Glu Gly Ser
 530 535 540
 Arg Leu Thr Tyr Glu Lys Arg Phe Ser Ser Pro His Gln Ser Leu Leu
 545 550 555 560
 Ser Ile Arg Gly Ser Leu Phe Ser Pro Arg Arg Asn Ser Arg Ala Ser
 565 570 575
 Leu Phe Ser Phe Arg Gly Arg Ala Lys Asp Ile Gly Ser Glu Asn Asp
 580 585 590
 Phe Ala Asp Asp Glu His Ser Thr Phe Glu Asp Asn Asp Ser Arg Arg
 595 600 605
 Asp Ser Leu Phe Val Pro His Arg His Gly Glu Arg Arg His Ser Asn
 610 615 620
 Val Ser Gln Ala Ser Arg Ala Ser Arg Val Leu Pro Ile Leu Pro Met
 625 630 635 640
 Asn Gly Lys Met His Ser Ala Val Asp Cys Asn Gly Val Val Ser Leu
 645 650 655
 Val Gly Gly Pro Ser Thr Leu Thr Ser Ala Gly Gln Leu Leu Pro Glu
 660 665 670
 Gly Thr Thr Thr Glu Thr Glu Ile Arg Lys Arg Arg Ser Ser Ser Tyr
 675 680 685
 His Val Ser Met Asp Leu Leu Glu Asp Pro Thr Ser Arg Gln Arg Ala
 690 695 700
 Met Ser Ile Ala Ser Ile Leu Thr Asn Thr Met Glu Glu Leu Glu Glu
 705 710 715 720
 Ser Arg Gln Lys Cys Pro Pro Cys Trp Tyr Lys Phe Ala Asn Met Cys
 725 730 735
 Leu Ile Trp Asp Cys Cys Lys Pro Trp Leu Lys Val Lys His Leu Val
 740 745 750
 Asn Leu Val Val Met Asp Pro Phe Val Asp Leu Ala Ile Thr Ile Cys
 755 760 765
 Ile Val Leu Asn Thr Leu Phe Met Ala Met Glu His Tyr Pro Met Thr
 770 775 780
 Glu Gln Phe Ser Ser Val Leu Ser Val Gly Asn Leu Val Phe Thr Gly
 785 790 795 800

SSCP Update Sequences.ST25

Ile Phe Thr Ala Glu Met Phe Leu Lys Ile Ile Ala Met Asp Pro Tyr
 805 810 815
 Tyr Tyr Phe Gln Glu Gly Trp Asn Ile Phe Asp Gly Phe Ile Val Ser
 820 825 830
 Leu Ser Leu Met Glu Leu Gly Leu Ala Asn Val Glu Gly Leu Ser Val
 835 840 845
 Leu Arg Ser Phe Arg Leu Leu Arg Val Phe Lys Leu Ala Lys Ser Trp
 850 855 860
 Pro Thr Leu Asn Met Leu Ile Lys Ile Ile Gly Asn Ser Val Gly Ala
 865 870 875 880
 Leu Gly Asn Leu Thr Leu Val Leu Ala Ile Ile Val Phe Ile Phe Ala
 885 890 895
 Val Val Gly Met Gln Leu Phe Gly Lys Ser Tyr Lys Glu Cys Val Cys
 900 905 910
 Lys Ile Ser Asn Asp Cys Glu Leu Pro Arg Trp His Met His Asp Phe
 915 920 925
 Phe His Ser Phe Leu Ile Val Phe Arg Val Leu Cys Gly Glu Trp Ile
 930 935 940
 Glu Thr Met Trp Asp Cys Met Glu Val Ala Gly Gln Thr Met Cys Leu
 945 950 955 960
 Thr Val Phe Met Met Val Met Val Ile Gly Asn Leu Val Val Leu Asn
 965 970 975
 Leu Phe Leu Ala Leu Leu Leu Ser Ser Phe Ser Ser Asp Asn Leu Ala
 980 985 990
 Ala Thr Asp Asp Asp Asn Glu Met Asn Asn Leu Gln Ile Ala Val Gly
 995 1000 1005
 Arg Met Gln Lys Gly Ile Asp Phe Val Lys Arg Lys Ile Arg Glu
 1010 1015 1020
 Phe Ile Gln Lys Ala Phe Val Arg Lys Gln Lys Ala Leu Asp Glu
 1025 1030 1035
 Ile Lys Pro Leu Glu Asp Leu Asn Asn Lys Lys Asp Ser Cys Ile
 1040 1045 1050
 Ser Asn His Thr Thr Ile Glu Ile Gly Lys Asp Leu Asn Tyr Leu
 1055 1060 1065

SSCP Update Sequences.ST25

Lys Asp Gly Asn Gly Thr Thr Ser Gly Ile Gly Ser Ser Val Glu
 1070 1075 1080
 Lys Tyr Val Val Asp Glu Ser Asp Tyr Met Ser Phe Ile Asn Asn
 1085 1090 1095
 Pro Ser Leu Thr Val Thr Val Pro Ile Ala Val Gly Glu Ser Asp
 1100 1105 1110
 Phe Glu Asn Leu Asn Thr Glu Glu Phe Ser Ser Glu Ser Asp Met
 1115 1120 1125
 Glu Glu Ser Lys Glu Lys Leu Asn Ala Thr Ser Ser Ser Glu Gly
 1130 1135 1140
 Ser Thr Val Asp Ile Gly Ala Pro Ala Glu Gly Glu Gln Pro Glu
 1145 1150 1155
 Val Glu Pro Glu Glu Ser Leu Glu Pro Glu Ala Cys Phe Thr Glu
 1160 1165 1170
 Asp Cys Val Arg Lys Phe Lys Cys Cys Gln Ile Ser Ile Glu Glu
 1175 1180 1185
 Gly Lys Gly Lys Leu Trp Trp Asn Leu Arg Lys Ala Cys Tyr Lys
 1190 1195 1200
 Ile Val Glu His Asn Trp Phe Glu Thr Phe Ile Val Phe Met Ile
 1205 1210 1215
 Leu Leu Ser Ser Gly Ala Leu Ala Phe Glu Asp Ile Tyr Ile Glu
 1220 1225 1230
 Gln Arg Lys Thr Ile Lys Thr Met Leu Glu Tyr Ala Asp Lys Val
 1235 1240 1245
 Phe Thr Tyr Ile Phe Ile Leu Glu Met Leu Leu Lys Trp Val Ala
 1250 1255 1260
 Tyr Gly Phe Gln Val Tyr Phe Thr Asn Ala Trp Cys Trp Leu Asp
 1265 1270 1275
 Phe Leu Ile Val Asp Val Ser Leu Val Ser Leu Thr Ala Asn Ala
 1280 1285 1290
 Leu Gly Tyr Ser Glu Leu Gly Ala Ile Lys Ser Leu Arg Thr Leu
 1295 1300 1305
 Arg Ala Leu Arg Pro Leu Arg Ala Leu Ser Arg Phe Glu Gly Met
 1310 1315 1320

SSCP Update Sequences.ST25

Arg Val Val Val Asn Ala Leu Leu Gly Ala Ile Pro Ser Ile Met
 1325 1330 1335
 Asn Val Leu Leu Val Cys Leu Ile Phe Trp Leu Ile Phe Ser Ile
 1340 1345 1350
 Met Gly Val Asn Leu Phe Ala Gly Lys Phe Tyr His Cys Ile Asn
 1355 1360 1365
 Tyr Thr Thr Gly Glu Met Phe Asp Val Ser Val Val Asn Asn Tyr
 1370 1375 1380
 Ser Glu Cys Lys Ala Leu Ile Glu Ser Asn Gln Thr Ala Arg Trp
 1385 1390 1395
 Lys Asn Val Lys Val Asn Phe Asp Asn Val Gly Leu Gly Tyr Leu
 1400 1405 1410
 Ser Leu Leu Gln Val Ala Thr Phe Lys Gly Trp Met Asp Ile Met
 1415 1420 1425
 Tyr Ala Ala Val Asp Ser Arg Asn Val Glu Leu Gln Pro Lys Tyr
 1430 1435 1440
 Glu Asp Asn Leu Tyr Met Tyr Leu Tyr Phe Val Ile Phe Ile Ile
 1445 1450 1455
 Phe Gly Ser Phe Phe Thr Leu Asn Leu Phe Ile Gly Val Ile Ile
 1460 1465 1470
 Asp Asn Phe Asn Gln Gln Lys Lys Lys Phe Gly Gly Gln Asp Ile
 1475 1480 1485
 Phe Met Thr Glu Glu Gln Lys Lys Tyr Tyr Asn Ala Met Lys Lys
 1490 1495 1500
 Leu Gly Ser Lys Lys Pro Gln Lys Pro Ile Pro Arg Pro Ala Asn
 1505 1510 1515
 Lys Phe Gln Gly Met Val Phe Asp Phe Val Thr Lys Gln Val Phe
 1520 1525 1530
 Asp Ile Ser Ile Met Ile Leu Ile Cys Leu Asn Met Val Thr Met
 1535 1540 1545
 Met Val Glu Thr Asp Asp Gln Ser Gln Glu Met Thr Asn Ile Leu
 1550 1555 1560
 Tyr Trp Ile Asn Leu Val Phe Ile Val Leu Phe Thr Gly Glu Cys
 1565 1570 1575

SSCP Update Sequences.ST25

Val	Leu	Lys	Leu	Ile	Ser	Leu	Arg	Tyr	Tyr	Tyr	Phe	Thr	Ile	Gly
	1580					1585					1590			
Trp	Asn	Ile	Phe	Asp	Phe	Val	Val	Val	Ile	Leu	Ser	Ile	Val	Gly
	1595					1600					1605			
Met	Phe	Leu	Ala	Glu	Leu	Ile	Glu	Lys	Tyr	Phe	Val	Ser	Pro	Thr
	1610					1615					1620			
Leu	Phe	Arg	Val	Ile	Arg	Leu	Ala	Arg	Ile	Gly	Arg	Ile	Leu	Arg
	1625					1630					1635			
Leu	Ile	Lys	Gly	Ala	Lys	Gly	Ile	Arg	Thr	Leu	Leu	Phe	Ala	Leu
	1640					1645					1650			
Met	Met	Ser	Leu	Pro	Ala	Leu	Phe	Asn	Ile	Gly	Leu	Leu	Leu	Phe
	1655					1660					1665			
Leu	Val	Met	Phe	Ile	Tyr	Ala	Ile	Phe	Gly	Met	Ser	Asn	Phe	Ala
	1670					1675					1680			
Tyr	Val	Lys	Arg	Glu	Val	Gly	Ile	Asp	Asp	Met	Phe	Asn	Phe	Glu
	1685					1690					1695			
Thr	Phe	Gly	Asn	Ser	Met	Ile	Cys	Leu	Phe	Gln	Ile	Thr	Thr	Ser
	1700					1705					1710			
Ala	Gly	Trp	Asp	Gly	Leu	Leu	Ala	Pro	Ile	Leu	Asn	Ser	Gly	Pro
	1715					1720					1725			
Pro	Asp	Cys	Asp	Pro	Asp	Lys	Asp	His	Pro	Gly	Ser	Ser	Val	Lys
	1730					1735					1740			
Gly	Asp	Cys	Gly	Asn	Pro	Ser	Val	Gly	Ile	Phe	Phe	Phe	Val	Ser
	1745					1750					1755			
Tyr	Ile	Ile	Ile	Ser	Phe	Leu	Val	Val	Leu	Asn	Met	Tyr	Ile	Ala
	1760					1765					1770			
Val	Ile	Leu	Glu	Asn	Phe	Ser	Val	Ala	Thr	Glu	Glu	Ser	Ala	Glu
	1775					1780					1785			
Pro	Leu	Ser	Glu	Asp	Asp	Phe	Glu	Met	Phe	Tyr	Glu	Val	Trp	Glu
	1790					1795					1800			
Lys	Phe	Asp	Pro	Asp	Ala	Thr	Gln	Phe	Ile	Glu	Phe	Ala	Lys	Leu
	1805					1810					1815			
Ser	Asp	Phe	Ala	Asp	Ala	Leu	Asp	Pro	Pro	Leu	Leu	Ile	Ala	Lys
	1820					1825					1830			

SSCP Update Sequences.ST25

Pro Asn Lys Val Gln Leu Ile Ala Met Asp Leu Pro Met Val Ser
 1835 1840 1845

Gly Asp Arg Ile His Cys Leu Asp Ile Leu Phe Ala Phe Thr Lys
 1850 1855 1860

Arg Val Leu Gly Glu Ser Gly Glu Met Asp Ala Leu Arg Ile Gln
 1865 1870 1875

Met Glu Glu Arg Phe Met Ala Ser Asn Pro Ser Lys Val Ser Tyr
 1880 1885 1890

Glu Pro Ile Thr Thr Thr Leu Lys Arg Lys Gln Glu Glu Val Ser
 1895 1900 1905

Ala Ile Ile Ile Gln Arg Ala Tyr Arg Arg Tyr Leu Leu Lys Gln
 1910 1915 1920

Lys Val Lys Lys Val Ser Ser Ile Tyr Lys Lys Asp Lys Gly Lys
 1925 1930 1935

Glu Cys Asp Gly Thr Pro Ile Lys Glu Asp Thr Leu Ile Asp Lys
 1940 1945 1950

Leu Asn Glu Asn Ser Thr Pro Glu Lys Thr Asp Met Thr Pro Ser
 1955 1960 1965

Thr Thr Ser Pro Pro Ser Tyr Asp Ser Val Thr Lys Pro Glu Lys
 1970 1975 1980

Glu Lys Phe Glu Lys Asp Lys Ser Glu Lys Glu Asp Lys Gly Lys
 1985 1990 1995

Asp Ile Arg Glu Ser Lys Lys
 2000 2005

<210> 87
 <211> 2005
 <212> PRT
 <213> Homo sapiens

<400> 87

Met Ala Gln Ser Val Leu Val Pro Pro Gly Pro Asp Ser Phe Arg Phe
 1 5 10 15

Phe Thr Arg Glu Ser Leu Ala Ala Ile Glu Gln Arg Ile Ala Glu Glu
 20 25 30

Lys Ala Lys Arg Pro Lys Gln Glu Arg Lys Asp Glu Asp Asp Glu Asn
 35 40 45

Gly Pro Lys Pro Asn Ser Asp Leu Glu Ala Gly Lys Ser Leu Pro Phe
 Page 207

SSCP Update Sequences.ST25

50

55

60

Ile Tyr Gly Asp Ile Pro Pro Glu Met Val Ser Val Pro Leu Glu Asp
65 70 75 80

Leu Asp Pro Tyr Tyr Ile Asn Lys Lys Thr Phe Ile Val Leu Asn Lys
85 90 95

Gly Lys Ala Ile Ser Arg Phe Ser Ala Thr Pro Ala Leu Tyr Ile Leu
100 105 110

Thr Pro Phe Asn Pro Ile Arg Lys Leu Ala Ile Lys Ile Leu Val His
115 120 125

Ser Leu Phe Asn Met Leu Ile Met Cys Thr Ile Leu Thr Asn Cys Val
130 135 140

Phe Met Thr Met Ser Asn Pro Pro Asp Trp Thr Lys Asn Val Glu Tyr
145 150 155 160

Thr Phe Thr Gly Ile Tyr Thr Phe Glu Ser Leu Ile Lys Ile Leu Ala
165 170 175

Arg Gly Phe Cys Leu Glu Asp Phe Thr Phe Leu Arg Asp Pro Trp Asn
180 185 190

Trp Leu Asp Phe Thr Val Ile Thr Phe Ala Tyr Val Thr Glu Phe Val
195 200 205

Asp Leu Gly Asn Val Ser Ala Leu Arg Thr Phe Arg Val Leu Arg Ala
210 215 220

Leu Lys Thr Ile Ser Val Ile Pro Gly Leu Lys Thr Ile Val Gly Ala
225 230 235 240

Leu Ile Gln Ser Val Lys Lys Leu Ser Asp Val Met Ile Leu Thr Val
245 250 255

Phe Cys Leu Ser Val Phe Ala Leu Ile Gly Leu Gln Leu Phe Met Gly
260 265 270

Asn Leu Arg Asn Lys Cys Leu Gln Trp Pro Pro Asp Asn Ser Ser Phe
275 280 285

Glu Ile Asn Ile Thr Ser Phe Phe Asn Asn Ser Leu Asp Gly Asn Gly
290 295 300

Thr Thr Phe Asn Arg Thr Val Ser Ile Phe Asn Trp Asp Glu Tyr Ile
305 310 315 320

Glu Asp Lys Ser His Phe Tyr Phe Leu Glu Gly Gln Asn Asp Ala Leu

SSCP Update Sequences.ST25

325

330

335

Leu Cys Gly Asn Ser Ser Asp Ala Gly Gln Cys Pro Glu Gly Tyr Ile
 340 345 350

Cys Val Lys Ala Gly Arg Asn Pro Asn Tyr Gly Tyr Thr Ser Phe Asp
 355 360 365

Thr Phe Ser Trp Ala Phe Leu Ser Leu Phe Arg Leu Met Thr Gln Asp
 370 375 380

Phe Trp Glu Asn Leu Tyr Gln Leu Thr Leu Arg Ala Ala Gly Lys Thr
 385 390 395 400

Tyr Met Ile Phe Phe Val Leu Val Ile Phe Leu Gly Ser Phe Tyr Leu
 405 410 415

Ile Asn Leu Ile Leu Ala Val Val Ala Met Ala Tyr Glu Glu Gln Asn
 420 425 430

Gln Ala Thr Leu Glu Glu Ala Glu Gln Lys Glu Ala Glu Phe Gln Gln
 435 440 445

Met Leu Glu Gln Leu Lys Lys Gln Gln Glu Glu Ala Gln Ala Ala Ala
 450 455 460

Ala Ala Ala Ser Ala Glu Ser Arg Asp Phe Ser Gly Ala Gly Gly Ile
 465 470 475 480

Gly Val Phe Ser Glu Ser Ser Ser Val Ala Ser Lys Leu Ser Ser Lys
 485 490 495

Ser Glu Lys Glu Leu Lys Asn Arg Arg Lys Lys Lys Lys Gln Lys Glu
 500 505 510

Gln Ser Gly Glu Glu Glu Lys Asn Asp Arg Val Leu Lys Ser Glu Ser
 515 520 525

Glu Asp Ser Ile Arg Arg Lys Gly Phe Arg Phe Ser Leu Glu Gly Ser
 530 535 540

Arg Leu Thr Tyr Glu Lys Arg Phe Ser Ser Pro His Gln Ser Leu Leu
 545 550 555 560

Ser Ile Arg Gly Ser Leu Phe Ser Pro Arg Arg Asn Ser Arg Ala Ser
 565 570 575

Leu Phe Ser Phe Arg Gly Arg Ala Lys Asp Ile Gly Ser Glu Asn Asp
 580 585 590

Phe Ala Asp Asp Glu His Ser Thr Phe Glu Asp Asn Asp Ser Arg Arg
 Page 209

SSCP Update Sequences.ST25
600 605

595

Asp Ser Leu Phe Val Pro His Arg His Gly Glu Arg Arg His Ser Asn
 610 615 620
 Val Ser Gln Ala Ser Arg Ala Ser Arg Val Leu Pro Ile Leu Pro Met
 625 630 635 640
 Asn Gly Lys Met His Ser Ala Val Asp Cys Asn Gly Val Val Ser Leu
 645 650 655
 Val Gly Gly Pro Ser Thr Leu Thr Ser Ala Gly Gln Leu Leu Pro Glu
 660 665 670
 Gly Thr Thr Thr Glu Thr Glu Ile Arg Lys Arg Arg Ser Ser Ser Tyr
 675 680 685
 His Val Ser Met Asp Leu Leu Glu Asp Pro Thr Ser Arg Gln Arg Ala
 690 695 700
 Met Ser Ile Ala Ser Ile Leu Thr Asn Thr Met Glu Glu Leu Glu Glu
 705 710 715 720
 Ser Arg Gln Lys Cys Pro Pro Cys Trp Tyr Lys Phe Ala Asn Met Cys
 725 730 735
 Leu Ile Trp Asp Cys Cys Lys Pro Trp Leu Lys Val Lys His Leu Val
 740 745 750
 Asn Leu Val Val Met Asp Pro Phe Val Asp Leu Ala Ile Thr Ile Cys
 755 760 765
 Ile Val Leu Asn Thr Leu Phe Met Ala Met Glu His Tyr Pro Met Thr
 770 775 780
 Glu Gln Phe Ser Ser Val Leu Ser Val Gly Asn Leu Val Phe Thr Gly
 785 790 795 800
 Ile Phe Thr Ala Glu Met Phe Leu Lys Ile Ile Ala Met Asp Pro Tyr
 805 810 815
 Tyr Tyr Phe Gln Glu Gly Trp Asn Ile Phe Asp Gly Phe Ile Val Ser
 820 825 830
 Leu Ser Leu Met Glu Leu Gly Leu Ala Asn Val Glu Gly Leu Ser Val
 835 840 845
 Leu Arg Ser Phe Arg Leu Leu Arg Val Phe Lys Leu Ala Lys Ser Trp
 850 855 860
 Pro Thr Leu Asn Met Leu Ile Lys Ile Ile Gly Asn Ser Val Gly Ala

SSCP Update Sequences.ST25

865 870 875 880
 Leu Gly Asn Leu Thr Leu Val Leu Ala Ile Ile Val Phe Ile Phe Ala
 885 890 895
 Val Val Gly Met Gln Leu Phe Gly Lys Ser Tyr Lys Glu Cys Val Cys
 900 905 910
 Lys Ile Ser Asn Asp Cys Glu Leu Pro Arg Trp His Met His Asp Phe
 915 920 925
 Phe His Ser Phe Leu Ile Val Phe Arg Val Leu Cys Gly Glu Trp Ile
 930 935 940
 Glu Thr Met Trp Asp Cys Met Glu Val Ala Gly Gln Thr Met Cys Leu
 945 950 955 960
 Thr Val Phe Met Met Val Met Val Ile Gly Asn Leu Val Val Leu Asn
 965 970 975
 Leu Phe Leu Ala Leu Leu Leu Ser Ser Phe Ser Ser Asp Asn Leu Ala
 980 985 990
 Ala Thr Asp Asp Asp Asn Glu Met Asn Asn Leu Gln Ile Ala Val Gly
 995 1000 1005
 Arg Met Gln Lys Gly Ile Asp Phe Val Lys Arg Lys Ile Arg Glu
 1010 1015 1020
 Phe Ile Gln Lys Ala Phe Val Arg Lys Gln Lys Ala Leu Asp Glu
 1025 1030 1035
 Ile Lys Pro Leu Glu Asp Leu Asn Asn Lys Lys Asp Ser Cys Ile
 1040 1045 1050
 Ser Asn His Thr Thr Ile Glu Ile Gly Lys Asp Leu Asn Tyr Leu
 1055 1060 1065
 Lys Asp Gly Asn Gly Thr Thr Ser Gly Ile Gly Ser Ser Val Glu
 1070 1075 1080
 Lys Tyr Val Val Asp Glu Ser Asp Tyr Met Ser Phe Ile Asn Asn
 1085 1090 1095
 Pro Ser Leu Thr Val Thr Val Pro Ile Ala Val Gly Glu Ser Asp
 1100 1105 1110
 Phe Glu Asn Leu Asn Thr Glu Glu Phe Ser Ser Glu Ser Asp Met
 1115 1120 1125
 Glu Glu Ser Lys Glu Lys Leu Asn Ala Thr Ser Ser Ser Glu Gly

SSCP Update Sequences.ST25

1130

1135

1140

Ser Thr Val Asp Ile Gly Ala Pro Ala Glu Gly Glu Gln Pro Glu
 1145 1150 1155

Val Glu Pro Glu Glu Ser Leu Glu Pro Glu Ala Cys Phe Thr Glu
 1160 1165 1170

Asp Cys Val Arg Lys Phe Lys Cys Cys Gln Ile Ser Ile Glu Glu
 1175 1180 1185

Gly Lys Gly Lys Leu Trp Trp Asn Leu Arg Lys Thr Cys Tyr Lys
 1190 1195 1200

Ile Val Glu His Asn Trp Phe Glu Thr Phe Ile Val Phe Met Ile
 1205 1210 1215

Leu Leu Ser Ser Gly Ala Leu Ala Phe Glu Asp Ile Tyr Ile Glu
 1220 1225 1230

Gln Arg Lys Thr Ile Lys Thr Met Leu Glu Tyr Ala Asp Lys Val
 1235 1240 1245

Phe Thr Tyr Ile Phe Ile Leu Glu Met Leu Leu Lys Trp Val Ala
 1250 1255 1260

Tyr Gly Phe Gln Val Tyr Phe Thr Asn Ala Trp Cys Trp Leu Asp
 1265 1270 1275

Phe Leu Ile Val Asp Val Ser Leu Val Ser Leu Thr Ala Asn Ala
 1280 1285 1290

Leu Gly Tyr Ser Glu Leu Gly Ala Ile Lys Ser Leu Arg Thr Leu
 1295 1300 1305

Arg Ala Leu Arg Pro Leu Arg Ala Leu Ser Gln Phe Glu Gly Met
 1310 1315 1320

Arg Val Val Val Asn Ala Leu Leu Gly Ala Ile Pro Ser Ile Met
 1325 1330 1335

Asn Val Leu Leu Val Cys Leu Ile Phe Trp Leu Ile Phe Ser Ile
 1340 1345 1350

Met Gly Val Asn Leu Phe Ala Gly Lys Phe Tyr His Cys Ile Asn
 1355 1360 1365

Tyr Thr Thr Gly Glu Met Phe Asp Val Ser Val Val Asn Asn Tyr
 1370 1375 1380

Ser Glu Cys Lys Ala Leu Ile Glu Ser Asn Gln Thr Ala Arg Trp

Page 213

SSCP Update Sequences.ST25

1640														
Met	Met	Ser	Leu	Pro	Ala	Leu	Phe	Asn	Ile	Gly	Leu	Leu	Leu	Phe
1655						1660					1665			
Leu	Val	Met	Phe	Ile	Tyr	Ala	Ile	Phe	Gly	Met	Ser	Asn	Phe	Ala
1670						1675					1680			
Tyr	Val	Lys	Arg	Glu	Val	Gly	Ile	Asp	Asp	Met	Phe	Asn	Phe	Glu
1685						1690					1695			
Thr	Phe	Gly	Asn	Ser	Met	Ile	Cys	Leu	Phe	Gln	Ile	Thr	Thr	Ser
1700						1705					1710			
Ala	Gly	Trp	Asp	Gly	Leu	Leu	Ala	Pro	Ile	Leu	Asn	Ser	Gly	Pro
1715						1720					1725			
Pro	Asp	Cys	Asp	Pro	Asp	Lys	Asp	His	Pro	Gly	Ser	Ser	Val	Lys
1730						1735					1740			
Gly	Asp	Cys	Gly	Asn	Pro	Ser	Val	Gly	Ile	Phe	Phe	Phe	Val	Ser
1745						1750					1755			
Tyr	Ile	Ile	Ile	Ser	Phe	Leu	Val	Val	Leu	Asn	Met	Tyr	Ile	Ala
1760						1765					1770			
Val	Ile	Leu	Glu	Asn	Phe	Ser	Val	Ala	Thr	Glu	Glu	Ser	Ala	Glu
1775						1780					1785			
Pro	Leu	Ser	Glu	Asp	Asp	Phe	Glu	Met	Phe	Tyr	Glu	Val	Trp	Glu
1790						1795					1800			
Lys	Phe	Asp	Pro	Asp	Ala	Thr	Gln	Phe	Ile	Glu	Phe	Ala	Lys	Leu
1805						1810					1815			
Ser	Asp	Phe	Ala	Asp	Ala	Leu	Asp	Pro	Pro	Leu	Leu	Ile	Ala	Lys
1820						1825					1830			
Pro	Asn	Lys	Val	Gln	Leu	Ile	Ala	Met	Asp	Leu	Pro	Met	Val	Ser
1835						1840					1845			
Gly	Asp	Arg	Ile	His	Cys	Leu	Asp	Ile	Leu	Phe	Ala	Phe	Thr	Lys
1850						1855					1860			
Arg	Val	Leu	Gly	Glu	Ser	Gly	Glu	Met	Asp	Ala	Leu	Arg	Ile	Gln
1865						1870					1875			
Met	Glu	Glu	Arg	Phe	Met	Ala	Ser	Asn	Pro	Ser	Lys	Val	Ser	Tyr
1880						1885					1890			
Glu	Pro	Ile	Thr	Thr	Thr	Leu	Lys	Arg	Lys	Gln	Glu	Glu	Val	Ser

SSCP Update Sequences.ST25

1895

1900

1905

Ala Ile Ile Ile Gln Arg Ala Tyr Arg Arg Tyr Leu Leu Lys Gln
 1910 1915 1920

Lys Val Lys Lys Val Ser Ser Ile Tyr Lys Lys Asp Lys Gly Lys
 1925 1930 1935

Glu Cys Asp Gly Thr Pro Ile Lys Glu Asp Thr Leu Ile Asp Lys
 1940 1945 1950

Leu Asn Glu Asn Ser Thr Pro Glu Lys Thr Asp Met Thr Pro Ser
 1955 1960 1965

Thr Thr Ser Pro Pro Ser Tyr Asp Ser Val Thr Lys Pro Glu Lys
 1970 1975 1980

Glu Lys Phe Glu Lys Asp Lys Ser Glu Lys Glu Asp Lys Gly Lys
 1985 1990 1995

Asp Ile Arg Glu Ser Lys Lys
 2000 2005

<210> 88
 <211> 468
 <212> PRT
 <213> Homo sapiens

<400> 88

Met Ala Ala Arg Gly Ser Gly Pro Arg Ala Leu Arg Leu Leu Leu Leu
 1 5 10 15

Val Gln Leu Val Ala Gly Ala Leu Arg Ser Ser Arg Ala Arg Arg Ala
 20 25 30

Ala Arg Arg Gly Leu Ser Glu Pro Ser Ser Ile Ala Lys His Glu Asp
 35 40 45

Ser Leu Leu Lys Asp Leu Phe Gln Asp Tyr Glu Arg Trp Val Arg Pro
 50 55 60

Val Glu His Leu Asn Asp Lys Ile Lys Ile Lys Phe Gly Leu Ala Ile
 65 70 75 80

Ser Gln Leu Val Asp Val Asp Glu Lys Asn Gln Leu Met Thr Thr Asn
 85 90 95

Val Trp Leu Lys Gln Glu Trp Ile Asp Val Lys Leu Arg Trp Asn Pro
 100 105 110

Asp Asp Tyr Gly Gly Ile Lys Val Ile Arg Val Pro Ser Asp Ser Ser
 115 120 125

SSCP Update Sequences.ST25

Trp Thr Pro Asp Ile Ile Leu Phe Asp Asn Ala Asp Gly Arg Phe Glu
 130 135 140
 Gly Thr Ser Thr Lys Thr Val Ile Arg Tyr Asn Gly Thr Val Thr Trp
 145 150 155 160
 Thr Pro Pro Ala Asn Tyr Lys Ser Ser Cys Thr Ile Asp Val Thr Phe
 165 170 175
 Phe Pro Phe Asp Leu Gln Asn Cys Ser Met Lys Phe Gly Ser Trp Thr
 180 185 190
 Tyr Asp Gly Ser Gln Val Asp Ile Ile Leu Glu Asp Gln Asp Val Asp
 195 200 205
 Lys Arg Asp Phe Phe Asp Asn Gly Glu Trp Glu Ile Val Ser Ala Thr
 210 215 220
 Gly Ser Lys Gly Asn Arg Thr Asp Ser Cys Cys Trp Tyr Pro Tyr Val
 225 230 235 240
 Thr Tyr Ser Phe Val Ile Lys Arg Leu Pro Leu Phe Tyr Thr Leu Phe
 245 250 255
 Leu Ile Ile Pro Cys Ile Gly Leu Ser Phe Leu Thr Val Leu Val Phe
 260 265 270
 Tyr Leu Pro Ser Asn Glu Gly Glu Lys Ile Cys Leu Cys Thr Ser Val
 275 280 285
 Leu Val Ser Leu Thr Val Phe Leu Leu Val Ile Glu Glu Ile Ile Pro
 290 295 300
 Ser Ser Ser Lys Val Ile Pro Leu Ile Gly Glu Tyr Leu Val Phe Thr
 305 310 315 320
 Met Ile Phe Val Thr Leu Ser Ile Met Val Thr Val Phe Ala Ile Asn
 325 330 335
 Ile His His Arg Ser Ser Ser Thr His Asn Ala Met Ala Pro Leu Val
 340 345 350
 Arg Lys Ile Phe Leu His Thr Leu Pro Lys Leu Leu Ser Met Arg Ser
 355 360 365
 His Val Asp Arg Tyr Phe Thr Gln Lys Glu Glu Thr Glu Ser Gly Ser
 370 375 380
 Gly Pro Lys Ser Ser Arg Asn Thr Leu Glu Ala Ala Leu Asp Ser Ile
 385 390 395 400

SSCP Update Sequences.ST25

Arg Tyr Ile Thr Thr His Ile Met Lys Glu Asn Asp Val Arg Glu Val
405 410 415

Val Glu Asp Trp Lys Phe Ile Ala Gln Val Leu Asp Arg Met Phe Leu
420 425 430

Trp Thr Phe Leu Phe Val Ser Ile Val Gly Ser Leu Gly Leu Phe Val
435 440 445

Pro Val Ile Tyr Lys Trp Ala Asn Ile Leu Ile Pro Val His Ile Gly
450 455 460

Asn Ala Asn Lys
465

<210> 89
<211> 529
<212> PRT
<213> Homo sapiens

<400> 89

Met Gly Pro Ser Cys Pro Val Phe Leu Ser Phe Thr Lys Leu Ser Leu
1 5 10 15

Trp Trp Leu Leu Leu Thr Pro Ala Gly Gly Glu Glu Ala Lys Arg Pro
20 25 30

Pro Pro Arg Ala Pro Gly Asp Pro Leu Ser Ser Pro Ser Pro Thr Ala
35 40 45

Leu Pro Gln Gly Gly Ser His Thr Glu Thr Glu Asp Arg Leu Phe Lys
50 55 60

His Leu Phe Arg Gly Tyr Asn Arg Trp Ala Arg Pro Val Pro Asn Thr
65 70 75 80

Ser Asp Val Val Ile Val Arg Phe Gly Leu Ser Ile Ala Gln Leu Ile
85 90 95

Asp Val Asp Glu Lys Asn Gln Met Met Thr Thr Asn Val Trp Leu Lys
100 105 110

Gln Glu Trp Ser Asp Tyr Lys Leu Arg Trp Asn Pro Thr Asp Phe Gly
115 120 125

Asn Ile Thr Ser Leu Arg Val Pro Ser Glu Met Ile Trp Ile Pro Asp
130 135 140

Ile Val Leu Tyr Asn Asn Ala Asp Gly Glu Phe Ala Val Thr His Met
145 150 155 160

SSCP Update Sequences.ST25

Thr Lys Ala His Leu Phe Ser Thr Gly Thr Val His Trp Val Pro Pro
 165 170 175
 Ala Ile Tyr Lys Ser Ser Cys Ser Ile Asp Val Thr Phe Phe Pro Phe
 180 185 190
 Asp Gln Gln Asn Cys Lys Met Lys Phe Gly Ser Trp Thr Tyr Asp Lys
 195 200 205
 Ala Lys Ile Asp Leu Glu Gln Met Glu Gln Thr Val Asp Leu Lys Asp
 210 215 220
 Tyr Trp Glu Ser Gly Glu Trp Ala Ile Val Asn Ala Thr Gly Thr Tyr
 225 230 235 240
 Asn Ser Lys Lys Tyr Asp Cys Cys Ala Glu Ile Tyr Pro Asp Val Thr
 245 250 255
 Tyr Ala Phe Val Ile Arg Arg Leu Pro Leu Phe Tyr Thr Ile Asn Leu
 260 265 270
 Ile Ile Pro Cys Leu Leu Ile Ser Cys Leu Thr Val Leu Val Phe Tyr
 275 280 285
 Leu Pro Ser Asp Cys Gly Glu Lys Ile Thr Leu Cys Ile Ser Val Leu
 290 295 300
 Leu Ser Leu Thr Val Phe Leu Leu Leu Ile Thr Glu Ile Ile Pro Ser
 305 310 315 320
 Thr Ser Leu Val Ile Pro Leu Ile Gly Glu Tyr Leu Leu Phe Thr Met
 325 330 335
 Ile Phe Val Thr Leu Ser Ile Val Ile Thr Val Phe Val Leu Asn Val
 340 345 350
 His His Arg Ser Pro Ser Thr His Thr Met Pro His Trp Val Arg Gly
 355 360 365
 Ala Leu Leu Gly Cys Val Pro Arg Trp Leu Leu Met Asn Arg Pro Pro
 370 375 380
 Pro Pro Val Glu Leu Cys His Pro Leu Arg Leu Lys Leu Ser Pro Ser
 385 390 395 400
 Tyr His Trp Leu Glu Ser Asn Val Asp Ala Glu Glu Arg Glu Val Val
 405 410 415
 Val Glu Glu Glu Asp Arg Trp Ala Cys Ala Gly His Val Ala Pro Ser
 420 425 430

SSCP Update Sequences.ST25

Val Gly Thr Leu Cys Ser His Gly His Leu His Ser Gly Ala Ser Gly
435 440 445

Pro Lys Ala Glu Ala Leu Leu Gln Glu Gly Glu Leu Leu Leu Ser Pro
450 455 460

His Met Gln Lys Ala Leu Glu Gly Val His Tyr Ile Ala Asp His Leu
465 470 475 480

Arg Ser Glu Asp Ala Asp Ser Ser Val Lys Glu Asp Trp Lys Tyr Val
485 490 495

Ala Met Val Ile Asp Arg Ile Phe Leu Trp Leu Phe Ile Ile Val Cys
500 505 510

Phe Leu Gly Thr Ile Gly Leu Phe Leu Pro Pro Phe Leu Ala Gly Met
515 520 525

Ile

<210> 90
<211> 505
<212> PRT
<213> Homo sapiens

<400> 90

Met Gly Ser Gly Pro Leu Ser Leu Pro Leu Ala Leu Ser Pro Pro Arg
1 5 10 15

Leu Leu Leu Leu Leu Leu Leu Ser Leu Leu Pro Val Ala Arg Ala Ser
20 25 30

Glu Ala Glu His His Leu Phe Glu Arg Leu Phe Glu Asp Tyr Asn Glu
35 40 45

Ile Ile Arg Pro Val Ala Asn Val Ser Asp Pro Val Ile Ile His Phe
50 55 60

Glu Val Ser Met Ser Gln Leu Val Lys Val Asp Glu Val Asn Gln Ile
65 70 75 80

Met Glu Thr Asn Leu Trp Leu Lys Gln Ile Trp Asn Asp Tyr Lys Leu
85 90 95

Lys Trp Asn Pro Ser Asp Tyr Gly Gly Ala Glu Phe Met Arg Val Pro
100 105 110

Ala Gln Lys Ile Trp Lys Pro Asp Ile Val Leu Tyr Asn Asn Ala Val
115 120 125

SSCP Update Sequences.ST25

Gly Asp Phe Gln Val Asp Asp Lys Thr Lys Ala Leu Leu Lys Tyr Thr
 130 135 140
 Gly Glu Val Thr Trp Ile Pro Pro Ala Ile Phe Lys Ser Ser Cys Lys
 145 150 155 160
 Ile Asp Val Thr Tyr Phe Pro Phe Asp Tyr Gln Asn Cys Thr Met Lys
 165 170 175
 Phe Gly Ser Trp Ser Tyr Asp Lys Ala Lys Ile Asp Leu Val Leu Ile
 180 185 190
 Gly Ser Ser Met Asn Leu Lys Asp Tyr Trp Glu Ser Gly Glu Trp Ala
 195 200 205
 Ile Ile Lys Ala Pro Gly Tyr Lys His Asp Ile Lys Tyr Asn Cys Cys
 210 215 220
 Glu Glu Ile Tyr Pro Asp Ile Thr Tyr Ser Leu Tyr Ile Arg Arg Leu
 225 230 235 240
 Pro Leu Phe Tyr Thr Ile Asn Leu Ile Ile Pro Cys Leu Leu Ile Ser
 245 250 255
 Phe Leu Thr Val Leu Val Phe Tyr Leu Pro Ser Asp Cys Gly Glu Lys
 260 265 270
 Val Thr Leu Cys Ile Ser Val Leu Leu Ser Leu Thr Val Phe Leu Leu
 275 280 285
 Val Ile Thr Glu Thr Ile Pro Ser Thr Ser Leu Val Ile Pro Leu Ile
 290 295 300
 Gly Glu Tyr Leu Leu Phe Thr Met Ile Phe Val Thr Leu Ser Ile Val
 305 310 315 320
 Ile Thr Val Phe Val Leu Asn Val His Tyr Arg Thr Pro Thr Thr His
 325 330 335
 Thr Met Pro Ser Trp Val Lys Thr Val Phe Leu Asn Leu Leu Pro Arg
 340 345 350
 Val Met Phe Met Thr Arg Pro Thr Ser Asn Glu Gly Asn Ala Gln Lys
 355 360 365
 Pro Arg Pro Leu Tyr Gly Ala Glu Leu Ser Asn Leu Asn Cys Phe Ser
 370 375 380
 Arg Ala Glu Ser Lys Gly Cys Lys Glu Gly Tyr Pro Cys Gln Asp Gly
 385 390 395 400

SSCP Update Sequences.ST25

Met Cys Gly Tyr Cys His His Arg Arg Ile Lys Ile Ser Asn Phe Ser
 405 410 415

Ala Asn Leu Thr Arg Ser Ser Ser Ser Glu Ser Val Asp Ala Val Leu
 420 425 430

Ser Leu Ser Ala Leu Ser Pro Glu Ile Lys Glu Ala Ile Gln Ser Val
 435 440 445

Lys Tyr Ile Ala Glu Asn Met Lys Ala Gln Asn Glu Ala Lys Glu Ile
 450 455 460

Gln Asp Asp Trp Lys Tyr Val Ala Met Val Ile Asp Arg Ile Phe Leu
 465 470 475 480

Trp Val Phe Thr Leu Val Cys Ile Leu Gly Thr Ala Gly Leu Phe Leu
 485 490 495

Gln Pro Leu Met Ala Arg Glu Asp Ala
 500 505

<210> 91
 <211> 118
 <212> PRT
 <213> Homo sapiens

<400> 91

Met Val Gln Lys Ser Arg Asn Gly Gly Val Tyr Pro Gly Pro Ser Gly
 1 5 10 15

Glu Lys Lys Leu Lys Val Gly Phe Val Gly Leu Asp Pro Gly Ala Pro
 20 25 30

Asp Ser Thr Arg Asp Gly Ala Leu Leu Ile Ala Gly Ser Glu Ala Pro
 35 40 45

Lys Arg Gly Ser Ile Leu Ser Lys Pro Arg Ala Gly Gly Ala Gly Ala
 50 55 60

Gly Lys Pro Pro Gln Ala Gln Arg Leu Leu Pro Gln Ala Ala Glu Phe
 65 70 75 80

Pro Leu Gln Arg Ala Gly Ala Ala Ala Arg Leu Gly Val His Leu Pro
 85 90 95

Arg Leu Arg Val Pro Pro Gly Phe Leu Leu Pro Arg Ala Val Cys Val
 100 105 110

Phe His His Gln Gly Val
 115

<210> 92

SSCP Update Sequences.ST25

<211> 854
 <212> PRT
 <213> Homo sapiens

<400> 92

Met Val Gln Lys Ser Arg Asn Gly Gly Val Tyr Pro Gly Pro Ser Gly
 1 5 10 15

Glu Lys Lys Leu Lys Val Gly Phe Val Gly Leu Asp Pro Gly Ala Pro
 20 25 30

Asp Ser Thr Arg Asp Gly Ala Leu Leu Ile Ala Gly Ser Glu Ala Pro
 35 40 45

Lys Arg Gly Ser Ile Leu Ser Lys Pro Arg Ala Gly Gly Ala Gly Ala
 50 55 60

Gly Lys Pro Pro Lys Arg Asn Ala Phe Tyr Arg Lys Leu Gln Asn Phe
 65 70 75 80

Leu Tyr Asn Val Leu Glu Arg Pro Arg Gly Trp Ala Phe Ile Tyr His
 85 90 95

Ala Tyr Val Phe Leu Leu Val Phe Ser Cys Leu Val Leu Ser Val Phe
 100 105 110

Ser Thr Ile Lys Glu Tyr Glu Lys Ser Ser Glu Gly Ala Leu Tyr Ile
 115 120 125

Leu Glu Ile Val Thr Ile Val Val Phe Gly Val Glu Tyr Phe Val Arg
 130 135 140

Ile Trp Ala Ala Gly Cys Cys Cys Arg Tyr Arg Gly Trp Arg Gly Arg
 145 150 155 160

Leu Lys Phe Ala Arg Lys Pro Phe Cys Val Ile Asp Ile Met Val Leu
 165 170 175

Ile Ala Ser Ile Ala Val Leu Ala Ala Gly Ser Gln Gly Asn Val Phe
 180 185 190

Ala Thr Ser Ala Leu Arg Ser Leu Arg Phe Leu Gln Ile Leu Arg Met
 195 200 205

Ile Arg Met Asp Arg Arg Gly Gly Thr Trp Lys Leu Leu Gly Ser Val
 210 215 220

Val Tyr Ala His Ser Lys Glu Leu Val Thr Ala Trp Tyr Ile Gly Phe
 225 230 235 240

Leu Cys Leu Ile Leu Ala Ser Phe Leu Val Tyr Leu Ala Glu Lys Gly
 245 250 255

SSCP Update Sequences.ST25

Glu Asn Asp His Phe Asp Thr Tyr Ala Asp Ala Leu Trp Trp Gly Leu
 260 265 270
 Ile Thr Leu Thr Thr Ile Gly Tyr Gly Asp Lys Tyr Pro Gln Thr Trp
 275 280 285
 Asn Gly Arg Leu Leu Ala Ala Thr Phe Thr Leu Ile Gly Val Ser Phe
 290 295 300
 Phe Ala Leu Pro Ala Gly Ile Leu Gly Ser Gly Phe Ala Leu Lys Val
 305 310 315 320
 Gln Glu Gln His Arg Gln Lys His Phe Glu Lys Arg Arg Asn Pro Ala
 325 330 335
 Ala Gly Leu Ile Gln Ser Ala Trp Arg Phe Tyr Ala Thr Asn Leu Ser
 340 345 350
 Gly Thr Asp Leu His Ser Thr Trp Gln Tyr Tyr Glu Arg Thr Val Thr
 355 360 365
 Val Pro Met Tyr Ser Ser Gln Thr Gln Thr Tyr Gly Ala Ser Arg Leu
 370 375 380
 Ile Pro Pro Leu Asn Gln Leu Glu Leu Leu Arg Asn Leu Lys Ser Lys
 385 390 395 400
 Ser Gly Leu Ala Phe Arg Lys Asp Pro Pro Pro Glu Pro Ser Pro Ser
 405 410 415
 Gln Lys Val Ser Leu Lys Asp Arg Val Phe Ser Ser Pro Arg Gly Val
 420 425 430
 Ala Ala Lys Gly Lys Gly Ser Pro Gln Ala Gln Thr Val Arg Arg Ser
 435 440 445
 Pro Ser Ala Asp Gln Ser Leu Glu Asp Ser Pro Ser Lys Val Pro Lys
 450 455 460
 Ser Trp Ser Phe Gly Asp Arg Ser Arg Ala Arg Gln Ala Phe Arg Ile
 465 470 475 480
 Lys Gly Ala Ala Ser Arg Gln Asn Ser Glu Glu Ala Ser Leu Pro Gly
 485 490 495
 Glu Asp Ile Val Asp Asp Lys Ser Cys Pro Cys Glu Phe Val Thr Glu
 500 505 510
 Asp Leu Thr Pro Gly Leu Lys Val Ser Ile Arg Ala Val Cys Val Met
 515 520 525

SSCP Update Sequences.ST25

Arg Phe Leu Val Ser Lys Arg Lys Phe Lys Glu Ser Leu Arg Pro Tyr
 530 535 540
 Asp Val Met Asp Val Ile Glu Gln Tyr Ser Ala Gly His Leu Asp Met
 545 550 555 560
 Leu Ser Arg Ile Lys Ser Leu Gln Ser Arg Val Asp Gln Ile Val Gly
 565 570 575
 Arg Gly Pro Ala Ile Thr Asp Lys Asp Arg Thr Lys Gly Pro Ala Glu
 580 585 590
 Ala Glu Leu Pro Glu Asp Pro Ser Met Met Gly Arg Leu Gly Lys Val
 595 600 605
 Glu Lys Gln Val Leu Ser Met Glu Lys Lys Leu Asp Phe Leu Val Asn
 610 615 620
 Ile Tyr Met Gln Arg Met Gly Ile Pro Pro Thr Glu Thr Glu Ala Tyr
 625 630 635 640
 Phe Gly Ala Lys Glu Pro Glu Pro Ala Pro Pro Tyr His Ser Pro Glu
 645 650 655
 Asp Ser Arg Glu His Val Asp Arg His Gly Cys Ile Val Lys Ile Val
 660 665 670
 Arg Ser Ser Ser Ser Thr Gly Gln Lys Asn Phe Ser Ala Pro Pro Ala
 675 680 685
 Ala Pro Pro Val Gln Cys Pro Pro Ser Thr Ser Trp Gln Pro Gln Ser
 690 695 700
 His Pro Arg Gln Gly His Gly Thr Ser Pro Val Gly Asp His Gly Ser
 705 710 715 720
 Leu Val Arg Ile Pro Pro Pro Pro Ala His Glu Arg Ser Leu Ser Ala
 725 730 735
 Tyr Gly Gly Gly Asn Arg Ala Ser Met Glu Phe Leu Arg Gln Glu Asp
 740 745 750
 Thr Pro Gly Cys Arg Pro Pro Glu Gly Thr Leu Arg Asp Ser Asp Thr
 755 760 765
 Ser Ile Ser Ile Pro Ser Val Asp His Glu Glu Leu Glu Arg Ser Phe
 770 775 780
 Ser Gly Phe Ser Ile Ser Gln Ser Lys Glu Asn Leu Asp Ala Leu Asn
 785 790 795 800

Ser Cys Tyr Ala Ala Val Ala Pro Cys Ala Lys Val Arg Pro Tyr Ile
805 810 815

Ala Glu Gly Glu Ser Asp Thr Asp Ser Asp Leu Cys Thr Pro Cys Gly
820 825 830

Pro Pro Pro Arg Ser Ala Thr Gly Glu Gly Pro Phe Gly Asp Val Gly
835 840 845

```
<210> 93
<211> 429
<212> PRT
<213> Homo sapiens
<400> 93
```

Met Val Gln Lys Ser Arg Asn Gly Gly Val Tyr Pro Gly Pro Ser Gly
1 5 10 15

Glu Lys Lys Leu Lys Val Gly Phe Val Gly Leu Asp Pro Gly Ala Pro
20 25 30

Asp Ser Thr Arg Asp Gly Ala Leu Leu Ile Ala Gly Ser Glu Ala Pro
35 40 45

Lys Arg Gly Ser Ile Leu Ser Lys Pro Arg Ala Gly Gly Ala Gly Ala
50 55 60

Gly Lys Pro Pro Lys Arg Asn Ala Phe Tyr Arg Lys Leu Gln Asn Phe
65 70 75 80

Leu Tyr Asn Val Leu Glu Arg Pro Arg Gly Trp Ala Phe Ile Tyr His
85 90 95

Ala Tyr Val Phe Leu Leu Val Phe Ser Cys Leu Val Leu Ser Val Phe
100 105 110

Ser Thr Ile Lys Glu Tyr Glu Lys Ser Ser Glu Gly Ala Leu Tyr Ile
115 120 125

Leu Glu Ile Val Thr Ile Val Val Phe Gly Val Glu Tyr Phe Val Arg
130 135 140

```

Ile Trp Ala Ala Gly Cys Cys Cys Arg Tyr Arg Gly Trp Arg Gly Arg
145          150          155          160

```

Leu Lys Phe Ala Arg Lys Pro Phe Cys Val Ile Asp Ile Met Val Leu
165 170 175

SSCP Update Sequences.ST25

Ile Ala Ser Ile Ala Val Leu Ala Ala Gly Ser Gln Gly Asn Val Phe
 180 185 190
 Ala Thr Ser Ala Leu Arg Ser Leu Arg Phe Leu Gln Ile Leu Arg Met
 195 200 205
 Ile Arg Met Asp Arg Arg Gly Gly Thr Trp Lys Leu Leu Gly Ser Val
 210 215 220
 Val Tyr Ala His Ser Lys Glu Leu Val Thr Ala Trp Tyr Ile Gly Phe
 225 230 235 240
 Leu Cys Leu Ile Leu Ala Ser Phe Leu Val Tyr Leu Ala Glu Lys Gly
 245 250 255
 Glu Asn Asp His Phe Asp Thr Tyr Ala Asp Ala Leu Trp Trp Gly Leu
 260 265 270
 Ile Thr Leu Thr Thr Ile Gly Tyr Gly Asp Lys Tyr Pro Gln Thr Trp
 275 280 285
 Asn Gly Arg Leu Leu Ala Ala Thr Phe Thr Leu Ile Gly Val Ser Phe
 290 295 300
 Phe Ala Leu Pro Ala Gly Ile Leu Gly Ser Gly Phe Ala Leu Lys Val
 305 310 315 320
 Gln Glu Gln His Arg Gln Lys His Phe Glu Lys Arg Arg Asn Pro Ala
 325 330 335
 Ala Gly Leu Ile Gln Ser Ala Trp Arg Phe Tyr Ala Thr Asn Leu Ser
 340 345 350
 Arg Thr Asp Leu His Ser Thr Trp Gln Tyr Tyr Glu Arg Thr Val Thr
 355 360 365
 Val Pro Met Tyr Ser Ser Gln Thr Gln Thr Tyr Gly Ala Ser Arg Leu
 370 375 380
 Ile Pro Pro Leu Asn Gln Leu Glu Leu Leu Arg Asn Leu Lys Ser Lys
 385 390 395 400
 Ser Gly Leu Ala Phe Arg Lys Asp Pro Pro Pro Glu Pro Ser Pro Ser
 405 410 415
 Gln Lys Val Ser Leu Lys Asp Arg Val Phe Ser Ser Pro
 420 425

<210> 94
 <211> 854
 <212> PRT

SSCP Update Sequences.ST25

<213> Homo sapiens

<400> 94

Met Val Gln Lys Ser Arg Asn Gly Gly Val Tyr Pro Gly Pro Ser Gly
 1 5 10 15
 Glu Lys Lys Leu Lys Val Gly Phe Val Gly Leu Asp Pro Gly Ala Pro
 20 25 30
 Asp Ser Thr Arg Asp Gly Ala Leu Leu Ile Ala Gly Ser Glu Ala Pro
 35 40 45
 Lys Arg Gly Ser Ile Leu Ser Lys Pro Arg Ala Gly Gly Ala Gly Ala
 50 55 60
 Gly Lys Pro Pro Lys Arg Asn Ala Phe Tyr Arg Lys Leu Gln Asn Phe
 65 70 75 80
 Leu Tyr Asn Val Leu Glu Arg Pro Arg Gly Trp Ala Phe Ile Tyr His
 85 90 95
 Ala Tyr Val Phe Leu Leu Val Phe Ser Cys Leu Val Leu Ser Val Phe
 100 105 110
 Ser Thr Ile Lys Glu Tyr Glu Lys Ser Ser Glu Gly Ala Leu Tyr Ile
 115 120 125
 Leu Glu Ile Val Thr Ile Val Val Phe Gly Val Glu Tyr Phe Val Arg
 130 135 140
 Ile Trp Ala Ala Gly Cys Cys Cys Arg Tyr Arg Gly Trp Arg Gly Arg
 145 150 155 160
 Leu Lys Phe Ala Arg Lys Pro Phe Cys Val Ile Asp Ile Met Val Leu
 165 170 175
 Ile Ala Ser Ile Ala Val Leu Ala Ala Gly Ser Gln Gly Asn Val Phe
 180 185 190
 Ala Thr Ser Ala Leu Arg Ser Leu Arg Phe Leu Gln Ile Leu Arg Met
 195 200 205
 Ile Arg Met Asp Arg Arg Gly Gly Thr Trp Lys Leu Leu Gly Ser Val
 210 215 220
 Val Tyr Ala His Ser Lys Glu Leu Val Thr Ala Trp Tyr Ile Gly Phe
 225 230 235 240
 Leu Cys Leu Ile Leu Ala Ser Phe Leu Val Tyr Leu Ala Glu Lys Gly
 245 250 255

SSCP Update Sequences.ST25

Glu Asn Asp His Phe Asp Thr Tyr Ala Asp Ala Leu Trp Trp Gly Leu
 260 265 270
 Ile Thr Leu Thr Thr Ile Gly Tyr Gly Asp Lys Tyr Pro Gln Thr Trp
 275 280 285
 Asn Gly Arg Leu Leu Ala Ala Thr Phe Thr Leu Ile Gly Val Ser Phe
 290 295 300
 Phe Ala Leu Pro Ala Gly Ile Leu Gly Ser Gly Phe Ala Leu Lys Val
 305 310 315 320
 Gln Glu Gln His Arg Gln Lys His Phe Glu Lys Arg Arg Asn Pro Ala
 325 330 335
 Ala Gly Leu Ile Gln Ser Ala Trp Arg Phe Tyr Ala Thr Asn Leu Ser
 340 345 350
 Arg Thr Asp Leu His Ser Thr Trp Gln Tyr Tyr Glu Arg Thr Val Thr
 355 360 365
 Val Pro Met Tyr Ser Ser Gln Thr Gln Thr Tyr Gly Ala Ser Arg Leu
 370 375 380
 Ile Pro Pro Leu Asn Gln Leu Glu Leu Leu Arg Asn Leu Lys Ser Lys
 385 390 395 400
 Ser Gly Leu Ala Phe Arg Lys Asp Pro Pro Pro Glu Pro Ser Pro Ser
 405 410 415
 Gln Lys Val Ser Leu Lys Asp Arg Val Phe Ser Ser Pro Arg Gly Val
 420 425 430
 Ala Ala Lys Gly Lys Gly Ser Pro Gln Ala Gln Thr Val Arg Arg Ser
 435 440 445
 Pro Ser Ala Asp Gln Ser Leu Glu Asp Ser Pro Ser Lys Val Pro Lys
 450 455 460
 Ser Trp Ser Phe Gly Asp Arg Ser Arg Ala Arg Gln Ala Phe Arg Ile
 465 470 475 480
 Lys Gly Ala Ala Ser Arg Gln Asn Ser Glu Glu Ala Ser Leu Pro Gly
 485 490 495
 Glu Asp Ile Val Asp Asp Lys Ser Cys Pro Cys Glu Phe Val Thr Glu
 500 505 510
 Asp Leu Thr Pro Gly Leu Lys Val Ser Ile Arg Ala Val Cys Val Met
 515 520 525

SSCP Update Sequences.ST25

Arg Phe Leu Val Ser Lys Arg Lys Phe Lys Glu Ser Leu Arg Pro Tyr
 530 535 540
 Asp Val Met Asp Val Ile Glu Gln Tyr Ser Ala Gly His Leu Asp Met
 545 550 555 560
 Leu Ser Arg Ile Lys Ser Leu Gln Ser Ser Val Asp Gln Ile Val Gly
 565 570 575
 Arg Gly Pro Ala Ile Thr Asp Lys Asp Arg Thr Lys Gly Pro Ala Glu
 580 585 590
 Ala Glu Leu Pro Glu Asp Pro Ser Met Met Gly Arg Leu Gly Lys Val
 595 600 605
 Glu Lys Gln Val Leu Ser Met Glu Lys Lys Leu Asp Phe Leu Val Asn
 610 615 620
 Ile Tyr Met Gln Arg Met Gly Ile Pro Pro Thr Glu Thr Glu Ala Tyr
 625 630 635 640
 Phe Gly Ala Lys Glu Pro Glu Pro Ala Pro Pro Tyr His Ser Pro Glu
 645 650 655
 Asp Ser Arg Glu His Val Asp Arg His Gly Cys Ile Val Lys Ile Val
 660 665 670
 Arg Ser Ser Ser Ser Thr Gly Gln Lys Asn Phe Ser Ala Pro Pro Ala
 675 680 685
 Ala Pro Pro Val Gln Cys Pro Pro Ser Thr Ser Trp Gln Pro Gln Ser
 690 695 700
 His Pro Arg Gln Gly His Gly Thr Ser Pro Val Gly Asp His Gly Ser
 705 710 715 720
 Leu Val Arg Ile Pro Pro Pro Pro Ala His Glu Arg Ser Leu Ser Ala
 725 730 735
 Tyr Gly Gly Gly Asn Arg Ala Ser Met Glu Phe Leu Arg Gln Glu Asp
 740 745 750
 Thr Pro Gly Cys Arg Pro Pro Glu Gly Thr Leu Arg Asp Ser Asp Thr
 755 760 765
 Ser Ile Ser Ile Pro Ser Val Asp His Glu Glu Leu Glu Arg Ser Phe
 770 775 780
 Ser Gly Phe Ser Ile Ser Gln Ser Lys Glu Asn Leu Asp Ala Leu Asn
 785 790 795 800

SSCP Update Sequences.ST25

Ser Cys Tyr Ala Ala Val Ala Pro Cys Ala Lys Val Arg Pro Tyr Ile
805 810 815

Ala Glu Gly Glu Ser Asp Thr Asp Ser Asp Leu Cys Thr Pro Cys Gly
820 825 830

Pro Pro Pro Arg Ser Ala Thr Gly Glu Gly Pro Phe Gly Asp Val Gly
835 840 845

Trp Ala Gly Pro Arg Lys
850

<210> 95
<211> 854
<212> PRT
<213> Homo sapiens

<400> 95

Met Val Gln Lys Ser Arg Asn Gly Gly Val Tyr Pro Gly Pro Ser Gly
1 5 10 15

Glu Lys Lys Leu Lys Val Gly Phe Val Gly Leu Asp Pro Gly Ala Pro
20 25 30

Asp Ser Thr Arg Asp Gly Ala Leu Leu Ile Ala Gly Ser Glu Ala Pro
35 40 45

Lys Arg Gly Ser Ile Leu Ser Lys Pro Arg Ala Gly Gly Ala Gly Ala
50 55 60

Gly Lys Pro Pro Lys Arg Asn Ala Phe Tyr Arg Lys Leu Gln Asn Phe
65 70 75 80

Leu Tyr Asn Val Leu Glu Arg Pro Arg Gly Trp Ala Phe Ile Tyr His
85 90 95

Ala Tyr Val Phe Leu Leu Val Phe Ser Cys Leu Val Leu Ser Val Phe
100 105 110

Ser Thr Ile Lys Glu Tyr Glu Lys Ser Ser Glu Gly Ala Leu Tyr Ile
115 120 125

Leu Glu Ile Val Thr Ile Val Val Phe Gly Val Glu Tyr Phe Val Arg
130 135 140

Ile Trp Ala Ala Gly Cys Cys Cys Arg Tyr Arg Gly Trp Arg Gly Arg
145 150 155 160

Leu Lys Phe Ala Arg Lys Pro Phe Cys Val Ile Asp Ile Met Val Leu
165 170 175

Ile Ala Ser Ile Ala Val Leu Ala Ala Gly Ser Gln Gly Asn Val Phe
Page 230

SSCP Update Sequences.ST25

180

185

190

Ala Thr Ser Ala Leu Arg Ser Leu Arg Phe Leu Gln Ile Leu Arg Met
 195 200 205

Ile Arg Met Asp Arg Arg Gly Gly Thr Trp Lys Leu Leu Gly Ser Val
 210 215 220

Val Tyr Ala His Ser Lys Glu Leu Val Thr Ala Trp Tyr Ile Gly Phe
 225 230 235 240

Leu Cys Leu Ile Leu Ala Ser Phe Leu Val Tyr Leu Ala Glu Lys Gly
 245 250 255

Glu Asn Asp His Phe Asp Thr Tyr Ala Asp Ala Leu Trp Trp Gly Leu
 260 265 270

Ile Thr Leu Thr Thr Ile Gly Tyr Gly Asp Lys Tyr Pro Gln Thr Trp
 275 280 285

Asn Gly Arg Leu Leu Ala Ala Thr Phe Thr Leu Ile Gly Val Ser Phe
 290 295 300

Phe Ala Leu Pro Ala Gly Ile Leu Gly Ser Gly Phe Ala Leu Lys Val
 305 310 315 320

Gln Glu Gln His Arg Gln Lys His Phe Glu Lys Arg Arg Asn Pro Ala
 325 330 335

Ala Gly Leu Ile Gln Ser Ala Trp Arg Phe Tyr Ala Thr Asn Leu Ser
 340 345 350

Arg Thr Asp Leu His Ser Thr Trp Gln Tyr Tyr Glu Arg Thr Val Thr
 355 360 365

Val Pro Met Tyr Ser Ser Gln Thr Gln Thr Tyr Gly Ala Ser Arg Leu
 370 375 380

Ile Pro Pro Leu Asn Gln Leu Glu Leu Leu Arg Asn Leu Lys Ser Lys
 385 390 395 400

Ser Gly Leu Ala Phe Arg Lys Asp Pro Pro Pro Glu Pro Ser Pro Ser
 405 410 415

Gln Lys Val Ser Leu Lys Asp Arg Val Phe Ser Ser Pro Arg Gly Val
 420 425 430

Ala Ala Lys Gly Lys Gly Ser Pro Gln Ala Gln Thr Val Arg Arg Ser
 435 440 445

Pro Ser Ala Asp Gln Ser Leu Glu Asp Ser Pro Ser Lys Val Pro Lys

SSCP Update Sequences.ST25

450

455

460

Ser Trp Ser Phe Gly Asp Arg Ser Arg Ala Arg Gln Ala Phe Arg Ile
 465 470 475 480

Lys Gly Ala Ala Ser Arg Gln Asn Ser Glu Glu Ala Ser Leu Pro Gly
 485 490 495

Glu Asp Ile Val Asp Asp Lys Ser Cys Pro Cys Glu Phe Val Thr Glu
 500 505 510

Asp Leu Thr Pro Gly Leu Lys Val Ser Ile Arg Ala Val Cys Val Met
 515 520 525

Arg Phe Leu Val Ser Lys Arg Lys Phe Lys Glu Ser Leu Arg Pro Tyr
 530 535 540

Asp Val Met Asp Val Ile Glu Gln Tyr Ser Ala Gly His Leu Asp Met
 545 550 555 560

Leu Ser Arg Ile Lys Ser Leu Gln Ser Arg Val Asp Gln Ile Val Gly
 565 570 575

Arg Gly Pro Ala Ile Thr Asp Lys Asp Arg Thr Lys Gly Pro Ala Glu
 580 585 590

Ala Glu Leu Pro Glu Asp Pro Ser Met Met Gly Arg Leu Gly Lys Val
 595 600 605

Glu Lys Gln Val Leu Ser Met Glu Lys Lys Arg Asp Phe Leu Val Asn
 610 615 620

Ile Tyr Met Gln Arg Met Gly Ile Pro Pro Thr Glu Thr Glu Ala Tyr
 625 630 635 640

Phe Gly Ala Lys Glu Pro Glu Pro Ala Pro Pro Tyr His Ser Pro Glu
 645 650 655

Asp Ser Arg Glu His Val Asp Arg His Gly Cys Ile Val Lys Ile Val
 660 665 670

Arg Ser Ser Ser Ser Thr Gly Gln Lys Asn Phe Ser Ala Pro Pro Ala
 675 680 685

Ala Pro Pro Val Gln Cys Pro Pro Ser Thr Ser Trp Gln Pro Gln Ser
 690 695 700

His Pro Arg Gln Gly His Gly Thr Ser Pro Val Gly Asp His Gly Ser
 705 710 715 720

Leu Val Arg Ile Pro Pro Pro Pro Ala His Glu Arg Ser Leu Ser Ala

SSCP Update Sequences.ST25

725

730

735

Tyr Gly Gly Gly Asn Arg Ala Ser Met Glu Phe Leu Arg Gln Glu Asp
 740 745 750

Thr Pro Gly Cys Arg Pro Pro Glu Gly Thr Leu Arg Asp Ser Asp Thr
 755 760 765

Ser Ile Ser Ile Pro Ser Val Asp His Glu Glu Leu Glu Arg Ser Phe
 770 775 780

Ser Gly Phe Ser Ile Ser Gln Ser Lys Glu Asn Leu Asp Ala Leu Asn
 785 790 795 800

Ser Cys Tyr Ala Ala Val Ala Pro Cys Ala Lys Val Arg Pro Tyr Ile
 805 810 815

Ala Glu Gly Glu Ser Asp Thr Asp Ser Asp Leu Cys Thr Pro Cys Gly
 820 825 830

Pro Pro Pro Arg Ser Ala Thr Gly Glu Gly Pro Phe Gly Asp Val Gly
 835 840 845

Trp Ala Gly Pro Arg Lys
 850

INTERNATIONAL SEARCH REPORT

International application No.
PCT/AU2004/001051

A. CLASSIFICATION OF SUBJECT MATTER Int. Cl. ⁷ : C12Q 1/68, C12N 15/01, A61K 39/395 CO7K14/47 According to International Patent Classification (IPC) or to both national classification and IPC		
B. FIELDS SEARCHED Minimum documentation searched (classification system followed by classification symbols) See electronic databases Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched See electronic databases Electronic data base consulted during the international search (name of data base and, where practicable, search terms used) WPIDS, CA Medline. SCN1A, polymorphism/mutation/SNP, epilepsy/disease/febrile seizure		
C. DOCUMENTS CONSIDERED TO BE RELEVANT		
Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	Fujiwara T et al. Mutations of sodium channel α subunit type 1 (SCN1A) in intractable childhood epilepsies with frequent generalized tonic-clonic seizures. Brain, 2003. 126: 531-546	
A	Nabbout R et al. Spectrum of SCN1A mutations in severe myoclonic epilepsy of infancy. Neurology, 2003 Jun 24. 60(12):1961-7.	
A	WO 2003/008574 A1 (BIONOMICS LIMITED) 30 January 2003	
A	WO 2002/06521 A1 (BIONOMICS LIMITED) 24 January 2002	
A	WO 2002/50096 A1 ((BIONOMICS LIMITED) 27 June 2002	
<input type="checkbox"/> Further documents are listed in the continuation of Box C <input checked="" type="checkbox"/> See patent family annex		
* Special categories of cited documents: "A" document defining the general state of the art which is not considered to be of particular relevance "E" earlier application or patent but published on or after the international filing date "L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified) "O" document referring to an oral disclosure, use, exhibition or other means "P" document published prior to the international filing date but later than the priority date claimed	"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention "X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone "Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art "&" document member of the same patent family	
Date of the actual completion of the international search 28 September 2004		Date of mailing of the international search report 7 OCT 2004
Name and mailing address of the ISA/AU AUSTRALIAN PATENT OFFICE PO BOX 200, WODEN ACT 2606, AUSTRALIA E-mail address: pct@ipaustralia.gov.au Facsimile No. (02) 6285 3929		Authorized officer Gillian Allen Telephone No : (02) 6283 2266

INTERNATIONAL SEARCH REPORT

International application No.
PCT/AU2004/001051

Box No. II Observations where certain claims were found unsearchable (Continuation of item 2 of first sheet)

This international search report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1. ☐ Claims Nos.:
because they relate to subject matter not required to be searched by this Authority, namely:
2. ☒ Claims No **65 and 66**
because they relate to parts of the international application that do not comply with the prescribed requirements to such an extent that no meaningful international search can be carried out, specifically:
The scope of these claims is so unclear that no meaningful search can be performed.
3. ☐ Claims Nos.:
because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a)

Box No. III Observations where unity of invention is lacking (Continuation of item 3 of first sheet)

This International Searching Authority found multiple inventions in this international application, as follows:

The ISA found that the claims were directed to multiple invention

See Supplemental Box III for details

1. ☐ As all required additional search fees were timely paid by the applicant, this international search report covers all searchable claims.
2. ☐ As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment of any additional fee.
3. ☐ As only some of the required additional search fees were timely paid by the applicant, this international search report covers only those claims for which fees were paid, specifically claims Nos.:
4. ☒ No required additional search fees were timely paid by the applicant. Consequently, this international search report is restricted to the invention first mentioned in the claims; it is covered by:
Claims **1-16 19-27, 29-64, 67-85** in so far as they are directed to polymorphisms in SCN1A

Remark on Protest

- ☐ The additional search fees were accompanied by the applicant's protest.
- ☐ No protest accompanied the payment of additional search fees.

INTERNATIONAL SEARCH REPORT

International application No.

PCT/AU2004/001051

Supplemental Box

(To be used when the space in any of Boxes I to VIII is not sufficient)

Continuation of Box No: III

The present claims are to 72 different mutations in 18 different ion channel genes, the mutant genes and their encoded polypeptides and antibodies thereto, and to uses of these in diagnosis or therapy.

The unifying feature of the claimed inventions is a disease-associated mutation of an ion channel gene. However, ion channel disease-associated mutations are known for every one of the ion channels of the claims, ie SCN, CHRN, KCQN, and GABR.

Therefore, since the unifying feature of the different mutations is not novel, it cannot be accepted as a special technical feature that would unite the claims.

There are therefore 72 separate inventions claimed.

However, this office believes that all claimed mutations of any one of the claimed genes could be searched without undue effort, and has chose to search the claims in so far as they are directed to polymorphisms of SCN1A

INTERNATIONAL SEARCH REPORT

International application No.

PCT/AU2004/001051

This Annex lists the known "A" publication level patent family members relating to the patent documents cited in the above-mentioned international search report. The Australian Patent Office is in no way liable for these particulars which are merely given for the purpose of information.

Patent Document Cited in Search Report	Patent Family Member
WO 2003/008574	CA 2454073 EP 1407013
WO 2002/06521	AU 200172218
WO 2002/50096	AU 200216826 EP 1351968 US 2004110706 JP 2004515252T

Due to data integration issues this family listing may not include 10 digit Australian applications filed since May 2001.

END OF ANNEX